"dataset","source","term"
"CD000028_pub4_data","Analysis.group","1"
"CD000028_pub4_data","Analysis.group","2"
"CD000028_pub4_data","Analysis.group","3"
"CD000028_pub4_data","Analysis.name","All-cause mortality"
"CD000028_pub4_data","Analysis.name","Cause of cardiovascular mortality"
"CD000028_pub4_data","Analysis.name","Cardiovascular mortality and morbidity"
"CD000028_pub4_data","Analysis.name","Cerebrovascular mortality and morbidity"
"CD000028_pub4_data","Analysis.name","Coronary heart disease mortality and morbidity"
"CD000028_pub4_data","Analysis.name","Withdrawal due to adverse effects"
"CD000028_pub4_data","Analysis.name","Cardiovascular morbidity and mortality"
"CD000028_pub4_data","Analysis.name","Cerebrovascular morbidity and mortality"
"CD000028_pub4_data","Analysis.name","Coronary heart disease morbidity and mortality"
"CD000028_pub4_data","Analysis.name","Withdrawal due to adverse effects 60 years or older"
"CD000028_pub4_data","Subgroup","Fatal stroke"
"CD000028_pub4_data","Subgroup","Fatal CHD"
"CD000028_pub4_data","Subgroup","60 to 79 years old"
"CD000028_pub4_data","Subgroup","80 years or older"
"CD000143_pub2_data","Analysis.group","1"
"CD000143_pub2_data","Analysis.group","2"
"CD000143_pub2_data","Analysis.group","3"
"CD000143_pub2_data","Analysis.group","4"
"CD000143_pub2_data","Analysis.group","5"
"CD000143_pub2_data","Analysis.name","Extubation failure"
"CD000143_pub2_data","Analysis.name","Endotracheal reintubation"
"CD000143_pub2_data","Analysis.name","Bronchopulmonary dysplasia "
"CD000143_pub2_data","Analysis.name","Oxygen dependency at 28 days"
"CD000143_pub2_data","Analysis.name","Combined outcome of bronchopulmonary dysplasia and mortality"
"CD000143_pub2_data","Analysis.name","Mortality at any time up to 28 days or discharge from hospital"
"CD000143_pub2_data","Analysis.name","Intraventricular haemorrhage"
"CD000143_pub2_data","Analysis.name","Retinopathy of prematurity"
"CD000143_pub2_data","Subgroup","CPAP level ≥ 7 cm H2O "
"CD000143_pub2_data","Subgroup","CPAP level < 7 cm H2O"
"CD000143_pub2_data","Subgroup","Birthweight ≤ 1000g"
"CD000143_pub2_data","Subgroup","Birthweight > 1500g"
"CD000143_pub2_data","Subgroup","≤ 1500 g"
"CD000143_pub2_data","Subgroup","1001 to 1500 g"
"CD000143_pub2_data","Subgroup","> 1500 g "
"CD000143_pub2_data","Subgroup","Extubation within 14 days after birth "
"CD000143_pub2_data","Subgroup","Extubation more than 14 days after birth "
"CD000143_pub2_data","Subgroup","Methylxanthines given"
"CD000143_pub2_data","Subgroup","No Methylxanthine given"
"CD000143_pub2_data","Subgroup","No Rescue CPAP used"
"CD000143_pub2_data","Subgroup","Rescue CPAP used"
"CD000219_pub5_data","Analysis.group","1"
"CD000219_pub5_data","Analysis.group","2"
"CD000219_pub5_data","Analysis.name","Pain"
"CD000219_pub5_data","Analysis.name","Vomiting, diarrhoea or rash"
"CD000219_pub5_data","Analysis.name","Abnormal tympanometry"
"CD000219_pub5_data","Analysis.name","Tympanic membrane perforation"
"CD000219_pub5_data","Analysis.name","Contralateral otitis (in unilateral cases)"
"CD000219_pub5_data","Analysis.name","Late AOM recurrences"
"CD000219_pub5_data","Analysis.name","Abnormal tympanometry at 4 weeks"
"CD000219_pub5_data","Analysis.name","AOM recurrences"
"CD000219_pub5_data","Subgroup","Pain at 24 hours"
"CD000219_pub5_data","Subgroup","Pain at 2 to 3 days"
"CD000219_pub5_data","Subgroup","Pain at 4 to 7 days"
"CD000219_pub5_data","Subgroup","Pain at 10 to 12 days"
"CD000219_pub5_data","Subgroup","3 months"
"CD000219_pub5_data","Subgroup","2 to 4 weeks"
"CD000219_pub5_data","Subgroup","6 to 8 weeks"
"CD000219_pub5_data","Subgroup","Pain at 11 to 14 days"
"CD000219_pub5_data","Subgroup","Pain at 3 to 7 days"
"CD000478_pub5_data","Analysis.group","1"
"CD000478_pub5_data","Analysis.group","2"
"CD000478_pub5_data","Analysis.group","3"
"CD000478_pub5_data","Analysis.group","4"
"CD000478_pub5_data","Analysis.group","5"
"CD000478_pub5_data","Analysis.group","6"
"CD000478_pub5_data","Analysis.group","7"
"CD000478_pub5_data","Analysis.group","8"
"CD000478_pub5_data","Analysis.name","Failure to maintain remission"
"CD000478_pub5_data","Analysis.name","Any adverse event"
"CD000478_pub5_data","Analysis.name","Withdrawal due to adverse event"
"CD000478_pub5_data","Analysis.name","Pancreatitis"
"CD000478_pub5_data","Analysis.name","Bone marrow suppression"
"CD000478_pub5_data","Analysis.name","Failure to maintain remission - all trials"
"CD000478_pub5_data","Subgroup","Azathioprine versus placebo"
"CD000478_pub5_data","Subgroup","6-Mercaptopurine versus placebo"
"CD000478_pub5_data","Subgroup","6-MP versus methotrexate"
"CD000478_pub5_data","Subgroup","AZA versus cyclosporin"
"CD000478_pub5_data","Subgroup","Infliximab (IFX) + AZA (full dose) versus IFX monotherapy"
"CD000478_pub5_data","Subgroup","Infliximab (IFX) + AZA (half dose) versus IFX monotherapy"
"CD000478_pub5_data","Subgroup","Infliximab (IFX) + AZA (full dose) versus IFX + AZA (half dose)"
"CD000478_pub5_data","Subgroup","AZA versus L-AZA+ALLO"
"CD000478_pub5_data","Subgroup","AZA versus placebo"
"CD000478_pub5_data","Subgroup","6-MP versus GMA"
"CD000478_pub5_data","Subgroup","AZA vs L-AZA+ALLO"
"CD000478_pub5_data","Subgroup","Azathioprine versus cyclosporin"
"CD000478_pub5_data","Subgroup","6-Mercaptopurine versus 5-ASA"
"CD000478_pub5_data","Subgroup","6-Mercaptopurine versus GMA"
"CD000478_pub5_data","Subgroup","L-AZA/ALLO versus ALLO"
"CD000478_pub5_data","Subgroup","6-Mercaptopurine versus methotrexate"
"CD000478_pub5_data","Subgroup","Infliximab + AZA (full dose) versus infliximab monotherapy"
"CD000478_pub5_data","Subgroup","Infliximab + AZA (half dose) versus infliximab monotherapy"
"CD000478_pub5_data","Subgroup","Infliximab + AZA (full dose) versus infliximab + AZA (half dose)"
"CD000547_pub3_data","Analysis.group","1"
"CD000547_pub3_data","Analysis.group","2"
"CD000547_pub3_data","Analysis.group","3"
"CD000547_pub3_data","Analysis.group","4"
"CD000547_pub3_data","Analysis.group","5"
"CD000547_pub3_data","Analysis.group","6"
"CD000547_pub3_data","Analysis.name","Uterine volume (mL) (preoperative)"
"CD000547_pub3_data","Analysis.name","Fibroid volume (mL) (preoperative)"
"CD000547_pub3_data","Analysis.name","Haemoglobin (preoperative)"
"CD000547_pub3_data","Analysis.name","Total frequency of adverse events"
"CD000547_pub3_data","Analysis.name","Individual adverse events"
"CD000547_pub3_data","Analysis.name","Duration of surgery (minutes)"
"CD000547_pub3_data","Analysis.name","Intraoperative blood loss (mL)"
"CD000547_pub3_data","Analysis.name","Frequency of blood transfusions"
"CD000547_pub3_data","Analysis.name","Postoperative morbidity (complications)"
"CD000547_pub3_data","Analysis.name","Proportion with individual complications"
"CD000547_pub3_data","Analysis.name","Proportion with difficult surgery"
"CD000547_pub3_data","Analysis.name","Proportion undergoing vaginal rather than abdominal procedure"
"CD000547_pub3_data","Analysis.name","Proportion with vertical incision"
"CD000547_pub3_data","Analysis.name","Duration of hospital stay (days)"
"CD000547_pub3_data","Analysis.name","Postoperative haemoglobin"
"CD000547_pub3_data","Analysis.name","Proportion with postoperative recurrence of myomas"
"CD000547_pub3_data","Analysis.name","Difficulty of surgery (visual analogue scale)"
"CD000547_pub3_data","Analysis.name","Fibroid recurrence"
"CD000547_pub3_data","Analysis.name","Fibroid volume"
"CD000547_pub3_data","Analysis.name","Haemoglobin at end of preoperative treatment"
"CD000547_pub3_data","Analysis.name","Reduction in bleeding to PBAC < 75"
"CD000547_pub3_data","Analysis.name","Intraoperative blood loss > 1000 ml"
"CD000547_pub3_data","Analysis.name","Adverse events"
"CD000547_pub3_data","Analysis.name","Haemoglobin (g/dL)"
"CD000547_pub3_data","Analysis.name","Reduction in bleeding (PBAC < 75)"
"CD000547_pub3_data","Analysis.name","Change in menstrual blood loss from baseline to treatment end"
"CD000547_pub3_data","Analysis.name","Serious adverse events"
"CD000547_pub3_data","Analysis.name","Other adverse events"
"CD000547_pub3_data","Subgroup","GnRHa vs no pretreatment"
"CD000547_pub3_data","Subgroup","GnRHa vs placebo"
"CD000547_pub3_data","Subgroup","Insomnia"
"CD000547_pub3_data","Subgroup","Hot flushes"
"CD000547_pub3_data","Subgroup","Headache"
"CD000547_pub3_data","Subgroup","Pain"
"CD000547_pub3_data","Subgroup","Nausea"
"CD000547_pub3_data","Subgroup","Dizziness"
"CD000547_pub3_data","Subgroup","Depression"
"CD000547_pub3_data","Subgroup","Arthralgia"
"CD000547_pub3_data","Subgroup","Asthenia"
"CD000547_pub3_data","Subgroup","Vaginitis"
"CD000547_pub3_data","Subgroup","Abdominal/pelvic pain"
"CD000547_pub3_data","Subgroup","Skin changes"
"CD000547_pub3_data","Subgroup","Hirsutism"
"CD000547_pub3_data","Subgroup","Change in libido"
"CD000547_pub3_data","Subgroup","Change in breast size"
"CD000547_pub3_data","Subgroup","Sweating"
"CD000547_pub3_data","Subgroup","Breast pain/tenderness"
"CD000547_pub3_data","Subgroup","Uterine haemorrhage"
"CD000547_pub3_data","Subgroup","GnRHa vs no treatment"
"CD000547_pub3_data","Subgroup","Hypermenorrhoea"
"CD000547_pub3_data","Subgroup","Dysmenorrhoea"
"CD000547_pub3_data","Subgroup","Pelvic pain"
"CD000547_pub3_data","Subgroup","Difficult defecation"
"CD000547_pub3_data","Subgroup","Difficult urination"
"CD000547_pub3_data","Subgroup","Dyspareunia"
"CD000547_pub3_data","Subgroup","GnRH vs no pretreatment"
"CD000547_pub3_data","Subgroup","GnRH vs placebo"
"CD000547_pub3_data","Subgroup","GnRHa vs ulipristal acetate"
"CD000547_pub3_data","Subgroup","GnRHa vs cabergoline"
"CD000547_pub3_data","Subgroup","Ulipristal acetate 5 mg"
"CD000547_pub3_data","Subgroup","Ulipristal acetate 10 mg"
"CD000547_pub3_data","Subgroup","Weight gain"
"CD000547_pub3_data","Subgroup","Oedema"
"CD000547_pub3_data","Subgroup","Sleep disorder"
"CD000547_pub3_data","Subgroup","Mood disorder or anxiety"
"CD000547_pub3_data","Subgroup","Vaginal dryness"
"CD000547_pub3_data","Subgroup","Cutaneous disorder"
"CD000547_pub3_data","Subgroup","Abdominal or pelvic pain"
"CD000547_pub3_data","Subgroup","Procedural pain"
"CD000547_pub3_data","Subgroup","Fatigue"
"CD000547_pub3_data","Subgroup","Anaemia"
"CD000547_pub3_data","Subgroup","Nasopharyngitis"
"CD000547_pub3_data","Subgroup","Breast pain or tenderness"
"CD000547_pub3_data","Subgroup","Influenza"
"CD000547_pub3_data","Subgroup","Pharyngitis"
"CD000547_pub3_data","Subgroup","Bone sensitivity"
"CD000547_pub3_data","Subgroup","Muscular stiffness"
"CD000547_pub3_data","Subgroup","Comparator was mifepristone"
"CD000547_pub3_data","Subgroup","Comparator was UPA"
"CD000547_pub3_data","Subgroup","Breast cancer"
"CD000547_pub3_data","Subgroup","Ovarian haemorrhage"
"CD000547_pub3_data","Subgroup","Fibroid protruding through cervix"
"CD000547_pub3_data","Subgroup","Menometrorrhagia"
"CD000547_pub3_data","Subgroup","Hyperplasia"
"CD000547_pub3_data","Subgroup","Abdominal pain"
"CD000547_pub3_data","Subgroup","Pyrexia"
"CD000547_pub3_data","Subgroup","Hypercholesterolaemia"
"CD000547_pub3_data","Subgroup","Hypothyroidism"
"CD000547_pub3_data","Subgroup","Constipation"
"CD000547_pub3_data","Subgroup","Hypertriglyceridaemia"
"CD000547_pub3_data","Subgroup","Bladder pressure"
"CD000547_pub3_data","Subgroup","Micturition problem"
"CD000547_pub3_data","Subgroup","Lower back pain"
"CD000547_pub3_data","Subgroup","Proctodynia"
"CD000547_pub3_data","Subgroup","Coital pain"
"CD000547_pub3_data","Subgroup","Vomiting"
"CD000547_pub3_data","Subgroup","Diarrhoea"
"CD000547_pub3_data","Subgroup","Change of mood"
"CD000547_pub3_data","Subgroup","Lowered libido"
"CD000547_pub3_data","Subgroup","Weakness"
"CD000547_pub3_data","Subgroup","Dental pain"
"CD000547_pub3_data","Subgroup","Vaginal infections"
"CD000547_pub3_data","Subgroup","Vaginal discharge"
"CD001072_pub2_data","Analysis.group","1"
"CD001072_pub2_data","Analysis.name","Failure of treatment"
"CD001072_pub2_data","Analysis.name","Death in the first year"
"CD001072_pub2_data","Analysis.name","Tachycardia"
"CD001155_pub3_data","Analysis.group","1"
"CD001155_pub3_data","Analysis.group","2"
"CD001155_pub3_data","Analysis.group","3"
"CD001155_pub3_data","Analysis.group","4"
"CD001155_pub3_data","Analysis.group","5"
"CD001155_pub3_data","Analysis.group","6"
"CD001155_pub3_data","Analysis.group","7"
"CD001155_pub3_data","Analysis.group","8"
"CD001155_pub3_data","Analysis.group","9"
"CD001155_pub3_data","Analysis.group","10"
"CD001155_pub3_data","Analysis.group","11"
"CD001155_pub3_data","Analysis.group","12"
"CD001155_pub3_data","Analysis.group","13"
"CD001155_pub3_data","Analysis.group","14"
"CD001155_pub3_data","Analysis.group","15"
"CD001155_pub3_data","Analysis.group","16"
"CD001155_pub3_data","Analysis.group","17"
"CD001155_pub3_data","Analysis.group","18"
"CD001155_pub3_data","Analysis.group","19"
"CD001155_pub3_data","Analysis.group","20"
"CD001155_pub3_data","Analysis.group","21"
"CD001155_pub3_data","Analysis.group","22"
"CD001155_pub3_data","Analysis.group","23"
"CD001155_pub3_data","Analysis.group","24"
"CD001155_pub3_data","Analysis.group","25"
"CD001155_pub3_data","Analysis.group","26"
"CD001155_pub3_data","Analysis.group","27"
"CD001155_pub3_data","Analysis.group","28"
"CD001155_pub3_data","Analysis.group","29"
"CD001155_pub3_data","Analysis.group","30"
"CD001155_pub3_data","Analysis.group","31"
"CD001155_pub3_data","Analysis.group","32"
"CD001155_pub3_data","Analysis.group","33"
"CD001155_pub3_data","Analysis.group","34"
"CD001155_pub3_data","Analysis.group","35"
"CD001155_pub3_data","Analysis.group","36"
"CD001155_pub3_data","Analysis.group","37"
"CD001155_pub3_data","Analysis.name","Clinical vertebral fractures"
"CD001155_pub3_data","Analysis.name","Non-vertebral fractures"
"CD001155_pub3_data","Analysis.name","Hip fractures"
"CD001155_pub3_data","Analysis.name","Wrist fractures"
"CD001155_pub3_data","Analysis.name","Radiographic vertebral fractures"
"CD001155_pub3_data","Analysis.name","Withdrawals due to adverse events"
"CD001155_pub3_data","Analysis.name","Serious adverse events"
"CD001155_pub3_data","Analysis.name","Gastrointestinal adverse events"
"CD001155_pub3_data","Analysis.name","Atypical femoral fracture"
"CD001155_pub3_data","Analysis.name","Osteonecrosis of the Jaw"
"CD001155_pub3_data","Analysis.name","Osteonecrosis of the jaw"
"CD001155_pub3_data","Analysis.name","Alendronate vs Other active agent, Primary"
"CD001155_pub3_data","Analysis.name","Alendronate vs Other active agent, Secondary"
"CD001155_pub3_data","Analysis.name","Alendronate 70 mg/week vs Zolendronic acid 5 mg/year, Secondary"
"CD001155_pub3_data","Analysis.name","Alendronate 5 mg/day vs Alendronate 35 mg/week, Primary"
"CD001155_pub3_data","Analysis.name","Alendronate 10 mg/day vs Alendronate 70 mg/week, Secondary"
"CD001155_pub3_data","Subgroup","Clinical vertebral fractures, Primary"
"CD001155_pub3_data","Subgroup","Clinical vertebral fractures, Secondary"
"CD001155_pub3_data","Subgroup","Non-vertebral fracture, Primary"
"CD001155_pub3_data","Subgroup","Non-vertebral fracture, Secondary"
"CD001155_pub3_data","Subgroup","Hip fractures, Primary"
"CD001155_pub3_data","Subgroup","Hip fractures, Secondary"
"CD001155_pub3_data","Subgroup","Wrist fractures, Primary"
"CD001155_pub3_data","Subgroup","Wrist fractures, Secondary"
"CD001155_pub3_data","Subgroup","Radiographic vertebral fractures, Primary"
"CD001155_pub3_data","Subgroup","Radiographic vertebral fractures, Secondary"
"CD001155_pub3_data","Subgroup","Withdrawals due to adverse events, Primary"
"CD001155_pub3_data","Subgroup","Withdrawals due to adverse events, Secondary"
"CD001155_pub3_data","Subgroup","Serious adverse events, Primary"
"CD001155_pub3_data","Subgroup","Serious adverse events, Secondary"
"CD001155_pub3_data","Subgroup","Gastrointestinal adverse events, Primary"
"CD001155_pub3_data","Subgroup","Gastrointestinal adverse events, Secondary"
"CD001155_pub3_data","Subgroup","Atypical femoral fracture, Secondary"
"CD001155_pub3_data","Subgroup","Atypical femoral fracture, Primary"
"CD001155_pub3_data","Subgroup","Osteonecrosis of the jaw, Primary"
"CD001155_pub3_data","Subgroup","Non-vertebral fractures, Primary"
"CD001155_pub3_data","Subgroup","Non-vertebral fractures, Secondary"
"CD001155_pub3_data","Subgroup","Clinica vertebral fracture, Primary"
"CD001155_pub3_data","Subgroup","Hip fracture, Primary"
"CD001155_pub3_data","Subgroup","Radiographic vertebral fracture, Primary"
"CD001155_pub3_data","Subgroup","Clinical vertebral Fractures, Primary"
"CD001155_pub3_data","Subgroup","Non-vertebral Fractures, Primary"
"CD001155_pub3_data","Subgroup","Non-vertebral Fractures, Secondary"
"CD001155_pub3_data","Subgroup","Hip Fractures, Secondary"
"CD001155_pub3_data","Subgroup","Withdrawal due to adverse events, Secondary"
"CD001155_pub3_data","Subgroup","Withdrawal due to adverse events, Primary"
"CD001155_pub3_data","Subgroup","Osteonecrosis of the jaw, Secondary"
"CD001155_pub3_data","Subgroup","Hip Fractures, Primary"
"CD001155_pub3_data","Subgroup","Vertebral Fractures- clinical, Primary"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs HRT"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Zolendronic acid 5 mg/year, IV"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + HRT) vs HRT"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  Denosumab 60 mg/6 months, SC"
"CD001155_pub3_data","Subgroup","(Alendronate 70 mg/week + Teriparatide 20 μg/day, SC) vs Teriparatide 20 μg/day, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Romosozumab 210 mg/month, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Raloxifene 60 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs (Alendronate 10 mg/day + HRT)"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs HRT"
"CD001155_pub3_data","Subgroup","(Alendronate 70 mg+ Vitamin D3 5600 IU)/week vs Calcitriol 0.25 μg/day"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + HRT) vs Placebo"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + HRT) vs (Alendronate 5 mg/day + HRT)"
"CD001155_pub3_data","Subgroup","(Alendronate 5 mg/day + HRT) vs HRT"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Denosumab 60 mg/6 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  Risedronate 35 mg/week"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Isosorbide mononitrate 20 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  Ibandronate  150 mg/month"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Teriparatide 20 μg/day, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs (Alendronate 70 mg/week + Vitamin K1 10 mg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs cyclic Etidronate 400 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs intermittent cyclic Clodronate"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Strontium ranelate 2 g/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/weekly vs Ibandronate 2 mg/3 months"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + HRT) vs Raloxifene 60 mg/day"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + Raloxifene 60 mg/day) vs HRT"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + Raloxifene 60 mg/day) vs Raloxifene 60 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs  (Alendronate 10 mg/day + Raloxefene 60 mg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs cyclic Etidronate 400 mg /day"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs cyclic Etidronate 200 mg /day"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + HRT) vs (Alendronate 10 mg/day + Raloxefene 60 mg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  Ibandronate 150 mg/month"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  Zolendronic acid 5 mg/year, IV"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs (Alendronate 5 mg/day + Alfacalcidol 1  μg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs  (Alendronate 10 mg/day + HRT)"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  Isosorbide mononitrate 20 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs  Raloxifene 60 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs  HRT"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  Romosozumab 210 mg/month, SC"
"CD001155_pub3_data","Subgroup","Alendronate 35 mg/week vs Denosumab 60 mg/6 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs Teriparatide 40  μg/day, SC "
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs [Alendronate 70 mg/week +  PTH(1-34) 25 μg/day, SC]"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs [Alendronate 70 mg/week +  cyclic PTH(1-34) 25 μg/day, SC]"
"CD001155_pub3_data","Subgroup","[Alendronate 70 mg/week +  PTH(1-34) 25 μg/day, SC] vs [Alendronate 70 mg/week + cyclic PTH(1-34) 25 μg/day, SC]"
"CD001155_pub3_data","Subgroup","(Alendronate 70 mg + Vitamin D3 5600 IU)/week vs Calcitriol 0.25 μg/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Ibandronate 2 mg/3 months, IV"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Denosumab 6 mg/3 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Denosumab 14 mg/3 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Denosumab  30 mg/3 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Denosumab  14 mg/6 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Denosumab  100 mg/6 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Denosumab  60 mg/6 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Denosumab  210 mg/6 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs  MK-677 25 mg/day"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day +MK-677 25 mg/day) vs Placebo"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs Minodronate 1 mg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs  intermittent cyclic Clodronate"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs  (Alendronate 10 mg/day + MK-677 25 mg/day"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day +MK-677 25 mg/day) vs MK-677 25 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/weekly vs Ibandronate 2 mg/3 months, IV"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + HRT) vs (Alendronate 10 mg/day + Raloxifene 60 mg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs  (Alendronate 10 mg/day + Raloxifene 60 mg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  Strontium Ranelate 2 g/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs Calcitonin 100 IU/day, IN"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs Alfacalcidol 1 µg/day"
"CD001155_pub3_data","Subgroup","Alendronate 35 mg/week vs Denosumab 60 mg/6 months"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  Risedronate 5 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs  (Alendronate 10 mg/day + Raloxifen 60 mg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  [Alendronate 70 mg/week + Cyclic PTH(1-34)  25 μg/day , SC]"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  [Alendronate 70 mg/week + PTH(1-34)  25 μg/day, SC]"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs Raloxifene 60 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs  Intermittent cyclic Clodronate "
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs  Alfacalcidol 1 μg/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs  (Alendronate 10 mg/day + MK-677 25 mg/day)"
"CD001155_pub3_data","Subgroup","[Alendronate 70 mg/week + PTH(1-34)  25 μg/day , SC] vs  [Alendronate 70 mg/week + Cyclic PTH(1-34)  25 μg/day , SC]"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs Minodronate 1 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs cyclic Etidronate 200 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Ibandronate 150 mg/month"
"CD001155_pub3_data","Subgroup","(Alendronate 70 mg/2 weeks + Alfacalcidol 0.5 μg/day) vs Alfacalcidol 0.5 μg/day"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + Raloxifene 60 mg/day) vs Placebo"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/weekly vs Risedronate 35 mg/week"
"CD001155_pub3_data","Subgroup","Alendronate 70mg/week vs Teriparatide 20 µg/day, SC"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs Raloxifene 60 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs (Alendronate 10 mg/day + Raloxifene 60 mg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 35 mg/week vs Minodronate 50 mg/month"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Romosozumab 140 mg/3 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Romosozumab 210 mg/3 months, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Romosozumab 70 mg/month, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Romosozumab 140 mg/month, SC"
"CD001155_pub3_data","Subgroup","Alendronate 70mg/week vs Romosozumab 210 mg/month, SC"
"CD001155_pub3_data","Subgroup","(Alendronate 70 mg/week + Vitamin D3 2800 IU/day) vs Vitamin D3 2800 IU/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Strontium Ranelate 2 g/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs ONO-5334 300 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs Calcitonin 200 IU/day, IN"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs cyclic Etidronate 400 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs (Alendronate 70 mg/week + cyclic PTH(1-34) 25 μg/day, SC)"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs Calcitriol 0.5 μg/day"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs (Alendronate 5 mg/day + Alfacalcidol 1 μg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs ONO-5334 100 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs (Alendronate 10 mg/day + Calcitriol 0.5 μg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/weekly vs Ibandronate 3 mg/3 months, IV"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + Calcitriol 0.5 μg/day) vs Calcitriol 0.5 μg/day"
"CD001155_pub3_data","Subgroup","(Alendronate 10 mg/day + Calcitriol 0.5 μg/day) vs Placebo"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Silymarin 420 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs MK-5442 10 mg/day "
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs MK-5442 7.5 mg/day "
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Teriparatide 20  μg/day, SC "
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs MK-5442 5 mg/day "
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Qiang Gu Yin 20 g/day "
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs Minodronate 1 mg/day "
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs cyclic Etidronate 200 mg/day "
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs (Alendronate 35 mg/week  + Silymarin 420 mg/day)"
"CD001155_pub3_data","Subgroup","(Alendronate 35 mg/week + Silymarin 420 mg/day) vs Silymarin 420 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs MK-5442 15 mg/day "
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs cyclic Etidronate 400 mg/day "
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  (Alendronate 70 mg/week + PTH(1-34) 25 μg/day, SC)"
"CD001155_pub3_data","Subgroup","Alendronate 70mg/week vs Denosumab 60 mg/6 months, SC"
"CD001155_pub3_data","Subgroup","(Alendronate 70 mg/day + Vitamin D3 2800 IU/day) vs Vitamin D3 2800 IU/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs ONO-5334 100 mg /day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs ONO-5334 300 mg /day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/weekly vs Ibandronate 150 mg/month"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs (Alendronate 70 mg/week + Cyclic PTH(1-34) 25 μg/day, SC)"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day vs Alfacalcidol 1 μg/day"
"CD001155_pub3_data","Subgroup","[Alendronate 70 mg/week +  PTH(1-34) 25 μg/day, SC] vs [Alendronate 70 mg/week + Cyclic PTH(1-34) 25 μg/day, SC]"
"CD001155_pub3_data","Subgroup","[Alendronate 70 mg/week + PTH(1-34) 25 μg/day, SC] vs [Alendronate 70 mg/week + Cyclic PTH(1-34) 25 μg/day, SC]"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs  (Alendronate 70 mg/week + Vitamin K1  10 mg/day)"
"CD001155_pub3_data","Subgroup","Alendronate 10 mg/day vs [Alendronate 10 mg/day + Raloxifene 60 mg/day]"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day + Calcitriol 0.5 μg/day  vs Placebo"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day + Calcitriol 0.5 μg/day  vs Raloxifene 60 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day + Calcitriol 0.5 μg/day  vs Alendronate 5 mg/day + Calcitriol 0.5 μg/day + Raloxifene 60 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day + Calcitriol 0.5 μg/day +  Raloxifene 60 mg/day vs Placebo"
"CD001155_pub3_data","Subgroup","Alendronate 5 mg/day + Calcitriol 0.5 μg/day +  Raloxifene 60 mg/day  vs Raloxifene 60 mg/day"
"CD001155_pub3_data","Subgroup","Alendronate 70 mg/week vs Zoledronic acid 5 mg/year, IV"
"CD001155_pub3_data","Subgroup","Non-vertebral fractures"
"CD001155_pub3_data","Subgroup","Withdrawal due to adverse events"
"CD001155_pub3_data","Subgroup","Gastrointestinal adverse events"
"CD001155_pub3_data","Subgroup","Atypical femoral fracture"
"CD001155_pub3_data","Subgroup","Hip fractures"
"CD001155_pub3_data","Subgroup","Clinical vertebral fractures "
"CD001155_pub3_data","Subgroup","Radiographic vertebral fractures "
"CD001321_pub7_data","Analysis.group","1"
"CD001321_pub7_data","Analysis.group","2"
"CD001321_pub7_data","Analysis.group","3"
"CD001321_pub7_data","Analysis.group","4"
"CD001321_pub7_data","Analysis.group","5"
"CD001321_pub7_data","Analysis.group","6"
"CD001321_pub7_data","Analysis.group","7"
"CD001321_pub7_data","Analysis.group","8"
"CD001321_pub7_data","Analysis.group","9"
"CD001321_pub7_data","Analysis.group","10"
"CD001321_pub7_data","Analysis.group","11"
"CD001321_pub7_data","Analysis.name","Symptomatic UTI: culture-verified UTI"
"CD001321_pub7_data","Analysis.name","Clinical UTI: symptoms, no culture"
"CD001321_pub7_data","Analysis.name","Microbiological UTI: positive culture without known symptoms"
"CD001321_pub7_data","Analysis.name","Death"
"CD001321_pub7_data","Analysis.name","Gastrointestinal adverse events"
"CD001321_pub7_data","Analysis.name","Clinical UTI without culture verification"
"CD001321_pub7_data","Analysis.name","Symptomatic UTI: culture-verified UTI (low dose PAC < 40 mg/day)"
"CD001321_pub7_data","Analysis.name","Symptomatic UTI: culture-verified UTI (moderate dose PAC 40 to 80 mg/day)"
"CD001321_pub7_data","Analysis.name","Symptomatic UTI: culture-verified UTI (high dose PAC > 80 mg/day)"
"CD001321_pub7_data","Analysis.name","Symptomatic UTI: culture-verified UTI (commercial involvement)"
"CD001321_pub7_data","Analysis.name","Symptomatic UTI: culture-verified UTI (no commercial involvement)"
"CD001321_pub7_data","Analysis.name","Symptomatic UTI: culture-verified UTI (⪰ 108 CFU/L)"
"CD001321_pub7_data","Analysis.name","Symptomatic UTI: culture-verified UTI (< 108 CFU/L)"
"CD001321_pub7_data","Subgroup","Women with recurrent UTIs"
"CD001321_pub7_data","Subgroup","Elderly men and women in institutions"
"CD001321_pub7_data","Subgroup","Pregnant women"
"CD001321_pub7_data","Subgroup","Children"
"CD001321_pub7_data","Subgroup","People with a susceptibility to UTIs due to an intervention"
"CD001321_pub7_data","Subgroup","Adults with neuromuscular dysfunction of the bladder with incomplete bladder emptying"
"CD001321_pub7_data","Subgroup","Women with recurrent UTI"
"CD001321_pub7_data","Subgroup","People with a susceptibility to UTI due to interventions"
"CD001321_pub7_data","Subgroup","Elderly men and women"
"CD001321_pub7_data","Subgroup","Adults with bladder emptying issues or multiple sclerosis"
"CD001321_pub7_data","Subgroup","Elderly"
"CD001321_pub7_data","Subgroup","Adults (men and women) prone to UTI"
"CD001321_pub7_data","Subgroup","Adults with neuropathy or neuropathic bladders"
"CD001321_pub7_data","Subgroup","Adults with neuropathy"
"CD001321_pub7_data","Subgroup","People with a susceptibility to UTI due to an intervention"
"CD001396_pub4_data","Analysis.group","1"
"CD001396_pub4_data","Analysis.group","2"
"CD001396_pub4_data","Analysis.group","3"
"CD001396_pub4_data","Analysis.group","4"
"CD001396_pub4_data","Analysis.name","Self-rated overall premenstrual symptoms"
"CD001396_pub4_data","Analysis.name","Nausea"
"CD001396_pub4_data","Analysis.name","Insomnia or sleep disturbance"
"CD001396_pub4_data","Analysis.name","Sexual dysfunction or decreased libido"
"CD001396_pub4_data","Analysis.name","Fatigue or sedation"
"CD001396_pub4_data","Analysis.name","Dizziness or vertigo"
"CD001396_pub4_data","Analysis.name","Tremor"
"CD001396_pub4_data","Analysis.name","Somnolence/decreased concentration"
"CD001396_pub4_data","Analysis.name","Sweating"
"CD001396_pub4_data","Analysis.name","Dry mouth"
"CD001396_pub4_data","Analysis.name","Asthenia/decreased energy"
"CD001396_pub4_data","Analysis.name","Diarrhoea"
"CD001396_pub4_data","Analysis.name","Constipation"
"CD001396_pub4_data","Analysis.name","Withdrawal due to adverse effects"
"CD001396_pub4_data","Analysis.name","Psychological symptoms"
"CD001396_pub4_data","Analysis.name","Physical symptoms"
"CD001396_pub4_data","Analysis.name","Functional symptoms"
"CD001396_pub4_data","Analysis.name","Irritability"
"CD001396_pub4_data","Analysis.name","Response rates"
"CD001396_pub4_data","Analysis.name","Withdrawal for any reason"
"CD001396_pub4_data","Analysis.name","Self-rated overall premenstrual symptoms, SSRI type"
"CD001396_pub4_data","Analysis.name","Response rate"
"CD001396_pub4_data","Subgroup","Continuous administration"
"CD001396_pub4_data","Subgroup","Luteal administration"
"CD001396_pub4_data","Subgroup","PMS"
"CD001396_pub4_data","Subgroup","PMDD"
"CD001396_pub4_data","Subgroup","Escitalopram"
"CD001396_pub4_data","Subgroup","Fluoxetine"
"CD001396_pub4_data","Subgroup","Paroxetine"
"CD001396_pub4_data","Subgroup","Sertraline"
"CD001431_pub6_data","Analysis.group","1"
"CD001431_pub6_data","Analysis.group","2"
"CD001431_pub6_data","Analysis.group","3"
"CD001431_pub6_data","Analysis.group","4"
"CD001431_pub6_data","Analysis.group","5"
"CD001431_pub6_data","Analysis.group","6"
"CD001431_pub6_data","Analysis.group","7"
"CD001431_pub6_data","Analysis.group","8"
"CD001431_pub6_data","Analysis.group","9"
"CD001431_pub6_data","Analysis.group","10"
"CD001431_pub6_data","Analysis.group","11"
"CD001431_pub6_data","Analysis.group","12"
"CD001431_pub6_data","Analysis.group","13"
"CD001431_pub6_data","Analysis.name","Informed values-choice congruence - all studies"
"CD001431_pub6_data","Analysis.name","Informed values-choice congruence - without studies of high risk of bias"
"CD001431_pub6_data","Analysis.name","Informed values-choice congruence - old vs new studies"
"CD001431_pub6_data","Analysis.name","Informed values-chose congruence - using MMIC"
"CD001431_pub6_data","Analysis.name","Informed values-chose congruence - using non-MMIC measures"
"CD001431_pub6_data","Analysis.name","Knowledge - all studies"
"CD001431_pub6_data","Analysis.name","Knowledge - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Knowledge - old vs new studies"
"CD001431_pub6_data","Analysis.name","Accurate risk perceptions - all studies"
"CD001431_pub6_data","Analysis.name","Accurate risk perceptions - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Accurate risk perceptions - old vs new studies"
"CD001431_pub6_data","Analysis.name","Decisional conflict - uninformed - all studies"
"CD001431_pub6_data","Analysis.name","Decisional conflict - uninformed - without studies having high risk of bias"
"CD001431_pub6_data","Analysis.name","Decisional conflict - uninformed - old vs new studies"
"CD001431_pub6_data","Analysis.name","Decisional conflict - unclear values - all studies"
"CD001431_pub6_data","Analysis.name","Decisional conflict - unclear values - without studies having high risk of bias"
"CD001431_pub6_data","Analysis.name","Unclear values - old vs new studies"
"CD001431_pub6_data","Analysis.name","Participation in decision-making - all studies"
"CD001431_pub6_data","Analysis.name","Participation in decision-making - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Participation in decision-making - clinician-controlled - old vs new studies"
"CD001431_pub6_data","Analysis.name","Participation in decision-making - patient-controlled - old vs new studies"
"CD001431_pub6_data","Analysis.name","Participation in decision-making - shared decision-making - old vs new studies"
"CD001431_pub6_data","Analysis.name","Decision regret - all studies"
"CD001431_pub6_data","Analysis.name","Decision regret - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Decision regret - old vs new studies"
"CD001431_pub6_data","Analysis.name","Proportion undecided - all studies"
"CD001431_pub6_data","Analysis.name","Proportion undecided - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Proportion undecided - old vs new studies"
"CD001431_pub6_data","Analysis.name","Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9)"
"CD001431_pub6_data","Analysis.name","Discussed topic with provider"
"CD001431_pub6_data","Analysis.name","Patient-clinician communication - continuous measures (OPTION, CollaboRATE, SDM-Q-9) - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Discussed topic with provider - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Satisfaction with the decision-making process - all studies"
"CD001431_pub6_data","Analysis.name","Satisfaction with the decision-making process - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Satisfaction with the decision-making process - old vs new studies"
"CD001431_pub6_data","Analysis.name","Preparation for decision-making - all studies"
"CD001431_pub6_data","Analysis.name","Preparation for decision-making studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Preparation for decision-making - old vs new studies"
"CD001431_pub6_data","Analysis.name","Choice: surgery over conservative option (subgroup by condition)"
"CD001431_pub6_data","Analysis.name","Choice for screening"
"CD001431_pub6_data","Analysis.name","Choice: diabetes medication (uptake of new medication)"
"CD001431_pub6_data","Analysis.name","Choice: surgery over conservative option - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Choice for screening - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Choice: diabetes medication (uptake of new medication) - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Confidence - all studies"
"CD001431_pub6_data","Analysis.name","Confidence - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Confidence - old vs new studies"
"CD001431_pub6_data","Analysis.name","Consultation length - subgroup by timing of intervention (in consultation versus in preparation for consultation)"
"CD001431_pub6_data","Analysis.name","Consultation length - subgroup by timing of intervention - studies without high risk of bias"
"CD001431_pub6_data","Analysis.name","Consultation length - old vs new studies (in consultation)"
"CD001431_pub6_data","Analysis.name","Consultation length - old vs new studies (in preparation for consultation)"
"CD001431_pub6_data","Subgroup","Older studies (2014 and earlier)"
"CD001431_pub6_data","Subgroup","Newer studies (2015-2022)"
"CD001431_pub6_data","Subgroup","Older Studies (2014 and earlier)"
"CD001431_pub6_data","Subgroup","Clinician-controlled decision-making"
"CD001431_pub6_data","Subgroup","Shared decision-making"
"CD001431_pub6_data","Subgroup","Patient-controlled decision-making"
"CD001431_pub6_data","Subgroup","Collaborate"
"CD001431_pub6_data","Subgroup","SDM-Q-9"
"CD001431_pub6_data","Subgroup","OPTION-12"
"CD001431_pub6_data","Subgroup","OPTION-5"
"CD001431_pub6_data","Subgroup","Coronary revascularization"
"CD001431_pub6_data","Subgroup","Breast cancer - mastectomy vs lumpectomy"
"CD001431_pub6_data","Subgroup","Prostate cancer"
"CD001431_pub6_data","Subgroup","Left ventricular assist device (LVAD)"
"CD001431_pub6_data","Subgroup","Breast cancer - reconstruction"
"CD001431_pub6_data","Subgroup","Renal stone treatment"
"CD001431_pub6_data","Subgroup","Joint replacement"
"CD001431_pub6_data","Subgroup","Upper extremity conditions"
"CD001431_pub6_data","Subgroup","Bariatric surgery"
"CD001431_pub6_data","Subgroup","Benign prostatic hyperplasia"
"CD001431_pub6_data","Subgroup","Menorrhagia"
"CD001431_pub6_data","Subgroup","Abdominal aortic aneurysm"
"CD001431_pub6_data","Subgroup","Breast cancer - prophylactic mastectomy"
"CD001431_pub6_data","Subgroup","Breast cancer - surgery vs endocrine therapy"
"CD001431_pub6_data","Subgroup","PSA screening"
"CD001431_pub6_data","Subgroup","Colorectal cancer screening"
"CD001431_pub6_data","Subgroup","Breast cancer genetic testing"
"CD001431_pub6_data","Subgroup","Prenatal diagnostic testing"
"CD001431_pub6_data","Subgroup","Breast cancer screening (mammography)"
"CD001431_pub6_data","Subgroup","Study-specific questionnaire"
"CD001431_pub6_data","Subgroup","Decision Self-efficacy Scale"
"CD001431_pub6_data","Subgroup","Study-specific questionnaire - newer studies (2015-2022)"
"CD001431_pub6_data","Subgroup","Decision Self-efficacy Scale - older studies (2014 and earlier)"
"CD001431_pub6_data","Subgroup","Study-specific questionnaire - older studies (2014 and earlier)"
"CD001431_pub6_data","Subgroup","Decision Self-efficacy Scale - newer studies (2015-2022)"
"CD001431_pub6_data","Subgroup","In preparation for consultation"
"CD001431_pub6_data","Subgroup","In consultation"
"CD001431_pub6_data","Subgroup","Newer studies"
"CD001431_pub6_data","Subgroup","Older studies"
"CD001533_pub7_data","Analysis.group","1"
"CD001533_pub7_data","Analysis.group","2"
"CD001533_pub7_data","Analysis.group","3"
"CD001533_pub7_data","Analysis.group","4"
"CD001533_pub7_data","Analysis.group","5"
"CD001533_pub7_data","Analysis.group","6"
"CD001533_pub7_data","Analysis.group","7"
"CD001533_pub7_data","Analysis.group","8"
"CD001533_pub7_data","Analysis.group","9"
"CD001533_pub7_data","Analysis.group","10"
"CD001533_pub7_data","Analysis.group","11"
"CD001533_pub7_data","Analysis.group","12"
"CD001533_pub7_data","Analysis.group","13"
"CD001533_pub7_data","Analysis.group","14"
"CD001533_pub7_data","Analysis.group","15"
"CD001533_pub7_data","Analysis.group","16"
"CD001533_pub7_data","Analysis.name","Number with frequent relapses by 12 to 24 months"
"CD001533_pub7_data","Analysis.name","Number relapsing by 12 to 24 months"
"CD001533_pub7_data","Analysis.name","Number with frequent relapses by 12 to 24 months: stratified by risk of selection bias"
"CD001533_pub7_data","Analysis.name","Number relapsing by 12 to 24 months: stratified by risk of selection bias"
"CD001533_pub7_data","Analysis.name","Adverse events"
"CD001533_pub7_data","Analysis.name","Number with frequent relapses: stratified by risk of selection bias"
"CD001533_pub7_data","Analysis.name","Number relapsing by 6 to 12 months"
"CD001533_pub7_data","Analysis.name","Number with frequent relapses"
"CD001533_pub7_data","Analysis.name","Number with relapse"
"CD001533_pub7_data","Analysis.name","Relapse at 12 months"
"CD001533_pub7_data","Analysis.name","Number with FRNS"
"CD001533_pub7_data","Analysis.name","Time to remission [days]"
"CD001533_pub7_data","Analysis.name","Number with relapse with infection"
"CD001533_pub7_data","Analysis.name","Number of relapses/patient"
"CD001533_pub7_data","Analysis.name","Number of relapses/patient at 2 years"
"CD001533_pub7_data","Analysis.name","Number with remission"
"CD001533_pub7_data","Analysis.name","Number with relapse by 9 to 12 months"
"CD001533_pub7_data","Analysis.name","Number relapsing during therapy"
"CD001533_pub7_data","Analysis.name","Number with relapses by 9 to 12 months"
"CD001533_pub7_data","Analysis.name","Mean relapse rate/patient/year"
"CD001533_pub7_data","Analysis.name","Relapse by 6 months"
"CD001533_pub7_data","Analysis.name","Mean relapse rate"
"CD001533_pub7_data","Analysis.name","Number of days to remission"
"CD001533_pub7_data","Analysis.name","Number of days to remission according to age group"
"CD001533_pub7_data","Analysis.name","Serious adverse events"
"CD001533_pub7_data","Analysis.name","Cumulative steroid dose [mg/kg]"
"CD001533_pub7_data","Analysis.name","Number with HPA suppression"
"CD001533_pub7_data","Analysis.name","Time to remission"
"CD001533_pub7_data","Analysis.name","Number with FRNS or SDNS at 12 months"
"CD001533_pub7_data","Analysis.name","Cumulative prednisone dose to achieve remission [mg/kg]"
"CD001533_pub7_data","Analysis.name","Number of relapses in 12 months [number/year]"
"CD001533_pub7_data","Analysis.name","Number with relapse during treatment"
"CD001533_pub7_data","Analysis.name","Number with relapse by 6 months"
"CD001533_pub7_data","Analysis.name","Relapse at 6 months"
"CD001533_pub7_data","Analysis.name","Prednisone dose"
"CD001533_pub7_data","Analysis.name","Number with relapses"
"CD001533_pub7_data","Analysis.name","Relapse rate/patient/year"
"CD001533_pub7_data","Analysis.name","Number with FRNS or SDNS"
"CD001533_pub7_data","Analysis.name","Cumulative steroid dose"
"CD001533_pub7_data","Subgroup","Low risk of selection bias"
"CD001533_pub7_data","Subgroup","Unclear or high risk of selection bias"
"CD001533_pub7_data","Subgroup","Psychological disorders"
"CD001533_pub7_data","Subgroup","Hypertension"
"CD001533_pub7_data","Subgroup","Cataracts/eye disorders"
"CD001533_pub7_data","Subgroup","Retarded growth"
"CD001533_pub7_data","Subgroup","Cushingoid facies"
"CD001533_pub7_data","Subgroup","Infections"
"CD001533_pub7_data","Subgroup","Osteoporosis"
"CD001533_pub7_data","Subgroup","High or unclear risk of selection bias"
"CD001533_pub7_data","Subgroup","Eye complications"
"CD001533_pub7_data","Subgroup","Cushingoid appearance"
"CD001533_pub7_data","Subgroup","Addisonian crisis"
"CD001533_pub7_data","Subgroup","Growth"
"CD001533_pub7_data","Subgroup","Gastrointestinal bleeding"
"CD001533_pub7_data","Subgroup","Cushing's Syndrome"
"CD001533_pub7_data","Subgroup","Subgroup analysis: children receiving alternate-day prednisone"
"CD001533_pub7_data","Subgroup","Subgroup analysis: children receiving other immunosuppression without alternate-day prednisone"
"CD001533_pub7_data","Subgroup","Subgroup analysis: children receiving alternate-day prednisone and other immunosuppression"
"CD001533_pub7_data","Subgroup","All children"
"CD001533_pub7_data","Subgroup","Subgroup analysis: children not on alternate-day prednisone"
"CD001533_pub7_data","Subgroup","Total relapses (episodes/patient/year)"
"CD001533_pub7_data","Subgroup","Number of infection-related relapses/patient-years"
"CD001533_pub7_data","Subgroup","Daily versus intermittent therapy (2 months therapy)"
"CD001533_pub7_data","Subgroup","Alternate-day versus intermittent therapy (6 months therapy)"
"CD001533_pub7_data","Subgroup","Alternate-day therapy versus intermittent dose therapy (6 months therapy)"
"CD001533_pub7_data","Subgroup","Children aged 1 to 5 years"
"CD001533_pub7_data","Subgroup","Children aged 10 to 14 years"
"CD001533_pub7_data","Subgroup","Children aged 5 to 10 years"
"CD001533_pub7_data","Subgroup","Reduced growth in height"
"CD001533_pub7_data","Subgroup","Steroid adverse events"
"CD001533_pub7_data","Subgroup","Cataracts"
"CD001533_pub7_data","Subgroup","Bacterial infection"
"CD001533_pub7_data","Subgroup","Urticaria"
"CD001533_pub7_data","Subgroup","Viral infection"
"CD001533_pub7_data","Subgroup","Cushingoid features"
"CD001533_pub7_data","Subgroup","Serious infections"
"CD001533_pub7_data","Subgroup","Eye changes"
"CD001533_pub7_data","Subgroup","Induction dose"
"CD001533_pub7_data","Subgroup","Cumulative dose over 6 months"
"CD001533_pub7_data","Subgroup","Relapse by 6 months"
"CD001533_pub7_data","Subgroup","Relapse by 12 months"
"CD001533_pub7_data","Subgroup","Relapse by 2 years"
"CD001533_pub7_data","Subgroup","Relapse by 3 years"
"CD001533_pub7_data","Subgroup","Relapse rate at 1 year"
"CD001533_pub7_data","Subgroup","Relapse rate at 2 years"
"CD001533_pub7_data","Subgroup","Relapse rate at 3 years"
"CD001533_pub7_data","Subgroup","After 1 year"
"CD001533_pub7_data","Subgroup","After 2 years"
"CD001533_pub7_data","Subgroup","After 3 years"
"CD001533_pub7_data","Subgroup","Growth failure"
"CD001552_pub3_data","Analysis.group","1"
"CD001552_pub3_data","Analysis.group","2"
"CD001552_pub3_data","Analysis.group","3"
"CD001552_pub3_data","Analysis.group","4"
"CD001552_pub3_data","Analysis.group","5"
"CD001552_pub3_data","Analysis.group","6"
"CD001552_pub3_data","Analysis.group","7"
"CD001552_pub3_data","Analysis.group","8"
"CD001552_pub3_data","Analysis.name","Clinical improvement at short-term follow-up: 3 months or less"
"CD001552_pub3_data","Analysis.name","Clinical improvement at long-term follow-up: over 3 months"
"CD001552_pub3_data","Analysis.name","Symptoms at short-term follow-up: 3 months or less"
"CD001552_pub3_data","Analysis.name","Symptoms at long-term follow-up: over 3 months"
"CD001552_pub3_data","Analysis.name","Function at short-term follow-up: 3 months or less"
"CD001552_pub3_data","Analysis.name","Function at long-term follow-up: over 3 months"
"CD001552_pub3_data","Analysis.name","Health-related quality of life at long-term follow-up: over 3 months"
"CD001552_pub3_data","Analysis.name","Adverse effects"
"CD001552_pub3_data","Analysis.name","Need for surgery or secondary surgery at short-term follow-up: 3 months or less"
"CD001552_pub3_data","Analysis.name","Need for surgery or secondary surgery at long-term follow-up: over 3 months"
"CD001552_pub3_data","Analysis.name","Pain at short-term follow-up: 3 months or less"
"CD001552_pub3_data","Analysis.name","Pain at long-term follow-up: over 3 months"
"CD001552_pub3_data","Analysis.name","Health-related quality of life at short-term follow-up: 3 months or less"
"CD001552_pub3_data","Subgroup","All criteria"
"CD001552_pub3_data","Subgroup","Mental component summary"
"CD001552_pub3_data","Subgroup","Physical component summary"
"CD001703_pub4_data","Analysis.group","1"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: pain intensity (0 to 100) at immediate-term follow-up (≤ 4 weeks)"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: pain intensity (0 to 100) at short-term follow-up (> 4 to 16 weeks)"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: pain intensity (0 to 100) at mid-term follow-up (> 16 to 52 weeks)"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: disability (RMDQ, 0 to 24) at short-term follow-up (> 4 to 16 weeks): SNRI"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: disability (ODI, 0 to 100) at short-term follow-up (> 4 to 16 weeks): SSRI"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: disability (RMDQ, 0 to 24) at short-term follow-up (> 4 to 16 weeks): TCA"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: disability (RMDQ, 0 to 24) at mid-term follow-up (> 16 to 52 weeks): TCA"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: depressive symptoms (BDI, 0 to 63) at short-term follow-up (> 4 to 16 weeks): SNRI"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: depressive symptoms (MADRS, 0 to 60) at short-term follow-up (> 4 to 16 weeks): SSRI"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: depressive symptoms (BDI, 0 to 63) at short-term follow-up (> 4 to 16 weeks): TCA"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: depressive symptoms (BDI, 0 to 63) at mid-term follow-up (> 16 to 52 weeks): TCA"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: depressive symptoms (BDI, 0 to 63) at short-term follow-up (> 4 to 16 weeks): other antidepressants"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: HRQoL (EQ-5D, 0 to 1) at short-term follow-up (> 4 to 16 weeks): SNRI"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: HRQoL (SMD) at short-term follow-up (> 4 to 16 weeks): TCA"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain: HRQoL (EQ-5D, 0 to 100 VAS) at mid-term follow-up (> 16 to 52 weeks): TCA"
"CD001703_pub4_data","Analysis.name","Spine-related leg pain: pain intensity (0 to 100) at immediate-term follow-up (≤ 4 weeks)"
"CD001703_pub4_data","Analysis.name","Spine-related leg pain: pain intensity (0 to 100) at short-term follow-up (> 4 to 16 weeks)"
"CD001703_pub4_data","Analysis.name","Spine-related leg pain: pain intensity (0 to 100) at mid-term follow-up (> 16 to 52 weeks)"
"CD001703_pub4_data","Analysis.name","Spine-related leg pain: disability (SMD) at immediate-term follow-up (≤ 4 weeks)"
"CD001703_pub4_data","Analysis.name","Spine-related leg pain: disability (ODI, 0 to 100) at short-term follow-up (> 4 to 16 weeks)"
"CD001703_pub4_data","Analysis.name","Spine-related leg pain: disability (ODI, 0 to 100) at mid-term follow-up (> 16 to 52 weeks)"
"CD001703_pub4_data","Analysis.name","Spine-related leg pain: depressive symptoms (HADS-D, 0 to 21) at immediate-term follow-up (≤ 4 weeks)"
"CD001703_pub4_data","Analysis.name","Spine-related leg pain: depressive symptoms (BDI, 0 to 63) at short-term follow-up (> 4 to 16 weeks)"
"CD001703_pub4_data","Analysis.name","Spine-related leg pain: HRQoL (SF-36, 0 to 100) at short-term follow-up (> 4 to 16 weeks)"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain and spine-related leg pain: total adverse events"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain and spine-related leg pain: serious adverse events"
"CD001703_pub4_data","Analysis.name","Non-specific low back pain and spine-related leg pain: withdrawals due to adverse events"
"CD001703_pub4_data","Subgroup","TCA"
"CD001703_pub4_data","Subgroup","SNRI"
"CD001703_pub4_data","Subgroup","SSRI"
"CD001703_pub4_data","Subgroup","Other antidepressants"
"CD001703_pub4_data","Subgroup","TeCA"
"CD001797_pub4_data","Analysis.group","1"
"CD001797_pub4_data","Analysis.group","2"
"CD001797_pub4_data","Analysis.group","3"
"CD001797_pub4_data","Analysis.group","4"
"CD001797_pub4_data","Analysis.name","Significant improvement in disability within 6 weeks"
"CD001797_pub4_data","Analysis.name","Significant improvement in disability within 6 weeks; generic inverse variance approach"
"CD001797_pub4_data","Analysis.name","Improvement ≥ 1 point on Rankin scale"
"CD001797_pub4_data","Analysis.name","Change in mean disability score within 6 weeks"
"CD001797_pub4_data","Analysis.name","Change in mean disability score within 6 weeks; generic inverse variance approach"
"CD001797_pub4_data","Analysis.name","Change in mean disability score on Rankin scale within 6 weeks"
"CD001797_pub4_data","Analysis.name","Change in muscle strength (mean Medical Research Council sum score) within 6 weeks"
"CD001797_pub4_data","Analysis.name","Change in mean disability score at 24 weeks or later"
"CD001797_pub4_data","Analysis.name","Frequency of serious side effects"
"CD001797_pub4_data","Analysis.name","Frequency of any side effects"
"CD001797_pub4_data","Analysis.name","Improvement of ≥ 1 point on Rankin scale"
"CD001797_pub4_data","Analysis.name","Change in muscle strength (Medical Research Council sum score) within 6 weeks"
"CD001797_pub4_data","Subgroup","Parallel design"
"CD001797_pub4_data","Subgroup","Cross-over design"
"CD001797_pub4_data","Subgroup","Parallel"
"CD001837_pub4_data","Analysis.group","1"
"CD001837_pub4_data","Analysis.group","2"
"CD001837_pub4_data","Analysis.group","3"
"CD001837_pub4_data","Analysis.group","4"
"CD001837_pub4_data","Analysis.group","5"
"CD001837_pub4_data","Analysis.group","6"
"CD001837_pub4_data","Analysis.name","Quit at longest follow-up (6 + months)"
"CD001837_pub4_data","Analysis.name","Behavioural support"
"CD001837_pub4_data","Analysis.name","Combined (pharmacotherapy + behavioural) support versus no support post-discharge"
"CD001837_pub4_data","Analysis.name","Quitline referral vs control"
"CD001837_pub4_data","Analysis.name","Health system telephone counselling vs quitline"
"CD001837_pub4_data","Analysis.name","Asynchronous behavioural support"
"CD001837_pub4_data","Analysis.name","Bupropion vs placebo or no bupropion"
"CD001837_pub4_data","Analysis.name","Varenicline vs placebo or no varenicline"
"CD001837_pub4_data","Analysis.name","Combined (pharmacotherapy + behavioural) support vs neither"
"CD001837_pub4_data","Analysis.name","Patients with cardiovascular disease"
"CD001837_pub4_data","Analysis.name","Patients with respiratory disease"
"CD001837_pub4_data","Analysis.name","Patients with stroke"
"CD001837_pub4_data","Subgroup","Intensity 1 vs 0"
"CD001837_pub4_data","Subgroup","Intensity 2 vs 0"
"CD001837_pub4_data","Subgroup","Intensity 3 vs 0"
"CD001837_pub4_data","Subgroup","Intensity 4 vs 0"
"CD001837_pub4_data","Subgroup","NRT vs placebo or no NRT"
"CD001837_pub4_data","Subgroup","Varenicline vs placebo or no varenicline"
"CD001837_pub4_data","Subgroup","Bupropion vs placebo or no bupropion"
"CD001837_pub4_data","Subgroup","Asynchronous"
"CD001837_pub4_data","Subgroup","Synchronous"
"CD001837_pub4_data","Subgroup","Interested in quitting"
"CD001837_pub4_data","Subgroup","Not selected for interest in quitting"
"CD001837_pub4_data","Subgroup","Post-discharge intervention"
"CD001837_pub4_data","Subgroup","Varenicline vs no placebo or no varenicline"
"CD001837_pub4_data","Subgroup","Intensity 4 vs intensity 0"
"CD001837_pub4_data","Subgroup","Nicotine replacement therapy vs no placebo or no NRT"
"CD001837_pub4_data","Subgroup","Bupropion vs no placebo or no bupropion"
"CD001837_pub4_data","Subgroup","Intensity 2 vs intensity 0"
"CD001837_pub4_data","Subgroup","Intensity 1 vs intensity 0"
"CD001837_pub4_data","Subgroup","Intensity 3 vs intensity 0"
"CD001837_pub4_data","Subgroup","Counselling"
"CD001837_pub4_data","Subgroup","Nicotine replacement therapy"
"CD001837_pub4_data","Subgroup","Post-discharge pharmacotherapy + behavioural intervention"
"CD001837_pub4_data","Subgroup","Post-discharge behavioural intervention"
"CD001909_pub4_data","Analysis.group","1"
"CD001909_pub4_data","Analysis.group","2"
"CD001909_pub4_data","Analysis.group","3"
"CD001909_pub4_data","Analysis.name","≥ 50% reduction in seizure frequency (intention-to-treat analysis)"
"CD001909_pub4_data","Analysis.name","≥ 50% reduction in seizure frequency (worst-case analysis)"
"CD001909_pub4_data","Analysis.name","≥ 50% reduction in seizure frequency (best-case analysis)"
"CD001909_pub4_data","Analysis.name","Treatment withdrawal"
"CD001909_pub4_data","Analysis.name","Ataxia"
"CD001909_pub4_data","Analysis.name","Dizziness"
"CD001909_pub4_data","Analysis.name","Fatigue"
"CD001909_pub4_data","Analysis.name","Nausea"
"CD001909_pub4_data","Analysis.name","Somnolence"
"CD001909_pub4_data","Analysis.name","Diplopia"
"CD001909_pub4_data","Analysis.name","Headache"
"CD001909_pub4_data","Subgroup","Cross-over studies"
"CD001909_pub4_data","Subgroup","Parallel-group studies (lamotrigine 300 mg)"
"CD001909_pub4_data","Subgroup","Parallel-group studies (adults; lamotrigine extended-release)"
"CD001909_pub4_data","Subgroup","Parallel-group studies (lamotrigine 300 mg to 600 mg)"
"CD001909_pub4_data","Subgroup","Any dose of lamotrigine, adults or children"
"CD001909_pub4_data","Subgroup","Parallel-group studies (lamotrigine 500 mg)"
"CD001909_pub4_data","Subgroup","Parallel-group studies (children)"
"CD001909_pub4_data","Subgroup","Parallel-group studies (adults)"
"CD001909_pub4_data","Subgroup","Parallel-group studies (infants)"
"CD001920_pub4_data","Analysis.group","1"
"CD001920_pub4_data","Analysis.group","2"
"CD001920_pub4_data","Analysis.group","3"
"CD001920_pub4_data","Analysis.group","4"
"CD001920_pub4_data","Analysis.group","5"
"CD001920_pub4_data","Analysis.group","6"
"CD001920_pub4_data","Analysis.group","7"
"CD001920_pub4_data","Analysis.group","8"
"CD001920_pub4_data","Analysis.group","9"
"CD001920_pub4_data","Analysis.group","10"
"CD001920_pub4_data","Analysis.group","11"
"CD001920_pub4_data","Analysis.group","12"
"CD001920_pub4_data","Analysis.name","Independence in ADL scales"
"CD001920_pub4_data","Analysis.name","Motor function scales"
"CD001920_pub4_data","Analysis.name","Balance (Berg Balance Scale)"
"CD001920_pub4_data","Analysis.name","Gait velocity"
"CD001920_pub4_data","Analysis.name","Length of stay"
"CD001920_pub4_data","Analysis.name","Adverse events"
"CD001920_pub4_data","Analysis.name","Adverse eventsa"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other: Independence in ADL scales"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other: Motor function scales"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other: Balance (Berg Balance Scale)"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other: Gait velocity"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other: Length of hospital stay"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other approaches: Adverse events"
"CD001920_pub4_data","Analysis.name","Neurophysiological approaches compared to other: Independence in ADL scales"
"CD001920_pub4_data","Analysis.name","Neurophysiological approaches compared to other: Motor function scales"
"CD001920_pub4_data","Analysis.name","Neurophysiological approaches compared to other: Balance (Berg Balance Scale)"
"CD001920_pub4_data","Analysis.name","Neurophysiological approaches compared to other approaches: Gait velocity"
"CD001920_pub4_data","Analysis.name","Neurophysiological approach compared to other: Adverse events"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other approaches: Independence in ADL scales"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other approaches: Motor function scales"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other approaches: Balance (Berg Balance Scale)"
"CD001920_pub4_data","Analysis.name","Functional task training compared to other approaches: Gait velocity"
"CD001920_pub4_data","Analysis.name","Neurophysiological approaches compared to other approaches: Independence in ADL scales"
"CD001920_pub4_data","Analysis.name","Neurophysiological approaches compared to other approaches: Motor function scales"
"CD001920_pub4_data","Analysis.name","Neurophysiological approaches compared to other approaches: Balance (Berg Balance Scale)"
"CD001920_pub4_data","Analysis.name","Length of time post stroke"
"CD001920_pub4_data","Analysis.name","Geographical location - continent of study conduct"
"CD001920_pub4_data","Analysis.name","Amount of treatment (less or more than 2.5 hours/week)"
"CD001920_pub4_data","Analysis.name","Duration of intervention"
"CD001920_pub4_data","Analysis.name","Focus of treatment components"
"CD001920_pub4_data","Analysis.name","Named approaches"
"CD001920_pub4_data","Analysis.name","Provider of intervention"
"CD001920_pub4_data","Analysis.name","Amount of additional treatment (less or more than 2.5 hours/week)"
"CD001920_pub4_data","Subgroup","Barthel Index"
"CD001920_pub4_data","Subgroup","Other ADL measure"
"CD001920_pub4_data","Subgroup","Other motor function measure"
"CD001920_pub4_data","Subgroup","Fugl Meyer"
"CD001920_pub4_data","Subgroup","Timed walk (time to walk set distance)"
"CD001920_pub4_data","Subgroup","Gait speed (distance/time)"
"CD001920_pub4_data","Subgroup","Timed up and go test"
"CD001920_pub4_data","Subgroup","Other measure relating to gait speed"
"CD001920_pub4_data","Subgroup","Functional task training compared to 'less' functional task training"
"CD001920_pub4_data","Subgroup","Functional task training compared to Neurophysiological"
"CD001920_pub4_data","Subgroup","Functional task training compared to neurophysiological"
"CD001920_pub4_data","Subgroup","Functional Task Training compared to Neurophysiological"
"CD001920_pub4_data","Subgroup","Functional task training vs less functional task training"
"CD001920_pub4_data","Subgroup","Neurophysiological compared to no (or minimal) neurophysiological"
"CD001920_pub4_data","Subgroup","Neurophysiological compared to Functional Task Training"
"CD001920_pub4_data","Subgroup","Neurophysiological (Bobath) compared to Neurophysiological (other)"
"CD001920_pub4_data","Subgroup","Neurophysiological (Bobath) compared to neurophysiological (other)"
"CD001920_pub4_data","Subgroup","Neurophysiological compared to functional task training"
"CD001920_pub4_data","Subgroup","Neurophysiological compared to functional task training "
"CD001920_pub4_data","Subgroup","Early (2 weeks or less post-stroke)"
"CD001920_pub4_data","Subgroup","Later (more than 2 weeks post-stroke)"
"CD001920_pub4_data","Subgroup","Asia"
"CD001920_pub4_data","Subgroup","All other continents"
"CD001920_pub4_data","Subgroup","More than 2.5 hours/week"
"CD001920_pub4_data","Subgroup","Less than 2.5 hours/week"
"CD001920_pub4_data","Subgroup","Short (≤ 2 months)"
"CD001920_pub4_data","Subgroup","Longer (> 2 months)"
"CD001920_pub4_data","Subgroup","Mixed treatment components"
"CD001920_pub4_data","Subgroup","Functional task training"
"CD001920_pub4_data","Subgroup","Named as ""three-stage approach"""
"CD001920_pub4_data","Subgroup","Other"
"CD001920_pub4_data","Subgroup","Named as ""Bobath"" approach"
"CD001920_pub4_data","Subgroup","Medical/therapeutic staff"
"CD001920_pub4_data","Subgroup","Others/not stated"
"CD001920_pub4_data","Subgroup","Medical/therapeutic staff + family/carers"
"CD001920_pub4_data","Subgroup","Between 2.5 and 5 hours/week"
"CD001920_pub4_data","Subgroup","More than 5 hours/week"
"CD001920_pub4_data","Subgroup","Functional task training added to less functional approach"
"CD001920_pub4_data","Subgroup","Neurophysiological approach added to a mixed or other approach"
"CD001920_pub4_data","Subgroup","More than 5 hours / week"
"CD002042_pub6_data","Analysis.group","1"
"CD002042_pub6_data","Analysis.group","2"
"CD002042_pub6_data","Analysis.name","Participants exposed to blood transfusion (all trials)"
"CD002042_pub6_data","Analysis.name","Participants exposed to blood transfusion by clinical specialties"
"CD002042_pub6_data","Analysis.name","Participants exposed to blood transfusion by threshold difference"
"CD002042_pub6_data","Analysis.name","Participants exposed to blood transfusion by restrictive threshold"
"CD002042_pub6_data","Analysis.name","Units of blood transfused"
"CD002042_pub6_data","Analysis.name","30-day mortality"
"CD002042_pub6_data","Analysis.name","30-day mortality: subgroup by restrictive haemoglobin level"
"CD002042_pub6_data","Analysis.name","30-day mortality: subgroup by clinical specialties (random-effects model)"
"CD002042_pub6_data","Analysis.name","30-day mortality: subgroup by clinical specialties (fixed-effect model)"
"CD002042_pub6_data","Analysis.name","30-day mortality: subgroup by prospective trial registration vs no prospective registration"
"CD002042_pub6_data","Analysis.name","30-day mortality: sensitivity analysis by allocation concealment"
"CD002042_pub6_data","Analysis.name","30-day mortality sensitivity analysis excluding trials at high risk of non-anaemic participants"
"CD002042_pub6_data","Analysis.name","In-hospital mortality (as defined by triallists)"
"CD002042_pub6_data","Analysis.name","90-day mortality"
"CD002042_pub6_data","Analysis.name","6-month, 12-month mortality"
"CD002042_pub6_data","Analysis.name","Neurocritically ill patients: unfavourable neurological outcome (dichotomised GOS-E or Rankin) at 6 to 12 months"
"CD002042_pub6_data","Analysis.name","Morbidity: myocardial infarction"
"CD002042_pub6_data","Analysis.name","Morbidity: congestive heart failure"
"CD002042_pub6_data","Analysis.name","Morbidity: cerebrovascular accident (CVA) – stroke"
"CD002042_pub6_data","Analysis.name","Morbidity: infection (composite)"
"CD002042_pub6_data","Analysis.name","Morbidity: pneumonia"
"CD002042_pub6_data","Analysis.name","Morbidity: sepsis/bacteraemia"
"CD002042_pub6_data","Analysis.name","Morbidity: sepsis"
"CD002042_pub6_data","Analysis.name","Morbidity: bacteraemia"
"CD002042_pub6_data","Analysis.name","Morbidity: meningitis, ventriculitis or brain abscess"
"CD002042_pub6_data","Analysis.name","Morbidity: wound infection"
"CD002042_pub6_data","Analysis.name","Morbidity: thromboembolism"
"CD002042_pub6_data","Analysis.name","Morbidity: rebleeding"
"CD002042_pub6_data","Analysis.name","Morbidity: clinically significant bleeding through thrombocytopaenia at longest follow-up"
"CD002042_pub6_data","Analysis.name","Morbidity: acute kidney injury (AKI)"
"CD002042_pub6_data","Analysis.name","Morbidity: renal failure requiring dialysis/replacement therapy"
"CD002042_pub6_data","Analysis.name","Morbidity: delirium"
"CD002042_pub6_data","Analysis.name","Adverse events (composite of all)"
"CD002042_pub6_data","Analysis.name","Adverse events (serious only)"
"CD002042_pub6_data","Analysis.name","30-day mortality: subgroup by clinical specialties"
"CD002042_pub6_data","Analysis.name","30-day mortality (sensitivity analysis excluding Maitland study)"
"CD002042_pub6_data","Analysis.name","6-month mortality"
"CD002042_pub6_data","Analysis.name","Morbidity: cardiac events (aggregate)"
"CD002042_pub6_data","Analysis.name","Morbidity: pulmonary oedema"
"CD002042_pub6_data","Analysis.name","Morbidity: (N)MODS"
"CD002042_pub6_data","Analysis.name","Morbidity: cerebrovascular accident (CVA)"
"CD002042_pub6_data","Analysis.name","Morbidity: thrombosis"
"CD002042_pub6_data","Analysis.name","Morbidity: (re)bleeding"
"CD002042_pub6_data","Analysis.name","Morbidity: renal failure"
"CD002042_pub6_data","Subgroup","Cardiac surgery"
"CD002042_pub6_data","Subgroup","Acute myocardial infarction"
"CD002042_pub6_data","Subgroup","Orthopaedic surgery"
"CD002042_pub6_data","Subgroup","Critical care"
"CD002042_pub6_data","Subgroup","Neurocritical care"
"CD002042_pub6_data","Subgroup","Gastrointestinal bleeding"
"CD002042_pub6_data","Subgroup","Postpartum haemorrhage"
"CD002042_pub6_data","Subgroup","Haematological malignancies"
"CD002042_pub6_data","Subgroup","Trauma"
"CD002042_pub6_data","Subgroup","Vascular surgery"
"CD002042_pub6_data","Subgroup","Difference between liberal and restrictive haemoglobin thresholds ≥ 2.0 g/dL"
"CD002042_pub6_data","Subgroup","Difference between liberal and restrictive haemoglobin thresholds &lt; 2.0 g/dL"
"CD002042_pub6_data","Subgroup","Restrictive 7.0 g/dL to 7.5 g/dL"
"CD002042_pub6_data","Subgroup","Restrictive &nbsp;8.0 g/dL to 9.0 g/dL"
"CD002042_pub6_data","Subgroup","Restrictive 8.0 g/dL to 9.0 g/dL"
"CD002042_pub6_data","Subgroup","Gastrointestinal (GI) bleeding"
"CD002042_pub6_data","Subgroup","Prospectively registered trials"
"CD002042_pub6_data","Subgroup","Trials without prospective registration"
"CD002042_pub6_data","Subgroup","Low risk of bias"
"CD002042_pub6_data","Subgroup","6-month mortality"
"CD002042_pub6_data","Subgroup","12-month mortality"
"CD002042_pub6_data","Subgroup","6-month and 12-month mortality together"
"CD002042_pub6_data","Subgroup","Severe anaemia (largely malarial)"
"CD002042_pub6_data","Subgroup","Haematological malignancies/bone marrow disorders"
"CD002052_pub4_data","Analysis.group","1"
"CD002052_pub4_data","Analysis.group","2"
"CD002052_pub4_data","Analysis.group","3"
"CD002052_pub4_data","Analysis.group","4"
"CD002052_pub4_data","Analysis.name","Hypotension"
"CD002052_pub4_data","Analysis.name","Apnoea"
"CD002052_pub4_data","Analysis.name","All‐cause mortality until hospital discharge"
"CD002052_pub4_data","Analysis.name","Days on mechanical ventilation"
"CD002052_pub4_data","Analysis.name","Days of supplemental oxygen use"
"CD002052_pub4_data","Analysis.name","Intraventricular haemorrhage (any grade)"
"CD002052_pub4_data","Analysis.name","Pneumothorax"
"CD002052_pub4_data","Analysis.name","Length of NICU stay (days)"
"CD002052_pub4_data","Analysis.name","Apnea"
"CD002052_pub4_data","Analysis.name","All‐cause mortality until hospital discharge "
"CD002052_pub4_data","Analysis.name","Number of infants requiring additional medications for sedation or analgesia or both"
"CD002052_pub4_data","Analysis.name","Seizures"
"CD002052_pub4_data","Analysis.name","Irritability"
"CD002052_pub4_data","Analysis.name","Drowsiness"
"CD002052_pub4_data","Analysis.name","Successful sedation"
"CD002052_pub4_data","Analysis.name","Sedation 30 minutes post administration"
"CD002052_pub4_data","Analysis.name","Successful completion of the procedure"
"CD002112_pub2_data","Analysis.group","1"
"CD002112_pub2_data","Analysis.group","2"
"CD002112_pub2_data","Analysis.group","3"
"CD002112_pub2_data","Analysis.group","4"
"CD002112_pub2_data","Analysis.group","5"
"CD002112_pub2_data","Analysis.group","6"
"CD002112_pub2_data","Analysis.group","7"
"CD002112_pub2_data","Analysis.name","Mean number of wet nights at the end of treatment"
"CD002112_pub2_data","Analysis.name","Number of children achieving 14 consecutive dry nights by the end of treatment"
"CD002112_pub2_data","Analysis.name","Mean number of wet nights at follow-up"
"CD002112_pub2_data","Analysis.name","Number of children dry at follow-up (maintaining 14 consecutive dry nights after stopping treatment)"
"CD002112_pub2_data","Analysis.name","Number of children relapsing after cessation of treatment"
"CD002112_pub2_data","Analysis.name","Adverse events"
"CD002112_pub2_data","Analysis.name","Adverse effects "
"CD002112_pub2_data","Subgroup","100 mcg vs placebo"
"CD002112_pub2_data","Subgroup","200 mcg vs placebo"
"CD002112_pub2_data","Subgroup","400 mcg vs placebo"
"CD002112_pub2_data","Subgroup","600 mcg vs placebo"
"CD002112_pub2_data","Subgroup","dose titration vs placebo"
"CD002112_pub2_data","Subgroup","800 mcg vs placebo"
"CD002112_pub2_data","Subgroup","20 mcg vs placebo"
"CD002112_pub2_data","Subgroup","abrupt withdrawal vs placebo"
"CD002112_pub2_data","Subgroup","half-dose withdrawal vs placebo"
"CD002112_pub2_data","Subgroup","alternate-day withdrawal vs placebo"
"CD002112_pub2_data","Subgroup","100 vs 200 mcg"
"CD002112_pub2_data","Subgroup","200 vs 400 mcg"
"CD002112_pub2_data","Subgroup","200 vs 600 mcg"
"CD002112_pub2_data","Subgroup","400 vs 600 mcg"
"CD002112_pub2_data","Subgroup"," Oral tablets vs melts "
"CD002112_pub2_data","Subgroup","120 mcg vs 240 mcg "
"CD002112_pub2_data","Subgroup","200 mcg vs 400 mcg"
"CD002112_pub2_data","Subgroup","200 mcg vs 600 mcg"
"CD002112_pub2_data","Subgroup","400 mcg vs 600 mcg"
"CD002112_pub2_data","Subgroup","400 mcg vs 800 mcg"
"CD002112_pub2_data","Subgroup","Oral vs nasal"
"CD002112_pub2_data","Subgroup","100 mcg vs 200 mcg"
"CD002112_pub2_data","Subgroup","Abrupt withdrawal vs structured withdrawal half-dose"
"CD002112_pub2_data","Subgroup","Abrupt withdrawal vs structured withdrawal alternate-day"
"CD002112_pub2_data","Subgroup","Abrupt withdrawal vs structured withdrawal combination program"
"CD002112_pub2_data","Subgroup","Abrupt withdrawal vs tapered withdrawal"
"CD002112_pub2_data","Subgroup","Half-dose withdrawal vs alternate-days withdrawal"
"CD002112_pub2_data","Subgroup","Half-dose alternate days vs gradual structured withdrawal"
"CD002112_pub2_data","Subgroup","Desmopressin vs tricyclics"
"CD002112_pub2_data","Subgroup","Desmopressin vs anticholinergics"
"CD002112_pub2_data","Subgroup","Desmopressin vs indomethacin"
"CD002112_pub2_data","Subgroup","Desmopressin vs diclofenac"
"CD002112_pub2_data","Subgroup","Desmopressin vs albendazole"
"CD002112_pub2_data","Subgroup","Desmopressin vs retention control training"
"CD002112_pub2_data","Subgroup","Desmopressin vs laser acupuncture"
"CD002112_pub2_data","Subgroup","Desmopressin vs toileting, alarm clock, pelvic floor training, dietary and fluid adjustment etc."
"CD002112_pub2_data","Subgroup","Desmopressin vs homotoxicological remedy"
"CD002112_pub2_data","Subgroup","Desmopressin vs behavioural therapy"
"CD002112_pub2_data","Subgroup","Desmopressin vs pinching massage"
"CD002112_pub2_data","Subgroup","Desmopressin vs suo quon"
"CD002112_pub2_data","Subgroup","Desmopressin vs written guidelines"
"CD002112_pub2_data","Subgroup","Desmopressin vs checklist"
"CD002112_pub2_data","Subgroup","Desmopresin vs homotoxicological remedy"
"CD002112_pub2_data","Subgroup","Desmopressin + alarm vs alarm"
"CD002112_pub2_data","Subgroup","Desmopressin + behavioural therapy vs placebo + behavioural therapy"
"CD002112_pub2_data","Subgroup","Desmopressin + laser acupuncture vs laser acupuncture"
"CD002112_pub2_data","Subgroup","Desmopressin + tricyclics vs tricyclics"
"CD002112_pub2_data","Subgroup","Desmopressin + suo quon vs suo quon"
"CD002112_pub2_data","Subgroup","Desmopressin + alarm vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + anticholinergics vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + tricyclics vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + behavioural therapy vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + laser acupuncture vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + dietary vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + dietary + melatonin vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + dietary recommendations vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + dietary recommendations + melatonin vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + suo quon vs desmopressin"
"CD002112_pub2_data","Subgroup","Desmopressin + albendazole vs desmopressin"
"CD002115_pub6_data","Analysis.group","1"
"CD002115_pub6_data","Analysis.group","2"
"CD002115_pub6_data","Analysis.name","Self-reported improvement in faecal incontinence (continuous data)"
"CD002115_pub6_data","Analysis.name","Number of participants with self-reported improvement in constipation (dichotomous)"
"CD002115_pub6_data","Analysis.name","Number of participants with self-reported improvement in constipation (continuous)"
"CD002115_pub6_data","Analysis.name","Mean number of bowel movements per week (continuous)"
"CD002115_pub6_data","Analysis.name","Mean time spent on bowel care per week (continuous; time taken for defecation in minutes)"
"CD002115_pub6_data","Analysis.name","Mean time spent per week on bowel care (dichotmous; participants spending < 10 minutes to pass stool)"
"CD002115_pub6_data","Analysis.name","Condition-specific quality of life measures (continuous)"
"CD002115_pub6_data","Analysis.name","Number of participants with adverse events (dichotomous)"
"CD002115_pub6_data","Analysis.name","Self-reported improvement in faecal incontinence (continuous)"
"CD002115_pub6_data","Analysis.name","Neurogenic Bowel Dysfunction score (continuous; GIV)"
"CD002115_pub6_data","Analysis.name","Mean number of FI episodes (continuous)"
"CD002115_pub6_data","Analysis.name","Mean time spent per week on bowel care (continuous)"
"CD002115_pub6_data","Analysis.name","Number of participants with adverse effects (dichotomous)"
"CD002115_pub6_data","Subgroup","Assessment-based nursing intervention"
"CD002115_pub6_data","Subgroup","Holistic nursing "
"CD002115_pub6_data","Subgroup","One-off nursing assessment"
"CD002115_pub6_data","Subgroup","Probiotics"
"CD002115_pub6_data","Subgroup","Individual cognitive function training"
"CD002115_pub6_data","Subgroup","Bowel training and posture"
"CD002115_pub6_data","Subgroup","Holistic nursing"
"CD002115_pub6_data","Subgroup","Nurse assessment"
"CD002115_pub6_data","Subgroup","FMT"
"CD002115_pub6_data","Subgroup","Transanal irrigation"
"CD002115_pub6_data","Subgroup","Standing intervention"
"CD002115_pub6_data","Subgroup","Abdominal massage"
"CD002115_pub6_data","Subgroup","Osteopathic manipulative treatment"
"CD002115_pub6_data","Subgroup","Parkinson's disease"
"CD002115_pub6_data","Subgroup","Multiple sclerosis"
"CD002115_pub6_data","Subgroup","Spinal cord injury"
"CD002115_pub6_data","Subgroup","Spina bifida"
"CD002115_pub6_data","Subgroup","Massage therapy"
"CD002122_pub3_data","Analysis.group","1"
"CD002122_pub3_data","Analysis.group","2"
"CD002122_pub3_data","Analysis.group","3"
"CD002122_pub3_data","Analysis.group","4"
"CD002122_pub3_data","Analysis.group","5"
"CD002122_pub3_data","Analysis.group","6"
"CD002122_pub3_data","Analysis.group","7"
"CD002122_pub3_data","Analysis.group","8"
"CD002122_pub3_data","Analysis.group","9"
"CD002122_pub3_data","Analysis.group","10"
"CD002122_pub3_data","Analysis.group","11"
"CD002122_pub3_data","Analysis.group","12"
"CD002122_pub3_data","Analysis.group","13"
"CD002122_pub3_data","Analysis.group","14"
"CD002122_pub3_data","Analysis.name","Pain (visual analogue scale)&nbsp;"
"CD002122_pub3_data","Analysis.name","Pain (4-point verbal rating scale)"
"CD002122_pub3_data","Analysis.name","Pain (dichotomous)"
"CD002122_pub3_data","Analysis.name","Assessment of implant (continuous scale)"
"CD002122_pub3_data","Analysis.name","Assessment of implant (dichotomous)"
"CD002122_pub3_data","Analysis.name","Quality of life"
"CD002122_pub3_data","Analysis.name","Adverse effects"
"CD002122_pub3_data","Analysis.name","Pain (visual analogue scale)"
"CD002122_pub3_data","Analysis.name","Patient satisfaction"
"CD002122_pub3_data","Analysis.name","Assessment of implant (continuous)"
"CD002122_pub3_data","Analysis.name","Assessment of implant"
"CD002122_pub3_data","Analysis.name","Pain (4-point verbal scale)"
"CD002122_pub3_data","Analysis.name","Patient satisfaction (dichotomous)"
"CD002122_pub3_data","Subgroup","Overall pain (6 months)"
"CD002122_pub3_data","Subgroup","Pelvic pain (6 months)"
"CD002122_pub3_data","Subgroup","Pelvic pain (12 months)"
"CD002122_pub3_data","Subgroup","Pelvic pain (24 months)"
"CD002122_pub3_data","Subgroup","Dysmenorrhoea (24 months)"
"CD002122_pub3_data","Subgroup","Dyspareunia (3 months)"
"CD002122_pub3_data","Subgroup","Dyspareunia (6 months)"
"CD002122_pub3_data","Subgroup","Overall pain (3 months)"
"CD002122_pub3_data","Subgroup","Overall pain (12 months)"
"CD002122_pub3_data","Subgroup","Pelvic pain (3 months)"
"CD002122_pub3_data","Subgroup","Change in overall pain score at 12 months"
"CD002122_pub3_data","Subgroup","Dysmenorrhoea (3 months)"
"CD002122_pub3_data","Subgroup","Painful defecation (3 months)"
"CD002122_pub3_data","Subgroup","Painful defecation (6 months)"
"CD002122_pub3_data","Subgroup","Painful urination (3 months)"
"CD002122_pub3_data","Subgroup","Painful urination (6 months)"
"CD002122_pub3_data","Subgroup","American Fertility Society score"
"CD002122_pub3_data","Subgroup","Change in American Fertility Society score"
"CD002122_pub3_data","Subgroup","SF-36 (3 months)"
"CD002122_pub3_data","Subgroup","SF-36 (6 months)"
"CD002122_pub3_data","Subgroup","WHOQOL-BREF (3 months)"
"CD002122_pub3_data","Subgroup","WHOQOL-BREF (6 months)"
"CD002122_pub3_data","Subgroup","Study withdrawal due to side effects"
"CD002122_pub3_data","Subgroup","Any side effects"
"CD002122_pub3_data","Subgroup","Acne/greasy skin/seborrhoea"
"CD002122_pub3_data","Subgroup","Oedema"
"CD002122_pub3_data","Subgroup","Muscle cramps/joint pains"
"CD002122_pub3_data","Subgroup","Irregular bleeding including spotting/breakthrough bleeding/genital bleeding"
"CD002122_pub3_data","Subgroup","Amenorrhoea"
"CD002122_pub3_data","Subgroup","Breast Pain/tension"
"CD002122_pub3_data","Subgroup","Vaginal discharge"
"CD002122_pub3_data","Subgroup","Dermatitis/skin rash/itching"
"CD002122_pub3_data","Subgroup","Hair loss"
"CD002122_pub3_data","Subgroup","Hot flushes"
"CD002122_pub3_data","Subgroup","Headache/migraine"
"CD002122_pub3_data","Subgroup","Nausea/vomiting/bloating"
"CD002122_pub3_data","Subgroup","Drowsiness/tiredness/asthenia"
"CD002122_pub3_data","Subgroup","Mood changes/depression/irritability"
"CD002122_pub3_data","Subgroup","Paraesthesia"
"CD002122_pub3_data","Subgroup","Backache"
"CD002122_pub3_data","Subgroup","Skin dryness"
"CD002122_pub3_data","Subgroup","Dysmenorrhoea (6 months)"
"CD002122_pub3_data","Subgroup","Irregular bleeding"
"CD002122_pub3_data","Subgroup","Breast pain"
"CD002122_pub3_data","Subgroup","Nausea/vomiting"
"CD002122_pub3_data","Subgroup","Drowsiness/tiredness"
"CD002122_pub3_data","Subgroup","Back pain"
"CD002122_pub3_data","Subgroup","Meteorism"
"CD002122_pub3_data","Subgroup","Painful defecation"
"CD002122_pub3_data","Subgroup","Breast pain/tension"
"CD002122_pub3_data","Subgroup","Weight gain"
"CD002122_pub3_data","Subgroup","Dysmenorrhoea (12 months)"
"CD002122_pub3_data","Subgroup","Dyspareunia (12 months)"
"CD002122_pub3_data","Subgroup","Painful defecation (12 months)"
"CD002122_pub3_data","Subgroup","SF-36 physical functioning (6 months)"
"CD002122_pub3_data","Subgroup","SF-36 pain (6 months)"
"CD002122_pub3_data","Subgroup","SF-36 general health perception (6 months)"
"CD002122_pub3_data","Subgroup","Hospital Anxiety and Depression Scale (6 months)"
"CD002122_pub3_data","Subgroup","Revised Sabbatsberg Sexual Rating Scale (6 months)"
"CD002122_pub3_data","Subgroup","Decreased libido"
"CD002122_pub3_data","Subgroup","Dermatitis"
"CD002122_pub3_data","Subgroup","Acne"
"CD002122_pub3_data","Subgroup","Headache"
"CD002122_pub3_data","Subgroup","Nausea (listed separate from bloating)"
"CD002122_pub3_data","Subgroup","Mood changes"
"CD002122_pub3_data","Subgroup","Hypertriglyceridemia"
"CD002122_pub3_data","Subgroup","Bloating (listed separate from nausea)"
"CD002122_pub3_data","Subgroup","Sleep disorder/insomnia"
"CD002122_pub3_data","Subgroup","Fatigue"
"CD002122_pub3_data","Subgroup","Spotting"
"CD002122_pub3_data","Subgroup","Breakthrough bleeding"
"CD002122_pub3_data","Subgroup","Depression"
"CD002122_pub3_data","Subgroup","Irritability"
"CD002122_pub3_data","Subgroup","Vaginal dryness"
"CD002122_pub3_data","Subgroup","Overall pain (6 months – change from baseline)"
"CD002122_pub3_data","Subgroup","Pelvic pain (6 months – change from baseline)"
"CD002122_pub3_data","Subgroup","Dysmenorrhoea (6 months – change from baseline)"
"CD002122_pub3_data","Subgroup","Dyspareunia (6 months – change from baseline)"
"CD002122_pub3_data","Subgroup","Change in endometrioma size"
"CD002122_pub3_data","Subgroup","FertiQoL (3 months)"
"CD002122_pub3_data","Subgroup","SF-36 physical health (6 months)"
"CD002122_pub3_data","Subgroup","SF-36 improvement in physical health (6 months)"
"CD002122_pub3_data","Subgroup","SF-36 mental health (6 months)"
"CD002122_pub3_data","Subgroup","SF-36 improvement in mental health (6 months)"
"CD002122_pub3_data","Subgroup","Patient satisfaction (6 months)"
"CD002122_pub3_data","Subgroup","Any side effects (cumulative)"
"CD002122_pub3_data","Subgroup","Joint pain/muscle cramps"
"CD002122_pub3_data","Subgroup","Sweating problems"
"CD002122_pub3_data","Subgroup","Allergic reaction"
"CD002122_pub3_data","Subgroup","Dizziness/faintness"
"CD002122_pub3_data","Subgroup","Nausea"
"CD002122_pub3_data","Subgroup","Hirsutism/hypertrichosis"
"CD002122_pub3_data","Subgroup","Cramping/bloating"
"CD002122_pub3_data","Subgroup","American Fertility Society score (12 months)"
"CD002122_pub3_data","Subgroup","Muscle cramps"
"CD002122_pub3_data","Subgroup","Patient satisfaction (3 months)"
"CD002122_pub3_data","Subgroup","Patient satisfaction (9 months)"
"CD002122_pub3_data","Subgroup","Patient satisfaction (12 months)"
"CD002122_pub3_data","Subgroup","Patients satisfaction (15 months)"
"CD002122_pub3_data","Subgroup","Breakthrough bleeding/spotting"
"CD002122_pub3_data","Subgroup","Injection site reaction"
"CD002122_pub3_data","Subgroup","Severe adverse effect"
"CD002122_pub3_data","Subgroup","Overall pain (9 months)"
"CD002122_pub3_data","Subgroup","Overall pain (18 months)"
"CD002122_pub3_data","Subgroup","Overall pain (24 months)"
"CD002122_pub3_data","Subgroup","Overall pain (30 months)"
"CD002122_pub3_data","Subgroup","Overall pain (36 months)"
"CD002122_pub3_data","Subgroup","Dyspareunia (24 months)"
"CD002122_pub3_data","Subgroup","Dyspareunia (30 months)"
"CD002122_pub3_data","Subgroup","Patient satisfied or very satisfied (6 months)"
"CD002122_pub3_data","Subgroup","Mood changes/depression/ irritability"
"CD002122_pub3_data","Subgroup","Therapy-resistant dysmenorrhoea"
"CD002122_pub3_data","Subgroup","Therapy-resistant pelvic pain"
"CD002122_pub3_data","Subgroup","Moderate or severe side effects"
"CD002203_pub5_data","Analysis.group","1"
"CD002203_pub5_data","Analysis.group","2"
"CD002203_pub5_data","Analysis.group","3"
"CD002203_pub5_data","Analysis.name","FEV1 % predicted (mean change from baseline)"
"CD002203_pub5_data","Analysis.name","FVC % predicted (percentage change from baseline)"
"CD002203_pub5_data","Analysis.name","Number free of pulmonary exacerbation"
"CD002203_pub5_data","Analysis.name","Time to first pulmonary exacerbation"
"CD002203_pub5_data","Analysis.name","Adverse effects of antibiotic treatment"
"CD002203_pub5_data","Analysis.name","Serious adverse events"
"CD002203_pub5_data","Analysis.name","Admission to hospital"
"CD002203_pub5_data","Analysis.name","Number of days in hospital"
"CD002203_pub5_data","Analysis.name","Acquisition of Pseudomonas aeruginosa"
"CD002203_pub5_data","Analysis.name","Acquisition of Staphylococcal aureus"
"CD002203_pub5_data","Analysis.name","Eradication of Staphylococcal aureus present at baseline"
"CD002203_pub5_data","Analysis.name","Acquisition of macrolide-resistant Staphylococcal aureus"
"CD002203_pub5_data","Analysis.name","Acquisition of meticillin-resistant Staphylococcus aureus (MRSA)"
"CD002203_pub5_data","Analysis.name","Acquisition of Haemophilus influenzae"
"CD002203_pub5_data","Analysis.name","Acquisition of macrolide-resistant Haemophilus influenzae"
"CD002203_pub5_data","Analysis.name","Acquisition of non-tuberculous mycobacterium"
"CD002203_pub5_data","Analysis.name","Need for additional oral antibiotics"
"CD002203_pub5_data","Analysis.name","Number of courses of oral antibiotics"
"CD002203_pub5_data","Analysis.name","Number of days of additional oral antibiotics"
"CD002203_pub5_data","Analysis.name","Need for intravenous antibiotics"
"CD002203_pub5_data","Analysis.name","Number of courses of intravenous antibiotics"
"CD002203_pub5_data","Analysis.name","Number of days of intravenous antibiotics"
"CD002203_pub5_data","Analysis.name","Development of allergic bronchopulmonary aspergillosis"
"CD002203_pub5_data","Analysis.name","Change in BMI z score"
"CD002203_pub5_data","Analysis.name","Mean BMI score at 3 years of age"
"CD002203_pub5_data","Analysis.name","Change in weight (kg) from baseline"
"CD002203_pub5_data","Analysis.name","Change in total quality of life score (CFQ-R)"
"CD002203_pub5_data","Analysis.name","Change in physical domain of CFQ-R QoL score"
"CD002203_pub5_data","Analysis.name","Change in respiratory symptom domain of CFQ-R QoL score"
"CD002203_pub5_data","Analysis.name","Change in psychosocial domain of CFQ-R QoL score"
"CD002203_pub5_data","Analysis.name","Change in body image domain of CFQ-R QoL score"
"CD002203_pub5_data","Analysis.name","Change in eating disorder domain of CFQ-R QoL score"
"CD002203_pub5_data","Analysis.name","Change in problems with body weight domain of the CFQ-R QoL score"
"CD002203_pub5_data","Analysis.name","Change in inflammatory markers: IL-8 pg/mL"
"CD002203_pub5_data","Analysis.name","Change in inflammatory markers: neutrophil elastase µg/mL"
"CD002203_pub5_data","Analysis.name","Change in CRP"
"CD002203_pub5_data","Analysis.name","Pulmonary exacerbation rate (per child, per month)"
"CD002203_pub5_data","Analysis.name","Weight (kg) absolute values"
"CD002203_pub5_data","Analysis.name","Relative change in FEV1 (% predicted)"
"CD002203_pub5_data","Analysis.name","Days to first pulmonary exacerbation"
"CD002203_pub5_data","Analysis.name","Adverse events"
"CD002203_pub5_data","Analysis.name","Days in hospital"
"CD002203_pub5_data","Analysis.name","Number of hospital admissions"
"CD002203_pub5_data","Analysis.name","Acquisition of azithromycin-resistant Staphylococcal aureus"
"CD002203_pub5_data","Subgroup","at 1 month"
"CD002203_pub5_data","Subgroup","at 2 months"
"CD002203_pub5_data","Subgroup","at 3 months"
"CD002203_pub5_data","Subgroup","at 4 months"
"CD002203_pub5_data","Subgroup","at 6 months"
"CD002203_pub5_data","Subgroup","at 8 months"
"CD002203_pub5_data","Subgroup","at 10 months"
"CD002203_pub5_data","Subgroup","at 12 months"
"CD002203_pub5_data","Subgroup","Nausea"
"CD002203_pub5_data","Subgroup","Diarrhoea"
"CD002203_pub5_data","Subgroup","Wheezing"
"CD002203_pub5_data","Subgroup","Cough"
"CD002203_pub5_data","Subgroup","Productive cough"
"CD002203_pub5_data","Subgroup","Sore throat"
"CD002203_pub5_data","Subgroup","Constipation"
"CD002203_pub5_data","Subgroup","Respiratory, thoracic and mediastinal disorders"
"CD002203_pub5_data","Subgroup","Any adverse events occuring during the study"
"CD002203_pub5_data","Subgroup","Decreased lung function"
"CD002203_pub5_data","Subgroup","Decreased appetite"
"CD002203_pub5_data","Subgroup","Increased sputum"
"CD002203_pub5_data","Subgroup","Rhinorrhoea"
"CD002203_pub5_data","Subgroup","Headache"
"CD002203_pub5_data","Subgroup","Abdominal pain"
"CD002203_pub5_data","Subgroup","Fever"
"CD002203_pub5_data","Subgroup","Fatigue"
"CD002203_pub5_data","Subgroup","Dyspnea"
"CD002203_pub5_data","Subgroup","Nasal congestion"
"CD002203_pub5_data","Subgroup","Hemoptysis"
"CD002203_pub5_data","Subgroup","Dizziness (except vertigo)"
"CD002203_pub5_data","Subgroup","Vomiting"
"CD002203_pub5_data","Subgroup","Hearing impairment"
"CD002203_pub5_data","Subgroup","Tinnitus"
"CD002203_pub5_data","Subgroup","Pulmonary congestion"
"CD002203_pub5_data","Subgroup","Rash"
"CD002203_pub5_data","Subgroup","Overall serious adverse events"
"CD002203_pub5_data","Subgroup","DIOS"
"CD002203_pub5_data","Subgroup","After 6 months"
"CD002203_pub5_data","Subgroup","At 6 weeks"
"CD002203_pub5_data","Subgroup","At 18 months"
"CD002203_pub5_data","Subgroup","after 6 months"
"CD002203_pub5_data","Subgroup","after 12 months"
"CD002203_pub5_data","Subgroup","At 36 months"
"CD002203_pub5_data","Subgroup","after 2 months"
"CD002203_pub5_data","Subgroup","after 18 months"
"CD002203_pub5_data","Subgroup","After 18 months"
"CD002203_pub5_data","Subgroup","After 6 weeks"
"CD002203_pub5_data","Subgroup","After 12 months"
"CD002203_pub5_data","Subgroup","after 36 months"
"CD002203_pub5_data","Subgroup","After 2 months"
"CD002203_pub5_data","Subgroup","Baseline to 6 months"
"CD002203_pub5_data","Subgroup","At 3 months"
"CD002203_pub5_data","Subgroup","At 6 months"
"CD002203_pub5_data","Subgroup","Gastrointestinal"
"CD002203_pub5_data","Subgroup","Abnormal liver transaminases"
"CD002203_pub5_data","Subgroup","Total adverse events"
"CD002203_pub5_data","Subgroup","Study withdrawal"
"CD002243_pub5_data","Analysis.group","1"
"CD002243_pub5_data","Analysis.group","2"
"CD002243_pub5_data","Analysis.name","28-day all-cause mortality"
"CD002243_pub5_data","Analysis.name","28-day all-cause mortality - sensitivity analysis based on methodological quality"
"CD002243_pub5_data","Analysis.name","28-day all-cause mortality by subgroups based on study drug"
"CD002243_pub5_data","Analysis.name","28-day all-cause mortality by subgroups based on treatment dose/duration"
"CD002243_pub5_data","Analysis.name","28-day all-cause mortality based on mode of drug administration"
"CD002243_pub5_data","Analysis.name","28-day all-cause mortality based on mode of drug termination"
"CD002243_pub5_data","Analysis.name","28-day all-cause mortality by subgroups based on age"
"CD002243_pub5_data","Analysis.name","28-day all-cause mortality by subgroups based on targeted population"
"CD002243_pub5_data","Analysis.name","28-day mortality in participants with versus without critical illness-related corticosteroid insufficiency"
"CD002243_pub5_data","Analysis.name","Long-term mortality"
"CD002243_pub5_data","Analysis.name","Hospital mortality"
"CD002243_pub5_data","Analysis.name","90-day all-cause mortality"
"CD002243_pub5_data","Analysis.name","Intensive care unit mortality"
"CD002243_pub5_data","Analysis.name","Length of intensive care unit stay for all participants"
"CD002243_pub5_data","Analysis.name","Length of intensive care unit stay for survivors"
"CD002243_pub5_data","Analysis.name","Length of hospital stay for all participants"
"CD002243_pub5_data","Analysis.name","Length of hospital stay for survivors"
"CD002243_pub5_data","Analysis.name","Number of participants with shock reversal at day 7"
"CD002243_pub5_data","Analysis.name","Number of participants with shock reversal at 28 days"
"CD002243_pub5_data","Analysis.name","SOFA score at day 7"
"CD002243_pub5_data","Analysis.name","Number of participants with adverse events"
"CD002243_pub5_data","Analysis.name","Number of participants with shock reversal at day 28"
"CD002243_pub5_data","Subgroup","Adequate generation of allocation sequence"
"CD002243_pub5_data","Subgroup","Adequate allocation concealment"
"CD002243_pub5_data","Subgroup","Blinded trials"
"CD002243_pub5_data","Subgroup","Studies judged at low risk of bias"
"CD002243_pub5_data","Subgroup","Hydrocortisone"
"CD002243_pub5_data","Subgroup","Hydrocortisone plus fludrocortisone"
"CD002243_pub5_data","Subgroup","Prednisone/prednisolone"
"CD002243_pub5_data","Subgroup","Methylprednisolone"
"CD002243_pub5_data","Subgroup","Dexamethasone"
"CD002243_pub5_data","Subgroup","Hydrocortisone plus vitamin C plus thiamine"
"CD002243_pub5_data","Subgroup","Long course of low-dose corticosteroids"
"CD002243_pub5_data","Subgroup","Short course of high-dose corticosteroids"
"CD002243_pub5_data","Subgroup","Intravenous bolus"
"CD002243_pub5_data","Subgroup","Continuous infusion"
"CD002243_pub5_data","Subgroup","Without taper off"
"CD002243_pub5_data","Subgroup","With taper off"
"CD002243_pub5_data","Subgroup","Adults"
"CD002243_pub5_data","Subgroup","Children"
"CD002243_pub5_data","Subgroup","Sepsis"
"CD002243_pub5_data","Subgroup","Septic shock only"
"CD002243_pub5_data","Subgroup","Sepsis and ARDS"
"CD002243_pub5_data","Subgroup","Sepsis and community-acquired pneumonia"
"CD002243_pub5_data","Subgroup","COVID-19"
"CD002243_pub5_data","Subgroup","Patients with critical illness associated with corticosteroid insufficiency"
"CD002243_pub5_data","Subgroup","Patients without critical illness associated with corticosteroid insufficiency"
"CD002243_pub5_data","Subgroup","Gastroduodenal bleeding"
"CD002243_pub5_data","Subgroup","Superinfection"
"CD002243_pub5_data","Subgroup","Hyperglycaemia"
"CD002243_pub5_data","Subgroup","Hypernatraemia"
"CD002243_pub5_data","Subgroup","Muscle weakness"
"CD002243_pub5_data","Subgroup","Neuropsychiatric event"
"CD002243_pub5_data","Subgroup","Stroke"
"CD002243_pub5_data","Subgroup","Cardiac event"
"CD002243_pub5_data","Subgroup","Gastrointestinal bleeding"
"CD002290_pub6_data","Analysis.group","1"
"CD002290_pub6_data","Analysis.group","2"
"CD002290_pub6_data","Analysis.group","3"
"CD002290_pub6_data","Analysis.group","4"
"CD002290_pub6_data","Analysis.group","5"
"CD002290_pub6_data","Analysis.group","6"
"CD002290_pub6_data","Analysis.group","7"
"CD002290_pub6_data","Analysis.group","8"
"CD002290_pub6_data","Analysis.group","9"
"CD002290_pub6_data","Analysis.group","10"
"CD002290_pub6_data","Analysis.group","11"
"CD002290_pub6_data","Analysis.group","12"
"CD002290_pub6_data","Analysis.group","13"
"CD002290_pub6_data","Analysis.group","14"
"CD002290_pub6_data","Analysis.group","15"
"CD002290_pub6_data","Analysis.group","16"
"CD002290_pub6_data","Analysis.group","17"
"CD002290_pub6_data","Analysis.group","18"
"CD002290_pub6_data","Analysis.group","19"
"CD002290_pub6_data","Analysis.group","20"
"CD002290_pub6_data","Analysis.group","21"
"CD002290_pub6_data","Analysis.group","22"
"CD002290_pub6_data","Analysis.group","23"
"CD002290_pub6_data","Analysis.group","24"
"CD002290_pub6_data","Analysis.group","25"
"CD002290_pub6_data","Analysis.group","26"
"CD002290_pub6_data","Analysis.group","27"
"CD002290_pub6_data","Analysis.group","28"
"CD002290_pub6_data","Analysis.name","Relapse"
"CD002290_pub6_data","Analysis.name","Adverse events"
"CD002290_pub6_data","Analysis.name","Relapse at 12 months"
"CD002290_pub6_data","Analysis.name","Relapse by 12 months"
"CD002290_pub6_data","Analysis.name","Relapse rate"
"CD002290_pub6_data","Analysis.name","Infection rate"
"CD002290_pub6_data","Analysis.name","Relapse/treatment failure during MMF therapy (to 505 days)"
"CD002290_pub6_data","Analysis.name","Relapse rate with RTX during MMF therapy (to 505 days)"
"CD002290_pub6_data","Analysis.name","Steroid dose during MMF therapy (to 505 days) [mg/m2/day]"
"CD002290_pub6_data","Analysis.name","Relapse/treatment failure during entire study"
"CD002290_pub6_data","Analysis.name","Relapse rate/year"
"CD002290_pub6_data","Analysis.name","GFR at 12 months [mL/min]"
"CD002290_pub6_data","Analysis.name","Alopecia"
"CD002290_pub6_data","Analysis.name","Mean relapse rate/patient/month"
"CD002290_pub6_data","Analysis.name","Relapse during treatment according to risk of bias"
"CD002290_pub6_data","Analysis.name","Number with FRNS or SDNS"
"CD002290_pub6_data","Analysis.name","Sustained remission"
"CD002290_pub6_data","Analysis.name","Treatment failure"
"CD002290_pub6_data","Analysis.name","Serious adverse events"
"CD002290_pub6_data","Analysis.name","Infrequent or no relapses at 12 months"
"CD002290_pub6_data","Analysis.name","Number needing cytotoxic agents"
"CD002290_pub6_data","Analysis.name","Creatinine at end of study [µmol/L]"
"CD002290_pub6_data","Analysis.name","Remission"
"CD002290_pub6_data","Analysis.name","Overall reduction in prednisone dose"
"CD002290_pub6_data","Analysis.name","Changing versus fixed dose: relapse"
"CD002290_pub6_data","Analysis.name","Changing versus fixed dose: adverse events"
"CD002290_pub6_data","Analysis.name","High versus lower CSA target level: 2-year outcomes"
"CD002290_pub6_data","Analysis.name","High versus lower CSA target level: adverse effects"
"CD002290_pub6_data","Analysis.name","Relapse rate "
"CD002290_pub6_data","Analysis.name","Cumulative prednisone dose [mg]"
"CD002290_pub6_data","Analysis.name","Relapse at 6 to 12 months"
"CD002290_pub6_data","Analysis.name","Relapse at 12 to 24 months"
"CD002290_pub6_data","Analysis.name","Leucopenia"
"CD002290_pub6_data","Analysis.name","Relapse at 24 months"
"CD002290_pub6_data","Analysis.name","Continuing frequently relapsing or steroid dependent SSNS at 6 months"
"CD002290_pub6_data","Analysis.name","Relapse at 6 months"
"CD002290_pub6_data","Subgroup","6 months"
"CD002290_pub6_data","Subgroup","12 months"
"CD002290_pub6_data","Subgroup","3 months"
"CD002290_pub6_data","Subgroup","Moderate to severe infusion reactions"
"CD002290_pub6_data","Subgroup","Severe infection"
"CD002290_pub6_data","Subgroup","Arthropathy"
"CD002290_pub6_data","Subgroup","Cytopenia"
"CD002290_pub6_data","Subgroup","Acute kidney injury"
"CD002290_pub6_data","Subgroup","Infection"
"CD002290_pub6_data","Subgroup","Gastrointestinal disorders"
"CD002290_pub6_data","Subgroup","Infections"
"CD002290_pub6_data","Subgroup","Neutropenia"
"CD002290_pub6_data","Subgroup","24 months"
"CD002290_pub6_data","Subgroup","Adverse events (neutropenia, articular pain) within 6 months"
"CD002290_pub6_data","Subgroup","Adverse events related to infusion"
"CD002290_pub6_data","Subgroup","Relapses at 12 months"
"CD002290_pub6_data","Subgroup","Frequent relapses at 12 months"
"CD002290_pub6_data","Subgroup","Relapse by 6 months"
"CD002290_pub6_data","Subgroup","Peritonitis"
"CD002290_pub6_data","Subgroup","Abdominal pain"
"CD002290_pub6_data","Subgroup","Anaemia"
"CD002290_pub6_data","Subgroup","Leucopenia"
"CD002290_pub6_data","Subgroup","Hypertension"
"CD002290_pub6_data","Subgroup","Hypertrichosis"
"CD002290_pub6_data","Subgroup","Lymphopenia"
"CD002290_pub6_data","Subgroup","Gum hypertrophy"
"CD002290_pub6_data","Subgroup","Reduced GFR"
"CD002290_pub6_data","Subgroup","Pneumonia"
"CD002290_pub6_data","Subgroup","Diarrhoea"
"CD002290_pub6_data","Subgroup","Relapse at 6 to 12 months"
"CD002290_pub6_data","Subgroup","Relapse during treatment (4 to 12 months)"
"CD002290_pub6_data","Subgroup","ANCA positive/arthritis"
"CD002290_pub6_data","Subgroup","Studies at low risk of bias"
"CD002290_pub6_data","Subgroup","Studies at unclear or high risk of bias"
"CD002290_pub6_data","Subgroup","Frequent relapse at 1 year"
"CD002290_pub6_data","Subgroup","Any relapse"
"CD002290_pub6_data","Subgroup","Previous FRNS"
"CD002290_pub6_data","Subgroup","Previous SDNS"
"CD002290_pub6_data","Subgroup","Elevated transaminases"
"CD002290_pub6_data","Subgroup","Relapse at end of therapy"
"CD002290_pub6_data","Subgroup","Relapse at 6 to 9 months after therapy"
"CD002290_pub6_data","Subgroup","Relapse at 12 months after therapy"
"CD002290_pub6_data","Subgroup","Relapse at 24 months after therapy"
"CD002290_pub6_data","Subgroup","Abnormal liver function tests"
"CD002290_pub6_data","Subgroup","Relapse at 12 months"
"CD002290_pub6_data","Subgroup","Relapse at 6 months"
"CD002290_pub6_data","Subgroup","Relapse at 24 months"
"CD002290_pub6_data","Subgroup","Psychological disorder"
"CD002290_pub6_data","Subgroup","Obesity"
"CD002290_pub6_data","Subgroup","Hirsutism"
"CD002290_pub6_data","Subgroup","Transient elevated creatinine"
"CD002290_pub6_data","Subgroup","Gastrointestinal events"
"CD002290_pub6_data","Subgroup","Convulsions"
"CD002290_pub6_data","Subgroup","Fatigue"
"CD002290_pub6_data","Subgroup","Number with relapse"
"CD002290_pub6_data","Subgroup","Number with FRNS and SDNS"
"CD002290_pub6_data","Subgroup","Encephalopathy"
"CD002290_pub6_data","Subgroup","Renal toxicity"
"CD002290_pub6_data","Subgroup","Relapse at end of CSA therapy (6 to 9 months) "
"CD002290_pub6_data","Subgroup","Relapse after completing CSA (12 to 24 months)"
"CD002290_pub6_data","Subgroup","Serum creatinine"
"CD002290_pub6_data","Subgroup","Cyclophosphamide versus prednisone (6 or 12 months)"
"CD002290_pub6_data","Subgroup","Chlorambucil versus prednisone or placebo (at 6 months)"
"CD002290_pub6_data","Subgroup","Cyclophosphamide versus prednisone (12 to 24 months)"
"CD002290_pub6_data","Subgroup","Chlorambucil versus prednisone or placebo (at 12 months)"
"CD002290_pub6_data","Subgroup","Cyclophosphamide"
"CD002290_pub6_data","Subgroup","Chlorambucil"
"CD002290_pub6_data","Subgroup","8 weeks versus 2 weeks"
"CD002290_pub6_data","Subgroup","12 weeks versus 8 weeks"
"CD002290_pub6_data","Subgroup","Leukopenia"
"CD002290_pub6_data","Subgroup","Alopecia"
"CD002290_pub6_data","Subgroup","Gastrointestinal"
"CD002290_pub6_data","Subgroup","Genitourinary"
"CD002290_pub6_data","Subgroup","Relapse at 12 to 24 months (end of study)"
"CD002290_pub6_data","Subgroup","Hair loss"
"CD002290_pub6_data","Subgroup","All infections"
"CD002290_pub6_data","Subgroup","Nausea and vomiting"
"CD002290_pub6_data","Subgroup","Thrombocytopenia"
"CD002290_pub6_data","Subgroup","Haematuria"
"CD002290_pub6_data","Subgroup","During treatment"
"CD002290_pub6_data","Subgroup","Hyperuricaemia"
"CD002290_pub6_data","Subgroup","Hepatic dysfunction"
"CD002290_pub6_data","Subgroup","Malaise"
"CD002290_pub6_data","Subgroup","Gastrointestinal upset"
"CD002303_pub4_data","Analysis.group","1"
"CD002303_pub4_data","Analysis.group","2"
"CD002303_pub4_data","Analysis.group","3"
"CD002303_pub4_data","Analysis.group","4"
"CD002303_pub4_data","Analysis.name","Reulceration at 6 months"
"CD002303_pub4_data","Analysis.name","Reulceration"
"CD002303_pub4_data","Analysis.name","Noncompliance "
"CD002303_pub4_data","Analysis.name","Reulceration at 18 months"
"CD002303_pub4_data","Analysis.name","Noncompliance  at 18 months"
"CD002971_pub6_data","Analysis.group","1"
"CD002971_pub6_data","Analysis.name","Necrotising enterocolitis"
"CD002971_pub6_data","Analysis.name","Late-onset invasive infection"
"CD002971_pub6_data","Analysis.name","All-cause mortality"
"CD002971_pub6_data","Analysis.name","In-hospital rate of weight gain (g/kg/day) until term equivalent"
"CD002971_pub6_data","Analysis.name","In-hospital rate of head circumference growth (mm/week) until term equivalent"
"CD002971_pub6_data","Analysis.name","Weight (kg) at 18 months post-term"
"CD002971_pub6_data","Analysis.name","Head circumference (cm) at 18 months post-term"
"CD002971_pub6_data","Analysis.name","Bayley Mental Development Index at 18 months"
"CD002971_pub6_data","Analysis.name","Bayley Psychomotor Development Index at 18 months"
"CD002971_pub6_data","Analysis.name","Bayley-III"
"CD002971_pub6_data","Analysis.name","Cerebral palsy"
"CD002971_pub6_data","Analysis.name","Hearing impairment"
"CD002971_pub6_data","Analysis.name","Visual impairment"
"CD002971_pub6_data","Analysis.name","Bayley-III score < 70"
"CD002971_pub6_data","Analysis.name","Neurodevelopmental disability at 18 months"
"CD002971_pub6_data","Subgroup","Supplement to maternal milk"
"CD002971_pub6_data","Subgroup","Sole diet"
"CD002971_pub6_data","Subgroup","Supplement"
"CD002971_pub6_data","Subgroup","Cognitive"
"CD002971_pub6_data","Subgroup","Language"
"CD002971_pub6_data","Subgroup","Motor"
"CD003129_pub2_data","Analysis.group","1"
"CD003129_pub2_data","Analysis.group","2"
"CD003129_pub2_data","Analysis.group","3"
"CD003129_pub2_data","Analysis.name","Treatment response"
"CD003129_pub2_data","Analysis.name","Pain (visual analogue scale) "
"CD003129_pub2_data","Analysis.name","Participant global assessment of well-being"
"CD003129_pub2_data","Analysis.name","Serious adverse events"
"CD003129_pub2_data","Analysis.name","Withdrawals due to adverse events"
"CD003129_pub2_data","Analysis.name","Sustained clinically inactive disease (Wallace criteria or as defined by study authors)"
"CD003129_pub2_data","Analysis.name","Treatment response (American College of Rheumatology criteria or as defined by study authors)"
"CD003129_pub2_data","Analysis.name","Function (Childhood Health Assessment Questionnaire or equivalent)"
"CD003214_pub4_data","Analysis.group","1"
"CD003214_pub4_data","Analysis.name","Mortality"
"CD003214_pub4_data","Analysis.name","Chronic lung disease at 28 days"
"CD003214_pub4_data","Analysis.name","Duration of oxygen supplementation (days)"
"CD003214_pub4_data","Analysis.name","Duration of assisted ventilation (days)"
"CD003214_pub4_data","Analysis.name","Age of weaning from ventilatory support (days)"
"CD003214_pub4_data","Analysis.name","Need for intravenous dexamethasone"
"CD003214_pub4_data","Analysis.name","Infants with one or more episodes of respiratory infection"
"CD003214_pub4_data","Analysis.name","Infants with one or more episodes of sepsis (positive blood culture)"
"CD003216_pub3_data","Analysis.group","1"
"CD003216_pub3_data","Analysis.group","2"
"CD003216_pub3_data","Analysis.group","3"
"CD003216_pub3_data","Analysis.group","4"
"CD003216_pub3_data","Analysis.group","5"
"CD003216_pub3_data","Analysis.group","6"
"CD003216_pub3_data","Analysis.group","7"
"CD003216_pub3_data","Analysis.group","8"
"CD003216_pub3_data","Analysis.group","9"
"CD003216_pub3_data","Analysis.group","10"
"CD003216_pub3_data","Analysis.group","11"
"CD003216_pub3_data","Analysis.group","12"
"CD003216_pub3_data","Analysis.group","13"
"CD003216_pub3_data","Analysis.group","14"
"CD003216_pub3_data","Analysis.group","15"
"CD003216_pub3_data","Analysis.group","16"
"CD003216_pub3_data","Analysis.group","17"
"CD003216_pub3_data","Analysis.name","Incidence of pressure ulcers"
"CD003216_pub3_data","Analysis.name","At least one adverse gastrointestinal effect"
"CD003216_pub3_data","Analysis.name","Pressure ulcers healed"
"CD003216_pub3_data","Analysis.name","Change in pressure ulcer area (cm²)"
"CD003216_pub3_data","Analysis.name","PUSH score"
"CD003216_pub3_data","Analysis.name","Change in pressure ulcer area (percentage)"
"CD003216_pub3_data","Analysis.name","Change in PUSH score"
"CD003216_pub3_data","Analysis.name","DESIGN-R score"
"CD003216_pub3_data","Analysis.name","At least one adverse gastrointestinal effects"
"CD003216_pub3_data","Analysis.name","Costs (EUR)"
"CD003216_pub3_data","Analysis.name","Acceptability: non adherence"
"CD003216_pub3_data","Analysis.name","At least one side effect"
"CD003216_pub3_data","Analysis.name","Pressure ulcer episodes"
"CD003216_pub3_data","Analysis.name","Diarrhoea episodes"
"CD003216_pub3_data","Analysis.name","Side effects"
"CD003216_pub3_data","Analysis.name","Change in pressure ulcer volume (mL)"
"CD003218_pub3_data","Analysis.group","1"
"CD003218_pub3_data","Analysis.name","Mean improvement in the Maintenance of Wakefulness Test"
"CD003218_pub3_data","Analysis.name","Mean improvement in the Epworth Sleepiness Scale"
"CD003218_pub3_data","Analysis.name","Mean improvement in the Multiple Sleep Latency Test"
"CD003218_pub3_data","Analysis.name","Quality of life"
"CD003218_pub3_data","Analysis.name","Proportion of participants with at least 1 adverse event"
"CD003218_pub3_data","Subgroup","Mean improvement in total score of Short Form 36"
"CD003331_pub6_data","Analysis.group","1"
"CD003331_pub6_data","Analysis.name","All-cause mortality up to 12 months' follow-up"
"CD003331_pub6_data","Analysis.name","All-cause mortality more than 12 months' follow-up"
"CD003331_pub6_data","Analysis.name","Hospital admissions (all-cause) up to 12 months' follow-up"
"CD003331_pub6_data","Analysis.name","Hospital admissions (all-cause) more than 12 months' follow-up"
"CD003331_pub6_data","Analysis.name","Hospital admissions (heart failure only) up to 12 months' follow-up"
"CD003331_pub6_data","Analysis.name","Hospital admissions (heart failure only) more than 12 months' follow-up"
"CD003331_pub6_data","Analysis.name","Health-related quality of life (MLWHF) up to 12 months' follow-up"
"CD003331_pub6_data","Analysis.name","Health-related quality of life (all scales) up to 12 months' follow-up"
"CD003331_pub6_data","Analysis.name","Health-related quality of life (MLWHF) more than 12 months' follow-up"
"CD003331_pub6_data","Subgroup","High ROB"
"CD003331_pub6_data","Subgroup","Low ROB"
"CD003333_pub4_data","Analysis.group","1"
"CD003333_pub4_data","Analysis.group","2"
"CD003333_pub4_data","Analysis.name","All-cause mortality"
"CD003333_pub4_data","Analysis.name","Non-fatal cardiovascular events (non-fatal stroke, myocardial infarction, pulmonary embolism, peripheral arterial embolism)"
"CD003333_pub4_data","Analysis.name","Major bleeding events"
"CD003357_pub5_data","Analysis.group","1"
"CD003357_pub5_data","Analysis.group","2"
"CD003357_pub5_data","Analysis.group","3"
"CD003357_pub5_data","Analysis.name","Live birth rate per woman"
"CD003357_pub5_data","Analysis.name","Clinical pregnancy rate per woman"
"CD003357_pub5_data","Analysis.name","Multiple pregnancy rate per woman"
"CD003357_pub5_data","Analysis.name","Miscarriage rate"
"CD003357_pub5_data","Analysis.name","Incidence of OHSS per woman"
"CD003357_pub5_data","Analysis.name","Miscarriage rate per woman"
"CD003357_pub5_data","Subgroup","Pretreated women IVF vs IUI + gonadotropins"
"CD003357_pub5_data","Subgroup","Treatment-naive women IVF vs IUI + gonadotrophins (1 IVF to 1 IUI cycle) "
"CD003357_pub5_data","Subgroup","Treatment-naive women IVF vs IUI + gonadotropins (1 IVF to 2-3 IUI cycles)"
"CD003357_pub5_data","Subgroup","Treatment-naive women IVF vs IUI + CC"
"CD003357_pub5_data","Subgroup","Treatment-naive women IVF vs IUI + gonadotropins"
"CD003357_pub5_data","Subgroup","Treatment-naive women IVF vs IUI + gonadotrophins (1 IVF to 1 IUI cycle)"
"CD003357_pub5_data","Subgroup","Treatment-naive women IUI + gonadotropins"
"CD003376_pub4_data","Analysis.group","1"
"CD003376_pub4_data","Analysis.group","2"
"CD003376_pub4_data","Analysis.group","3"
"CD003376_pub4_data","Analysis.group","4"
"CD003376_pub4_data","Analysis.group","5"
"CD003376_pub4_data","Analysis.group","6"
"CD003376_pub4_data","Analysis.group","7"
"CD003376_pub4_data","Analysis.group","8"
"CD003376_pub4_data","Analysis.group","9"
"CD003376_pub4_data","Analysis.group","10"
"CD003376_pub4_data","Analysis.group","11"
"CD003376_pub4_data","Analysis.group","12"
"CD003376_pub4_data","Analysis.group","13"
"CD003376_pub4_data","Analysis.group","14"
"CD003376_pub4_data","Analysis.group","15"
"CD003376_pub4_data","Analysis.group","16"
"CD003376_pub4_data","Analysis.group","17"
"CD003376_pub4_data","Analysis.group","18"
"CD003376_pub4_data","Analysis.group","19"
"CD003376_pub4_data","Analysis.group","20"
"CD003376_pub4_data","Analysis.group","21"
"CD003376_pub4_data","Analysis.group","22"
"CD003376_pub4_data","Analysis.group","23"
"CD003376_pub4_data","Analysis.group","24"
"CD003376_pub4_data","Analysis.group","25"
"CD003376_pub4_data","Analysis.name","Clinical vertebral fractures"
"CD003376_pub4_data","Analysis.name","Non-vertebral fractures"
"CD003376_pub4_data","Analysis.name","Hip fractures"
"CD003376_pub4_data","Analysis.name","Wrist fractures"
"CD003376_pub4_data","Analysis.name","Radiographic vertebral fractures"
"CD003376_pub4_data","Analysis.name","Withdrawals due to adverse events"
"CD003376_pub4_data","Analysis.name","Serious adverse events"
"CD003376_pub4_data","Analysis.name","Gastrointestinal adverse events"
"CD003376_pub4_data","Analysis.name","Atypical femoral fractures"
"CD003376_pub4_data","Analysis.name","Treatment versus reference, secondary"
"CD003376_pub4_data","Analysis.name","Treatment versus reference, primary"
"CD003376_pub4_data","Subgroup","Clinical vertebral fractures, primary"
"CD003376_pub4_data","Subgroup","Non-vertebral fractures, secondary"
"CD003376_pub4_data","Subgroup","Non-vertebral fractures, primary"
"CD003376_pub4_data","Subgroup","Hip fractures, primary"
"CD003376_pub4_data","Subgroup","Hip fractures, secondary"
"CD003376_pub4_data","Subgroup","Wrist fractures, secondary"
"CD003376_pub4_data","Subgroup","Radiographic vertebral fractures, primary"
"CD003376_pub4_data","Subgroup","Radiographic vertebral fractures, secondary"
"CD003376_pub4_data","Subgroup","Withdrawals due to adverse events, secondary"
"CD003376_pub4_data","Subgroup","Withdrawals due to adverse events, primary"
"CD003376_pub4_data","Subgroup","Serious adverse events, primary"
"CD003376_pub4_data","Subgroup","Serious adverse events, secondary"
"CD003376_pub4_data","Subgroup","Gastrointestinal adverse events, primary"
"CD003376_pub4_data","Subgroup","Atypical femoral fractures, primary"
"CD003376_pub4_data","Subgroup","Atypical femoral fractures, secondary"
"CD003376_pub4_data","Subgroup","Hip Fractures, primary"
"CD003376_pub4_data","Subgroup","Gastrointestinal adverse events, secondary"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus alendronate 5 mg/day"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus intermittent/cyclic clodronate"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus HRT"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus etidronate 400 mg/day plus HRT"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus HRT"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day plus HRT versus placebo"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day plus HRT versus HRT"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus alendronate 5 mg/day"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus fluoride 50 mg/day"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus alfacalcidol 1 μg/day"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus risedronate 2.5 mg/day"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus calcitonin 20 IU/week, IV"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus menatetrenone 45 mg/day"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus alendronate 5 mg/day"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus etidronate 200 mg/day plus alfacalcidol 1 μg/day)"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus etidronate 200 mg/day plus alfacalcidol 1 μg/day"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus alendronate 10 mg/day"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus etidronate 400 mg/day + HRT"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day + calcitriol 0.5 μg/day versus calcitriol 0.5 μg/day"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day + HRT versus placebo"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day + HRT versus HRT"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus calcitriol 0.5 μg/day"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/day versus etidronate 200 mg/day + alfacalcidol 1 μg/day"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day + calcitriol 0.5 μg/day versus calcitonin 100 IU/2 days, IN + calcitriol 0.25 μg/day"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus etidronate 400 mg/day + calcitriol 0.5 μg/day"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus intermittent/cyclic alendronate 10 mg/day"
"CD003376_pub4_data","Subgroup","Etidronate 400 mg/day versus ADFR"
"CD003376_pub4_data","Subgroup","Etidronate 200 mg/d versus menatetrenone 45 mg/day"
"CD003414_pub4_data","Analysis.group","1"
"CD003414_pub4_data","Analysis.group","2"
"CD003414_pub4_data","Analysis.group","3"
"CD003414_pub4_data","Analysis.group","4"
"CD003414_pub4_data","Analysis.group","5"
"CD003414_pub4_data","Analysis.name","Live birth rate per woman"
"CD003414_pub4_data","Analysis.name","Miscarriage rate per woman"
"CD003414_pub4_data","Analysis.name","Ongoing pregnancy rate per woman"
"CD003414_pub4_data","Analysis.name","Clinical pregnancy rate per woman"
"CD003414_pub4_data","Analysis.name","Ectopic pregnancy rate per woman"
"CD003414_pub4_data","Analysis.name","Multiple pregnancy rate per woman"
"CD003414_pub4_data","Analysis.name","Endometrial thickness"
"CD003414_pub4_data","Analysis.name","Cycle cancellation rate per woman"
"CD003414_pub4_data","Subgroup","Natural cycle FET versus HT FET"
"CD003414_pub4_data","Subgroup","Natural cycle FET versus HT + GnRHa FET"
"CD003414_pub4_data","Subgroup","Natural cycle FET versus modified natural cycle FET (HCG trigger)"
"CD003414_pub4_data","Subgroup","Modified natural cycle FET versus HT FET"
"CD003414_pub4_data","Subgroup","Modified natural cycle FET versus HT + GnRHa FET"
"CD003414_pub4_data","Subgroup","Modified natural cycle FET versus FSH + HCG FET"
"CD003414_pub4_data","Subgroup","Modified natural cycle FET versus clomiphene + HCG FET"
"CD003414_pub4_data","Subgroup","HT FET versus HT + GnRHa"
"CD003414_pub4_data","Subgroup","HT FET versus letrozole + HMG FET"
"CD003414_pub4_data","Subgroup","HT FET versus clomiphene + HCG FET"
"CD003414_pub4_data","Subgroup","HT FET versus HT + letrozole FET"
"CD003414_pub4_data","Subgroup","HT FET versus FSH FET"
"CD003414_pub4_data","Subgroup","HT FET versus HT + letrozole "
"CD003429_pub5_data","Analysis.group","1"
"CD003429_pub5_data","Analysis.name","Annualized joint bleeding rates"
"CD003429_pub5_data","Analysis.name","Joint function protection (number of participants with no joint damage)"
"CD003429_pub5_data","Analysis.name","Sensitivity analysis (fixed-effect model): joint function protection (number of participants with no joint damage)"
"CD003429_pub5_data","Analysis.name","Quality of life"
"CD003429_pub5_data","Analysis.name","Annualized overall bleeding rates"
"CD003429_pub5_data","Analysis.name","Radiologic joint score (Pettersson score)"
"CD003429_pub5_data","Analysis.name","Clotting factor concentrate usage "
"CD003429_pub5_data","Analysis.name","Sensitivity analysis (fixed-effect model): clotting factor concentrate usage "
"CD003429_pub5_data","Analysis.name","Number of clotting factor infusions (per participant per month)"
"CD003429_pub5_data","Analysis.name","Adverse events"
"CD003429_pub5_data","Subgroup","Haemo-QoL – total score"
"CD003429_pub5_data","Subgroup","Haemo-QoL – 'family' domain"
"CD003429_pub5_data","Subgroup","Factor concentrate usage (× 1000 IU/month) "
"CD003429_pub5_data","Subgroup","Factor concentrate usage [× 1000 IU/month] – standard prophylaxis dose"
"CD003429_pub5_data","Subgroup","Factor concentrate usage [× 1000 IU/month] "
"CD003429_pub5_data","Subgroup","Infections"
"CD003429_pub5_data","Subgroup","Development of inhibitors"
"CD003429_pub5_data","Subgroup","Hospitalization"
"CD003451_pub3_data","Analysis.group","1"
"CD003451_pub3_data","Analysis.group","2"
"CD003451_pub3_data","Analysis.group","3"
"CD003451_pub3_data","Analysis.group","4"
"CD003451_pub3_data","Analysis.group","5"
"CD003451_pub3_data","Analysis.group","6"
"CD003451_pub3_data","Analysis.group","7"
"CD003451_pub3_data","Analysis.group","8"
"CD003451_pub3_data","Analysis.group","9"
"CD003451_pub3_data","Analysis.group","10"
"CD003451_pub3_data","Analysis.group","11"
"CD003451_pub3_data","Analysis.group","12"
"CD003451_pub3_data","Analysis.group","13"
"CD003451_pub3_data","Analysis.name","Overjet"
"CD003451_pub3_data","Analysis.name","ANB"
"CD003451_pub3_data","Analysis.name","Wits"
"CD003451_pub3_data","Analysis.name","Piers-Harris self-concept scale"
"CD003451_pub3_data","Analysis.name","Oral Aesthetic Subjective Impact Score (OASIS)"
"CD003451_pub3_data","Analysis.name","Need for surgery in adulthood (6-year follow-up)"
"CD003451_pub3_data","Analysis.name","Wits appraisal"
"CD003451_pub3_data","Analysis.name","A-NPerp"
"CD003451_pub3_data","Subgroup","Facemask"
"CD003451_pub3_data","Subgroup","Orthodontic removable traction appliance (ORTA)"
"CD003451_pub3_data","Subgroup","Tandem traction bow appliance (TTBA)"
"CD003451_pub3_data","Subgroup","Reverse Forsus"
"CD003451_pub3_data","Subgroup","Orthodontic removable traction appliance (ORTA) "
"CD003451_pub3_data","Subgroup","Tandem traction bow appliance "
"CD003451_pub3_data","Subgroup","Reverse Twin Block with lip pads and rapid maxillary expander"
"CD003451_pub3_data","Subgroup","Chin cup"
"CD003451_pub3_data","Subgroup","ORTA (orthodontic removable traction appliance)"
"CD003451_pub3_data","Subgroup","Reverse Twin Block with lip pads and rapid maxillary expander "
"CD003451_pub3_data","Subgroup","15-month follow-up"
"CD003451_pub3_data","Subgroup","3-year follow-up"
"CD003451_pub3_data","Subgroup","6-year follow-up"
"CD003451_pub3_data","Subgroup","With facemask"
"CD003451_pub3_data","Subgroup","With Class III elastics"
"CD003451_pub3_data","Subgroup","Mini maxillary protractor"
"CD003451_pub3_data","Subgroup","Pushing Splints"
"CD003451_pub3_data","Subgroup","Modified tandem appliance"
"CD003451_pub3_data","Subgroup","Frankel III functional appliance"
"CD003451_pub3_data","Subgroup","Reverse chin cup"
"CD003451_pub3_data","Subgroup","Tongue plate appliance"
"CD003451_pub3_data","Subgroup","Facemask (RME) versus facemask (miniscrew)"
"CD003451_pub3_data","Subgroup","Facemask (RME) versus upper removable appliance (URA) with miniscrews and Class III elastics"
"CD003451_pub3_data","Subgroup","Facemask (RME) versus surgical miniplates (facemask)"
"CD003451_pub3_data","Subgroup","Facemask with transpalatal arch (TPA) versus facemask with TPA and miniscrew"
"CD003451_pub3_data","Subgroup","Bone-anchored intermaxillary traction (BAIMT) versus removable mandibular retractor (RMR)"
"CD003477_pub5_data","Analysis.group","1"
"CD003477_pub5_data","Analysis.group","2"
"CD003477_pub5_data","Analysis.group","3"
"CD003477_pub5_data","Analysis.group","4"
"CD003477_pub5_data","Analysis.group","5"
"CD003477_pub5_data","Analysis.name","Emotional well-being including quality of life"
"CD003477_pub5_data","Analysis.name","Mood disturbance or negative affect: depression"
"CD003477_pub5_data","Analysis.name","Mood disturbance or negative affect: anxiety"
"CD003477_pub5_data","Analysis.name","Behaviour problems: agitation or aggression"
"CD003477_pub5_data","Analysis.name","Behaviour problems: overall"
"CD003477_pub5_data","Analysis.name","Social behaviour"
"CD003477_pub5_data","Analysis.name","Cognition"
"CD003477_pub5_data","Analysis.name","Behavioural problems: agitation or aggression"
"CD003477_pub5_data","Analysis.name","Behavioural problems: overall"
"CD003477_pub5_data","Analysis.name","Music-based therapeutic interventions versus usual care for behaviour problems: agitation or aggression at end of treatment; subgroup analysis: individual therapy versus group therapy"
"CD003477_pub5_data","Subgroup","Group therapy"
"CD003477_pub5_data","Subgroup","Individual therapy"
"CD003511_pub6_data","Analysis.group","1"
"CD003511_pub6_data","Analysis.name","Miscarriage (all trials)"
"CD003511_pub6_data","Analysis.name","Miscarriage (placebo-controlled trials only)"
"CD003511_pub6_data","Analysis.name","Miscarriage (women with previous recurrent miscarriage only)"
"CD003511_pub6_data","Analysis.name","Miscarriage (by route of administration versus placebo)"
"CD003511_pub6_data","Analysis.name","Live birth rate"
"CD003511_pub6_data","Analysis.name","Preterm birth"
"CD003511_pub6_data","Analysis.name","Neonatal death"
"CD003511_pub6_data","Analysis.name","Fetal genital abnormalities/virilization"
"CD003511_pub6_data","Analysis.name","Stillbirth"
"CD003511_pub6_data","Subgroup","New Subgroup"
"CD003511_pub6_data","Subgroup","Trials with placebo control group"
"CD003511_pub6_data","Subgroup","Trials without placebo controls"
"CD003511_pub6_data","Subgroup","Women with a history of 3 or more prior miscarriages"
"CD003511_pub6_data","Subgroup","Women with a history of 2 or more prior miscarriages"
"CD003511_pub6_data","Subgroup","Oral versus placebo/control"
"CD003511_pub6_data","Subgroup","Intramuscular versus placebo/control"
"CD003511_pub6_data","Subgroup","Vaginal versus placebo/control"
"CD003519_pub5_data","Analysis.group","1"
"CD003519_pub5_data","Analysis.group","2"
"CD003519_pub5_data","Analysis.group","3"
"CD003519_pub5_data","Analysis.group","4"
"CD003519_pub5_data","Analysis.group","5"
"CD003519_pub5_data","Analysis.group","6"
"CD003519_pub5_data","Analysis.group","7"
"CD003519_pub5_data","Analysis.name","Exclusive breastfeeding at hospital discharge to 1 month post birth"
"CD003519_pub5_data","Analysis.name","Exclusive breastfeeding at hospital discharge to 1 month post birth - Marin 2010 sensitivity analysis"
"CD003519_pub5_data","Analysis.name","Exclusive breastfeeding at hospital discharge to 1 month post birth - Perez-Jimenez 2023 sensitivity analysis"
"CD003519_pub5_data","Analysis.name","Exclusive breastfeeding 6 weeks to 6 months post birth"
"CD003519_pub5_data","Analysis.name","Exclusive breastfeeding 6 weeks to 6 months post birth &nbsp;- Mulupuru 2019 sensitivity analysis"
"CD003519_pub5_data","Analysis.name","Infant axillary temperature 30 minutes to 2.5 hours post birth"
"CD003519_pub5_data","Analysis.name","Blood glucose mg/dL at 75-180 minutes post birth"
"CD003519_pub5_data","Analysis.name","SCRIP score first 6 hours post birth"
"CD003519_pub5_data","Analysis.name","Placental separation time/duration of the third stage of labor&nbsp;"
"CD003519_pub5_data","Analysis.name","Placental separation time/duration of the third stage of labor - Gunduz 2023 sensitivity analysis"
"CD003519_pub5_data","Analysis.name","Maternal postpartum blood loss (mL) - vaginal delivery&nbsp;"
"CD003519_pub5_data","Analysis.name","Breastfeeding 1 month to 4 months post birth"
"CD003519_pub5_data","Analysis.name","Breastfeeding 1 month to 4 months post birth - Sosa 1976a sensitivity analysis"
"CD003519_pub5_data","Analysis.name","Duration of breastfeeding in days"
"CD003519_pub5_data","Analysis.name","Duration of breastfeeding in days - Sosa 1976a sensitivity analysis"
"CD003519_pub5_data","Analysis.name","Breastfeeding status one month post birth"
"CD003519_pub5_data","Analysis.name","Success of the first breastfeeding (IBFAT or LATCH score)"
"CD003519_pub5_data","Analysis.name","Successful first breastfeeding (IBFAT score 10-12 or BAT score 8-12 or not specified)"
"CD003519_pub5_data","Analysis.name","Time postbirth of first breastfeeding initiation"
"CD003519_pub5_data","Analysis.name","Infant transferred to the neonatal intensive care unit"
"CD003519_pub5_data","Analysis.name","Infant transferred to the neonatal intensive care unit - Marin 2010 sensitivity analysis"
"CD003519_pub5_data","Analysis.name","Infant body weight change (grams) day 14 post birth"
"CD003519_pub5_data","Analysis.name","Maternal pain during to 2-hours post-episiotomy or perineal laceration repair"
"CD003519_pub5_data","Analysis.name","Maternal state anxiety 2 hours to 3 days post birth"
"CD003519_pub5_data","Analysis.name","Mother's most certain preference for same postdelivery care in the future"
"CD003519_pub5_data","Analysis.name","Success of the first breastfeeding (IBFAT score)"
"CD003519_pub5_data","Analysis.name","Maternal pain post cesarean birth - at arrival to recovery to 4 hours post-op"
"CD003519_pub5_data","Analysis.name","Maternal plasma hemoglobin 2 to 3-days postbirth"
"CD003519_pub5_data","Analysis.name","Exclusive breastfeeding at hospital discharge to 1 month postbirth"
"CD003519_pub5_data","Analysis.name","Exclusive breastfeeding 6 weeks to 6 months postbirth"
"CD003519_pub5_data","Analysis.name","Number of infants transferred to the NICU"
"CD003519_pub5_data","Subgroup","Immediate contact (less than 10 minutes post birth)"
"CD003519_pub5_data","Subgroup","Early contact (10 minutes to 24 hours post birth)"
"CD003519_pub5_data","Subgroup","Immediate contact (less than 10 mintutes post birth)"
"CD003519_pub5_data","Subgroup","Low dose (60 minutes or less)"
"CD003519_pub5_data","Subgroup","High dose (more than 60 minutes)"
"CD003519_pub5_data","Subgroup","Low dose (equal to or less than 60 minutes)"
"CD003519_pub5_data","Subgroup","World Bank country income classification (low or low middle)"
"CD003519_pub5_data","Subgroup","World Bank country income classification (upper middle or high)"
"CD003594_pub7_data","Analysis.group","1"
"CD003594_pub7_data","Analysis.group","2"
"CD003594_pub7_data","Analysis.group","3"
"CD003594_pub7_data","Analysis.group","4"
"CD003594_pub7_data","Analysis.group","5"
"CD003594_pub7_data","Analysis.group","6"
"CD003594_pub7_data","Analysis.group","7"
"CD003594_pub7_data","Analysis.group","8"
"CD003594_pub7_data","Analysis.group","9"
"CD003594_pub7_data","Analysis.group","10"
"CD003594_pub7_data","Analysis.group","11"
"CD003594_pub7_data","Analysis.group","12"
"CD003594_pub7_data","Analysis.group","13"
"CD003594_pub7_data","Analysis.group","14"
"CD003594_pub7_data","Analysis.group","15"
"CD003594_pub7_data","Analysis.group","16"
"CD003594_pub7_data","Analysis.group","17"
"CD003594_pub7_data","Analysis.group","18"
"CD003594_pub7_data","Analysis.group","19"
"CD003594_pub7_data","Analysis.name","Complete remission"
"CD003594_pub7_data","Analysis.name","Complete or partial remission"
"CD003594_pub7_data","Analysis.name","Kidney failure"
"CD003594_pub7_data","Analysis.name","Adverse events"
"CD003594_pub7_data","Analysis.name","Treatment response at 3 to 6 months"
"CD003594_pub7_data","Analysis.name","Death"
"CD003594_pub7_data","Analysis.name","Mean time to remission"
"CD003594_pub7_data","Analysis.name","Treatment response at 6 months"
"CD003594_pub7_data","Analysis.name","Treatment response at 12 months"
"CD003594_pub7_data","Analysis.name","Relapse following complete or partial remission"
"CD003594_pub7_data","Analysis.name","Kidney function: change in eGFR over 12 months"
"CD003594_pub7_data","Analysis.name","Treatment response at 52 weeks"
"CD003594_pub7_data","Analysis.name","Sustainable remission of proteinuria (weeks 52 to 78)"
"CD003594_pub7_data","Analysis.name","Kidney failure by 78 weeks"
"CD003594_pub7_data","Analysis.name","Death by 52 weeks"
"CD003594_pub7_data","Analysis.name","Kidney function: 50% decline in GFR by 78 weeks"
"CD003594_pub7_data","Analysis.name","Adverse events (weeks 0 to 26)"
"CD003594_pub7_data","Analysis.name","Complete or partial response at one year"
"CD003594_pub7_data","Analysis.name","Relapse or treatment failure by one year"
"CD003594_pub7_data","Analysis.name","Relapses [number/year]"
"CD003594_pub7_data","Analysis.name","Prednisone dose [mg/kg/d]"
"CD003594_pub7_data","Analysis.name","Kidney function: change in GFR [mL/min]"
"CD003594_pub7_data","Analysis.name","Remission at 6 months"
"CD003594_pub7_data","Analysis.name","Relapse at 12 months"
"CD003594_pub7_data","Analysis.name","Urinary protein-creatinine ratio at 6 months"
"CD003594_pub7_data","Analysis.name","Relapse by one year"
"CD003594_pub7_data","Analysis.name","Treatment failure"
"CD003594_pub7_data","Analysis.name","Death (any cause)"
"CD003594_pub7_data","Analysis.name","Partial remission"
"CD003594_pub7_data","Analysis.name","Continuing remission at one year"
"CD003594_pub7_data","Analysis.name","Kidney function: renal insufficiency"
"CD003594_pub7_data","Analysis.name","Time to remission [days]"
"CD003594_pub7_data","Analysis.name","Mean duration of remission [months]"
"CD003594_pub7_data","Analysis.name","Treatment response at 18 months"
"CD003594_pub7_data","Analysis.name","Complete or partial resistance in subgroups"
"CD003594_pub7_data","Analysis.name","Kidney function: serum creatinine [mg/dL]"
"CD003594_pub7_data","Analysis.name","Serum albumin [g/L]"
"CD003594_pub7_data","Analysis.name","Active disease at end of treatment (12 months)"
"CD003594_pub7_data","Analysis.name","Active disease one year after treatment"
"CD003594_pub7_data","Analysis.name","Short-term response (remission)"
"CD003594_pub7_data","Analysis.name","Long-term response (remission at 12 months)"
"CD003594_pub7_data","Analysis.name","Reduction in proteinuria and stable GFR"
"CD003594_pub7_data","Analysis.name","Proteinuria [g/day]"
"CD003594_pub7_data","Analysis.name","Tubular proteinuria [mg/L]"
"CD003594_pub7_data","Analysis.name","Systolic blood pressure [mm Hg]"
"CD003594_pub7_data","Analysis.name","Serum potassium [mmol/L]"
"CD003594_pub7_data","Analysis.name","Kidney function: creatinine clearance [mL/min]"
"CD003594_pub7_data","Analysis.name","Partial remission (> 40% reduction in UPCR) at 8 weeks"
"CD003594_pub7_data","Analysis.name","Complete remission of proteinuria (any time during follow-up to week 108)"
"CD003594_pub7_data","Analysis.name","Partial remission at 36 weeks"
"CD003594_pub7_data","Analysis.name","Composite outcome: 40% reduction in GFR/death/kidney failure"
"CD003594_pub7_data","Subgroup","All renal pathologies"
"CD003594_pub7_data","Subgroup","FSGS"
"CD003594_pub7_data","Subgroup","Worsening of hypertension"
"CD003594_pub7_data","Subgroup","Infection"
"CD003594_pub7_data","Subgroup","Complete remission"
"CD003594_pub7_data","Subgroup","Partial remission"
"CD003594_pub7_data","Subgroup","Complete or partial remission"
"CD003594_pub7_data","Subgroup","Treatment failure (non response, serious infection, persistently elevated creatinine) at 6 months"
"CD003594_pub7_data","Subgroup","Any serious adverse effect"
"CD003594_pub7_data","Subgroup","Medications ceased due to adverse events"
"CD003594_pub7_data","Subgroup","Serious infections"
"CD003594_pub7_data","Subgroup","Persistent nephrotoxicity"
"CD003594_pub7_data","Subgroup","Complete and partial remission"
"CD003594_pub7_data","Subgroup","Reversible nephrotoxicity"
"CD003594_pub7_data","Subgroup","Worsening hypertension"
"CD003594_pub7_data","Subgroup","Headache"
"CD003594_pub7_data","Subgroup","Paraesthesia"
"CD003594_pub7_data","Subgroup","Hypertrichosis"
"CD003594_pub7_data","Subgroup","Gingival hyperplasia"
"CD003594_pub7_data","Subgroup","Acne or skin infections"
"CD003594_pub7_data","Subgroup","Diarrhoea"
"CD003594_pub7_data","Subgroup","Sepsis/pneumonia"
"CD003594_pub7_data","Subgroup","No sustainable remission"
"CD003594_pub7_data","Subgroup","Serious infection requiring hospitalisation"
"CD003594_pub7_data","Subgroup","Total Infections"
"CD003594_pub7_data","Subgroup","Total hospitalisations"
"CD003594_pub7_data","Subgroup","Gastrointestinal adverse events"
"CD003594_pub7_data","Subgroup","Neuropsychiatric conditions"
"CD003594_pub7_data","Subgroup","Hypertension"
"CD003594_pub7_data","Subgroup","Complete response"
"CD003594_pub7_data","Subgroup","Partial response"
"CD003594_pub7_data","Subgroup","Complete or partial response"
"CD003594_pub7_data","Subgroup","Treatment failure"
"CD003594_pub7_data","Subgroup","Frequent relapses"
"CD003594_pub7_data","Subgroup","Steroid resistance"
"CD003594_pub7_data","Subgroup","All serious adverse events"
"CD003594_pub7_data","Subgroup","Hypovolaemia"
"CD003594_pub7_data","Subgroup","Hypertension with seizures"
"CD003594_pub7_data","Subgroup","Cystitis"
"CD003594_pub7_data","Subgroup","Bone marrow suppression"
"CD003594_pub7_data","Subgroup","Bacterial infection"
"CD003594_pub7_data","Subgroup","Vomiting"
"CD003594_pub7_data","Subgroup","Alopecia"
"CD003594_pub7_data","Subgroup","Sustained remission/steroid-sensitive relapses"
"CD003594_pub7_data","Subgroup","CKD"
"CD003594_pub7_data","Subgroup","Initial SRNS"
"CD003594_pub7_data","Subgroup","Late SRNS"
"CD003594_pub7_data","Subgroup","Minimal change disease"
"CD003594_pub7_data","Subgroup","FSGS or MesPGN"
"CD003594_pub7_data","Subgroup","Cataract/glaucoma"
"CD003594_pub7_data","Subgroup","Cushingoid features"
"CD003594_pub7_data","Subgroup","Leucopenia"
"CD003594_pub7_data","Subgroup","Bacterial infections"
"CD003594_pub7_data","Subgroup","Hypokalaemia"
"CD003594_pub7_data","Subgroup","Steroid encephalopathy"
"CD003594_pub7_data","Subgroup","Hair loss"
"CD003594_pub7_data","Subgroup","Complete remission in initial steroid resistance"
"CD003594_pub7_data","Subgroup","Complete remission in delayed steroid resistance"
"CD003594_pub7_data","Subgroup","Complete remission in all patients"
"CD003594_pub7_data","Subgroup","Initially resistant patients"
"CD003594_pub7_data","Subgroup","Delayed resistant patients"
"CD003594_pub7_data","Subgroup","Abdominal pain"
"CD003594_pub7_data","Subgroup","Bronchospasm/treatment discontinued"
"CD003594_pub7_data","Subgroup","Hypotension"
"CD003594_pub7_data","Subgroup","Skin rash"
"CD003594_pub7_data","Subgroup","Mild dyspnoea"
"CD003594_pub7_data","Subgroup","MMF versus CPA"
"CD003594_pub7_data","Subgroup","LEF versus MMF"
"CD003594_pub7_data","Subgroup","LEF versus CPA"
"CD003594_pub7_data","Subgroup","Adalimumab versus conservative therapy"
"CD003594_pub7_data","Subgroup","Galactose versus conservative therapy"
"CD003594_pub7_data","Subgroup","After 4 weeks of treatment"
"CD003594_pub7_data","Subgroup","After 8 weeks of treatment"
"CD003594_pub7_data","Subgroup","After 12 weeks of treatment"
"CD003594_pub7_data","Subgroup","Retinol binding protein"
"CD003594_pub7_data","Subgroup","Beta-2 microglobulin"
"CD003594_pub7_data","Subgroup","Any treatment-related adverse event"
"CD003594_pub7_data","Subgroup","Serious adverse events requiring study withdrawal"
"CD003594_pub7_data","Subgroup","Peripheral oedema"
"CD003594_pub7_data","Subgroup","Hyperkalaemia"
"CD003594_pub7_data","Subgroup","Treatment ceased due to adverse event"
"CD003594_pub7_data","Subgroup","Acute kidney injury"
"CD003594_pub7_data","Subgroup","Adverse events due to hyperkalaemia"
"CD003598_pub3_data","Analysis.group","1"
"CD003598_pub3_data","Analysis.group","2"
"CD003598_pub3_data","Analysis.group","3"
"CD003598_pub3_data","Analysis.group","4"
"CD003598_pub3_data","Analysis.group","5"
"CD003598_pub3_data","Analysis.group","6"
"CD003598_pub3_data","Analysis.group","7"
"CD003598_pub3_data","Analysis.group","8"
"CD003598_pub3_data","Analysis.group","9"
"CD003598_pub3_data","Analysis.group","10"
"CD003598_pub3_data","Analysis.group","11"
"CD003598_pub3_data","Analysis.group","12"
"CD003598_pub3_data","Analysis.group","13"
"CD003598_pub3_data","Analysis.group","14"
"CD003598_pub3_data","Analysis.group","15"
"CD003598_pub3_data","Analysis.group","16"
"CD003598_pub3_data","Analysis.group","17"
"CD003598_pub3_data","Analysis.group","18"
"CD003598_pub3_data","Analysis.group","19"
"CD003598_pub3_data","Analysis.name","All-cause death"
"CD003598_pub3_data","Analysis.name","Graft loss"
"CD003598_pub3_data","Analysis.name","Creatinine clearance [mL/min]"
"CD003598_pub3_data","Analysis.name","eGFR [mL/min/1.73 m²]"
"CD003598_pub3_data","Analysis.name","Serum creatinine [µmol/L]"
"CD003598_pub3_data","Analysis.name","Cardiovascular death"
"CD003598_pub3_data","Analysis.name","Systolic blood pressure [mm Hg]"
"CD003598_pub3_data","Analysis.name","Diastolic blood pressure [mm Hg]"
"CD003598_pub3_data","Analysis.name","Mean arterial pressure [mm Hg]"
"CD003598_pub3_data","Analysis.name","Any rejection"
"CD003598_pub3_data","Analysis.name","Acute rejection"
"CD003598_pub3_data","Analysis.name","Rejection"
"CD003598_pub3_data","Analysis.name","Rejection rate"
"CD003598_pub3_data","Analysis.name","Proteinuria [g/24 hours]"
"CD003598_pub3_data","Analysis.name","Nonfatal myocardial infarction"
"CD003598_pub3_data","Analysis.name","Fatal myocardial infarction"
"CD003598_pub3_data","Analysis.name","Thrombosis of the graft arteria"
"CD003598_pub3_data","Analysis.name","Any adverse event"
"CD003598_pub3_data","Analysis.name","Hypotension"
"CD003598_pub3_data","Analysis.name","New onset hypertension"
"CD003598_pub3_data","Analysis.name","New onset diabetes"
"CD003598_pub3_data","Analysis.name","Hyperglycaemia"
"CD003598_pub3_data","Analysis.name","Oedema of legs"
"CD003598_pub3_data","Analysis.name","Withdrawal due to adverse events"
"CD003598_pub3_data","Analysis.name","Withdrawal due to rejection"
"CD003598_pub3_data","Analysis.name","Withdrawal due to congestive heart failure"
"CD003598_pub3_data","Analysis.name","Withdrawal due to heart block"
"CD003598_pub3_data","Analysis.name","Withdrawal due to hypotension"
"CD003598_pub3_data","Analysis.name","Withdrawal due to fatigue"
"CD003598_pub3_data","Analysis.name","Doubling of serum creatinine"
"CD003598_pub3_data","Analysis.name","Acute kidney injury"
"CD003598_pub3_data","Analysis.name","Controlled blood pressure"
"CD003598_pub3_data","Analysis.name","Proteinuria at end of treatment"
"CD003598_pub3_data","Analysis.name","Urinary albumin/creatinine ratio [mg/mg]"
"CD003598_pub3_data","Analysis.name","Myocardial infarction"
"CD003598_pub3_data","Analysis.name","Fatal stroke"
"CD003598_pub3_data","Analysis.name","Cardiovascular events"
"CD003598_pub3_data","Analysis.name","Heart failure"
"CD003598_pub3_data","Analysis.name","Angina pectoris"
"CD003598_pub3_data","Analysis.name","Thromboembolic episodes"
"CD003598_pub3_data","Analysis.name","Haemoglobin [g/dL]"
"CD003598_pub3_data","Analysis.name","Haematocrit [%]"
"CD003598_pub3_data","Analysis.name","Serum potassium [mmol/L]"
"CD003598_pub3_data","Analysis.name","Hyperkalaemia"
"CD003598_pub3_data","Analysis.name","Cough"
"CD003598_pub3_data","Analysis.name","Peripheral oedema"
"CD003598_pub3_data","Analysis.name","Infection"
"CD003598_pub3_data","Analysis.name","Withdrawal due to acute kidney injury"
"CD003598_pub3_data","Analysis.name","Withdrawal due to hyperkalaemia"
"CD003598_pub3_data","Analysis.name","Withdrawal due to cough"
"CD003598_pub3_data","Analysis.name","Sudden death"
"CD003598_pub3_data","Analysis.name","Nonfatal stroke"
"CD003598_pub3_data","Analysis.name","Urinary albumin/creatinine ratio [mg/g]"
"CD003598_pub3_data","Analysis.name","Withdrawal due to acute rejection"
"CD003598_pub3_data","Analysis.name","Fatigue"
"CD003598_pub3_data","Analysis.name","New-onset hypertension"
"CD003598_pub3_data","Analysis.name","Clearance creatinine [mL/min]"
"CD003598_pub3_data","Analysis.name","Serum creatinine [μmol/L]"
"CD003598_pub3_data","Analysis.name","Withdrawn due to adverse events"
"CD003598_pub3_data","Analysis.name","Withdrawn due to graft loss"
"CD003598_pub3_data","Analysis.name","Withdrawn due to heart failure"
"CD003598_pub3_data","Analysis.name","Withdrawn due to hypotension"
"CD003598_pub3_data","Analysis.name","Withdrawn due to kidney transplant artery stenoses"
"CD003598_pub3_data","Analysis.name","Withdrawn due to hyperkalaemia"
"CD003598_pub3_data","Analysis.name","Withdrawn due to cough"
"CD003598_pub3_data","Analysis.name","Withdrawn due to ankle oedema"
"CD003598_pub3_data","Analysis.name","Withdrawn due to fatigue"
"CD003598_pub3_data","Analysis.name","Serum potassium (mmol/L)"
"CD003598_pub3_data","Analysis.name","Proteinuria remission"
"CD003598_pub3_data","Analysis.name","Withdrawal due to peripheral oedema"
"CD003598_pub3_data","Analysis.name","Haemoglobin [g/L]"
"CD003598_pub3_data","Subgroup","Presumed and treated"
"CD003598_pub3_data","Subgroup","Proven or suspected"
"CD003598_pub3_data","Subgroup","Cellular: interstitial"
"CD003598_pub3_data","Subgroup","Cellular: vascular"
"CD003598_pub3_data","Subgroup","Non-dihydropyridine CCB"
"CD003598_pub3_data","Subgroup","Dihydropyridine CCB"
"CD003743_pub3_data","Analysis.group","1"
"CD003743_pub3_data","Analysis.name","Weight gain (g/day)"
"CD003743_pub3_data","Analysis.name","Breastfeeding: stopped any breastfeeding on discharge from home support or hospital"
"CD003743_pub3_data","Analysis.name","Breastfeeding: stopped fully breastfeeding on discharge from home support or hospital"
"CD003743_pub3_data","Analysis.name","Infection up to discharge from home support or hospital"
"CD003743_pub3_data","Analysis.name","Length of hospitalisation (days)"
"CD003743_pub3_data","Analysis.name","Breastfeeding: stopped any breastfeeding at 3 months' post discharge"
"CD003743_pub3_data","Analysis.name","Breastfeeding: stopped fully breastfeeding at 3 months' post discharge"
"CD003743_pub3_data","Analysis.name","Breastfeeding: stopped any breastfeeding at 6 months' post discharge"
"CD003743_pub3_data","Analysis.name","Breastfeeding: stopped fully breastfeeding at 6 months' post discharge"
"CD003743_pub3_data","Analysis.name","Rehospitalisation up to 12 months' post discharge from home support or hospital"
"CD003743_pub3_data","Analysis.name","Death up to 12 months' post discharge from home support or hospital"
"CD003743_pub3_data","Analysis.name","Parental satisfaction: Parental anxiety on discharge from home support or hospital (STAI)"
"CD003743_pub3_data","Analysis.name","Parental satisfaction: recollection of feelings on discharge from home support or hospital, assessed at 12 months later (Borg's CR-10 scale)"
"CD003743_pub3_data","Analysis.name","Parental satisfaction: recollection of experiences from discharge from home support or hospital to 12 months later"
"CD003743_pub3_data","Analysis.name","Other health service use from discharge from home support or hospital to 12 months"
"CD003743_pub3_data","Subgroup","Respiratory infections"
"CD003743_pub3_data","Subgroup","Intravenous antibiotics"
"CD003743_pub3_data","Subgroup","Conjunctivitis"
"CD003743_pub3_data","Subgroup","Infection work up"
"CD003743_pub3_data","Subgroup","Oral antibiotics"
"CD003743_pub3_data","Subgroup","Topical antibiotics"
"CD003743_pub3_data","Subgroup","Length of hospitalisation: total (days)"
"CD003743_pub3_data","Subgroup","Length of hospitalisation: excluding 'test period' (days)"
"CD003743_pub3_data","Subgroup","Trait anxiety, mothers"
"CD003743_pub3_data","Subgroup","Trait anxiety, fathers"
"CD003743_pub3_data","Subgroup","State anxiety, mothers"
"CD003743_pub3_data","Subgroup","State anxiety, fathers"
"CD003743_pub3_data","Subgroup","General anxiety, mothers"
"CD003743_pub3_data","Subgroup","General anxiety, fathers"
"CD003743_pub3_data","Subgroup","Confidence in handling the baby, mothers"
"CD003743_pub3_data","Subgroup","Confidence in handling the baby, fathers"
"CD003743_pub3_data","Subgroup","Feeling prepared to take responsibility for the caring of the baby, mothers"
"CD003743_pub3_data","Subgroup","Feeling prepared to take responsibility for the caring of the baby, fathers"
"CD003743_pub3_data","Subgroup","Anxiety related to care of infant, mothers"
"CD003743_pub3_data","Subgroup","Anxiety related to care of infant, fathers"
"CD003743_pub3_data","Subgroup","Long period of mental imbalance related to birth of infant, mothers"
"CD003743_pub3_data","Subgroup","Long period of mental imbalance related to birth of infant, fathers"
"CD003743_pub3_data","Subgroup","Visits to hospital emergency room"
"CD003743_pub3_data","Subgroup","Visits to paediatric outpatient clinic"
"CD003743_pub3_data","Subgroup","Visits to general practitioner"
"CD003743_pub3_data","Subgroup","Visits to Child Health Centre"
"CD003774_pub5_data","Analysis.group","1"
"CD003774_pub5_data","Analysis.group","2"
"CD003774_pub5_data","Analysis.group","3"
"CD003774_pub5_data","Analysis.group","4"
"CD003774_pub5_data","Analysis.group","5"
"CD003774_pub5_data","Analysis.group","6"
"CD003774_pub5_data","Analysis.group","7"
"CD003774_pub5_data","Analysis.group","8"
"CD003774_pub5_data","Analysis.group","9"
"CD003774_pub5_data","Analysis.group","10"
"CD003774_pub5_data","Analysis.group","11"
"CD003774_pub5_data","Analysis.name","CMV disease"
"CD003774_pub5_data","Analysis.name","All symptomatic CMV disease stratified by antibody status"
"CD003774_pub5_data","Analysis.name","CMV disease in all patients by antiviral medication"
"CD003774_pub5_data","Analysis.name","CMV disease for different organ transplants"
"CD003774_pub5_data","Analysis.name","CMV disease and ganciclovir duration"
"CD003774_pub5_data","Analysis.name","CMV disease and ATG therapy and antiviral efficacy"
"CD003774_pub5_data","Analysis.name","CMV disease and immunosuppression without ATG induction and antiviral efficacy"
"CD003774_pub5_data","Analysis.name","All-cause death according to antiviral medication"
"CD003774_pub5_data","Analysis.name","All-cause death according to CMV status"
"CD003774_pub5_data","Analysis.name","All-cause death for different organ transplants"
"CD003774_pub5_data","Analysis.name","All-cause death and ganciclovir duration"
"CD003774_pub5_data","Analysis.name","All-cause death with or without ATG therapy and antiviral efficacy"
"CD003774_pub5_data","Analysis.name","CMV infection"
"CD003774_pub5_data","Analysis.name","Death due to CMV disease or other causes"
"CD003774_pub5_data","Analysis.name","Additional outcomes: all medications"
"CD003774_pub5_data","Analysis.name","Acute rejection according to method of diagnosis"
"CD003774_pub5_data","Analysis.name","Valaciclovir: additional outcomes"
"CD003774_pub5_data","Analysis.name","Adverse effects"
"CD003774_pub5_data","Analysis.name","Allocation concealment"
"CD003774_pub5_data","Analysis.name","Blinding of participants/investigators"
"CD003774_pub5_data","Analysis.name","Intention-to-treat analysis (ITT)"
"CD003774_pub5_data","Analysis.name","CMV disease by time of outcome assessment"
"CD003774_pub5_data","Analysis.name","CMV disease by trial publication date"
"CD003774_pub5_data","Analysis.name","Blinding of participants and investigators"
"CD003774_pub5_data","Analysis.name","All-cause death and time of outcome assessment or trial publication date"
"CD003774_pub5_data","Analysis.name","All-cause death and trial publication date"
"CD003774_pub5_data","Analysis.name","CMV disease in all treated patients"
"CD003774_pub5_data","Analysis.name","CMV disease by antibody +ve recipients"
"CD003774_pub5_data","Analysis.name","CMV disease by +ve donors / CMV -ve recipients"
"CD003774_pub5_data","Analysis.name","CMV -ve donor / CMV -ve recipient"
"CD003774_pub5_data","Analysis.name","CMV disease and effect of prophylaxis for different transplanted organs"
"CD003774_pub5_data","Analysis.name","Death"
"CD003774_pub5_data","Analysis.name","CMV infection by antibody +ve recipients"
"CD003774_pub5_data","Analysis.name","CMV infection by +ve donors / CMV -ve recipients"
"CD003774_pub5_data","Analysis.name","CMV infection and effect of prophylaxis for different transplanted organs"
"CD003774_pub5_data","Analysis.name","Additional outcomes"
"CD003774_pub5_data","Analysis.name","CMV infection in all treated patients"
"CD003774_pub5_data","Analysis.name","CMV disease in CMV donor +ve / recipient -ve"
"CD003774_pub5_data","Analysis.name","CMV infection in CMV donor +ve / recipient -ve"
"CD003774_pub5_data","Analysis.name","Kidney function at end of study"
"CD003774_pub5_data","Analysis.name","IV doses given at different frequencies"
"CD003774_pub5_data","Analysis.name","Oral versus IV ganciclovir"
"CD003774_pub5_data","Analysis.name","CMV syndrome"
"CD003774_pub5_data","Analysis.name","CMV invasive disease"
"CD003774_pub5_data","Analysis.name","All-cause death"
"CD003774_pub5_data","Analysis.name","Graft loss"
"CD003774_pub5_data","Analysis.name","Acute rejection"
"CD003774_pub5_data","Analysis.name","Other outcomes"
"CD003774_pub5_data","Analysis.name","Adverse events"
"CD003774_pub5_data","Subgroup","All symptomatic CMV disease"
"CD003774_pub5_data","Subgroup","CMV syndrome"
"CD003774_pub5_data","Subgroup","CMV organ involvement"
"CD003774_pub5_data","Subgroup","CMV antibody +ve recipients"
"CD003774_pub5_data","Subgroup","CMV +ve donor / CMV -ve recipient"
"CD003774_pub5_data","Subgroup","CMV -ve donor / CMV -ve recipient"
"CD003774_pub5_data","Subgroup","CMV +ve donor / CMV +ve recipient"
"CD003774_pub5_data","Subgroup","CMV -ve donor / CMV +ve recipient"
"CD003774_pub5_data","Subgroup","Aciclovir"
"CD003774_pub5_data","Subgroup","Ganciclovir"
"CD003774_pub5_data","Subgroup","Valaciclovir"
"CD003774_pub5_data","Subgroup","Kidney transplant recipients"
"CD003774_pub5_data","Subgroup","Liver transplant recipients"
"CD003774_pub5_data","Subgroup","Heart transplant recipients"
"CD003774_pub5_data","Subgroup","Six weeks or less"
"CD003774_pub5_data","Subgroup","More than 6 weeks"
"CD003774_pub5_data","Subgroup","CMV disease in all treated patients"
"CD003774_pub5_data","Subgroup","CMV +ve recipients"
"CD003774_pub5_data","Subgroup","CMV -ve recipients of CMV +ve organs"
"CD003774_pub5_data","Subgroup","Liver transplant patients"
"CD003774_pub5_data","Subgroup","Without ATG therapy"
"CD003774_pub5_data","Subgroup","With ATG therapy"
"CD003774_pub5_data","Subgroup","Total CMV infection"
"CD003774_pub5_data","Subgroup","CMV disease"
"CD003774_pub5_data","Subgroup","Other causes"
"CD003774_pub5_data","Subgroup","Graft loss"
"CD003774_pub5_data","Subgroup","Acute rejection"
"CD003774_pub5_data","Subgroup","Herpes simplex and H. zoster infection"
"CD003774_pub5_data","Subgroup","Invasive fungal infection"
"CD003774_pub5_data","Subgroup","Bacterial infection"
"CD003774_pub5_data","Subgroup","EBV-associated PTLD"
"CD003774_pub5_data","Subgroup","Protozoal infections"
"CD003774_pub5_data","Subgroup","Biopsy-proven acute rejection"
"CD003774_pub5_data","Subgroup","Clinical diagnosis of acute rejection or method not stated"
"CD003774_pub5_data","Subgroup","Total with acute rejection"
"CD003774_pub5_data","Subgroup","Acute rejection in donor CMV +ve / recipient CMV -ve grafts"
"CD003774_pub5_data","Subgroup","Acute rejection in CMV +ve recipients"
"CD003774_pub5_data","Subgroup","Kidney dysfunction with aciclovir"
"CD003774_pub5_data","Subgroup","Neurological dysfunction with aciclovir"
"CD003774_pub5_data","Subgroup","Leucopenia with ganciclovir"
"CD003774_pub5_data","Subgroup","Kidney dysfunction with ganciclovir"
"CD003774_pub5_data","Subgroup","Neurological dysfunction with ganciclovir"
"CD003774_pub5_data","Subgroup","Leucopenia with valaciclovir"
"CD003774_pub5_data","Subgroup","Neurological dysfunction with valaciclovir"
"CD003774_pub5_data","Subgroup","Leucopenia for all medications"
"CD003774_pub5_data","Subgroup","Kidney dysfunction for all medications"
"CD003774_pub5_data","Subgroup","Adequate"
"CD003774_pub5_data","Subgroup","Inadequate/unclear"
"CD003774_pub5_data","Subgroup","Blinding"
"CD003774_pub5_data","Subgroup","No blinding"
"CD003774_pub5_data","Subgroup","ITT undertaken"
"CD003774_pub5_data","Subgroup","ITT not undertaken"
"CD003774_pub5_data","Subgroup","Outcome at 9-12 months"
"CD003774_pub5_data","Subgroup","Outcome at 3-6 months"
"CD003774_pub5_data","Subgroup","Trials published before 1997"
"CD003774_pub5_data","Subgroup","Trials published in 1997 and later"
"CD003774_pub5_data","Subgroup","Outcome at 4-6 months"
"CD003774_pub5_data","Subgroup","Outcome in trials published before 1997"
"CD003774_pub5_data","Subgroup","Outcome in trials published in 1997 or later"
"CD003774_pub5_data","Subgroup","CMV disease in all patients"
"CD003774_pub5_data","Subgroup","CMV disease in patients treated with ganciclovir for 3 months"
"CD003774_pub5_data","Subgroup","CMV disease in patients treated with ganciclovir for 2-4 weeks then aciclovir"
"CD003774_pub5_data","Subgroup","CMV disease in kidney transplant patients"
"CD003774_pub5_data","Subgroup","CMV disease in liver transplant patients"
"CD003774_pub5_data","Subgroup","CMV disease in heart or lung transplant patients"
"CD003774_pub5_data","Subgroup","Death associated with CMV disease"
"CD003774_pub5_data","Subgroup","All-cause death"
"CD003774_pub5_data","Subgroup","CMV infection"
"CD003774_pub5_data","Subgroup","CMV infection in kidney transplant patients"
"CD003774_pub5_data","Subgroup","CMV infection in liver transplant patients"
"CD003774_pub5_data","Subgroup","CMV infection in heart or lung transplant patients"
"CD003774_pub5_data","Subgroup","Kidney dysfunction"
"CD003774_pub5_data","Subgroup","Other viral infections"
"CD003774_pub5_data","Subgroup","Invasive fungal infections"
"CD003774_pub5_data","Subgroup","Bacterial infections"
"CD003774_pub5_data","Subgroup","Obliterative bronchiolitis in lung transplant recipients"
"CD003774_pub5_data","Subgroup","Leucopenia"
"CD003774_pub5_data","Subgroup","Neurological dysfunction"
"CD003774_pub5_data","Subgroup","EBV infection"
"CD003774_pub5_data","Subgroup","CMV disease by 6 months"
"CD003774_pub5_data","Subgroup","CMV disease by 1 year"
"CD003774_pub5_data","Subgroup","CMV syndrome by 6 months"
"CD003774_pub5_data","Subgroup","CMV syndrome by 1 year"
"CD003774_pub5_data","Subgroup","Tissue invasive CMV disease by 6 months"
"CD003774_pub5_data","Subgroup","Tissue invasive CMV disease by 1 year"
"CD003774_pub5_data","Subgroup","CMV disease in liver transplant recipients by 6 months"
"CD003774_pub5_data","Subgroup","CMV disease in renal transplant recipients by 6 months"
"CD003774_pub5_data","Subgroup","CMV disease in heart transplant recipients by 6 months"
"CD003774_pub5_data","Subgroup","CMV disease in renal-pancreas transplant recipients by 6 months"
"CD003774_pub5_data","Subgroup","CMV infection by 6 months"
"CD003774_pub5_data","Subgroup","CMV infection by 1 year"
"CD003774_pub5_data","Subgroup","Death due to CMV disease"
"CD003774_pub5_data","Subgroup","Acute rejection in all recipients"
"CD003774_pub5_data","Subgroup","Opportunistic infections"
"CD003774_pub5_data","Subgroup","Neutrophil count < 1000/mm³"
"CD003774_pub5_data","Subgroup","Medications ceased because of neutropenia"
"CD003774_pub5_data","Subgroup","Anaemia (< 80 g/L)"
"CD003774_pub5_data","Subgroup","Thrombocytopenia"
"CD003774_pub5_data","Subgroup","Tremor"
"CD003774_pub5_data","Subgroup","CMV disease in donor +ve or -ve/recipient +ve"
"CD003774_pub5_data","Subgroup","CMV disease in donor +ve/recipient -ve"
"CD003774_pub5_data","Subgroup","CMV infection in donor +ve or -ve/recipient +ve"
"CD003774_pub5_data","Subgroup","CMV infection in donor +ve/recipient -ve"
"CD003774_pub5_data","Subgroup","Anaemia"
"CD003774_pub5_data","Subgroup","Dose reduction or cessation for adverse effects"
"CD003774_pub5_data","Subgroup","Other herpes virus infections"
"CD003774_pub5_data","Subgroup","Non-viral infections"
"CD003774_pub5_data","Subgroup","Polyoma viremia"
"CD003774_pub5_data","Subgroup","Polyomavirus associated nephropathy"
"CD003774_pub5_data","Subgroup","Neutropenia"
"CD003774_pub5_data","Subgroup","Serum creatinine"
"CD003774_pub5_data","Subgroup","Calculated GFR"
"CD003774_pub5_data","Subgroup","Invasive CMV disease"
"CD003774_pub5_data","Subgroup","Bacteraemia"
"CD003774_pub5_data","Subgroup","Bronchiolitis obliterans syndrome"
"CD003774_pub5_data","Subgroup","CMV invasive organ disease"
"CD003774_pub5_data","Subgroup","Leucopenia due to ganciclovir"
"CD003774_pub5_data","Subgroup","Medications ceased due to leucopenia"
"CD003774_pub5_data","Subgroup","CMV disease at end of treatment"
"CD003774_pub5_data","Subgroup","CMV disease at 9 months"
"CD003774_pub5_data","Subgroup","CMV disease at 12 months"
"CD003774_pub5_data","Subgroup","CMV disease at 24 months"
"CD003774_pub5_data","Subgroup","Number at 12 months"
"CD003774_pub5_data","Subgroup","Number at 24 months"
"CD003774_pub5_data","Subgroup","Number at 2 years"
"CD003774_pub5_data","Subgroup","CMV infection at end of treatment"
"CD003774_pub5_data","Subgroup","CMV infection at 9 months"
"CD003774_pub5_data","Subgroup","CMV infection at 12 months"
"CD003774_pub5_data","Subgroup","Biopsy-proven acute rejection at 24 months"
"CD003774_pub5_data","Subgroup","Biopsy-proved acute rejection < 100 days"
"CD003774_pub5_data","Subgroup","Biopsy-proven acute rejection at 12 months"
"CD003774_pub5_data","Subgroup","Post-transplant diabetes mellitus"
"CD003774_pub5_data","Subgroup","Total treatment-related adverse effects"
"CD003774_pub5_data","Subgroup","Treatment-related serious adverse effects"
"CD003774_pub5_data","Subgroup","Leukopenia"
"CD003774_pub5_data","Subgroup","Leucopenia leading to VGCV cessation"
"CD003774_pub5_data","Subgroup","Termination due to treatment related adverse effects"
"CD003774_pub5_data","Subgroup","Hospitalisations due to CMV disease"
"CD003774_pub5_data","Subgroup","Hospitalisations due to adverse effects"
"CD003774_pub5_data","Subgroup","CMV mutations known to confer ganciclovir resistance"
"CD003833_pub5_data","Analysis.group","1"
"CD003833_pub5_data","Analysis.name","Walking distance"
"CD003833_pub5_data","Analysis.name","Ankle brachial index"
"CD003833_pub5_data","Analysis.name","Cholesterol"
"CD003833_pub5_data","Analysis.name","Triglycerides"
"CD003833_pub5_data","Analysis.name","Blood pressure"
"CD003833_pub5_data","Analysis.name","Vascular events"
"CD003833_pub5_data","Subgroup","Pain-free walking distance"
"CD003833_pub5_data","Subgroup","Maximum walking distance"
"CD003833_pub5_data","Subgroup","Post-intervention"
"CD003833_pub5_data","Subgroup","High-density lipoprotein cholesterol"
"CD003833_pub5_data","Subgroup","Very low-density lipoprotein cholesterol"
"CD003833_pub5_data","Subgroup","Low-density lipoprotein cholesterol"
"CD003833_pub5_data","Subgroup","Total cholesterol"
"CD003833_pub5_data","Subgroup","Systolic blood pressure "
"CD003833_pub5_data","Subgroup","Diastolic blood pressure"
"CD003833_pub5_data","Subgroup","Non-fatal stroke"
"CD003833_pub5_data","Subgroup","Non-fatal coronary events"
"CD003962_pub3_data","Analysis.group","1"
"CD003962_pub3_data","Analysis.group","2"
"CD003962_pub3_data","Analysis.group","3"
"CD003962_pub3_data","Analysis.group","4"
"CD003962_pub3_data","Analysis.group","5"
"CD003962_pub3_data","Analysis.group","6"
"CD003962_pub3_data","Analysis.group","7"
"CD003962_pub3_data","Analysis.group","8"
"CD003962_pub3_data","Analysis.name","Kidney failure or doubling of serum creatinine"
"CD003962_pub3_data","Analysis.name","Complete remission of proteinuria"
"CD003962_pub3_data","Analysis.name","Partial remission of proteinuria"
"CD003962_pub3_data","Analysis.name","Proteinuria"
"CD003962_pub3_data","Analysis.name","Haematuria"
"CD003962_pub3_data","Analysis.name","Serum creatinine"
"CD003962_pub3_data","Analysis.name","Doubling of serum creatinine"
"CD003962_pub3_data","Analysis.name","> 50% increase in serum creatinine"
"CD003962_pub3_data","Analysis.name","Change in serum creatinine"
"CD003962_pub3_data","Analysis.name","Creatinine clearance"
"CD003962_pub3_data","Analysis.name","Adverse events"
"CD003962_pub3_data","Analysis.name","Serious adverse events"
"CD003962_pub3_data","Analysis.name","Death"
"CD003962_pub3_data","Analysis.name","Kidney failure"
"CD003962_pub3_data","Analysis.name","Remission of proteinuria"
"CD003962_pub3_data","Analysis.name","Complete remission"
"CD003962_pub3_data","Analysis.name","Partial remission"
"CD003962_pub3_data","Analysis.name","Change in creatinine clearance"
"CD003962_pub3_data","Analysis.name","Cardiovascular events"
"CD003962_pub3_data","Analysis.name","Gastrointestinal hemorrhage"
"CD003962_pub3_data","Analysis.name","Leukopenia"
"CD003962_pub3_data","Analysis.name","Hyperkalaemia"
"CD003962_pub3_data","Analysis.name","Nausea"
"CD003962_pub3_data","Analysis.name","Infection"
"CD003962_pub3_data","Analysis.name","Systolic blood pressure"
"CD003962_pub3_data","Analysis.name","Change in proteinuria"
"CD003962_pub3_data","Analysis.name","Change in haematuria (cells/mL x 105)"
"CD003962_pub3_data","Analysis.name","> 50% decrease in creatinine clearance"
"CD003962_pub3_data","Analysis.name","Relapse of proteinuria"
"CD003962_pub3_data","Analysis.name","Remission of haematuria"
"CD003962_pub3_data","Analysis.name","Relapse of haematuria"
"CD003962_pub3_data","Analysis.name","Remission in proteinuria"
"CD003962_pub3_data","Analysis.name","Remission in haematuria"
"CD003962_pub3_data","Analysis.name","Diarrhoea"
"CD003962_pub3_data","Analysis.name","Diastolic blood pressure"
"CD003962_pub3_data","Analysis.name","Body weight"
"CD003962_pub3_data","Analysis.name","BMI"
"CD003962_pub3_data","Analysis.name","Waist circumference"
"CD003962_pub3_data","Analysis.name","> 50% decrease in proteinuria"
"CD003962_pub3_data","Analysis.name","Proteinuria (UPCR)"
"CD003962_pub3_data","Analysis.name","Albuminuria"
"CD003962_pub3_data","Analysis.name","Annual eGFR loss (mL/min/1.73 m2)"
"CD003962_pub3_data","Analysis.name","Change in eGFR (mL/min/1.73 m2)"
"CD003962_pub3_data","Analysis.name","Dizziness"
"CD003962_pub3_data","Subgroup","ARB versus placebo"
"CD003962_pub3_data","Subgroup","ACEi versus ARB"
"CD003962_pub3_data","Subgroup","ACEi versus antiplatelet agent"
"CD003962_pub3_data","Subgroup","ACEi versus CCB or BB"
"CD003962_pub3_data","Subgroup","ACEi versus placebo"
"CD003962_pub3_data","Subgroup","ACEi or ARB + steroids + tonsillectomy vs steroids + tonsillectomy (24 months)"
"CD003962_pub3_data","Subgroup","ACEi or ARB versus placebo"
"CD003962_pub3_data","Subgroup","CCB versus placebo"
"CD003962_pub3_data","Subgroup","ACEi versus antiplatelet"
"CD003962_pub3_data","Subgroup","ACEi or ARB + standard care versus standard care"
"CD003962_pub3_data","Subgroup","ACEi versus herbal medicine"
"CD003962_pub3_data","Subgroup","ACEi or ARB + herbal medicine versus herbal medicine"
"CD003962_pub3_data","Subgroup","ACEi or ARB or ACEi + ARB versus other antihypertensive to manage BP as required"
"CD003962_pub3_data","Subgroup","ACEi + ARB versus ARB or ACEi"
"CD003962_pub3_data","Subgroup","ACEi or ARB versus CCB"
"CD003962_pub3_data","Subgroup","ARB versus antiplatelet therapy"
"CD003962_pub3_data","Subgroup","ARB + herbal versus herbal medicine"
"CD003962_pub3_data","Subgroup","High versus low-dose ARB"
"CD003962_pub3_data","Subgroup","ACEi + antiplatelet versus antiplatelet"
"CD003962_pub3_data","Subgroup","ACEi versus CCB"
"CD003962_pub3_data","Subgroup","ACEi versus other antihypertensive to manage BP as required"
"CD003962_pub3_data","Subgroup","ACEi or ARB versus anticoagulant/antiplatelet"
"CD003962_pub3_data","Subgroup","ACEi + standard care versus standard care"
"CD003962_pub3_data","Subgroup","RASi versus placebo"
"CD003962_pub3_data","Subgroup","ACEi or ARB + steroids + tonsillectomy vs steroids + tonsillectomy"
"CD003962_pub3_data","Subgroup","Anticoagulant + other treatment versus other treatment"
"CD003962_pub3_data","Subgroup","Anticoagulant + ACEi or ARB versus ACEi or ARB"
"CD003962_pub3_data","Subgroup","Anticoagulant versus placebo or no treatment"
"CD003962_pub3_data","Subgroup","Low-dose anticoagulant versus placebo"
"CD003962_pub3_data","Subgroup","High-dose anticoagulant versus placebo"
"CD003962_pub3_data","Subgroup","Anticoagulant + antiplatelet versus standard care"
"CD003962_pub3_data","Subgroup","Anticoagulant versus hirudin"
"CD003962_pub3_data","Subgroup","Anticoagulant versus other treatment"
"CD003962_pub3_data","Subgroup","Anticoagulant versus no treatment"
"CD003962_pub3_data","Subgroup","Anticoagulant + steroid versus steroid"
"CD003962_pub3_data","Subgroup","Anticoagulant versus vitamin B"
"CD003962_pub3_data","Subgroup","Anticoagulant versus vitamin B12"
"CD003962_pub3_data","Subgroup","Anticoagulant + steroid versus steroid alone"
"CD003962_pub3_data","Subgroup","Fish oil versus placebo/no treatment"
"CD003962_pub3_data","Subgroup","Fish oil versus symptomatic treatment of blood pressure"
"CD003962_pub3_data","Subgroup","High versus low-dose fish oil"
"CD003962_pub3_data","Subgroup","Fish oil versus symptomatic treatment of BP"
"CD003962_pub3_data","Subgroup","Statins + other treatment versus other treatment"
"CD003962_pub3_data","Subgroup","Statins+other treatment versus other treatment"
"CD003962_pub3_data","Subgroup","Children"
"CD003962_pub3_data","Subgroup","Adults"
"CD003962_pub3_data","Subgroup","Microscopic haematuria"
"CD003962_pub3_data","Subgroup","Macroscopic haematuria"
"CD003962_pub3_data","Subgroup","Adults "
"CD003962_pub3_data","Subgroup","Herbal medicine versus placebo/no treatment"
"CD003962_pub3_data","Subgroup","Herbal medicine versus Western medicine: Children"
"CD003962_pub3_data","Subgroup","Herbal medicine versus Western medicine: Adults"
"CD003962_pub3_data","Subgroup","Herbal medicine versus other treatment"
"CD003962_pub3_data","Subgroup","Herbal medicine versus placebo/no treatment or standard care"
"CD003962_pub3_data","Subgroup","Herbal medicine + standard care versus standard care"
"CD003962_pub3_data","Subgroup","Vitamin E versus placebo/no treatment"
"CD003962_pub3_data","Subgroup","Low calorie diet versus usual diet"
"CD003962_pub3_data","Subgroup","Antioxidant versus other treatment"
"CD003962_pub3_data","Subgroup","Phenytoin versus placebo/no treatment"
"CD003962_pub3_data","Subgroup","Sodium cromoglycate versus placebo/no treatment"
"CD003962_pub3_data","Subgroup","Urokinase + ACEi versus ACEi"
"CD003962_pub3_data","Subgroup","Antimalarial versus placebo"
"CD003962_pub3_data","Subgroup","Vitamin D versus no treatment/standard care"
"CD003962_pub3_data","Subgroup","Allopurinol versus no placebo/no treatment"
"CD003962_pub3_data","Subgroup","Urokinase+ACEi versus ACEi"
"CD003962_pub3_data","Subgroup","Vitamin D versus no treatement/standard of care"
"CD003962_pub3_data","Subgroup","Vitamin D versus no treatment"
"CD003962_pub3_data","Subgroup","Vitamin D versus no treatment/standard of care"
"CD004184_pub3_data","Analysis.group","1"
"CD004184_pub3_data","Analysis.group","2"
"CD004184_pub3_data","Analysis.name","All-cause mortality"
"CD004184_pub3_data","Analysis.name","Serious adverse events"
"CD004184_pub3_data","Analysis.name","Overall adverse events"
"CD004184_pub3_data","Analysis.name","Withdrawals from treatment due to adverse events"
"CD004184_pub3_data","Analysis.name","24-hour mean systolic blood pressure (SBP) change by ambulatory blood pressure monitoring (ABPM) (mmHg)"
"CD004184_pub3_data","Analysis.name","24-hour mean diastolic blood pressure (DBP) change by ABPM (mmHg)"
"CD004184_pub3_data","Analysis.name","Mean SBP change by ABPM (mmHg)"
"CD004184_pub3_data","Analysis.name","Mean DBP change by ABPM (mmHg)"
"CD004184_pub3_data","Analysis.name","Surge of SBP (mmHg)"
"CD004184_pub3_data","Analysis.name","Surge of DBP (mmHg)"
"CD004184_pub3_data","Subgroup","Calcium channel blockers"
"CD004184_pub3_data","Subgroup","Angiotensin II receptor blockers"
"CD004184_pub3_data","Subgroup","Angiotensin-converting enzyme inhibitors"
"CD004184_pub3_data","Subgroup","Diuretics"
"CD004184_pub3_data","Subgroup","β-blockers"
"CD004184_pub3_data","Subgroup","α-blockers"
"CD004184_pub3_data","Subgroup","Calcium channel blocker"
"CD004307_pub7_data","Analysis.group","1"
"CD004307_pub7_data","Analysis.group","2"
"CD004307_pub7_data","Analysis.name","Smoking cessation (subgrouped by when incentives were provided)"
"CD004307_pub7_data","Analysis.name","Smoking cessation (grouped by substance misuse)"
"CD004307_pub7_data","Analysis.name","Smoking cessation in mixed populations (generic inverse-variance analysis - including new cluster trials)"
"CD004307_pub7_data","Analysis.name","Smoking cessation at longest follow-up"
"CD004307_pub7_data","Analysis.name","Abstinence at end of pregnancy"
"CD004307_pub7_data","Analysis.name","Contingent rewards versus guaranteed payments"
"CD004307_pub7_data","Subgroup","Incentives provided at longest follow-up"
"CD004307_pub7_data","Subgroup","Incentives not provided at longest follow-up"
"CD004307_pub7_data","Subgroup","Substance misusers"
"CD004307_pub7_data","Subgroup","Non-substance misusers"
"CD004372_pub3_data","Analysis.group","1"
"CD004372_pub3_data","Analysis.name","Mean difference in HADS-D scores at 3-month follow-up"
"CD004372_pub3_data","Analysis.name","Mean difference in HADS-D scores at 12-month follow-up"
"CD004376_pub4_data","Analysis.group","1"
"CD004376_pub4_data","Analysis.group","2"
"CD004376_pub4_data","Analysis.group","3"
"CD004376_pub4_data","Analysis.group","4"
"CD004376_pub4_data","Analysis.name","Knee pain severity immediately post-intervention"
"CD004376_pub4_data","Analysis.name","Self-reported physical function immediately post-intervention"
"CD004376_pub4_data","Analysis.name","Quality of life immediately post-intervention"
"CD004376_pub4_data","Analysis.name","Participant-reported treatment success immediately post-intervention"
"CD004376_pub4_data","Analysis.name","Study withdrawals at final follow-up"
"CD004376_pub4_data","Analysis.name","Adverse events at final follow-up"
"CD004376_pub4_data","Analysis.name","Knee pain severity"
"CD004376_pub4_data","Analysis.name","Self-reported physical function"
"CD004376_pub4_data","Analysis.name","Quality of life"
"CD004376_pub4_data","Analysis.name","Selection bias: knee pain severity"
"CD004376_pub4_data","Analysis.name","Selection bias: self-reported physical function"
"CD004376_pub4_data","Analysis.name","Attrition bias: knee pain severity"
"CD004376_pub4_data","Analysis.name","Attrition bias: self-reported physical function"
"CD004376_pub4_data","Analysis.name","Detection bias: knee pain severity"
"CD004376_pub4_data","Analysis.name","Detection bias: self-reported physical function"
"CD004376_pub4_data","Analysis.name","Exercise vs attention control/placebo (pain severity)"
"CD004376_pub4_data","Analysis.name","Exercise vs attention control/placebo (physical function)"
"CD004376_pub4_data","Analysis.name","Exercise vs no treatment/usual care/limited education (pain severity)"
"CD004376_pub4_data","Analysis.name","Exercise vs no treatment/usual care/limited education (physical function)"
"CD004376_pub4_data","Analysis.name","Exercise when added to another co-intervention (compared to that co-intervention alone) (pain severity)"
"CD004376_pub4_data","Analysis.name","Exercise when added to another co-intervention (compared to that co-intervention alone) (physical function)"
"CD004376_pub4_data","Subgroup","A) Exercise vs attention control/placebo"
"CD004376_pub4_data","Subgroup","B) Exercise vs no treatment/usual care/limited education"
"CD004376_pub4_data","Subgroup","C) Exercise when added to another co-intervention"
"CD004376_pub4_data","Subgroup","Mixed"
"CD004376_pub4_data","Subgroup","Stretching"
"CD004376_pub4_data","Subgroup","Mind-body"
"CD004376_pub4_data","Subgroup","Aerobic"
"CD004376_pub4_data","Subgroup","Strengthening"
"CD004376_pub4_data","Subgroup","Balance/proprioceptive"
"CD004406_pub6_data","Analysis.group","1"
"CD004406_pub6_data","Analysis.group","2"
"CD004406_pub6_data","Analysis.group","3"
"CD004406_pub6_data","Analysis.group","4"
"CD004406_pub6_data","Analysis.group","5"
"CD004406_pub6_data","Analysis.group","6"
"CD004406_pub6_data","Analysis.name","Resolution of symptoms post-treatment (ITT analysis)"
"CD004406_pub6_data","Analysis.name","Resolution of symptoms post-treatment (evaluable participants)"
"CD004406_pub6_data","Analysis.name","Resolution of symptoms within 24 hours of treatment (ITT analysis)"
"CD004406_pub6_data","Analysis.name","Resolution of symptoms ITT (subgroup sponsored versus no sponsor reported)"
"CD004406_pub6_data","Analysis.name","Sore throat (ITT analysis)"
"CD004406_pub6_data","Analysis.name","Fever (ITT analysis)"
"CD004406_pub6_data","Analysis.name","Incidence of relapse (evaluable participants)"
"CD004406_pub6_data","Analysis.name","Complications (ITT analysis)"
"CD004406_pub6_data","Analysis.name","Adverse events (ITT analysis)"
"CD004406_pub6_data","Analysis.name","Resolution of symptoms post-treatment (evaluable participants only)"
"CD004406_pub6_data","Analysis.name","Sore throat post-treatment (ITT analysis)"
"CD004406_pub6_data","Analysis.name","Fever post-treatment (ITT analysis)"
"CD004406_pub6_data","Analysis.name","Clinical cure at 24 to 28 days (ITT)"
"CD004406_pub6_data","Analysis.name","Clinical cure at 24 to 28 days (bacteriological per protocol population)"
"CD004406_pub6_data","Analysis.name","Relapse on day 38 to 45 (ITT)"
"CD004406_pub6_data","Analysis.name","Relapse on day 38 to 45 (bacteriological per protocol)"
"CD004406_pub6_data","Analysis.name","Adverse events (all participants)"
"CD004406_pub6_data","Subgroup","Adults"
"CD004406_pub6_data","Subgroup","Children"
"CD004406_pub6_data","Subgroup","Sponsor not reported"
"CD004406_pub6_data","Subgroup","Sponsored studies"
"CD004417_pub6_data","Analysis.group","1"
"CD004417_pub6_data","Analysis.group","2"
"CD004417_pub6_data","Analysis.group","3"
"CD004417_pub6_data","Analysis.group","4"
"CD004417_pub6_data","Analysis.group","5"
"CD004417_pub6_data","Analysis.group","6"
"CD004417_pub6_data","Analysis.group","7"
"CD004417_pub6_data","Analysis.name","Number of participants with pain on days 3 to 6: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Pain severity on day 3: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Duration of pain: delayed versus immediate antibiotics (days)"
"CD004417_pub6_data","Analysis.name","Duration of pain: delayed versus no antibiotics (days) "
"CD004417_pub6_data","Analysis.name","Number of participants with malaise on days 3 to 6: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Malaise severity on day 3: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Duration of malaise: delayed versus immediate antibiotics "
"CD004417_pub6_data","Analysis.name","Duration of malaise: delayed versus no antibiotics"
"CD004417_pub6_data","Analysis.name","Number of participants with fever on days 3 to 6: delayed (prescription at time of visit) versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Fever severity on day 3: delayed (prescription at time of visit) versus immediate antibiotic"
"CD004417_pub6_data","Analysis.name","Duration of fever: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Duration of fever: delayed versus no antibiotics"
"CD004417_pub6_data","Analysis.name","Antibiotic use: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Antibiotic use: delayed versus no antibiotics"
"CD004417_pub6_data","Analysis.name","Patient satisfaction: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Patient satisfaction: delayed versus no antibiotics"
"CD004417_pub6_data","Analysis.name","Vomiting: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Vomiting: delayed (prescription collection) versus no antibiotics"
"CD004417_pub6_data","Analysis.name","Diarrhoea: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Diarrhoea: delayed (prescription collection) versus no antibiotics"
"CD004417_pub6_data","Analysis.name","Rash: delayed (prescription collection) versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Rash: delayed (prescription collection) versus no antibiotics"
"CD004417_pub6_data","Analysis.name","Reconsultation rate: delayed versus immediate antibiotics"
"CD004417_pub6_data","Analysis.name","Reconsultation rate: delayed versus no antibiotics"
"CD004417_pub6_data","Subgroup","Delayed (prescription at time of visit) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Delayed (prescription collection) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Pharyngitis: delayed (prescription at time of visit) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Pharyngitis: delayed (prescription collection) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Acute otitis media: delayed (prescription at time of visit) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Pharyngitis pain: delayed (prescription at time of visit) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Pharyngitis pain: delayed (prescription collection) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Acute otitis media pain: delayed (prescription at time of visit) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Delayed (all strategies) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Delayed (both strategies) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Delayed (prescription collection) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Delayed (prescription at time of visit) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Pharyngitis: Delayed (prescription at time of visit) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Pharyngitis: delayed (prescription at time of visit) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Antibiotic use: delayed (prescription at time of visit) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Antibiotic use: delayed (prescription collection) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Antibiotic use: delayed (both strategies) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Antibiotic use: delayed (prescription at time of visit) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Antibiotic use: delayed (prescription collection) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Antibiotic use: delayed (all strategies) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Patient satisfaction: delayed (prescription collection) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Patient satisfaction: delayed (prescription at time of visit) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Patient satisfaction: delayed (all strategies) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Patient satisfaction: delayed (prescription collection) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Patient satisfaction: delayed (all strategies) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Patient satisfaction: delayed (prescription at time of visit) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Reconsultation rate: delayed (prescription at time of visit) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Reconsultation rate: delayed (all strategies) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Reconsultation rate: delayed (prescription collection) versus immediate antibiotics"
"CD004417_pub6_data","Subgroup","Reconsultation rate: delayed (prescription at time of visit) versus no antibiotics "
"CD004417_pub6_data","Subgroup","Reconsultation rate: delayed (prescription collection) versus no antibiotics"
"CD004417_pub6_data","Subgroup","Reconsultation rate: delayed (all strategies) versus no antibiotics "
"CD004508_pub5_data","Analysis.group","1"
"CD004508_pub5_data","Analysis.name","Postoperative ileus"
"CD004508_pub5_data","Analysis.name","Nausea or vomiting, or both (random-effects model)"
"CD004508_pub5_data","Analysis.name","Nausea (random-effects model)"
"CD004508_pub5_data","Analysis.name","Vomiting"
"CD004508_pub5_data","Analysis.name","Abdominal distension"
"CD004508_pub5_data","Analysis.name","Postoperative placement of nasogastric tube"
"CD004508_pub5_data","Analysis.name","Time to the presence of bowel sounds (random-effects model)"
"CD004508_pub5_data","Analysis.name","Time to the first passage of flatus"
"CD004508_pub5_data","Analysis.name","Time to the first passage of stool"
"CD004508_pub5_data","Analysis.name","Time to the first solid diet (random-effects model)"
"CD004508_pub5_data","Analysis.name","Hospital stay (random-effects model)"
"CD004508_pub5_data","Analysis.name","Febrile morbidity"
"CD004508_pub5_data","Analysis.name","Infectious complications"
"CD004508_pub5_data","Analysis.name","Wound complications"
"CD004508_pub5_data","Analysis.name","Pneumonia"
"CD004508_pub5_data","Analysis.name","Satisfaction"
"CD004661_pub4_data","Analysis.group","1"
"CD004661_pub4_data","Analysis.group","2"
"CD004661_pub4_data","Analysis.group","3"
"CD004661_pub4_data","Analysis.group","4"
"CD004661_pub4_data","Analysis.group","5"
"CD004661_pub4_data","Analysis.group","6"
"CD004661_pub4_data","Analysis.group","7"
"CD004661_pub4_data","Analysis.group","8"
"CD004661_pub4_data","Analysis.group","9"
"CD004661_pub4_data","Analysis.group","10"
"CD004661_pub4_data","Analysis.group","11"
"CD004661_pub4_data","Analysis.name","Death (fetal, neonatal, or later (up to 2 years' corrected age))"
"CD004661_pub4_data","Analysis.name","Cerebral palsy (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Death or cerebral palsy (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Major neurodevelopmental disability (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Death or major neurodevelopmental disability (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Death (fetal, neonatal, or later (up to school age))"
"CD004661_pub4_data","Analysis.name","Cerebral palsy (school age)"
"CD004661_pub4_data","Analysis.name","Death or cerebral palsy (up to school age)"
"CD004661_pub4_data","Analysis.name","Major neurodevelopmental disability (school age)"
"CD004661_pub4_data","Analysis.name","Death or major neurodevelopmental disability (up to school age)"
"CD004661_pub4_data","Analysis.name","Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)"
"CD004661_pub4_data","Analysis.name","Adverse effects severe enough to stop treatment"
"CD004661_pub4_data","Analysis.name","Fetal death"
"CD004661_pub4_data","Analysis.name","Neonatal death"
"CD004661_pub4_data","Analysis.name","Birthweight"
"CD004661_pub4_data","Analysis.name","Length at birth"
"CD004661_pub4_data","Analysis.name","Head circumference at birth"
"CD004661_pub4_data","Analysis.name","Gestational age at birth (weeks)"
"CD004661_pub4_data","Analysis.name","Apgar score less than 7 at 5 minutes"
"CD004661_pub4_data","Analysis.name","Use of active resuscitation at birth"
"CD004661_pub4_data","Analysis.name","Intraventricular haemorrhage"
"CD004661_pub4_data","Analysis.name","Severe intraventricular haemorrhage (grade 3 or 4)"
"CD004661_pub4_data","Analysis.name","Cystic periventricular leukomalacia"
"CD004661_pub4_data","Analysis.name","Ventriculomegaly"
"CD004661_pub4_data","Analysis.name","Neonatal encephalopathy"
"CD004661_pub4_data","Analysis.name","Neonatal convulsions"
"CD004661_pub4_data","Analysis.name","Neonatal hypotonia"
"CD004661_pub4_data","Analysis.name","Necrotising enterocolitis"
"CD004661_pub4_data","Analysis.name","Retinopathy of prematurity"
"CD004661_pub4_data","Analysis.name","Patent ductus arteriosus"
"CD004661_pub4_data","Analysis.name","Respiratory distress syndrome"
"CD004661_pub4_data","Analysis.name","Chronic lung disease/bronchopulmonary dysplasia"
"CD004661_pub4_data","Analysis.name","Use of respiratory support (endotracheal intubation)"
"CD004661_pub4_data","Analysis.name","Use of respiratory support (mechanical ventilation or continuous positive airway pressure) "
"CD004661_pub4_data","Analysis.name","Use of inotropic support"
"CD004661_pub4_data","Analysis.name","Air leak syndrome"
"CD004661_pub4_data","Analysis.name","Early- or late-onset sepsis"
"CD004661_pub4_data","Analysis.name","Severe adverse neonatal outcome composite"
"CD004661_pub4_data","Analysis.name","Later death (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Cerebral palsy severity (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Any neurodevelopmental disability (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Death or any neurodevelopmental disability (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Blindness (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Deafness (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Developmental delay/intellectual impairment (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Gross motor dysfunction (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Psychomotor dysfunction (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Death or substantial gross motor dysfunction (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Growth (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Respiratory function (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Blood pressure (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Behaviour (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Later death (school age)"
"CD004661_pub4_data","Analysis.name","Cerebral palsy severity (school age)"
"CD004661_pub4_data","Analysis.name","Any neurodevelopmental disability (school age)"
"CD004661_pub4_data","Analysis.name","Death or any neurodevelopmental disability (school age)"
"CD004661_pub4_data","Analysis.name","Blindness (school age)"
"CD004661_pub4_data","Analysis.name","Deafness (school age)"
"CD004661_pub4_data","Analysis.name","Developmental delay/intellectual impairment (school age)"
"CD004661_pub4_data","Analysis.name","Gross motor dysfunction (school age)"
"CD004661_pub4_data","Analysis.name","Death or substantial gross motor dysfunction (school age)"
"CD004661_pub4_data","Analysis.name","Growth (school age)"
"CD004661_pub4_data","Analysis.name","Respiratory function (school age)"
"CD004661_pub4_data","Analysis.name","Behaviour (school age)"
"CD004661_pub4_data","Analysis.name","Educational achievement (school age)"
"CD004661_pub4_data","Analysis.name","Death"
"CD004661_pub4_data","Analysis.name","Cardiac arrest"
"CD004661_pub4_data","Analysis.name","Respiratory arrest"
"CD004661_pub4_data","Analysis.name","Side effects of treatment"
"CD004661_pub4_data","Analysis.name","Side effect: respiratory depression"
"CD004661_pub4_data","Analysis.name","Side effect: hypotension"
"CD004661_pub4_data","Analysis.name","Side effect: tachycardia"
"CD004661_pub4_data","Analysis.name","Side effect: warmth over body/flushing"
"CD004661_pub4_data","Analysis.name","Side effect: arm discomfort with infusion"
"CD004661_pub4_data","Analysis.name","Side effect: mouth dryness"
"CD004661_pub4_data","Analysis.name","Side effect: nausea or vomiting"
"CD004661_pub4_data","Analysis.name","Side effect: sleepiness"
"CD004661_pub4_data","Analysis.name","Side effect: sweating"
"CD004661_pub4_data","Analysis.name","Side effect: dizziness"
"CD004661_pub4_data","Analysis.name","Side effect: blurred vision"
"CD004661_pub4_data","Analysis.name","Side effect: tendon reflex abolition"
"CD004661_pub4_data","Analysis.name","Side effect: ""curarisation"""
"CD004661_pub4_data","Analysis.name","Side effect: headache"
"CD004661_pub4_data","Analysis.name","Mode of birth: caesarean birth"
"CD004661_pub4_data","Analysis.name","Chorioamnionitis"
"CD004661_pub4_data","Analysis.name","Postpartum haemorrhage"
"CD004661_pub4_data","Analysis.name","Maternal admission to the intensive care unit"
"CD004661_pub4_data","Analysis.name","Length of postnatal hospitalisation for women (days)"
"CD004661_pub4_data","Analysis.name","Length of neonatal/infant hospitalisation (days)"
"CD004661_pub4_data","Analysis.name","Hospital admissions (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Postdischarge service (up to 2 years' corrected age)"
"CD004661_pub4_data","Analysis.name","Hospital admissions (school age)"
"CD004661_pub4_data","Subgroup","Defined, where possible, as up to hospital discharge"
"CD004661_pub4_data","Subgroup","Variously defined"
"CD004661_pub4_data","Subgroup","Birthweight (z-scores)"
"CD004661_pub4_data","Subgroup","Birthweight (grams)"
"CD004661_pub4_data","Subgroup","Length (z-scores)"
"CD004661_pub4_data","Subgroup","Length (cm)"
"CD004661_pub4_data","Subgroup","Head circumference (z-scores)"
"CD004661_pub4_data","Subgroup","Head circumference (cm)"
"CD004661_pub4_data","Subgroup","Chest compressions"
"CD004661_pub4_data","Subgroup","Any"
"CD004661_pub4_data","Subgroup","Intubation"
"CD004661_pub4_data","Subgroup","Supplementary oxygen"
"CD004661_pub4_data","Subgroup","Sepsis"
"CD004661_pub4_data","Subgroup","Early onset sepsis"
"CD004661_pub4_data","Subgroup","Late onset sepsis"
"CD004661_pub4_data","Subgroup","Maternal-fetal infection"
"CD004661_pub4_data","Subgroup","Moderate to severe"
"CD004661_pub4_data","Subgroup","Mild"
"CD004661_pub4_data","Subgroup","Substantial"
"CD004661_pub4_data","Subgroup","Weight (kg)"
"CD004661_pub4_data","Subgroup","Height (cm)"
"CD004661_pub4_data","Subgroup","Head circumference (z-score)"
"CD004661_pub4_data","Subgroup","Weight (z-score)"
"CD004661_pub4_data","Subgroup","Height (z-score)"
"CD004661_pub4_data","Subgroup","Asthma or wheezing"
"CD004661_pub4_data","Subgroup","Childhood respiratory morbidity"
"CD004661_pub4_data","Subgroup","Hypertension (any)"
"CD004661_pub4_data","Subgroup","Systolic hypertension"
"CD004661_pub4_data","Subgroup","Diastolic hypertension"
"CD004661_pub4_data","Subgroup","Systolic blood pressure (mmHg)"
"CD004661_pub4_data","Subgroup","Diastolic blood pressure (mmHg)"
"CD004661_pub4_data","Subgroup","Systolic blood pressure (z-score)"
"CD004661_pub4_data","Subgroup","Diastolic blood pressure (z-score)"
"CD004661_pub4_data","Subgroup","Child Behavior Checklist, sleeping problem (scores in clinical range (> 97.5th percentile))"
"CD004661_pub4_data","Subgroup","Child Behavior Checklist, destructive behaviour (scores in clinical range (> 97.5th percentile))"
"CD004661_pub4_data","Subgroup","Child Behavior Checklist, total (scores in clinical range (> 97.5th percentile))"
"CD004661_pub4_data","Subgroup","Child Behavior Checklist, anxiety (scores in clinical range (> 97.5th percentile))"
"CD004661_pub4_data","Subgroup","Child Behavior Checklist, withdrawal (scores in clinical range (> 97.5th percentile))"
"CD004661_pub4_data","Subgroup","Child Behavior Checklist, somatic problem (scores in clinical range (> 97.5th percentile))"
"CD004661_pub4_data","Subgroup","Child Behavior Checklist, aggressive behaviour (scores in clinical range (> 97.5th percentile))"
"CD004661_pub4_data","Subgroup","Child Behavior Checklist, other (scores in clinical range (> 97.5th percentile))"
"CD004661_pub4_data","Subgroup","Severe"
"CD004661_pub4_data","Subgroup","Mild to moderate"
"CD004661_pub4_data","Subgroup","Moderate"
"CD004661_pub4_data","Subgroup","Motor deficits: no cerebral palsy, other motor disorder"
"CD004661_pub4_data","Subgroup","Motor dysfunction/deficits"
"CD004661_pub4_data","Subgroup","Movement Assessment Battery for Children (MABC): suspect/abnormal"
"CD004661_pub4_data","Subgroup","Gross Motor Function Classification System (GMFCS): levels I-V"
"CD004661_pub4_data","Subgroup","Height (SD scores)"
"CD004661_pub4_data","Subgroup","BMI (SD scores)"
"CD004661_pub4_data","Subgroup","Head circumference (SD scores)"
"CD004661_pub4_data","Subgroup","Weight (SD scores)"
"CD004661_pub4_data","Subgroup","Borderline and abnormal Conduct Problem Scale"
"CD004661_pub4_data","Subgroup","Borderline and abnormal Peer Problems Scale"
"CD004661_pub4_data","Subgroup","Borderline and abnormal Hyperactivity Scale"
"CD004661_pub4_data","Subgroup","Borderline and abnormal Prosocial Scale"
"CD004661_pub4_data","Subgroup","Borderline and abnormal Emotional Symptoms Scale"
"CD004661_pub4_data","Subgroup","'Behavioral and psychiatric disorder' (moderate)"
"CD004661_pub4_data","Subgroup","Borderline and abnormal Total Difficulties Score"
"CD004661_pub4_data","Subgroup","BRIEF teacher T scores: global executive composite"
"CD004661_pub4_data","Subgroup","BRIEF teacher T scores: metacognition index"
"CD004661_pub4_data","Subgroup","BRIEF teacher T scores: behavioral regulation index"
"CD004661_pub4_data","Subgroup","CADS teacher T scores: DSM-IV inattentive"
"CD004661_pub4_data","Subgroup","CADS teacher T scores: DSM-IV hyperactive-impulsive"
"CD004661_pub4_data","Subgroup","CADS teacher T scores: ADHD index"
"CD004661_pub4_data","Subgroup","CADS teacher T scores: DSM-IV"
"CD004661_pub4_data","Subgroup","CADS parent T scores: DSM-IV hyperactive-impulsive"
"CD004661_pub4_data","Subgroup","CADS parent T scores: DSM-IV"
"CD004661_pub4_data","Subgroup","CADS parent T scores: ADHD index"
"CD004661_pub4_data","Subgroup","CADS parent T scores: DSM-IV inattentive"
"CD004661_pub4_data","Subgroup","Language disorder"
"CD004661_pub4_data","Subgroup","Schooling: specialised class room"
"CD004661_pub4_data","Subgroup","Schooling: specialised institution"
"CD004661_pub4_data","Subgroup","Schooling: home education services"
"CD004661_pub4_data","Subgroup","Schooling: repeated grades"
"CD004661_pub4_data","Subgroup","Schooling: specific education assistance"
"CD004661_pub4_data","Subgroup","General cognitive function: working memory index"
"CD004661_pub4_data","Subgroup","General cognitive function: verbal comprehension index"
"CD004661_pub4_data","Subgroup","General cognitive function: perceptual reasoning index"
"CD004661_pub4_data","Subgroup","General cognitive function: processing speed index"
"CD004661_pub4_data","Subgroup","Academic skills: reading"
"CD004661_pub4_data","Subgroup","Academic skills: spelling"
"CD004661_pub4_data","Subgroup","General cognitive function: full scale IQ"
"CD004661_pub4_data","Subgroup","Academic skills: arithmetic"
"CD004661_pub4_data","Subgroup","As defined"
"CD004661_pub4_data","Subgroup","Postpartum haemorrhage"
"CD004661_pub4_data","Subgroup","Severe postpartum haemorrhage"
"CD004661_pub4_data","Subgroup","< 30 weeks' gestation"
"CD004661_pub4_data","Subgroup","< 32 weeks' gestation"
"CD004661_pub4_data","Subgroup","< 34 weeks' gestation"
"CD004661_pub4_data","Subgroup","4 g"
"CD004661_pub4_data","Subgroup","> 4 g"
"CD004661_pub4_data","Subgroup","2 g/hour"
"CD004661_pub4_data","Subgroup","1 g/hour"
"CD004661_pub4_data","Subgroup","No"
"CD004661_pub4_data","Subgroup","Yes"
"CD004667_pub6_data","Analysis.group","1"
"CD004667_pub6_data","Analysis.group","2"
"CD004667_pub6_data","Analysis.group","3"
"CD004667_pub6_data","Analysis.group","5"
"CD004667_pub6_data","Analysis.name","Spontaneous vaginal birth (as defined by trial authors)"
"CD004667_pub6_data","Analysis.name","Caesarean birth"
"CD004667_pub6_data","Analysis.name","Regional analgesia (epidural/spinal)"
"CD004667_pub6_data","Analysis.name","Intact perineum"
"CD004667_pub6_data","Analysis.name","Fetal loss at or after 24 weeks gestation"
"CD004667_pub6_data","Analysis.name","Preterm birth (< 37 weeks)"
"CD004667_pub6_data","Analysis.name","Neonatal death (baby born alive at any gestation and dies within 28 days)"
"CD004667_pub6_data","Analysis.name","Maternal death"
"CD004667_pub6_data","Analysis.name","Induction of labour"
"CD004667_pub6_data","Analysis.name","Instrumental vaginal birth (forceps/vacuum)"
"CD004667_pub6_data","Analysis.name","Episiotomy"
"CD004667_pub6_data","Analysis.name","Third or fourth degree tear"
"CD004667_pub6_data","Analysis.name","Postpartum haemorrhage (as defined by trial authors)"
"CD004667_pub6_data","Analysis.name","Breastfeeding initiation"
"CD004667_pub6_data","Analysis.name","Maternal readmission within 28 days"
"CD004667_pub6_data","Analysis.name","Attendance at birth by known midwife"
"CD004667_pub6_data","Analysis.name","Birth weight less than 2500 g"
"CD004667_pub6_data","Analysis.name","Apgar score less than or equal to 7 at 5 minutes"
"CD004667_pub6_data","Analysis.name","Admission to special care nursery/neonatal intensive care unit"
"CD004667_pub6_data","Analysis.name","Fetal loss before 24 weeks gestation"
"CD004667_pub6_data","Subgroup","Caseload/one-to-one"
"CD004667_pub6_data","Subgroup","Team"
"CD004667_pub6_data","Subgroup","Low risk"
"CD004667_pub6_data","Subgroup","Mixed risk"
"CD004667_pub6_data","Subgroup","High, medium, and low HDI"
"CD004667_pub6_data","Subgroup","Very high HDI"
"CD004703_pub3_data","Analysis.group","1"
"CD004703_pub3_data","Analysis.group","2"
"CD004703_pub3_data","Analysis.group","3"
"CD004703_pub3_data","Analysis.name","Serious adverse events"
"CD004703_pub3_data","Analysis.name","Chronic pain (persisting for > 6 months after surgery)"
"CD004703_pub3_data","Analysis.name","Hernia recurrence"
"CD004703_pub3_data","Analysis.name","Bleeding"
"CD004703_pub3_data","Analysis.name","Conversion to another hernia repair method"
"CD004703_pub3_data","Analysis.name","Conversion from laparoscopic technique  to open surgery"
"CD004703_pub3_data","Analysis.name","Return to work (days)"
"CD004703_pub3_data","Analysis.name","Early postoperative pain (6 hours postoperative)"
"CD004703_pub3_data","Analysis.name","Early postoperative pain (12 hours postoperative)"
"CD004703_pub3_data","Analysis.name","Early postoperative pain (30th postoperative day)"
"CD004703_pub3_data","Analysis.name","Haematoma or seroma"
"CD004736_pub6_data","Analysis.group","1"
"CD004736_pub6_data","Analysis.group","2"
"CD004736_pub6_data","Analysis.group","3"
"CD004736_pub6_data","Analysis.group","4"
"CD004736_pub6_data","Analysis.group","5"
"CD004736_pub6_data","Analysis.group","6"
"CD004736_pub6_data","Analysis.name","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Maternal iron deficiency at term (as defined by trialists, based on any indicator of iron status at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)"
"CD004736_pub6_data","Analysis.name","Adverse effects (any reported throughout the intervention period) (ALL)"
"CD004736_pub6_data","Analysis.name","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Adverse effects (any reported throughout the intervention period): SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Maternal clinical malaria"
"CD004736_pub6_data","Analysis.name","Low birthweight (less than 2500 g) (ALL)"
"CD004736_pub6_data","Analysis.name","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Low birthweight (less than 2500 g): SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Birthweight (g) (ALL)"
"CD004736_pub6_data","Analysis.name","Birthweight (g): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Birthweight (g): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Birthweight (g): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Birthweight (g): SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Preterm birth (less than 37 weeks of gestation) (ALL)"
"CD004736_pub6_data","Analysis.name","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Neonatal death (within 28 days after delivery) (ALL)"
"CD004736_pub6_data","Analysis.name","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Congenital anomalies (ALL)"
"CD004736_pub6_data","Analysis.name","Congenital anomalies: SUBGROUP ANALYSIS by gestational age at the start of supplementation)"
"CD004736_pub6_data","Analysis.name","Congenital anomalies: SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Congenital anomalies: SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Congenital anomalies: SUBGROUP ANALYSIS by malarial status of setting"
"CD004736_pub6_data","Analysis.name","Maternal anaemia at or near term (Hb less than 110 g/L at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal iron deficiency at or near term (as defined by as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal iron-deficiency anaemia at or near term (Hb less than 110 g/L and at least one additional laboratory indicator at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal Hb concentration at or near term (in g/L, at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal Hb concentration within 6 weeks postpartum (in g/L) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal high haemoglobin concentrations during second or third trimester (Hb more than 130 g/L) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal high haemoglobin concentrations at or near term (Hb more than 130 g/L at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Moderate anaemia at postpartum (Hb more than 80 g/L and less than 110 g/L) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Severe anaemia postpartum (Hb less than 80 g/L) (ALL)"
"CD004736_pub6_data","Analysis.name","Puerperal infection (ALL)"
"CD004736_pub6_data","Analysis.name","Antepartum haemorrhage (ALL)"
"CD004736_pub6_data","Analysis.name","Postpartum haemorrhage (ALL)"
"CD004736_pub6_data","Analysis.name","Transfusion provided (ALL)"
"CD004736_pub6_data","Analysis.name","Diarrhoea (ALL)"
"CD004736_pub6_data","Analysis.name","Constipation (ALL)"
"CD004736_pub6_data","Analysis.name","Nausea (ALL)"
"CD004736_pub6_data","Analysis.name","Heartburn (ALL)"
"CD004736_pub6_data","Analysis.name","Vomiting (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal wellbeing/satisfaction (ALL)"
"CD004736_pub6_data","Analysis.name","Placental abruption (ALL)"
"CD004736_pub6_data","Analysis.name","Pre-eclampsia (ALL)"
"CD004736_pub6_data","Analysis.name","Very low birthweight (less than 1500 g) (ALL)"
"CD004736_pub6_data","Analysis.name","Very premature birth (less than 34 weeks' gestation) (ALL)"
"CD004736_pub6_data","Analysis.name","Infant Hb concentration within the first 6 months (in g/L counting the last reported measure after birth within this period) (ALL)"
"CD004736_pub6_data","Analysis.name","Infant serum ferritin concentration within first 6 months (in μg/L counting the last reported measure after birth within this period) (ALL)"
"CD004736_pub6_data","Analysis.name","Admission to special care unit (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestation at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by gestation at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Infection during pregnancy (including urinary tract infections) (ALL)"
"CD004736_pub6_data","Analysis.name","Birthweight (ALL)"
"CD004736_pub6_data","Analysis.name","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by gestation at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Preterm birth (less than 37 weeks of gestation): SUBGROUP ANALYSIS by malarial status of settings"
"CD004736_pub6_data","Analysis.name","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestation at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by malarial status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal iron deficiency at or near term (as defined by trialists, based on any indicator of iron status at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at or near term (Hb less than 70 g/L at 34 weeks' gestation or more ) (ALL)"
"CD004736_pub6_data","Analysis.name","Severe anaemia at postpartum (Hb less than 80 g/L) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks gestation or more): SUBGROUP ANALYSIS by anaemia status at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal iron-deficiency anaemia at term (Hb less than 110 g/L and at least one additional laboratory indicator at 37 weeks' gestation or more): SUBGROUP ANALYSIS by gestational age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at any time during second and third trimester (Hb less than 70 g/L): SUBGROUP ANALYSIS by anaemia status age at the start of supplementation"
"CD004736_pub6_data","Analysis.name","Infant Hb concentration in the first 6 months (in g/L, counting the last reported measure after birth within this period) (ALL)"
"CD004736_pub6_data","Analysis.name","Infant serum ferritin concentration in the first 6 months (in μg/L, counting the last reported measure after birth within this period) (ALL)"
"CD004736_pub6_data","Analysis.name","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by gestational age at start of supplementation"
"CD004736_pub6_data","Analysis.name","Neonatal death (within 28 days after delivery): SUBGROUP ANALYSIS by anaemia status at start of supplementation"
"CD004736_pub6_data","Analysis.name","Maternal Hb concentration at term or near term (in g/L, at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal Hb concentration within 6 weeks postpartum (g/L) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal severe anaemia at term or near (Hb less than 70 g/L at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Analysis.name","Maternal anaemia at term (Hb less than 110 g/L at 37 weeks' gestation or more ): SUBGROUP ANALYSIS by dose of iron"
"CD004736_pub6_data","Analysis.name","Maternal Hb concentration at or near term (in g/L at 34 weeks' gestation or more) (ALL)"
"CD004736_pub6_data","Subgroup","Early gestational age (supplementation started before 20 weeks' gestation or prior to pregnancy)"
"CD004736_pub6_data","Subgroup","Late gestational age (supplementation started at 20 weeks of gestation or later)"
"CD004736_pub6_data","Subgroup","Unspecified or mixed gestational age"
"CD004736_pub6_data","Subgroup","Non-anaemic at the start of supplementation"
"CD004736_pub6_data","Subgroup","Unspecified or mixed anaemia status"
"CD004736_pub6_data","Subgroup","Low daily dose (30 mg or less of elemental iron)"
"CD004736_pub6_data","Subgroup","Medium daily dose (more than 30 mg and less than 60 mg elemental iron)"
"CD004736_pub6_data","Subgroup","Higher daily dose (60 mg elemental iron or more)"
"CD004736_pub6_data","Subgroup","Malarial setting"
"CD004736_pub6_data","Subgroup","Non-malarial setting"
"CD004736_pub6_data","Subgroup","Unspecified/mixed anaemia status"
"CD004736_pub6_data","Subgroup","Unspecified or mixed gestational age at the start of supplementation"
"CD004736_pub6_data","Subgroup","Low daily dose of iron (30 mg or less of elemental iron)"
"CD004736_pub6_data","Subgroup","Higher daily dose of iron (60 mg elemental iron or more)"
"CD004736_pub6_data","Subgroup","Early gestational age (less than 20 weeks of gestation or pre-pregnancy) at start of supplementation"
"CD004736_pub6_data","Subgroup","Late gestational age (20 weeks or more of gestation) at start of supplementation"
"CD004736_pub6_data","Subgroup","Unspecified or mixed gestational age at start of supplementation"
"CD004736_pub6_data","Subgroup","Non-anaemic at start of supplementation"
"CD004736_pub6_data","Subgroup","Unspecified or mixed anaemic status at start of supplementation"
"CD004736_pub6_data","Subgroup","Higher daily dose (60 mg elemental iron and above)"
"CD004736_pub6_data","Subgroup","Low daily dose (30 mg elemental iron or less)"
"CD004736_pub6_data","Subgroup","Medium daily dose (31 mg to 59 mg elemental iron)"
"CD004736_pub6_data","Subgroup","Daily low dose (60 mg elemental iron or less)"
"CD004736_pub6_data","Subgroup","Medium dose (31 mg to 59 mg elemental iron)"
"CD004736_pub6_data","Subgroup","High dose (60 mg elemental iron and above)"
"CD004762_pub3_data","Analysis.group","1"
"CD004762_pub3_data","Analysis.group","2"
"CD004762_pub3_data","Analysis.group","3"
"CD004762_pub3_data","Analysis.group","4"
"CD004762_pub3_data","Analysis.name","Improvement of myotonia: visual analogue scale "
"CD004762_pub3_data","Analysis.name","Relaxation time (seconds, 90% to 5%)"
"CD004762_pub3_data","Analysis.name","Quality of life: 36-item Short Form"
"CD004762_pub3_data","Analysis.name","Quality of life: Individualized Neuromuscular Quality of Life"
"CD004762_pub3_data","Analysis.name","Improvement of myotonia: stiffness reported on interactive voice response system"
"CD004762_pub3_data","Analysis.name","Relaxation time (seconds)"
"CD004762_pub3_data","Analysis.name","Electromyographic (EMG) relaxation time"
"CD004762_pub3_data","Analysis.name","Relaxation time (seconds, log transformed) "
"CD004762_pub3_data","Analysis.name","Quality of life: 36-item Short Form (overall health status)"
"CD004762_pub3_data","Analysis.name","Relaxation time"
"CD004762_pub3_data","Subgroup","Mexiletine 150 mg 3 times daily "
"CD004762_pub3_data","Subgroup","Mexiletine 200 mg 3 times daily "
"CD004762_pub3_data","Subgroup","Mental Component Summary (MCS)"
"CD004762_pub3_data","Subgroup","Physical Component Summary (PCS)"
"CD004762_pub3_data","Subgroup","First treatment period"
"CD004762_pub3_data","Subgroup","Second treatment period"
"CD004762_pub3_data","Subgroup","Entire treatment period"
"CD004762_pub3_data","Subgroup","Eye closure"
"CD004762_pub3_data","Subgroup","Hand grip"
"CD004762_pub3_data","Subgroup","Quantitative hand grip (90% to 5%)"
"CD004762_pub3_data","Subgroup","Needle EMG: right abductor digiti minimi"
"CD004762_pub3_data","Subgroup","Needle EMG: right tibialis anterior "
"CD004762_pub3_data","Subgroup","Needle EMG: left rectus femoris"
"CD004762_pub3_data","Subgroup","Physical Component Score (PCS)"
"CD004762_pub3_data","Subgroup","Mental Component Score: entire treatment period"
"CD004762_pub3_data","Subgroup","Mental Component Score (MCS): second treatment period"
"CD004762_pub3_data","Subgroup","Mental Component Score (MCS): first treatment period"
"CD004762_pub3_data","Subgroup","Hand grip  (log transformed effect size) "
"CD004762_pub3_data","Subgroup","Eyelid (log transformed effect size) "
"CD004871_pub5_data","Analysis.group","1"
"CD004871_pub5_data","Analysis.group","2"
"CD004871_pub5_data","Analysis.group","3"
"CD004871_pub5_data","Analysis.name","Pain (short-term)"
"CD004871_pub5_data","Analysis.name","Pain (dichotomous data; short-term)"
"CD004871_pub5_data","Analysis.name","Function-disability (short-term)"
"CD004871_pub5_data","Analysis.name","Participant-reported treatment success (short-term)"
"CD004871_pub5_data","Analysis.name","Participant-reported treatment success at short-term (dichotomous data)"
"CD004871_pub5_data","Analysis.name","Health-related quality of life (short-term)"
"CD004871_pub5_data","Analysis.name","Minor adverse events (dichotomous data; short-term)"
"CD004871_pub5_data","Analysis.name","Pain (short-term): subgroup analysis by disorder classification"
"CD004871_pub5_data","Analysis.name","Pain (dichotomous data; short-term): subgroup analysis by dosage"
"CD004871_pub5_data","Analysis.name","Pain (long-term)"
"CD004871_pub5_data","Analysis.name","Function-disability (long-term)"
"CD004871_pub5_data","Analysis.name","Health-related quality of life (long-term)"
"CD004871_pub5_data","Analysis.name","Pain (short-term): subgroup analysis by dose"
"CD004871_pub5_data","Analysis.name","Pain (short-term): subgroup analysis by symptom duration"
"CD004871_pub5_data","Analysis.name","Function-disability (short-term): subgroup analysis by dose"
"CD004871_pub5_data","Analysis.name","Function-disability (short-term): subgroup analysis by disorder classification"
"CD004871_pub5_data","Analysis.name","Function-disability (short-term): subgroup analysis by disorder duration"
"CD004871_pub5_data","Subgroup","Low-dose (single session)"
"CD004871_pub5_data","Subgroup","High-dose"
"CD004871_pub5_data","Subgroup","Medium-dose"
"CD004871_pub5_data","Subgroup","Whiplash-associated disorder"
"CD004871_pub5_data","Subgroup","Neck pain without radiculopathy"
"CD004871_pub5_data","Subgroup","3 x 60 minutes/week conventional massage versus no treatment (short-term)"
"CD004871_pub5_data","Subgroup","1 x 60 minutes/week conventional massage versus no treatment (short-term)"
"CD004871_pub5_data","Subgroup","3 x 30 minutes/week conventional massage versus no treatment (short-term)"
"CD004871_pub5_data","Subgroup","2 x 60 minutes/week conventional massage versus no treatment (short-term)"
"CD004871_pub5_data","Subgroup","2 x 30 minutes/week conventional massage versus no treatment (short-term)"
"CD004871_pub5_data","Subgroup","Massage as an adjunct to a passive treatment method"
"CD004871_pub5_data","Subgroup","Massage as an adjunct to an active (including exercise) treatment method"
"CD004871_pub5_data","Subgroup","Medium-dose adjuvant to an active (including exercise) method"
"CD004871_pub5_data","Subgroup","Medium-dose adjuvant to a passive method"
"CD004871_pub5_data","Subgroup","Massage adjuvant to a passive method"
"CD004871_pub5_data","Subgroup","Massage adjuvant to an active (including exercise) method"
"CD004871_pub5_data","Subgroup","Low-dose"
"CD004871_pub5_data","Subgroup","Radiculopathy"
"CD004871_pub5_data","Subgroup","Cervicogenic headache"
"CD004871_pub5_data","Subgroup","Subacute "
"CD004871_pub5_data","Subgroup","Chronic"
"CD004871_pub5_data","Subgroup","Medium-dose "
"CD004871_pub5_data","Subgroup","Low-dose (single session) "
"CD004871_pub5_data","Subgroup","Subacute"
"CD004904_pub4_data","Analysis.group","1"
"CD004904_pub4_data","Analysis.name","Postpartum endometritis"
"CD004904_pub4_data","Analysis.name","Postpartum haemorrhage "
"CD004904_pub4_data","Analysis.name","Newborn intensive care admission"
"CD004925_pub4_data","Analysis.group","1"
"CD004925_pub4_data","Analysis.name","Urine leak and obstruction"
"CD004925_pub4_data","Analysis.name","Subgroup analysis for major urological complications: duration of stenting"
"CD004925_pub4_data","Analysis.name","Subgroup analysis for major urological complications: surgeon's experience"
"CD004925_pub4_data","Analysis.name","UTI"
"CD004925_pub4_data","Analysis.name","UTI: diagnostic criteria"
"CD004925_pub4_data","Analysis.name","UTI: antibiotic regimen"
"CD004925_pub4_data","Analysis.name","Haematuria"
"CD004925_pub4_data","Subgroup","Urine leak"
"CD004925_pub4_data","Subgroup","Ureteric obstruction"
"CD004925_pub4_data","Subgroup","Combined: urine leak and obstruction"
"CD004925_pub4_data","Subgroup","Stent duration not specified"
"CD004925_pub4_data","Subgroup","Stent duration ≤ 14 days"
"CD004925_pub4_data","Subgroup","Stent duration > 14 days"
"CD004925_pub4_data","Subgroup","Same surgeon"
"CD004925_pub4_data","Subgroup","Many surgeons"
"CD004925_pub4_data","Subgroup","Culture only"
"CD004925_pub4_data","Subgroup","Culture plus symptoms/signs"
"CD004925_pub4_data","Subgroup","Co-trimoxazole: 480 mg once/day (960 mg on alternate days)"
"CD004925_pub4_data","Subgroup","Other regimen"
"CD004953_pub5_data","Analysis.group","1"
"CD004953_pub5_data","Analysis.group","2"
"CD004953_pub5_data","Analysis.name","Death in the delivery room"
"CD004953_pub5_data","Analysis.name","Death during hospitalisation"
"CD004953_pub5_data","Analysis.name","Death"
"CD004953_pub5_data","Analysis.name","Rate of mechanical ventilation"
"CD004953_pub5_data","Analysis.name","Chronic lung disease"
"CD004953_pub5_data","Analysis.name","Pneumothorax during hospitalisation"
"CD004953_pub5_data","Analysis.name","Cranial ultrasound abnormalities"
"CD004953_pub5_data","Analysis.name","Endotracheal intubation"
"CD004953_pub5_data","Analysis.name","Surfactant administration"
"CD004953_pub5_data","Analysis.name","Duration of mechanical ventilation"
"CD004953_pub5_data","Analysis.name","Sensitivity analysis - Duration of mechanical ventilation"
"CD004953_pub5_data","Analysis.name","Retinopathy of prematurity (ROP) stage ≥ 3"
"CD004953_pub5_data","Analysis.name","Patent ductus arteriosus (PDA)"
"CD004953_pub5_data","Analysis.name","Chronic lung disease, moderate to severe"
"CD004953_pub5_data","Analysis.name","Surfactant administration in the delivery room"
"CD004953_pub5_data","Analysis.name","Patent ductus arteriosus (PDA)  - pharmacological treatment"
"CD004953_pub5_data","Subgroup","Death in the delivery room"
"CD004953_pub5_data","Subgroup","Death during hospitalisation"
"CD004953_pub5_data","Subgroup","BPD any grade"
"CD004953_pub5_data","Subgroup","Moderate to severe BPD"
"CD004953_pub5_data","Subgroup","Intraventricular haemorrhage grade 3-4"
"CD004953_pub5_data","Subgroup","IVH any grade"
"CD004953_pub5_data","Subgroup","Cystic periventricular leukomalacia"
"CD004953_pub5_data","Subgroup","intubation in the delivery room (DR)"
"CD004953_pub5_data","Subgroup","intubation in the first 72 hours of age"
"CD004953_pub5_data","Subgroup","Surfactant given in the delivery room"
"CD004953_pub5_data","Subgroup","Surfactant given at any time"
"CD004953_pub5_data","Subgroup","PDA - pharmacological treatment"
"CD004953_pub5_data","Subgroup","PDA - surgical closure"
"CD004953_pub5_data","Subgroup","PDA - unclear if treated or how"
"CD004953_pub5_data","Subgroup","Death before discharge"
"CD004953_pub5_data","Subgroup","Intraventricular haemorrhage grade 3 to 4"
"CD004992_pub4_data","Analysis.group","1"
"CD004992_pub4_data","Analysis.name","Recurrence of pelvic pain"
"CD004992_pub4_data","Analysis.name","Recurrence of endometrioma"
"CD004992_pub4_data","Analysis.name","Requirement for further endometrioma surgery"
"CD004992_pub4_data","Analysis.name","Spontaneous pregnancy rate over the 12 months after surgery"
"CD004992_pub4_data","Analysis.name","Serum anti-Müllerian hormone levels (ng/mL) three months after surgery (short term)"
"CD004992_pub4_data","Analysis.name","Serum anti-Müllerian hormone levels (ng/mL) six months after surgery"
"CD004992_pub4_data","Analysis.name","Antral follicle count (number of follicles) six months after surgery"
"CD004992_pub4_data","Analysis.name","Ovarian volume (cm3) six months after surgery"
"CD004992_pub4_data","Analysis.name","Ovarian response (number of dominant follicles) after surgery"
"CD004992_pub4_data","Subgroup","Recurrence of dysmenorrhoea"
"CD004992_pub4_data","Subgroup","Recurrence of dyspareunia"
"CD004992_pub4_data","Subgroup","Excision vs drainage and ablation"
"CD004992_pub4_data","Subgroup","Excision vs three-step drainage and ablation"
"CD004992_pub4_data","Subgroup","Excision vs 3 step drainage and ablation"
"CD005133_pub4_data","Analysis.group","1"
"CD005133_pub4_data","Analysis.group","2"
"CD005133_pub4_data","Analysis.group","3"
"CD005133_pub4_data","Analysis.group","4"
"CD005133_pub4_data","Analysis.group","5"
"CD005133_pub4_data","Analysis.name","All symptomatic CMV disease"
"CD005133_pub4_data","Analysis.name","Death (any cause)"
"CD005133_pub4_data","Analysis.name","CMV organ involvement"
"CD005133_pub4_data","Analysis.name","CMV-associated symptoms"
"CD005133_pub4_data","Analysis.name","Acute rejection"
"CD005133_pub4_data","Analysis.name","Other infections"
"CD005133_pub4_data","Analysis.name","Graft loss"
"CD005133_pub4_data","Analysis.name","Adverse events"
"CD005133_pub4_data","Analysis.name","CMV infection"
"CD005133_pub4_data","Analysis.name","Time to to development CMV disease"
"CD005133_pub4_data","Analysis.name","High-risk recipients: D+/R- serostatus"
"CD005133_pub4_data","Analysis.name","Low-risk recipients: D+ or D-/R+ serostatus"
"CD005133_pub4_data","Analysis.name","CMV disease"
"CD005133_pub4_data","Subgroup","Leucopenia"
"CD005133_pub4_data","Subgroup","Kidney dysfunction"
"CD005133_pub4_data","Subgroup","More than 1 treatment-emergent adverse event"
"CD005133_pub4_data","Subgroup","Blood and lymphatic system disorders"
"CD005133_pub4_data","Subgroup","Congenital, familial and genetic disorders"
"CD005133_pub4_data","Subgroup","Ear and labyrinth disorders"
"CD005133_pub4_data","Subgroup","Eye disorders"
"CD005133_pub4_data","Subgroup","Gastro-intestinal disorders"
"CD005133_pub4_data","Subgroup","General disorders and administration site conditions"
"CD005133_pub4_data","Subgroup","Injury, poisoning and procedural complications"
"CD005133_pub4_data","Subgroup","Metabolism and nutrition disorders"
"CD005133_pub4_data","Subgroup","Musculoskeletal and connective tissue disorders"
"CD005133_pub4_data","Subgroup","Nervous system disorders"
"CD005133_pub4_data","Subgroup","Renal and urinary disorders"
"CD005133_pub4_data","Subgroup","Respiratory, thoracic and mediastinal disorders"
"CD005133_pub4_data","Subgroup","Vascular disorders"
"CD005133_pub4_data","Subgroup","Bacterial"
"CD005133_pub4_data","Subgroup","Viral"
"CD005133_pub4_data","Subgroup","Fungal"
"CD005133_pub4_data","Subgroup","Herpes simplex virus"
"CD005133_pub4_data","Subgroup","Acute pyelonephritis"
"CD005133_pub4_data","Subgroup","Polyomavirus BK viremia"
"CD005133_pub4_data","Subgroup","Pneumonia"
"CD005133_pub4_data","Subgroup","Sepsis"
"CD005133_pub4_data","Subgroup","Other viral infections"
"CD005133_pub4_data","Subgroup","Urinary tract infections"
"CD005133_pub4_data","Subgroup","Varicella zoster virus"
"CD005133_pub4_data","Subgroup","CMV disease within 100 days"
"CD005133_pub4_data","Subgroup","CMV disease after 100 days"
"CD005133_pub4_data","Subgroup","Neurological dysfunction"
"CD005133_pub4_data","Subgroup","Anaemia"
"CD005133_pub4_data","Subgroup","Thrombocytopenia"
"CD005133_pub4_data","Subgroup","Malignancy"
"CD005133_pub4_data","Subgroup","Hypertension"
"CD005133_pub4_data","Subgroup","Neutropenia"
"CD005133_pub4_data","Subgroup","Diarrhoea"
"CD005133_pub4_data","Subgroup","Pericardial effusion"
"CD005133_pub4_data","Subgroup","Kidney stones"
"CD005133_pub4_data","Subgroup","Hallucinations/confusion"
"CD005133_pub4_data","Subgroup","Nausea"
"CD005133_pub4_data","Subgroup","Headache"
"CD005133_pub4_data","Subgroup","Tremor"
"CD005133_pub4_data","Subgroup","Insomnia"
"CD005133_pub4_data","Subgroup","New-onset diabetes or impaired glucose tolerance"
"CD005133_pub4_data","Subgroup","Cardiovascular events"
"CD005133_pub4_data","Subgroup","Hypercholesterolaemia/hyperlipidemia"
"CD005133_pub4_data","Subgroup","Symptomatic CMV disease"
"CD005133_pub4_data","Subgroup","CMV infection"
"CD005133_pub4_data","Subgroup","Symptomatic CMV"
"CD005133_pub4_data","Subgroup","Deterioration of kidney function"
"CD005133_pub4_data","Subgroup","Kidney and urinary disorders"
"CD005133_pub4_data","Subgroup","Gastrointestinal disorders"
"CD005187_pub6_data","Analysis.group","1"
"CD005187_pub6_data","Analysis.group","2"
"CD005187_pub6_data","Analysis.name","Influenza"
"CD005187_pub6_data","Analysis.name","Lower respiratory tract infection"
"CD005187_pub6_data","Analysis.name","Admission to hospital for respiratory illness"
"CD005187_pub6_data","Analysis.name","Deaths from lower respiratory tract infection "
"CD005187_pub6_data","Analysis.name","Death from any cause"
"CD005187_pub6_data","Analysis.name","Deaths from influenza or its complications"
"CD005187_pub6_data","Subgroup","Unvaccinated residents"
"CD005187_pub6_data","Subgroup","Vaccinated and unvaccinated residents"
"CD005187_pub6_data","Subgroup","Vaccinated residents"
"CD005343_pub7_data","Analysis.group","1"
"CD005343_pub7_data","Analysis.name","Overall survival"
"CD005343_pub7_data","Analysis.name","Overall survival by age"
"CD005343_pub7_data","Analysis.name","Overall survival by stage"
"CD005343_pub7_data","Analysis.name","Overall survival by residual disease"
"CD005343_pub7_data","Analysis.name","Progression-free survival"
"CD005343_pub7_data","Analysis.name","Postoperative mortality"
"CD005343_pub7_data","Analysis.name","Surgically-related adverse effects (G3+)"
"CD005343_pub7_data","Analysis.name","Surgical resection"
"CD005343_pub7_data","Analysis.name","EORTC QLQ-C30 QoL at 6 months: functional status"
"CD005343_pub7_data","Analysis.name","EORTC QLQ-C30 QoL at 6 months; symptoms"
"CD005343_pub7_data","Analysis.name","EORTC QLQ-C30 QoL at 12 months; functional status"
"CD005343_pub7_data","Analysis.name","EORTC QLQ-C30 QoL at 12 months; symptoms"
"CD005343_pub7_data","Analysis.name","EORTC QLQ OV-28 score at 6 months"
"CD005343_pub7_data","Analysis.name","EORTC QLQ OV-28 score 12 months"
"CD005343_pub7_data","Analysis.name","Chemotherapy-related G3+AEs"
"CD005343_pub7_data","Subgroup","Age < 50 years"
"CD005343_pub7_data","Subgroup","Age 50-70 years"
"CD005343_pub7_data","Subgroup","Age > 70 years"
"CD005343_pub7_data","Subgroup","Age <60 years"
"CD005343_pub7_data","Subgroup","Age 60-70 years"
"CD005343_pub7_data","Subgroup","Age 50-60 years"
"CD005343_pub7_data","Subgroup","Stage 3"
"CD005343_pub7_data","Subgroup","Stage 4"
"CD005343_pub7_data","Subgroup","Residual disease up to 0.5cm"
"CD005343_pub7_data","Subgroup","Residual disease 1-2cm"
"CD005343_pub7_data","Subgroup","No macroscopic residual disease (NMRD)"
"CD005343_pub7_data","Subgroup","0.5cm > Residual disease ≤ 1cm"
"CD005343_pub7_data","Subgroup","Residual disease > 1 cm"
"CD005343_pub7_data","Subgroup","Residual disease >2cm"
"CD005343_pub7_data","Subgroup","Haemorrhage (G3+)"
"CD005343_pub7_data","Subgroup","Venous thromboembolism (G3+)"
"CD005343_pub7_data","Subgroup","Infection (G3+)"
"CD005343_pub7_data","Subgroup","Gastrointestinal fistula (G3+)"
"CD005343_pub7_data","Subgroup","Urinary/vaginal fistula (G3+)"
"CD005343_pub7_data","Subgroup","Nausea (G3+)"
"CD005343_pub7_data","Subgroup","Vomiting (G3+)"
"CD005343_pub7_data","Subgroup","Diarrhoea (G3+)"
"CD005343_pub7_data","Subgroup","Neutropenia (G3+)"
"CD005343_pub7_data","Subgroup","Neutrotoxicity (G3+)"
"CD005343_pub7_data","Subgroup","Thrombocytopenia (G3+)"
"CD005343_pub7_data","Subgroup","Febrile neutropenia (G3+)"
"CD005343_pub7_data","Subgroup","Need for blood transfusion"
"CD005343_pub7_data","Subgroup","Renal toxicity (G3+)"
"CD005343_pub7_data","Subgroup","Overall post-operative adverse events (G3+)"
"CD005343_pub7_data","Subgroup","Stoma formation"
"CD005343_pub7_data","Subgroup","Bowel resection"
"CD005343_pub7_data","Subgroup","Splenectomy"
"CD005343_pub7_data","Subgroup","Global health"
"CD005343_pub7_data","Subgroup","Financial difficulties"
"CD005343_pub7_data","Subgroup","Physical functioning"
"CD005343_pub7_data","Subgroup","Cognitive functioning"
"CD005343_pub7_data","Subgroup","Role functioning"
"CD005343_pub7_data","Subgroup","Emotional functioning "
"CD005343_pub7_data","Subgroup","Social functioning "
"CD005343_pub7_data","Subgroup","Fatigue"
"CD005343_pub7_data","Subgroup","Nausea and vomiting"
"CD005343_pub7_data","Subgroup","Pain"
"CD005343_pub7_data","Subgroup","Dyspneoa"
"CD005343_pub7_data","Subgroup","Insomnia"
"CD005343_pub7_data","Subgroup","Apetite loss"
"CD005343_pub7_data","Subgroup","Constipation"
"CD005343_pub7_data","Subgroup","Diarrhoea"
"CD005343_pub7_data","Subgroup","Emotional functioning (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Physical functioning (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Global health (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Role functioning (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Cognitive functioning (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Financial difficulties (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Social functioning (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Diarrhoea (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Constipation (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Insomnia (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Pain (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Dyspneoa (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Nausea and vomiting (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Fatigue (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Apetite loss (QLQ-C30 score)"
"CD005343_pub7_data","Subgroup","Abdominal GI symptoms"
"CD005343_pub7_data","Subgroup","Hair loss"
"CD005343_pub7_data","Subgroup","Sexuality"
"CD005343_pub7_data","Subgroup","Hormonal/menopausal symptoms"
"CD005343_pub7_data","Subgroup","Peripheral neuropathy"
"CD005343_pub7_data","Subgroup","Other chemotherapy side effects"
"CD005343_pub7_data","Subgroup","Body image "
"CD005343_pub7_data","Subgroup","Attitude to disease/treatment"
"CD005495_pub5_data","Analysis.group","1"
"CD005495_pub5_data","Analysis.group","2"
"CD005495_pub5_data","Analysis.group","3"
"CD005495_pub5_data","Analysis.group","4"
"CD005495_pub5_data","Analysis.group","5"
"CD005495_pub5_data","Analysis.group","6"
"CD005495_pub5_data","Analysis.group","7"
"CD005495_pub5_data","Analysis.name","Cognitive outcome in infancy - Developmental Quotient"
"CD005495_pub5_data","Analysis.name","Cognitive outcome at preschool age - Intelligence Quotient "
"CD005495_pub5_data","Analysis.name","Cognitive outcome at school age - Intelligence Quotient "
"CD005495_pub5_data","Analysis.name","Motor outcome in infancy - Developmental Quotient"
"CD005495_pub5_data","Analysis.name","Motor outcome at preschool age "
"CD005495_pub5_data","Analysis.name","Motor outcome at school age "
"CD005495_pub5_data","Analysis.name","Rate of cerebral palsy"
"CD005495_pub5_data","Analysis.name","Cognitive outcome at preschool age - Intelligence Quotient"
"CD005495_pub5_data","Analysis.name","Motor outcome at school age"
"CD005495_pub5_data","Analysis.name","Motor outcome at school age (low score on MABC)"
"CD005495_pub5_data","Analysis.name","Motor outcome in infancy "
"CD005495_pub5_data","Analysis.name","Motor outcome at preschool age"
"CD005495_pub5_data","Subgroup","28 to < 32 weeks"
"CD005495_pub5_data","Subgroup","< 28 weeks"
"CD005495_pub5_data","Subgroup","1500 to < 2500 grams birthweight"
"CD005495_pub5_data","Subgroup","1000 to < 1500 grams birthweight"
"CD005495_pub5_data","Subgroup","< 1000 grams birthweight"
"CD005495_pub5_data","Subgroup","Absence of PVL/IVH"
"CD005495_pub5_data","Subgroup","Presence of PVL/IVH"
"CD005495_pub5_data","Subgroup","Inpatient"
"CD005495_pub5_data","Subgroup","Post hospital discharge"
"CD005495_pub5_data","Subgroup","Parent-infant relationship"
"CD005495_pub5_data","Subgroup","Infant development"
"CD005495_pub5_data","Subgroup","Parent-infant relationship and Infant development"
"CD005495_pub5_data","Subgroup","Parent-infant relationship and infant development"
"CD005495_pub5_data","Subgroup","Parent-infant and infant development"
"CD005495_pub5_data","Subgroup","Low risk of selection bias"
"CD005495_pub5_data","Subgroup","High risk of selection bias"
"CD005566_pub4_data","Analysis.group","1"
"CD005566_pub4_data","Analysis.group","2"
"CD005566_pub4_data","Analysis.group","3"
"CD005566_pub4_data","Analysis.group","4"
"CD005566_pub4_data","Analysis.group","5"
"CD005566_pub4_data","Analysis.group","6"
"CD005566_pub4_data","Analysis.name","Mortality, including 'no major complications'"
"CD005566_pub4_data","Analysis.name","Cardiac complications, including 'no major complications'"
"CD005566_pub4_data","Analysis.name","Pulmonary complications, including 'no major complications'"
"CD005566_pub4_data","Analysis.name","Infectious complications"
"CD005566_pub4_data","Analysis.name","Gastrointestinal bleeding"
"CD005566_pub4_data","Analysis.name","Atrial fibrillation"
"CD005566_pub4_data","Analysis.name","Re-thoracotomy"
"CD005566_pub4_data","Analysis.name","Neurological complication (stroke)"
"CD005566_pub4_data","Analysis.name","Renal failure"
"CD005566_pub4_data","Analysis.name","Inotropic support"
"CD005566_pub4_data","Analysis.name","Postoperative bleeding (mL)"
"CD005566_pub4_data","Analysis.name","Mechanical ventilation time (minutes)"
"CD005566_pub4_data","Analysis.name","ICU stay (hours)"
"CD005566_pub4_data","Analysis.name","Hospital stay (days)"
"CD005566_pub4_data","Analysis.name","Mortality"
"CD005566_pub4_data","Analysis.name","Cardiac complications"
"CD005566_pub4_data","Analysis.name","Pulmonary complications"
"CD005566_pub4_data","Analysis.name","Mechanical ventilation (minutes)"
"CD005566_pub4_data","Analysis.name","Length of ICU stay (hours)"
"CD005566_pub4_data","Analysis.name","Length of hospital stay (days)"
"CD005566_pub4_data","Analysis.name","Mortality (sensitivity analysis)"
"CD005566_pub4_data","Analysis.name","Cardiac complications (sensitivity analysis)"
"CD005566_pub4_data","Analysis.name","Pulmonary complications (sensitivity analysis)"
"CD005566_pub4_data","Subgroup","Low dose"
"CD005566_pub4_data","Subgroup","High dose"
"CD005566_pub4_data","Subgroup","CABG"
"CD005566_pub4_data","Subgroup","Mixed"
"CD005566_pub4_data","Subgroup","Valve"
"CD005566_pub4_data","Subgroup","Dexamethasone"
"CD005566_pub4_data","Subgroup","Prednisolone"
"CD005566_pub4_data","Subgroup","Hydrocortisone"
"CD005566_pub4_data","Subgroup","Methylprednisolone"
"CD005566_pub4_data","Subgroup","Methylprednisolone and hydrocortisone"
"CD005566_pub4_data","Subgroup","Methylprednisolone and dexamethasone"
"CD005566_pub4_data","Subgroup","Betamethasone dipropionate"
"CD005582_pub5_data","Analysis.group","1"
"CD005582_pub5_data","Analysis.name","The presence of PHN six months after the onset of acute herpetic rash"
"CD005582_pub5_data","Analysis.name","The main effect of prednisone compared with no prednisone on six months evaluation of pain (generic inverse variance)"
"CD005582_pub5_data","Analysis.name","Serious adverse events"
"CD005582_pub5_data","Analysis.name","Non-serious adverse events"
"CD005595_pub4_data","Analysis.group","1"
"CD005595_pub4_data","Analysis.group","2"
"CD005595_pub4_data","Analysis.group","3"
"CD005595_pub4_data","Analysis.group","4"
"CD005595_pub4_data","Analysis.group","5"
"CD005595_pub4_data","Analysis.name","Activity limitation (using OMAS; at the end of treatment)"
"CD005595_pub4_data","Analysis.name","Activity limitation (using OMAS; short-term follow-up,  ≤ 6 months)"
"CD005595_pub4_data","Analysis.name","Activity limitation (using different measurement tools; long-term follow-up, > 6 months)"
"CD005595_pub4_data","Analysis.name","HRQoL (using different measurement tools; at end of treatment)"
"CD005595_pub4_data","Analysis.name","HRQoL (using different measurement tools; short-term follow-up, ≤ 6 months)"
"CD005595_pub4_data","Analysis.name","HRQoL (using different measurement tools; long-term follow-up, > 6 months)"
"CD005595_pub4_data","Analysis.name","Participant satisfaction (VAS, /10; end of treatment, and short-term follow-up of ≤ 6 months)"
"CD005595_pub4_data","Analysis.name","Pain (VAS; end of treatment)"
"CD005595_pub4_data","Analysis.name","Pain (VAS; short-term follow-up, ≤ 6 months)"
"CD005595_pub4_data","Analysis.name","Adverse events"
"CD005595_pub4_data","Analysis.name","Activity limitation after surgical fracture management (using different measurement tools; end of treatment)"
"CD005595_pub4_data","Analysis.name","Activity limitation (using different measurement tools; short-term follow-up, ≤ 6months)"
"CD005595_pub4_data","Analysis.name","Activity limitation after non-surgical fracture management (using OMAS; end of treatment)"
"CD005595_pub4_data","Analysis.name","HRQoL (using different measurement tools; end of treatment)"
"CD005595_pub4_data","Analysis.name","Pain after surgical fracture management (numbers with pain; all time points)"
"CD005595_pub4_data","Analysis.name","Pain after non-surgical fracture management (VAS; end of treatment)"
"CD005595_pub4_data","Analysis.name","Pain after non-surgical fracture management (VAS; short-term and long-term follow-up)"
"CD005595_pub4_data","Analysis.name","Adverse events (after surgical fracture management)"
"CD005595_pub4_data","Analysis.name","Adverse events (after non-surgical fracture management)"
"CD005595_pub4_data","Analysis.name","Activity limitation (using different measurement tools; at end of treatment)"
"CD005595_pub4_data","Analysis.name","Activity limitation (using different measurement tools; short-term follow-up, ≤ 6 months)"
"CD005595_pub4_data","Analysis.name","Participant satisfaction (100-mm VAS; end of treatment)"
"CD005595_pub4_data","Analysis.name","Pain (using different measures; at end of treatment"
"CD005595_pub4_data","Analysis.name","Pain (using different measurement tools; short-term follow-up, ≤ 6 months)"
"CD005595_pub4_data","Analysis.name","Pain (using different measurement tools; long-term follow-up, > 6 months)"
"CD005595_pub4_data","Analysis.name","Pain (numbers with pain; long-term/end of follow-up"
"CD005595_pub4_data","Analysis.name","Adverse events (during initial fracture management period after surgical treatment)"
"CD005595_pub4_data","Analysis.name","Adverse events (after initial fracture management period after either surgical or non-surgical treatment)"
"CD005595_pub4_data","Analysis.name","Activity limitation (interventions given during initial fracture management period; OMAS; all time points)"
"CD005595_pub4_data","Analysis.name","Pain (10-cm VAS; end of treatment)"
"CD005595_pub4_data","Analysis.name","Pain (interventions given during the initial fracture management period; VAS; short-term follow-up, ≤ 6 months)"
"CD005595_pub4_data","Analysis.name","Pain (numbers with pain; long-term follow-up, > 6 months)"
"CD005595_pub4_data","Analysis.name","Pain (using different measurement instruments; at end of treatment)"
"CD005595_pub4_data","Analysis.name","Adverse events (interventions during initial fracture management with surgical treatment)"
"CD005595_pub4_data","Subgroup","End of treatment"
"CD005595_pub4_data","Subgroup","Short-term follow-up (6  months)"
"CD005595_pub4_data","Subgroup","Prominent implant or metalwork irritation"
"CD005595_pub4_data","Subgroup","Surgical site infection"
"CD005595_pub4_data","Subgroup","Malunion"
"CD005595_pub4_data","Subgroup","Symptomatic pulmonary embolism"
"CD005595_pub4_data","Subgroup","Ankle metalwork or implant breakage"
"CD005595_pub4_data","Subgroup","Complex regional pain syndrome"
"CD005595_pub4_data","Subgroup","Nerve palsy"
"CD005595_pub4_data","Subgroup","Vascular injury"
"CD005595_pub4_data","Subgroup","Fall"
"CD005595_pub4_data","Subgroup","Re-fracture of the same ankle"
"CD005595_pub4_data","Subgroup","Re-operation"
"CD005595_pub4_data","Subgroup","Re-dislocation"
"CD005595_pub4_data","Subgroup","Delayed union"
"CD005595_pub4_data","Subgroup","Non-union"
"CD005595_pub4_data","Subgroup","Loss of fixation"
"CD005595_pub4_data","Subgroup","Loss of reduction"
"CD005595_pub4_data","Subgroup","DVT"
"CD005595_pub4_data","Subgroup","Deep infection"
"CD005595_pub4_data","Subgroup","Low grade infection or superficial infection"
"CD005595_pub4_data","Subgroup","Wound dehiscence"
"CD005595_pub4_data","Subgroup","Wound healing complications"
"CD005595_pub4_data","Subgroup","Dystrophy/atrophy"
"CD005595_pub4_data","Subgroup","Swelling, skin irritation and/or blistering"
"CD005595_pub4_data","Subgroup","After surgical fracture management"
"CD005595_pub4_data","Subgroup","After non-surgical fracture management"
"CD005595_pub4_data","Subgroup","Short-term follow-up ≤ 6 months"
"CD005595_pub4_data","Subgroup","Long-term follow-up > 6 months"
"CD005595_pub4_data","Subgroup","Refracture of the lateral malleolus"
"CD005595_pub4_data","Subgroup","Pulmonary embolism"
"CD005595_pub4_data","Subgroup","Low grade/superficial infection"
"CD005595_pub4_data","Subgroup","Dystrophy"
"CD005595_pub4_data","Subgroup","Numbness at side of foot"
"CD005595_pub4_data","Subgroup","Chronic allodynia"
"CD005595_pub4_data","Subgroup","Local skin necrosis"
"CD005595_pub4_data","Subgroup","Unplanned return to theatre"
"CD005595_pub4_data","Subgroup","Pressure sore/ulcer"
"CD005595_pub4_data","Subgroup","Fixation/implant failure"
"CD005595_pub4_data","Subgroup","Skin irritation"
"CD005595_pub4_data","Subgroup","Dysesthesia of the skin"
"CD005595_pub4_data","Subgroup","Loss of congruity"
"CD005595_pub4_data","Subgroup","Nerve compression"
"CD005595_pub4_data","Subgroup","Skin irritation/ulceration"
"CD005595_pub4_data","Subgroup","During initial fracture management period after surgical treatment"
"CD005595_pub4_data","Subgroup","After the initial fracture management period after either surgical or non-surgical treatment"
"CD005595_pub4_data","Subgroup","After initial fracture management period after surgical or non-surgical treatment"
"CD005595_pub4_data","Subgroup","After initial fracture management period after either surgical or non-surgical treatment"
"CD005595_pub4_data","Subgroup","After initial fracture managment period after either surgical or non-surgical treatment"
"CD005595_pub4_data","Subgroup","Supination trauma"
"CD005595_pub4_data","Subgroup","Sacral burn"
"CD005595_pub4_data","Subgroup","Set screw breakage"
"CD005595_pub4_data","Subgroup","Neuropathic pain from hip to ankle"
"CD005595_pub4_data","Subgroup","Loosening hem around large fragment screw"
"CD005595_pub4_data","Subgroup","Sensitivity disorders"
"CD005595_pub4_data","Subgroup","Achilles tendon pain"
"CD005595_pub4_data","Subgroup","Low grade infection/superficial infection"
"CD005595_pub4_data","Subgroup","Full body rash and pruritus"
"CD005595_pub4_data","Subgroup","Rheumatic episode"
"CD005595_pub4_data","Subgroup","Depression"
"CD005595_pub4_data","Subgroup","Metatarsal fracture (contralateral foot)"
"CD005595_pub4_data","Subgroup","Scar impingement"
"CD005595_pub4_data","Subgroup","Pseudarthrosis of the tibia shaft"
"CD005595_pub4_data","Subgroup","Material fracture in pseudarthrosis treatment on the tibia shaft"
"CD005595_pub4_data","Subgroup","Syndesmosis insufficiency"
"CD005595_pub4_data","Subgroup","Tendinopathy M.tibialis posterior tendon"
"CD005595_pub4_data","Subgroup","Tear of the anterior cruciate ligament after a fall"
"CD005595_pub4_data","Subgroup","Wedge-shaped bone defect distal tibial joint surface ventral"
"CD005595_pub4_data","Subgroup","Subjective change in skin colour in ankle and foot"
"CD005595_pub4_data","Subgroup","Hardly adjustable hypertension"
"CD005595_pub4_data","Subgroup","Neuritis in the head"
"CD005595_pub4_data","Subgroup","Recent falls (in previous 3 months)"
"CD005595_pub4_data","Subgroup","Increase in pain"
"CD005595_pub4_data","Subgroup","Condition worsened"
"CD005595_pub4_data","Subgroup","Total adverse events (type not specified)"
"CD005595_pub4_data","Subgroup","Pain"
"CD005595_pub4_data","Subgroup","Short-term follow-up"
"CD005595_pub4_data","Subgroup","Long-term follow-up"
"CD005595_pub4_data","Subgroup","After initial fracture management period"
"CD005595_pub4_data","Subgroup","During initial fracture management period"
"CD005595_pub4_data","Subgroup","During immobilisation after surgical management"
"CD005595_pub4_data","Subgroup","During initial fracture management period after non-surgical treatment"
"CD005595_pub4_data","Subgroup","During initial fracture management period after surgical management"
"CD005595_pub4_data","Subgroup","Fracture displacement"
"CD005951_pub5_data","Analysis.group","1"
"CD005951_pub5_data","Analysis.group","2"
"CD005951_pub5_data","Analysis.group","3"
"CD005951_pub5_data","Analysis.group","4"
"CD005951_pub5_data","Analysis.name","Death or dependence (mRS 4–6) at day 90"
"CD005951_pub5_data","Analysis.name","Intracerebral haemorrhage expansion by 24 hours"
"CD005951_pub5_data","Analysis.name","All serious adverse events"
"CD005951_pub5_data","Analysis.name","Thromboembolic adverse events"
"CD005951_pub5_data","Analysis.name","Death from any cause by day 90"
"CD005951_pub5_data","Analysis.name","Death or dependence (Extended Glasgow Outcome Scale (GOS-E) 1–4) at day 90"
"CD005951_pub5_data","Analysis.name","Death by day 90"
"CD005951_pub5_data","Analysis.name","Death by day 7"
"CD005951_pub5_data","Analysis.name","Quality of life (EuroQoL health utility score)"
"CD005951_pub5_data","Analysis.name","Mood (Zung Depression Scale)"
"CD005951_pub5_data","Analysis.name","Cognitive function (Modified Telephone Interview for Cognitive Status (TICS-M))"
"CD005951_pub5_data","Analysis.name","Cognitive function (Mini-Mental State Examination (MMSE))"
"CD005951_pub5_data","Analysis.name","Barthel Index"
"CD005951_pub5_data","Analysis.name","Death or dependence (mRS 4–6) at 90 days"
"CD005951_pub5_data","Subgroup","Acute spontaneous ICH undergoing craniotomy"
"CD005951_pub5_data","Subgroup","Acute spontaneous ICH"
"CD005951_pub5_data","Subgroup","Acute antiplatelet-associated ICH"
"CD005951_pub5_data","Subgroup","Acute anticoagulant-associated ICH"
"CD006023_pub4_data","Analysis.group","1"
"CD006023_pub4_data","Analysis.group","2"
"CD006023_pub4_data","Analysis.group","3"
"CD006023_pub4_data","Analysis.group","4"
"CD006023_pub4_data","Analysis.group","5"
"CD006023_pub4_data","Analysis.group","6"
"CD006023_pub4_data","Analysis.group","7"
"CD006023_pub4_data","Analysis.group","8"
"CD006023_pub4_data","Analysis.group","9"
"CD006023_pub4_data","Analysis.group","10"
"CD006023_pub4_data","Analysis.group","11"
"CD006023_pub4_data","Analysis.group","12"
"CD006023_pub4_data","Analysis.group","13"
"CD006023_pub4_data","Analysis.group","14"
"CD006023_pub4_data","Analysis.group","15"
"CD006023_pub4_data","Analysis.group","16"
"CD006023_pub4_data","Analysis.group","17"
"CD006023_pub4_data","Analysis.group","18"
"CD006023_pub4_data","Analysis.group","19"
"CD006023_pub4_data","Analysis.group","20"
"CD006023_pub4_data","Analysis.group","21"
"CD006023_pub4_data","Analysis.group","22"
"CD006023_pub4_data","Analysis.group","23"
"CD006023_pub4_data","Analysis.group","24"
"CD006023_pub4_data","Analysis.group","25"
"CD006023_pub4_data","Analysis.group","26"
"CD006023_pub4_data","Analysis.group","27"
"CD006023_pub4_data","Analysis.group","28"
"CD006023_pub4_data","Analysis.group","29"
"CD006023_pub4_data","Analysis.group","30"
"CD006023_pub4_data","Analysis.group","31"
"CD006023_pub4_data","Analysis.group","32"
"CD006023_pub4_data","Analysis.group","33"
"CD006023_pub4_data","Analysis.name","Death (all causes)"
"CD006023_pub4_data","Analysis.name","Cardiovascular death"
"CD006023_pub4_data","Analysis.name","Hypercalcaemia"
"CD006023_pub4_data","Analysis.name","Nausea"
"CD006023_pub4_data","Analysis.name","Constipation"
"CD006023_pub4_data","Analysis.name","Serum phosphate [mg/dL]"
"CD006023_pub4_data","Analysis.name","Coronary artery calcium score"
"CD006023_pub4_data","Analysis.name","Myocardial infarction"
"CD006023_pub4_data","Analysis.name","Stroke"
"CD006023_pub4_data","Analysis.name","Hospitalisation"
"CD006023_pub4_data","Analysis.name","Fracture"
"CD006023_pub4_data","Analysis.name","Pruritus"
"CD006023_pub4_data","Analysis.name","Vomiting"
"CD006023_pub4_data","Analysis.name","Abdominal pain"
"CD006023_pub4_data","Analysis.name","Diarrhoea"
"CD006023_pub4_data","Analysis.name","Abdominal bloating"
"CD006023_pub4_data","Analysis.name","Kidney failure"
"CD006023_pub4_data","Analysis.name","Start dialysis"
"CD006023_pub4_data","Analysis.name","Serum calcium"
"CD006023_pub4_data","Analysis.name","Serum calcium-by-phosphate product"
"CD006023_pub4_data","Analysis.name","Serum iPTH"
"CD006023_pub4_data","Analysis.name","Serum alkaline phosphatase"
"CD006023_pub4_data","Analysis.name","Serum bicarbonate"
"CD006023_pub4_data","Analysis.name","eGFR"
"CD006023_pub4_data","Analysis.name","Bone mineral density: lumbar spine"
"CD006023_pub4_data","Analysis.name","Bone mineral density: hip"
"CD006023_pub4_data","Analysis.name","Klotho"
"CD006023_pub4_data","Analysis.name","Arteriovenous fistula operation"
"CD006023_pub4_data","Analysis.name","Serum phosphate"
"CD006023_pub4_data","Analysis.name","Coronary artery calcification score"
"CD006023_pub4_data","Analysis.name","Vascular calcification score"
"CD006023_pub4_data","Analysis.name","Serum FGF23"
"CD006023_pub4_data","Analysis.name","Calciphylaxis"
"CD006023_pub4_data","Analysis.name","Soluble Klotho"
"CD006023_pub4_data","Analysis.name","Fatigue"
"CD006023_pub4_data","Analysis.name","Nonfatal myocardial infarction"
"CD006023_pub4_data","Analysis.name","Nonfatal stroke"
"CD006023_pub4_data","Analysis.name","Serum fetuin-A"
"CD006023_pub4_data","Analysis.name","Commencing dialysis"
"CD006023_pub4_data","Analysis.name","α-Klotho"
"CD006023_pub4_data","Analysis.name","Shunt stenosis"
"CD006023_pub4_data","Analysis.name","Hyperkalaemia"
"CD006023_pub4_data","Analysis.name","Hypercalcemia"
"CD006023_pub4_data","Analysis.name","FGF23"
"CD006023_pub4_data","Analysis.name","Shunt occlusion"
"CD006023_pub4_data","Analysis.name","Arteriovenous fistula site complication"
"CD006023_pub4_data","Analysis.name","Shunt malfunction"
"CD006023_pub4_data","Analysis.name","Arteriovenous fistula site haemorrhage"
"CD006023_pub4_data","Analysis.name","Arteriovenous fistula thrombosis"
"CD006023_pub4_data","Analysis.name","Arteriovenous shunt operation"
"CD006023_pub4_data","Analysis.name","Serum PTH"
"CD006023_pub4_data","Analysis.name","Death (all cause)"
"CD006023_pub4_data","Analysis.name","Abnominal pain"
"CD006023_pub4_data","Analysis.name","Diarrohea"
"CD006023_pub4_data","Analysis.name","Fracture (femoral)"
"CD006023_pub4_data","Analysis.name","Shunt disorder"
"CD006023_pub4_data","Analysis.name","Death (all causes): age"
"CD006023_pub4_data","Analysis.name","Death (all causes): CKD GFR category"
"CD006023_pub4_data","Analysis.name","Death (all causes): study duration"
"CD006023_pub4_data","Analysis.name","Cardiovascular death: age"
"CD006023_pub4_data","Analysis.name","Cardiovascular death: CKD GFR category"
"CD006023_pub4_data","Analysis.name","Cardiovascular death: study duration"
"CD006023_pub4_data","Analysis.name","Death (all causes): random sequence generation and allocation concealment"
"CD006023_pub4_data","Analysis.name","Cardiovascular death: random sequence generation and allocation concealment"
"CD006023_pub4_data","Subgroup","Mean study age above 60 years"
"CD006023_pub4_data","Subgroup","Mean study age 60 years or below"
"CD006023_pub4_data","Subgroup","Stage 2-5"
"CD006023_pub4_data","Subgroup","Stage 5D"
"CD006023_pub4_data","Subgroup","Less than 12 months"
"CD006023_pub4_data","Subgroup","Equal to or longer than 12 months"
"CD006023_pub4_data","Subgroup","Stage 2 to 5"
"CD006023_pub4_data","Subgroup","Low risk"
"CD006023_pub4_data","Subgroup","Unclear/high risk"
"CD006027_pub3_data","Analysis.group","1"
"CD006027_pub3_data","Analysis.group","2"
"CD006027_pub3_data","Analysis.group","3"
"CD006027_pub3_data","Analysis.group","4"
"CD006027_pub3_data","Analysis.group","5"
"CD006027_pub3_data","Analysis.group","6"
"CD006027_pub3_data","Analysis.group","7"
"CD006027_pub3_data","Analysis.group","8"
"CD006027_pub3_data","Analysis.group","9"
"CD006027_pub3_data","Analysis.group","10"
"CD006027_pub3_data","Analysis.group","11"
"CD006027_pub3_data","Analysis.group","12"
"CD006027_pub3_data","Analysis.group","13"
"CD006027_pub3_data","Analysis.group","14"
"CD006027_pub3_data","Analysis.group","15"
"CD006027_pub3_data","Analysis.group","16"
"CD006027_pub3_data","Analysis.group","17"
"CD006027_pub3_data","Analysis.name","Pain (change from baseline in pain score (VAS-10 cm) at 30 minutes)"
"CD006027_pub3_data","Analysis.name","Need for rescue medication"
"CD006027_pub3_data","Analysis.name","Pain (post-intervention pain score (VAS-10 cm) at 30 minutes)"
"CD006027_pub3_data","Analysis.name","Pain recurrence within 24 hours"
"CD006027_pub3_data","Analysis.name","Minor adverse events"
"CD006027_pub3_data","Analysis.name","Serious adverse events"
"CD006027_pub3_data","Analysis.name","Pain (post-intervention pain score (VAS-10 cm) at 60 minutes)"
"CD006027_pub3_data","Analysis.name","Significant pain relief"
"CD006027_pub3_data","Analysis.name","Pain (post-Intervention pain score (VAS-10 cm) at 30 minutes)"
"CD006027_pub3_data","Analysis.name","Pain recurrence"
"CD006027_pub3_data","Analysis.name","Pain (change  from basline in pain score (VAS-10 cm) at 60 minutes)"
"CD006124_pub3_data","Analysis.group","1"
"CD006124_pub3_data","Analysis.group","2"
"CD006124_pub3_data","Analysis.group","3"
"CD006124_pub3_data","Analysis.group","4"
"CD006124_pub3_data","Analysis.name","Analgesia requirements"
"CD006124_pub3_data","Analysis.name","Duration of procedure"
"CD006124_pub3_data","Analysis.name","Blood loss"
"CD006124_pub3_data","Analysis.name","Perioperative complications"
"CD006124_pub3_data","Analysis.name","Reoperations"
"CD006124_pub3_data","Analysis.name","Warm ischaemia time"
"CD006124_pub3_data","Analysis.name","Hospital stay"
"CD006124_pub3_data","Analysis.name","Early graft loss"
"CD006124_pub3_data","Analysis.name","Delayed graft function"
"CD006124_pub3_data","Analysis.name","Acute rejection"
"CD006124_pub3_data","Analysis.name","Ureteric complications"
"CD006124_pub3_data","Analysis.name","Kidney function at one year"
"CD006124_pub3_data","Analysis.name","One year graft loss"
"CD006124_pub3_data","Analysis.name","One-year graft loss"
"CD006124_pub3_data","Subgroup","Pre-2010"
"CD006124_pub3_data","Subgroup","2010 onwards"
"CD006140_pub3_data","Analysis.group","1"
"CD006140_pub3_data","Analysis.group","2"
"CD006140_pub3_data","Analysis.group","3"
"CD006140_pub3_data","Analysis.group","4"
"CD006140_pub3_data","Analysis.group","5"
"CD006140_pub3_data","Analysis.name","Any illicit opioid use (urine drug screen)"
"CD006140_pub3_data","Analysis.name","Days of illicit opioid use"
"CD006140_pub3_data","Analysis.name","Opioid negative urine drug screens (proportion or count)"
"CD006140_pub3_data","Analysis.name","Retention"
"CD006140_pub3_data","Analysis.name","Acceptability"
"CD006140_pub3_data","Analysis.name","Any serious adverse event"
"CD006140_pub3_data","Analysis.name","Any non-serious adverse event"
"CD006140_pub3_data","Analysis.name","Death"
"CD006140_pub3_data","Analysis.name","Overdose"
"CD006140_pub3_data","Analysis.name","Study treatment terminated due to adverse event"
"CD006140_pub3_data","Analysis.name","Opioid craving"
"CD006140_pub3_data","Analysis.name","Days of alcohol use"
"CD006140_pub3_data","Analysis.name","Days of amphetamine or cocaine use"
"CD006140_pub3_data","Analysis.name","Days of benzodiazepine use"
"CD006140_pub3_data","Analysis.name","Days of cannabis use"
"CD006140_pub3_data","Analysis.name","Depression"
"CD006140_pub3_data","Analysis.name","Anxiety"
"CD006140_pub3_data","Analysis.name","Insomnia"
"CD006140_pub3_data","Analysis.name","Psychiatric disorder"
"CD006140_pub3_data","Analysis.name","Quality of life"
"CD006140_pub3_data","Analysis.name","Arrest or reincarceration"
"CD006140_pub3_data","Analysis.name","Any illicit opioid use (self report)"
"CD006140_pub3_data","Analysis.name","Opioid negative urine drug screens (count)"
"CD006140_pub3_data","Analysis.name","Time to dropout (days)"
"CD006140_pub3_data","Analysis.name","Days of amphetamines or cocaine use"
"CD006140_pub3_data","Analysis.name","Any arrest or reincarceration"
"CD006182_pub3_data","Analysis.group","1"
"CD006182_pub3_data","Analysis.group","2"
"CD006182_pub3_data","Analysis.group","3"
"CD006182_pub3_data","Analysis.group","4"
"CD006182_pub3_data","Analysis.group","5"
"CD006182_pub3_data","Analysis.group","6"
"CD006182_pub3_data","Analysis.group","7"
"CD006182_pub3_data","Analysis.group","8"
"CD006182_pub3_data","Analysis.group","9"
"CD006182_pub3_data","Analysis.group","10"
"CD006182_pub3_data","Analysis.group","11"
"CD006182_pub3_data","Analysis.group","12"
"CD006182_pub3_data","Analysis.group","13"
"CD006182_pub3_data","Analysis.name","Mortality or NDI at 18-24 months"
"CD006182_pub3_data","Analysis.name","NDI at 18-24 months among surivors"
"CD006182_pub3_data","Analysis.name","Moderate to severe CP among surviving infants"
"CD006182_pub3_data","Analysis.name","Mortality before discharge from hospital"
"CD006182_pub3_data","Analysis.name","Mortality before 18 to 24 months"
"CD006182_pub3_data","Analysis.name","Subsequent laparotomy during initial hospitalisation"
"CD006182_pub3_data","Analysis.name","Mortality within 28 days of the primary procedure"
"CD006182_pub3_data","Analysis.name","Mortality within 90 days of the primary procedure"
"CD006182_pub3_data","Analysis.name","Mortality within 6 months of primary procedure"
"CD006182_pub3_data","Analysis.name","Mortality before corrected age of one year"
"CD006182_pub3_data","Analysis.name","Subsequent laparotomy within 7 days of the primary procedure"
"CD006182_pub3_data","Analysis.name","Laparotomy after 7 days of the primary procedure"
"CD006182_pub3_data","Analysis.name","Intraoperative Complications"
"CD006182_pub3_data","Analysis.name","Abdominal abscess"
"CD006182_pub3_data","Analysis.name","Intestinal fistula "
"CD006182_pub3_data","Analysis.name","Intestinal stricture"
"CD006182_pub3_data","Analysis.name","Wound dehiscence"
"CD006182_pub3_data","Analysis.name","Severe intraventricular hemorrhage"
"CD006182_pub3_data","Analysis.name","Sepsis"
"CD006182_pub3_data","Analysis.name","PN-Associated Cholestasis"
"CD006182_pub3_data","Analysis.name","Recurrent NEC after primary procedure"
"CD006182_pub3_data","Analysis.name","Time to full enteral feeds among survivors (days)"
"CD006182_pub3_data","Analysis.name","Duration of parenteral nutrition (days)"
"CD006182_pub3_data","Analysis.name","Need for TPN for more than 3 months after the primary procedure among survivors"
"CD006182_pub3_data","Analysis.name","Duration of mechanical ventilation (days)"
"CD006182_pub3_data","Analysis.name","Length of stay in the hospital among survivors to discharge (days)"
"CD006182_pub3_data","Analysis.name","Final bowel length (cm)"
"CD006182_pub3_data","Analysis.name","Survival with Neurodevelopmental Impairmentat 18-24 months"
"CD006182_pub3_data","Analysis.name","Mortality or Moderate to Severe CP at 18 to 24 months"
"CD006182_pub3_data","Analysis.name","Mortality or cognitive score worse than 1SD below the mean at 18-24 months"
"CD006182_pub3_data","Analysis.name","Cognitive score worse than 1SD below the mean at 18-24 months"
"CD006182_pub3_data","Analysis.name","Cognitive score worse than 2SD below the mean at 18-24 months"
"CD006182_pub3_data","Analysis.name","Mortality or cognitive score worse than 2SD below the mean at 18-24 months"
"CD006182_pub3_data","Analysis.name","Blindness"
"CD006182_pub3_data","Analysis.name","Hearing loss"
"CD006182_pub3_data","Analysis.name","Need for laparotomy any time after the primary procedure"
"CD006182_pub3_data","Subgroup","BW <1000g"
"CD006182_pub3_data","Subgroup","BW ≥1000g"
"CD006182_pub3_data","Subgroup","<1000 gm"
"CD006182_pub3_data","Subgroup","< 1000 gm"
"CD006182_pub3_data","Subgroup","Preoperative diagnosis of NEC"
"CD006182_pub3_data","Subgroup","Preoperative diagnosis of SIP"
"CD006185_pub6_data","Analysis.group","1"
"CD006185_pub6_data","Analysis.group","2"
"CD006185_pub6_data","Analysis.group","3"
"CD006185_pub6_data","Analysis.group","4"
"CD006185_pub6_data","Analysis.group","5"
"CD006185_pub6_data","Analysis.group","6"
"CD006185_pub6_data","Analysis.name","Independent walking at end of intervention phase, all electromechanical devices used (critical outcome)"
"CD006185_pub6_data","Analysis.name","Independent walking at follow-up after study end (critical outcome)"
"CD006185_pub6_data","Analysis.name","Walking velocity (metres per second) at end of intervention phase"
"CD006185_pub6_data","Analysis.name","Walking velocity (metres per second) at follow-up"
"CD006185_pub6_data","Analysis.name","Walking capacity (metres walked in 6 minutes) at end of intervention phase"
"CD006185_pub6_data","Analysis.name","Walking capacity (metres walked in 6 minutes) at follow-up"
"CD006185_pub6_data","Analysis.name","Lost to study during intervention phase, dropouts"
"CD006185_pub6_data","Analysis.name","Death from all causes until end of intervention phase"
"CD006185_pub6_data","Analysis.name","Regaining independent walking ability"
"CD006185_pub6_data","Analysis.name","Independent walking at end of intervention phase, all electromechanical devices used"
"CD006185_pub6_data","Analysis.name","Recovery of independent walking: ambulatory status at start of study"
"CD006185_pub6_data","Analysis.name","Walking velocity: ambulatory status at start of study"
"CD006185_pub6_data","Analysis.name","Walking capacity: ambulatory status at start of study"
"CD006185_pub6_data","Analysis.name","Different devices for regaining walking ability"
"CD006185_pub6_data","Analysis.name","Different devices for regaining walking speed"
"CD006185_pub6_data","Analysis.name","Different devices for regaining walking capacity"
"CD006185_pub6_data","Analysis.name","Independent walking at end of intervention phase, all electromechanical devices used (primary outcome)"
"CD006185_pub6_data","Subgroup","All studies using end-effector devices"
"CD006185_pub6_data","Subgroup","All studies using exoskeleton devices"
"CD006185_pub6_data","Subgroup","All studies using mobile devices"
"CD006185_pub6_data","Subgroup","All studies using ankle devices"
"CD006185_pub6_data","Subgroup","All studies with adequate sequence generation process"
"CD006185_pub6_data","Subgroup","All studies with adequate concealed allocation"
"CD006185_pub6_data","Subgroup","All studies with blinded assessors for primary outcome"
"CD006185_pub6_data","Subgroup","All studies without incomplete outcome data"
"CD006185_pub6_data","Subgroup","All studies excluding the largest study - Pohl 2007"
"CD006185_pub6_data","Subgroup","Acute phase: less than or equal to 3 months after stroke"
"CD006185_pub6_data","Subgroup","Chronic phase: more than 3 months after stroke"
"CD006185_pub6_data","Subgroup","Studies that included independent walkers"
"CD006185_pub6_data","Subgroup","Studies that included dependent and independent walkers"
"CD006185_pub6_data","Subgroup","Studies that included dependent walkers"
"CD006185_pub6_data","Subgroup","Subgroup control group contents physiotherapy or gait training"
"CD006185_pub6_data","Subgroup","Subgroup control group contents usual care but not physiotherapy or no gait therapy"
"CD006214_pub5_data","Analysis.group","1"
"CD006214_pub5_data","Analysis.name","Mean time to complete healing (days)"
"CD006257_pub2_data","Analysis.group","1"
"CD006257_pub2_data","Analysis.group","2"
"CD006257_pub2_data","Analysis.group","3"
"CD006257_pub2_data","Analysis.group","4"
"CD006257_pub2_data","Analysis.group","5"
"CD006257_pub2_data","Analysis.group","6"
"CD006257_pub2_data","Analysis.group","7"
"CD006257_pub2_data","Analysis.group","8"
"CD006257_pub2_data","Analysis.group","9"
"CD006257_pub2_data","Analysis.group","10"
"CD006257_pub2_data","Analysis.group","11"
"CD006257_pub2_data","Analysis.group","12"
"CD006257_pub2_data","Analysis.group","13"
"CD006257_pub2_data","Analysis.group","14"
"CD006257_pub2_data","Analysis.name","Death: any cause"
"CD006257_pub2_data","Analysis.name","Withdrawn"
"CD006257_pub2_data","Analysis.name","Cardiovascular death"
"CD006257_pub2_data","Analysis.name","Kidney failure"
"CD006257_pub2_data","Analysis.name","Fatal or nonfatal myocardial infarction"
"CD006257_pub2_data","Analysis.name","Fatal or nonfatal stroke"
"CD006257_pub2_data","Analysis.name","Doubling of serum creatinine"
"CD006257_pub2_data","Analysis.name","Reduction in GFR"
"CD006257_pub2_data","Analysis.name","Change in GFR [mL/min/1.73 m²]"
"CD006257_pub2_data","Analysis.name","GFR (at end of treatment) [mL/min/1.73 m²]"
"CD006257_pub2_data","Analysis.name","Micro- to macroalbuminuria"
"CD006257_pub2_data","Analysis.name","Micro- to normoalbuminuria"
"CD006257_pub2_data","Analysis.name","Hyperkalaemia"
"CD006257_pub2_data","Analysis.name","Cough"
"CD006257_pub2_data","Analysis.name","Headache"
"CD006257_pub2_data","Analysis.name","Impotence"
"CD006257_pub2_data","Analysis.name","Dizziness"
"CD006257_pub2_data","Analysis.name","Fatal and nonfatal myocardial infarction"
"CD006257_pub2_data","Analysis.name","Withdrawn: any cause"
"CD006257_pub2_data","Analysis.name","Hypekalaemia"
"CD006257_pub2_data","Analysis.name","GFR (at end of treatment) [mL/min/1.7 3m²]"
"CD006257_pub2_data","Analysis.name","Macro-to microalbuminuria"
"CD006257_pub2_data","Analysis.name","Macro-to normoalbuminuria"
"CD006257_pub2_data","Analysis.name","Type of diabetes"
"CD006257_pub2_data","Analysis.name","Presence of hypertension"
"CD006257_pub2_data","Analysis.name","Microalbuminuria versus macroalbuminuria"
"CD006257_pub2_data","Subgroup","ACEi"
"CD006257_pub2_data","Subgroup","ARB"
"CD006257_pub2_data","Subgroup","Type I"
"CD006257_pub2_data","Subgroup","Type II"
"CD006257_pub2_data","Subgroup","Patients with hypertension"
"CD006257_pub2_data","Subgroup","Patients without hypertension"
"CD006257_pub2_data","Subgroup","Microalbuminuria"
"CD006257_pub2_data","Subgroup","Macroalbuminuria"
"CD006273_pub4_data","Analysis.group","1"
"CD006273_pub4_data","Analysis.group","2"
"CD006273_pub4_data","Analysis.group","3"
"CD006273_pub4_data","Analysis.name","Adverse events"
"CD006273_pub4_data","Analysis.name","Quality of life from single-study data"
"CD006273_pub4_data","Analysis.name","Adverse events from single-study data: pain at injection site"
"CD006273_pub4_data","Analysis.name","Adverse events from single-study data: swelling at injection site"
"CD006404_pub5_data","Analysis.group","1"
"CD006404_pub5_data","Analysis.group","2"
"CD006404_pub5_data","Analysis.group","3"
"CD006404_pub5_data","Analysis.group","4"
"CD006404_pub5_data","Analysis.name","Total failure: day 28 (polymerase chain reaction-adjusted)"
"CD006404_pub5_data","Analysis.name","Total failure: day 42 (polymerase chain reaction-adjusted)"
"CD006404_pub5_data","Analysis.name","Total failure: day 28 (unadjusted)"
"CD006404_pub5_data","Analysis.name","Total failure: day 42 (unadjusted)"
"CD006404_pub5_data","Analysis.name","Early treatment failure"
"CD006404_pub5_data","Analysis.name","Serious adverse events"
"CD006404_pub5_data","Analysis.name","Adverse events leading to withdrawal"
"CD006404_pub5_data","Analysis.name","First treatment, alanine aminotransferase increase greater than five times the upper limit of normal"
"CD006404_pub5_data","Analysis.name","First treatment, aspartate aminotransferase increase greater than five times the upper limit of normal"
"CD006404_pub5_data","Analysis.name","First treatment, bilirubin increase greater than 2.5 times the upper limit of normal"
"CD006404_pub5_data","Analysis.name","Subsequent treatment(s), alanine aminotransferase increase greater than five times the upper limit of normal"
"CD006404_pub5_data","Analysis.name","Subsequent treatment(s), aspartate aminotransferase increase greater than five times the upper limit of normal"
"CD006404_pub5_data","Analysis.name","Subsequent treatment(s), bilirubin increase greater than 2.5 times the upper limit of normal"
"CD006404_pub5_data","Analysis.name","Paediatric trials — total failure: day 28 (polymerase chain reaction-adjusted)"
"CD006404_pub5_data","Analysis.name","Trials in children — total failure: day 42 (polymerase chain reaction-adjusted)"
"CD006404_pub5_data","Analysis.name","Trials in children — total failure: day 28 (unadjusted)"
"CD006404_pub5_data","Analysis.name","Trials in children — total failure: day 42 (unadjusted)"
"CD006404_pub5_data","Analysis.name","Trials in children — first treatment, alanine aminotransferase increase greater than five times the upper limit of normal"
"CD006404_pub5_data","Analysis.name","Trials in children — first treatment, aspartate aminotransferase increase greater than five times the upper limit of normal"
"CD006404_pub5_data","Analysis.name","Sensitivity analysis: first treatment, alanine aminotransferase increase greater than five times the upper limit of normal"
"CD006404_pub5_data","Analysis.name","Other adverse events"
"CD006404_pub5_data","Analysis.name","Serious adverse events (pregnant women)"
"CD006404_pub5_data","Analysis.name","Other adverse events (pregnant women)"
"CD006404_pub5_data","Subgroup","Blood and lymphatic: anaemias"
"CD006404_pub5_data","Subgroup","Blood and lymphatic: eosinophilic disorders"
"CD006404_pub5_data","Subgroup","Blood and lymphatic: leukocytosis"
"CD006404_pub5_data","Subgroup","Blood and lymphatic: neutropenias"
"CD006404_pub5_data","Subgroup","Cardiac: cardiac arrhythmias"
"CD006404_pub5_data","Subgroup","Cardiac: cardiac signs and symptoms"
"CD006404_pub5_data","Subgroup","Cardiac: myocardial disorders"
"CD006404_pub5_data","Subgroup","Ear: ear disorders"
"CD006404_pub5_data","Subgroup","Gastrointestinal: diarrhoea (excl infective)"
"CD006404_pub5_data","Subgroup","Gastrointestinal: dyspeptic signs and symptoms"
"CD006404_pub5_data","Subgroup","Gastrointestinal: gastrointestinal and abdominal pains"
"CD006404_pub5_data","Subgroup","Gastrointestinal: nausea and vomiting symptoms"
"CD006404_pub5_data","Subgroup","General: asthenic conditions"
"CD006404_pub5_data","Subgroup","General: general signs and symptoms"
"CD006404_pub5_data","Subgroup","General: feelings and sensations"
"CD006404_pub5_data","Subgroup","General: febrile disorders"
"CD006404_pub5_data","Subgroup","General: pain and discomfort"
"CD006404_pub5_data","Subgroup","Infections and infestations: eye and eyelid"
"CD006404_pub5_data","Subgroup","Infections and infestations: lower respiratory tract infection and lung"
"CD006404_pub5_data","Subgroup","Infections and infestations: upper respiratory tract infection"
"CD006404_pub5_data","Subgroup","Investigations: electrocardiograph"
"CD006404_pub5_data","Subgroup","Investigations: skeletal/cardiac muscle analyses"
"CD006404_pub5_data","Subgroup","Investigations: physical examination"
"CD006404_pub5_data","Subgroup","Investigations: platelets"
"CD006404_pub5_data","Subgroup","Investigations: protein"
"CD006404_pub5_data","Subgroup","Metabolism and nutrition: appetite disorders"
"CD006404_pub5_data","Subgroup","Metabolism and nutrition: hypoglycaemia conditions"
"CD006404_pub5_data","Subgroup","Metabolism and nutrition: metabolic disorders"
"CD006404_pub5_data","Subgroup","Musculoskeletal and connective tissue: muscle pains"
"CD006404_pub5_data","Subgroup","Musculoskeletal and connective tissue: pain and discomfort"
"CD006404_pub5_data","Subgroup","Nervous system: headaches"
"CD006404_pub5_data","Subgroup","Nervous system: sleep disturbance"
"CD006404_pub5_data","Subgroup","Nervous system: paraesthesias and dysaesthesias"
"CD006404_pub5_data","Subgroup","Respiratory: coughing and associated symptoms"
"CD006404_pub5_data","Subgroup","Respiratory: upper respiratory tract signs and symptoms"
"CD006404_pub5_data","Subgroup","Renal and urinary: urinary abnormalities"
"CD006404_pub5_data","Subgroup","Skin and subcutaneous tissue: dermatitis and eczema"
"CD006404_pub5_data","Subgroup","Skin and subcutaneous tissue: pruritis"
"CD006404_pub5_data","Subgroup","Skin and subcutaneous tissue: rashes, eruptions, exanthems"
"CD006404_pub5_data","Subgroup","Skin and subcutaneous tissue: urticaria"
"CD006404_pub5_data","Subgroup","Vascular: vascular hypotensive disorders"
"CD006404_pub5_data","Subgroup","Spontaneous abortions"
"CD006404_pub5_data","Subgroup","In utero deaths"
"CD006404_pub5_data","Subgroup","Preterm birth"
"CD006475_pub3_data","Analysis.group","1"
"CD006475_pub3_data","Analysis.group","2"
"CD006475_pub3_data","Analysis.group","3"
"CD006475_pub3_data","Analysis.group","4"
"CD006475_pub3_data","Analysis.name","Asthma by 2 years of age"
"CD006475_pub3_data","Analysis.name","Eczema by 2 years of age"
"CD006475_pub3_data","Analysis.name","Allergic rhinitis by 2 years "
"CD006475_pub3_data","Analysis.name","Food allergy by 2 years"
"CD006475_pub3_data","Analysis.name","Cow's milk protein allergy by 2 years"
"CD006475_pub3_data","Analysis.name","Sensitivity analysis: eczema by 2 years by definition of allergic disease"
"CD006475_pub3_data","Analysis.name","Sensitivity analysis: eczema by 2 years by risk of bias"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 2 years by risk of allergy"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 2 years by method of feeding"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 2 years by probiotic type"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 2 years by period of supplementation"
"CD006475_pub3_data","Analysis.name","Food allergy by 2 years of age"
"CD006475_pub3_data","Analysis.name","Sensitivity analysis: eczema by 2 years of age by definition of allergic disease"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 2 years of age by risk of allergy"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 2 years of age by synbiotic type"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 2 years of age by period of supplementation"
"CD006475_pub3_data","Analysis.name","Asthma by 10 years of age"
"CD006475_pub3_data","Analysis.name","Eczema by 10 years of age"
"CD006475_pub3_data","Analysis.name","Allergic rhinitis by 10 years of age"
"CD006475_pub3_data","Analysis.name","Sensitivity analysis: eczema by 10 years of age by definition of allergic disease"
"CD006475_pub3_data","Analysis.name","Sensitivity analysis: asthma by 10 years of age by risk of bias"
"CD006475_pub3_data","Analysis.name","Sensitivity analysis: eczema by 10 years of age by risk of bias"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 10 years of age by risk of allergy"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 10 years of age by method of feeding"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 10 years of age by probiotic type"
"CD006475_pub3_data","Analysis.name","Subgroup analysis: eczema by 10 years of age by period of supplementation"
"CD006475_pub3_data","Subgroup","Eczema"
"CD006475_pub3_data","Subgroup","Atopic eczema"
"CD006475_pub3_data","Subgroup","Infant at high risk of allergy or food hypersensitivity"
"CD006475_pub3_data","Subgroup","Infant not selected for risk of allergy or food hypersensitivity"
"CD006475_pub3_data","Subgroup","Infants fed predominately human milk"
"CD006475_pub3_data","Subgroup","Infants fed predominately cow's milk formula"
"CD006475_pub3_data","Subgroup","Probiotic containing L. rhamnosus"
"CD006475_pub3_data","Subgroup","Probiotic not containing L. rhamnosus"
"CD006475_pub3_data","Subgroup","Mothers received prenatal probiotic"
"CD006475_pub3_data","Subgroup","Mothers did not receive prenatal probiotic"
"CD006475_pub3_data","Subgroup","Synbiotic containing L. rhamnosus"
"CD006475_pub3_data","Subgroup","Synbiotic not containing L. rhamnosus"
"CD006475_pub3_data","Subgroup","Mothers received prenatal synbiotic"
"CD006475_pub3_data","Subgroup","Mothers did not receive prenatal synbiotic"
"CD006475_pub3_data","Subgroup","Infants not selected for risk of allergy"
"CD006515_pub2_data","Analysis.group","1"
"CD006515_pub2_data","Analysis.name","Death"
"CD006515_pub2_data","Analysis.name","Hospital admissions"
"CD006515_pub2_data","Analysis.name","Peritonitis"
"CD006515_pub2_data","Analysis.name","Change of dialysis modality"
"CD006515_pub2_data","Analysis.name","Residual kidney function (end of study CrCl) [mL/min]"
"CD006515_pub2_data","Analysis.name","Health-related quality of life (HRQoL)"
"CD006515_pub2_data","Analysis.name","Overhydration"
"CD006515_pub2_data","Analysis.name","Blood pressure [mm Hg]"
"CD006515_pub2_data","Analysis.name","Other infectious complications"
"CD006515_pub2_data","Analysis.name","Mechanical complications"
"CD006515_pub2_data","Analysis.name","PD catheter removal"
"CD006515_pub2_data","Analysis.name","Dialysis adequacy measures"
"CD006515_pub2_data","Subgroup","Change to any other form of dialysis modality including other forms of PD"
"CD006515_pub2_data","Subgroup","Change to haemodialysis"
"CD006515_pub2_data","Subgroup","Karnofsky score"
"CD006515_pub2_data","Subgroup","Systolic blood pressure"
"CD006515_pub2_data","Subgroup","Diastolic blood pressure"
"CD006515_pub2_data","Subgroup","Exit-site infections"
"CD006515_pub2_data","Subgroup","Tunnel infections"
"CD006515_pub2_data","Subgroup","Hernias"
"CD006515_pub2_data","Subgroup","PD fluid leaks"
"CD006515_pub2_data","Subgroup","Hydrothoraces"
"CD006515_pub2_data","Subgroup","Number removed due to peritonitis episodes"
"CD006515_pub2_data","Subgroup","Removal due to all causes"
"CD006515_pub2_data","Subgroup","Weekly Kt/V"
"CD006515_pub2_data","Subgroup","Weekly CrCl (L/week/1.73 m2)"
"CD006536_pub5_data","Analysis.group","1"
"CD006536_pub5_data","Analysis.group","2"
"CD006536_pub5_data","Analysis.group","3"
"CD006536_pub5_data","Analysis.group","4"
"CD006536_pub5_data","Analysis.group","5"
"CD006536_pub5_data","Analysis.group","6"
"CD006536_pub5_data","Analysis.group","7"
"CD006536_pub5_data","Analysis.group","8"
"CD006536_pub5_data","Analysis.group","9"
"CD006536_pub5_data","Analysis.group","10"
"CD006536_pub5_data","Analysis.name","All-cause mortality"
"CD006536_pub5_data","Analysis.name","Cardiovascular mortality"
"CD006536_pub5_data","Analysis.name","Composite measure of death, reinfarction, re-hospitalisation for heart failure"
"CD006536_pub5_data","Analysis.name","Incidence of reinfarction"
"CD006536_pub5_data","Analysis.name","Incidence of re-hospitalisation for heart failure"
"CD006536_pub5_data","Analysis.name","Incidence of arrhythmias"
"CD006536_pub5_data","Analysis.name","Incidence of restenosis"
"CD006536_pub5_data","Analysis.name","Incidence of target vessel revascularisation"
"CD006536_pub5_data","Analysis.name","Quality of life measures"
"CD006536_pub5_data","Analysis.name","NYHA classification"
"CD006536_pub5_data","Analysis.name","Exercise tolerance"
"CD006536_pub5_data","Analysis.name","Maximum VO2 (mL/kg/min)"
"CD006536_pub5_data","Analysis.name","VE/VCO2 slope"
"CD006536_pub5_data","Analysis.name","Peak heart rate (bpm)"
"CD006536_pub5_data","Analysis.name","LVEF measured by MRI (< 12 months)"
"CD006536_pub5_data","Analysis.name","LVEF measured by MRI (≥ 12 months)"
"CD006536_pub5_data","Analysis.name","LVEF measured by echocardiography (< 12 months)"
"CD006536_pub5_data","Analysis.name","LVEF measured by echocardiography (≥ 12 months)"
"CD006536_pub5_data","Analysis.name","LVEF measured by SPECT (< 12 months)"
"CD006536_pub5_data","Analysis.name","LVEF measured by SPECT (≥ 12 months)"
"CD006536_pub5_data","Analysis.name","LVEF measured by left ventricular angiography (< 12 months)"
"CD006536_pub5_data","Analysis.name","LVEF measured by left ventricular angiography (≥ 12 months)"
"CD006536_pub5_data","Analysis.name","LVEF measured by radionuclide ventriculography (RNV) (< 12 months)"
"CD006536_pub5_data","Analysis.name","LVEF measured by radionuclide ventriculography (≥ 12 months)"
"CD006536_pub5_data","Analysis.name","All-cause mortality (random sequence generation)"
"CD006536_pub5_data","Analysis.name","All-cause mortality (allocation concealment)"
"CD006536_pub5_data","Analysis.name","All-cause mortality (< 12 months)"
"CD006536_pub5_data","Analysis.name","All-cause mortality (≥ 12 months)"
"CD006536_pub5_data","Subgroup","Long-term follow-up (≥ 12 months)"
"CD006536_pub5_data","Subgroup","Short-term follow-up (< 12 months)"
"CD006536_pub5_data","Subgroup","Mean change from baseline"
"CD006536_pub5_data","Subgroup","Mean value at endpoint"
"CD006536_pub5_data","Subgroup","Combined"
"CD006536_pub5_data","Subgroup","Mean difference"
"CD006536_pub5_data","Subgroup","Combined analysis"
"CD006536_pub5_data","Subgroup","Baseline LVEF < 45%"
"CD006536_pub5_data","Subgroup","Baseline LVEF ≥ 45%"
"CD006536_pub5_data","Subgroup","Mononuclear cells"
"CD006536_pub5_data","Subgroup","Mesenchymal stem cells"
"CD006536_pub5_data","Subgroup","Haematopoietic progenitor cells"
"CD006536_pub5_data","Subgroup","> 109 cells"
"CD006536_pub5_data","Subgroup","> 108 and ≤ 109 cells"
"CD006536_pub5_data","Subgroup","≤ 108 cells"
"CD006536_pub5_data","Subgroup","≤ 10 days since AMI"
"CD006536_pub5_data","Subgroup","> 10 days since AMI"
"CD006536_pub5_data","Subgroup","Heparin"
"CD006536_pub5_data","Subgroup","No heparin"
"CD006606_pub5_data","Analysis.group","1"
"CD006606_pub5_data","Analysis.name","Live birth – low risk of bias (odds ratio, random-effect)"
"CD006606_pub5_data","Analysis.name","Live birth – low risk of bias (risk ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Miscarriage – low risk of bias (odds ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Miscarriage – low risk of bias (risk ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Clinical pregnancy – low risk of bias (odds ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Clinical pregnancy – low risk of bias (risk ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Clinical pregnancy – all studies (odds ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Clinical pregnancy – all studies (risk ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Ovarian hyperstimulation syndrome – low risk of bias (odds ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Ovarian hyperstimulation syndrome – low risk of bias (risk ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Preterm birth – low risk of bias (odds ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Preterm birth – low risk of bias (risk ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Congenital anomaly – low risk of bias (odds ratio, random-effects)"
"CD006606_pub5_data","Analysis.name","Congenital anomaly – low risk of bias (risk ratio, random-effects)"
"CD006632_pub3_data","Analysis.group","1"
"CD006632_pub3_data","Analysis.group","2"
"CD006632_pub3_data","Analysis.name","Inhospital mortality"
"CD006632_pub3_data","Analysis.name","Mortality (up to 6 months)"
"CD006632_pub3_data","Analysis.name","Inhospital complications"
"CD006632_pub3_data","Analysis.name","Hospital readmission (up to 6 months)"
"CD006632_pub3_data","Analysis.name","Length of hospital stay (days)"
"CD006632_pub3_data","Analysis.name","Hospital cost and charges"
"CD006632_pub3_data","Analysis.name","Adherence to recommended practice"
"CD006632_pub3_data","Analysis.name","Sensitivity analysis: Risk of bias inhospital mortality (studies at high RoB excluded)"
"CD006632_pub3_data","Analysis.name","Sensitivity analysis: Risk of bias 6 months mortality (studies at high RoB excluded)"
"CD006632_pub3_data","Analysis.name","Sensitivity analysis: Risk of bias inhospital complications (studies at high RoB excluded)"
"CD006632_pub3_data","Analysis.name","Sensitivity analysis: Risk of bias hospital readmission (up to 6 months; studies at high RoB excluded)"
"CD006632_pub3_data","Analysis.name","Sensitivity analysis: Risk of bias length of hospital stay in days (studies at high RoB excluded)"
"CD006632_pub3_data","Analysis.name","Sensitivity analysis: Risk of bias 6-month mortality (studies at high risk of bias excluded)"
"CD006632_pub3_data","Subgroup","RCT"
"CD006632_pub3_data","Subgroup","NRCT"
"CD006632_pub3_data","Subgroup","CBA"
"CD006632_pub3_data","Subgroup","RCTs"
"CD006632_pub3_data","Subgroup","RCT studies"
"CD006632_pub3_data","Subgroup","NRCT studies"
"CD006632_pub3_data","Subgroup","RCT studies hospital cost and charges"
"CD006632_pub3_data","Subgroup","Hospital cost and charges"
"CD006632_pub3_data","Subgroup","Hospital charges"
"CD006632_pub3_data","Subgroup","Hospital costs"
"CD006689_pub3_data","Analysis.group","1"
"CD006689_pub3_data","Analysis.group","2"
"CD006689_pub3_data","Analysis.group","3"
"CD006689_pub3_data","Analysis.group","4"
"CD006689_pub3_data","Analysis.group","5"
"CD006689_pub3_data","Analysis.group","6"
"CD006689_pub3_data","Analysis.group","7"
"CD006689_pub3_data","Analysis.group","8"
"CD006689_pub3_data","Analysis.group","9"
"CD006689_pub3_data","Analysis.name","Maternal peripheral parasitaemia at delivery (amplification techniques)"
"CD006689_pub3_data","Analysis.name","Maternal peripheral parasitaemia at delivery (microscopy)"
"CD006689_pub3_data","Analysis.name","Maternal anaemia at delivery (< 11 g/dL)"
"CD006689_pub3_data","Analysis.name","Placental malaria (any test)"
"CD006689_pub3_data","Analysis.name","Placental malaria (blood smear)"
"CD006689_pub3_data","Analysis.name","Placental malaria (amplification techniques)"
"CD006689_pub3_data","Analysis.name","Placental malaria (histopathologic analysis)"
"CD006689_pub3_data","Analysis.name","Maternal peripheral parasitaemia during pregnancy (any test)"
"CD006689_pub3_data","Analysis.name","Clinical malaria episodes during pregnancy"
"CD006689_pub3_data","Analysis.name","Mean haemoglobin at delivery (in g/dL)"
"CD006689_pub3_data","Analysis.name","Maternal severe anaemia at delivery (< 7 g/dL)"
"CD006689_pub3_data","Analysis.name","Low birth weight (less than 2500 g)"
"CD006689_pub3_data","Analysis.name","Mean birth weight (g)"
"CD006689_pub3_data","Analysis.name","Cord blood parasitaemia (blood smear)"
"CD006689_pub3_data","Analysis.name","Cord blood parasitaemia (loop-mediated isothermal amplification)"
"CD006689_pub3_data","Analysis.name","Prematurity"
"CD006689_pub3_data","Analysis.name","Severe adverse events during pregnancy"
"CD006689_pub3_data","Analysis.name","Foetal loss"
"CD006689_pub3_data","Analysis.name","Congenital malformations"
"CD006689_pub3_data","Analysis.name","Maternal mortality"
"CD006689_pub3_data","Analysis.name","Neonatal mortality"
"CD006689_pub3_data","Analysis.name","Maternal peripheral parasitaemia at delivery (polymerase chain reaction)"
"CD006689_pub3_data","Analysis.name","Maternal anaemia at delivery (< 9.5 g/dL)"
"CD006689_pub3_data","Analysis.name","Placental malaria (polymerase chain reaction)"
"CD006689_pub3_data","Analysis.name","Maternal severe anaemia at delivery"
"CD006689_pub3_data","Analysis.name","Low birth weight (< 2500 g)"
"CD006689_pub3_data","Analysis.name","Cord blood parasitaemia"
"CD006689_pub3_data","Analysis.name","Adverse events: headache"
"CD006689_pub3_data","Analysis.name","Adverse events: vomiting"
"CD006689_pub3_data","Analysis.name","Adverse events: dizziness"
"CD006689_pub3_data","Analysis.name","Adverse events: fatigue/weakness"
"CD006689_pub3_data","Analysis.name","Mother-to-child transmission of HIV"
"CD006689_pub3_data","Analysis.name","Undetectable viral load"
"CD006689_pub3_data","Analysis.name","Maternal anaemia at delivery (< 11g/dL)"
"CD006689_pub3_data","Analysis.name","Mean haemoglobin at delivery (g/dL)"
"CD006689_pub3_data","Analysis.name","Maternal severe anaemia at delivery (< 7g/dL)"
"CD006689_pub3_data","Analysis.name","Cord blood parasitaemia (microscopy)"
"CD006689_pub3_data","Analysis.name","Prematurity "
"CD006689_pub3_data","Analysis.name","Severe adverse events during pregnancy "
"CD006689_pub3_data","Analysis.name","Congenital malformations "
"CD006689_pub3_data","Analysis.name","Adverse events: headache "
"CD006689_pub3_data","Analysis.name","Adverse events: gastrointestinal disorders after first IPTp dose"
"CD006689_pub3_data","Analysis.name","Adverse events: dizziness after first IPTp dose"
"CD006689_pub3_data","Analysis.name","Undetectable HIV viral load at delivery"
"CD006689_pub3_data","Analysis.name","Maternal peripheral parasitaemia at delivery (blood smear)"
"CD006689_pub3_data","Analysis.name","Maternal anaemia at delivery (haemoglobin < 11 g/dL)"
"CD006689_pub3_data","Analysis.name","Maternal haemoglobin at delivery (in g/dL)"
"CD006689_pub3_data","Analysis.name","Mean birth weight (in kg)"
"CD006689_pub3_data","Analysis.name","Spontaneous abortion"
"CD006689_pub3_data","Analysis.name","Stillbirth"
"CD006689_pub3_data","Analysis.name","Maternal peripheral parasitaemia during pregnancy"
"CD006689_pub3_data","Analysis.name","Maternal anaemia during delivery"
"CD006689_pub3_data","Analysis.name","Placental malaria (histology)"
"CD006689_pub3_data","Analysis.name","Placental malaria (microscopy or polymerase chain reaction)"
"CD006689_pub3_data","Analysis.name","Maternal haemoglobin level at delivery (in g/dL)"
"CD006689_pub3_data","Analysis.name","Mean birth weight (in grams)"
"CD006689_pub3_data","Analysis.name","Cord blood parasitaemia (rapid diagnostic test)"
"CD006689_pub3_data","Analysis.name","Congenital malaria"
"CD006689_pub3_data","Analysis.name","SAEs during pregnancy"
"CD006689_pub3_data","Analysis.name","Infant mortality"
"CD006689_pub3_data","Analysis.name","Adverse events: rash"
"CD006689_pub3_data","Analysis.name","Maternal peripheral parasitemia at delivery (blood smear)"
"CD006689_pub3_data","Analysis.name","Adverse events: nausea "
"CD006689_pub3_data","Analysis.name","Adverse events: dizziness "
"CD006689_pub3_data","Analysis.name","Adverse events: gastric pain"
"CD006689_pub3_data","Analysis.name","Maternal anaemia at delivery"
"CD006689_pub3_data","Analysis.name","Low birth weight (< 2.5 kg)"
"CD006689_pub3_data","Analysis.name","Adverse events: nausea"
"CD006689_pub3_data","Analysis.name","Adverse events: abdominal pain"
"CD006689_pub3_data","Analysis.name","Early neonatal mortality (< 7 days)"
"CD006689_pub3_data","Analysis.name","Infant mortality (≥ 7 days up to 6 weeks of age)"
"CD006689_pub3_data","Analysis.name","Maternal anaemia at delivery (packed cell volume <33%)"
"CD006689_pub3_data","Analysis.name","Maternal anaemia at delivery (< 120 g/L)"
"CD006689_pub3_data","Analysis.name","Placental malaria: acute infection (histology)"
"CD006689_pub3_data","Analysis.name","Placental malaria: chronic infection (histology)"
"CD006689_pub3_data","Analysis.name","Mean haemoglobin at delivery (in g/L)"
"CD006689_pub3_data","Analysis.name","Maternal viral load at delivery (≥ 10 000 copies/mL)"
"CD006712_pub3_data","Analysis.group","1"
"CD006712_pub3_data","Analysis.group","2"
"CD006712_pub3_data","Analysis.group","3"
"CD006712_pub3_data","Analysis.group","4"
"CD006712_pub3_data","Analysis.group","5"
"CD006712_pub3_data","Analysis.group","6"
"CD006712_pub3_data","Analysis.group","7"
"CD006712_pub3_data","Analysis.group","8"
"CD006712_pub3_data","Analysis.group","9"
"CD006712_pub3_data","Analysis.group","10"
"CD006712_pub3_data","Analysis.group","11"
"CD006712_pub3_data","Analysis.group","12"
"CD006712_pub3_data","Analysis.group","13"
"CD006712_pub3_data","Analysis.group","14"
"CD006712_pub3_data","Analysis.group","15"
"CD006712_pub3_data","Analysis.group","16"
"CD006712_pub3_data","Analysis.group","17"
"CD006712_pub3_data","Analysis.group","18"
"CD006712_pub3_data","Analysis.name","Pain with dilation"
"CD006712_pub3_data","Analysis.name","Pain with aspiration"
"CD006712_pub3_data","Analysis.name","Pain during procedure"
"CD006712_pub3_data","Analysis.name","Pain during procedure in patients who all also received topical cervical lidocaine spray"
"CD006712_pub3_data","Analysis.name","Pain with dilation (10 mL 2% lidocaine)"
"CD006712_pub3_data","Analysis.name","Pain with dilation (20 mL 1% lidocaine)"
"CD006712_pub3_data","Analysis.name","Pain with aspiration (lidocaine)"
"CD006712_pub3_data","Analysis.name","Pain with aspiration (20 mL 1% lidocaine)"
"CD006712_pub3_data","Subgroup","Normal saline"
"CD006712_pub3_data","Subgroup","Local anaesthetic"
"CD006714_pub3_data","Analysis.group","1"
"CD006714_pub3_data","Analysis.name","Abortion completed with intended method (defined as fetal expulsion)"
"CD006714_pub3_data","Analysis.name","Incomplete abortion requiring an additional procedure or intervention (immediate or delayed)"
"CD006714_pub3_data","Analysis.name","Bleeding: hemorrhage requiring transfusion"
"CD006714_pub3_data","Analysis.name","Bleeding: mean estimated blood loss (mL)"
"CD006714_pub3_data","Analysis.name","Bleeding: post-abortion bleeding severity > menstrual period "
"CD006714_pub3_data","Analysis.name","Injury: cervix, vagina, uterus "
"CD006714_pub3_data","Analysis.name","Requirement for overnight hospitalization"
"CD006714_pub3_data","Analysis.name","Patient experience of pain (mean pain score)"
"CD006714_pub3_data","Analysis.name","Patient satisfaction (overall satisfaction with assigned method)"
"CD006714_pub3_data","Analysis.name","Bleeding: hemorrhage not requiring transfusion"
"CD006714_pub3_data","Analysis.name","Nausea"
"CD006714_pub3_data","Analysis.name","Vomiting"
"CD006714_pub3_data","Analysis.name","Diarrhea"
"CD006714_pub3_data","Analysis.name","Psychological impact: Impact of Event Scale (IES)"
"CD006714_pub3_data","Analysis.name","Psychological impact: Hospital Anxiety and Depression Scale (HADS)"
"CD006714_pub3_data","Analysis.name","Psychological impact: General Health Questionnaire (GHQ-12)"
"CD006714_pub3_data","Analysis.name","Acceptability: would choose the same procedure again"
"CD006714_pub3_data","Analysis.name","Acceptability: rate experience worse than expected"
"CD006714_pub3_data","Subgroup","New Subgroup"
"CD006714_pub3_data","Subgroup","IES-Intrusion score"
"CD006714_pub3_data","Subgroup","IES-Avoidance score"
"CD006714_pub3_data","Subgroup","IES-Total score"
"CD006714_pub3_data","Subgroup","HAD-A score"
"CD006714_pub3_data","Subgroup","HAD-D score"
"CD006742_pub3_data","Analysis.group","1"
"CD006742_pub3_data","Analysis.name","All-Cause Mortality"
"CD006742_pub3_data","Analysis.name","Total cardiovascular events"
"CD006742_pub3_data","Analysis.name","Stroke"
"CD006742_pub3_data","Analysis.name","Coronary Heart Disease"
"CD006742_pub3_data","Analysis.name","Withdrawals due to adverse effects"
"CD006839_pub5_data","Analysis.group","1"
"CD006839_pub5_data","Analysis.group","2"
"CD006839_pub5_data","Analysis.group","3"
"CD006839_pub5_data","Analysis.group","4"
"CD006839_pub5_data","Analysis.name","Proportion of participants with clinical improvement in function compared to baseline"
"CD006839_pub5_data","Analysis.name","Postoperative motor nerve conduction velocity"
"CD006839_pub5_data","Analysis.name","Proportion of participants with deep/superficial wound infections"
"CD006839_pub5_data","Analysis.name","Proportion of participants with hematoma/pain from scarring"
"CD006839_pub5_data","Analysis.name","Proportion of participants with clinical improvement in function at 3 months compared to baseline. Corticosteroid injection versus placebo"
"CD006839_pub5_data","Analysis.name","Proportion of patients with adverse events at the injection site. Corticosteroid injection versus placebo"
"CD006839_pub5_data","Analysis.name","Proportion of participants with clinical improvement in function at 12 months compared to baseline"
"CD006839_pub5_data","Analysis.name","Proportion of participants with wound infection/pain/sensory loss"
"CD006839_pub5_data","Subgroup","Simple decompression versus subcutaneous transposition"
"CD006839_pub5_data","Subgroup","Simple decompression versus submuscular transposition"
"CD006839_pub5_data","Subgroup","Simple decompression vs subcutaneous transposition"
"CD006839_pub5_data","Subgroup","Simple decompression vs submuscular transposition"
"CD006839_pub5_data","Subgroup","Excellent/good outcome as measured with Bishop score at long follow-up (around 12 months)"
"CD006913_pub3_data","Analysis.group","1"
"CD006913_pub3_data","Analysis.group","2"
"CD006913_pub3_data","Analysis.group","3"
"CD006913_pub3_data","Analysis.group","4"
"CD006913_pub3_data","Analysis.group","5"
"CD006913_pub3_data","Analysis.group","6"
"CD006913_pub3_data","Analysis.group","7"
"CD006913_pub3_data","Analysis.group","8"
"CD006913_pub3_data","Analysis.group","9"
"CD006913_pub3_data","Analysis.group","10"
"CD006913_pub3_data","Analysis.group","11"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) -  psychotherapy vs care-as-usual, with Xiao"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) -  psychotherapy vs care-as-usual, revised"
"CD006913_pub3_data","Analysis.name","IBDQ (short-term) -  psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term) - psychotherapy vs care-as usual"
"CD006913_pub3_data","Analysis.name","IBDQ (long-term) - psychotherapy vs care-as-usual "
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by disease activity - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by disease activity - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by comorbidity - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by comorbidity - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by type of therapy - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by type of therapy - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by therapy intensity - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by therapy intensity - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by mode of application - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by training of provider - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (short-term) - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (long-term) - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Anxiety (short-term) - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Anxiety (long-term) - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (short-term) - psychotherapy vs care-as-usual (ITT)"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (short-term) - psychotherapy vs care-as-usual (PP, sensitivity analysis)"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (long-term) - psychotherapy vs care-asusual  (ITT)"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (long-term) - psychotherapy vs care-as-usual (PP, sensitivity analysis)"
"CD006913_pub3_data","Analysis.name","Disease activity (short-term) - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Disease activity (long-term) - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Number of patients completing program - psychotherapy vs any control, all populations"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - educational intervention vs care-as-usual, with Xiao"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - educational intervention vs care-as-usual, revised"
"CD006913_pub3_data","Analysis.name","IBDQ (short-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term) - educational intervention vs care-as usual"
"CD006913_pub3_data","Analysis.name","IBDQ (long-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by disease activity - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by disease activity - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by comorbidity - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by type of therapy - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by type of therapy - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-time), by therapy intensity - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by therapy intensity - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by mode of application - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by training of provider - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (short-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (long-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Anxiety (short-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Anxiety (long-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (short-term) (ITT) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (short-term) (PP, sensitivity analysis) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (long-term) (ITT) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (long-term) (PP, sensitivity analysis) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Disease activity (short-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Disease activity (long-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Emergency visits per person (long-term)  - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Days in hospital (short-term) - educational interventions vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Number of patients completing program"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - relaxation techniques vs care-as-usual, with You"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - relaxation techniques vs care-as-usual, revised"
"CD006913_pub3_data","Analysis.name","IBDQ (short-term) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","IBDQ (long-term) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by disease activity - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by disease activity - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by comorbidity - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by comorbidity - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by type of therapy - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by type of therapy - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by therapy intensity - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term), by therapy intensity - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by mode of application - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term), by training of provider - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (short-term) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (long-term) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Anxiety (short-term) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Anxiety (long-term) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Failure to induce and maintain remission (short-term) (ITT) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (short-term) (PP, sensitivity analysis) - relaxation techniques vs. care-as-usual"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (long-term) (ITT) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (long-term) (PP, sensitivity analysis) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Disease activity (short-term) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Disease activity (long-term) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Days off work – change from pre-treatment  values (reference period: two years) - relaxation techniques vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Number of patients completing program  - relaxation techniques vs any type of control, all populations"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - psychotherapy vs active control"
"CD006913_pub3_data","Analysis.name","IBDQ (short-term) - psychotherapy vs active control"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (short-term) - psychotherapy vs active control"
"CD006913_pub3_data","Analysis.name","Anxiety (short-term) - psychotherapy vs active control"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","IBDQ (short-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","IBDQ (long-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (shortterm) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (long-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Anxiety (short-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Anxiety (long-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (short-term) (ITT) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (short-term) (PP, sensitivity analysis) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (long-term) (ITT) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (long-term) (PP, sensitivity analysis) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Disease activity (short-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Disease activity (long-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - relaxation technique vs active control"
"CD006913_pub3_data","Analysis.name","IBDQ (short-term) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","IBDQ (long-term) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (shortterm) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (long-term) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Anxiety (short-term) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Anxiety (long-term) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (short-term) (ITT) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Failure to induce or maintain remission (long-term) (ITT) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Disease activity (short-term) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Disease activity (long-term) - relaxation techniques vs active control"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term)  - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Time off school - change from baseline (short-term) - psychotherapy vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term) - educational intervention vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (short-term) - relaxation technique vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Quality of life (long-term) - relaxation technique vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (short-term) - relaxation technique vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Depressive symptoms (long-term) - relaxation technique vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Anxiety - change from baseline (short-term) - relaxation technique vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Disease activity - change from baseline (short-term) - relaxation technique vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Time off school - change from baseline (short-term) - relaxation technique vs care-as-usual"
"CD006913_pub3_data","Analysis.name","Disease activity (short-term)- psychotherapy vs active control"
"CD006913_pub3_data","Analysis.name","Quality of life - change from baseline (long-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Depressive symptoms - change from baseline (short-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Depressive symptoms - change from baseline (long-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Anxiety (short- term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Anxiety - change from baseline (long-term) - educational intervention vs active control"
"CD006913_pub3_data","Analysis.name","Quality of life - change from baseline (short-term) - relaxation technique vs active control"
"CD006913_pub3_data","Analysis.name","Quality of life - change from baseline (long-term) - relaxation technique vs active control"
"CD006913_pub3_data","Analysis.name","Depressive symptoms - change from baseline (long-term) - relaxation technique vs active control"
"CD006913_pub3_data","Analysis.name","Depressive symptoms - change from baseline (short-term)  - relaxation technique vs active control"
"CD006913_pub3_data","Analysis.name","Anxiety (short-term) - relaxation technique vs active control"
"CD006913_pub3_data","Analysis.name","Anxiety - change from baseline (long-term) - relaxation technique vs active control"
"CD006913_pub3_data","Analysis.name","Disease activity (short-term) - relaxation technique vs active control"
"CD006913_pub3_data","Subgroup","Crohn's disease"
"CD006913_pub3_data","Subgroup","Ulcerative colitis"
"CD006913_pub3_data","Subgroup","IBD unspecified"
"CD006913_pub3_data","Subgroup","Acute flare/chronic active"
"CD006913_pub3_data","Subgroup","In remission"
"CD006913_pub3_data","Subgroup","Psychological / IBS comorbidity"
"CD006913_pub3_data","Subgroup","No explicit comorbidity "
"CD006913_pub3_data","Subgroup","CBT-based"
"CD006913_pub3_data","Subgroup","Hypnotherapy"
"CD006913_pub3_data","Subgroup","Single component therapy"
"CD006913_pub3_data","Subgroup","Multimodular"
"CD006913_pub3_data","Subgroup","Low intensity"
"CD006913_pub3_data","Subgroup","High intensity"
"CD006913_pub3_data","Subgroup","In person"
"CD006913_pub3_data","Subgroup","Phone or VC, live"
"CD006913_pub3_data","Subgroup","Tape or digital, not live"
"CD006913_pub3_data","Subgroup","Psychotherapist"
"CD006913_pub3_data","Subgroup","Other health professional"
"CD006913_pub3_data","Subgroup","Not a person"
"CD006913_pub3_data","Subgroup","Adults"
"CD006913_pub3_data","Subgroup","Children and  adolescents"
"CD006913_pub3_data","Subgroup","Psychiatric/psychological/IBS comorbidity"
"CD006913_pub3_data","Subgroup","Education"
"CD006913_pub3_data","Subgroup","IBD unspecified "
"CD006913_pub3_data","Subgroup","Children and adolescents"
"CD006913_pub3_data","Subgroup","Crohn's Disease"
"CD006913_pub3_data","Subgroup","Ulcerative Colitis"
"CD006913_pub3_data","Subgroup","No explicit comorbidity"
"CD006913_pub3_data","Subgroup","IBD unspecified (control - education)"
"CD006913_pub3_data","Subgroup","Crohn's disease (control - education)"
"CD006913_pub3_data","Subgroup","Crohn's disease (control - psychotherapy)"
"CD006913_pub3_data","Subgroup","IBD unspecified (control - psychotherapy)"
"CD006913_pub3_data","Subgroup","IBD unspecified (control - other education)"
"CD006913_pub3_data","Subgroup","Ulcerative colitis (control - relaxation)"
"CD006913_pub3_data","Subgroup","Ulcerative colitis (control - psychotherapy)"
"CD006913_pub3_data","Subgroup","Ulcerative colitis (control - education)"
"CD006913_pub3_data","Subgroup","Ulcerative colitis (comparison group - education)"
"CD006913_pub3_data","Subgroup","IBD unspecified (comparison group - psychotherapy)"
"CD006913_pub3_data","Subgroup","IBD unspecified (comparison group - education)"
"CD006913_pub3_data","Subgroup","IBD unspecified (comparison group - multicomponent)"
"CD006919_pub5_data","Analysis.group","1"
"CD006919_pub5_data","Analysis.group","2"
"CD006919_pub5_data","Analysis.group","3"
"CD006919_pub5_data","Analysis.group","4"
"CD006919_pub5_data","Analysis.group","5"
"CD006919_pub5_data","Analysis.group","6"
"CD006919_pub5_data","Analysis.group","7"
"CD006919_pub5_data","Analysis.group","8"
"CD006919_pub5_data","Analysis.group","9"
"CD006919_pub5_data","Analysis.group","10"
"CD006919_pub5_data","Analysis.name","Live birth/ongoing pregnancies primary analysis"
"CD006919_pub5_data","Analysis.name","Live birth/ongoing pregnancies all studies"
"CD006919_pub5_data","Analysis.name","Clinical pregnancies primary analysis"
"CD006919_pub5_data","Analysis.name","Clinical pregnancies all studies"
"CD006919_pub5_data","Analysis.name","Number of oocytes"
"CD006919_pub5_data","Analysis.name","Amount of gonadotropins administered"
"CD006919_pub5_data","Analysis.name","Cycle cancellation"
"CD006919_pub5_data","Analysis.name","Live birth and ongoing pregnancies"
"CD006919_pub5_data","Analysis.name","Clinical pregnancies"
"CD006919_pub5_data","Analysis.name","Ongoing pregnancy rate primary analysis"
"CD006919_pub5_data","Analysis.name","Ongoing pregnancy rate all studies"
"CD006919_pub5_data","Analysis.name","Ongoing pregnancy rate"
"CD006919_pub5_data","Analysis.name","OHSS"
"CD006919_pub5_data","Analysis.name","Adverse outcomes: OHSS and pregnancy loss"
"CD006919_pub5_data","Analysis.name","Live birth 500 µg versus 80 µg"
"CD006919_pub5_data","Analysis.name","Clinical pregnancy 500 µg vs 80 µg"
"CD006919_pub5_data","Analysis.name","Clinical pregnancy 100 µg vs 50 µg"
"CD006919_pub5_data","Analysis.name","Clinical pregnancy 100 µg vs 25 µg"
"CD006919_pub5_data","Analysis.name","Clinical pregnancy 50 µg vs 25 µg"
"CD006919_pub5_data","Analysis.name","Number of oocytes 500 µg vs 80 µg"
"CD006919_pub5_data","Analysis.name","Number of oocytes 100 µg vs 50 µg"
"CD006919_pub5_data","Analysis.name","Number of oocytes 100 µg vs 25 µg"
"CD006919_pub5_data","Analysis.name","Number of oocytes 50 µg vs 25 µg"
"CD006919_pub5_data","Analysis.name","Other outcomes: pregnancy loss"
"CD006919_pub5_data","Subgroup","Non-selected group"
"CD006919_pub5_data","Subgroup","Poor responder group"
"CD006919_pub5_data","Subgroup","Poor responders"
"CD006919_pub5_data","Subgroup","Non selected"
"CD006919_pub5_data","Subgroup","Miscarriages"
"CD006919_pub5_data","Subgroup","OHSS"
"CD006919_pub5_data","Subgroup","100 micrograms triptorelin versus 25 micrograms triptorelin"
"CD006919_pub5_data","Subgroup","500 micrograms buserelin versus 80 micrograms buserelin"
"CD006919_pub5_data","Subgroup","500 micrograms versus 80micrograms of buserelin"
"CD006919_pub5_data","Subgroup","100 micrograms triptorelin versus 50 micrograms triptorelin"
"CD006942_pub4_data","Analysis.group","1"
"CD006942_pub4_data","Analysis.group","2"
"CD006942_pub4_data","Analysis.group","3"
"CD006942_pub4_data","Analysis.group","4"
"CD006942_pub4_data","Analysis.group","5"
"CD006942_pub4_data","Analysis.group","6"
"CD006942_pub4_data","Analysis.group","7"
"CD006942_pub4_data","Analysis.name","Live birth or ongoing pregnancy rate per couple"
"CD006942_pub4_data","Analysis.name","Clinical pregnancy per couple"
"CD006942_pub4_data","Analysis.name","Multiple pregnancy per couple"
"CD006942_pub4_data","Analysis.name","Miscarriage per couple"
"CD006942_pub4_data","Analysis.name","Tubal pregnancy per couple"
"CD006942_pub4_data","Subgroup","0 to 33 hours versus 34 to 40 hours"
"CD006942_pub4_data","Subgroup","0 to 33 hours versus 34 to 40 hours (sensitivity analysis)*"
"CD006942_pub4_data","Subgroup","34 to 40 hours versus &gt; 40 hours"
"CD006942_pub4_data","Subgroup","0-33 hours versus 34-40 hours"
"CD006942_pub4_data","Subgroup","34-40 hours versus &nbsp;&gt;40 hours"
"CD006942_pub4_data","Subgroup","Stimulated cycle"
"CD006942_pub4_data","Subgroup","Natural cycle (sensitivity analysis)*"
"CD006942_pub4_data","Subgroup","Stimulated cycle (sensitivity analysis)*"
"CD006942_pub4_data","Subgroup","Sensitivity analyses"
"CD006942_pub4_data","Subgroup","Primary analysis"
"CD006942_pub4_data","Subgroup","Sensitivity analysis*"
"CD006982_pub5_data","Analysis.group","1"
"CD006982_pub5_data","Analysis.group","2"
"CD006982_pub5_data","Analysis.name","Growth (g) at 3 and 6 months"
"CD006982_pub5_data","Analysis.name","Growth (daily weight gain, grams/d) during neonatal care"
"CD006982_pub5_data","Analysis.name","Retinopathy of prematurity (any stage)"
"CD006982_pub5_data","Analysis.name","Retinopathy of prematurity (stage ≥ 3)"
"CD006982_pub5_data","Analysis.name","Duration of initial hospitalisation (days) "
"CD006982_pub5_data","Analysis.name","Duration of oxygen treatment (days)"
"CD006982_pub5_data","Analysis.name","Duration of initial hospitalisation (days)"
"CD006982_pub5_data","Subgroup","at 3 months"
"CD006982_pub5_data","Subgroup","at 6 months"
"CD007024_pub3_data","Analysis.group","1"
"CD007024_pub3_data","Analysis.group","2"
"CD007024_pub3_data","Analysis.group","3"
"CD007024_pub3_data","Analysis.name","Frequency of cocaine use"
"CD007024_pub3_data","Analysis.name","Amount of cocaine use"
"CD007024_pub3_data","Analysis.name","Continuous abstinence"
"CD007024_pub3_data","Analysis.name","Point abstinence"
"CD007024_pub3_data","Analysis.name","Dropout for any reason"
"CD007024_pub3_data","Analysis.name","Dropout due to adverse events"
"CD007024_pub3_data","Analysis.name","Any adverse events"
"CD007024_pub3_data","Analysis.name","Individual adverse events"
"CD007024_pub3_data","Analysis.name","Craving (measured on a visual analogue scale of 0–100 points)"
"CD007024_pub3_data","Analysis.name","Depression (measured on a scale of 0–52 points)"
"CD007024_pub3_data","Analysis.name","Anxiety (measured on a scale of 0–56 points)"
"CD007024_pub3_data","Analysis.name","Frequency of cocaine use (according to the presence of alcohol dependence)"
"CD007024_pub3_data","Analysis.name","Frequency of cocaine use (according to the presence of opioid dependence in opioid agonist treatment)"
"CD007024_pub3_data","Analysis.name","Dropout for any reason (according to the presence of comorbid alcohol dependence)"
"CD007024_pub3_data","Analysis.name","Dropout for any reason (according to the presence of opioid dependence in opioid agonist treatment)"
"CD007024_pub3_data","Subgroup","Versus no pharmacological treatment"
"CD007024_pub3_data","Subgroup","Versus placebo"
"CD007024_pub3_data","Subgroup","Headache"
"CD007024_pub3_data","Subgroup","Drowsiness"
"CD007024_pub3_data","Subgroup","Anxiety"
"CD007024_pub3_data","Subgroup","Nausea"
"CD007024_pub3_data","Subgroup","Decreased sexual desire"
"CD007024_pub3_data","Subgroup","Increased sexual desire"
"CD007024_pub3_data","Subgroup","Vomiting"
"CD007024_pub3_data","Subgroup","Skin rush"
"CD007024_pub3_data","Subgroup","Difficulty achieving orgasm"
"CD007024_pub3_data","Subgroup","Toothache"
"CD007024_pub3_data","Subgroup","Diarrhoea"
"CD007024_pub3_data","Subgroup","Slurred Speech"
"CD007024_pub3_data","Subgroup","Drowsiness/fatigue"
"CD007024_pub3_data","Subgroup","Anxiety/irritability"
"CD007024_pub3_data","Subgroup","Upper respiratory tract infection"
"CD007024_pub3_data","Subgroup","Mix of participants with and without alcohol dependence"
"CD007024_pub3_data","Subgroup","Without comorbid alcohol dependence"
"CD007024_pub3_data","Subgroup","With comorbid alcohol dependence"
"CD007024_pub3_data","Subgroup","Without comorbid opioid dependence"
"CD007024_pub3_data","Subgroup","With comorbid opioid dependence"
"CD007024_pub3_data","Subgroup","With intermediate comorbid alcohol dependence"
"CD007026_pub7_data","Analysis.group","1"
"CD007026_pub7_data","Analysis.group","2"
"CD007026_pub7_data","Analysis.name","All-cause death"
"CD007026_pub7_data","Analysis.name","Non-death attrition"
"CD007026_pub7_data","Analysis.name","Total number of people with SAEs"
"CD007026_pub7_data","Analysis.name","Total number of people with fatal SAEs"
"CD007026_pub7_data","Analysis.name","Total number of people with non-fatal SAEs"
"CD007026_pub7_data","Analysis.name","Total number of people with adverse events"
"CD007026_pub7_data","Analysis.name","All-cause death. Sensitivity 1. Best-case"
"CD007026_pub7_data","Analysis.name","All-cause death. Sensitivity 2. Worst-case"
"CD007026_pub7_data","Analysis.name","All-cause death. Sensitivity 3. Complete case (missing data excluded)"
"CD007026_pub7_data","Analysis.name","All-cause death. Sensitivity 4. Risk of bias"
"CD007026_pub7_data","Subgroup","Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days"
"CD007026_pub7_data","Subgroup","Cerebrolysin dose: 30 mL for 10 days"
"CD007026_pub7_data","Subgroup","Cerebrolysin dose: 50 mL for 21 days"
"CD007026_pub7_data","Subgroup","Cerebrolysin dose: 10 mL and 50 mL for 10 days"
"CD007026_pub7_data","Subgroup","Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days"
"CD007026_pub7_data","Subgroup","Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days "
"CD007026_pub7_data","Subgroup","Cerebrolysin dose 50 mL for 21 days"
"CD007026_pub7_data","Subgroup","High risk of bias for incomplete outcome data"
"CD007026_pub7_data","Subgroup","Low and unclear risk of bias"
"CD007079_pub4_data","Analysis.group","1"
"CD007079_pub4_data","Analysis.group","2"
"CD007079_pub4_data","Analysis.group","3"
"CD007079_pub4_data","Analysis.name","Preterm birth < 37 weeks' gestation"
"CD007079_pub4_data","Analysis.name","Preterm birth < 37 weeks' gestation by dose of calcium"
"CD007079_pub4_data","Analysis.name","Preterm birth < 37 weeks' gestation by started to take calcium"
"CD007079_pub4_data","Analysis.name","Preterm birth < 37 weeks' gestation by type of calcium"
"CD007079_pub4_data","Analysis.name","Preterm birth < 34 weeks' gestation"
"CD007079_pub4_data","Analysis.name","Maternal weight gain (g/week)"
"CD007079_pub4_data","Analysis.name","Maternal bone mineral density (g/cm2) – first phalanx (calcium 300 mg)"
"CD007079_pub4_data","Analysis.name","Maternal bone mineral density (g/cm2) – second metacarpal (calcium 300 mg)"
"CD007079_pub4_data","Analysis.name","Maternal bone mineral density (g/cm2) – fourth metacarpal (calcium 300 mg)"
"CD007079_pub4_data","Analysis.name","Maternal bone mineral density (g/cm2) – first phalanx (calcium 600 mg)"
"CD007079_pub4_data","Analysis.name","Maternal bone mineral density (g/cm2) – second metacarpal (calcium 600 mg)"
"CD007079_pub4_data","Analysis.name","Maternal bone mineral density (g/cm2) – fourth metacarpal (calcium 600 mg)"
"CD007079_pub4_data","Analysis.name","Maternal admission to intensive care unit"
"CD007079_pub4_data","Analysis.name","Maternal death"
"CD007079_pub4_data","Analysis.name","Mode of birth: vaginal birth"
"CD007079_pub4_data","Analysis.name","Mode of birth: instrumental vaginal birth"
"CD007079_pub4_data","Analysis.name","Mode of birth: caesarean section"
"CD007079_pub4_data","Analysis.name","Low birthweight (< 2500 g)"
"CD007079_pub4_data","Analysis.name","Low birthweight (< 2500 g) by starting time of taking calcium"
"CD007079_pub4_data","Analysis.name","Low birthweight (< 2500 g) by type of calcium"
"CD007079_pub4_data","Analysis.name","Stillbirth or fetal death"
"CD007079_pub4_data","Analysis.name","Perinatal mortality"
"CD007079_pub4_data","Analysis.name","Admission to neonatal intensive care unit"
"CD007079_pub4_data","Analysis.name","Birthweight (g)"
"CD007079_pub4_data","Analysis.name","Birth length (cm)"
"CD007079_pub4_data","Analysis.name","Head circumference (cm)"
"CD007079_pub4_data","Analysis.name","Intrauterine growth restriction"
"CD007079_pub4_data","Analysis.name","Neonatal bone mineral density (g/cm2)"
"CD007079_pub4_data","Analysis.name","Adverse effects of calcium supplementation – maternal cholestatic jaundice"
"CD007079_pub4_data","Analysis.name","Urinary stones"
"CD007079_pub4_data","Analysis.name","Urinary tract infection"
"CD007079_pub4_data","Analysis.name","Renal colic"
"CD007079_pub4_data","Analysis.name","Impaired renal function"
"CD007079_pub4_data","Analysis.name","Maternal anaemia"
"CD007079_pub4_data","Subgroup","Main analysis"
"CD007079_pub4_data","Subgroup","High dose"
"CD007079_pub4_data","Subgroup","Started calcium before 20 weeks"
"CD007079_pub4_data","Subgroup","Started calcium at 20 weeks or more"
"CD007079_pub4_data","Subgroup","Carbonate"
"CD007079_pub4_data","Subgroup","Gluconate"
"CD007079_pub4_data","Subgroup","Total body"
"CD007079_pub4_data","Subgroup","Midshaft radius"
"CD007079_pub4_data","Subgroup","Lumbar spine"
"CD007079_pub4_data","Subgroup","Gall stones"
"CD007079_pub4_data","Subgroup","Headache, vomiting, backache, swelling, vaginal and urinary complaints, dyspepsia, abdominal pain"
"CD007079_pub4_data","Subgroup","Gastrointestinal symptoms (including nausea, heartburn and diarrhoea)"
"CD007110_pub4_data","Analysis.group","1"
"CD007110_pub4_data","Analysis.group","2"
"CD007110_pub4_data","Analysis.group","3"
"CD007110_pub4_data","Analysis.group","4"
"CD007110_pub4_data","Analysis.group","5"
"CD007110_pub4_data","Analysis.group","6"
"CD007110_pub4_data","Analysis.group","7"
"CD007110_pub4_data","Analysis.group","8"
"CD007110_pub4_data","Analysis.group","9"
"CD007110_pub4_data","Analysis.group","10"
"CD007110_pub4_data","Analysis.group","11"
"CD007110_pub4_data","Analysis.group","12"
"CD007110_pub4_data","Analysis.group","13"
"CD007110_pub4_data","Analysis.group","14"
"CD007110_pub4_data","Analysis.group","15"
"CD007110_pub4_data","Analysis.name","All trials"
"CD007110_pub4_data","Analysis.name","Subgroup analysis – no interim PET vs interim PET-negative individuals only"
"CD007110_pub4_data","Analysis.name","Subgroup analysis – ABVD chemotherapy vs EBVP chemotherapy"
"CD007110_pub4_data","Analysis.name","Second-cancer-related mortality"
"CD007110_pub4_data","Analysis.name","Cardiac disease-related mortality"
"CD007110_pub4_data","Analysis.name","Subgroup analysis – involved field radiotherapy vs mixed radiotherapy"
"CD007110_pub4_data","Analysis.name","Infection-related mortality"
"CD007110_pub4_data","Analysis.name","Subgroup analysis – radiotherapy after chemotherapy vs chemotherapy after radiotherapy"
"CD007110_pub4_data","Analysis.name","Subgroup analysis – CVPP chemotherapy vs eBEACOPP and ABVD chemotherapy"
"CD007110_pub4_data","Analysis.name","Subgroup analysis – bulky disease vs non-bulky disease"
"CD007110_pub4_data","Subgroup","Interim PET-negative individuals only"
"CD007110_pub4_data","Subgroup","No interim PET"
"CD007110_pub4_data","Subgroup","ABVD"
"CD007110_pub4_data","Subgroup","EBVP"
"CD007110_pub4_data","Subgroup","Involved field"
"CD007110_pub4_data","Subgroup","Mixed radiotherapy"
"CD007110_pub4_data","Subgroup","Chemotherapy after radiotherapy"
"CD007110_pub4_data","Subgroup","Radiotherapy after chemotherapy"
"CD007110_pub4_data","Subgroup","eBEACOPP and ABVD"
"CD007110_pub4_data","Subgroup","CVPP"
"CD007110_pub4_data","Subgroup","Bulky disease"
"CD007110_pub4_data","Subgroup","Non-bulky disease"
"CD007130_pub5_data","Analysis.group","1"
"CD007130_pub5_data","Analysis.name","Total mortality"
"CD007130_pub5_data","Analysis.name","Exercise capacity ≤ 12 months"
"CD007130_pub5_data","Analysis.name","Exercise capacity 12 to 24 months"
"CD007130_pub5_data","Analysis.name","Completers"
"CD007130_pub5_data","Analysis.name","Total cholesterol 3 to 12 months (mmol/L)"
"CD007130_pub5_data","Analysis.name","HDL cholesterol 3 to 12 months (mmol/L)"
"CD007130_pub5_data","Analysis.name","LDL cholesterol 3 to 12 months (mmol/L)"
"CD007130_pub5_data","Analysis.name","Triglycerides 3 to 12 months (mmol/L)"
"CD007130_pub5_data","Analysis.name","Systolic blood pressure 3 to 12 months (mmHg)"
"CD007130_pub5_data","Analysis.name","Diastolic blood pressure 3 to 12 months (mmHg)"
"CD007130_pub5_data","Analysis.name","Smoking 3 to 12 months"
"CD007156_pub3_data","Analysis.group","1"
"CD007156_pub3_data","Analysis.group","2"
"CD007156_pub3_data","Analysis.group","3"
"CD007156_pub3_data","Analysis.group","4"
"CD007156_pub3_data","Analysis.group","5"
"CD007156_pub3_data","Analysis.group","6"
"CD007156_pub3_data","Analysis.group","7"
"CD007156_pub3_data","Analysis.group","8"
"CD007156_pub3_data","Analysis.group","9"
"CD007156_pub3_data","Analysis.group","10"
"CD007156_pub3_data","Analysis.group","11"
"CD007156_pub3_data","Analysis.group","12"
"CD007156_pub3_data","Analysis.group","13"
"CD007156_pub3_data","Analysis.group","14"
"CD007156_pub3_data","Analysis.name","Interincisal distance (mm)"
"CD007156_pub3_data","Analysis.name","Burning sensation (VAS)"
"CD007156_pub3_data","Analysis.name","Difficulty in speech"
"CD007156_pub3_data","Analysis.name","Difficulty in swallowing"
"CD007156_pub3_data","Analysis.name","Difficulty in mouth opening"
"CD007156_pub3_data","Analysis.name","Intolerance to spicy food"
"CD007156_pub3_data","Subgroup","Vasodilators vs placebo"
"CD007156_pub3_data","Subgroup","Antioxidants vs placebo"
"CD007156_pub3_data","Subgroup","Pentoxifylline vs placebo"
"CD007156_pub3_data","Subgroup","Intralesional dexamethasone injections vs placebo"
"CD007156_pub3_data","Subgroup","Antioxidant vs placebo"
"CD007156_pub3_data","Subgroup","Dexamethasone vs placebo"
"CD007156_pub3_data","Subgroup","Vasodilator vs placebo"
"CD007156_pub3_data","Subgroup","Physiotherapy vs control"
"CD007156_pub3_data","Subgroup","Hydrocortisone + hyaluronidase vs placebo"
"CD007156_pub3_data","Subgroup","Pentoxifylline vs usual care"
"CD007156_pub3_data","Subgroup","Curcumin or lycopene vs placebo"
"CD007156_pub3_data","Subgroup","Steroid vs alternative (medicinal treatment)"
"CD007156_pub3_data","Subgroup","Levamisole vs alternative (antioxidant)"
"CD007156_pub3_data","Subgroup","Topical curcumin gel vs alternative (topical aloe vera gel)"
"CD007156_pub3_data","Subgroup","Spirulina vs alternative (oxitard)"
"CD007156_pub3_data","Subgroup","Oxitard capsules vs alternative (aloe vera gel)"
"CD007156_pub3_data","Subgroup","Steroid vs alternative (steroid + adjunct)"
"CD007156_pub3_data","Subgroup","Steroid vs alternative"
"CD007156_pub3_data","Subgroup","Pentoxifylline vs alternative (spirulina)"
"CD007156_pub3_data","Subgroup","Antioxidant vs topical aloe vera"
"CD007156_pub3_data","Subgroup","Steroids vs alternative"
"CD007156_pub3_data","Subgroup","Abdominal dermal fat graft vs alternative (nasolabial flap)"
"CD007156_pub3_data","Subgroup","Buccal fat pad vs alternative (extended nasolabial flap)"
"CD007156_pub3_data","Subgroup","Extended nasolabial flap vs alternative (buccal fat pad)"
"CD007156_pub3_data","Subgroup","Ultrasound + jaw opening exercises vs jaw opening exercises"
"CD007156_pub3_data","Subgroup","Tongue depressor stretches vs Local injection hyaluronidase + steroid"
"CD007156_pub3_data","Subgroup","Heister jaw opener vs wooden tongue depressors"
"CD007310_pub3_data","Analysis.group","1"
"CD007310_pub3_data","Analysis.group","2"
"CD007310_pub3_data","Analysis.group","3"
"CD007310_pub3_data","Analysis.group","4"
"CD007310_pub3_data","Analysis.group","5"
"CD007310_pub3_data","Analysis.group","6"
"CD007310_pub3_data","Analysis.group","7"
"CD007310_pub3_data","Analysis.group","8"
"CD007310_pub3_data","Analysis.group","9"
"CD007310_pub3_data","Analysis.group","10"
"CD007310_pub3_data","Analysis.group","11"
"CD007310_pub3_data","Analysis.group","12"
"CD007310_pub3_data","Analysis.group","13"
"CD007310_pub3_data","Analysis.group","14"
"CD007310_pub3_data","Analysis.group","15"
"CD007310_pub3_data","Analysis.name","Dilation achieved (mm)"
"CD007310_pub3_data","Analysis.name","Need for additional dilation"
"CD007310_pub3_data","Analysis.name","Ability to complete procedure (number completed on first attempt)"
"CD007310_pub3_data","Analysis.name","Adverse events (pre-procedure expulsion)"
"CD007310_pub3_data","Analysis.name","Side effects: nausea"
"CD007310_pub3_data","Analysis.name","Side effects: vomiting"
"CD007310_pub3_data","Analysis.name","Side effects: diarrhea"
"CD007310_pub3_data","Analysis.name","Side effects: fever/chills"
"CD007310_pub3_data","Analysis.name","Complications"
"CD007310_pub3_data","Analysis.name","Patient acceptability and/or satisfaction"
"CD007310_pub3_data","Analysis.name","Pain experienced by participants between initiation of cervical preparation method and abortion procedure"
"CD007310_pub3_data","Analysis.name","Provider acceptability and/or satisfaction"
"CD007310_pub3_data","Analysis.name","Provider assessment of difficulty of procedure"
"CD007310_pub3_data","Analysis.name","Procedure time (minutes)"
"CD007310_pub3_data","Analysis.name","Ability to complete procedure"
"CD007310_pub3_data","Analysis.name","Side effects: nausea/vomiting"
"CD007310_pub3_data","Analysis.name","Patient acceptability"
"CD007310_pub3_data","Analysis.name","Procedure time"
"CD007310_pub3_data","Analysis.name","Adverse events: cervical tear requiring suturing"
"CD007310_pub3_data","Analysis.name","Side effects: chills"
"CD007310_pub3_data","Analysis.name","Patient acceptability/satisfaction"
"CD007310_pub3_data","Analysis.name","Provider acceptability/satisfaction"
"CD007310_pub3_data","Analysis.name","Provider assessment of the procedure as very difficult"
"CD007310_pub3_data","Analysis.name","Adverse events: cervical laceration"
"CD007310_pub3_data","Analysis.name","Side effects: fever"
"CD007310_pub3_data","Analysis.name","Patient satisfaction"
"CD007310_pub3_data","Analysis.name","Adverse events"
"CD007310_pub3_data","Analysis.name","Complications: uterine perforations"
"CD007310_pub3_data","Analysis.name","Complications: uterine perforation"
"CD007310_pub3_data","Analysis.name","Provider assessment of difficulty"
"CD007310_pub3_data","Analysis.name","Adverse events: cervical injury"
"CD007310_pub3_data","Analysis.name","Adverse events: cervical tear"
"CD007310_pub3_data","Analysis.name","Nausea"
"CD007310_pub3_data","Analysis.name","Vomiting"
"CD007310_pub3_data","Analysis.name","Diarrhea"
"CD007310_pub3_data","Analysis.name","Side effects: fever and/or chills"
"CD007310_pub3_data","Analysis.name","Adverse events: pre-procedure expulsion"
"CD007310_pub3_data","Analysis.name","Side effects: nausea and/or vomiting"
"CD007310_pub3_data","Subgroup","Any nausea"
"CD007310_pub3_data","Subgroup","Nausea 3-4 hours after miso or placebo"
"CD007310_pub3_data","Subgroup","Vomiting"
"CD007310_pub3_data","Subgroup","Vomiting 3-4 hours after miso or placebo"
"CD007310_pub3_data","Subgroup","Chills"
"CD007310_pub3_data","Subgroup","Fever"
"CD007310_pub3_data","Subgroup","Haemorrhage requiring transfusion"
"CD007310_pub3_data","Subgroup","Endometritis requiring antibiotics"
"CD007310_pub3_data","Subgroup","Uterine perforation"
"CD007310_pub3_data","Subgroup","After procedure"
"CD007310_pub3_data","Subgroup","Overnight"
"CD007310_pub3_data","Subgroup","After pills"
"CD007310_pub3_data","Subgroup","Fever only"
"CD007310_pub3_data","Subgroup","Hemorrhage requiring transfusion"
"CD007310_pub3_data","Subgroup","Hospitalization"
"CD007310_pub3_data","Subgroup","Reaspiration"
"CD007310_pub3_data","Subgroup","After day 1 medication"
"CD007310_pub3_data","Subgroup","After day 2 medication"
"CD007310_pub3_data","Subgroup","Any time between initiation of preparation method and abortion procedure"
"CD007310_pub3_data","Subgroup","Would have the same procedure again"
"CD007310_pub3_data","Subgroup","Would recommend to a friend"
"CD007310_pub3_data","Subgroup","Immediately before abortion"
"CD007310_pub3_data","Subgroup","Cervical laceration"
"CD007310_pub3_data","Subgroup","Bleeding requiring uterotonics"
"CD007310_pub3_data","Subgroup","Satisfied with the procedure"
"CD007310_pub3_data","Subgroup","Satisfied with overall clinic experience"
"CD007310_pub3_data","Subgroup","Overnight pain"
"CD007310_pub3_data","Subgroup","Pain immediately before procedure"
"CD007310_pub3_data","Subgroup","Nausea first medication"
"CD007310_pub3_data","Subgroup","Nausea second medication"
"CD007310_pub3_data","Subgroup","“I did not mind taking the medication in my cheeks”"
"CD007310_pub3_data","Subgroup","“I did not mind taking the medication in my vagina”"
"CD007310_pub3_data","Subgroup","Medications were easy to take"
"CD007310_pub3_data","Subgroup","Would choose the same method again"
"CD007310_pub3_data","Subgroup","Would recommend this method"
"CD007310_pub3_data","Subgroup","Would use the same method again for this patient"
"CD007310_pub3_data","Subgroup","Would recommend this method for other patients"
"CD007310_pub3_data","Subgroup","Night before procedure"
"CD007310_pub3_data","Subgroup","Morning of procedure"
"CD007310_pub3_data","Subgroup","Diarrhea"
"CD007310_pub3_data","Subgroup","Moderate/severe pain in the morning of the procedure"
"CD007310_pub3_data","Subgroup","Moderate/severe pain in the night prior to the procedure"
"CD007310_pub3_data","Subgroup","Mife + sublingual miso v sublingual miso"
"CD007310_pub3_data","Subgroup","Mife + vaginal miso v vaginal miso"
"CD007310_pub3_data","Subgroup","Pre-procedure expulsion"
"CD007374_pub3_data","Analysis.group","1"
"CD007374_pub3_data","Analysis.group","2"
"CD007374_pub3_data","Analysis.name","Death"
"CD007374_pub3_data","Analysis.name","HbA1c [%]"
"CD007374_pub3_data","Analysis.name","Attaining HbA1c < 6.5%"
"CD007374_pub3_data","Analysis.name","Kidney failure"
"CD007374_pub3_data","Analysis.name","Patient-oriented measures: beliefs at the end of treatment (attitude scales)"
"CD007374_pub3_data","Analysis.name","Patient-oriented measures: beliefs at the end of follow-up (attitude scales)"
"CD007374_pub3_data","Analysis.name","Patient-oriented measures: knowledge of diabetes at the end of treatment"
"CD007374_pub3_data","Analysis.name","Patient-oriented measures: general knowledge of diabetes"
"CD007374_pub3_data","Analysis.name","Patient-oriented measures: self-efficacy at the end of treatment"
"CD007374_pub3_data","Analysis.name","Patient-oriented measures: self-efficacy at the end of follow-up"
"CD007374_pub3_data","Analysis.name","Patient-oriented measures: self-management behaviour changes at the end of treatment"
"CD007374_pub3_data","Analysis.name","Patient-oriented measures: behavioural changes at the end of treatment"
"CD007374_pub3_data","Analysis.name","Patient-oriented measures: behavioural changes at the end of follow-up"
"CD007374_pub3_data","Analysis.name","Estimated GFR [mL/min/1.73 m2]"
"CD007374_pub3_data","Analysis.name","Urinary albumin-creatinine ratio [mg/g]"
"CD007374_pub3_data","Analysis.name","Blood pressure [mm Hg]"
"CD007374_pub3_data","Analysis.name","Glycaemic events"
"CD007374_pub3_data","Analysis.name","Non-fatal cardiovascular events"
"CD007374_pub3_data","Analysis.name","Quality of life"
"CD007374_pub3_data","Analysis.name","Lipids [mmol/L]"
"CD007374_pub3_data","Analysis.name","Adverse events: non-fatal (including hypoglycaemic and CVD events)"
"CD007374_pub3_data","Analysis.name","Serious adverse events: emergency hospitalisation or death (including serious hypoglycaemic and CVD events)"
"CD007374_pub3_data","Analysis.name","Estimated GFR  [mL/min/1.73 m2]"
"CD007374_pub3_data","Analysis.name","Lipids [mg/dL]"
"CD007374_pub3_data","Subgroup","Cardiovascular disease-related death"
"CD007374_pub3_data","Subgroup","DKD-related death"
"CD007374_pub3_data","Subgroup","Death (any cause)"
"CD007374_pub3_data","Subgroup","Seriousness"
"CD007374_pub3_data","Subgroup","Treatment effectiveness"
"CD007374_pub3_data","Subgroup","Personal control"
"CD007374_pub3_data","Subgroup","Diagnosis"
"CD007374_pub3_data","Subgroup","Monitoring"
"CD007374_pub3_data","Subgroup","Hypoglycaemia"
"CD007374_pub3_data","Subgroup","Hyperglycaemia"
"CD007374_pub3_data","Subgroup","Medication: insulin"
"CD007374_pub3_data","Subgroup","Medication: oral"
"CD007374_pub3_data","Subgroup","Personal health habits"
"CD007374_pub3_data","Subgroup","Diet"
"CD007374_pub3_data","Subgroup","Exercise"
"CD007374_pub3_data","Subgroup","Chronic complications"
"CD007374_pub3_data","Subgroup","Living with diabetes and coping with stress"
"CD007374_pub3_data","Subgroup","At the end of treatment"
"CD007374_pub3_data","Subgroup","At the end of follow-up"
"CD007374_pub3_data","Subgroup","Total"
"CD007374_pub3_data","Subgroup","Home blood glucose monitoring"
"CD007374_pub3_data","Subgroup","Diabetes self-efficacy scale total"
"CD007374_pub3_data","Subgroup","Checking feet"
"CD007374_pub3_data","Subgroup","Using lotion"
"CD007374_pub3_data","Subgroup","Wearing appropriate shoes and socks"
"CD007374_pub3_data","Subgroup","Blood glucose self-monitoring"
"CD007374_pub3_data","Subgroup","Carries carbohydrate"
"CD007374_pub3_data","Subgroup","Eye examination"
"CD007374_pub3_data","Subgroup","Stopped smoking"
"CD007374_pub3_data","Subgroup","Diet: general"
"CD007374_pub3_data","Subgroup","Diet: specific diet"
"CD007374_pub3_data","Subgroup","Foot care"
"CD007374_pub3_data","Subgroup","Diastolic blood pressure"
"CD007374_pub3_data","Subgroup","Systolic blood pressure"
"CD007374_pub3_data","Subgroup","Serious hypoglycaemia"
"CD007374_pub3_data","Subgroup","Total cardivascualar events"
"CD007374_pub3_data","Subgroup","Myocardial infarction"
"CD007374_pub3_data","Subgroup","Heart failure"
"CD007374_pub3_data","Subgroup","Stroke"
"CD007374_pub3_data","Subgroup","Patient Health Questionnaire (PHQ) stress score"
"CD007374_pub3_data","Subgroup","KDQoL: physical composite summary"
"CD007374_pub3_data","Subgroup","KDQoL: mental composite summary"
"CD007374_pub3_data","Subgroup","KDQoL: kidney disease composite summary"
"CD007374_pub3_data","Subgroup","KDQoL: general health composite summary"
"CD007374_pub3_data","Subgroup","LDL cholesterol"
"CD007374_pub3_data","Subgroup","Total cholesterol"
"CD007374_pub3_data","Subgroup","HDL cholesterol"
"CD007374_pub3_data","Subgroup","Triglycerides"
"CD007388_pub3_data","Analysis.group","1"
"CD007388_pub3_data","Analysis.group","2"
"CD007388_pub3_data","Analysis.group","3"
"CD007388_pub3_data","Analysis.group","4"
"CD007388_pub3_data","Analysis.group","5"
"CD007388_pub3_data","Analysis.group","6"
"CD007388_pub3_data","Analysis.group","7"
"CD007388_pub3_data","Analysis.group","8"
"CD007388_pub3_data","Analysis.group","9"
"CD007388_pub3_data","Analysis.name","Recurrence of convulsion"
"CD007388_pub3_data","Analysis.name","Maternal death"
"CD007388_pub3_data","Analysis.name","Maternal admission to intensive care unit"
"CD007388_pub3_data","Analysis.name","Caesarean section"
"CD007388_pub3_data","Analysis.name","Vaginal birth"
"CD007388_pub3_data","Analysis.name","Recurrence of convulsions"
"CD007388_pub3_data","Analysis.name","Perinatal death"
"CD007388_pub3_data","Analysis.name","Severe morbidity: renal failure"
"CD007388_pub3_data","Analysis.name","Placental abruption"
"CD007388_pub3_data","Analysis.name","Stillbirth"
"CD007388_pub3_data","Analysis.name","Neonatal death"
"CD007388_pub3_data","Analysis.name","Severe morbidity: left heart failure and pulmonary oedema"
"CD007388_pub3_data","Analysis.name","Postpartum haemorrhage"
"CD007388_pub3_data","Analysis.name","Side effect: respiratory failure"
"CD007388_pub3_data","Analysis.name","Side effect: nausea"
"CD007388_pub3_data","Analysis.name","Side effect: flushing"
"CD007388_pub3_data","Analysis.name","Eclampsia"
"CD007388_pub3_data","Analysis.name","Admission to intensive care unit (maternal)"
"CD007388_pub3_data","Analysis.name","Poor blood pressure control: non-use of antihypertensive drugs"
"CD007388_pub3_data","Analysis.name","Severe maternal morbidity: HELLP syndrome"
"CD007388_pub3_data","Analysis.name","Severe morbidity: liver failure"
"CD007388_pub3_data","Analysis.name","Severe morbidity: coagulopathy"
"CD007388_pub3_data","Analysis.name","Admission to neonatal intensive care unit"
"CD007388_pub3_data","Analysis.name","Neonatal respiratory morbidity: respiratory depression requiring intubation"
"CD007388_pub3_data","Analysis.name","Vaginal delivery"
"CD007388_pub3_data","Analysis.name","Assisted vaginal delivery"
"CD007388_pub3_data","Analysis.name","Severe morbidity"
"CD007388_pub3_data","Analysis.name","Side effect: respiratory depression"
"CD007388_pub3_data","Analysis.name","Treatment discontinued because of side effects or adverse effects"
"CD007388_pub3_data","Analysis.name","Poor blood pressure control: progression to more severe pre-eclampsia"
"CD007388_pub3_data","Analysis.name","Poor blood pressure control: postpartum IV antihypertensive therapy"
"CD007388_pub3_data","Analysis.name","Need for additional anticonvulsant"
"CD007388_pub3_data","Analysis.name","Severe morbidity: disseminated intravascular coagulation"
"CD007388_pub3_data","Analysis.name","Severe morbidity: stroke"
"CD007388_pub3_data","Analysis.name","Severe morbidity: pulmonary oedema"
"CD007388_pub3_data","Analysis.name","Side effects"
"CD007388_pub3_data","Analysis.name","Severe morbidity: kidney failure"
"CD007388_pub3_data","Analysis.name","Side effects: flushing"
"CD007388_pub3_data","Analysis.name","Side effects: nausea"
"CD007388_pub3_data","Analysis.name","Side effects: vomiting"
"CD007388_pub3_data","Analysis.name","Side effects: problems at injection site"
"CD007388_pub3_data","Analysis.name","Maternal intensive care unit admission"
"CD007388_pub3_data","Analysis.name","Need for additional anticonvulsant: need to extend treatment"
"CD007388_pub3_data","Analysis.name","Need for additional anticonvulsant: need to reinitiate treatment"
"CD007388_pub3_data","Analysis.name","Instrumental vaginal delivery"
"CD007388_pub3_data","Analysis.name","Admission to special care nursery or neonatal intensive care unit"
"CD007388_pub3_data","Analysis.name","Composite neonatal morbidity"
"CD007388_pub3_data","Analysis.name","Side effect"
"CD007388_pub3_data","Analysis.name","Treatment discontinuation"
"CD007388_pub3_data","Analysis.name","Neonatal respiratory morbidity"
"CD007388_pub3_data","Subgroup","Lower dose vs. Pritchard regimen"
"CD007388_pub3_data","Subgroup","Short (12 hours) vs standard (24 hours) IV maintenance regimen"
"CD007388_pub3_data","Subgroup","Short maintenance regimen for 12 hours"
"CD007388_pub3_data","Subgroup","Stop maintenance dose immediately after birth"
"CD007388_pub3_data","Subgroup","Short maintenance regimen for 6h"
"CD007388_pub3_data","Subgroup","Short maintenance regimen for 6 hours"
"CD007388_pub3_data","Subgroup","Short: for 12 hours"
"CD007388_pub3_data","Subgroup","Stop maintenance immediately after birth"
"CD007388_pub3_data","Subgroup","2 g per hour IV maintenance vs 1 g per hour IV maintenance"
"CD007388_pub3_data","Subgroup","2gr IV per hour vs weight-adjusted maintenance dose"
"CD007388_pub3_data","Subgroup","2g per hour vs 1g per hour maintenance dose"
"CD007388_pub3_data","Subgroup","2g per hour maintenance dose vs 1gr per hour maintenance dose"
"CD007388_pub3_data","Subgroup","2gr IV per hour vs 1gr per hour maintenance dose"
"CD007388_pub3_data","Subgroup","2g per hour vs weight-adjusted maintenance dose"
"CD007388_pub3_data","Subgroup","2g per hour maintenance dose vs 1g per hour maintenance dose"
"CD007388_pub3_data","Subgroup","2gr per hour vs 1g per hour"
"CD007388_pub3_data","Subgroup","2g per hour vs weigth-adjusted maintenance dose"
"CD007491_pub3_data","Analysis.group","1"
"CD007491_pub3_data","Analysis.name","Mortality at 3 months using IPD"
"CD007491_pub3_data","Analysis.name","Mortality at 6 months' follow-up (using published data, and IPD from Wilson and Shepperd)"
"CD007491_pub3_data","Analysis.name","Readmission to hospital after discharge from hospital at home or inpatient care (3 to 12 months' follow-up)"
"CD007491_pub3_data","Analysis.name","Living in residential care at follow-up"
"CD007491_pub3_data","Subgroup","Readmission for older patients with a medical condition using IPD and published data. N=1856"
"CD007491_pub3_data","Subgroup","With a medical condition (6 months' follow-up)"
"CD007569_pub4_data","Analysis.group","1"
"CD007569_pub4_data","Analysis.group","2"
"CD007569_pub4_data","Analysis.group","3"
"CD007569_pub4_data","Analysis.group","4"
"CD007569_pub4_data","Analysis.name","Return to work"
"CD007569_pub4_data","Analysis.name","Quality of life"
"CD007569_pub4_data","Analysis.name","Return to work (odds ratios)"
"CD007572_pub4_data","Analysis.group","1"
"CD007572_pub4_data","Analysis.group","2"
"CD007572_pub4_data","Analysis.group","3"
"CD007572_pub4_data","Analysis.name","Failure to induce clinical remission (6 to 12 weeks)"
"CD007572_pub4_data","Analysis.name","Failure to induce clinical remission (subgroup analyses anti-TNF pre-treated vs anti-TNF naive participants)"
"CD007572_pub4_data","Analysis.name","Failure to induce clinical remission (8 weeks, sensitivity analysis)"
"CD007572_pub4_data","Analysis.name","Failure to induce clinical response (≥ 100 points)"
"CD007572_pub4_data","Analysis.name","Disease activity (change in CDAI)"
"CD007572_pub4_data","Analysis.name","Failure to induce endoscopic remission"
"CD007572_pub4_data","Analysis.name","Failure to induce endoscopic response"
"CD007572_pub4_data","Analysis.name","Quality of life (IBDQ score)"
"CD007572_pub4_data","Analysis.name","Serious adverse events"
"CD007572_pub4_data","Analysis.name","Serious adverse events (8 weeks, sensitivity analysis)"
"CD007572_pub4_data","Analysis.name","Withdrawals due to adverse events"
"CD007572_pub4_data","Analysis.name","Failure to induce clinical remission (8 weeks)"
"CD007572_pub4_data","Analysis.name","Failure to induce clinical response (PCDAI ≥ 15 points)"
"CD007572_pub4_data","Analysis.name","Failure to induce clinical remission (8 to 12 weeks)"
"CD007572_pub4_data","Subgroup","1.0 mg/kg IV "
"CD007572_pub4_data","Subgroup","3.0 mg/kg IV "
"CD007572_pub4_data","Subgroup","4.5 mg/kg IV "
"CD007572_pub4_data","Subgroup","6.0 mg/kg IV "
"CD007572_pub4_data","Subgroup","130 mg IV "
"CD007572_pub4_data","Subgroup","Anti-TNF naive"
"CD007572_pub4_data","Subgroup","Anti-TNF pre-treated"
"CD007572_pub4_data","Subgroup","6.0 mg IV "
"CD007572_pub4_data","Subgroup","1.0 mg/kg IV once"
"CD007572_pub4_data","Subgroup","3.0 mg/kg IV once"
"CD007572_pub4_data","Subgroup","6.0 mg/kg IV once"
"CD007572_pub4_data","Subgroup","130 mg IV once"
"CD007572_pub4_data","Subgroup","Ustekinumab (6 mg/kg IV at week 0, 90 mc sc at week 8) versus adalimumab (160 mg sc at week 0, 80 mg sc at week 2, 40 mg sc every 2 weeks) "
"CD007572_pub4_data","Subgroup","Ustekinumab (6 mg/kg IV at week 0, 90 mg sc at week 8) versus guselkumab (1200 mg IV at weeks 0,4,8)"
"CD007639_pub3_data","Analysis.group","1"
"CD007639_pub3_data","Analysis.group","2"
"CD007639_pub3_data","Analysis.group","3"
"CD007639_pub3_data","Analysis.group","4"
"CD007639_pub3_data","Analysis.group","5"
"CD007639_pub3_data","Analysis.group","6"
"CD007639_pub3_data","Analysis.group","7"
"CD007639_pub3_data","Analysis.group","8"
"CD007639_pub3_data","Analysis.group","9"
"CD007639_pub3_data","Analysis.group","10"
"CD007639_pub3_data","Analysis.group","11"
"CD007639_pub3_data","Analysis.group","12"
"CD007639_pub3_data","Analysis.group","13"
"CD007639_pub3_data","Analysis.name","Bronchoconstriction (sidestream versus Pari LC plus)"
"CD007639_pub3_data","Analysis.name","Increased cough (Sidestream versus Pari LC plus)"
"CD007639_pub3_data","Analysis.name","Chest pain (Sidestream versus Pari LC plus)"
"CD007639_pub3_data","Analysis.name","Bronchoconstriction (CR60 versus Portaneb)"
"CD007639_pub3_data","Analysis.name","FEV1 (% predicted)"
"CD007639_pub3_data","Analysis.name","Satisfaction with device"
"CD007639_pub3_data","Analysis.name","Treatment time (minutes)"
"CD007639_pub3_data","Analysis.name","Deposition (serum Cmax)"
"CD007639_pub3_data","Analysis.name","Deposition (serum AUC)"
"CD007639_pub3_data","Analysis.name","Deposition (serum levels)"
"CD007639_pub3_data","Analysis.name","Deposition (plasma levels)"
"CD007639_pub3_data","Analysis.name","Deposition (sputum Cmax)"
"CD007639_pub3_data","Analysis.name","Deposition (sputum AUC)"
"CD007639_pub3_data","Analysis.name","Deposition (lung)"
"CD007639_pub3_data","Analysis.name","Deposition (lung - central to peripheral ratio)"
"CD007639_pub3_data","Analysis.name","Adherence"
"CD007639_pub3_data","Analysis.name","Adverse events"
"CD007639_pub3_data","Analysis.name","FEV1: reduction over 10%"
"CD007639_pub3_data","Analysis.name","FEV1: reduction over 20%"
"CD007639_pub3_data","Analysis.name","Change in FEV1 "
"CD007639_pub3_data","Analysis.name","Device malfunctions"
"CD007639_pub3_data","Analysis.name","Treatment time "
"CD007639_pub3_data","Analysis.name","C max"
"CD007639_pub3_data","Analysis.name","Serum AUC"
"CD007639_pub3_data","Analysis.name","Tmax"
"CD007639_pub3_data","Analysis.name","C Trough"
"CD007639_pub3_data","Analysis.name","FEV1 % predicted (change from baseline)"
"CD007639_pub3_data","Analysis.name","Satisfaction"
"CD007639_pub3_data","Analysis.name","Treatment time"
"CD007639_pub3_data","Analysis.name","Serum concentration levels"
"CD007639_pub3_data","Analysis.name","Deposition by gamma scintigraphy"
"CD007639_pub3_data","Analysis.name","Cmax"
"CD007639_pub3_data","Analysis.name","AUC 0-24"
"CD007639_pub3_data","Analysis.name","C trough"
"CD007639_pub3_data","Analysis.name","Treatment time (seconds)"
"CD007639_pub3_data","Analysis.name","Deposition (lung uptake MBq)"
"CD007639_pub3_data","Analysis.name","Deposition (lung uptake as % of dose used)"
"CD007639_pub3_data","Analysis.name","FEV1 (% change)"
"CD007639_pub3_data","Analysis.name","Adverse events: haemoptysis"
"CD007639_pub3_data","Analysis.name","Adverse events: chest pain"
"CD007639_pub3_data","Analysis.name","Adverse events:pharyngitis"
"CD007639_pub3_data","Analysis.name","Adverse events: voice alteration"
"CD007639_pub3_data","Analysis.name","Adverse events: cough"
"CD007639_pub3_data","Analysis.name","% Change in FEV1 (multiple nebuliser comparison)"
"CD007639_pub3_data","Analysis.name","% Change in FEV1"
"CD007639_pub3_data","Analysis.name","FVC"
"CD007639_pub3_data","Analysis.name","FEF25-75"
"CD007639_pub3_data","Analysis.name","Deposition (sputum) (µg)"
"CD007639_pub3_data","Analysis.name","Lung function (FEV1 % predicted)"
"CD007639_pub3_data","Analysis.name","Lung function (FVC % predicted)"
"CD007639_pub3_data","Analysis.name","Lung function (FEF25 - 75% predicted)"
"CD007639_pub3_data","Analysis.name","Participant preference"
"CD007639_pub3_data","Analysis.name","Radio-labelled saline: deposition (mg)"
"CD007639_pub3_data","Analysis.name","Carbenicillin: deposition (mg)"
"CD007639_pub3_data","Analysis.name","Sodium chloride: deposition"
"CD007639_pub3_data","Analysis.name","Intrapulmonary deposition"
"CD007639_pub3_data","Analysis.name","SCG: treatment time (min)"
"CD007639_pub3_data","Analysis.name","SCG: deposition measured by urinary levels (mg)"
"CD007639_pub3_data","Analysis.name","SCG: residual medication in nebuliser (mg)"
"CD007639_pub3_data","Analysis.name","Amiloride: pulmonary deposition (µg)"
"CD007639_pub3_data","Analysis.name","Amiloride: extrapulmonary deposition (counts/s)"
"CD007639_pub3_data","Analysis.name","Amiloride: respiratory function tests"
"CD007639_pub3_data","Subgroup","Single dose"
"CD007639_pub3_data","Subgroup","2 to 4 weeks"
"CD007639_pub3_data","Subgroup","Up to 1 week"
"CD007639_pub3_data","Subgroup","2 to 3 weeks"
"CD007639_pub3_data","Subgroup","4 weeks"
"CD007639_pub3_data","Subgroup","Up to 4 weeks"
"CD007639_pub3_data","Subgroup","At 1 hour"
"CD007639_pub3_data","Subgroup","Over 3 weeks "
"CD007639_pub3_data","Subgroup","3 to 4 weeks"
"CD007639_pub3_data","Subgroup","At 24 hours"
"CD007639_pub3_data","Subgroup","At 12 hours"
"CD007639_pub3_data","Subgroup","3 - 4 weeks"
"CD007639_pub3_data","Subgroup","6 months"
"CD007639_pub3_data","Subgroup","At 6 months"
"CD007639_pub3_data","Subgroup","1 to 2 weeks"
"CD007639_pub3_data","Subgroup","1 to 2 weeks: Marquest Acorn II® with De Vilbiss PulmoAide® compressor V's Pari LC Plus® with Pariboy® compressor."
"CD007639_pub3_data","Subgroup","1 to 2 weeks: Marquest Acorn II® with De Vilbiss PulmoAide® compressor Vs 2. Hudson T Updraft®"
"CD007639_pub3_data","Subgroup","1 to 2 weeks:  Pari LC Plus with PariBoy compressor V's Hudson T Updraft®"
"CD007639_pub3_data","Subgroup","2 to 3 weeks: Marquest Acorn II® with De Vilbiss PulmoAide® compressor  V's  Hudson T Updraft®;"
"CD007639_pub3_data","Subgroup","2 to 3 weeks: Marquest Acorn II® with De Vilbiss PulmoAide® compressor  V's Pari LC Plus® with Pariboy® compressor."
"CD007639_pub3_data","Subgroup","2 to 3 weeks: Pari LC Plus with PariBoy compressor V's Hudson T Updraft®"
"CD007639_pub3_data","Subgroup","After 14 days"
"CD007639_pub3_data","Subgroup","After  14 days"
"CD007639_pub3_data","Subgroup","Ages 6 - 13 years"
"CD007639_pub3_data","Subgroup","Aged 14 years +"
"CD007639_pub3_data","Subgroup","Initial dose"
"CD007639_pub3_data","Subgroup","Peripheral deposition"
"CD007639_pub3_data","Subgroup","Central deposition"
"CD007639_pub3_data","Subgroup","Lung deposition"
"CD007639_pub3_data","Subgroup","Oropharangeal deposition"
"CD007639_pub3_data","Subgroup","Central to peripheral count ratios"
"CD007639_pub3_data","Subgroup","Alpha1-Proteinase Inhibitor (human)"
"CD007639_pub3_data","Subgroup","Total lung"
"CD007639_pub3_data","Subgroup","Left lung"
"CD007639_pub3_data","Subgroup","Right lung"
"CD007639_pub3_data","Subgroup","Central right lung"
"CD007639_pub3_data","Subgroup","Peripheral right lung"
"CD007639_pub3_data","Subgroup","Upper right lung"
"CD007639_pub3_data","Subgroup","Lower right lung"
"CD007639_pub3_data","Subgroup","Oropharynx"
"CD007639_pub3_data","Subgroup","Stomach"
"CD007639_pub3_data","Subgroup","FEV1 (L)"
"CD007639_pub3_data","Subgroup","FVC (L)"
"CD007639_pub3_data","Subgroup","PEF (L min-1)"
"CD007674_pub3_data","Analysis.group","1"
"CD007674_pub3_data","Analysis.group","2"
"CD007674_pub3_data","Analysis.group","3"
"CD007674_pub3_data","Analysis.group","4"
"CD007674_pub3_data","Analysis.name","Reduction in anxiety severity"
"CD007674_pub3_data","Analysis.name","Clinical recovery or improvement"
"CD007674_pub3_data","Analysis.name","Symptoms of worry"
"CD007674_pub3_data","Analysis.name","Symptoms of depression"
"CD007674_pub3_data","Analysis.name","Dropout rates"
"CD007674_pub3_data","Analysis.name","Quality of life"
"CD007674_pub3_data","Analysis.name","Overall quality of life (post-treatment)"
"CD007674_pub3_data","Analysis.name","Reduction in anxiety severity - individual or group intervention"
"CD007674_pub3_data","Analysis.name","Clinical recovery or improvement - individual or group intervention"
"CD007674_pub3_data","Analysis.name","Reduction in anxiety severity - waiting list or other comparator"
"CD007674_pub3_data","Analysis.name","Clinical recovery or improvement - waiting list or other comparator"
"CD007674_pub3_data","Analysis.name","Reduction in anxiety severity - GAD versus mixed anxiety disorders"
"CD007674_pub3_data","Analysis.name","Clinical recovery or improvement - GAD versus mixed anxiety disorders"
"CD007674_pub3_data","Analysis.name","Reduction in anxiety severity - adapted for older people versus not adapted"
"CD007674_pub3_data","Analysis.name","Clinical recovery or improvement - adapted for older people versus not adapted"
"CD007674_pub3_data","Analysis.name","Reduction in anxiety severity - high quality studies"
"CD007674_pub3_data","Analysis.name","Reduction in anxiety severity - available cases (no imputed data)"
"CD007674_pub3_data","Analysis.name","Clinical recovery or improvement - high quality studies"
"CD007674_pub3_data","Analysis.name","Clinical recovery or improvement - best and worst case scenario"
"CD007674_pub3_data","Subgroup","3 to 6 months post-treatment"
"CD007674_pub3_data","Subgroup","Post-treatment"
"CD007674_pub3_data","Subgroup","Physical component - 6 months post-treatment"
"CD007674_pub3_data","Subgroup","Physical component - post-treatment"
"CD007674_pub3_data","Subgroup","Mental component - post-treatment"
"CD007674_pub3_data","Subgroup","Mental component - 6 months post-treatment"
"CD007674_pub3_data","Subgroup","4 to 6 months post-treatment"
"CD007674_pub3_data","Subgroup","4 months post-treatment"
"CD007674_pub3_data","Subgroup","Post-treatment - group intervention"
"CD007674_pub3_data","Subgroup","Post-treatment - individual intervention"
"CD007674_pub3_data","Subgroup","Post-treatment group intervention"
"CD007674_pub3_data","Subgroup","Post-treatment individual intervention"
"CD007674_pub3_data","Subgroup","Post-treatment - other minimal management comparator"
"CD007674_pub3_data","Subgroup","Post-treatment - waiting-list comparator"
"CD007674_pub3_data","Subgroup","Post-treatment waiting list"
"CD007674_pub3_data","Subgroup","Post-treatment other comparator (minimal management)"
"CD007674_pub3_data","Subgroup","Post-treatment - GAD only"
"CD007674_pub3_data","Subgroup","Post-treatment - mixed anxiety disorders"
"CD007674_pub3_data","Subgroup","Post-treatment - mix of anxiety diagnoses"
"CD007674_pub3_data","Subgroup","Post-treatment - not adapted for older people"
"CD007674_pub3_data","Subgroup","Post-treatment - adapted for older people"
"CD007674_pub3_data","Subgroup","Post-treatment best-case scenario"
"CD007674_pub3_data","Subgroup","Post-treatment worst-case scenario"
"CD007693_pub3_data","Analysis.group","1"
"CD007693_pub3_data","Analysis.group","2"
"CD007693_pub3_data","Analysis.group","3"
"CD007693_pub3_data","Analysis.group","4"
"CD007693_pub3_data","Analysis.group","5"
"CD007693_pub3_data","Analysis.group","6"
"CD007693_pub3_data","Analysis.group","7"
"CD007693_pub3_data","Analysis.group","8"
"CD007693_pub3_data","Analysis.group","9"
"CD007693_pub3_data","Analysis.group","10"
"CD007693_pub3_data","Analysis.group","11"
"CD007693_pub3_data","Analysis.group","12"
"CD007693_pub3_data","Analysis.name","Fluorosis"
"CD007693_pub3_data","Subgroup","At 12 months or younger versus older than 12 months"
"CD007693_pub3_data","Subgroup","At 24 months or younger versus older than 24 months"
"CD007693_pub3_data","Subgroup","Younger than 24 months versus older than 24 months"
"CD007693_pub3_data","Subgroup","Younger than 12 months versus older than 12 months"
"CD007693_pub3_data","Subgroup","Younger than 4 years versus older than 4 years"
"CD007693_pub3_data","Subgroup","Less than twice per day versus twice or more per day"
"CD007693_pub3_data","Subgroup","Less than twice a day versus twice or more per day"
"CD007693_pub3_data","Subgroup","Less than once per day versus once or more per day"
"CD007693_pub3_data","Subgroup","Less than half the brush versus half the brush or more"
"CD007693_pub3_data","Subgroup","Pea-sized amount or less versus more than pea-sized amount"
"CD007693_pub3_data","Subgroup","550 ppm versus 1000 ppm"
"CD007693_pub3_data","Subgroup","440 ppm versus 1450 ppm"
"CD007693_pub3_data","Subgroup","Less than 1000 ppm versus 1000 ppm or higher"
"CD007693_pub3_data","Subgroup","Biannual fluoride varnish applied before 4 years of age versus placebo varnish"
"CD007693_pub3_data","Subgroup","Fluoride varnish applied before 4 years of age versus no varnish"
"CD007784_pub3_data","Analysis.group","1"
"CD007784_pub3_data","Analysis.group","2"
"CD007784_pub3_data","Analysis.name","Major cardiovascular events"
"CD007784_pub3_data","Analysis.name","Death"
"CD007784_pub3_data","Analysis.name","Rhabdomyolysis"
"CD007784_pub3_data","Analysis.name","Cardiovascular death"
"CD007784_pub3_data","Analysis.name","Myocardial infarction"
"CD007784_pub3_data","Analysis.name","Stroke"
"CD007784_pub3_data","Analysis.name","Revascularisation procedure"
"CD007784_pub3_data","Analysis.name","Hospitilsation due to heart failure"
"CD007784_pub3_data","Analysis.name","Kidney failure"
"CD007784_pub3_data","Analysis.name","Doubling serum creatinine"
"CD007784_pub3_data","Analysis.name","End of treatment kidney function"
"CD007784_pub3_data","Analysis.name","End of treatment proteinuria"
"CD007784_pub3_data","Analysis.name","Elevated liver enzymes"
"CD007784_pub3_data","Analysis.name","Withdrawal due to adverse events"
"CD007784_pub3_data","Analysis.name","Cancer"
"CD007784_pub3_data","Analysis.name","Onset of diabetes"
"CD007784_pub3_data","Analysis.name","Elevated creatine kinase"
"CD007784_pub3_data","Analysis.name","Total cholesterol"
"CD007784_pub3_data","Analysis.name","LDL cholesterol"
"CD007784_pub3_data","Analysis.name","Triglycerides"
"CD007784_pub3_data","Analysis.name","HDL cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (cardiovascular disease): death"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (cardiovascular disease): major cardiovascular events"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (statin dose): major cardiovascular death"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (statin dose): death"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (statin dose): withdrawal due to adverse events"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (statin dose): total cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (statin dose): LDL cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (statin dose): HDL cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (statin dose): triglycerides"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (age): total cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (age): withdrawal due to adverse events"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (age): LDL cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (age): HDL cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (age): triglycerides"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (diabetes mellitus): withdrawal due to adverse events"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (diabetes mellitus): death"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (diabetes mellitus): major cardiovascular death"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (diabetes mellitus): total cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (diabetes mellitus): LDL cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (diabetes mellitus): HDL cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (diabetes mellitus): triglycerides"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (baseline cholesterol): total cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (baseline cholesterol): LDL cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (baseline cholesterol): withdrawal due to adverse events"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (baseline cholesterol): HDL cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (baseline cholesterol): triglycerides"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (allocation concealment): death"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (allocation concealment): total cholesterol"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (allocation concealment): major cardiovascular events"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (allocation concealment): triglycerides"
"CD007784_pub3_data","Analysis.name","Subgroup analysis (kidney function): end of treatment kidney function"
"CD007784_pub3_data","Analysis.name","Sensitivity analysis (excluding SHARP): major cardiovascular events"
"CD007784_pub3_data","Analysis.name","Sensitivity analysis (excluding SHARP): death"
"CD007784_pub3_data","Analysis.name","Sensitivity analysis (funding): major cardiovascular events"
"CD007784_pub3_data","Analysis.name","Sensitivity analysis (funding): death"
"CD007784_pub3_data","Analysis.name","Sensitivity analysis (funding): withdrawal due to adverse events"
"CD007784_pub3_data","Analysis.name","Sensitvitiy analysis (funding): total cholesterol"
"CD007784_pub3_data","Analysis.name","Sensitivity analysis (funding): LDL cholesterol"
"CD007784_pub3_data","Analysis.name","Sensitivy analysis (funding): HDL cholesterol"
"CD007784_pub3_data","Analysis.name","Sensitivity analysis (funding): triglycerides"
"CD007784_pub3_data","Analysis.name","Hospitilisation due to heart failure"
"CD007784_pub3_data","Analysis.name","Serious adverse events"
"CD007784_pub3_data","Analysis.name","Elevated liver enzyme"
"CD007784_pub3_data","Analysis.name","eGFR [mL/min/1.73 m2]"
"CD007784_pub3_data","Subgroup","CrCl [mL/min]"
"CD007784_pub3_data","Subgroup","eGFR [mL/min/1.73 m²]"
"CD007784_pub3_data","Subgroup","No cardiovascular disease"
"CD007784_pub3_data","Subgroup","Cardiovascular disease"
"CD007784_pub3_data","Subgroup","< 20 mg/day simvastatin equivalent"
"CD007784_pub3_data","Subgroup","≥ 20 mg/day simvastatin equivalent"
"CD007784_pub3_data","Subgroup","≥20 mg/dL simvastatin equivalent"
"CD007784_pub3_data","Subgroup","< 55 years"
"CD007784_pub3_data","Subgroup","≥ 55 years"
"CD007784_pub3_data","Subgroup","≥ 20% with DM"
"CD007784_pub3_data","Subgroup","< 20% with DM "
"CD007784_pub3_data","Subgroup","< 20% with DM"
"CD007784_pub3_data","Subgroup","< 20% with DM or not reported"
"CD007784_pub3_data","Subgroup","< 230 mg/dL"
"CD007784_pub3_data","Subgroup","≥ 230 mg/dL"
"CD007784_pub3_data","Subgroup","Low RoB"
"CD007784_pub3_data","Subgroup","High/Unclear RoB"
"CD007784_pub3_data","Subgroup","< 55 mL/min"
"CD007784_pub3_data","Subgroup","≥ 55 mL/min"
"CD007784_pub3_data","Subgroup","Non-industry funding/not reported"
"CD007784_pub3_data","Subgroup","Non industry funding/not reported"
"CD007809_pub3_data","Analysis.group","1"
"CD007809_pub3_data","Analysis.group","2"
"CD007809_pub3_data","Analysis.group","3"
"CD007809_pub3_data","Analysis.group","4"
"CD007809_pub3_data","Analysis.group","5"
"CD007809_pub3_data","Analysis.group","6"
"CD007809_pub3_data","Analysis.name","Pain (0-10 numerical rating scale) at 12 weeks"
"CD007809_pub3_data","Analysis.name","Function (FHSQ) at 12 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (Assessment of Quality of Life instrument) at 12 weeks"
"CD007809_pub3_data","Analysis.name","Number of participants reporting an adverse event at 12 weeks"
"CD007809_pub3_data","Analysis.name","Number of participants withdrawing due to an adverse event at 12 weeks"
"CD007809_pub3_data","Analysis.name","Pain (FHSQ) "
"CD007809_pub3_data","Analysis.name","Function (FHSQ)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-12 Physical Component Summary)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-12 Mental Component Summary)"
"CD007809_pub3_data","Analysis.name","Number of participants reporting an adverse event"
"CD007809_pub3_data","Analysis.name","Number of participants withdrawing due to an adverse event"
"CD007809_pub3_data","Analysis.name","Pain (FHSQ)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Physical Functioning)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Role-Physical)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Bodily Pain)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - General Health)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Vitality)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Social Functioning)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Role-Emotional)"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Mental Health)"
"CD007809_pub3_data","Analysis.name","Passive, non-weightbearing peak dorsiflexion of the big toe"
"CD007809_pub3_data","Analysis.name","Function (FHSQ) "
"CD007809_pub3_data","Analysis.name","Pain (VAS) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Pain (VAS) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Function (FAOS Function in Daily Living) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Function (FAOS Function in Daily Living) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Physical Functioning) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Physical Functioning) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Role-Physical) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Role-Physical) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Bodily Pain) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Bodily Pain) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - General Health) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - General Health) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Vitality) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Vitality) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Social Functioning) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Social Functioning) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Role-Emotional) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Role-Emotional) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Mental Health) at 2 weeks"
"CD007809_pub3_data","Analysis.name","Quality of life (SF-36 - Mental Health) at 6 weeks"
"CD007809_pub3_data","Analysis.name","Pain (0-10 numerical rating scale)"
"CD007809_pub3_data","Analysis.name","Number of participants reporting an adverse event "
"CD007809_pub3_data","Analysis.name","Big toe joint passive dorsiflexion range of motion "
"CD007809_pub3_data","Subgroup","4 weeks"
"CD007809_pub3_data","Subgroup","12 weeks"
"CD007809_pub3_data","Subgroup","52 weeks"
"CD007809_pub3_data","Subgroup","1 month"
"CD007809_pub3_data","Subgroup","6 months"
"CD007809_pub3_data","Subgroup","3 months"
"CD007809_pub3_data","Subgroup","2 weeks"
"CD007809_pub3_data","Subgroup","6 weeks"
"CD007837_pub3_data","Analysis.group","1"
"CD007837_pub3_data","Analysis.group","2"
"CD007837_pub3_data","Analysis.group","3"
"CD007837_pub3_data","Analysis.group","4"
"CD007837_pub3_data","Analysis.name","Cobb angle (°)"
"CD007837_pub3_data","Analysis.name","Angle of trunk rotation (ATR) (°)"
"CD007837_pub3_data","Analysis.name","Objective surface measurements (waist asymmetry) (cm)"
"CD007837_pub3_data","Analysis.name","Subjective evaluation (Spinal Appearance Questionnaire – General) (points)"
"CD007837_pub3_data","Analysis.name","Subjective evaluation (SRS-22 Self-Image) (points)"
"CD007837_pub3_data","Analysis.name","Quality of life (SRS-22 Total score) (points)"
"CD007837_pub3_data","Analysis.name","Back pain (SRS-22 Pain, SF-36 Pain)"
"CD007837_pub3_data","Analysis.name","Mental health (SRS-22 Mental Health, SF-36 Mental Health) (points)"
"CD007837_pub3_data","Analysis.name","Angle of trunk rotation (°)"
"CD007837_pub3_data","Analysis.name","Back pain (SRS-22 Pain) (points)"
"CD007837_pub3_data","Analysis.name","Back pain (Visual Analogue Scale 0–10 scale)"
"CD007837_pub3_data","Analysis.name","Mental health (SRS-22 Mental Health) (points)"
"CD007837_pub3_data","Analysis.name","Number progressed > 5° Cobb angle"
"CD007837_pub3_data","Analysis.name","Subjective evaluation (SRS-22 Self-Image, WRVAS) (points)"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) vs no treatment"
"CD007837_pub3_data","Subgroup","Generic therapeutic exercise (GTE) vs no treatment"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) versus no treatment"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) vs  no treatment"
"CD007837_pub3_data","Subgroup","Generic therapeutic exercise (GTE) versus no treatment"
"CD007837_pub3_data","Subgroup","GTE plus other non-surgical vs non-surgical"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) plus other non-surgical vs non-surgical"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) plus bracing versus bracing"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) plus other non-surgical versus other non-surgical"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) plus bracing versus bracing alone"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) plus other non-surgical versus other non-surgical surgical"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) versus bracing"
"CD007837_pub3_data","Subgroup","Physiotherapeutic scoliosis-specific exercise (PSSE) versus generic therapeutic exercise (GTE) "
"CD007859_pub5_data","Analysis.group","1"
"CD007859_pub5_data","Analysis.group","2"
"CD007859_pub5_data","Analysis.group","3"
"CD007859_pub5_data","Analysis.group","4"
"CD007859_pub5_data","Analysis.group","5"
"CD007859_pub5_data","Analysis.group","6"
"CD007859_pub5_data","Analysis.name","Alignment rate (LII reduction; mm): multistrand StSt versus conventional StSt"
"CD007859_pub5_data","Analysis.name","Alignment rate (LII reduction; mm): multistrand StSt versus superelastic nickel-titanium (NiTi)"
"CD007859_pub5_data","Analysis.name","Alignment rate (LII reduction; mm): multistrand StSt versus thermoelastic nickel-titanium (NiTi)"
"CD007859_pub5_data","Analysis.name","Pain (100-mm VAS): multistrand StSt versus superelastic nickel-titanium (NiTi)"
"CD007859_pub5_data","Analysis.name","Alignment rate (LII reduction; mm)"
"CD007859_pub5_data","Analysis.name","Time to working arch wire (months)"
"CD007859_pub5_data","Analysis.name","Pain (100-mm VAS)"
"CD007859_pub5_data","Analysis.name","Pain (analgesic consumption)"
"CD007859_pub5_data","Analysis.name","Alignment rate (change in arch width; mm)"
"CD007859_pub5_data","Analysis.name","Time to alignment (alignment rate ratio)"
"CD007859_pub5_data","Analysis.name","Root resorption (root length reduction until alignment; mm)"
"CD007859_pub5_data","Analysis.name","Time to alignment (months)"
"CD007859_pub5_data","Analysis.name","Pain (100-mm VAS): 0.014-inch versus 0.016-inch"
"CD007859_pub5_data","Analysis.name","Pain (100-mm VAS): 0.014-inch versus 0.018-inch"
"CD007859_pub5_data","Analysis.name","Pain (100-mm VAS): 0.016-inch versus 0.018-inch"
"CD007859_pub5_data","Subgroup","Lower 3-3 over 8 weeks"
"CD007859_pub5_data","Subgroup","Lower 6-6 over 8 weeks"
"CD007859_pub5_data","Subgroup","Upper 3-3 over 8 weeks"
"CD007859_pub5_data","Subgroup","Upper 6-6 over 8 weeks"
"CD007859_pub5_data","Subgroup","Day 0 (1 hour)"
"CD007859_pub5_data","Subgroup","Day 0 (2 hours)"
"CD007859_pub5_data","Subgroup","Day 0 (4 hours)"
"CD007859_pub5_data","Subgroup","Day 0 (6 hours)"
"CD007859_pub5_data","Subgroup","Day 0 (12 hours)"
"CD007859_pub5_data","Subgroup","Day 1"
"CD007859_pub5_data","Subgroup","Day 2"
"CD007859_pub5_data","Subgroup","Day 3"
"CD007859_pub5_data","Subgroup","Day 4"
"CD007859_pub5_data","Subgroup","Day 5"
"CD007859_pub5_data","Subgroup","Day 6"
"CD007859_pub5_data","Subgroup","Day 7"
"CD007859_pub5_data","Subgroup","Day 10"
"CD007859_pub5_data","Subgroup","Day 14"
"CD007859_pub5_data","Subgroup","Lower 3-3 until next arch wire (about 10 weeks)"
"CD007859_pub5_data","Subgroup","Upper 3-3 until next arch wire (about 5 weeks)"
"CD007859_pub5_data","Subgroup","Lower"
"CD007859_pub5_data","Subgroup","Day 0 (within 1 hour)"
"CD007859_pub5_data","Subgroup","Day 0 (3 hours)"
"CD007859_pub5_data","Subgroup","Day 0 (5 hours)"
"CD007859_pub5_data","Subgroup","Day 0 (7 hours)"
"CD007859_pub5_data","Subgroup","Day 0 (8 hours)"
"CD007859_pub5_data","Subgroup","Day 0 (9 hours)"
"CD007859_pub5_data","Subgroup","Day 0 (10 hours)"
"CD007859_pub5_data","Subgroup","Day 0 (11 hours)"
"CD007859_pub5_data","Subgroup","within 7 days"
"CD007859_pub5_data","Subgroup","Lower 3-3 over 6 weeks"
"CD007859_pub5_data","Subgroup","Lower 3-3 over 2 weeks"
"CD007859_pub5_data","Subgroup","Lower 3-3 over 4 weeks"
"CD007859_pub5_data","Subgroup","Lower 3-3 arch width increase over 2 weeks"
"CD007859_pub5_data","Subgroup","Lower 3-3 arch width increase over 4 weeks"
"CD007859_pub5_data","Subgroup","Lower 3-3 arch width increase over 6 weeks"
"CD007859_pub5_data","Subgroup","Lower 6-6 arch width reduction over 2 weeks"
"CD007859_pub5_data","Subgroup","Lower 6-6 arch width reduction over 4 weeks"
"CD007859_pub5_data","Subgroup","Lower 6-6 arch width reduction over 6 weeks"
"CD007859_pub5_data","Subgroup","Lower 3-3"
"CD007859_pub5_data","Subgroup","Lower 3-3 over 12 weeks"
"CD007859_pub5_data","Subgroup","Lower 3-3 over 16 weeks"
"CD007859_pub5_data","Subgroup","Upper 3-3 over 4 weeks"
"CD007859_pub5_data","Subgroup","Upper 3-3 over 12 weeks"
"CD007859_pub5_data","Subgroup","Upper 3-3 over 16 weeks"
"CD007859_pub5_data","Subgroup","Lower 6-6 arch width increase over 4 weeks"
"CD007859_pub5_data","Subgroup","Lower 6-6 arch width increase over 8 weeks"
"CD007859_pub5_data","Subgroup","Lower 6-6 arch width increase over 12 weeks"
"CD007859_pub5_data","Subgroup","Upper 6-6 arch width increase over 4 weeks"
"CD007859_pub5_data","Subgroup","Upper 6-6 arch width increase over 8 weeks"
"CD007859_pub5_data","Subgroup","Lower 3-3 arch width increase over 8 weeks"
"CD007859_pub5_data","Subgroup","Lower 3-3 arch width increase over 12 weeks"
"CD007859_pub5_data","Subgroup","Upper 3-3 arch width increase over 4 weeks"
"CD007859_pub5_data","Subgroup","Upper 3-3 arch width increase over 8 weeks"
"CD007859_pub5_data","Subgroup","Lower 2 (lateral incisors)"
"CD007859_pub5_data","Subgroup","Lower 1 (central incisors)"
"CD007859_pub5_data","Subgroup","Upper 1 (central incisors)"
"CD007859_pub5_data","Subgroup","Lower 3 (canines)"
"CD007859_pub5_data","Subgroup","Upper 2 (lateral incisors)"
"CD007859_pub5_data","Subgroup","Upper 3 (canines)"
"CD007859_pub5_data","Subgroup","Upper 3-3"
"CD007859_pub5_data","Subgroup","Day 0"
"CD007859_pub5_data","Subgroup","Within 7 days"
"CD007859_pub5_data","Subgroup","Until next appointment (more than 4 days)"
"CD007859_pub5_data","Subgroup","Lower 6-6 arch width reduction over 8 weeks"
"CD007859_pub5_data","Subgroup","Lower 6-6 arch width reduction over 12 weeks"
"CD007872_pub4_data","Analysis.group","1"
"CD007872_pub4_data","Analysis.name","Estimated blood loss ≥ 500 mL"
"CD007872_pub4_data","Analysis.name","Estimated blood loss ≥ 1000 mL"
"CD007872_pub4_data","Analysis.name","Maternal death"
"CD007872_pub4_data","Analysis.name","Severe morbidity"
"CD007872_pub4_data","Analysis.name","Receipt of blood transfusion"
"CD007872_pub4_data","Analysis.name","Receipt of additional surgical interventions to control postpartum haemorrhage"
"CD007872_pub4_data","Analysis.name","Thromboembolic events"
"CD007872_pub4_data","Analysis.name","Receipt of additional uterotonics"
"CD007872_pub4_data","Analysis.name","Hysterectomy"
"CD007872_pub4_data","Analysis.name","Breastfeeding at discharge"
"CD007872_pub4_data","Analysis.name","Clinical diagnosis of postpartum haemorrhage"
"CD007872_pub4_data","Analysis.name","Estimated mean blood loss"
"CD007872_pub4_data","Analysis.name","Myocardial infarction"
"CD007872_pub4_data","Analysis.name","Stroke"
"CD007872_pub4_data","Analysis.name","Seizures"
"CD007872_pub4_data","Analysis.name","Organ failure/dysfunction                     "
"CD007872_pub4_data","Analysis.name","ICU admission"
"CD007872_pub4_data","Analysis.name","Nausea"
"CD007872_pub4_data","Analysis.name","Vomiting"
"CD007872_pub4_data","Subgroup","Women at high risk of PPH"
"CD007872_pub4_data","Subgroup","Women at low risk of PPH"
"CD007872_pub4_data","Subgroup","Women with anaemia "
"CD007872_pub4_data","Subgroup","Women with no anaemia"
"CD007872_pub4_data","Subgroup","Women with anaemia"
"CD007872_pub4_data","Subgroup","Measured within 24 hours or by hospital discharge"
"CD007872_pub4_data","Subgroup","Measured in the delivery room"
"CD007895_pub3_data","Analysis.group","1"
"CD007895_pub3_data","Analysis.name","Systolic blood pressure, measured as change-from-baseline"
"CD007895_pub3_data","Analysis.name","Diastolic blood pressure, measured as change-from-baseline"
"CD007895_pub3_data","Analysis.name","Heart rate, measured as change-from-baseline"
"CD007895_pub3_data","Analysis.name","Withdrawals due to adverse effects"
"CD007896_pub4_data","Analysis.group","1"
"CD007896_pub4_data","Analysis.group","2"
"CD007896_pub4_data","Analysis.group","3"
"CD007896_pub4_data","Analysis.group","4"
"CD007896_pub4_data","Analysis.group","5"
"CD007896_pub4_data","Analysis.group","6"
"CD007896_pub4_data","Analysis.group","7"
"CD007896_pub4_data","Analysis.group","8"
"CD007896_pub4_data","Analysis.group","9"
"CD007896_pub4_data","Analysis.name","Systolic blood pressure"
"CD007896_pub4_data","Analysis.name","Diastolic blood pressure"
"CD007896_pub4_data","Analysis.name","Heart rate (beats per minute)"
"CD007896_pub4_data","Analysis.name","Withdrawals due to adverse effects"
"CD007896_pub4_data","Subgroup","Age ≥ 18 years"
"CD007896_pub4_data","Subgroup","Age < 18 years"
"CD007896_pub4_data","Subgroup","Trial duration ≥ 8 weeks"
"CD007896_pub4_data","Subgroup","Trial duration ≤ 4 weeks"
"CD007896_pub4_data","Subgroup","Trial duration > 4 weeks to < 8 weeks"
"CD008063_pub3_data","Analysis.group","1"
"CD008063_pub3_data","Analysis.group","2"
"CD008063_pub3_data","Analysis.group","3"
"CD008063_pub3_data","Analysis.group","4"
"CD008063_pub3_data","Analysis.name","Extent of substance use"
"CD008063_pub3_data","Analysis.name","Readiness to change"
"CD008063_pub3_data","Analysis.name","Retention in treatment"
"CD008063_pub3_data","Subgroup","Post-intervention"
"CD008063_pub3_data","Subgroup","Short-term follow-up"
"CD008063_pub3_data","Subgroup","Long-term follow-up"
"CD008063_pub3_data","Subgroup","Medium-term follow-up"
"CD008145_pub4_data","Analysis.group","1"
"CD008145_pub4_data","Analysis.group","2"
"CD008145_pub4_data","Analysis.group","3"
"CD008145_pub4_data","Analysis.group","4"
"CD008145_pub4_data","Analysis.group","5"
"CD008145_pub4_data","Analysis.group","6"
"CD008145_pub4_data","Analysis.group","7"
"CD008145_pub4_data","Analysis.group","8"
"CD008145_pub4_data","Analysis.group","9"
"CD008145_pub4_data","Analysis.group","10"
"CD008145_pub4_data","Analysis.group","11"
"CD008145_pub4_data","Analysis.name","Reception of DTP3 by 1 year of age"
"CD008145_pub4_data","Analysis.name","Uptake of BCG vaccine"
"CD008145_pub4_data","Analysis.name","Uptake of OPV3 vaccine"
"CD008145_pub4_data","Analysis.name","Uptake of HBV3 vaccine"
"CD008145_pub4_data","Analysis.name","Uptake of BCG + DTP3 + OPV vaccines"
"CD008145_pub4_data","Analysis.name","Uptake of measles vaccine"
"CD008145_pub4_data","Analysis.name","Uptake of at least 1 vaccine"
"CD008145_pub4_data","Analysis.name","Reception of all recommended vaccines by 2 years of age"
"CD008145_pub4_data","Analysis.name","Uptake of measles/MMR vaccine"
"CD008145_pub4_data","Analysis.name","Under 5 years of age fully immunised with all scheduled vaccine"
"CD008145_pub4_data","Analysis.name","Uptake of DTP3 vaccine"
"CD008145_pub4_data","Analysis.name","Reception of all recommended vaccines by 2 years of age "
"CD008145_pub4_data","Analysis.name","Reception of DTP3/Penta 3 by 2 years of age"
"CD008145_pub4_data","Analysis.name","Uptake of DTP3 (SMS + monetary incentive intervention)"
"CD008145_pub4_data","Analysis.name","Uptake of yellow fever vaccine"
"CD008145_pub4_data","Analysis.name","Reception of DTP3/Penta 3 vaccine by 2 years of age"
"CD008145_pub4_data","Analysis.name","Uptake of all recommended vaccines by 2 years of age "
"CD008145_pub4_data","Analysis.name","Uptake of all recommended vaccines by 2 years of age"
"CD008145_pub4_data","Analysis.name","Under 5 years of age fully immunised with all scheduled vaccines"
"CD008145_pub4_data","Analysis.name","Reception of DTP3/Penta 3 by 1 year of age"
"CD008145_pub4_data","Analysis.name","Reception of DTP3/Penta 3 vaccine by 1 year of age"
"CD008145_pub4_data","Subgroup","Community-based health education"
"CD008145_pub4_data","Subgroup","Facility-based health education"
"CD008145_pub4_data","Subgroup","Community-based education"
"CD008145_pub4_data","Subgroup","Facility-based education"
"CD008145_pub4_data","Subgroup","Household monetary incentive"
"CD008145_pub4_data","Subgroup","Service-level monetary incentive"
"CD008145_pub4_data","Subgroup","Household + service-level monetary incentive"
"CD008145_pub4_data","Subgroup","HBR + health education"
"CD008145_pub4_data","Subgroup","Home-based record only"
"CD008145_pub4_data","Subgroup","HBR + sticker"
"CD008145_pub4_data","Subgroup","Urban"
"CD008145_pub4_data","Subgroup","Rural"
"CD008145_pub4_data","Subgroup","Urban + rural"
"CD008145_pub4_data","Subgroup","Phone call/SMS only"
"CD008145_pub4_data","Subgroup","SMS + monetary incentive"
"CD008145_pub4_data","Subgroup","Phone call/SMS + monetary incentive"
"CD008145_pub4_data","Subgroup","Outreach only"
"CD008145_pub4_data","Subgroup","Outreach + Health Education"
"CD008145_pub4_data","Subgroup","Outreach + incentive"
"CD008165_pub5_data","Analysis.group","1"
"CD008165_pub5_data","Analysis.name","Medication appropriateness (as measured by an implicit tool)"
"CD008165_pub5_data","Analysis.name","Medication appropriateness (as measured by an implicit tool) (excluding Crotty 2004a)"
"CD008165_pub5_data","Analysis.name","Number of potentially inappropriate medications"
"CD008165_pub5_data","Analysis.name","Proportion of patients with one or more potentially inappropriate medication"
"CD008165_pub5_data","Analysis.name","Number of potential prescribing omissions"
"CD008165_pub5_data","Analysis.name","Proportion of patients with one or more potential prescribing omission"
"CD008176_pub3_data","Analysis.group","1"
"CD008176_pub3_data","Analysis.group","2"
"CD008176_pub3_data","Analysis.group","3"
"CD008176_pub3_data","Analysis.group","4"
"CD008176_pub3_data","Analysis.group","5"
"CD008176_pub3_data","Analysis.group","6"
"CD008176_pub3_data","Analysis.group","7"
"CD008176_pub3_data","Analysis.name","Cardiovascular death"
"CD008176_pub3_data","Analysis.name","Death (any cause)"
"CD008176_pub3_data","Analysis.name","Cardiovascular disease"
"CD008176_pub3_data","Analysis.name","Coronary heart disease"
"CD008176_pub3_data","Analysis.name","Heart failure"
"CD008176_pub3_data","Analysis.name","Cerebrovascular disease"
"CD008176_pub3_data","Analysis.name","Peripheral vascular disease"
"CD008176_pub3_data","Analysis.name","Kidney failure"
"CD008176_pub3_data","Analysis.name","eGFR at end of study"
"CD008176_pub3_data","Analysis.name","Change in eGFR"
"CD008176_pub3_data","Analysis.name","Serum creatinine at end of study"
"CD008176_pub3_data","Analysis.name","Change in serum creatinine"
"CD008176_pub3_data","Analysis.name","Urinary albumin/creatinine ratio at end of study"
"CD008176_pub3_data","Analysis.name","Change in urinary albumin/creatinine ratio"
"CD008176_pub3_data","Analysis.name","Proteinuria at end of study"
"CD008176_pub3_data","Analysis.name","Change in proteinuria"
"CD008176_pub3_data","Analysis.name","Albuminuria at end of study"
"CD008176_pub3_data","Analysis.name","Change in albuminuria"
"CD008176_pub3_data","Analysis.name","Vascular access thrombosis"
"CD008176_pub3_data","Analysis.name","Graft loss"
"CD008176_pub3_data","Analysis.name","Graft failure"
"CD008176_pub3_data","Analysis.name","Delayed graft function"
"CD008176_pub3_data","Analysis.name","Malignancy"
"CD008176_pub3_data","Analysis.name","Major bleeding"
"CD008176_pub3_data","Analysis.name","Infection"
"CD008176_pub3_data","Analysis.name","Sensitivity analysis: change in eGFR without imputed SD"
"CD008176_pub3_data","Analysis.name","Sensitivity analysis: change in serum creatinine without imputed SD"
"CD008176_pub3_data","Analysis.name","Sensitivity analysis: change in urinary albumin/creatinine ratio without imputed SD"
"CD008176_pub3_data","Subgroup","CKD stages 3-5"
"CD008176_pub3_data","Subgroup","Kidney transplant"
"CD008176_pub3_data","Subgroup","CKD stage 5D"
"CD008176_pub3_data","Subgroup","CKD stages 5D"
"CD008237_pub4_data","Analysis.group","1"
"CD008237_pub4_data","Analysis.group","2"
"CD008237_pub4_data","Analysis.name","Composite score of competency"
"CD008237_pub4_data","Analysis.name","Independent procedure completion: type of endoscopic procedure under study"
"CD008237_pub4_data","Analysis.name","Independent procedure completion: level of participant endoscopy experience"
"CD008237_pub4_data","Analysis.name","Performance time"
"CD008237_pub4_data","Analysis.name","Patient discomfort: level of participant endoscopy experience"
"CD008237_pub4_data","Analysis.name","Overall global rating of performance or competency"
"CD008237_pub4_data","Analysis.name","Visualisation of mucosa"
"CD008237_pub4_data","Analysis.name","Independent procedure completion"
"CD008237_pub4_data","Subgroup","Colonoscopy"
"CD008237_pub4_data","Subgroup","Oesophagogastroduodenoscopy"
"CD008237_pub4_data","Subgroup","Limited prior training in endoscopy"
"CD008237_pub4_data","Subgroup","No prior training in endoscopy"
"CD008237_pub4_data","Subgroup","Sigmoidoscopy"
"CD008309_pub3_data","Analysis.group","1"
"CD008309_pub3_data","Analysis.group","2"
"CD008309_pub3_data","Analysis.group","3"
"CD008309_pub3_data","Analysis.group","4"
"CD008309_pub3_data","Analysis.group","5"
"CD008309_pub3_data","Analysis.group","6"
"CD008309_pub3_data","Analysis.group","7"
"CD008309_pub3_data","Analysis.name","Composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA)"
"CD008309_pub3_data","Analysis.name","Failure to place LMA or ETT at first attempt"
"CD008309_pub3_data","Analysis.name","Bradycardia (heart rate < 100 beats per minute) during the intervention"
"CD008309_pub3_data","Analysis.name","Hypoxaemia (oxygen saturation < 80%) during the intervention"
"CD008309_pub3_data","Analysis.name","Apnoea (cessation of spontaneous breathing > 20 seconds) during the intervention"
"CD008309_pub3_data","Analysis.name","Surfactant reflux during the intervention"
"CD008309_pub3_data","Analysis.name","Postintervention intratracheal surfactant received"
"CD008309_pub3_data","Analysis.name","Number of doses of intratracheal surfactant received postintervention"
"CD008309_pub3_data","Analysis.name","Mechanical ventilation within first 72 hours"
"CD008309_pub3_data","Analysis.name","Mechanical ventilation within first 72 hours or not ventilated but reached failure criteria as defined by the study authors"
"CD008309_pub3_data","Analysis.name","Mechanical ventilation at any time"
"CD008309_pub3_data","Analysis.name","Pulmonary air leak, any (during first hospitalisation)"
"CD008309_pub3_data","Analysis.name","Duration of any respiratory support (mechanical ventilation, continuous positive airway pressure, high flow) (days; in survivors)"
"CD008309_pub3_data","Analysis.name","Postnatal systemic corticosteroid therapy for BPD prevention"
"CD008309_pub3_data","Analysis.name","BPD (clinical definition) among survivors to 36 weeks' PMA"
"CD008309_pub3_data","Analysis.name","Any intraventricular haemorrhage"
"CD008309_pub3_data","Analysis.name","Intraventricular haemorrhage grade III and IV"
"CD008309_pub3_data","Analysis.name","Cystic periventricular leukomalacia"
"CD008309_pub3_data","Analysis.name","Patent ductus arteriosus requiring medical therapy"
"CD008309_pub3_data","Analysis.name","Necrotising enterocolitis, modified Bell stage 2 or greater"
"CD008309_pub3_data","Analysis.name","Spontaneous intestinal perforation"
"CD008309_pub3_data","Analysis.name","Retinopathy of prematurity (ROP), any grade"
"CD008309_pub3_data","Analysis.name","ROP, stage 3 or greater"
"CD008309_pub3_data","Analysis.name","Duration of hospitalisation (days)"
"CD008309_pub3_data","Analysis.name","Neonatal death (all causes) during the first 28 days"
"CD008309_pub3_data","Analysis.name","Death (all causes) during the first hospitalisation"
"CD008309_pub3_data","Analysis.name","Use of home oxygen"
"CD008309_pub3_data","Analysis.name","Number of hospital readmissions with respiratory illness in the first two years"
"CD008309_pub3_data","Analysis.name","Duration of mechanical ventilation via ETT (days; in survivors)"
"CD008309_pub3_data","Analysis.name","Duration of oxygen therapy (days; in survivors)"
"CD008309_pub3_data","Analysis.name","Bronchopulmonary dysplasia (clinical definition) among survivors to 36 weeks' PMA"
"CD008309_pub3_data","Analysis.name","Composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' PMA"
"CD008309_pub3_data","Subgroup","Sedation or analgesia for InSurE"
"CD008309_pub3_data","Subgroup","No sedation or analgesia"
"CD008309_pub3_data","Subgroup","32 to 36 weeks"
"CD008309_pub3_data","Subgroup","28 to 36 weeks"
"CD008349_pub5_data","Analysis.group","1"
"CD008349_pub5_data","Analysis.group","2"
"CD008349_pub5_data","Analysis.name","Upper limb function post intervention (composite measure)"
"CD008349_pub5_data","Analysis.name","Hand function post intervention (grip strength)"
"CD008349_pub5_data","Analysis.name","Upper limb function post intervention: amount of use (subjective)"
"CD008349_pub5_data","Analysis.name","Upper limb function at short term follow-up (up to 3 months)"
"CD008349_pub5_data","Analysis.name","Upper limb function: subgroup analysis based on amount of therapy "
"CD008349_pub5_data","Analysis.name","Upper limb function: subgroup analysis based on time since onset of stroke"
"CD008349_pub5_data","Analysis.name","Upper limb function: subgroup analysis based on virtual reality application being customised or non-customised for rehabilitation settings "
"CD008349_pub5_data","Analysis.name","Upper limb function: subgroup analysis based on level of immersion of customised virtual reality application "
"CD008349_pub5_data","Analysis.name","Gait speed post intervention "
"CD008349_pub5_data","Analysis.name","Timed Up and Go Test post intervention "
"CD008349_pub5_data","Analysis.name","Balance post intervention "
"CD008349_pub5_data","Analysis.name","Cognitive function post intervention"
"CD008349_pub5_data","Analysis.name","Activity limitation post intervention "
"CD008349_pub5_data","Analysis.name","Participation restriction and quality of life post intervention "
"CD008349_pub5_data","Analysis.name","Upper limb function: subgroup analysis based on amount of therapy"
"CD008349_pub5_data","Analysis.name","Gait speed post intervention"
"CD008349_pub5_data","Analysis.name","Mobility: Timed Up and Go Test post intervention"
"CD008349_pub5_data","Analysis.name","Balance post intervention"
"CD008349_pub5_data","Analysis.name","Global motor function post intervention"
"CD008349_pub5_data","Analysis.name","Activity limitation post intervention"
"CD008349_pub5_data","Analysis.name","Participation restriction and quality of life post intervention"
"CD008349_pub5_data","Subgroup","Less than 15 hours of intervention"
"CD008349_pub5_data","Subgroup","More than 15 hours of intervention"
"CD008349_pub5_data","Subgroup","Less than 6 months"
"CD008349_pub5_data","Subgroup","More than 6 months"
"CD008349_pub5_data","Subgroup","Specialised"
"CD008349_pub5_data","Subgroup","Gaming"
"CD008349_pub5_data","Subgroup","Immersive virtual reality "
"CD008349_pub5_data","Subgroup","Non-immersive virtual reality "
"CD008349_pub5_data","Subgroup","Customised "
"CD008349_pub5_data","Subgroup","Non-customised"
"CD008469_pub3_data","Analysis.group","1"
"CD008469_pub3_data","Analysis.group","2"
"CD008469_pub3_data","Analysis.name","Exacerbations leading to emergency department (ED) visits: subgrouped by time frame of follow-up"
"CD008469_pub3_data","Analysis.name","Exacerbations requiring a course of oral corticosteroids: subgrouped by time frame of follow-up"
"CD008469_pub3_data","Analysis.name","Quality of life"
"CD008469_pub3_data","Analysis.name","Day symptoms (change in mean symptom-free days in 2 weeks)"
"CD008469_pub3_data","Analysis.name","Days missed from school"
"CD008469_pub3_data","Analysis.name","Exacerbations leading to hospitalisations: subgrouped by time frame of follow-up"
"CD008469_pub3_data","Analysis.name","Exacerbations leading to emergency department visits"
"CD008469_pub3_data","Analysis.name","Exacerbations requiring a course of oral corticosteroids"
"CD008469_pub3_data","Analysis.name","Day symptoms (change in mean symptom-free days in past 2 weeks)"
"CD008469_pub3_data","Analysis.name","Exacerbations leading to hospitalisation "
"CD008469_pub3_data","Subgroup","ED visits – long time frame (> 6 months)"
"CD008469_pub3_data","Subgroup","ED visits – short time frame (≤ 6 months)"
"CD008469_pub3_data","Subgroup","Exacerbations requiring a course of oral corticosteroids: short time frame (≤ 6 months) "
"CD008469_pub3_data","Subgroup","Exacerbations requiring a course of oral corticosteroids: long time frame (> 6 months)"
"CD008469_pub3_data","Subgroup","Caregiver quality of life"
"CD008469_pub3_data","Subgroup","Children quality of life"
"CD008469_pub3_data","Subgroup","Mean days off school in 6 months"
"CD008469_pub3_data","Subgroup","Annual exacerbation rate"
"CD008469_pub3_data","Subgroup","Hospitalisations – short time frame (≤ 6 months)"
"CD008469_pub3_data","Subgroup","Hospitalisation – long time frame (> 6 months)"
"CD008493_pub5_data","Analysis.group","1"
"CD008493_pub5_data","Analysis.group","2"
"CD008493_pub5_data","Analysis.group","3"
"CD008493_pub5_data","Analysis.group","4"
"CD008493_pub5_data","Analysis.name","Short-term mortality"
"CD008493_pub5_data","Analysis.name","Major adverse cardiac events"
"CD008493_pub5_data","Analysis.name","Myocardial infarction"
"CD008493_pub5_data","Analysis.name","Atrial fibrillation"
"CD008493_pub5_data","Analysis.name","Stroke"
"CD008493_pub5_data","Analysis.name","Renal failure"
"CD008493_pub5_data","Analysis.name","Length of stay in the intensive care unit (hours)"
"CD008493_pub5_data","Analysis.name","Length of stay in the hospital (days)"
"CD008493_pub5_data","Analysis.name","Mortality"
"CD008493_pub5_data","Subgroup","Statins discontinuation ≤ 21 days before surgery"
"CD008493_pub5_data","Subgroup","Statins discontinuation > 21 days before surgery or statin-naive participants"
"CD008493_pub5_data","Subgroup","Non-CABG"
"CD008493_pub5_data","Subgroup","CABG"
"CD008552_pub8_data","Analysis.group","1"
"CD008552_pub8_data","Analysis.group","2"
"CD008552_pub8_data","Analysis.group","3"
"CD008552_pub8_data","Analysis.group","4"
"CD008552_pub8_data","Analysis.name","Vegetable intake"
"CD008552_pub8_data","Analysis.name","Vegetable intake - sensitivity analysis - risk of bias"
"CD008552_pub8_data","Analysis.name","Vegetable intake - sensitivity analysis - primary outcome"
"CD008552_pub8_data","Analysis.name","Vegetable intake - sensitivity analysis - missing data"
"CD008552_pub8_data","Analysis.name","Vegetable intake - subgroup analysis - setting"
"CD008552_pub8_data","Analysis.name","Vegetable intake - subgroup analysis - modality"
"CD008552_pub8_data","Analysis.name","Vegetable intake - subgroup analysis - age"
"CD008552_pub8_data","Analysis.name","Fruit and vegetable intake"
"CD008552_pub8_data","Analysis.name","Fruit and vegetable intake - sensitivity analysis - risk of bias"
"CD008552_pub8_data","Analysis.name","Fruit and vegetable intake - sensitivity analysis - primary outcome"
"CD008552_pub8_data","Analysis.name","Fruit and vegetable intake - sensitivity analysis - missing data"
"CD008552_pub8_data","Analysis.name","Fruit and vegetable intake - subgroup analysis - setting"
"CD008552_pub8_data","Analysis.name","Fruit and vegetable intake - subgroup analysis - modality"
"CD008552_pub8_data","Analysis.name","Fruit and vegetable intake - subgroup analysis - age"
"CD008552_pub8_data","Subgroup","Preschool or childcare"
"CD008552_pub8_data","Subgroup","Home"
"CD008552_pub8_data","Subgroup","Home + lab"
"CD008552_pub8_data","Subgroup","Healthcare setting"
"CD008552_pub8_data","Subgroup","Home or health facility"
"CD008552_pub8_data","Subgroup","Face-to-face + written materials"
"CD008552_pub8_data","Subgroup","Audiovisual only"
"CD008552_pub8_data","Subgroup","Face-to-face only"
"CD008552_pub8_data","Subgroup","Face-to-face + telephone"
"CD008552_pub8_data","Subgroup","< 12 months"
"CD008552_pub8_data","Subgroup","≥ 12 months"
"CD008552_pub8_data","Subgroup","Preschool + home"
"CD008552_pub8_data","Subgroup","School or preschool or childcare"
"CD008552_pub8_data","Subgroup","Community + home"
"CD008552_pub8_data","Subgroup","Face-to-face + audiovisual"
"CD008552_pub8_data","Subgroup","Face-to-face + written materials + online"
"CD008552_pub8_data","Subgroup","Face-to-face + written materials + telephone"
"CD008552_pub8_data","Subgroup","Face-to-face + written materials + telephone + audiovisual"
"CD008552_pub8_data","Subgroup","Healthcare setting + home"
"CD008552_pub8_data","Subgroup","Healthcare setting only"
"CD008552_pub8_data","Subgroup","Other (mobile phone app)"
"CD008552_pub8_data","Subgroup","Community"
"CD008552_pub8_data","Subgroup","mHealth"
"CD008552_pub8_data","Subgroup","Face-to-face + telephone + written materials"
"CD008552_pub8_data","Subgroup","Telephone + written materials"
"CD008564_pub3_data","Analysis.group","1"
"CD008564_pub3_data","Analysis.group","2"
"CD008564_pub3_data","Analysis.group","3"
"CD008564_pub3_data","Analysis.group","4"
"CD008564_pub3_data","Analysis.group","5"
"CD008564_pub3_data","Analysis.group","6"
"CD008564_pub3_data","Analysis.name","Total mortality"
"CD008564_pub3_data","Analysis.name","Total serious adverse events"
"CD008564_pub3_data","Analysis.name","Total cardiovascular events"
"CD008564_pub3_data","Analysis.name","Cardiovascular mortality"
"CD008564_pub3_data","Analysis.name","Progression to end-stage renal disease "
"CD008564_pub3_data","Analysis.name","Participant withdrawals due to adverse events"
"CD008564_pub3_data","Analysis.name","Doubling of serum creatinine level or 50% reduction in GFR at the end of study"
"CD008564_pub3_data","Analysis.name","Systolic blood pressure change from baseline at one year"
"CD008564_pub3_data","Analysis.name","Diastolic blood pressure change from baseline at one year"
"CD008564_pub3_data","Analysis.name","Proportion of participants reaching target blood pressure levels at end of study"
"CD008564_pub3_data","Analysis.name","Number of antihypertensive drugs that each participant needed at end of study"
"CD008564_pub3_data","Analysis.name","Progression to end-stage renal disease"
"CD008564_pub3_data","Subgroup","Participants without diabetes"
"CD008564_pub3_data","Subgroup","Participants with diabetes"
"CD008564_pub3_data","Subgroup","Females"
"CD008564_pub3_data","Subgroup","Males"
"CD008564_pub3_data","Subgroup","75 years and older"
"CD008564_pub3_data","Subgroup","Younger than 75 years"
"CD008564_pub3_data","Subgroup","Primary prevention"
"CD008564_pub3_data","Subgroup","Secondary prevention"
"CD008564_pub3_data","Subgroup","GFR 30 to 60 mL/min"
"CD008564_pub3_data","Subgroup","GFR < 30 mL/min"
"CD008628_pub3_data","Analysis.group","1"
"CD008628_pub3_data","Analysis.group","2"
"CD008628_pub3_data","Analysis.name","Function in the long term; measured using AOFAS"
"CD008628_pub3_data","Analysis.name","Function in the long term; using measurement tools other than AOFAS score "
"CD008628_pub3_data","Analysis.name","Function in the long term; number of people with scores of excellent, good, or satisfactory/fair"
"CD008628_pub3_data","Analysis.name","Chronic pain; number of people with pain"
"CD008628_pub3_data","Analysis.name","Chronic pain; measured using VAS"
"CD008628_pub3_data","Analysis.name","HRQoL in the long term; measured using SF-36 (PCS)"
"CD008628_pub3_data","Analysis.name","Return to normal activity (work) "
"CD008628_pub3_data","Analysis.name","Postoperative complications requiring unplanned return to theatre"
"CD008628_pub3_data","Analysis.name","Postoperative complications not requiring return to theatre"
"CD008628_pub3_data","Analysis.name","Ability to wear usual footwear"
"CD008628_pub3_data","Analysis.name","Radiological measurements: Böhler angle"
"CD008628_pub3_data","Analysis.name","Function in the long term"
"CD008628_pub3_data","Analysis.name","Chronic pain"
"CD008628_pub3_data","Analysis.name","HRQoL in the long term"
"CD008628_pub3_data","Analysis.name","Return to normal activity"
"CD008628_pub3_data","Subgroup","Open reduction and internal fixation"
"CD008628_pub3_data","Subgroup","Minimally-invasive surgery"
"CD008628_pub3_data","Subgroup","Minimally invasive surgery"
"CD008628_pub3_data","Subgroup","Excellent"
"CD008628_pub3_data","Subgroup","Satisfactory/Fair"
"CD008628_pub3_data","Subgroup","Good"
"CD008628_pub3_data","Subgroup","Amputation"
"CD008628_pub3_data","Subgroup","Implant removal"
"CD008628_pub3_data","Subgroup","Wound debridement"
"CD008628_pub3_data","Subgroup","Deep infection"
"CD008628_pub3_data","Subgroup","Subtalar arthrodesis"
"CD008628_pub3_data","Subgroup","Superficial infection"
"CD008628_pub3_data","Subgroup","Wound breakdown/dehiscence"
"CD008688_pub3_data","Analysis.group","1"
"CD008688_pub3_data","Analysis.name","Pancreatic fistula (free definition)"
"CD008688_pub3_data","Analysis.name","Postoperative pancreatic fistula (ISGPS)"
"CD008688_pub3_data","Analysis.name","Postoperative mortality"
"CD008688_pub3_data","Analysis.name","Overall postoperative morbidity"
"CD008688_pub3_data","Analysis.name","Delayed gastric emptying"
"CD008688_pub3_data","Analysis.name","Postoperative haemorrhage"
"CD008688_pub3_data","Analysis.name","Intra-abdominal fluid collection"
"CD008688_pub3_data","Analysis.name","Operation time"
"CD008709_pub4_data","Analysis.group","1"
"CD008709_pub4_data","Analysis.group","2"
"CD008709_pub4_data","Analysis.group","3"
"CD008709_pub4_data","Analysis.group","4"
"CD008709_pub4_data","Analysis.name","Objective cure or improvement of urinary incontinence: between 12 and 24 months"
"CD008709_pub4_data","Analysis.name","Dyspareunia"
"CD008709_pub4_data","Analysis.name","Number of women affected by mesh exposure, extrusion or erosion in any area"
"CD008709_pub4_data","Analysis.name","Bladder or urethral injuries: less than 30 days after surgery"
"CD008709_pub4_data","Analysis.name","Infections (e.g. UTI, mesh infection)"
"CD008709_pub4_data","Analysis.name","Subjective cure or improvement of urinary incontinence: at 12 months"
"CD008709_pub4_data","Analysis.name","Subjective cure or improvement of urinary incontinence: 36 + months"
"CD008709_pub4_data","Analysis.name","Objective cure or improvement of urinary incontinence: at 12 months"
"CD008709_pub4_data","Analysis.name","Objective cure or improvement of urinary incontinence: 36+ months"
"CD008709_pub4_data","Analysis.name","Patient-reported pain: 30 days to 12 months"
"CD008709_pub4_data","Analysis.name","Patient-reported pain: 12 to 24 months"
"CD008709_pub4_data","Analysis.name","Urinary retention"
"CD008709_pub4_data","Analysis.name","Other injuries: less than 30 days after surgery"
"CD008709_pub4_data","Analysis.name","De novo urgency"
"CD008709_pub4_data","Analysis.name","Requiring repeat continence surgery or mesh revision"
"CD008709_pub4_data","Analysis.name","Subjective cure or improvement of urinary incontinence: 12 months"
"CD008709_pub4_data","Analysis.name","Subjective cure or improvement of urinary incontinence: 12 to 24 months"
"CD008709_pub4_data","Analysis.name","Subjective cure or improvement of urinary incontinence: 24 to 36 months"
"CD008709_pub4_data","Analysis.name","Subjective cure or improvement of urinary incontinence: 36+ months"
"CD008709_pub4_data","Analysis.name","Objective cure or improvement of incontinence: at 12 months"
"CD008709_pub4_data","Analysis.name","Objective cure or improvement of incontinence: 12 to 24 months"
"CD008709_pub4_data","Analysis.name","Objective cure or improvement of incontinence: 24 to 36 months"
"CD008709_pub4_data","Analysis.name","Objective cure or improvement of incontinence: 36+ months"
"CD008709_pub4_data","Analysis.name","Patient-reported pain: 24+ months"
"CD008709_pub4_data","Analysis.name","Infections (e.g. UTI, mesh infections)"
"CD008709_pub4_data","Analysis.name","Quality of life: at 12 months"
"CD008709_pub4_data","Analysis.name","Subjective cure or improvement of urinary incontinence: 24 months"
"CD008709_pub4_data","Analysis.name","Objective cure or improvement of urinary incontinence: 24 months"
"CD008709_pub4_data","Analysis.name","Infections"
"CD008709_pub4_data","Subgroup","Trials including other SIS (not TVT-S)"
"CD008709_pub4_data","Subgroup","Trials including TVT-S"
"CD008771_pub3_data","Analysis.group","1"
"CD008771_pub3_data","Analysis.name","Length"
"CD008771_pub3_data","Analysis.name","Head circumference"
"CD008771_pub3_data","Analysis.name","Neurodevelopmental outcome"
"CD008771_pub3_data","Analysis.name","Nitrogen balance"
"CD008771_pub3_data","Analysis.name","Metabolic acidosis, pH within first 24 hours of birth"
"CD008771_pub3_data","Analysis.name","Metabolic acidosis, pH at 2 days after birth"
"CD008771_pub3_data","Analysis.name","Metabolic acidosis, bicarbonate level within first 24 hours of birth"
"CD008771_pub3_data","Analysis.name","Metabolic acidosis, bicarbonate level at 2 days after birth"
"CD008771_pub3_data","Analysis.name","Metabolic acidosis, bicarbonate level at days 3 to 4"
"CD008771_pub3_data","Analysis.name","Plasma ammonia level at day 1 after birth"
"CD008771_pub3_data","Analysis.name","Plasma ammonia level at days 3 to 4 after birth"
"CD008771_pub3_data","Analysis.name","BUN level in first 2 days after birth"
"CD008771_pub3_data","Analysis.name","BUN level at days 3 to 4 after birth"
"CD008771_pub3_data","Analysis.name","BUN level at days 6 to 7 after birth"
"CD008771_pub3_data","Analysis.name","Direct bilirubin level at day 1 after birth"
"CD008771_pub3_data","Analysis.name","Direct bilirubin level at day 4 after birth"
"CD008771_pub3_data","Analysis.name","Blood glucose level at day 1 after birth"
"CD008771_pub3_data","Analysis.name","Blood glucose level at day 2 after birth"
"CD008771_pub3_data","Analysis.name","Hypoglycaemia"
"CD008771_pub3_data","Analysis.name","Time to regain birthweight in days"
"CD008771_pub3_data","Analysis.name","Duration of hospital stay in days"
"CD008771_pub3_data","Analysis.name","Time to full feeds in days"
"CD008858_pub5_data","Analysis.group","1"
"CD008858_pub5_data","Analysis.group","2"
"CD008858_pub5_data","Analysis.name","Cumulative incidence of herpes zoster"
"CD008858_pub5_data","Analysis.name","Participants with adverse events"
"CD008858_pub5_data","Analysis.name","Duration in days of adverse events"
"CD008858_pub5_data","Analysis.name","Dropouts"
"CD008858_pub5_data","Analysis.name","Participants with no follow-up"
"CD008858_pub5_data","Analysis.name","Cumulative incidence of herpes zoster at least 3.2 years follow-up"
"CD008858_pub5_data","Analysis.name","Incidence of herpes zoster at least 4 years follow-up"
"CD008858_pub5_data","Subgroup","3.1 years follow-up"
"CD008858_pub5_data","Subgroup","30 days of vaccination"
"CD008858_pub5_data","Subgroup","42 days of vaccination"
"CD008858_pub5_data","Subgroup","3.3 to 7.8 years after vaccination substudy"
"CD008858_pub5_data","Subgroup","Mean 5 years follow-up"
"CD008858_pub5_data","Subgroup","Death"
"CD008858_pub5_data","Subgroup","1 or more serious adverse events regardless of type of storage of the vaccine"
"CD008858_pub5_data","Subgroup","Vaccine-related serious adverse events"
"CD008858_pub5_data","Subgroup","Hospitalised"
"CD008858_pub5_data","Subgroup","Hospitalisation related to herpes zoster"
"CD008858_pub5_data","Subgroup","1 or more adverse events"
"CD008858_pub5_data","Subgroup","Vaccine-related adverse events"
"CD008858_pub5_data","Subgroup","Systemic adverse events"
"CD008858_pub5_data","Subgroup","Vaccine-related systemic adverse events"
"CD008858_pub5_data","Subgroup","Systemic pruritus"
"CD008858_pub5_data","Subgroup","General malaise"
"CD008858_pub5_data","Subgroup","Headache"
"CD008858_pub5_data","Subgroup","Varicella-like rash not at injection site (day of vaccination to day 42)"
"CD008858_pub5_data","Subgroup","Rash unrelated to herpes zoster (day of vaccination to day 42)"
"CD008858_pub5_data","Subgroup","Injection site adverse events"
"CD008858_pub5_data","Subgroup","Erythema inoculation site"
"CD008858_pub5_data","Subgroup","Pain inoculation site"
"CD008858_pub5_data","Subgroup","Pruritus inoculation site"
"CD008858_pub5_data","Subgroup","Swelling inoculation site"
"CD008858_pub5_data","Subgroup","Warmth inoculation site"
"CD008858_pub5_data","Subgroup","Rash inoculation site"
"CD008858_pub5_data","Subgroup","Haematoma inoculation site"
"CD008858_pub5_data","Subgroup","Mass inoculation or induration site"
"CD008858_pub5_data","Subgroup","Varicella-like rash at injection site (day of vaccination to day 42)"
"CD008858_pub5_data","Subgroup","Vaccine-unrelated adverse event"
"CD008858_pub5_data","Subgroup","Herpes zoster-like rash (day of vaccination to day 42)"
"CD008858_pub5_data","Subgroup","Erythema"
"CD008858_pub5_data","Subgroup","Pain"
"CD008858_pub5_data","Subgroup","Pruritus"
"CD008858_pub5_data","Subgroup","Swelling"
"CD008858_pub5_data","Subgroup","Rash"
"CD008858_pub5_data","Subgroup","Haematoma"
"CD008858_pub5_data","Subgroup","For any reason"
"CD008858_pub5_data","Subgroup","Discontinued due to vaccine-related adverse events"
"CD008858_pub5_data","Subgroup","Clinical adverse event"
"CD008858_pub5_data","Subgroup","Physician decision"
"CD008858_pub5_data","Subgroup","Withdrew consent"
"CD008858_pub5_data","Subgroup","Lost to follow-up"
"CD008858_pub5_data","Subgroup","Protocol deviation"
"CD008858_pub5_data","Subgroup","Death within 30 days after vaccination"
"CD008858_pub5_data","Subgroup","Any symptom"
"CD008858_pub5_data","Subgroup","Grade 3 any symptom"
"CD008858_pub5_data","Subgroup","Grade 3 any symptom related to vaccination"
"CD008858_pub5_data","Subgroup","Any systemic symptom"
"CD008858_pub5_data","Subgroup","Potential immune-mediated disease"
"CD008858_pub5_data","Subgroup","Myalgia"
"CD008858_pub5_data","Subgroup","Fatigue"
"CD008858_pub5_data","Subgroup","Fever"
"CD008858_pub5_data","Subgroup","Shivering"
"CD008858_pub5_data","Subgroup","Gastrointestinal symptom"
"CD008858_pub5_data","Subgroup","Any local symptom"
"CD008858_pub5_data","Subgroup","Grade 3 any local symptom"
"CD008858_pub5_data","Subgroup","Local redness"
"CD008858_pub5_data","Subgroup","Local pain"
"CD008858_pub5_data","Subgroup","Local swelling"
"CD008858_pub5_data","Subgroup","Serious adverse events"
"CD008858_pub5_data","Subgroup","Serious adverse events within 30 days after vaccination"
"CD008858_pub5_data","Subgroup","Serious adverse events within 30 days after vaccination related to vaccination"
"CD008858_pub5_data","Subgroup","Grade 3 any systemic adverse events"
"CD008858_pub5_data","Subgroup","Unsolicited report of adverse events"
"CD008858_pub5_data","Subgroup","Grade 3 unsolicited report of adverse events"
"CD008858_pub5_data","Subgroup","Did not receive vaccine according to protocol"
"CD008858_pub5_data","Subgroup","Received wrong vaccine"
"CD008858_pub5_data","Subgroup","Diagnosis of herpes zoster < 30 days after dose 2"
"CD008858_pub5_data","Subgroup","Did not receive second dose"
"CD008873_pub5_data","Analysis.group","1"
"CD008873_pub5_data","Analysis.group","2"
"CD008873_pub5_data","Analysis.group","3"
"CD008873_pub5_data","Analysis.name","Pre-eclampsia (ALL)"
"CD008873_pub5_data","Analysis.name","Gestational diabetes (ALL)"
"CD008873_pub5_data","Analysis.name","Maternal adverse events"
"CD008873_pub5_data","Analysis.name","Preterm birth (less than 37 weeks' gestation) (ALL)"
"CD008873_pub5_data","Analysis.name","Low birthweight (less than 2500 g) (ALL)"
"CD008873_pub5_data","Analysis.name","Caesarean section"
"CD008873_pub5_data","Analysis.name","Gestational hypertension"
"CD008873_pub5_data","Analysis.name","Maternal death (death while pregnant or within 42 days of termination of pregnancy) (ALL)"
"CD008873_pub5_data","Analysis.name","Maternal vitamin D concentration at term (25-hydroxyvitamin D) (nmol/L) (ALL)"
"CD008873_pub5_data","Analysis.name","Birth length (cm)"
"CD008873_pub5_data","Analysis.name","Head circumference at birth (cm)"
"CD008873_pub5_data","Analysis.name","Birthweight (g)"
"CD008873_pub5_data","Analysis.name","Stillbirth"
"CD008873_pub5_data","Analysis.name","Neonatal death"
"CD008873_pub5_data","Analysis.name","Apgar score less than seven at five minutes"
"CD008873_pub5_data","Analysis.name","Maternal death (death while pregnant or within 42 days of termination of pregnancy)"
"CD008873_pub5_data","Subgroup","Severe postpartum haemorrhage"
"CD008873_pub5_data","Subgroup","Nephritic syndrome"
"CD008873_pub5_data","Subgroup","Hypercalcaemia"
"CD008873_pub5_data","Subgroup","Hypercalciuria"
"CD008879_pub3_data","Analysis.group","1"
"CD008879_pub3_data","Analysis.group","2"
"CD008879_pub3_data","Analysis.group","3"
"CD008879_pub3_data","Analysis.group","4"
"CD008879_pub3_data","Analysis.group","5"
"CD008879_pub3_data","Analysis.name","Non-infectious complications"
"CD008879_pub3_data","Analysis.name","Infectious complications"
"CD008879_pub3_data","Analysis.name","Length of hospital stay (days)"
"CD008879_pub3_data","Analysis.name","Oral standard nutritional supplements compared to usual care or control including malnourished and weight-losing participants for infections"
"CD008940_pub4_data","Analysis.group","1"
"CD008940_pub4_data","Analysis.group","2"
"CD008940_pub4_data","Analysis.group","3"
"CD008940_pub4_data","Analysis.group","4"
"CD008940_pub4_data","Analysis.group","5"
"CD008940_pub4_data","Analysis.group","6"
"CD008940_pub4_data","Analysis.group","7"
"CD008940_pub4_data","Analysis.group","8"
"CD008940_pub4_data","Analysis.group","9"
"CD008940_pub4_data","Analysis.group","10"
"CD008940_pub4_data","Analysis.group","11"
"CD008940_pub4_data","Analysis.group","12"
"CD008940_pub4_data","Analysis.group","13"
"CD008940_pub4_data","Analysis.group","14"
"CD008940_pub4_data","Analysis.group","15"
"CD008940_pub4_data","Analysis.group","16"
"CD008940_pub4_data","Analysis.group","17"
"CD008940_pub4_data","Analysis.group","18"
"CD008940_pub4_data","Analysis.group","19"
"CD008940_pub4_data","Analysis.group","20"
"CD008940_pub4_data","Analysis.group","21"
"CD008940_pub4_data","Analysis.group","22"
"CD008940_pub4_data","Analysis.group","23"
"CD008940_pub4_data","Analysis.name","Participants abstinent at end of treatment"
"CD008940_pub4_data","Analysis.name","Participants experiencing adverse events"
"CD008940_pub4_data","Analysis.name","Participants experiencing severe adverse events"
"CD008940_pub4_data","Analysis.name","Participants withdrawn due to adverse effects"
"CD008940_pub4_data","Analysis.name","Completion of scheduled treatment"
"CD008940_pub4_data","Analysis.name","Cannabis use at end of treatment"
"CD008940_pub4_data","Analysis.name","Use of cannabis at end of treatment"
"CD008940_pub4_data","Subgroup","Amount of cannabis"
"CD008940_pub4_data","Subgroup","Frequency of use"
"CD008940_pub4_data","Subgroup","Urine THC levels"
"CD008940_pub4_data","Subgroup","Amount of cannabis used"
"CD008940_pub4_data","Subgroup","Frequency of cannabis use"
"CD008973_pub3_data","Analysis.group","1"
"CD008973_pub3_data","Analysis.name","Complete resolution of phimosis"
"CD008973_pub3_data","Analysis.name","Partial resolution of phimosis"
"CD008973_pub3_data","Analysis.name","Change in retractability score"
"CD008973_pub3_data","Analysis.name","Long-term complete resolution of phimosis"
"CD008973_pub3_data","Analysis.name","Adverse effects (any)"
"CD008973_pub3_data","Analysis.name","Complete resolution of phimosis (subgroup analysis based on age)"
"CD008973_pub3_data","Analysis.name","Complete resolution of phimosis (subgroup analysis based on duration of treatment)"
"CD008973_pub3_data","Analysis.name","Complete resolution of phimosis (subgroup analysis based on potency of corticosteroid)"
"CD008973_pub3_data","Subgroup","< 3 years of age"
"CD008973_pub3_data","Subgroup","≥ 3 years of age"
"CD008973_pub3_data","Subgroup","6–8 weeks' treatment"
"CD008973_pub3_data","Subgroup","4 weeks' treatment"
"CD008973_pub3_data","Subgroup","Medium-potency corticosteroid"
"CD008973_pub3_data","Subgroup","Low-potency corticosteroid"
"CD008973_pub3_data","Subgroup","High-potency corticosteroid"
"CD008995_pub3_data","Analysis.group","1"
"CD008995_pub3_data","Analysis.name","Live birth rate"
"CD008995_pub3_data","Analysis.name","Clinical pregnancy"
"CD008995_pub3_data","Analysis.name","Genital tract colonization"
"CD008995_pub3_data","Analysis.name","Miscarriage"
"CD009022_pub4_data","Analysis.group","1"
"CD009022_pub4_data","Analysis.name","Postoperative pain at 12 hours"
"CD009022_pub4_data","Analysis.name","Postoperative pain at 24 hours: VAS pain score"
"CD009022_pub4_data","Analysis.name","Wound cosmesis: Body Image Questionnaire (BIQ score)"
"CD009022_pub4_data","Analysis.name","Wound cosmesis: VAS scale"
"CD009022_pub4_data","Analysis.name","Operating time (minutes)"
"CD009022_pub4_data","Analysis.name","Visceral or vascular injury (rate)"
"CD009022_pub4_data","Analysis.name","Conversion to laparoscopic (use of more than one additional port)/open surgery (rate)"
"CD009022_pub4_data","Analysis.name","Use of additional port site (rate)"
"CD009022_pub4_data","Analysis.name","Wound infection (rate)"
"CD009022_pub4_data","Analysis.name","Intra-abdominal collection (rate)"
"CD009022_pub4_data","Analysis.name","Postoperative ileus (rate)"
"CD009022_pub4_data","Analysis.name","Length of hospital stay (days)"
"CD009022_pub4_data","Analysis.name","Return to normal activities (days)"
"CD009102_pub2_data","Analysis.group","1"
"CD009102_pub2_data","Analysis.name","Death before discharge"
"CD009102_pub2_data","Analysis.name","Intubation and mechanical ventilation in DR"
"CD009102_pub2_data","Analysis.name","Chest compressions in DR"
"CD009102_pub2_data","Analysis.name","Use of adrenaline (epinephrine) in the DR"
"CD009102_pub2_data","Analysis.name","Apgar scores at 5 minutes"
"CD009102_pub2_data","Analysis.name","Intubation and mechanical ventilation within 24 hours of birth"
"CD009102_pub2_data","Analysis.name","Intubation and mechanical ventilation outside the DR (during hospitalisation) "
"CD009102_pub2_data","Analysis.name","Air leak (pneumothorax, pneumomediastinum, pneumopericardium, pulmonary interstitial emphysema) reported either individually or as a composite outcome"
"CD009102_pub2_data","Analysis.name","Duration of respiratory support, i.e. nasal continuous airway pressure and ventilation via an endotracheal tube, considered separately and in total (days)"
"CD009102_pub2_data","Analysis.name","Duration of supplemental oxygen requirement (days)"
"CD009102_pub2_data","Analysis.name","Need for supplemental oxygen at 36 weeks' corrected gestational age"
"CD009102_pub2_data","Analysis.name","Cranial ultrasound abnormalities (IVH grade ≥ 3 or periventricular leukomalacia)"
"CD009102_pub2_data","Subgroup","Duration in days of ETT ventilation"
"CD009102_pub2_data","Subgroup","Duration of nCPAP (days)"
"CD009235_pub4_data","Analysis.group","1"
"CD009235_pub4_data","Analysis.group","2"
"CD009235_pub4_data","Analysis.group","3"
"CD009235_pub4_data","Analysis.name","Duration of mechanical ventilation"
"CD009235_pub4_data","Analysis.name","Mortality"
"CD009235_pub4_data","Analysis.name","ICU length of stay"
"CD009235_pub4_data","Analysis.name","Hospital length of stay"
"CD009235_pub4_data","Analysis.name","Time from randomization to first extubation"
"CD009235_pub4_data","Analysis.name","Time from intubation (or ICU admission if admitted ventilated) to successful extubation"
"CD009235_pub4_data","Analysis.name","Time from intubation to randomization"
"CD009235_pub4_data","Analysis.name","Duration of weaning"
"CD009235_pub4_data","Analysis.name","Reintubation"
"CD009235_pub4_data","Analysis.name","Self-extubation"
"CD009235_pub4_data","Analysis.name","Non invasive ventilation following extubation"
"CD009235_pub4_data","Analysis.name","Prolonged mechanical ventilation"
"CD009235_pub4_data","Analysis.name","Tracheostomy"
"CD009235_pub4_data","Analysis.name","Duration of mechanical ventilation by study population"
"CD009235_pub4_data","Analysis.name","ICU length of stay by study population"
"CD009235_pub4_data","Analysis.name","Reintubation by study population"
"CD009235_pub4_data","Analysis.name","Duration of mechanical ventilation by automated system"
"CD009235_pub4_data","Analysis.name","ICU length of stay by automated system"
"CD009235_pub4_data","Analysis.name","Reintubation by automated system"
"CD009235_pub4_data","Analysis.name","Duration of mechanical ventilation by non-automated strategy (control arm)"
"CD009235_pub4_data","Analysis.name","ICU length of stay by non-automated strategy (control arm)"
"CD009235_pub4_data","Analysis.name","Reintubation by non-automated strategy (control arm)"
"CD009235_pub4_data","Analysis.name","Duration of mechanical ventilation (hours)"
"CD009235_pub4_data","Analysis.name","ICU length of stay (days)"
"CD009235_pub4_data","Analysis.name","Hospital length of stay (days)"
"CD009235_pub4_data","Subgroup","ICU mortality"
"CD009235_pub4_data","Subgroup","Hospital mortality"
"CD009235_pub4_data","Subgroup","30 day mortality"
"CD009235_pub4_data","Subgroup","Medical ICU population"
"CD009235_pub4_data","Subgroup","Mixed ICU patient population"
"CD009235_pub4_data","Subgroup","Surgical ICU population"
"CD009235_pub4_data","Subgroup","Mixed ICU population"
"CD009235_pub4_data","Subgroup","ASV"
"CD009235_pub4_data","Subgroup","SmartCare/PS"
"CD009235_pub4_data","Subgroup","Intellivent-ASV"
"CD009235_pub4_data","Subgroup","PAV+"
"CD009235_pub4_data","Subgroup","NAVA"
"CD009235_pub4_data","Subgroup","Automode"
"CD009235_pub4_data","Subgroup","Other"
"CD009235_pub4_data","Subgroup","usual care"
"CD009235_pub4_data","Subgroup","protocolized weaning (non-automated)"
"CD009235_pub4_data","Subgroup","Usual care"
"CD009235_pub4_data","Subgroup","Protocolized weaning (non-automated)"
"CD009244_pub3_data","Analysis.group","1"
"CD009244_pub3_data","Analysis.group","2"
"CD009244_pub3_data","Analysis.group","3"
"CD009244_pub3_data","Analysis.group","4"
"CD009244_pub3_data","Analysis.group","5"
"CD009244_pub3_data","Analysis.group","6"
"CD009244_pub3_data","Analysis.group","7"
"CD009244_pub3_data","Analysis.group","8"
"CD009244_pub3_data","Analysis.group","9"
"CD009244_pub3_data","Analysis.name","Development of anal cancer"
"CD009244_pub3_data","Analysis.name","AIN eradication"
"CD009244_pub3_data","Analysis.name","Downgrading from AIN-III or II to AIN-I, or from HSIL to LSIL"
"CD009244_pub3_data","Analysis.name","Recurrence"
"CD009244_pub3_data","Analysis.name","AIN HSIL eradication"
"CD009244_pub3_data","Analysis.name","Development of  anal cancer"
"CD009244_pub3_data","Analysis.name","AIN HSIL recurrence"
"CD009252_pub2_data","Analysis.group","2"
"CD009252_pub2_data","Analysis.group","3"
"CD009252_pub2_data","Analysis.group","4"
"CD009252_pub2_data","Analysis.group","5"
"CD009252_pub2_data","Analysis.group","6"
"CD009252_pub2_data","Analysis.name","Lower urinary tract symptom-specific quality of life"
"CD009252_pub2_data","Analysis.name","Number or change in number of leakage episodes in 24 hours"
"CD009252_pub2_data","Analysis.name","Subjective symptom of cure or improvement"
"CD009252_pub2_data","Analysis.name","Satisfaction with treatment outcome"
"CD009252_pub2_data","Analysis.name","Lower urinary tract symptom-specific quality of life (diagnosis subgroup analysis)"
"CD009252_pub2_data","Analysis.name","Lower urinary tract symptom-specific quality of life (difference in supervision subgroup analysis)"
"CD009252_pub2_data","Analysis.name","Lower urinary tract symptom-specific quality of life (selection bias)"
"CD009252_pub2_data","Analysis.name","Lower urinary tract symptom-specific quality of life (attrition bias)"
"CD009252_pub2_data","Subgroup","SUI or SP-MUI "
"CD009252_pub2_data","Subgroup","Other combinations of UI"
"CD009252_pub2_data","Subgroup","Authors report the same amount of supervision in both randomised groups"
"CD009252_pub2_data","Subgroup","Authors report different amounts of supervision in randomised groups"
"CD009252_pub2_data","Subgroup","Authors don’t report on amount of supervision in groups"
"CD009252_pub2_data","Subgroup","Low risk of bias"
"CD009252_pub2_data","Subgroup","Unclear risk"
"CD009252_pub2_data","Subgroup","High risk"
"CD009298_pub3_data","Analysis.group","1"
"CD009298_pub3_data","Analysis.name","Operative delivery"
"CD009298_pub3_data","Analysis.name","Operative delivery (Subgroup analysis: occiput posterior versus occiput transverse)"
"CD009298_pub3_data","Analysis.name","Operative delivery (Subgroup analysis: nulliparous versus multiparous)"
"CD009298_pub3_data","Analysis.name","Operative delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)"
"CD009298_pub3_data","Analysis.name","Maternal mortality"
"CD009298_pub3_data","Analysis.name","Maternal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)"
"CD009298_pub3_data","Analysis.name","Maternal mortality (Subgroup analysis: nulliparous versus multiparous)"
"CD009298_pub3_data","Analysis.name","Maternal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)"
"CD009298_pub3_data","Analysis.name","Perinatal mortality"
"CD009298_pub3_data","Analysis.name","Perinatal mortality (Subgroup analysis: occiput posterior versus occiput transverse position)"
"CD009298_pub3_data","Analysis.name","Perinatal mortality (Subgroup analysis: nulliparous versus multiparous)"
"CD009298_pub3_data","Analysis.name","Perinatal mortality (Subgroup analysis: digital (fingers) versus whole-hand rotation)"
"CD009298_pub3_data","Analysis.name","Caesarean section"
"CD009298_pub3_data","Analysis.name","Caesarean section (Subgroup analysis: occiput posterior versus occiput transverse position)"
"CD009298_pub3_data","Analysis.name","Caesarean section (Subgroup analysis: nulliparous versus multiparous)"
"CD009298_pub3_data","Analysis.name","Caesarean section (Subgroup analysis: digital (fingers) versus whole-hand rotation)"
"CD009298_pub3_data","Analysis.name","Instrumental delivery"
"CD009298_pub3_data","Analysis.name","Instrumental delivery (Subgroup analysis: occiput posterior versus occiput transverse position)"
"CD009298_pub3_data","Analysis.name","Instrumental delivery (Subgroup analysis: nulliparous versus multiparous)"
"CD009298_pub3_data","Analysis.name","Instrumental delivery (Subgroup analysis: digital (fingers) versus whole-hand rotation)"
"CD009298_pub3_data","Analysis.name","Third- or fourth-degree perineal trauma"
"CD009298_pub3_data","Analysis.name","Third- or fourth-degree perineal trauma (Subgroup analysis: occiput posterior versus occiput transverse position)"
"CD009298_pub3_data","Analysis.name","Third- or fourth-degree perineal trauma (Subgroup analysis: nulliparous versus multiparous)"
"CD009298_pub3_data","Analysis.name","Third- or fourth-degree perineal trauma (Subgroup analysis: digital (fingers) versus whole-hand rotation)"
"CD009298_pub3_data","Analysis.name","Postpartum haemorrhage ≥ 500 mL"
"CD009298_pub3_data","Analysis.name","Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: occiput posterior versus occiput transverse position)"
"CD009298_pub3_data","Analysis.name","Postpartum haemorrhage ≥ 500 mL &nbsp;(Subgroup analysis: nulliparous versus multiparous)"
"CD009298_pub3_data","Analysis.name","Postpartum haemorrhage ≥ 500 mL (Subgroup analysis: digital (fingers) versus whole-hand rotation)"
"CD009298_pub3_data","Analysis.name","Forceps delivery"
"CD009298_pub3_data","Analysis.name","Vacuum-assisted delivery"
"CD009298_pub3_data","Analysis.name","Episiotomy"
"CD009298_pub3_data","Analysis.name","Duration from intervention to delivery (minutes)"
"CD009298_pub3_data","Analysis.name","Duration of second stage of labour (minutes)"
"CD009298_pub3_data","Analysis.name","Maternal postnatal infection"
"CD009298_pub3_data","Analysis.name","Duration of maternal hospital stay (days)"
"CD009298_pub3_data","Analysis.name","Negative experience of childbirth at 6 weeks post delivery (as defined by trial authors)"
"CD009298_pub3_data","Analysis.name","Postnatal depression at &lt; 6 months' follow up"
"CD009298_pub3_data","Analysis.name","Postnatal depression at ≥ 6 months' follow up"
"CD009298_pub3_data","Analysis.name","Breastfeeding not successful &lt; 6 months' follow up"
"CD009298_pub3_data","Analysis.name","Breastfeeding not successful at ≥ 6 months' follow up"
"CD009298_pub3_data","Analysis.name","Non-reassuring or pathological cardiotocograph during procedure"
"CD009298_pub3_data","Analysis.name","Non-reassuring or pathological cardiotocograph at any time after allocation"
"CD009298_pub3_data","Analysis.name","Cord blood gas acidosis"
"CD009298_pub3_data","Analysis.name","Admission to neonatal intensive care unit"
"CD009298_pub3_data","Analysis.name","Neonatal resuscitation (positive pressure ventilation, cardiac compression or drug therapy)"
"CD009298_pub3_data","Analysis.name","Mechanical ventilation (intermittent positive-pressure ventilation/continuous positive airways pressure after resuscitation)"
"CD009298_pub3_data","Analysis.name","Neonatal jaundice treated with phototherapy"
"CD009298_pub3_data","Analysis.name","Neonatal exchange transfusion"
"CD009298_pub3_data","Analysis.name","Polycythaemia treated with partial volume exchange transfusion"
"CD009298_pub3_data","Analysis.name","Neonatal stroke"
"CD009298_pub3_data","Analysis.name","Neonatal intracranial bleed"
"CD009298_pub3_data","Analysis.name","Neonatal fracture"
"CD009298_pub3_data","Analysis.name","Scalp haematoma (e.g. cephalohaematoma or subgaleal haemorrhage)"
"CD009298_pub3_data","Analysis.name","Neonatal encephalopathy"
"CD009298_pub3_data","Analysis.name","Neonatal neuropraxia"
"CD009298_pub3_data","Subgroup","Occiput posterior"
"CD009298_pub3_data","Subgroup","Occiput transverse"
"CD009298_pub3_data","Subgroup","Position unknown"
"CD009298_pub3_data","Subgroup","Nulliparous"
"CD009298_pub3_data","Subgroup","Multiparous"
"CD009298_pub3_data","Subgroup","Digital (fingers) rotation"
"CD009298_pub3_data","Subgroup","Whole-hand rotation"
"CD009298_pub3_data","Subgroup","Method unknown"
"CD009298_pub3_data","Subgroup","Occiput posterior position"
"CD009298_pub3_data","Subgroup","Occiput transverse postion"
"CD009298_pub3_data","Subgroup","Position not known"
"CD009298_pub3_data","Subgroup","Occiput position unknown"
"CD009362_pub4_data","Analysis.group","1"
"CD009362_pub4_data","Analysis.group","2"
"CD009362_pub4_data","Analysis.group","3"
"CD009362_pub4_data","Analysis.group","4"
"CD009362_pub4_data","Analysis.group","5"
"CD009362_pub4_data","Analysis.group","6"
"CD009362_pub4_data","Analysis.group","7"
"CD009362_pub4_data","Analysis.group","8"
"CD009362_pub4_data","Analysis.group","9"
"CD009362_pub4_data","Analysis.group","10"
"CD009362_pub4_data","Analysis.group","11"
"CD009362_pub4_data","Analysis.group","12"
"CD009362_pub4_data","Analysis.group","13"
"CD009362_pub4_data","Analysis.group","14"
"CD009362_pub4_data","Analysis.group","15"
"CD009362_pub4_data","Analysis.group","16"
"CD009362_pub4_data","Analysis.group","17"
"CD009362_pub4_data","Analysis.group","18"
"CD009362_pub4_data","Analysis.group","19"
"CD009362_pub4_data","Analysis.group","20"
"CD009362_pub4_data","Analysis.name","Pressure ulcer"
"CD009362_pub4_data","Analysis.name","Pressure ulcer stage"
"CD009362_pub4_data","Analysis.name","Time to pressure ulcer development"
"CD009362_pub4_data","Analysis.name","Anatomical location of pressure ulcer development"
"CD009362_pub4_data","Analysis.name","Pressure ulcer "
"CD009362_pub4_data","Analysis.name","Adverse event"
"CD009362_pub4_data","Analysis.name","Anatomical location of pressure ulcer"
"CD009362_pub4_data","Subgroup","Stage 2"
"CD009362_pub4_data","Subgroup","Stage 1"
"CD009362_pub4_data","Subgroup","Stage 3"
"CD009362_pub4_data","Subgroup","Deep tissue injury"
"CD009362_pub4_data","Subgroup","Unstageable"
"CD009362_pub4_data","Subgroup","Stage 4"
"CD009362_pub4_data","Subgroup","Sacral pressure ulcer"
"CD009362_pub4_data","Subgroup","Heel pressure ulcer"
"CD009362_pub4_data","Subgroup","Foam dressing versus film dressing"
"CD009362_pub4_data","Subgroup","Stage 1 pressure ulcer "
"CD009362_pub4_data","Subgroup","Stage 2 pressure ulcer"
"CD009362_pub4_data","Subgroup","Polyurethane film versus hydrocolloid dressing"
"CD009362_pub4_data","Subgroup","Pressure ulcer stage 2"
"CD009362_pub4_data","Subgroup","Pressure ulcer stage 1"
"CD009362_pub4_data","Subgroup","Fatty acid versus placebo"
"CD009362_pub4_data","Subgroup","Shoulder pressure ulcer"
"CD009362_pub4_data","Subgroup","Iliac pressure ulcer"
"CD009362_pub4_data","Subgroup","Buttock pressure ulcer"
"CD009362_pub4_data","Subgroup","Earlobe pressure ulcer"
"CD009362_pub4_data","Subgroup","Pressure ulcer stage 3"
"CD009362_pub4_data","Subgroup","Pressure ulcer stage 4"
"CD009417_pub3_data","Analysis.group","1"
"CD009417_pub3_data","Analysis.name","Mortality (any cause during hospitalisation or follow-up)"
"CD009417_pub3_data","Analysis.name","Length of hospitalisation (days)"
"CD009417_pub3_data","Analysis.name","Adverse events of any severity or seriousness"
"CD009417_pub3_data","Analysis.name","Serious adverse events"
"CD009417_pub3_data","Analysis.name","Need for mechanical ventilation"
"CD009417_pub3_data","Analysis.name","Duration of mechanical ventilation"
"CD009417_pub3_data","Analysis.name","Need for supplemental oxygen"
"CD009417_pub3_data","Analysis.name","Duration of supplemental oxygen"
"CD009417_pub3_data","Analysis.name","Need for ICU admission"
"CD009417_pub3_data","Analysis.name","Duration of stay in the ICU"
"CD009508_pub2_data","Analysis.group","1"
"CD009508_pub2_data","Analysis.group","2"
"CD009508_pub2_data","Analysis.group","3"
"CD009508_pub2_data","Analysis.name","Incontinence quality of life"
"CD009508_pub2_data","Analysis.name","Incontinence episodes"
"CD009508_pub2_data","Analysis.name","Subjective cure/improvement"
"CD009508_pub2_data","Analysis.name","Satisfaction"
"CD009508_pub2_data","Analysis.name","Incontinence episode frequency"
"CD009508_pub2_data","Subgroup","Co-ordinated PFMT versus direct PFMT"
"CD009508_pub2_data","Subgroup","Indirect training versus direct PFMT"
"CD009508_pub2_data","Subgroup","Combined indirect training with direct PFMT versus direct PFMT"
"CD009508_pub2_data","Subgroup","PFMT more days per week (higher) versus PFMT fewer days per week (lower)"
"CD009508_pub2_data","Subgroup","PFMT with resistance device (higher) versus PFMT without resistance device (lower)"
"CD009508_pub2_data","Subgroup","Maximal PFM contractions (higher) versus sub-maximal PFM contractions (lower)"
"CD009508_pub2_data","Subgroup","PFMT in antigravity body positions (higher) versus PFMT in supine (lower)"
"CD009508_pub2_data","Subgroup","In-person individual supervision versus in-person group supervision"
"CD009508_pub2_data","Subgroup","In-person clinic supervision (more) versus e-health supervision (less)"
"CD009508_pub2_data","Subgroup","In-person clinic supervision (more) versus no clinic supervision (less)"
"CD009508_pub2_data","Subgroup","PFMT delivered via technology (more) versus PFMT delivered via written instruction only (less)"
"CD009508_pub2_data","Subgroup","More clinician contact (more) versus less clinician contact (less)"
"CD009508_pub2_data","Subgroup","PFMT with more clinician contact (more) versus PFMT with less clinician contact (less)"
"CD009508_pub2_data","Subgroup","PFMT with clinic visits (more) versus PFMT at home (less)"
"CD009508_pub2_data","Subgroup","In-person individual supervision versus in-person group supervision of PFMT"
"CD009531_pub3_data","Analysis.group","1"
"CD009531_pub3_data","Analysis.group","2"
"CD009531_pub3_data","Analysis.group","3"
"CD009531_pub3_data","Analysis.group","4"
"CD009531_pub3_data","Analysis.name","Quality of life: average change in mental health component - 12 months"
"CD009531_pub3_data","Analysis.name","Mental state: clinically important change (binary) - 12 months "
"CD009531_pub3_data","Analysis.name","Psychiatric hospital admissions - 12 months"
"CD009531_pub3_data","Analysis.name","Quality of life"
"CD009531_pub3_data","Analysis.name","Mental state"
"CD009531_pub3_data","Analysis.name","Psychiatric hospital admissions: number of participants admitted to hospital (greater than 12 months)"
"CD009531_pub3_data","Analysis.name","Other hospital admissions"
"CD009531_pub3_data","Analysis.name","Physical health status"
"CD009531_pub3_data","Analysis.name","Medication adherence (patient-reported) (DAI-10)"
"CD009531_pub3_data","Analysis.name","Medication adherence (patient-reported) (MARS)"
"CD009531_pub3_data","Analysis.name","Social functioning (binary)"
"CD009531_pub3_data","Analysis.name","Social functioning/disability"
"CD009531_pub3_data","Analysis.name","Death"
"CD009531_pub3_data","Analysis.name","Cost of treatment"
"CD009531_pub3_data","Analysis.name","Cost of treatment (international dollars)"
"CD009531_pub3_data","Analysis.name","Attrition/leaving the study early"
"CD009531_pub3_data","Analysis.name","Mental state: clinically important change (sensitivity analysis: assumptions for attrition)"
"CD009531_pub3_data","Analysis.name","Psychiatric hospital admissions (sensitivity analysis: assumptions for attrition)"
"CD009531_pub3_data","Analysis.name","Quality of life, physical health at 6 months - subgroup analysis: quality of study"
"CD009531_pub3_data","Analysis.name","Quality of life, mental health at 6 months - subgroup analysis: quality of study"
"CD009531_pub3_data","Analysis.name","Quality of life, physical health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems "
"CD009531_pub3_data","Analysis.name","Quality of life, mental health at 6 months - subgroup analysis: variations in implementation of the collaborative care intervention and healthcare systems "
"CD009531_pub3_data","Subgroup","Number of participants admitted to hospital (up to 12 months)"
"CD009531_pub3_data","Subgroup","Quality of life: average endpoint in physical health - up to 6 months"
"CD009531_pub3_data","Subgroup","Quality of life: average endpoint in physical health - 12 months"
"CD009531_pub3_data","Subgroup","Quality of life: average endpoint in physical health - more than 12 months"
"CD009531_pub3_data","Subgroup","Quality of life: average endpoint in mental health - up to 6 months"
"CD009531_pub3_data","Subgroup","Quality of life: average endpoint in mental health component (more than 12 months)"
"CD009531_pub3_data","Subgroup","Quality of life: overall endpoint (WHOQOL-BREF) - 12 months"
"CD009531_pub3_data","Subgroup","Quality of life: overall endpoint (WHOQOL-BREF) - 6 months"
"CD009531_pub3_data","Subgroup","Mental state (depressive symptoms) up to 6 months"
"CD009531_pub3_data","Subgroup","Mental state (depressive symptoms) more than 12 months"
"CD009531_pub3_data","Subgroup","Mental state (manic symptoms) more than 12 months"
"CD009531_pub3_data","Subgroup","Mental state (negative symptoms) 12 months"
"CD009531_pub3_data","Subgroup","Mental state (negative symptoms) 6 months"
"CD009531_pub3_data","Subgroup","Mental state (positive symptoms) 6 months"
"CD009531_pub3_data","Subgroup","Mental state (overall general score) up to 6 months"
"CD009531_pub3_data","Subgroup","Mental state (depressive symptoms) 12 months"
"CD009531_pub3_data","Subgroup","Mental state (positive symptoms) 12 months"
"CD009531_pub3_data","Subgroup","Mental state (general psychopathology) 12 months"
"CD009531_pub3_data","Subgroup","Mental state (general psychopathology) 6 months"
"CD009531_pub3_data","Subgroup","Mental state (manic symptoms) up to 6 months"
"CD009531_pub3_data","Subgroup","Mental state (manic symptoms) 12 months"
"CD009531_pub3_data","Subgroup","Number of participants admitted to hospital (in year 3)"
"CD009531_pub3_data","Subgroup","Number of participants admitted to hospital (in year 2)"
"CD009531_pub3_data","Subgroup","Blood pressure, mmHg diastolic - 12 months"
"CD009531_pub3_data","Subgroup","Triglycerides up to 6 months"
"CD009531_pub3_data","Subgroup","Total cholesterol - 6 months"
"CD009531_pub3_data","Subgroup","High-density lipoprotein (HDL) - 6 months"
"CD009531_pub3_data","Subgroup","High-density lipoprotein (HDL) - 12 months"
"CD009531_pub3_data","Subgroup","High-density lipoprotein (HDL) - 24 months"
"CD009531_pub3_data","Subgroup","HbA1c up to 6 months"
"CD009531_pub3_data","Subgroup","Waist circumference - 24 months"
"CD009531_pub3_data","Subgroup","Waist circumference - 12 months"
"CD009531_pub3_data","Subgroup","Low-density lipoprotein (LDL) - 24 months"
"CD009531_pub3_data","Subgroup","Waist circumference - 6 months"
"CD009531_pub3_data","Subgroup","Blood pressure, mmHg systolic - up to 6 months"
"CD009531_pub3_data","Subgroup","Blood pressure, mmHg diastolic - 6 months"
"CD009531_pub3_data","Subgroup","Blood pressure, mmHg systolic - 24 months"
"CD009531_pub3_data","Subgroup","Blood pressure, mmHg diastolic - 24 months"
"CD009531_pub3_data","Subgroup","Body mass index (BMI) - 6 months"
"CD009531_pub3_data","Subgroup","Total cholesterol - 12 months"
"CD009531_pub3_data","Subgroup","BMI  - 12 months"
"CD009531_pub3_data","Subgroup","BMI  - 24 months"
"CD009531_pub3_data","Subgroup","Low-density lipoprotein (LDL) - 6 months"
"CD009531_pub3_data","Subgroup","Blood pressure, mmHg systolic - 12 months"
"CD009531_pub3_data","Subgroup","Total cholesterol - 24 months"
"CD009531_pub3_data","Subgroup","Low-density lipoprotein (LDL) - 12 months"
"CD009531_pub3_data","Subgroup","Medication adherence (patient at 12 months)"
"CD009531_pub3_data","Subgroup","Medication adherence (patient at 6 months)"
"CD009531_pub3_data","Subgroup","Medication adherence (up to 6 months)"
"CD009531_pub3_data","Subgroup","Social functioning/disability (more than 12 months)"
"CD009531_pub3_data","Subgroup","Social functioning/disability - 12 months"
"CD009531_pub3_data","Subgroup","Social functioning/disability (up to 6 months)"
"CD009531_pub3_data","Subgroup","Number of participants that died from natural causes (36 months)"
"CD009531_pub3_data","Subgroup","Death from natural causes (6 months)"
"CD009531_pub3_data","Subgroup","Any deaths (12 months)"
"CD009531_pub3_data","Subgroup","Number of participants that died from suicide (12 months)"
"CD009531_pub3_data","Subgroup","Number of participants that died from suicide (36 months)"
"CD009531_pub3_data","Subgroup","Intervention costs (at 36 months)"
"CD009531_pub3_data","Subgroup","Total costs at 12 months"
"CD009531_pub3_data","Subgroup","Attrition/leaving the study early (lost to follow-up at 36 months)"
"CD009531_pub3_data","Subgroup","Attrition/leaving the study early (lost to follow-up 6 months)"
"CD009531_pub3_data","Subgroup","Attrition/leaving the study early (lost to follow-up 24 months)"
"CD009531_pub3_data","Subgroup","Attrition/leaving the study early (lost to follow-up 12 months)"
"CD009531_pub3_data","Subgroup","Number of participants admitted to hospital up to 12 months (assumptions for attrition)"
"CD009531_pub3_data","Subgroup","Number of participants admitted to hospital in year 2 (sensitivity analysis: assumptions for attrition)"
"CD009531_pub3_data","Subgroup","Number of participants admitted to hospital in year 3 (sensitivity analysis: assumptions for attrition)"
"CD009531_pub3_data","Subgroup","Physical health at 6 months (lower-quality studies)"
"CD009531_pub3_data","Subgroup","Physical health at 6 months (higher-quality studies)"
"CD009531_pub3_data","Subgroup","Mental health at 6 months (lower-quality studies)"
"CD009531_pub3_data","Subgroup","Mental health at 6 months (higher-quality studies)"
"CD009531_pub3_data","Subgroup","Physical health at 6 months (no pharmacy collaborative care)"
"CD009531_pub3_data","Subgroup","Physical health at 6 months (pharmacy collaborative care)"
"CD009531_pub3_data","Subgroup","Mental health at 6 months (pharmacy collaborative care)"
"CD009531_pub3_data","Subgroup","Mental health at 6 months (no pharmacy collaborative care)"
"CD009535_pub3_data","Analysis.group","1"
"CD009535_pub3_data","Analysis.name","Cardiovascular death"
"CD009535_pub3_data","Analysis.name","All-cause death"
"CD009535_pub3_data","Analysis.name","All-cause annual hospital admission rate (number of admissions/patient-year)"
"CD009535_pub3_data","Analysis.name","All-cause hospitalisation days/patient-year"
"CD009535_pub3_data","Analysis.name","Kidney transplantation during study period"
"CD009535_pub3_data","Analysis.name","Physical functioning (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","Role: Physical (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","Bodily pain (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","General health (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","Vitality (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","Social functioning (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","Role: Emotional (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","Mental health (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","Physical Component Summary (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","Mental Component Summary (SF-12; SF-36)"
"CD009535_pub3_data","Analysis.name","Symptoms and problems (KDQOL-SF)"
"CD009535_pub3_data","Analysis.name","Effects of kidney disease (KDQOL-SF)"
"CD009535_pub3_data","Analysis.name","Burden of kidney disease (KDQOL-SF)"
"CD009535_pub3_data","Analysis.name","Work status (KDQOL-SF)"
"CD009535_pub3_data","Analysis.name","Cognitive function (KDQOL-SF)"
"CD009535_pub3_data","Analysis.name","Quality of social interaction (KDQOL-SF)"
"CD009535_pub3_data","Analysis.name","Sexual function (KDQOL-SF)"
"CD009535_pub3_data","Analysis.name","Sleep (KDQOL-SF)"
"CD009535_pub3_data","Analysis.name","Recovery time"
"CD009535_pub3_data","Analysis.name","Annual direct healthcare costs in first year of dialysis (currency as reported)"
"CD009535_pub3_data","Analysis.name","Annual direct healthcare costs in second year of dialysis (currency as reported)"
"CD009535_pub3_data","Analysis.name","Systolic blood pressure (NRSIs)"
"CD009535_pub3_data","Analysis.name","Diastolic blood pressure (NSRIs)"
"CD009535_pub3_data","Analysis.name","Mean arterial pressure"
"CD009535_pub3_data","Analysis.name","Left ventricular mass index [g/m2]"
"CD009535_pub3_data","Subgroup","SF-36"
"CD009535_pub3_data","Subgroup","SF-12"
"CD009535_pub3_data","Subgroup","Year 1 of dialysis"
"CD009535_pub3_data","Subgroup","Dialysis vintage not specified"
"CD009535_pub3_data","Subgroup","Year 2 of dialysis"
"CD009535_pub3_data","Subgroup","NRSIs, pre-dialysis measurement"
"CD009535_pub3_data","Subgroup","NRSIs, clinic or other measurements"
"CD009535_pub3_data","Subgroup","NRSIs, clinic or other measurement"
"CD009609_pub3_data","Analysis.group","1"
"CD009609_pub3_data","Analysis.name","Length of hospital stay"
"CD009609_pub3_data","Analysis.name","Adverse events"
"CD009609_pub3_data","Analysis.name","Change in respiratory rate at 1 hour"
"CD009609_pub3_data","Analysis.name","Change in respiratory rate at 4 to 6 hours"
"CD009609_pub3_data","Analysis.name","Change in respiratory rate at 24 hours"
"CD009609_pub3_data","Analysis.name","Change in heart rate at 1 hour"
"CD009609_pub3_data","Analysis.name","Change in heart rate at 4 to 6 hours"
"CD009609_pub3_data","Analysis.name","Change in heart rate at 24 hours"
"CD009609_pub3_data","Analysis.name","Need for treatment escalation"
"CD009609_pub3_data","Analysis.name","Duration of oxygen therapy"
"CD009679_pub3_data","Analysis.group","1"
"CD009679_pub3_data","Analysis.group","2"
"CD009679_pub3_data","Analysis.group","3"
"CD009679_pub3_data","Analysis.group","4"
"CD009679_pub3_data","Analysis.group","5"
"CD009679_pub3_data","Analysis.name","Generic quality of life (SF-36 scores) at 24 months"
"CD009679_pub3_data","Analysis.name","Patient-reported lower limb function (Hospital for Special Surgery (HSS) score)"
"CD009679_pub3_data","Analysis.name","WOMAC Pain score"
"CD009679_pub3_data","Analysis.name","WOMAC Stiffness score"
"CD009679_pub3_data","Analysis.name","WOMAC Function score"
"CD009679_pub3_data","Analysis.name","Reoperation (24 months)"
"CD009679_pub3_data","Analysis.name","Radiological outcomes (postoperatively)"
"CD009679_pub3_data","Analysis.name","Radiological evidence of tibiofemoral joint osteoarthritis"
"CD009679_pub3_data","Analysis.name","Knee range of motion (degrees) at 24 months"
"CD009679_pub3_data","Analysis.name","Intraoperative measures (length of surgery, blood loss)"
"CD009679_pub3_data","Analysis.name","Return to pre-injury activity level"
"CD009679_pub3_data","Analysis.name","Length of hospital stay (days)"
"CD009679_pub3_data","Analysis.name","Patient-reported lower limb function"
"CD009679_pub3_data","Analysis.name","Knee range of motion"
"CD009679_pub3_data","Analysis.name","Operative duration (minutes)"
"CD009679_pub3_data","Analysis.name","Intraoperative blood loss (mL)"
"CD009679_pub3_data","Analysis.name","Time to radiological union (weeks)"
"CD009679_pub3_data","Analysis.name","Complications"
"CD009679_pub3_data","Analysis.name","Reoperations (up to 24 months)"
"CD009679_pub3_data","Analysis.name","Knee range of motion (degrees)"
"CD009679_pub3_data","Analysis.name","Perioperative blood loss (mL)"
"CD009679_pub3_data","Analysis.name","Incision length (cm)"
"CD009679_pub3_data","Analysis.name","Hospital length of stay (days)"
"CD009679_pub3_data","Analysis.name","Patient-reported functional score"
"CD009679_pub3_data","Analysis.name","Pain"
"CD009679_pub3_data","Analysis.name","Incision length (cm) "
"CD009679_pub3_data","Analysis.name","Blood loss (mL)"
"CD009679_pub3_data","Analysis.name","Time to radiological union (months)"
"CD009679_pub3_data","Analysis.name","Generic quality of life"
"CD009679_pub3_data","Analysis.name","Lower limb function"
"CD009679_pub3_data","Analysis.name","Lower limb function – Lysholm Knee Score"
"CD009679_pub3_data","Analysis.name","Adverse events"
"CD009679_pub3_data","Analysis.name","Knee range of motion at 12 months"
"CD009679_pub3_data","Analysis.name","Intraoperative results"
"CD009679_pub3_data","Subgroup","General health"
"CD009679_pub3_data","Subgroup","Physical function"
"CD009679_pub3_data","Subgroup","Role-physical"
"CD009679_pub3_data","Subgroup","Role-emotional"
"CD009679_pub3_data","Subgroup","Social function"
"CD009679_pub3_data","Subgroup","Bodily pain"
"CD009679_pub3_data","Subgroup","Vitality"
"CD009679_pub3_data","Subgroup","Mental health"
"CD009679_pub3_data","Subgroup","At 6 months"
"CD009679_pub3_data","Subgroup","At 12 months"
"CD009679_pub3_data","Subgroup","At 24 months"
"CD009679_pub3_data","Subgroup","Reoperation: incision and drainage"
"CD009679_pub3_data","Subgroup","Reoperation: split-thickness skin graft"
"CD009679_pub3_data","Subgroup","Reoperation: screw removal"
"CD009679_pub3_data","Subgroup","Reoperation: knee manipulation"
"CD009679_pub3_data","Subgroup","Reoperation: plate removal"
"CD009679_pub3_data","Subgroup","Reoperation: total knee arthroplasty"
"CD009679_pub3_data","Subgroup","Reoperation: above knee amputation"
"CD009679_pub3_data","Subgroup","Reoperation: soft-tissue flap"
"CD009679_pub3_data","Subgroup","Reoperation: revision ORIF"
"CD009679_pub3_data","Subgroup","Unplanned reoperation"
"CD009679_pub3_data","Subgroup","Lateral plateau step > 5 mm"
"CD009679_pub3_data","Subgroup","Medial plateau step > 5 mm"
"CD009679_pub3_data","Subgroup","Medial plateau depression > 5 mm"
"CD009679_pub3_data","Subgroup","Lateral plateau depression > 5 mm"
"CD009679_pub3_data","Subgroup","Fracture gap deformity > 5 mm"
"CD009679_pub3_data","Subgroup","Metaphyseal-diaphyseal angulation > 5 degrees"
"CD009679_pub3_data","Subgroup","Length of surgery (minutes)"
"CD009679_pub3_data","Subgroup","Blood loss (mL)"
"CD009679_pub3_data","Subgroup","Hospital for Special Surgery (HSS) score at 12 months"
"CD009679_pub3_data","Subgroup","Rasmussen score at 12 months"
"CD009679_pub3_data","Subgroup","Knee flexion (degrees) at 12 months"
"CD009679_pub3_data","Subgroup","Functional lower-limb scores: medium term"
"CD009679_pub3_data","Subgroup","Functional lower-limb scores: short term"
"CD009679_pub3_data","Subgroup","International Knee Documentation Committee (IKDC) score: short term"
"CD009679_pub3_data","Subgroup","Seroma"
"CD009679_pub3_data","Subgroup","Haematoma"
"CD009679_pub3_data","Subgroup","Superficial infection"
"CD009679_pub3_data","Subgroup","Deep infection"
"CD009679_pub3_data","Subgroup","Deep venous thrombosis"
"CD009679_pub3_data","Subgroup","Hardware failure"
"CD009679_pub3_data","Subgroup","Hardware irritation"
"CD009679_pub3_data","Subgroup","Fracture nonunion"
"CD009679_pub3_data","Subgroup","Loss of fracture reduction"
"CD009679_pub3_data","Subgroup","Loss of alignment"
"CD009679_pub3_data","Subgroup","Wounds dehiscence"
"CD009679_pub3_data","Subgroup","Development of osteoarthritis"
"CD009679_pub3_data","Subgroup","Fracture delayed union"
"CD009679_pub3_data","Subgroup","Knee stiffness"
"CD009679_pub3_data","Subgroup","Total complications"
"CD009679_pub3_data","Subgroup","Metalwork removal"
"CD009679_pub3_data","Subgroup","Revision fixation"
"CD009679_pub3_data","Subgroup","Short-term results"
"CD009679_pub3_data","Subgroup","Medium-term results"
"CD009679_pub3_data","Subgroup","Superficial wound infection"
"CD009679_pub3_data","Subgroup","Overall complications"
"CD009679_pub3_data","Subgroup","Valgus deformity"
"CD009679_pub3_data","Subgroup","Deep vein thrombosis"
"CD009679_pub3_data","Subgroup","Purulent wound discharge"
"CD009679_pub3_data","Subgroup","Loss of reduction"
"CD009679_pub3_data","Subgroup","Postoperative pain"
"CD009679_pub3_data","Subgroup","Knee extension lag"
"CD009679_pub3_data","Subgroup","Infection (unspecified)"
"CD009679_pub3_data","Subgroup","Development of traumatic knee osteoarthritis"
"CD009679_pub3_data","Subgroup","Serous wound discharge"
"CD009679_pub3_data","Subgroup","Pain at implant site"
"CD009679_pub3_data","Subgroup","Ability to walk (excellent or good)"
"CD009679_pub3_data","Subgroup","Stair climbing (excellent or good)"
"CD009679_pub3_data","Subgroup","Squatting (excellent or good)"
"CD009679_pub3_data","Subgroup","Jumping (excellent or good)"
"CD009679_pub3_data","Subgroup","Blood transfusion"
"CD009679_pub3_data","Subgroup","Infection"
"CD009679_pub3_data","Subgroup","Nonunion"
"CD009679_pub3_data","Subgroup","Prominent metalwork"
"CD009679_pub3_data","Subgroup","Loose screws"
"CD009679_pub3_data","Subgroup","Condylar widening"
"CD009679_pub3_data","Subgroup","Varus-valgus angulation"
"CD009679_pub3_data","Subgroup","Joint swelling"
"CD009679_pub3_data","Subgroup","Joint line depression"
"CD009679_pub3_data","Subgroup","Loss of reduction-fracture displacement"
"CD009679_pub3_data","Subgroup","Varus malunion"
"CD009679_pub3_data","Subgroup","Reoperation (for complication)"
"CD009679_pub3_data","Subgroup","Flexion ≥ 120 degrees"
"CD009679_pub3_data","Subgroup","Full extension"
"CD009679_pub3_data","Subgroup","Operative duration (minutes)"
"CD009730_pub3_data","Analysis.group","1"
"CD009730_pub3_data","Analysis.group","2"
"CD009730_pub3_data","Analysis.group","3"
"CD009730_pub3_data","Analysis.group","4"
"CD009730_pub3_data","Analysis.group","5"
"CD009730_pub3_data","Analysis.group","6"
"CD009730_pub3_data","Analysis.group","7"
"CD009730_pub3_data","Analysis.group","8"
"CD009730_pub3_data","Analysis.group","9"
"CD009730_pub3_data","Analysis.group","10"
"CD009730_pub3_data","Analysis.group","11"
"CD009730_pub3_data","Analysis.group","12"
"CD009730_pub3_data","Analysis.group","13"
"CD009730_pub3_data","Analysis.group","14"
"CD009730_pub3_data","Analysis.group","15"
"CD009730_pub3_data","Analysis.group","16"
"CD009730_pub3_data","Analysis.group","17"
"CD009730_pub3_data","Analysis.group","18"
"CD009730_pub3_data","Analysis.group","19"
"CD009730_pub3_data","Analysis.name","FVC % predicted (relative change)"
"CD009730_pub3_data","Analysis.name","Weight (relative change)"
"CD009730_pub3_data","Analysis.name","FEV1 % predicted (absolute change)"
"CD009730_pub3_data","Analysis.name","FVC % predicted (absolute change)"
"CD009730_pub3_data","Analysis.name","FEV1 (litres) absolute change from baseline – ceftazidime versus aztreonam (varying doses)"
"CD009730_pub3_data","Analysis.name","FEV1 % predicted absolute change from baseline – colistin versus tobramycin (varying doses)"
"CD009730_pub3_data","Analysis.name","Time to next pulmonary exacerbation (days) – colistin versus tobramycin (varying doses)"
"CD009730_pub3_data","Analysis.name","FEV1 % predicted (relative change)"
"CD009730_pub3_data","Analysis.name","Time to next exacerbation (weeks)"
"CD009730_pub3_data","Analysis.name","Weight (absolute change (kg))"
"CD009730_pub3_data","Analysis.name","Adverse effects – sensitivity reaction"
"CD009730_pub3_data","Analysis.name","Adverse effects"
"CD009730_pub3_data","Analysis.name","Adverse effects – serum"
"CD009730_pub3_data","Analysis.name","FEV1 (millilitres) (absolute change)"
"CD009730_pub3_data","Analysis.name","FEV1 % (relative change)"
"CD009730_pub3_data","Analysis.name","FEV1 (all measures)"
"CD009730_pub3_data","Analysis.name","FVC (millilitres) (absolute change)"
"CD009730_pub3_data","Analysis.name","FVC (all measures)"
"CD009730_pub3_data","Analysis.name","Time to readmission (months)"
"CD009730_pub3_data","Analysis.name","Proportion readmitted, requiring IV antibiotics or death in subsequent 3 months"
"CD009730_pub3_data","Analysis.name","Weight (% change)"
"CD009730_pub3_data","Analysis.name","Mortality"
"CD009730_pub3_data","Analysis.name","Renal toxicity"
"CD009730_pub3_data","Analysis.name","Antibiotic resistance – number of participants isolating resistant strains"
"CD009730_pub3_data","Analysis.name","FEV1% predicted (relative change)"
"CD009730_pub3_data","Analysis.name","FEV1 (litres) (relative change)"
"CD009730_pub3_data","Analysis.name","FEV1 % predicted (relative % change)"
"CD009730_pub3_data","Analysis.name","Participants experiencing an exacerbation"
"CD009730_pub3_data","Analysis.name","Antibiotic resistance"
"CD009730_pub3_data","Analysis.name","Adverse effects – antibiotic resistance"
"CD009730_pub3_data","Analysis.name","FEV1 % predicted change from baseline after 14 days"
"CD009730_pub3_data","Analysis.name","Quality of life – number of participants achieving a minimal clinically important difference in the CFQ-R respiratory domain"
"CD009730_pub3_data","Analysis.name","FEV1 (litres) (absolute change)"
"CD009730_pub3_data","Analysis.name","FVC (litres) (absolute change)"
"CD009730_pub3_data","Analysis.name","Proportion experiencing exacerbation 9–30 days post-treatment"
"CD009730_pub3_data","Analysis.name","FEV1"
"CD009730_pub3_data","Analysis.name","FVC"
"CD009730_pub3_data","Analysis.name","FEV1 % predicted absolute change from baseline "
"CD009730_pub3_data","Analysis.name","FEV1 % predicted relative change from baseline"
"CD009730_pub3_data","Analysis.name","Symptom score – change in CRISS score"
"CD009730_pub3_data","Analysis.name","Change in weight (kilograms) from baseline"
"CD009730_pub3_data","Analysis.name","Adverse events"
"CD009730_pub3_data","Analysis.name","Symptom score – change from baseline in CRISS score"
"CD009730_pub3_data","Subgroup","Ceftazidime 200 mg/kg/day"
"CD009730_pub3_data","Subgroup","Ticarcillin plus tobramycin"
"CD009730_pub3_data","Subgroup","Ceftazidime 2 g 3 times daily versus aztreonam 2 g 3 times daily"
"CD009730_pub3_data","Subgroup","Ceftazidime 8 g 4 times daily versus aztreonam 8 g 4 times daily"
"CD009730_pub3_data","Subgroup","Standard colistin (2.5 mg/kg/day 3 times daily) versus tobramycin"
"CD009730_pub3_data","Subgroup","Modified colistin (5 mg/kg/day twice daily) versus tobramycin"
"CD009730_pub3_data","Subgroup","Azlocillin plus placebo versus azlocillin plus tobramycin"
"CD009730_pub3_data","Subgroup","Oxacillin plus placebo versus oxacillin plus sisomycin plus carbenicillin"
"CD009730_pub3_data","Subgroup","Tobramycin plus placebo versus tobramycin plus ceftazidime"
"CD009730_pub3_data","Subgroup","Tobramycin plus placebo versus piperacillin 50 mg/kg (6 times daily) plus tobramycin"
"CD009730_pub3_data","Subgroup","Tobramycin plus placebo versus piperacillin 100 mg/kg (3 times daily) plus tobramycin"
"CD009730_pub3_data","Subgroup","Piperacillin (all regimens)"
"CD009730_pub3_data","Subgroup","Nephrotoxicity"
"CD009730_pub3_data","Subgroup","All adverse effects"
"CD009730_pub3_data","Subgroup","Ototoxicity"
"CD009730_pub3_data","Subgroup","Proteinuria"
"CD009730_pub3_data","Subgroup","Infusion site irritation"
"CD009730_pub3_data","Subgroup","Tinnitus"
"CD009730_pub3_data","Subgroup","N-acetyl glucosamine"
"CD009730_pub3_data","Subgroup","Creatinine"
"CD009730_pub3_data","Subgroup","Colistin versus colistin plus 'other'"
"CD009730_pub3_data","Subgroup","Aztreonam versus tobramycin plus azlocillin"
"CD009730_pub3_data","Subgroup","Ceftazidime versus tobramycin plus piperacillin"
"CD009730_pub3_data","Subgroup","Ceftazidime versus tobramycin plus ticarcillin"
"CD009730_pub3_data","Subgroup","Aztreonam versus azlocillin plus tobramycin"
"CD009730_pub3_data","Subgroup","Ceftazidime versus carbenicillin plus gentamicin"
"CD009730_pub3_data","Subgroup","Piperacillin versus piperacillin plus tobramycin"
"CD009730_pub3_data","Subgroup","Liver transaminase enzyme elevation"
"CD009730_pub3_data","Subgroup","Neurological adverse effects"
"CD009730_pub3_data","Subgroup","Rash"
"CD009730_pub3_data","Subgroup","Thrombophlebitis"
"CD009730_pub3_data","Subgroup","Fever"
"CD009730_pub3_data","Subgroup","Change in blood urea (mmol/L)"
"CD009730_pub3_data","Subgroup","Change in serum creatinine (mol/L)"
"CD009730_pub3_data","Subgroup","All antibiotics"
"CD009730_pub3_data","Subgroup","Ceftazidime versus gentamicin"
"CD009730_pub3_data","Subgroup","Ceftazidime versus carbenicillin"
"CD009730_pub3_data","Subgroup","Single antibiotic plus placebo versus combination regimen"
"CD009730_pub3_data","Subgroup","Single antibiotic (no placebo) versus combination regimen"
"CD009730_pub3_data","Subgroup","Single antibiotic with placebo versus combination regimen"
"CD009730_pub3_data","Subgroup","At 14 days"
"CD009730_pub3_data","Subgroup","At up to 1 month"
"CD009730_pub3_data","Subgroup","At 10 days"
"CD009730_pub3_data","Subgroup","At 4 weeks after end of treatment"
"CD009730_pub3_data","Subgroup","During treatment up to 10 days"
"CD009730_pub3_data","Subgroup","12-month follow-up"
"CD009730_pub3_data","Subgroup","During treatment"
"CD009730_pub3_data","Subgroup","At 10–17 days"
"CD009730_pub3_data","Subgroup","Liver transaminase elevation"
"CD009730_pub3_data","Subgroup","At 2 weeks"
"CD009730_pub3_data","Subgroup","Liver transaminases: aspartate aminotransferase and alanine aminotransferase"
"CD009730_pub3_data","Subgroup","Thrombocytopenia"
"CD009730_pub3_data","Subgroup","Raised liver transaminases"
"CD009730_pub3_data","Subgroup","At 3 months"
"CD009730_pub3_data","Subgroup","At 6 weeks"
"CD009730_pub3_data","Subgroup","Treatment-related events"
"CD009730_pub3_data","Subgroup","IV azlocillin plus IV gentamicin versus oral ciprofloxacin"
"CD009730_pub3_data","Subgroup","IV azlocillin plus IV tobramycin versus oral ciprofloxacin"
"CD009730_pub3_data","Subgroup","Any adverse event"
"CD009730_pub3_data","Subgroup","Serious adverse events"
"CD009749_pub3_data","Analysis.group","1"
"CD009749_pub3_data","Analysis.group","2"
"CD009749_pub3_data","Analysis.name","Live birth/ongoing pregnancy rate - DHEA"
"CD009749_pub3_data","Analysis.name","Live birth/ongoing pregnancy rate - T"
"CD009749_pub3_data","Analysis.name","Miscarriage rate - DHEA"
"CD009749_pub3_data","Analysis.name","Miscarriage rate - T"
"CD009749_pub3_data","Analysis.name","Clinical pregnancy rate - DHEA"
"CD009749_pub3_data","Analysis.name","Clinical pregnancy rate - T"
"CD009749_pub3_data","Analysis.name","Multiple pregnancy"
"CD009749_pub3_data","Analysis.name","Adverse effects to the woman"
"CD009749_pub3_data","Analysis.name","Pregnancy complications"
"CD009749_pub3_data","Analysis.name","Sensitivity analyses "
"CD009749_pub3_data","Analysis.name","Live birth/ongoing pregnancy"
"CD009749_pub3_data","Analysis.name","Clinical pregnancy rate"
"CD009749_pub3_data","Subgroup","DHEA 8 weeks"
"CD009749_pub3_data","Subgroup","DHEA 16 weeks"
"CD009749_pub3_data","Subgroup","DHEA 12 weeks"
"CD009749_pub3_data","Subgroup","7-12 days"
"CD009749_pub3_data","Subgroup","14 to 20 days"
"CD009749_pub3_data","Subgroup","21 to 28 days"
"CD009749_pub3_data","Subgroup","42 days"
"CD009749_pub3_data","Subgroup","56 days"
"CD009749_pub3_data","Subgroup","12 weeks"
"CD009749_pub3_data","Subgroup","16 weeks"
"CD009749_pub3_data","Subgroup","8 weeks"
"CD009749_pub3_data","Subgroup","21-28 days"
"CD009749_pub3_data","Subgroup","14-20 days"
"CD009749_pub3_data","Subgroup","DHEA"
"CD009749_pub3_data","Subgroup","Testosterone"
"CD009749_pub3_data","Subgroup","Insomnia"
"CD009749_pub3_data","Subgroup","Hot flushes"
"CD009749_pub3_data","Subgroup","Itch"
"CD009749_pub3_data","Subgroup","Increased acne - DHEA"
"CD009749_pub3_data","Subgroup","Gastrointestinal upset"
"CD009749_pub3_data","Subgroup","Hypertension"
"CD009749_pub3_data","Subgroup","Pre-term Birth"
"CD009749_pub3_data","Subgroup","Obstetric Cholestasis"
"CD009749_pub3_data","Subgroup","Live birth rate for Testosterone"
"CD009749_pub3_data","Subgroup","Live birth rate for DHEA "
"CD009749_pub3_data","Subgroup","Clinical pregnancy rate for DHEA"
"CD009749_pub3_data","Subgroup","Clinical pregnancy rate for Testosterone "
"CD009749_pub3_data","Subgroup","Miscarriage rate for Testosterone"
"CD009749_pub3_data","Subgroup","Miscarriage rate for DHEA"
"CD009749_pub3_data","Subgroup","Testosterone vs Estradiol + OCP"
"CD009749_pub3_data","Subgroup","Testosterone vs Estradiol"
"CD009752_pub3_data","Analysis.group","1"
"CD009752_pub3_data","Analysis.group","2"
"CD009752_pub3_data","Analysis.group","3"
"CD009752_pub3_data","Analysis.group","4"
"CD009752_pub3_data","Analysis.group","5"
"CD009752_pub3_data","Analysis.group","6"
"CD009752_pub3_data","Analysis.group","7"
"CD009752_pub3_data","Analysis.name","All-cause mortality: short term (0 to 30 days post surgery)"
"CD009752_pub3_data","Analysis.name","All-cause mortality: long term (31 days to two years post-surgery)"
"CD009752_pub3_data","Analysis.name","Severe adverse events: cardiac events"
"CD009752_pub3_data","Analysis.name","Severe adverse events: acute lung injury"
"CD009752_pub3_data","Analysis.name","Severe adverse events: stroke"
"CD009752_pub3_data","Analysis.name","Severe adverse events: thromboembolism"
"CD009752_pub3_data","Analysis.name","Severe adverse events: renal failure (needing renal replacement therapy) "
"CD009752_pub3_data","Analysis.name","Severe adverse events: infection"
"CD009752_pub3_data","Analysis.name","Severe adverse events: haemorrhage (return to theatre for bleeding)"
"CD009752_pub3_data","Analysis.name","Haemoglobin (g/dL) levels postoperatively "
"CD009752_pub3_data","Analysis.name","Number of participants receiving any red cell transfusion"
"CD009752_pub3_data","Analysis.name","Number of participants receiving any fresh frozen plasma "
"CD009752_pub3_data","Analysis.name","Number of participants receiving any platelet transfusion"
"CD009752_pub3_data","Analysis.name","Postoperative drain output mg/kg/hr"
"CD009752_pub3_data","Analysis.name","Postoperative chest drain output mL per participant"
"CD009752_pub3_data","Analysis.name","Duration of mechanical ventilation (hours)"
"CD009752_pub3_data","Analysis.name","Duration of ICU stay (days)"
"CD009752_pub3_data","Analysis.name","Cerebral oxygen content post surgery (rSO2)"
"CD009752_pub3_data","Analysis.name","'Peak' lactate levels (mmol/L)"
"CD009752_pub3_data","Analysis.name","All-cause mortality: long term (31 days to 2 years post-surgery)"
"CD009752_pub3_data","Analysis.name","Severe adverse event: thromboembolism"
"CD009752_pub3_data","Analysis.name","Haematocrit (%) levels postoperatively"
"CD009752_pub3_data","Analysis.name","Duration of intensive care unit stay (days)"
"CD009752_pub3_data","Analysis.name","Postoperative chest drain output (number of days of mediastinal drainage)"
"CD009752_pub3_data","Analysis.name","'Peak' lactate levels (mmol/L) "
"CD009752_pub3_data","Analysis.name","Lactate levels prior to cardiopulmonary bypass in prime"
"CD009752_pub3_data","Analysis.name","Lactate levels (mmol/L) in CPB circuit prime after line connection and 5 min recirculation"
"CD009752_pub3_data","Analysis.name","Lactate levels (mmol/L) at up to 15 minutes after the start of cardiopulmonary bypass"
"CD009752_pub3_data","Analysis.name","Lactate levels at 28 degrees during rewarming"
"CD009752_pub3_data","Analysis.name","Lactate levels (mmol/L) immediately after cardiopulmonary bypass and clamp of arterial cannula"
"CD009752_pub3_data","Analysis.name","Sodium (Na+) levels (mmol/L) prior to cardiopulmonary bypass in prime"
"CD009752_pub3_data","Analysis.name","Sodium (Na+) levels (mmol/L) at 36 degrees after rewarming"
"CD009752_pub3_data","Analysis.name","Sodium (Na+) levels (mmol/L) immediately after cardiopulmonary bypass and clamp of arterial cannula"
"CD009752_pub3_data","Analysis.name","Potassium (K+) levels (mmol/L) prior to cardiopulmonary bypass in prime"
"CD009752_pub3_data","Analysis.name","Potassium (K+) levels (mmol/L) at 28 degrees during rewarming"
"CD009752_pub3_data","Analysis.name","Potassium (K+) levels (mmol/L) immediately after cardiopulmonary bypass and clamp of arterial cannula"
"CD009752_pub3_data","Analysis.name","Blood glucose (mg/dL) in prime prior to CPB "
"CD009752_pub3_data","Analysis.name","Blood glucose levels (mg/dL) at up to 15 minutes after the start of cardiopulmonary bypass"
"CD009752_pub3_data","Analysis.name","Oxygen content post surgery CaO2 (ml dl-1)"
"CD009752_pub3_data","Analysis.name","All-cause mortality: short term (0 to 30 days post-surgery)"
"CD009752_pub3_data","Analysis.name","Duration of intensive care unit stay"
"CD009752_pub3_data","Analysis.name","Lactate levels (mmol/L at up to 15 minutes after the start of cardiopulmonary bypass"
"CD009752_pub3_data","Analysis.name","Severe adverse events: renal failure (creatinine increasing at least twofold within 72 hours of surgery) "
"CD009752_pub3_data","Subgroup","Postoperative day 2"
"CD009752_pub3_data","Subgroup","Postoperative day 1"
"CD009752_pub3_data","Subgroup","Postoperative day 0"
"CD009788_pub3_data","Analysis.group","1"
"CD009788_pub3_data","Analysis.name","Service use: hospitalization"
"CD009788_pub3_data","Analysis.name","Functioning – general"
"CD009788_pub3_data","Analysis.name","Satisfaction with care: clinically important change in satisfaction"
"CD009788_pub3_data","Analysis.name","Global state (secondary outcomes)"
"CD009788_pub3_data","Analysis.name","Service use: number of hospitalizations"
"CD009788_pub3_data","Analysis.name","Service use: time in hospital (days)"
"CD009788_pub3_data","Analysis.name","Service use: emergency care visits"
"CD009788_pub3_data","Analysis.name","Functioning – specific: social skills"
"CD009788_pub3_data","Analysis.name","Mental state"
"CD009788_pub3_data","Analysis.name","Quality of life"
"CD009788_pub3_data","Analysis.name","Leaving the study early"
"CD009788_pub3_data","Subgroup","Long-term follow-up"
"CD009788_pub3_data","Subgroup","Short-term follow-up (3–6 months)"
"CD009788_pub3_data","Subgroup","Multnomah Community Ability Scale (MCASA)"
"CD009788_pub3_data","Subgroup","Health Promoting Lifestyle Profile (HPLP)"
"CD009788_pub3_data","Subgroup","Activities of Daily Living (ADL)"
"CD009788_pub3_data","Subgroup","Discharge list (DL)"
"CD009788_pub3_data","Subgroup","Substance Dependence Severity Scale (SDSS)"
"CD009788_pub3_data","Subgroup","Brief Psychiatric Rating Scale (BPRS)"
"CD009788_pub3_data","Subgroup","Hamilton Rating Scale for Depression (HAM-D)"
"CD009788_pub3_data","Subgroup","Brief Symptom Inventory"
"CD009788_pub3_data","Subgroup","Short-term follow-up"
"CD009945_pub3_data","Analysis.group","1"
"CD009945_pub3_data","Analysis.name","50% responder"
"CD009945_pub3_data","Analysis.name","Treatment withdrawal"
"CD009945_pub3_data","Analysis.name","Any adverse effects"
"CD010001_pub4_data","Analysis.group","1"
"CD010001_pub4_data","Analysis.group","2"
"CD010001_pub4_data","Analysis.group","3"
"CD010001_pub4_data","Analysis.group","4"
"CD010001_pub4_data","Analysis.name","Live birth or ongoing pregnancy"
"CD010001_pub4_data","Analysis.name","Vasodilator side effects"
"CD010001_pub4_data","Analysis.name","Specific vasodilator side effects"
"CD010001_pub4_data","Analysis.name","Clinical pregnancy"
"CD010001_pub4_data","Analysis.name","Endometrial thickness"
"CD010001_pub4_data","Analysis.name","Other adverse effects"
"CD010001_pub4_data","Analysis.name","Clinical pregnancy: vasodilators versus placebo or no treatment"
"CD010001_pub4_data","Analysis.name","Endometrial thickness: vasodilators versus placebo or not treatment"
"CD010001_pub4_data","Analysis.name","Clinical pregnancy: vasodilators versus oestrogens"
"CD010001_pub4_data","Analysis.name","Live birth or ongoing pregnancy: vasodilators versus placebo or no treatment"
"CD010001_pub4_data","Analysis.name","Side effects: vasodilators versus placebo or no treatment"
"CD010001_pub4_data","Analysis.name","Clinical pregnancy: vasodilator versus placebo or no treatment"
"CD010001_pub4_data","Analysis.name","Endometrial thickness: vasodilator versus placebo or no treatment"
"CD010001_pub4_data","Analysis.name","Clinical pregnancy: vasodilator versus oestrogen"
"CD010001_pub4_data","Analysis.name","Endometrial thickness: vasodilators versus oestrogens"
"CD010001_pub4_data","Subgroup","Pentoxifylline + vitamin E"
"CD010001_pub4_data","Subgroup","Nifedipine"
"CD010001_pub4_data","Subgroup","Glyceryl trinitrate"
"CD010001_pub4_data","Subgroup","Sildenafil"
"CD010001_pub4_data","Subgroup","Isosorbide mononitrate"
"CD010001_pub4_data","Subgroup","Tachycardia"
"CD010001_pub4_data","Subgroup","Dizziness"
"CD010001_pub4_data","Subgroup","Hot flushes"
"CD010001_pub4_data","Subgroup","Headache"
"CD010001_pub4_data","Subgroup","Hypotension"
"CD010001_pub4_data","Subgroup","Blurred vision"
"CD010001_pub4_data","Subgroup","Gastrointestinal disturbances"
"CD010001_pub4_data","Subgroup","Pentoxifylline (PTX) + vitamin E"
"CD010001_pub4_data","Subgroup","Tadalafil"
"CD010001_pub4_data","Subgroup","Sildenafil + oestrogen"
"CD010001_pub4_data","Subgroup","Amlodipine"
"CD010001_pub4_data","Subgroup","Pentoxifylline"
"CD010001_pub4_data","Subgroup","Multiple gestation or birth"
"CD010001_pub4_data","Subgroup","Ectopic pregnancy"
"CD010001_pub4_data","Subgroup","Miscarriage"
"CD010001_pub4_data","Subgroup","Hot flashes"
"CD010001_pub4_data","Subgroup","Sildenafil versus oestrogens"
"CD010001_pub4_data","Subgroup","Sildenafil + oestrogens versus oestrogens"
"CD010001_pub4_data","Subgroup","Spontaneous miscarriage"
"CD010001_pub4_data","Subgroup","Thin endometrium among inclusion criteria"
"CD010001_pub4_data","Subgroup","Thin endometrium not among inclusion criteria"
"CD010001_pub4_data","Subgroup","Oral administration"
"CD010001_pub4_data","Subgroup","Skin patches"
"CD010001_pub4_data","Subgroup","Sublingual spray"
"CD010001_pub4_data","Subgroup","Vaginal route of administration"
"CD010001_pub4_data","Subgroup","Vaginal administration"
"CD010136_pub4_data","Analysis.group","1"
"CD010136_pub4_data","Analysis.group","2"
"CD010136_pub4_data","Analysis.name","Swelling at 7 days"
"CD010136_pub4_data","Analysis.name","Number of participants who required ibuprofen"
"CD010136_pub4_data","Analysis.name","Pain at 24 hours"
"CD010136_pub4_data","Analysis.name","Pain at 48 hours"
"CD010136_pub4_data","Analysis.name","Pain at 72 hours"
"CD010136_pub4_data","Analysis.name","Pain at 7 days"
"CD010136_pub4_data","Analysis.name","Swelling at 24 hours"
"CD010136_pub4_data","Analysis.name","Swelling at 48 hours"
"CD010136_pub4_data","Analysis.name","Swelling at 72 hours"
"CD010136_pub4_data","Analysis.name","Percussion pain at 24 hours"
"CD010136_pub4_data","Analysis.name","Percussion pain at 48 hours"
"CD010136_pub4_data","Analysis.name","Percussion pain at 72 hours"
"CD010136_pub4_data","Analysis.name","Percussion pain at 7 days"
"CD010136_pub4_data","Analysis.name","Incidence of endodontic flare-up"
"CD010136_pub4_data","Analysis.name","Total number of ibuprofen tablets"
"CD010136_pub4_data","Analysis.name","Total number of paracetamol (acetaminophen) with codeine tablets"
"CD010145_pub2_data","Analysis.group","1"
"CD010145_pub2_data","Analysis.group","2"
"CD010145_pub2_data","Analysis.group","3"
"CD010145_pub2_data","Analysis.name","Quality of life via FACT (short term)"
"CD010145_pub2_data","Analysis.name","Change in quality of life after treatment via QLQ-C30 (short term)"
"CD010145_pub2_data","Analysis.name","Change in quality of life after treatment via QLI (short term)"
"CD010145_pub2_data","Analysis.name","Quality of life via FACT (intermediate term)"
"CD010145_pub2_data","Analysis.name","Change in sleep after treatment via PSQI (short term)"
"CD010145_pub2_data","Analysis.name","Adverse event (headache)"
"CD010145_pub2_data","Analysis.name","Adverse event (fatigue)"
"CD010145_pub2_data","Analysis.name","Adverse event (nausea)"
"CD010145_pub2_data","Analysis.name","One-year survival rate"
"CD010145_pub2_data","Analysis.name","Two-year survival rate"
"CD010145_pub2_data","Analysis.name","Three-year survival rate"
"CD010145_pub2_data","Analysis.name","Two-year disease-free survival (DFS) rate"
"CD010145_pub2_data","Analysis.name","Five-year disease-free survival (DFS) rate"
"CD010145_pub2_data","Analysis.name","Tumour complete response rate (CR) (short term)"
"CD010145_pub2_data","Analysis.name","Tumour partial response rate (PR) (short term)"
"CD010145_pub2_data","Analysis.name","Tumour stable disease rate (SD) (short term)"
"CD010145_pub2_data","Analysis.name","Tumour progressive disease rate (PD) (short term)"
"CD010145_pub2_data","Analysis.name","Positive tumour response rate (CR + PR) (intermediate term)"
"CD010145_pub2_data","Analysis.name","Negative tumour response rate (SD + PD) (intermediate term)"
"CD010145_pub2_data","Analysis.name","Improvement in quality of life via Karnofsky's score"
"CD010145_pub2_data","Analysis.name","Five-year survival rate"
"CD010145_pub2_data","Analysis.name","Progression-free survival (PFS)"
"CD010145_pub2_data","Analysis.name","One-year disease-free survival (DFS) rate"
"CD010145_pub2_data","Analysis.name","Tumour complete response rate (CR) defined by RECIST (intermediate term)"
"CD010145_pub2_data","Analysis.name","Tumour partial response rate (PR) defined by RECIST (intermediate term)"
"CD010145_pub2_data","Analysis.name","Tumour stable disease rate (SD) defined by RECIST (intermediate term)"
"CD010145_pub2_data","Analysis.name","Tumour progressive disease rate (PD) defined by RECIST (intermediate term)"
"CD010145_pub2_data","Analysis.name","Tumour complete response rate (CR) defined by RECIST (long term)"
"CD010145_pub2_data","Analysis.name","Tumour partial response rate (PR) defined by RECIST (long term)"
"CD010145_pub2_data","Analysis.name","Tumour stable disease rate (SD) defined by RECIST (long term)"
"CD010145_pub2_data","Analysis.name","Tumour progressive disease rate (PD) defined by RECIST (long term)"
"CD010145_pub2_data","Analysis.name","(Additional table) CR until progression of the disease"
"CD010145_pub2_data","Analysis.name","(Additional table) PR until progression of the disease"
"CD010145_pub2_data","Analysis.name","(Additional table) SD until progression of the disease"
"CD010145_pub2_data","Analysis.name","(Additional table) PD until progression of the disease"
"CD010145_pub2_data","Analysis.name","One-year survival rate without Novik 2021"
"CD010145_pub2_data","Analysis.name","Adverse events (related to the study treatment)"
"CD010145_pub2_data","Analysis.name","Incidence of anaemia at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of neutropenia at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of nausea at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of vomiting at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of anorexia at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of renal failure at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of oral mucositis at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of cheilitis at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of radiation skin injury at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of dermatitis at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of allergies at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of pneumonia at least grade 3"
"CD010145_pub2_data","Analysis.name","Incidence of asthenia at least grade 3"
"CD010145_pub2_data","Subgroup","Melatonin plus chemotherapy versus placebo plus chemotherapy"
"CD010145_pub2_data","Subgroup","Melatonin plus surgery versus placebo plus surgery"
"CD010145_pub2_data","Subgroup","Melatonin plus surgery versus placebo plus surgery "
"CD010145_pub2_data","Subgroup","Melatonin plus chemotherapy versus chemotherapy"
"CD010145_pub2_data","Subgroup","Melatonin plus immunotherapy versus immunotherapy"
"CD010145_pub2_data","Subgroup","Melatonin plus hormonotherapy versus hormonotherapy"
"CD010145_pub2_data","Subgroup","Melatonin plus radiotherapy versus radiotherapy"
"CD010145_pub2_data","Subgroup","Melatonin plus supportive care versus supportive care"
"CD010145_pub2_data","Subgroup","Melatonin plus surgery versus surgery"
"CD010163_pub3_data","Analysis.group","1"
"CD010163_pub3_data","Analysis.group","2"
"CD010163_pub3_data","Analysis.name","Tumour response"
"CD010163_pub3_data","Analysis.name","All-cause mortality at 2-year follow-up"
"CD010163_pub3_data","Analysis.name","Any adverse events or complications"
"CD010163_pub3_data","Analysis.name","Recurrence of liver metastases "
"CD010163_pub3_data","Subgroup","Distant recurrence"
"CD010163_pub3_data","Subgroup","Local progression"
"CD010189_pub3_data","Analysis.group","1"
"CD010189_pub3_data","Analysis.name","Overall survival"
"CD010189_pub3_data","Analysis.name","Disease free survival"
"CD010189_pub3_data","Analysis.name","Incidence of non-relapse or transplant-related mortality"
"CD010189_pub3_data","Analysis.name","Incidence of extensive chronic GvHD"
"CD010189_pub3_data","Analysis.name","Incidence of acute GvHD grade III-IV"
"CD010189_pub3_data","Analysis.name","Incidence of overall chronic GvHD"
"CD010189_pub3_data","Analysis.name","Incidence of relapse"
"CD010189_pub3_data","Analysis.name","Time to platelet engraftment"
"CD010189_pub3_data","Analysis.name","Time to neutrophil engraftment"
"CD010189_pub3_data","Analysis.name","Incidence of acute GvHD grade II-IV"
"CD010189_pub3_data","Subgroup","Related donor"
"CD010189_pub3_data","Subgroup","Unrelated donor"
"CD010216_pub9_data","Analysis.group","1"
"CD010216_pub9_data","Analysis.group","2"
"CD010216_pub9_data","Analysis.group","3"
"CD010216_pub9_data","Analysis.group","4"
"CD010216_pub9_data","Analysis.group","5"
"CD010216_pub9_data","Analysis.group","6"
"CD010216_pub9_data","Analysis.group","7"
"CD010216_pub9_data","Analysis.group","8"
"CD010216_pub9_data","Analysis.group","9"
"CD010216_pub9_data","Analysis.group","10"
"CD010216_pub9_data","Analysis.group","11"
"CD010216_pub9_data","Analysis.group","12"
"CD010216_pub9_data","Analysis.group","13"
"CD010216_pub9_data","Analysis.group","14"
"CD010216_pub9_data","Analysis.group","15"
"CD010216_pub9_data","Analysis.group","16"
"CD010216_pub9_data","Analysis.group","17"
"CD010216_pub9_data","Analysis.name","Smoking cessation"
"CD010216_pub9_data","Analysis.name","Adverse events"
"CD010216_pub9_data","Analysis.name","Serious adverse events"
"CD010216_pub9_data","Analysis.name","Carbon monoxide (ppm)"
"CD010216_pub9_data","Analysis.name","Heart rate (bpm)"
"CD010216_pub9_data","Analysis.name","Systolic blood pressure"
"CD010216_pub9_data","Analysis.name","Blood oxygen saturation"
"CD010216_pub9_data","Analysis.name","3-HPMA (pmol/mg creatinine)"
"CD010216_pub9_data","Analysis.name","NNAL (pmol/mg creatinine))"
"CD010216_pub9_data","Analysis.name","2-HPMA (pmol/mg creatinine)"
"CD010216_pub9_data","Analysis.name","HMPMA (pmol/mg creatinine)"
"CD010216_pub9_data","Analysis.name","PheT (pmol/mg creatinine)"
"CD010216_pub9_data","Analysis.name","CEMA (pmol/mg creatinine)"
"CD010216_pub9_data","Analysis.name","AAMA (pmol/mg creatinine)"
"CD010216_pub9_data","Analysis.name","FEV1"
"CD010216_pub9_data","Analysis.name","FEV1/FVC (%)"
"CD010216_pub9_data","Analysis.name","PEF (L/min)"
"CD010216_pub9_data","Analysis.name","Product use at 6+ months"
"CD010216_pub9_data","Analysis.name","Adverse events at 12 weeks"
"CD010216_pub9_data","Analysis.name","SAEs at 12 weeks"
"CD010216_pub9_data","Analysis.name","Carbon monoxide (ppm) absolute values at 12 weeks"
"CD010216_pub9_data","Analysis.name","VO2 Max at 12 weeks"
"CD010216_pub9_data","Analysis.name","Heart rate"
"CD010216_pub9_data","Analysis.name","FeNO (ppb)"
"CD010216_pub9_data","Analysis.name","FEV1 (l)"
"CD010216_pub9_data","Analysis.name","FEV1/FVC"
"CD010216_pub9_data","Analysis.name","NNAL (pmol/mg creatinine)"
"CD010216_pub9_data","Analysis.name","3-HPMA (SMD)"
"CD010216_pub9_data","Analysis.name","NNAL (SMD)"
"CD010216_pub9_data","Analysis.name","S-PMA (nanograms)"
"CD010216_pub9_data","Analysis.name","FEV1 (SMD)"
"CD010216_pub9_data","Analysis.name","FEF 25-75 (litres/second))"
"CD010216_pub9_data","Analysis.name","PEF 25-75 (litres/minute)"
"CD010216_pub9_data","Analysis.name","Adverse events at 1 week"
"CD010216_pub9_data","Analysis.name","FVC (l)"
"CD010216_pub9_data","Analysis.name","NNAL (pg/mg creatinine) at 24 weeks"
"CD010216_pub9_data","Analysis.name","NNAL (ng/g)"
"CD010216_pub9_data","Analysis.name","FEV1 (% predicted)"
"CD010216_pub9_data","Analysis.name","Exhaled CO"
"CD010216_pub9_data","Analysis.name","Serious adverse events at 24 weeks"
"CD010216_pub9_data","Analysis.name","Change in carbon monoxide (ppm) at 6 months"
"CD010216_pub9_data","Analysis.name","Adverse events at 3 months"
"CD010216_pub9_data","Analysis.name","Serious adverse events at 3 months"
"CD010216_pub9_data","Analysis.name","FEV1 (%)"
"CD010216_pub9_data","Analysis.name","FVC (%)"
"CD010216_pub9_data","Analysis.name","Study product use at 6+ months"
"CD010216_pub9_data","Analysis.name","Serious adverse events at 12 weeks"
"CD010216_pub9_data","Subgroup","Not selected on pregnancy"
"CD010216_pub9_data","Subgroup","Pregnant population"
"CD010216_pub9_data","Subgroup","12 weeks"
"CD010216_pub9_data","Subgroup","4 weeks"
"CD010216_pub9_data","Subgroup","6 months"
"CD010216_pub9_data","Subgroup","3 months after end of pregnancy"
"CD010216_pub9_data","Subgroup","1 year"
"CD010216_pub9_data","Subgroup","Absolute values at follow-up"
"CD010216_pub9_data","Subgroup","Change from baseline"
"CD010216_pub9_data","Subgroup","1 week"
"CD010216_pub9_data","Subgroup","8 weeks"
"CD010216_pub9_data","Subgroup","16 weeks"
"CD010216_pub9_data","Subgroup","4 to 6 weeks"
"CD010216_pub9_data","Subgroup","8 months"
"CD010216_pub9_data","Subgroup","change from baseline"
"CD010216_pub9_data","Subgroup","7 months"
"CD010216_pub9_data","Subgroup","5 weeks"
"CD010290_pub4_data","Analysis.group","1"
"CD010290_pub4_data","Analysis.group","2"
"CD010290_pub4_data","Analysis.group","3"
"CD010290_pub4_data","Analysis.group","4"
"CD010290_pub4_data","Analysis.name","Live birth rate per woman by urinary gonadotropins"
"CD010290_pub4_data","Analysis.name","Live birth rate per woman by sponsor"
"CD010290_pub4_data","Analysis.name","Multiple pregnancy per woman by urinary gonadotropins"
"CD010290_pub4_data","Analysis.name","Multiple pregnancy per woman by sponsor"
"CD010290_pub4_data","Analysis.name","Clinical pregnancy rate per woman by urinary gonadotropins"
"CD010290_pub4_data","Analysis.name","Multiple pregnancy per clinical pregnancy by urinary gonadotropins"
"CD010290_pub4_data","Analysis.name","Miscarriage rate per woman by urinary gonadotropins"
"CD010290_pub4_data","Analysis.name","Ectopic pregnancy "
"CD010290_pub4_data","Analysis.name","Incidence of OHSS per woman by urinary gonadotropins"
"CD010290_pub4_data","Analysis.name","Total gonadotrophin dose per woman (IU) by urinary gonadotropins"
"CD010290_pub4_data","Analysis.name","Total duration of stimulation per woman (days) by urinary gonadotropins"
"CD010290_pub4_data","Analysis.name","Sensitivity analysis: live birth rate per woman - low risk studies"
"CD010290_pub4_data","Analysis.name","Sensitivity analysis: live birth rate per woman - random effects model"
"CD010290_pub4_data","Analysis.name","Sensitivity analysis: live birth rate per woman - odds ratio"
"CD010290_pub4_data","Analysis.name","Sensitivity analysis: multiple pregnancy per woman - low risk studies"
"CD010290_pub4_data","Analysis.name","Sensitivity analysis: multiple pregnancy per woman - random effects model"
"CD010290_pub4_data","Analysis.name","Sensitivity analysis: multiple pregnancy per woman - odds ratio"
"CD010290_pub4_data","Analysis.name","Live birth rate per woman"
"CD010290_pub4_data","Analysis.name","Multiple pregnancy per woman"
"CD010290_pub4_data","Analysis.name","Clinical pregnancy rate per woman"
"CD010290_pub4_data","Analysis.name","Multiple pregnancy per clinical pregnancy"
"CD010290_pub4_data","Analysis.name","Miscarriage rate per woman"
"CD010290_pub4_data","Analysis.name","Incidence of OHSS per woman"
"CD010290_pub4_data","Analysis.name","Ongoing pregnancy rate per woman"
"CD010290_pub4_data","Analysis.name","Multiple pregnancy (per clinical pregnancy)"
"CD010290_pub4_data","Analysis.name","Ectopic pregnancy per woman"
"CD010290_pub4_data","Analysis.name","Stillbirth"
"CD010290_pub4_data","Analysis.name","Birthweight per live birth"
"CD010290_pub4_data","Subgroup","rFSH versus HP-HMG"
"CD010290_pub4_data","Subgroup","rFSH versus HP-FSH"
"CD010290_pub4_data","Subgroup","rFSH versus uFSH"
"CD010290_pub4_data","Subgroup","Ferring"
"CD010290_pub4_data","Subgroup","unknown"
"CD010290_pub4_data","Subgroup","MSD - Organon"
"CD010290_pub4_data","Subgroup","Merck - Serono"
"CD010290_pub4_data","Subgroup","Unknown"
"CD010333_pub4_data","Analysis.group","1"
"CD010333_pub4_data","Analysis.name","Cerebral palsy"
"CD010333_pub4_data","Analysis.name","Mental Developmental Index (Bayley II) at 18 to 22 months' corrected age"
"CD010333_pub4_data","Analysis.name","Normal auditory functioning at discharge (measured using automated auditory brainstem response)"
"CD010333_pub4_data","Analysis.name","All-cause mortality during hospital stay"
"CD010333_pub4_data","Analysis.name","Weight (kg) at 18 to 22 months' corrected age"
"CD010333_pub4_data","Analysis.name","Height (cm) at 18 to 22 months' corrected age"
"CD010333_pub4_data","Analysis.name","Days of assisted ventilation"
"CD010333_pub4_data","Analysis.name","Days of initial hospitalisation"
"CD010441_pub3_data","Analysis.group","1"
"CD010441_pub3_data","Analysis.group","2"
"CD010441_pub3_data","Analysis.name","Incidence of perineal trauma (tears or episiotomy or both)"
"CD010441_pub3_data","Analysis.name","Incidence of episiotomy"
"CD010441_pub3_data","Analysis.name","Incidence of first and second degree perineal lacerations"
"CD010441_pub3_data","Analysis.name","Incidence of third and fourth degree perineal trauma"
"CD010441_pub3_data","Analysis.name","Incidence of perineal oedema 1 hour after vaginal delivery"
"CD010441_pub3_data","Analysis.name","Incidence of perineal oedema 24 hours after vaginal delivery"
"CD010441_pub3_data","Analysis.name","Incidence of neonatal Apgar scores less than 7 at five minutes"
"CD010533_pub3_data","Analysis.group","1"
"CD010533_pub3_data","Analysis.group","2"
"CD010533_pub3_data","Analysis.group","3"
"CD010533_pub3_data","Analysis.group","4"
"CD010533_pub3_data","Analysis.group","5"
"CD010533_pub3_data","Analysis.group","6"
"CD010533_pub3_data","Analysis.group","7"
"CD010533_pub3_data","Analysis.group","8"
"CD010533_pub3_data","Analysis.group","9"
"CD010533_pub3_data","Analysis.group","10"
"CD010533_pub3_data","Analysis.group","11"
"CD010533_pub3_data","Analysis.group","12"
"CD010533_pub3_data","Analysis.name","Overall survival (OS)"
"CD010533_pub3_data","Analysis.name","Progression-free survival (PFS)"
"CD010533_pub3_data","Analysis.name","Treatment-related mortality"
"CD010533_pub3_data","Analysis.name","Incidence of second primary malignancy"
"CD010533_pub3_data","Analysis.name","Serious adverse events"
"CD010533_pub3_data","Analysis.name","Overall survival"
"CD010533_pub3_data","Analysis.name","Progression-free survival"
"CD010533_pub3_data","Analysis.name","Adverse events, grade 3-4"
"CD010533_pub3_data","Analysis.name","Any grade adverse event"
"CD010533_pub3_data","Analysis.name","Incidence of secondary malignancy"
"CD010533_pub3_data","Analysis.name","progression-free survival"
"CD010533_pub3_data","Subgroup","Additional chemotherapy in adaptation arm"
"CD010533_pub3_data","Subgroup","No additional chemotherapy in adaptation arm"
"CD010533_pub3_data","Subgroup","Additional chemotherapy in de-escalation arm"
"CD010533_pub3_data","Subgroup","No additional chemotherapy in de-escalation arm"
"CD010533_pub3_data","Subgroup","NLPHL"
"CD010533_pub3_data","Subgroup","Additional chemotherapy in treatment adaptation arm"
"CD010533_pub3_data","Subgroup","No additional chemotherapy in treatment adaptation arm"
"CD010533_pub3_data","Subgroup","ABVD as initial treatment"
"CD010533_pub3_data","Subgroup","BEACOPP as initial treatment"
"CD010583_pub6_data","Analysis.group","1"
"CD010583_pub6_data","Analysis.group","2"
"CD010583_pub6_data","Analysis.group","3"
"CD010583_pub6_data","Analysis.group","4"
"CD010583_pub6_data","Analysis.name","Mortality (30 days)"
"CD010583_pub6_data","Analysis.name","Mortality (90 days)"
"CD010583_pub6_data","Analysis.name","Intra-abdominal infection"
"CD010583_pub6_data","Analysis.name","Wound infection"
"CD010583_pub6_data","Analysis.name","Morbidity"
"CD010583_pub6_data","Analysis.name","Length of hospital stay (days)"
"CD010583_pub6_data","Analysis.name","Additional open procedures for postoperative complications"
"CD010583_pub6_data","Analysis.name","Additional radiological interventions for postoperative complications"
"CD010583_pub6_data","Analysis.name","Hospital costs"
"CD010583_pub6_data","Subgroup","Open pancreaticoduodenectomy"
"CD010583_pub6_data","Subgroup","Open or laparoscopic pancreaticoduodenectomy"
"CD010583_pub6_data","Subgroup","Open or laparoscopic distal pancreatectomy"
"CD010583_pub6_data","Subgroup","Open, laparoscopic, or robotic distal pancreatectomy"
"CD010583_pub6_data","Subgroup","Open, laparoscopic, or robotic pancreaticoduodenectomy"
"CD010779_pub2_data","Analysis.group","1"
"CD010779_pub2_data","Analysis.group","2"
"CD010779_pub2_data","Analysis.name","Passive range of motion without standardised force"
"CD010779_pub2_data","Analysis.name","Passive range of motion with standardised force "
"CD010779_pub2_data","Analysis.name","Stiffness (newton-metres)"
"CD010779_pub2_data","Analysis.name","Pain"
"CD010779_pub2_data","Analysis.name","Function"
"CD010779_pub2_data","Analysis.name","Passive range of motion with standardised force"
"CD010779_pub2_data","Subgroup","Shoulder flexion"
"CD010779_pub2_data","Subgroup","Wrist extension"
"CD010779_pub2_data","Subgroup","Elbow extension"
"CD010856_pub3_data","Analysis.group","1"
"CD010856_pub3_data","Analysis.name","Change in the number of decayed, missing or filled primary teeth (dmft)"
"CD010856_pub3_data","Analysis.name","Change in the number of decayed, missing or filled permanent teeth (DMFT)"
"CD010856_pub3_data","Analysis.name","Change in the number of decayed, missing or filled permanent surfaces (DMFS) "
"CD010856_pub3_data","Analysis.name","Change in the proportion of caries-free participants (primary teeth)"
"CD010856_pub3_data","Analysis.name","Change in the proportion of caries-free participants (permanent teeth)"
"CD010856_pub3_data","Analysis.name","Sensitivity analysis - all included studies: change in the number of decayed, missing or filled primary teeth (dmft)"
"CD010856_pub3_data","Analysis.name","Sensitivity analysis - all included studies: change in the number of decayed, missing or filled permanent teeth (DMFT)"
"CD010856_pub3_data","Analysis.name","Sensitivity analysis - all included studies: change in the proportion of caries-free participants (primary teeth)"
"CD010856_pub3_data","Analysis.name","Sensitivity analysis - all included studies: change in the proportion of caries-free participants (permanent teeth)"
"CD010856_pub3_data","Analysis.name","Sensitivity analysis - change in analytical approach: change in the number of decayed, missing or filled primary teeth (dmft)"
"CD010856_pub3_data","Analysis.name","Sensitivity analysis - excluding studies with imputed standard deviations: change in the number of decayed, missing or filled primary teeth (dmft)"
"CD010856_pub3_data","Analysis.name","Sensitivity analysis - excluding studies with imputed standard deviations: change in the number of decayed, missing or filled permanent teeth (DMFT)"
"CD010856_pub3_data","Subgroup","Studies conducted in 1975 or earlier"
"CD010856_pub3_data","Subgroup","Studies conducted after 1975"
"CD010861_pub3_data","Analysis.group","1"
"CD010861_pub3_data","Analysis.group","2"
"CD010861_pub3_data","Analysis.group","3"
"CD010861_pub3_data","Analysis.group","4"
"CD010861_pub3_data","Analysis.group","5"
"CD010861_pub3_data","Analysis.group","6"
"CD010861_pub3_data","Analysis.group","7"
"CD010861_pub3_data","Analysis.group","8"
"CD010861_pub3_data","Analysis.name","Maternal mortality"
"CD010861_pub3_data","Analysis.name","Fatigue 0-7 days"
"CD010861_pub3_data","Analysis.name","Fatigue 8-28 days"
"CD010861_pub3_data","Analysis.name","Fatigue > 28 days"
"CD010861_pub3_data","Analysis.name","Psychological wellbeing"
"CD010861_pub3_data","Analysis.name","Infection"
"CD010861_pub3_data","Analysis.name","Compliance to treatment"
"CD010861_pub3_data","Analysis.name","Serious adverse events"
"CD010861_pub3_data","Analysis.name","Anaphylaxis or evidence of hypersensitivity"
"CD010861_pub3_data","Analysis.name","Flushing/Fishbane reaction"
"CD010861_pub3_data","Analysis.name","Injection site discomfort / reaction"
"CD010861_pub3_data","Analysis.name","Constipation"
"CD010861_pub3_data","Analysis.name","Nausea"
"CD010861_pub3_data","Analysis.name","Gastrointestinal pain"
"CD010861_pub3_data","Analysis.name","Number of RBC transfused women"
"CD010861_pub3_data","Analysis.name","Hb (g/dL) 0-7 days"
"CD010861_pub3_data","Analysis.name","Hb (g/dL) 8-28 days"
"CD010861_pub3_data","Analysis.name","Hg (g/dL) > 28 days"
"CD010861_pub3_data","Analysis.name","Maternal mortality "
"CD010861_pub3_data","Analysis.name","Breastfeeding at hospital discharge"
"CD010861_pub3_data","Analysis.name","Breastfeeding > 6 weeks postpartum"
"CD010861_pub3_data","Analysis.name","Hb (g/dL) > 28 days"
"CD010861_pub3_data","Analysis.name","Persistent anaemia symptoms"
"CD010861_pub3_data","Analysis.name","Length of hospital stay"
"CD010861_pub3_data","Analysis.name","IV vs. oral iron - Hb (g/dL) 0-7 days (iron dosage and type)"
"CD010861_pub3_data","Analysis.name","IV vs. oral iron - Hb (g/dL) 8-28 days (iron dosage and type)"
"CD010861_pub3_data","Analysis.name","IV vs. oral iron - Hb (g/dL) > 28 days (iron dosage and type)"
"CD010861_pub3_data","Analysis.name","IV vs. oral iron - Hb (g/dL) 0-7 days (bias in allocation excluded)"
"CD010861_pub3_data","Analysis.name","IV vs. oral iron - Hb (g/dL) 8-28 days (bias in allocation excluded)"
"CD010861_pub3_data","Analysis.name","IV vs. oral iron - Hb (g/dL) > 28 days (bias in allocation excluded)"
"CD010861_pub3_data","Subgroup","Low dose iron (total of 400-900 mg. iron sucrose divided in 2-3 doses)"
"CD010861_pub3_data","Subgroup","High dose iron (≥ 1000 mg ferrous carboxymaltose or isomaltoside)"
"CD010861_pub3_data","Subgroup","High dose iron (≥ 1000 mg ferrous carboxymaltose, isomaltoside or dextran)"
"CD010966_pub4_data","Analysis.group","1"
"CD010966_pub4_data","Analysis.group","2"
"CD010966_pub4_data","Analysis.group","3"
"CD010966_pub4_data","Analysis.group","4"
"CD010966_pub4_data","Analysis.group","5"
"CD010966_pub4_data","Analysis.group","6"
"CD010966_pub4_data","Analysis.group","7"
"CD010966_pub4_data","Analysis.group","8"
"CD010966_pub4_data","Analysis.group","9"
"CD010966_pub4_data","Analysis.group","10"
"CD010966_pub4_data","Analysis.group","11"
"CD010966_pub4_data","Analysis.group","12"
"CD010966_pub4_data","Analysis.group","13"
"CD010966_pub4_data","Analysis.group","14"
"CD010966_pub4_data","Analysis.group","15"
"CD010966_pub4_data","Analysis.group","16"
"CD010966_pub4_data","Analysis.group","17"
"CD010966_pub4_data","Analysis.group","18"
"CD010966_pub4_data","Analysis.group","19"
"CD010966_pub4_data","Analysis.group","20"
"CD010966_pub4_data","Analysis.group","21"
"CD010966_pub4_data","Analysis.group","22"
"CD010966_pub4_data","Analysis.group","23"
"CD010966_pub4_data","Analysis.group","24"
"CD010966_pub4_data","Analysis.group","25"
"CD010966_pub4_data","Analysis.group","26"
"CD010966_pub4_data","Analysis.group","27"
"CD010966_pub4_data","Analysis.group","28"
"CD010966_pub4_data","Analysis.group","29"
"CD010966_pub4_data","Analysis.group","30"
"CD010966_pub4_data","Analysis.group","31"
"CD010966_pub4_data","Analysis.group","32"
"CD010966_pub4_data","Analysis.group","33"
"CD010966_pub4_data","Analysis.group","34"
"CD010966_pub4_data","Analysis.group","35"
"CD010966_pub4_data","Analysis.group","36"
"CD010966_pub4_data","Analysis.group","37"
"CD010966_pub4_data","Analysis.group","38"
"CD010966_pub4_data","Analysis.name","FEV1 % predicted (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Adverse effects: 100 mg and 200 mg lumacaftor groups (combined data) versus placebo at up to 1 month"
"CD010966_pub4_data","Analysis.name","Adverse effects: 200 mg lumacaftor group versus placebo at up to 1 month"
"CD010966_pub4_data","Analysis.name","Adverse effects requiring study drug discontinuation at up to 1 month"
"CD010966_pub4_data","Analysis.name","Sweat chloride concentration (change from baseline at up to 1 month) [mmol/L]"
"CD010966_pub4_data","Analysis.name","Sweat chloride concentration (change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQR respiratory domain: absolute change from baseline"
"CD010966_pub4_data","Analysis.name","CFQR eating domain: absolute change from baseline"
"CD010966_pub4_data","Analysis.name","Adverse events occurring in > 10% of participants at up to 1 month"
"CD010966_pub4_data","Analysis.name","Sweat chloride"
"CD010966_pub4_data","Analysis.name","FEV1 % predicted (relative change from baseline at up to 1 month)"
"CD010966_pub4_data","Analysis.name","Treatment-emergent adverse events (mild) at up to 1 month"
"CD010966_pub4_data","Analysis.name","Treatment-emergent adverse events (moderate) at up to 1 month"
"CD010966_pub4_data","Analysis.name","Treatment-emergent adverse events (serious or severe) at up to 1 month"
"CD010966_pub4_data","Analysis.name","Mean change in CFQ-R respiratory domain"
"CD010966_pub4_data","Analysis.name","FEV1 % predicted absolute change (% points)"
"CD010966_pub4_data","Analysis.name","Adverse events at up to 1 month"
"CD010966_pub4_data","Analysis.name","Sweat chloride change from baseline (mmol/L)"
"CD010966_pub4_data","Analysis.name","Adverse events occurring in more than 3% of participants in all treatment groups (combined data) versus placebo at up to 1 month"
"CD010966_pub4_data","Analysis.name","Participants requiring study drug termination or a reduced dosage at up to 1 month"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in lung clearance index 2.5 (LCI2.5) "
"CD010966_pub4_data","Analysis.name","Most common adverse events (occurring in at least 10% of participants in either group)"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in sweat chloride"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in MRI global chest score"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in weight-for-age z score"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in BMI-for-age z score"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in stature-for-age z score "
"CD010966_pub4_data","Analysis.name","Quality of life - Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Quality of life - CFQ-R respiratory domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Quality of life - EQ-5D-3L VAS score (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","FEV1 % predicted (relative change from baseline)"
"CD010966_pub4_data","Analysis.name","Adverse events by end of study (at 6 months)"
"CD010966_pub4_data","Analysis.name","Time to first pulmonary exacerbation"
"CD010966_pub4_data","Analysis.name","Rate of exacerbations"
"CD010966_pub4_data","Analysis.name","Weight (kg) (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","BMI (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","BMI (relative change from baseline)"
"CD010966_pub4_data","Analysis.name","Adverse events occurring in 10% or more participants (from days 15 to 21)"
"CD010966_pub4_data","Analysis.name","Sweat chloride concentration (mmol/L) (change from baseline)"
"CD010966_pub4_data","Analysis.name","LCI2.5 (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Treatment-emergent adverse events with incidence > 10% in any treatment group (at 6 months)"
"CD010966_pub4_data","Analysis.name","Sweat chloride concentration (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CT Brody score (mean change)"
"CD010966_pub4_data","Analysis.name","CT Brody score bronchiectasis score (mean change)"
"CD010966_pub4_data","Analysis.name","CT Brody score air trapping score (mean change)"
"CD010966_pub4_data","Analysis.name","BMI-for-age z score (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in CFQ-R respiratory domain score"
"CD010966_pub4_data","Analysis.name","Relative change from baseline in % predicted FEV1"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in % predicted FEV1"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in body weight (kg)"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline BMI"
"CD010966_pub4_data","Analysis.name","CFQ-R respiratory domain (absolute change from baseline) "
"CD010966_pub4_data","Analysis.name","CFQ-R physical functioning domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R treatment burden domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R health perceptions domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R vitality domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R social functioning domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R role functioning domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R eating problems domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R emotional functioning (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R weight domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R digestive symptoms domain(absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R body image domain (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","FEV1 % predicted (relative change from baseline) "
"CD010966_pub4_data","Analysis.name","FEV1 % predicted (absolute change from baseline) "
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in mucociliary clearance "
"CD010966_pub4_data","Analysis.name","Number of participants with at least 1 pulmonary exacerbation"
"CD010966_pub4_data","Analysis.name","Number of pulmonary exacerbations"
"CD010966_pub4_data","Analysis.name","Sweat chloride (change from baseline) "
"CD010966_pub4_data","Analysis.name","Absolute change in total Brody/CF-CT score from baseline"
"CD010966_pub4_data","Analysis.name","Lung infection (pseudomonal)"
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in body weight"
"CD010966_pub4_data","Analysis.name","BMI (change from baseline) "
"CD010966_pub4_data","Analysis.name","Absolute change from baseline in BMI z score"
"CD010966_pub4_data","Analysis.name","Quality of life: change in CFQ-R respiratory domain"
"CD010966_pub4_data","Analysis.name","FEV1 L (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Adverse events (at 1 month)"
"CD010966_pub4_data","Analysis.name","Sweat chloride (change from baseline) (mmol/L)"
"CD010966_pub4_data","Analysis.name","Adverse events (at up to 1 month)"
"CD010966_pub4_data","Analysis.name","Sweat chloride (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Most common adverse events (occurring in at least 10% of participants in either group) (6 months)"
"CD010966_pub4_data","Analysis.name","Body weight (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","BMI (change from baseline)"
"CD010966_pub4_data","Analysis.name","BMI z score (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Quality of life: absolute change in CFQ-R respiratory domain"
"CD010966_pub4_data","Analysis.name","Sweat chloride (absolute change from baseline) "
"CD010966_pub4_data","Analysis.name","Quality of life: change in CFQ-R respiratory sub-domain"
"CD010966_pub4_data","Analysis.name","Adverse events at (1 month)"
"CD010966_pub4_data","Analysis.name","Quality of life: CFQ-R respiratory domain (change from baseline)"
"CD010966_pub4_data","Analysis.name","Adverse events (at up to 6 months)"
"CD010966_pub4_data","Analysis.name","Hospitalisation"
"CD010966_pub4_data","Analysis.name","Exacerbation (need for antibiotics)"
"CD010966_pub4_data","Analysis.name","Weight (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Weight (change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R respiratory domain score (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Most common adverse events (occurring in at least 10% of participants in either group) (day 43)"
"CD010966_pub4_data","Analysis.name","FEV1% predicted (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","CFQ-R Respiratory domain score (absolute change from baseline)"
"CD010966_pub4_data","Analysis.name","Most common adverse events (occurring in at least 10% of participants in either group) (at day 71)"
"CD010966_pub4_data","Analysis.name","Most common adverse events (occurring in at least 10% of participants in either group) (at day 57)"
"CD010966_pub4_data","Analysis.name","Most common adverse events (occurring in at least 10% of participants in either group) (at day 85)"
"CD010966_pub4_data","Subgroup","At up to 1 month"
"CD010966_pub4_data","Subgroup","Cough"
"CD010966_pub4_data","Subgroup","Headache"
"CD010966_pub4_data","Subgroup","Rales"
"CD010966_pub4_data","Subgroup","Productive cough"
"CD010966_pub4_data","Subgroup","Dyspnoea"
"CD010966_pub4_data","Subgroup","Pulmonary exacerbation"
"CD010966_pub4_data","Subgroup","Fatigue"
"CD010966_pub4_data","Subgroup","Fever"
"CD010966_pub4_data","Subgroup","Nasal congestion"
"CD010966_pub4_data","Subgroup","Wheezing"
"CD010966_pub4_data","Subgroup","Diarrhoea"
"CD010966_pub4_data","Subgroup","Oropharyngeal pain"
"CD010966_pub4_data","Subgroup","Upper respiratory tract infection"
"CD010966_pub4_data","Subgroup","Sinus congestion"
"CD010966_pub4_data","Subgroup","Respiration abnormal"
"CD010966_pub4_data","Subgroup","Haemoptysis"
"CD010966_pub4_data","Subgroup","Constipation"
"CD010966_pub4_data","Subgroup","Abdominal pain"
"CD010966_pub4_data","Subgroup","Myalgia"
"CD010966_pub4_data","Subgroup","Post-tussive vomiting"
"CD010966_pub4_data","Subgroup","Nausea"
"CD010966_pub4_data","Subgroup","Nasopharyngitis"
"CD010966_pub4_data","Subgroup","Dizziness"
"CD010966_pub4_data","Subgroup","Back pain"
"CD010966_pub4_data","Subgroup","Upper abdominal pain"
"CD010966_pub4_data","Subgroup","Sputum abnormal"
"CD010966_pub4_data","Subgroup","Epistaxis"
"CD010966_pub4_data","Subgroup","C-reactive protein increased"
"CD010966_pub4_data","Subgroup","Paranasal sinus hypersecretion"
"CD010966_pub4_data","Subgroup","Lung hyperinflation"
"CD010966_pub4_data","Subgroup","Prothrombin time prolonged"
"CD010966_pub4_data","Subgroup","25 mg lumacaftor"
"CD010966_pub4_data","Subgroup","50 mg lumacaftor"
"CD010966_pub4_data","Subgroup","100 mg lumacaftor"
"CD010966_pub4_data","Subgroup","200 mg lumacaftor"
"CD010966_pub4_data","Subgroup","Chest discomfort"
"CD010966_pub4_data","Subgroup","5 mg/day N6022"
"CD010966_pub4_data","Subgroup","10 mg/day N6022"
"CD010966_pub4_data","Subgroup","20 mg/day N6022"
"CD010966_pub4_data","Subgroup","40 mg/day N6022"
"CD010966_pub4_data","Subgroup","Serious adverse events"
"CD010966_pub4_data","Subgroup","Blood CK increase"
"CD010966_pub4_data","Subgroup","Flatulence"
"CD010966_pub4_data","Subgroup","Respiratory exacerbation"
"CD010966_pub4_data","Subgroup","Rhinorrhoea"
"CD010966_pub4_data","Subgroup","Increased sputum"
"CD010966_pub4_data","Subgroup","Dry mouth"
"CD010966_pub4_data","Subgroup","Lethargy"
"CD010966_pub4_data","Subgroup","Total number of participants experiencing at least 1 adverse event"
"CD010966_pub4_data","Subgroup","Infective respiratory exacerbation"
"CD010966_pub4_data","Subgroup","Asthenia"
"CD010966_pub4_data","Subgroup","Pain"
"CD010966_pub4_data","Subgroup","Lung disease"
"CD010966_pub4_data","Subgroup","Rhinitis"
"CD010966_pub4_data","Subgroup","Bad taste in mouth"
"CD010966_pub4_data","Subgroup","30 g 4PBA"
"CD010966_pub4_data","Subgroup","At week 48"
"CD010966_pub4_data","Subgroup","Infective pulmonary exacerbation of cystic fibrosis"
"CD010966_pub4_data","Subgroup","Number of serious adverse events"
"CD010966_pub4_data","Subgroup","Abdominal pain upper"
"CD010966_pub4_data","Subgroup","Gastroenteritis"
"CD010966_pub4_data","Subgroup","Bacterial disease carrier"
"CD010966_pub4_data","Subgroup","Pyrexia"
"CD010966_pub4_data","Subgroup","Nasal polyps"
"CD010966_pub4_data","Subgroup","Vomiting"
"CD010966_pub4_data","Subgroup","Faeces pale"
"CD010966_pub4_data","Subgroup","Other (not including serious) adverse events"
"CD010966_pub4_data","Subgroup","Lung infiltration"
"CD010966_pub4_data","Subgroup","Pseudomonas test positive"
"CD010966_pub4_data","Subgroup","At 6 months"
"CD010966_pub4_data","Subgroup","Any adverse event"
"CD010966_pub4_data","Subgroup","Discontinuation due to an adverse event"
"CD010966_pub4_data","Subgroup","At least 1 serious adverse event"
"CD010966_pub4_data","Subgroup","Infective pulmonary exacerbation"
"CD010966_pub4_data","Subgroup","Abnormal respiration"
"CD010966_pub4_data","Subgroup","At 14 days (before addition of ivacaftor)"
"CD010966_pub4_data","Subgroup","At 21 days"
"CD010966_pub4_data","Subgroup","Any serious adverse event"
"CD010966_pub4_data","Subgroup","Sputum increased"
"CD010966_pub4_data","Subgroup","Respiratory events"
"CD010966_pub4_data","Subgroup","At 3 months"
"CD010966_pub4_data","Subgroup","Musculoskeletal pain"
"CD010966_pub4_data","Subgroup","Muscle strain"
"CD010966_pub4_data","Subgroup","Aspartate aminotransferase increased"
"CD010966_pub4_data","Subgroup","Chronic sinusitis"
"CD010966_pub4_data","Subgroup","Dyspepsia"
"CD010966_pub4_data","Subgroup","Oxygen saturation decreased"
"CD010966_pub4_data","Subgroup","Tinnitus"
"CD010966_pub4_data","Subgroup","Non-cardiac chest pain"
"CD010966_pub4_data","Subgroup","Acute sinusitis"
"CD010966_pub4_data","Subgroup","Breath sounds abnormal"
"CD010966_pub4_data","Subgroup","Vitamin D decreased"
"CD010966_pub4_data","Subgroup","Iron deficiency"
"CD010966_pub4_data","Subgroup","Pulmonary function test decreased"
"CD010966_pub4_data","Subgroup","Weight decreased"
"CD010966_pub4_data","Subgroup","Alanine aminotransferase increased"
"CD010966_pub4_data","Subgroup","Heart rate increased"
"CD010966_pub4_data","Subgroup","Forced expiratory volume decreased"
"CD010966_pub4_data","Subgroup","Testicular pain"
"CD010966_pub4_data","Subgroup","Amenorrhoea"
"CD010966_pub4_data","Subgroup","Nasal oedema"
"CD010966_pub4_data","Subgroup","Lower respiratory tract congestion"
"CD010966_pub4_data","Subgroup","Number of participants with serious adverse events"
"CD010966_pub4_data","Subgroup","Hyposmia"
"CD010966_pub4_data","Subgroup","Sputum discoloured"
"CD010966_pub4_data","Subgroup","Rash"
"CD010966_pub4_data","Subgroup","Muscle spasms"
"CD010966_pub4_data","Subgroup","Sinus headache"
"CD010966_pub4_data","Subgroup","Pneumothorax"
"CD010966_pub4_data","Subgroup","Number of participants with treatment-emergent adverse events"
"CD010966_pub4_data","Subgroup","At 1 month"
"CD010966_pub4_data","Subgroup","Up to and including 6 months"
"CD010966_pub4_data","Subgroup","At week 4"
"CD010966_pub4_data","Subgroup","Nasal congestion or nasopharyngitis"
"CD010966_pub4_data","Subgroup","Pharyngitis"
"CD010966_pub4_data","Subgroup","Migraine"
"CD010966_pub4_data","Subgroup","Lower respiratory tract infection"
"CD010966_pub4_data","Subgroup","Influenza"
"CD010966_pub4_data","Subgroup","Sunburn"
"CD010966_pub4_data","Subgroup","Bacterial test positive"
"CD010966_pub4_data","Subgroup","Arthralgia"
"CD010966_pub4_data","Subgroup","Renal impairment"
"CD010966_pub4_data","Subgroup","Lung infection pseudomonal"
"CD010966_pub4_data","Subgroup","At 18 months"
"CD010966_pub4_data","Subgroup","Up to 19 months"
"CD010966_pub4_data","Subgroup","Over 1 month and up to and including 6 months"
"CD010966_pub4_data","Subgroup","Number experiencing moderate adverse events"
"CD010966_pub4_data","Subgroup","Number experiencing severe adverse events"
"CD010966_pub4_data","Subgroup","URTI"
"CD010966_pub4_data","Subgroup","Number of participants experiencing at least one adverse event"
"CD010966_pub4_data","Subgroup","Infective pulmonary exacerbations"
"CD010966_pub4_data","Subgroup","Raised blood creatine phosphokinase"
"CD010966_pub4_data","Subgroup","Infective respiratory exacerbations"
"CD010966_pub4_data","Subgroup","Insomnia"
"CD010966_pub4_data","Subgroup","Ear pain"
"CD010966_pub4_data","Subgroup","Viral URTI"
"CD010966_pub4_data","Subgroup","Abdominal discomfort"
"CD010966_pub4_data","Subgroup","Oral candidiasis"
"CD010966_pub4_data","Subgroup","Hypertension"
"CD010966_pub4_data","Subgroup","Photosensitivity reaction"
"CD010966_pub4_data","Subgroup","Decreased pulmonary function tests"
"CD010966_pub4_data","Subgroup","Increased blood creatine phosphokinase"
"CD010966_pub4_data","Subgroup","Elevated AST"
"CD010966_pub4_data","Subgroup","At up to 6 months"
"CD010966_pub4_data","Subgroup","Number with any adverse event"
"CD010966_pub4_data","Subgroup","Number with moderate adverse events"
"CD010966_pub4_data","Subgroup","Number with severe adverse events"
"CD010966_pub4_data","Subgroup","Number with serious adverse events"
"CD010966_pub4_data","Subgroup","Adverse event leading to discontinuation of treatment"
"CD010966_pub4_data","Subgroup","Infective pulmonary exacerbation of CF"
"CD010966_pub4_data","Subgroup","Number with mild adverse events"
"CD010966_pub4_data","Subgroup","Number experiencing mild adverse events"
"CD010966_pub4_data","Subgroup","Adverse event leading to discontinuation of trial drug"
"CD010966_pub4_data","Subgroup","Elevated transaminase"
"CD010966_pub4_data","Subgroup","Number experiencing serious adverse events"
"CD010966_pub4_data","Subgroup","Number experiencing  severe adverse events"
"CD010966_pub4_data","Subgroup","Number of participants with moderate adverse events"
"CD010966_pub4_data","Subgroup","Paranasal sinus discomfort"
"CD010966_pub4_data","Subgroup","Chest pain"
"CD010966_pub4_data","Subgroup","At 2 months"
"CD010966_pub4_data","Subgroup","Number of participants with moderate adverse events "
"CD010966_pub4_data","Subgroup","At day 15"
"CD010966_pub4_data","Subgroup","Ear discomfort"
"CD010966_pub4_data","Subgroup","Abdominal distension"
"CD010966_pub4_data","Subgroup","Colitis"
"CD010966_pub4_data","Subgroup","Anxiety"
"CD010966_pub4_data","Subgroup","Dysphonia"
"CD010966_pub4_data","Subgroup","Blood alkaline phosphatase increased"
"CD010966_pub4_data","Subgroup","Gamma-glutamyltransferase increased"
"CD010966_pub4_data","Subgroup","Lymphadenopathy"
"CD010966_pub4_data","Subgroup","Vessel puncture site haemorrhage"
"CD010966_pub4_data","Subgroup","Viral infection"
"CD010966_pub4_data","Subgroup","Viral upper respiratory tract infection"
"CD010966_pub4_data","Subgroup","Hypoglycaemia"
"CD010966_pub4_data","Subgroup","Musculoskeletal chest pain"
"CD010966_pub4_data","Subgroup","Respiration abnormal "
"CD010966_pub4_data","Subgroup","Sinus congestion "
"CD010966_pub4_data","Subgroup","Seasonal allergy"
"CD010966_pub4_data","Subgroup","Faeces soft"
"CD010966_pub4_data","Subgroup","Blood bilirubin increased"
"CD010966_pub4_data","Subgroup","Procedural haemorrhage"
"CD010966_pub4_data","Subgroup","Dyspnoea exertional"
"CD010966_pub4_data","Subgroup","Gamma-glutamyltransferase increased "
"CD010966_pub4_data","Subgroup","Dysgeusia"
"CD010966_pub4_data","Subgroup","Breast tenderness"
"CD010966_pub4_data","Subgroup","Procedural dizziness"
"CD010966_pub4_data","Subgroup","Anaemia"
"CD010966_pub4_data","Subgroup","Thirst"
"CD010966_pub4_data","Subgroup","Platelet count increased"
"CD010966_pub4_data","Subgroup","Breast discomfort"
"CD010966_pub4_data","Subgroup","Chromaturia"
"CD010966_pub4_data","Subgroup","Pulmonary pain"
"CD010966_pub4_data","Subgroup","Respiratory tract congestion "
"CD010966_pub4_data","Subgroup","Rhinorrhoea "
"CD010966_pub4_data","Subgroup","Pneumonia"
"CD010966_pub4_data","Subgroup","Tendon pain"
"CD010966_pub4_data","Subgroup","Bronchospasm"
"CD010966_pub4_data","Subgroup","Erythema"
"CD010966_pub4_data","Subgroup","Incision site pain"
"CD010966_pub4_data","Subgroup","Eye swelling"
"CD010966_pub4_data","Subgroup","Upper respiratory tract congestion"
"CD010966_pub4_data","Subgroup","Night sweats "
"CD010966_pub4_data","Subgroup","Through 1 month"
"CD010966_pub4_data","Subgroup","Nasopharyngitis "
"CD010966_pub4_data","Subgroup","Cough "
"CD010966_pub4_data","Subgroup","Diarrhoea "
"CD010966_pub4_data","Subgroup","At one month"
"CD010966_pub4_data","Subgroup","Adjustment disorder"
"CD010966_pub4_data","Subgroup","Anorectal discomfort"
"CD010966_pub4_data","Subgroup","Folliculitis"
"CD011039_pub2_data","Analysis.group","1"
"CD011039_pub2_data","Analysis.name","All-cause mortality"
"CD011039_pub2_data","Analysis.name","Morbidity due to any cause"
"CD011039_pub2_data","Analysis.name","Morbidity (by type)"
"CD011039_pub2_data","Analysis.name","Serious adverse events"
"CD011039_pub2_data","Analysis.name","Serious adverse events (by type)"
"CD011039_pub2_data","Analysis.name","Participants who did not receive a liver transplant"
"CD011039_pub2_data","Analysis.name","Participants without improvement in kidney function (first 24 months of follow-up)"
"CD011039_pub2_data","Analysis.name","Improvement in kidney function (parameters)"
"CD011039_pub2_data","Analysis.name","Improvement in liver function (parameters)"
"CD011039_pub2_data","Analysis.name","Length of hospitalisation measured in days (first 12 months of follow-up)"
"CD011039_pub2_data","Subgroup","Bacterial peritonitis"
"CD011039_pub2_data","Subgroup","Refractory ascites"
"CD011039_pub2_data","Subgroup","Encephalopathy"
"CD011039_pub2_data","Subgroup","Heart failure"
"CD011039_pub2_data","Subgroup","Gastrointestinal bleeding"
"CD011039_pub2_data","Subgroup","Hyponatraemia"
"CD011039_pub2_data","Subgroup","Glomerular filtration rate (mL/min)"
"CD011039_pub2_data","Subgroup","Urinary sodium excretion (mmol/day)"
"CD011039_pub2_data","Subgroup","Prothrombin time"
"CD011039_pub2_data","Subgroup","Bilirubin (mg/dL)"
"CD011039_pub2_data","Subgroup","Albumin (g/dL)"
"CD011044_pub3_data","Analysis.group","1"
"CD011044_pub3_data","Analysis.group","2"
"CD011044_pub3_data","Analysis.group","3"
"CD011044_pub3_data","Analysis.group","4"
"CD011044_pub3_data","Analysis.group","5"
"CD011044_pub3_data","Analysis.name","Overall survival"
"CD011044_pub3_data","Analysis.name","Progression-free survival"
"CD011044_pub3_data","Analysis.name","Degradation of QoL at 6 months"
"CD011044_pub3_data","Analysis.name","Response rates"
"CD011044_pub3_data","Analysis.name","Grade 3/4 anaemia"
"CD011044_pub3_data","Analysis.name","Grade 3/4 neutropenia"
"CD011044_pub3_data","Analysis.name","Grade 3/4 thrombocytopaenia"
"CD011044_pub3_data","Analysis.name","Grade 3/4 nausea"
"CD011044_pub3_data","Analysis.name","Grade 3/4 diarrhoea"
"CD011044_pub3_data","Analysis.name","Grade 3/4 neuropathy"
"CD011044_pub3_data","Analysis.name","Grade 3/4 fatigue"
"CD011044_pub3_data","Analysis.name","Response rate"
"CD011044_pub3_data","Subgroup","5-fluorouracil"
"CD011044_pub3_data","Subgroup","FOLFIRINOX"
"CD011044_pub3_data","Subgroup","CO-101"
"CD011044_pub3_data","Subgroup","ZD9331"
"CD011044_pub3_data","Subgroup","Fixed dose rate gemcitabine"
"CD011044_pub3_data","Subgroup","Exatecan"
"CD011044_pub3_data","Subgroup","Exatecan (DX-8951f)"
"CD011044_pub3_data","Subgroup","Gemcitabine plus platinum agent"
"CD011044_pub3_data","Subgroup","Gemcitabine plus fluoropyrimidine"
"CD011044_pub3_data","Subgroup","Gemcitabine plus topoisomerase inhibitor"
"CD011044_pub3_data","Subgroup","Gemcitabine plus taxane"
"CD011044_pub3_data","Subgroup","Gemcitabine plus other combinations of chemotherapy"
"CD011044_pub3_data","Subgroup","Gemcitabine plus other agent(s)"
"CD011044_pub3_data","Subgroup","Gemcitabane plus other combinations of chemotherapy"
"CD011044_pub3_data","Subgroup","Different dosing of gemcitabine plus nab-paclitaxel compared to standard dosing"
"CD011044_pub3_data","Subgroup","Fluoropyrimidine-based combination vs gemcitabine plus nab-paclitaxel"
"CD011044_pub3_data","Subgroup","Fluoropyrimidine-based combinations vs gemcitabine plus nab-paclitaxel"
"CD011060_pub2_data","Analysis.group","1"
"CD011060_pub2_data","Analysis.name","Readmission for hyperbilirubinemia"
"CD011060_pub2_data","Analysis.name","Exchange transfusion"
"CD011060_pub2_data","Analysis.name","Phototherapy before discharge"
"CD011060_pub2_data","Analysis.name","Acute bilirubin encephalopathy"
"CD011120_pub3_data","Analysis.group","1"
"CD011120_pub3_data","Analysis.group","2"
"CD011120_pub3_data","Analysis.group","3"
"CD011120_pub3_data","Analysis.group","4"
"CD011120_pub3_data","Analysis.group","5"
"CD011120_pub3_data","Analysis.group","6"
"CD011120_pub3_data","Analysis.group","7"
"CD011120_pub3_data","Analysis.group","8"
"CD011120_pub3_data","Analysis.group","9"
"CD011120_pub3_data","Analysis.name","Tobacco use cessation"
"CD011120_pub3_data","Analysis.name","Quit attempts"
"CD011120_pub3_data","Analysis.name","Serious adverse events"
"CD011120_pub3_data","Analysis.name","All-cause mortality"
"CD011120_pub3_data","Analysis.name","Adverse events"
"CD011120_pub3_data","Subgroup","Behavioural support vs brief advice"
"CD011120_pub3_data","Subgroup","Behavioural support + NRT vs brief advice + NRT"
"CD011120_pub3_data","Subgroup","Behavioural support + varenicline vs varenicline"
"CD011192_pub4_data","Analysis.group","1"
"CD011192_pub4_data","Analysis.name","Pre-eclampsia or pregnancy loss at any time after conception"
"CD011192_pub4_data","Analysis.name","Pre-eclampsia"
"CD011192_pub4_data","Analysis.name","Pregnancy loss at any time after conception"
"CD011192_pub4_data","Analysis.name","Maternal death"
"CD011192_pub4_data","Analysis.name","Maternal death or severe morbidity"
"CD011192_pub4_data","Analysis.name","Eclampsia"
"CD011192_pub4_data","Analysis.name","HELLP syndrome"
"CD011192_pub4_data","Analysis.name","ICU admission"
"CD011192_pub4_data","Analysis.name","Stroke"
"CD011192_pub4_data","Analysis.name","Pulmonary oedema"
"CD011192_pub4_data","Analysis.name","Acute kidney injury"
"CD011192_pub4_data","Analysis.name","Placental abruption"
"CD011192_pub4_data","Analysis.name","Hypertension"
"CD011192_pub4_data","Analysis.name","Gestational hypertension"
"CD011192_pub4_data","Analysis.name","Severe hypertension"
"CD011192_pub4_data","Analysis.name","Proteinuria"
"CD011192_pub4_data","Analysis.name","Raised liver enzymes"
"CD011192_pub4_data","Analysis.name","Low platelets"
"CD011192_pub4_data","Analysis.name","Preterm delivery before 37 weeks"
"CD011192_pub4_data","Analysis.name","Stillbirth"
"CD011192_pub4_data","Analysis.name","Early preterm birth < 34 weeks"
"CD011192_pub4_data","Analysis.name","Apgar score less than 7 at 5 minutes"
"CD011197_pub3_data","Analysis.group","1"
"CD011197_pub3_data","Analysis.name","Mortality"
"CD011197_pub3_data","Analysis.name","Serious adverse events"
"CD011197_pub3_data","Analysis.name","AF recurrence"
"CD011197_pub3_data","Analysis.name","AFSS symptom severity"
"CD011197_pub3_data","Analysis.name","AFSS symptom burden"
"CD011197_pub3_data","Analysis.name","AFSS episode frequency"
"CD011197_pub3_data","Analysis.name","AFSS episode duration"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 mental component score"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 physical component score"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 physical function"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 physical role functioning"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 bodily pain"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 general health"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 vitality"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 social functioning"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 role emotional"
"CD011197_pub3_data","Analysis.name","Quality of life, SF-36 mental health"
"CD011197_pub3_data","Analysis.name","Exercise capacity (VO2peak)"
"CD011197_pub3_data","Analysis.name","Exercise capacity (6MWT)"
"CD011197_pub3_data","Analysis.name","Exercise capacity (SMD)"
"CD011204_pub3_data","Analysis.group","1"
"CD011204_pub3_data","Analysis.group","2"
"CD011204_pub3_data","Analysis.group","3"
"CD011204_pub3_data","Analysis.group","4"
"CD011204_pub3_data","Analysis.group","5"
"CD011204_pub3_data","Analysis.group","6"
"CD011204_pub3_data","Analysis.group","7"
"CD011204_pub3_data","Analysis.group","8"
"CD011204_pub3_data","Analysis.group","9"
"CD011204_pub3_data","Analysis.group","10"
"CD011204_pub3_data","Analysis.group","11"
"CD011204_pub3_data","Analysis.group","12"
"CD011204_pub3_data","Analysis.group","13"
"CD011204_pub3_data","Analysis.group","14"
"CD011204_pub3_data","Analysis.group","15"
"CD011204_pub3_data","Analysis.group","16"
"CD011204_pub3_data","Analysis.group","17"
"CD011204_pub3_data","Analysis.group","18"
"CD011204_pub3_data","Analysis.group","19"
"CD011204_pub3_data","Analysis.group","20"
"CD011204_pub3_data","Analysis.group","21"
"CD011204_pub3_data","Analysis.group","22"
"CD011204_pub3_data","Analysis.group","23"
"CD011204_pub3_data","Analysis.group","24"
"CD011204_pub3_data","Analysis.group","25"
"CD011204_pub3_data","Analysis.group","26"
"CD011204_pub3_data","Analysis.group","27"
"CD011204_pub3_data","Analysis.group","28"
"CD011204_pub3_data","Analysis.group","29"
"CD011204_pub3_data","Analysis.group","30"
"CD011204_pub3_data","Analysis.name","Cognitive function, assessed with ADAS-cog: change from baseline at 3 months"
"CD011204_pub3_data","Analysis.name","Cognitive function, assessed with ADAS-cog, change from baseline at 6 months"
"CD011204_pub3_data","Analysis.name","Cognitive function, assessed with ADAS-cog: change from baseline at 6 months"
"CD011204_pub3_data","Analysis.name","ADAS-cog, ≥ 4-point improvement at 3 months (ITT)"
"CD011204_pub3_data","Analysis.name","ADAS-cog, ≥ 4-point improvement at 6 months (ITT)"
"CD011204_pub3_data","Analysis.name","ADAS-cog, ≥ 4-point improvement at 3 months (OC)"
"CD011204_pub3_data","Analysis.name","ADAS-cog, ≥ 4-point improvement at 6 months (OC)"
"CD011204_pub3_data","Analysis.name","MMSE, change from baseline at 6 months (ITT)"
"CD011204_pub3_data","Analysis.name","MMSE, change from baseline at 24 months (ITT)"
"CD011204_pub3_data","Analysis.name","MMSE, change from baseline at 6 months (OC)"
"CD011204_pub3_data","Analysis.name","Global rating, no change or improvement at 3 months (ITT)"
"CD011204_pub3_data","Analysis.name","Global rating, no change or improvement at 6 months (ITT)"
"CD011204_pub3_data","Analysis.name","Global rating, no change or improvement at 3 months (OC)"
"CD011204_pub3_data","Analysis.name","Global rating, no change or improvement at 6 months (OC)"
"CD011204_pub3_data","Analysis.name","Global rating, no change or improvement, galantamine 8 mg/day"
"CD011204_pub3_data","Analysis.name","Global rating, no change or improvement, galantamine 16 to 24 mg/day"
"CD011204_pub3_data","Analysis.name","Global rating, no change or improvement, galantamine 24 to 32 mg/day"
"CD011204_pub3_data","Analysis.name","Global rating, no change or improvement, galantamine 32 to 36 mg/day"
"CD011204_pub3_data","Analysis.name","Global rating, no change or improvement, galantamine 30 mg/day"
"CD011204_pub3_data","Analysis.name","ADCS/ADL, change from baseline at 6 months (ITT)"
"CD011204_pub3_data","Analysis.name","ADCS/ADL, change from baseline at 6 months (OC)"
"CD011204_pub3_data","Analysis.name","DAD, change from baseline at 3 months (ITT)"
"CD011204_pub3_data","Analysis.name","DAD, change from baseline at 6 months (ITT)"
"CD011204_pub3_data","Analysis.name","DAD, change from baseline at 12 months (ITT)"
"CD011204_pub3_data","Analysis.name","DAD, change from baseline at 24 months (ITT)"
"CD011204_pub3_data","Analysis.name","DAD, change from baseline at 3 months (OC)"
"CD011204_pub3_data","Analysis.name","DAD, change from baseline at 6 months (OC)"
"CD011204_pub3_data","Analysis.name","NPI, change from baseline at 3 months (ITT)"
"CD011204_pub3_data","Analysis.name","NPI, change from baseline at 6 months (ITT)"
"CD011204_pub3_data","Analysis.name","NPI, change from baseline at 3 months (OC)"
"CD011204_pub3_data","Analysis.name","NPI, change from baseline at 6 months (OC)"
"CD011204_pub3_data","Analysis.name","Proportion of all-cause discontinuations at 3 months"
"CD011204_pub3_data","Analysis.name","Proportion of all-cause discontinuations at 6 months"
"CD011204_pub3_data","Analysis.name","Proportion of all-cause discontinuations at 24 months"
"CD011204_pub3_data","Analysis.name","Proportion of discontinuations due to adverse events at 3 months"
"CD011204_pub3_data","Analysis.name","Proportion of discontinuations due to adverse events at 6 months"
"CD011204_pub3_data","Analysis.name","Proportion of discontinuations due to adverse events at 24 months"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing nausea & vomiting"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing dizziness"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing diarrhoea"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing abdominal pain"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing decreased appetite"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing nausea"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing vomiting"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing anorexia"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing somnolence"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing agitation"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing headache"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing weight loss"
"CD011204_pub3_data","Analysis.name","Proportion of participants experiencing tremor"
"CD011204_pub3_data","Analysis.name","Proportion of participants deceased at 3 months"
"CD011204_pub3_data","Analysis.name","Proportion of participants deceased at 6 months"
"CD011204_pub3_data","Analysis.name","Proportion of participants deceased at 24 months"
"CD011204_pub3_data","Analysis.name"," ADAS-cog, change from baseline at 12 months (ITT)"
"CD011204_pub3_data","Analysis.name"," ADAS-cog, change from baseline at 24 months (ITT)"
"CD011204_pub3_data","Analysis.name"," ADAS-ADL-MCI, change from baseline at 12 months (ITT)"
"CD011204_pub3_data","Analysis.name"," ADAS-ADL-MCI, change from baseline at 24 months (ITT)"
"CD011204_pub3_data","Analysis.name"," CDR-SB, change from 0.5 to ≥ 1.0 at 24 months (ITT)"
"CD011204_pub3_data","Analysis.name"," Proportion of all-cause discontinuations at 24 months"
"CD011204_pub3_data","Analysis.name"," Proportion of discontinuations due to adverse events at 24 months"
"CD011204_pub3_data","Subgroup","Galantamine 16 to 24 mg/day (8 to 12 mg twice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 18 mg/day (6 mg thrice daily) "
"CD011204_pub3_data","Subgroup","Galantamine 24 mg/day (8 mg thrice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 16 to 24 mg/day prolonged release"
"CD011204_pub3_data","Subgroup","Galantamine 24 to 32 mg/day (12 to 16 mg twice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 36 mg/day (12 mg thrice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 32 mg/day (16 mg twice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 8 mg/day (4 mg twice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 32 mg/day (given in 3 doses)"
"CD011204_pub3_data","Subgroup","Galantamine 24 mg/day (12 mg twice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 32 mg/day (16 mg twice daily) "
"CD011204_pub3_data","Subgroup","Galantamine 16 mg/day (8 mg twice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 16 to 24 mg/day extended release"
"CD011204_pub3_data","Subgroup","Galantamine 24 mg/day (once daily)"
"CD011204_pub3_data","Subgroup","Galantamine 18 mg/day (6 mg thrice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 24 to 32 mg/day (12 to 16 mg twice daily) "
"CD011204_pub3_data","Subgroup","Galantamine 16 to 24 mg/day prolonged/extended release"
"CD011204_pub3_data","Subgroup","Galantamine 24 mg/day once daily"
"CD011204_pub3_data","Subgroup","Galantamine 24 mg/day to 24-32 mg/day"
"CD011204_pub3_data","Subgroup","Galantamine 30 mg/day (10 mg thrice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 15 mg/day (5 mg thrice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 24 to 32 mg/day (in 2 or 3 doses)"
"CD011204_pub3_data","Subgroup","Galantamine 24 to 32 mg/day (12 to 16 twice daily)"
"CD011204_pub3_data","Subgroup","Galantamine 24 to 32 mg/day (given in 3 doses)"
"CD011218_pub2_data","Analysis.group","1"
"CD011218_pub2_data","Analysis.group","2"
"CD011218_pub2_data","Analysis.group","3"
"CD011218_pub2_data","Analysis.group","4"
"CD011218_pub2_data","Analysis.name","Frequency of wearing a seat belt (Fernandez 2008)"
"CD011218_pub2_data","Analysis.name","Frequency of wearing a seat belt (Suffoletto 2022)"
"CD011218_pub2_data","Analysis.name","Frequency of wearing a seat belt (Johnston 2002)"
"CD011218_pub2_data","Analysis.name","Frequency of wearing a seat belt (Ehrlich 2010)"
"CD011218_pub2_data","Analysis.name","Frequency of wearing a seat belt (Kreuter 1996)"
"CD011218_pub2_data","Analysis.name","Frequency of wearing a seat belt (Hempel 1992)"
"CD011218_pub2_data","Analysis.name","Frequency of wearing a seat belt (Bojesen 2020)"
"CD011218_pub2_data","Analysis.name","Frequency of wearing a seat belt (Sullman 2019)"
"CD011218_pub2_data","Subgroup","At 6-month follow-up (back-seat passenger)"
"CD011218_pub2_data","Subgroup","At 3-month follow-up (front-seat passenger)"
"CD011218_pub2_data","Subgroup","At 6-month follow-up"
"CD011218_pub2_data","Subgroup","At 6-month follow-up (front-seat passenger)"
"CD011218_pub2_data","Subgroup","At 3-month follow-up (back-seat passenger)"
"CD011218_pub2_data","Subgroup","At 3-month follow-up"
"CD011218_pub2_data","Subgroup","At 6-week follow-up"
"CD011218_pub2_data","Subgroup","At 12-week follow-up"
"CD011218_pub2_data","Subgroup","Enhanced HRA vs control"
"CD011218_pub2_data","Subgroup","Typical HRA vs control"
"CD011305_pub3_data","Analysis.group","1"
"CD011305_pub3_data","Analysis.name","All-cause mortality at 0 to 7 days"
"CD011305_pub3_data","Analysis.name","All-cause mortality at 8 to 30 days"
"CD011305_pub3_data","Analysis.name","All-cause mortality at 31 to 100 days"
"CD011305_pub3_data","Analysis.name","Death due to infection (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Death due to bleeding  (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Chemotherapy-related mortality (0 to 30 days)"
"CD011305_pub3_data","Analysis.name","Transplant-related mortality (0 to 30 days)"
"CD011305_pub3_data","Analysis.name","Any bleeding - WHO/CTCAE grade ≥ 1 or equivalent (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Clinically significant bleeding - WHO/CTCAE grade ≥ 2 or equivalent (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Severe bleeding - WHO/CTCAE grade ≥ 3 or equivalent (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Adverse transfusion reactions (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Serious infectious episodes (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Toxicity score for HSCT recipients - Bearman Toxicity Score ≥ grade 3 or equivalent (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Number of participants with VOD (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Mean number of RBC transfusions (units) per participant (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Interval between RBC transfusions (days) (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Number of participants with PLT transfusions from study entry (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Number of PLT transfusion episodes per participant (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Number of PLT transfusions (doses) per participant (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Length of hospital admission (days) (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Length of intensive care admission (0 to 3 months)"
"CD011305_pub3_data","Analysis.name","Hospital readmission (0 to 3 months)"
"CD011330_pub2_data","Analysis.group","1"
"CD011330_pub2_data","Analysis.group","2"
"CD011330_pub2_data","Analysis.group","3"
"CD011330_pub2_data","Analysis.group","4"
"CD011330_pub2_data","Analysis.name","Global symptoms score"
"CD011330_pub2_data","Analysis.name","Menopausal side effects"
"CD011330_pub2_data","Analysis.name","Withdrawal due to adverse events"
"CD011330_pub2_data","Analysis.name","Psychological symptoms"
"CD011330_pub2_data","Analysis.name","Physical symptoms"
"CD011330_pub2_data","Analysis.name","Functional symptoms"
"CD011330_pub2_data","Analysis.name","All continuous outcomes"
"CD011330_pub2_data","Analysis.name","Withdrawal due to adverse effects"
"CD011330_pub2_data","Subgroup","Intramuscularly"
"CD011330_pub2_data","Subgroup","Subcutaneously"
"CD011330_pub2_data","Subgroup","Nasally"
"CD011330_pub2_data","Subgroup","Implant depot"
"CD011330_pub2_data","Subgroup","Global symptoms"
"CD011330_pub2_data","Subgroup","Psychological symptoms"
"CD011330_pub2_data","Subgroup","Physical symptoms"
"CD011330_pub2_data","Subgroup","Tibolone"
"CD011330_pub2_data","Subgroup","Oestrogen plus cyclical progestogen"
"CD011330_pub2_data","Subgroup","Estrogen plus cyclical progestogen"
"CD011330_pub2_data","Subgroup","Global symptoms score"
"CD011330_pub2_data","Subgroup","Psychological symptoms score"
"CD011330_pub2_data","Subgroup","Physical symptoms score"
"CD011381_pub3_data","Analysis.group","1"
"CD011381_pub3_data","Analysis.group","2"
"CD011381_pub3_data","Analysis.group","3"
"CD011381_pub3_data","Analysis.name","Comparisons for relapse (12 months) "
"CD011381_pub3_data","Analysis.name","Comparisons for relapse (24 months)"
"CD011381_pub3_data","Analysis.name","Comparisons for relapse (36 months)"
"CD011381_pub3_data","Analysis.name","Comparisons for disability worsening (24 months)"
"CD011381_pub3_data","Analysis.name","Comparisons for disability worsening (36 months)"
"CD011381_pub3_data","Analysis.name","Number of patients who discontinued treatment due to adverse effects"
"CD011381_pub3_data","Analysis.name","Number of patients with any serious adverse effect"
"CD011381_pub3_data","Analysis.name","Comparisons for new gadolinium-enhancing positive T1-weighted MRI lesions (12 months) "
"CD011381_pub3_data","Analysis.name","Comparisons for new gadolinium-enhancing positive T1-weighted MRI lesions (24 months) "
"CD011381_pub3_data","Analysis.name","Comparisons for new or enlarging T2-weighted MRI lesions (12 months)"
"CD011381_pub3_data","Analysis.name","Comparisons for new or enlarging T2-weighted MRI lesions (24 months)"
"CD011381_pub3_data","Analysis.name","Comparisons for quality of life total (non-MS related: EQ-5D VAS)"
"CD011381_pub3_data","Analysis.name","Comparisons for quality of life total (non-MS related) (INDEX)"
"CD011381_pub3_data","Analysis.name","Comparisons for quality of life - physical (non-MS related: SF-36)"
"CD011381_pub3_data","Analysis.name","Comparisons for quality of life - physical (MS related: MSQOL-54 PH; MSQoL-54; MSIS29 Psychological)"
"CD011381_pub3_data","Analysis.name","Comparisons for quality of life - mental (Non-MS related: SF-36)"
"CD011381_pub3_data","Analysis.name","Comparisons for quality of life - mental (MS related: MSQOL-54 PH; MSQoL-54; MSIS29 Psychological)"
"CD011381_pub3_data","Analysis.name","Mortality"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Betaferon) versus glatiramer acetate"
"CD011381_pub3_data","Subgroup","Azathioprine versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Immunoglobulins versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Betaferon) versus fingolimod"
"CD011381_pub3_data","Subgroup","Natalizumab versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Glatiramer acetate versus fingolimod"
"CD011381_pub3_data","Subgroup","Pegylated interferon beta-1a versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Daclizumab versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Glatiramer acetate versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Natalizumab versus interferon beta-1b (Betaferon)"
"CD011381_pub3_data","Subgroup","Interferon beta-1a and 1b versus azathioprine"
"CD011381_pub3_data","Subgroup","Interferon beta-1a (Avonex, Rebif) versus fingolimod"
"CD011381_pub3_data","Subgroup","Interferon beta-1a (Avonex, Rebif) versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Mitoxantrone versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Teriflunomide versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Dimethyl fumarate versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Fingolimod versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Interferon beta-1a (Avonex, Rebif) versus alemtuzumab"
"CD011381_pub3_data","Subgroup","Interferon beta-1a (Avonex, Rebif) versus interferon beta-1b (Betaferon)"
"CD011381_pub3_data","Subgroup","Cladribine versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Betaferon) versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Interferon beta-1a (Avonex, Rebif) versus glatiramer acetate"
"CD011381_pub3_data","Subgroup","Laquinimod versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Laquinimod versus interferon beta-1a (Avonex, Rebif)"
"CD011381_pub3_data","Subgroup","Glatiramer acetate versus dimethyl fumurate"
"CD011381_pub3_data","Subgroup","Teriflunomide versus ponesimod"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Avonex, Rebif) versus daclizumab"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Avonex, Rebif) versus glatiramer acetate"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Avonex, Rebif) versus alemtuzumab"
"CD011381_pub3_data","Subgroup","Glatiramer acetate versus dimethyl fumerate"
"CD011381_pub3_data","Subgroup","Dimethyl fumerate versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Interferon beta-1a and 1b versus glatiramer acetate"
"CD011381_pub3_data","Subgroup","Ozanimod versus interferon beta-1a (Avonex, Rebif)"
"CD011381_pub3_data","Subgroup","Ocrelizumab versus interferon beta-1a (Avonex, Rebif)"
"CD011381_pub3_data","Subgroup","Interferon beta-1a and 1b versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Teriflunomide versus ofatumumab"
"CD011381_pub3_data","Subgroup","Interferon beta-1a (Avonex, Rebif) versus daclizumab"
"CD011381_pub3_data","Subgroup","Glatiramer acetate versus dimethyl fumarate"
"CD011381_pub3_data","Subgroup","Ozanimod versus interferon beta-1b (Avonex, Rebif)"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Avonex, Rebif) versus placebo/no treatment"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Avonex, Rebif) versus fingolimod"
"CD011381_pub3_data","Subgroup","Laquinimod versus interferon beta-1b (Avonex, Rebif)"
"CD011381_pub3_data","Subgroup","Ocrelizumab versus interferon beta-1b (Avonex, Rebif)"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Avonex, Rebif) versus interferon beta-1b (Betaferon)"
"CD011381_pub3_data","Subgroup","Ocrelizumab versus interferon beta-1a (Avonex, Rebif) "
"CD011381_pub3_data","Subgroup","Ozanimod versus interferon beta-1a (Avonex, Rebif) "
"CD011381_pub3_data","Subgroup","Interferon beta-1a (Avonex, Rebif) versus immunoglobulins"
"CD011381_pub3_data","Subgroup","Interferon beta-1b (Betaferon) versus immunoglobulins"
"CD011381_pub3_data","Subgroup","Interferon beta-1a (Avonex, Rebif) versus placebo/no treatment "
"CD011381_pub3_data","Subgroup","Daclizumab versus placebo/no treatment "
"CD011381_pub3_data","Subgroup","Interferon beta 1a (Avonex, Rebif) versus glatiramer acetate"
"CD011381_pub3_data","Subgroup","Interferon beta 1a (Avonex, Rebif) versus alemtuzumab"
"CD011381_pub3_data","Subgroup","Ozanimod versus interferon beta 1a (Avonex, Rebif)"
"CD011381_pub3_data","Subgroup","Natalizumab versus placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Ocrelizumab versus interferon beta 1a (Avonex, Rebif)"
"CD011381_pub3_data","Subgroup","Interferon beta 1a and 1b versus azathioprine"
"CD011381_pub3_data","Subgroup","Fingolimod versus placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Interferon beta 1a (Avonex, Rebif) versus interferon beta 1b (Betaferon)"
"CD011381_pub3_data","Subgroup","Cladribine versus Placebo/no treatment"
"CD011381_pub3_data","Subgroup","Teriflunomide versus Placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Daclizumab versus Placebo/No treatment"
"CD011381_pub3_data","Subgroup","Interferon beta 1a Avonex/Rebif versus Daclizumab"
"CD011381_pub3_data","Subgroup","Interferon beta 1b Betaferon versus Interferon beta 1a Avonex Rebif "
"CD011381_pub3_data","Subgroup","Interferon beta 1a Avonex Rebif  versus Ozanimod"
"CD011381_pub3_data","Subgroup","Interferon beta 1b Betaferon versus Interferon beta 1a Avonex Rebif"
"CD011381_pub3_data","Subgroup","Interferon beta 1a Avonex Rebif versus Ozanimod"
"CD011381_pub3_data","Subgroup","Laquinimod versus placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Teriflunomide versus placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Laquinimod versus interferon beta 1a (Avonex, Rebif)"
"CD011381_pub3_data","Subgroup","Interferon beta 1a (Avonex, Rebif) versus placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Glatiramer acetate versus placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Interferon beta 1a (Avonex, Rebif) versus fingolimod"
"CD011381_pub3_data","Subgroup","Cladribine versus placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Daclizumab versus placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Dimethyl fumarate versus placebo/ no treatment"
"CD011381_pub3_data","Subgroup","Interferon beta 1b (Betaferon) versus glatiramer acetate"
"CD011381_pub3_data","Subgroup","Interferon beta 1a (Avonex, Rebif) versus daclizumab"
"CD011468_pub2_data","Analysis.group","1"
"CD011468_pub2_data","Analysis.group","2"
"CD011468_pub2_data","Analysis.group","3"
"CD011468_pub2_data","Analysis.name","Secondary patency"
"CD011468_pub2_data","Analysis.name","Post-thrombotic syndrome"
"CD011468_pub2_data","Analysis.name","Quality of life"
"CD011468_pub2_data","Analysis.name","Adverse events"
"CD011468_pub2_data","Subgroup","VCSS"
"CD011468_pub2_data","Subgroup","CIVIQ"
"CD011468_pub2_data","Subgroup","Limb pain"
"CD011535_pub7_data","Analysis.group","1"
"CD011535_pub7_data","Analysis.group","2"
"CD011535_pub7_data","Analysis.group","3"
"CD011535_pub7_data","Analysis.group","4"
"CD011535_pub7_data","Analysis.group","5"
"CD011535_pub7_data","Analysis.group","6"
"CD011535_pub7_data","Analysis.group","7"
"CD011535_pub7_data","Analysis.group","8"
"CD011535_pub7_data","Analysis.name","Non-targeted treatments versus placebo"
"CD011535_pub7_data","Analysis.name","Ciclosporin versus methotrexate"
"CD011535_pub7_data","Analysis.name","Fumaric acid esters versus methotrexate"
"CD011535_pub7_data","Analysis.name","Anti-TNF alpha versus placebo"
"CD011535_pub7_data","Analysis.name","Anti-IL12/23 versus placebo"
"CD011535_pub7_data","Analysis.name","Anti-IL17 versus placebo"
"CD011535_pub7_data","Analysis.name","Anti-IL23 versus placebo"
"CD011535_pub7_data","Analysis.name","Biologics versus non-targeted treatements"
"CD011535_pub7_data","Analysis.name","Etanercept versus other anti-TNF alpha"
"CD011535_pub7_data","Analysis.name","Anti-TNF alpha versus other biologics"
"CD011535_pub7_data","Analysis.name","Anti-IL12/23 versus other biologics"
"CD011535_pub7_data","Analysis.name","Anti-IL17 versus other biologics"
"CD011535_pub7_data","Analysis.name","Phosphodiesterase-4 inhibitors versus placebo"
"CD011535_pub7_data","Analysis.name","TYK-2 inhibitors versus placebo"
"CD011535_pub7_data","Analysis.name","Apremilast versus other systemic treatements"
"CD011535_pub7_data","Analysis.name","Etanercept versus other anti TNF alpha"
"CD011535_pub7_data","Analysis.name","Ixekizumab versus secukinumab"
"CD011535_pub7_data","Analysis.name","Anti IL12/23 versus placebo"
"CD011535_pub7_data","Analysis.name","Anti TNF alpha versus other biologics"
"CD011535_pub7_data","Analysis.name","Anti IL12/23 versus other biologics"
"CD011535_pub7_data","Analysis.name","Biologic 1 versus biologic 2"
"CD011535_pub7_data","Analysis.name","Small molecule 1 versus small molecule 2"
"CD011535_pub7_data","Subgroup","Fumaric acid esters"
"CD011535_pub7_data","Subgroup","Methotrexate"
"CD011535_pub7_data","Subgroup","Adalimumab"
"CD011535_pub7_data","Subgroup","Certolizumab"
"CD011535_pub7_data","Subgroup","Etanercept"
"CD011535_pub7_data","Subgroup","Infliximab"
"CD011535_pub7_data","Subgroup","Bimekizumab"
"CD011535_pub7_data","Subgroup","Brodalumab"
"CD011535_pub7_data","Subgroup","Ixekizumab"
"CD011535_pub7_data","Subgroup","Izokibep"
"CD011535_pub7_data","Subgroup","Netakimab"
"CD011535_pub7_data","Subgroup","Secukinumab"
"CD011535_pub7_data","Subgroup","Sonelokimab"
"CD011535_pub7_data","Subgroup","Xeligekimab"
"CD011535_pub7_data","Subgroup","Guselkumab"
"CD011535_pub7_data","Subgroup","JNJ-77242113"
"CD011535_pub7_data","Subgroup","Risankizumab"
"CD011535_pub7_data","Subgroup","Tildrakizumab"
"CD011535_pub7_data","Subgroup","Experimental: Adalimumab; Control: Methotrexate"
"CD011535_pub7_data","Subgroup","Experimental: Brodalumab; Control: Fumaric acid esters"
"CD011535_pub7_data","Subgroup","Experimental: Etanercept; Control: Acitretin"
"CD011535_pub7_data","Subgroup","Experimental: Guselkumab; Control: Fumaric acid esters"
"CD011535_pub7_data","Subgroup","Experimental: Infliximab; Control: Methotrexate"
"CD011535_pub7_data","Subgroup","Experimental: Ixekizumab; Control: Fumaric acid esters"
"CD011535_pub7_data","Subgroup","Experimental: Ixekizumab; Control: Methotrexate"
"CD011535_pub7_data","Subgroup","Experimental: Risankizumab; Control: Fumaric acid esters"
"CD011535_pub7_data","Subgroup","Experimental: Risankizumab; Control: Methotrexate"
"CD011535_pub7_data","Subgroup","Experimental: Secukinumab; Control: Fumaric acid esters"
"CD011535_pub7_data","Subgroup","Experimental: Adalimumab; Control: Bimekizumab"
"CD011535_pub7_data","Subgroup","Experimental: Adalimumab; Control: Guselkumab"
"CD011535_pub7_data","Subgroup","Experimental: Adalimumab; Control: Ixekizumab"
"CD011535_pub7_data","Subgroup","Experimental: Adalimumab; Control: Risankizumab"
"CD011535_pub7_data","Subgroup","Experimental: Etanercept; Control: Ixekizumab"
"CD011535_pub7_data","Subgroup","Experimental: Etanercept; Control: Secukinumab"
"CD011535_pub7_data","Subgroup","Experimental: Etanercept; Control: Tildrakizumab"
"CD011535_pub7_data","Subgroup","Experimental: Ixekizumab; Control: Guselkumab"
"CD011535_pub7_data","Subgroup","Experimental: Secukinumab; Control: Bimekizumab"
"CD011535_pub7_data","Subgroup","Experimental: Secukinumab; Control: Guselkumab"
"CD011535_pub7_data","Subgroup","Experimental: Secukinumab; Control: Risankizumab"
"CD011535_pub7_data","Subgroup","Experimental: Secukinumab; Control: Sonelokimab"
"CD011535_pub7_data","Subgroup","Apremilast"
"CD011535_pub7_data","Subgroup","Orismilast"
"CD011535_pub7_data","Subgroup","Roflumilast"
"CD011535_pub7_data","Subgroup","Deucravacitinib"
"CD011535_pub7_data","Subgroup","Zasocitinib"
"CD011535_pub7_data","Subgroup","Ciclosporin"
"CD011535_pub7_data","Subgroup","Experimental: Brodalumab; Control: Guselkumab"
"CD011535_pub7_data","Subgroup","Acitretin"
"CD011535_pub7_data","Subgroup","Secukinumab versus ustekinumab"
"CD011535_pub7_data","Subgroup","Risankizumab versus ustekinumab"
"CD011535_pub7_data","Subgroup","Ixekizumab versus ustekinumab"
"CD011535_pub7_data","Subgroup","Bimekizumab versus ustekinumab"
"CD011535_pub7_data","Subgroup","Risankizumab versus secukinumab"
"CD011535_pub7_data","Subgroup","Bimekizumab versus secukinumab"
"CD011535_pub7_data","Subgroup","Guselkumab versus secukinumab"
"CD011535_pub7_data","Subgroup","Guselkumab versus adalimumab"
"CD011535_pub7_data","Subgroup","Ixekizumab versus adalimumab"
"CD011535_pub7_data","Subgroup","Secukinumab 150 versus secukinumab 300"
"CD011535_pub7_data","Subgroup","Guselkumab 100 versus guselkumab 50"
"CD011535_pub7_data","Subgroup","Ixekizumab Q2W versus Ixekizumab Q4W"
"CD011535_pub7_data","Subgroup","Risankizumab 75 versus risankizumab 150"
"CD011535_pub7_data","Subgroup","Apremilast 30 mg versus apremilast 20 mg"
"CD011535_pub7_data","Subgroup","Ixekizumab Q2W versus ixekizumab Q4W"
"CD011535_pub7_data","Subgroup","Apremilast 30 versus apremilast other"
"CD011575_pub3_data","Analysis.group","1"
"CD011575_pub3_data","Analysis.name","All-cause mortality"
"CD011575_pub3_data","Analysis.name","Stroke"
"CD011575_pub3_data","Analysis.name","Serious cardiovascular adverse events"
"CD011575_pub3_data","Analysis.name","Cardiovascular mortality"
"CD011575_pub3_data","Analysis.name","Non-cardiovascular mortality"
"CD011575_pub3_data","Analysis.name","Myocardial infarction/acute coronary syndrome"
"CD011575_pub3_data","Analysis.name","Heart failure (decompensation/hospitalisation/death)"
"CD011575_pub3_data","Analysis.name","Renal failure"
"CD011575_pub3_data","Analysis.name","Total serious adverse events"
"CD011575_pub3_data","Analysis.name","Total minor adverse events"
"CD011575_pub3_data","Analysis.name","Withdrawals due to adverse effects"
"CD011575_pub3_data","Analysis.name","Mean systolic BP achieved"
"CD011575_pub3_data","Analysis.name","Mean diastolic BP achieved"
"CD011575_pub3_data","Analysis.name","All-cause mortality (excluding Wei)"
"CD011575_pub3_data","Analysis.name","Stroke (excluding Wei)"
"CD011575_pub3_data","Analysis.name","Serious cardiovascular adverse events (excluding Wei)"
"CD011575_pub3_data","Analysis.name","Cardiovascular mortality (excluding Wei)"
"CD011575_pub3_data","Analysis.name","All-cause mortality (excluding JATOS)"
"CD011575_pub3_data","Analysis.name","Serious cardioavascular adverse events (excluding JATOS)"
"CD011575_pub3_data","Analysis.name","Stroke (excluding JATOS)"
"CD011575_pub3_data","Analysis.name","Cardiovascular mortality (excluding JATOS)"
"CD011575_pub3_data","Subgroup","New Subgroup"
"CD011600_pub3_data","Analysis.group","1"
"CD011600_pub3_data","Analysis.group","2"
"CD011600_pub3_data","Analysis.name","Moderate-to-severe exacerbations (Rate)"
"CD011600_pub3_data","Analysis.name","Moderate-to-severe exacerbations (Time-to-first)"
"CD011600_pub3_data","Analysis.name","Moderate-to-severe exacerbations (≥ 1 exacerbation)"
"CD011600_pub3_data","Analysis.name","Moderate-to-severe exacerbations (Rate, stratified by eosinophil count)"
"CD011600_pub3_data","Analysis.name","Moderate-to-severe exacerbations (Rate, stratified by baseline ICS use)"
"CD011600_pub3_data","Analysis.name","Severe exacerbations (Rate)"
"CD011600_pub3_data","Analysis.name","Severe exacerbations (Time-to-first)"
"CD011600_pub3_data","Analysis.name","All exacerbations (Rate)"
"CD011600_pub3_data","Analysis.name","Change in SGRQ"
"CD011600_pub3_data","Analysis.name","SGRQ, ≥ 4 decrease from baseline"
"CD011600_pub3_data","Analysis.name","SGRQ, end of study"
"CD011600_pub3_data","Analysis.name","Pneumonia"
"CD011600_pub3_data","Analysis.name","Pneumonia (Time-to-first)"
"CD011600_pub3_data","Analysis.name","Serious adverse events, pneumonia"
"CD011600_pub3_data","Analysis.name","Serious adverse event, all-cause"
"CD011600_pub3_data","Analysis.name","Change in E-RS"
"CD011600_pub3_data","Analysis.name","TDI, ≥ 1-unit increase"
"CD011600_pub3_data","Analysis.name","TDI (Focal score), over 24 weeks"
"CD011600_pub3_data","Analysis.name","Change in trough FEV1 (mL)"
"CD011600_pub3_data","Analysis.name","Trough FEV1, end of study (mL)"
"CD011600_pub3_data","Analysis.name","FEV1 AUC 0 to 4 (mL), end of study"
"CD011600_pub3_data","Analysis.name","Change in trough FVC (mL)"
"CD011600_pub3_data","Analysis.name","Death, all causes"
"CD011600_pub3_data","Analysis.name","Death, all causes (Time-to-event)"
"CD011600_pub3_data","Analysis.name","Death, cardiovascular causes"
"CD011600_pub3_data","Analysis.name","Death, respiratory causes"
"CD011600_pub3_data","Analysis.name","Death, COPD-related"
"CD011600_pub3_data","Subgroup","High Eosinophils"
"CD011600_pub3_data","Subgroup","Low Eosinophils"
"CD011600_pub3_data","Subgroup","Baseline ICS Use"
"CD011600_pub3_data","Subgroup","No Baseline ICS Use"
"CD011624_pub3_data","Analysis.group","1"
"CD011624_pub3_data","Analysis.name","Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, eclampsia)"
"CD011624_pub3_data","Analysis.name","Perinatal (foetal and neonatal) mortality"
"CD011624_pub3_data","Analysis.name","Large-for-gestational-age"
"CD011624_pub3_data","Analysis.name","Composite of mortality or serious morbidity (as defined by trial)"
"CD011624_pub3_data","Analysis.name","Caesarean section"
"CD011624_pub3_data","Analysis.name","Gestational weight gain"
"CD011624_pub3_data","Analysis.name","Induction of labour"
"CD011624_pub3_data","Analysis.name","Maternal hypoglycaemia"
"CD011624_pub3_data","Analysis.name","Mean daily fasting blood glucose mmol/L"
"CD011624_pub3_data","Analysis.name","Mean daily postprandial blood glucose"
"CD011624_pub3_data","Analysis.name","Glycated haemoglobin"
"CD011624_pub3_data","Analysis.name","Use of pharmacological therapy"
"CD011624_pub3_data","Analysis.name","Triglycerides mg/dL"
"CD011624_pub3_data","Analysis.name","NEFA mmol/L"
"CD011624_pub3_data","Analysis.name","Total cholesterol mg/dL"
"CD011624_pub3_data","Analysis.name","LDL mg/dL"
"CD011624_pub3_data","Analysis.name","HDL mg/dL"
"CD011624_pub3_data","Analysis.name","Breastfeeding"
"CD011624_pub3_data","Analysis.name","Adherence with treatment"
"CD011624_pub3_data","Analysis.name","Composite of serious maternal health outcomes"
"CD011624_pub3_data","Analysis.name","Stillbirth"
"CD011624_pub3_data","Analysis.name","Neonatal death"
"CD011624_pub3_data","Analysis.name","Macrosomia"
"CD011624_pub3_data","Analysis.name","Small-for-gestational-age"
"CD011624_pub3_data","Analysis.name","Shoulder dystocia"
"CD011624_pub3_data","Analysis.name","Gestational age at birth (weeks)"
"CD011624_pub3_data","Analysis.name","Birthweight"
"CD011624_pub3_data","Analysis.name","Birthweight z score"
"CD011624_pub3_data","Analysis.name","Head circumference"
"CD011624_pub3_data","Analysis.name","Head circumference z score"
"CD011624_pub3_data","Analysis.name","Length"
"CD011624_pub3_data","Analysis.name","Length z score"
"CD011624_pub3_data","Analysis.name","Infant hypoglycaemia"
"CD011624_pub3_data","Analysis.name","Neonatal jaundice (hyperbilirubinaemia)"
"CD011624_pub3_data","Analysis.name","Adiposity (% fat mass)"
"CD011624_pub3_data","Analysis.name","C-peptide ng/mL"
"CD011624_pub3_data","Analysis.name","Cord leptin/adiponectin ratio"
"CD011624_pub3_data","Analysis.name","ANGPTL4 in cord serum ng/mL"
"CD011624_pub3_data","Analysis.name","Cord adiponectin ng/mL"
"CD011624_pub3_data","Analysis.name","Cord leptin ng/mL"
"CD011624_pub3_data","Analysis.name","Admission to neonatal intensive care unit/nursery"
"CD011624_pub3_data","Analysis.name","Length of antenatal stay"
"CD011624_pub3_data","Analysis.name","Length of postnatal stay (maternal)"
"CD011624_pub3_data","Analysis.name","Length of postnatal stay (infant)"
"CD011626_pub3_data","Analysis.group","1"
"CD011626_pub3_data","Analysis.group","2"
"CD011626_pub3_data","Analysis.name","Cardiac T2* value (ms)"
"CD011626_pub3_data","Analysis.name","Myocardial iron concentration (mg/g)"
"CD011626_pub3_data","Analysis.name","Left ventricular ejection fraction (%)"
"CD011626_pub3_data","Analysis.name","Serum ferritin (μg/mL)"
"CD011626_pub3_data","Analysis.name","Liver T2* value (ms)"
"CD011626_pub3_data","Analysis.name","Liver iron concentration (mg/g)"
"CD011626_pub3_data","Analysis.name","Adverse events"
"CD011626_pub3_data","Analysis.name","Cardiac T2* (ms)"
"CD011626_pub3_data","Subgroup","At 6 months"
"CD011626_pub3_data","Subgroup","At 12 months"
"CD011626_pub3_data","Subgroup","Oedema"
"CD011626_pub3_data","Subgroup","Dizziness"
"CD011626_pub3_data","Subgroup","Mild cutaneous allergy"
"CD011626_pub3_data","Subgroup","Joint swelling"
"CD011626_pub3_data","Subgroup","Hypotension"
"CD011626_pub3_data","Subgroup","Gastrointestinal symptoms"
"CD011627_pub3_data","Analysis.group","1"
"CD011627_pub3_data","Analysis.group","2"
"CD011627_pub3_data","Analysis.group","3"
"CD011627_pub3_data","Analysis.name","Number of participants with incontinence-associated dermatitis"
"CD011627_pub3_data","Analysis.name","Number of participants with intervention-related pain"
"CD011627_pub3_data","Analysis.name","Number of participants with intervention-related itch"
"CD011627_pub3_data","Analysis.name","Number of participants satisfied with skin care products or procedures for prevention of IAD "
"CD011627_pub3_data","Subgroup","No-rinse skin cleansing product (A) versus soap and water (B)"
"CD011627_pub3_data","Subgroup","Tena Wash Mousse (A) versus Clinisan Foam Cleanser (B)"
"CD011627_pub3_data","Subgroup","Disposable washcloth containing 3% Dimethicone (A) versus soft washcloth using water and PH-neutral soap (B)"
"CD011627_pub3_data","Subgroup","Sudocrem (A) versus zinc oxide (B) "
"CD011627_pub3_data","Subgroup","3M skin protective film (A) versus IV3000 translucent semipermeable film (B)"
"CD011627_pub3_data","Subgroup","Petroleum jelly (A) versus zinc oxide (B)"
"CD011627_pub3_data","Subgroup","Dimethicone silicone oil (A) versus acrylate terpolymer film spray (B)"
"CD011627_pub3_data","Subgroup","Stoma skincare power (A) versus tannic acid (B)"
"CD011627_pub3_data","Subgroup","Stoma skincare power (A) versus Comfeel skin protection (B)"
"CD011627_pub3_data","Subgroup","Tannic acid (A) versus Comfeel skin protection (B)"
"CD011627_pub3_data","Subgroup","One-step cleanser with moisturiser and dimethicone (Comfort Shield Perineal Care Washcloth Dimethicone 3%) (A) versus no-rinse cleanser, moisturiser with gylcerin dimethicone and film forming spray (Cavilon Skin Cleanser and Cavilon No Sting Barrier Film) (B)"
"CD011627_pub3_data","Subgroup","Skin cleansing plus stomahesive protective powder (Brava) and film-forming skin product (3M) (A) versus cleansing with water using a soft washcloth and application of zinc oxide (B)"
"CD011627_pub3_data","Subgroup","Skin cleansing and application of a skin protectant (A) versus skin cleansing alone (B)"
"CD011627_pub3_data","Subgroup","Cavilon Antiseptic Skin Cleanser plus Cavilon Durable Barrier Cream (A) versus soap and water plus a lotion (B)  "
"CD011627_pub3_data","Subgroup","Triple Care Cleanser skin cleanser plus Triple Care Cream (A) versus soap and water plus Triple Care Cream (B)"
"CD011627_pub3_data","Subgroup","3M skin protective film plus IV3000 translucent semi-permeable film (A) versus 3M skin protective film alone (B)"
"CD011627_pub3_data","Subgroup","Acrylate terpolymer skin protection film spray plus dimethicone silicone oil (A) versus dimethicone silicone oil alone (B)"
"CD011627_pub3_data","Subgroup","Petroleum jelly plus zinc oxide powder (A) versus zinc oxide powder alone (B)"
"CD011627_pub3_data","Subgroup","Cavilon Antiseptic Skin Cleanser plus Cavilon Durable Barrier Cream (A) versus soap and water plus a lotion (B) "
"CD011670_pub3_data","Analysis.group","1"
"CD011670_pub3_data","Analysis.group","2"
"CD011670_pub3_data","Analysis.name","Overall morbidity"
"CD011670_pub3_data","Analysis.name","Wound infection"
"CD011670_pub3_data","Analysis.name","Abdominal abscess"
"CD011670_pub3_data","Analysis.name","Bowel obstruction"
"CD011670_pub3_data","Analysis.name","Faecal fistula"
"CD011670_pub3_data","Analysis.name","Unplanned bowel resection"
"CD011670_pub3_data","Analysis.name","Total length of hospital stay (days)"
"CD011670_pub3_data","Analysis.name","Time away from normal activities (days)"
"CD011670_pub3_data","Analysis.name","Quality of life (score on a scale from 0 to 100)"
"CD011671_pub3_data","Analysis.group","1"
"CD011671_pub3_data","Analysis.name","Delayed graft function"
"CD011671_pub3_data","Analysis.name","Delayed graft function: type of donor"
"CD011671_pub3_data","Analysis.name","Delayed graft function: era of study"
"CD011671_pub3_data","Analysis.name","Delayed graft function: preservation times"
"CD011671_pub3_data","Analysis.name","Graft survival (12 month follow-up)"
"CD011671_pub3_data","Analysis.name","Graft survival (at maximum follow-up)"
"CD011671_pub3_data","Analysis.name","Primary non-function"
"CD011671_pub3_data","Analysis.name","Duration of delayed graft function"
"CD011671_pub3_data","Analysis.name","Patient survival (12 month follow up, time-to-event)"
"CD011671_pub3_data","Analysis.name","Patient survival (12-month follow up, dichotomous)"
"CD011671_pub3_data","Analysis.name","Acute rejection in the first year"
"CD011671_pub3_data","Subgroup","Continuous (from donor hospital to implanting centre)"
"CD011671_pub3_data","Subgroup","Not specified"
"CD011671_pub3_data","Subgroup","Mix of continuous and end-ischaemic"
"CD011671_pub3_data","Subgroup","Type of donor not specified"
"CD011671_pub3_data","Subgroup","DBD"
"CD011671_pub3_data","Subgroup","DCD"
"CD011671_pub3_data","Subgroup","Pre-2008"
"CD011671_pub3_data","Subgroup","Modern era"
"CD011671_pub3_data","Subgroup","Cold ischaemic time not reported"
"CD011671_pub3_data","Subgroup","Long mean cold ischaemic time (≥ 24 hours)"
"CD011671_pub3_data","Subgroup","Short mean cold ischaemic time (< 24 hours)"
"CD011689_pub4_data","Analysis.group","1"
"CD011689_pub4_data","Analysis.group","2"
"CD011689_pub4_data","Analysis.group","3"
"CD011689_pub4_data","Analysis.group","4"
"CD011689_pub4_data","Analysis.group","5"
"CD011689_pub4_data","Analysis.group","6"
"CD011689_pub4_data","Analysis.group","8"
"CD011689_pub4_data","Analysis.group","9"
"CD011689_pub4_data","Analysis.group","10"
"CD011689_pub4_data","Analysis.group","11"
"CD011689_pub4_data","Analysis.group","12"
"CD011689_pub4_data","Analysis.group","13"
"CD011689_pub4_data","Analysis.group","14"
"CD011689_pub4_data","Analysis.group","16"
"CD011689_pub4_data","Analysis.group","17"
"CD011689_pub4_data","Analysis.group","18"
"CD011689_pub4_data","Analysis.group","20"
"CD011689_pub4_data","Analysis.group","21"
"CD011689_pub4_data","Analysis.group","24"
"CD011689_pub4_data","Analysis.group","26"
"CD011689_pub4_data","Analysis.group","28"
"CD011689_pub4_data","Analysis.group","29"
"CD011689_pub4_data","Analysis.group","30"
"CD011689_pub4_data","Analysis.group","31"
"CD011689_pub4_data","Analysis.group","32"
"CD011689_pub4_data","Analysis.group","33"
"CD011689_pub4_data","Analysis.group","34"
"CD011689_pub4_data","Analysis.group","36"
"CD011689_pub4_data","Analysis.group","37"
"CD011689_pub4_data","Analysis.group","38"
"CD011689_pub4_data","Analysis.group","39"
"CD011689_pub4_data","Analysis.group","40"
"CD011689_pub4_data","Analysis.group","41"
"CD011689_pub4_data","Analysis.group","42"
"CD011689_pub4_data","Analysis.group","44"
"CD011689_pub4_data","Analysis.group","45"
"CD011689_pub4_data","Analysis.group","46"
"CD011689_pub4_data","Analysis.group","48"
"CD011689_pub4_data","Analysis.group","49"
"CD011689_pub4_data","Analysis.group","52"
"CD011689_pub4_data","Analysis.group","54"
"CD011689_pub4_data","Analysis.group","56"
"CD011689_pub4_data","Analysis.group","57"
"CD011689_pub4_data","Analysis.group","58"
"CD011689_pub4_data","Analysis.group","59"
"CD011689_pub4_data","Analysis.group","60"
"CD011689_pub4_data","Analysis.group","61"
"CD011689_pub4_data","Analysis.group","62"
"CD011689_pub4_data","Analysis.group","64"
"CD011689_pub4_data","Analysis.group","65"
"CD011689_pub4_data","Analysis.group","66"
"CD011689_pub4_data","Analysis.group","67"
"CD011689_pub4_data","Analysis.group","68"
"CD011689_pub4_data","Analysis.group","69"
"CD011689_pub4_data","Analysis.group","70"
"CD011689_pub4_data","Analysis.group","72"
"CD011689_pub4_data","Analysis.group","73"
"CD011689_pub4_data","Analysis.group","74"
"CD011689_pub4_data","Analysis.group","76"
"CD011689_pub4_data","Analysis.group","77"
"CD011689_pub4_data","Analysis.group","80"
"CD011689_pub4_data","Analysis.group","82"
"CD011689_pub4_data","Analysis.group","84"
"CD011689_pub4_data","Analysis.name","Death"
"CD011689_pub4_data","Analysis.name","PPH >= 1000 mL"
"CD011689_pub4_data","Analysis.name","Blood transfusion"
"CD011689_pub4_data","Analysis.name","Severe maternal morbidity: intensive care admissions"
"CD011689_pub4_data","Analysis.name","PPH >= 500 mL"
"CD011689_pub4_data","Analysis.name","Additional uterotonics"
"CD011689_pub4_data","Analysis.name","Blood loss"
"CD011689_pub4_data","Analysis.name","Change in haemoglobin"
"CD011689_pub4_data","Analysis.name","Breastfeeding"
"CD011689_pub4_data","Analysis.name","Nausea"
"CD011689_pub4_data","Analysis.name","Vomiting"
"CD011689_pub4_data","Analysis.name","Headache"
"CD011689_pub4_data","Analysis.name","Abdominal pain"
"CD011689_pub4_data","Analysis.name","Shivering"
"CD011689_pub4_data","Analysis.name","Fever"
"CD011689_pub4_data","Analysis.name","Maternal sense of well-being"
"CD011689_pub4_data","Analysis.name","Maternal satisfaction"
"CD011689_pub4_data","Analysis.name","Diarrhoea"
"CD011689_pub4_data","Analysis.name","Hypertension"
"CD011689_pub4_data","Analysis.name","Maternal well-being"
"CD011689_pub4_data","Subgroup","Women’s perceptions of well-being at 3 months postpartum: less energy than before birth"
"CD011689_pub4_data","Subgroup","Women’s perceptions of well-being at 3 months postpartum: experiencing (some) fatigue"
"CD011689_pub4_data","Subgroup","Did management influence positively the childbirth experiences of the mothers?"
"CD011689_pub4_data","Subgroup","Did management influence negatively the childbirth experiences of the mothers?"
"CD011689_pub4_data","Subgroup","Did management make no difference in the childbirth experiences of the mothers?"
"CD011689_pub4_data","Subgroup","General health at 6 weeks postpartum (Worse than prepregnancy)"
"CD011689_pub4_data","Subgroup","General health at 6 weeks postpartum (Exhausted since birth)"
"CD011689_pub4_data","Subgroup","General health at 6 weeks postpartum (Exhausted at 6 weeks)"
"CD011689_pub4_data","Subgroup","General health at 6 weeks postpartum (Blues)"
"CD011689_pub4_data","Subgroup","General health at 6 weeks postpartum (Depressed)"
"CD011689_pub4_data","Subgroup","General health at 6 weeks postpartum (Help for depression)"
"CD011689_pub4_data","Subgroup","General health at 6 weeks postpartum (Admission to hospital for depression)"
"CD011689_pub4_data","Subgroup","General health at 6 weeks postpartum (No health problems reported)"
"CD011689_pub4_data","Subgroup","Satisfied with third-stage management"
"CD011689_pub4_data","Subgroup","Felt in control during third stage"
"CD011689_pub4_data","Subgroup","Satisfied or very satisfied with drug"
"CD011689_pub4_data","Subgroup","Complaints about or problems with drug"
"CD011689_pub4_data","Subgroup","Would take drug again after subsequent deliveries"
"CD011689_pub4_data","Subgroup","Would recommend drug to a friend"
"CD011689_pub4_data","Subgroup","Woman's satisfaction using an eight item Client Satisfaction Questionnaire"
"CD011689_pub4_data","Subgroup","Vaginal birth"
"CD011689_pub4_data","Subgroup","Caesarean"
"CD011689_pub4_data","Subgroup","Vaginal birth - Women’s perceptions of well-being at 3 months postpartum: Less energy than before birth"
"CD011689_pub4_data","Subgroup","Vaginal birth - Women’s perceptions of well-being at 3 months postpartum: Experiencing (some) fatigue"
"CD011689_pub4_data","Subgroup","Vaginal birth - Did management influence positively the childbirth experiences of the mothers?"
"CD011689_pub4_data","Subgroup","Vaginal birth - Did management influence negatively the childbirth experiences of the mothers?"
"CD011689_pub4_data","Subgroup","Vaginal birth - Did management make no difference in the childbirth experiences of the mothers?"
"CD011689_pub4_data","Subgroup","vaginal birth"
"CD011689_pub4_data","Subgroup","Vaginal delivery"
"CD011689_pub4_data","Subgroup","Vaginal birth - General health at 6 weeks postpartum (Worse than prepregnancy)"
"CD011689_pub4_data","Subgroup","Vaginal birth - General health at 6 weeks postpartum (Exhausted since birth)"
"CD011689_pub4_data","Subgroup","Vaginal birth - General health at 6 weeks postpartum (Exhausted at 6 weeks)"
"CD011689_pub4_data","Subgroup","Vaginal birth - General health at 6 weeks postpartum (Blues)"
"CD011689_pub4_data","Subgroup","Vaginal birth - General health at 6 weeks postpartum (Depressed)"
"CD011689_pub4_data","Subgroup","Vaginal birth - General health at 6 weeks postpartum (Help for depression)"
"CD011689_pub4_data","Subgroup","Vaginal birth - General health at 6 weeks postpartum (Admission to hospital for depression)"
"CD011689_pub4_data","Subgroup","Vaginal birth - General health at 6 weeks postpartum (No health problems reported)"
"CD011689_pub4_data","Subgroup","Vaginal birth - Satisfied with third-stage management"
"CD011689_pub4_data","Subgroup","Vaginal birth - Felt in control during third stage"
"CD011689_pub4_data","Subgroup","Both caesarean and vaginal birth"
"CD011689_pub4_data","Subgroup","Community setting"
"CD011689_pub4_data","Subgroup","Both community and hospital setting"
"CD011689_pub4_data","Subgroup","Hospital setting"
"CD011689_pub4_data","Subgroup","Community setting - Women’s perceptions of well-being at 3 months postpartum: Less energy than before birth"
"CD011689_pub4_data","Subgroup","Community setting - Women’s perceptions of well-being at 3 months postpartum: Experiencing (some) fatigue"
"CD011689_pub4_data","Subgroup","Hospital setting - Did management influence positively the childbirth experiences of the mothers?"
"CD011689_pub4_data","Subgroup","Hospital setting - Did management influence negatively the childbirth experiences of the mothers?"
"CD011689_pub4_data","Subgroup","Hospital setting - Did management make no difference in the childbirth experiences of the mothers?"
"CD011689_pub4_data","Subgroup","Hospital setting - General health at 6 weeks postpartum (Worse than prepregnancy)"
"CD011689_pub4_data","Subgroup","Hospital setting - General health at 6 weeks postpartum (Exhausted since birth)"
"CD011689_pub4_data","Subgroup","Hospital setting - General health at 6 weeks postpartum (Exhausted at 6 weeks)"
"CD011689_pub4_data","Subgroup","Hospital setting - General health at 6 weeks postpartum (Blues)"
"CD011689_pub4_data","Subgroup","Hospital setting - General health at 6 weeks postpartum (Depressed)"
"CD011689_pub4_data","Subgroup","Hospital setting - General health at 6 weeks postpartum (Help for depression)"
"CD011689_pub4_data","Subgroup","Hospital setting - General health at 6 weeks postpartum (Admission to hospital for depression)"
"CD011689_pub4_data","Subgroup","Hospital setting - General health at 6 weeks postpartum (No health problems reported)"
"CD011689_pub4_data","Subgroup","Hospital setting - Satisfied with third-stage management"
"CD011689_pub4_data","Subgroup","Hospital setting - Felt in control during third stage"
"CD011689_pub4_data","Subgroup","Community setting - Complaints about or problems with drug"
"CD011689_pub4_data","Subgroup","Community setting - Satisfied or very satisfied with drug"
"CD011689_pub4_data","Subgroup","Community setting - Would take drug again after subsequent deliveries"
"CD011689_pub4_data","Subgroup","Community setting - Would recommend drug to a friend"
"CD011762_pub2_data","Analysis.group","1"
"CD011762_pub2_data","Analysis.group","2"
"CD011762_pub2_data","Analysis.group","3"
"CD011762_pub2_data","Analysis.group","4"
"CD011762_pub2_data","Analysis.group","5"
"CD011762_pub2_data","Analysis.group","6"
"CD011762_pub2_data","Analysis.group","7"
"CD011762_pub2_data","Analysis.group","8"
"CD011762_pub2_data","Analysis.group","9"
"CD011762_pub2_data","Analysis.group","10"
"CD011762_pub2_data","Analysis.group","11"
"CD011762_pub2_data","Analysis.group","12"
"CD011762_pub2_data","Analysis.name","All-cause mortality"
"CD011762_pub2_data","Analysis.name","Major VTE"
"CD011762_pub2_data","Analysis.name","Symptomatic VTE"
"CD011762_pub2_data","Analysis.name","Major bleeding"
"CD011762_pub2_data","Analysis.name","Major bleeding: rivaroxaban versus LMWH"
"CD011762_pub2_data","Analysis.name","Major bleeding: other direct factor Xa inhibitors (excluding rivaroxaban) versus LMWH"
"CD011762_pub2_data","Analysis.name","Serious hepatic adverse events"
"CD011762_pub2_data","Analysis.name","Serious non-hepatic adverse events"
"CD011762_pub2_data","Analysis.name","Fatal VTE"
"CD011762_pub2_data","Analysis.name","Asymptomatic distal DVT"
"CD011762_pub2_data","Analysis.name","Fatal bleeding"
"CD011762_pub2_data","Analysis.name","Liver enzymes elevation"
"CD011762_pub2_data","Analysis.name","Minor adverse events"
"CD011762_pub2_data","Analysis.name","Volume of blood loss"
"CD011762_pub2_data","Analysis.name","Major bleeding: rivaroxaban 10 mg/day, apixaban 5 mg/day, and other direct factor Xa drugs at low dose vs LMWH "
"CD011762_pub2_data","Subgroup","Apixaban"
"CD011762_pub2_data","Subgroup","Darexaban"
"CD011762_pub2_data","Subgroup","Edoxaban"
"CD011762_pub2_data","Subgroup","Letaxaban"
"CD011762_pub2_data","Subgroup","Rivaroxaban"
"CD011762_pub2_data","Subgroup","LY517717"
"CD011762_pub2_data","Subgroup","Betrixaban"
"CD011762_pub2_data","Subgroup","Erixaban"
"CD011762_pub2_data","Subgroup","Short prophylaxis (≤ 14 days)"
"CD011762_pub2_data","Subgroup","Extended prophylaxis (> 14 days)"
"CD011762_pub2_data","Subgroup","Short prophylaxis (≤ 14 days) rivaroxaban"
"CD011762_pub2_data","Subgroup","Extended prophylaxis (> 14 days) rivaroxaban"
"CD011762_pub2_data","Subgroup","Extended prophylaxis (> 14 days) Other DFXa"
"CD011762_pub2_data","Subgroup","Short prophylaxis (≤ 14 days) Other DFXa"
"CD011762_pub2_data","Subgroup","Start of comparator before surgery"
"CD011762_pub2_data","Subgroup","Start of comparator after surgery"
"CD011762_pub2_data","Subgroup","Once daily administration"
"CD011762_pub2_data","Subgroup","Twice daily administration"
"CD011762_pub2_data","Subgroup","Total hip replacement surgery only"
"CD011762_pub2_data","Subgroup","Total knee replacement surgery only"
"CD011762_pub2_data","Subgroup","Total hip or knee replacement surgery"
"CD011762_pub2_data","Subgroup","Hip fracture surgery only"
"CD011762_pub2_data","Subgroup","Rivaroxaban dose (5 to 30 mg/day)"
"CD011762_pub2_data","Subgroup","Edoxaban dose (30 to 60 mg/day)"
"CD011762_pub2_data","Subgroup","Apixaban dose (2.5 to 20 mg/day)"
"CD011762_pub2_data","Subgroup","LY517717 low dose (≤ 50 mg/day)"
"CD011762_pub2_data","Subgroup","Darexaban low dose (≤ 40 mg/day)"
"CD011762_pub2_data","Subgroup","Betrixaban dose (40 to 160 mg/day)"
"CD011762_pub2_data","Subgroup","Letaxaban low dose (≤ 40 mg/day)"
"CD011762_pub2_data","Subgroup","Erixaban low dose (≤ 2.5 mg/day)"
"CD011762_pub2_data","Subgroup","Apixaban 5 mg/day"
"CD011762_pub2_data","Subgroup","Other direct factor Xa inhibitors at low dose"
"CD011762_pub2_data","Subgroup","Rivaroxaban 10 mg/day"
"CD011762_pub2_data","Subgroup","Other direct factor Xa inhibitors"
"CD011762_pub2_data","Subgroup","Rivaroxaban versus LMWH"
"CD011762_pub2_data","Subgroup","Other direct factor Xa inhibitors versus LMWH"
"CD011778_pub2_data","Analysis.group","1"
"CD011778_pub2_data","Analysis.group","2"
"CD011778_pub2_data","Analysis.group","3"
"CD011778_pub2_data","Analysis.name","PPD (change from baseline (mm)); 3 months"
"CD011778_pub2_data","Analysis.name","PPD (change from baseline (mm)); 6 months"
"CD011778_pub2_data","Analysis.name","BOP (change from baseline (%)); 3 months"
"CD011778_pub2_data","Analysis.name","BOP (change from baseline (%)); 6 months"
"CD011778_pub2_data","Analysis.name","CAL (change from baseline (mm)); 3 months"
"CD011778_pub2_data","Analysis.name","CAL (change from baseline (mm)); 6 months"
"CD011778_pub2_data","Analysis.name","REC (change from baseline (mm)); 3 months"
"CD011778_pub2_data","Analysis.name","REC (change from baseline (mm)); 6 months"
"CD011778_pub2_data","Analysis.name","PPD at 6 months. Subgroup analysis according to type of control (placebo or negative control)"
"CD011778_pub2_data","Analysis.name","CAL at 6 months. Subgroup analysis according to type of control (placebo or negative control)"
"CD011778_pub2_data","Analysis.name","PPD (change from baseline(mm)); 3 months"
"CD011778_pub2_data","Subgroup","Single session"
"CD011778_pub2_data","Subgroup","Multiple sessions"
"CD011778_pub2_data","Subgroup","Negative control"
"CD011778_pub2_data","Subgroup","Placebo control "
"CD011793_pub3_data","Analysis.group","1"
"CD011793_pub3_data","Analysis.name","Mortality"
"CD011793_pub3_data","Analysis.name","Cardiopulmonary bypass time (minutes)"
"CD011793_pub3_data","Analysis.name","Aortic cross-clamp time (minutes)"
"CD011793_pub3_data","Analysis.name","Length of hospital stay (days)"
"CD011793_pub3_data","Analysis.name","Postoperative blood loss (mL)"
"CD011793_pub3_data","Analysis.name","Deep sternal wound infection"
"CD011793_pub3_data","Analysis.name","Pain scores"
"CD011793_pub3_data","Analysis.name","Quality of life"
"CD011793_pub3_data","Analysis.name","Index admission costs"
"CD011793_pub3_data","Analysis.name","Intensive care unit stay (days)"
"CD011793_pub3_data","Analysis.name","Postoperative pulmonary function tests (% FEV1)"
"CD011793_pub3_data","Analysis.name","Re-exploration"
"CD011793_pub3_data","Analysis.name","Postoperative atrial fibrillation"
"CD011793_pub3_data","Analysis.name","Postoperative ventilation time (hours)"
"CD011800_pub2_data","Analysis.group","1"
"CD011800_pub2_data","Analysis.group","2"
"CD011800_pub2_data","Analysis.name","Vitamin D status (achieved 25-hydroxyvitamin D level)"
"CD011800_pub2_data","Analysis.name","Secondary hyperparathyroidism (achieved parathyroid hormone level)"
"CD011800_pub2_data","Analysis.name","Adverse events"
"CD011800_pub2_data","Analysis.name","Vitamin D status (change in 25OHD level from baseline)"
"CD011800_pub2_data","Analysis.name","All-cause mortality"
"CD011800_pub2_data","Analysis.name","Bone mineral density change – lumbar spine  "
"CD011800_pub2_data","Analysis.name","Bone mineral density change – hip  "
"CD011800_pub2_data","Analysis.name","Bone mineral density change – forearm  "
"CD011800_pub2_data","Analysis.name","Secondary hyperparathyroidism (change in parathyroid hormone level from baseline)"
"CD011806_pub2_data","Analysis.group","1"
"CD011806_pub2_data","Analysis.group","2"
"CD011806_pub2_data","Analysis.group","3"
"CD011806_pub2_data","Analysis.name","Clinical response"
"CD011806_pub2_data","Analysis.name","Clinical relapse (mixed IBD)"
"CD011806_pub2_data","Analysis.name","Clinical relapse (mixed IBD) – sensitivity analysis (fixed-effect)"
"CD011806_pub2_data","Analysis.name","Quality of life (QoL) (end of follow-up/change in score)"
"CD011806_pub2_data","Analysis.name","QoL (end of follow-up/change in score) – sensitivity analysis (fixed-effect)"
"CD011806_pub2_data","Analysis.name","Withdrawals due to adverse events"
"CD011806_pub2_data","Analysis.name","Withdrawals due to adverse events – sensitivity analysis (fixed-effect)"
"CD011806_pub2_data","Analysis.name","Withdrawals due to adverse events – sensitivity analysis (removal of studies at risk of bias)"
"CD011806_pub2_data","Analysis.name","Disease activity at end of follow-up (Crohn's disease)"
"CD011806_pub2_data","Analysis.name","Disease activity at end of follow-up (Crohn's disease) – sensitivity analysis (fixed-effect)"
"CD011806_pub2_data","Analysis.name","Disease activity at end of follow-up – change in disease activity score (Crohn's disease)"
"CD011806_pub2_data","Analysis.name","Disease activity at end of follow-up (ulcerative colitis)"
"CD011806_pub2_data","Analysis.name","Disease activity at end of follow-up (ulcerative colitis) – sensitivity analysis (fixed-effect)"
"CD011806_pub2_data","Analysis.name","Normalisation of vitamin D levels – vitamin D levels at end of study period (continuous outcomes)"
"CD011806_pub2_data","Analysis.name","Normalisation of vitamin D levels – vitamin D levels at end of study period (continuous outcomes) – sensitivity analysis (fixed effect)"
"CD011806_pub2_data","Analysis.name","Normalisation of vitamin D levels – numbers of people with vitamin D deficiency at end of study (dichotomous outcome)"
"CD011806_pub2_data","Analysis.name","Total serious adverse events – mixed dose (mixed population)"
"CD011806_pub2_data","Analysis.name","Total serious adverse events – mixed dose (mixed population) – sensitivity analysis (fixed-effect)"
"CD011806_pub2_data","Analysis.name","Total serious adverse events – mixed dose (mixed population) – sensitivity analysis (removal of studies at risk of bias)"
"CD011806_pub2_data","Analysis.name","Clinical relapse (Crohn's disease)"
"CD011806_pub2_data","Analysis.name","Withdrawals due to adverse events – high-dose vitamin D versus low-dose vitamin D (mixed population)"
"CD011806_pub2_data","Analysis.name","Normalisation of vitamin D levels (vitamin D level at end of follow-up) – high-treatment-dose vitamin D versus low-treatment-dose vitamin D (mixed measures)"
"CD011806_pub2_data","Analysis.name","Normalisation of vitamin D levels (change in vitamin D levels) – high-treatment-dose vitamin D versus low-treatment-dose vitamin D (mixed measures)"
"CD011806_pub2_data","Analysis.name","Disease activity at end of follow-up – any-treatment-dose vitamin D versus supplemental-dose vitamin D (Crohn's disease – Pediatric Crohn's Disease Activity Index < 10 at end of follow-up)"
"CD011806_pub2_data","Analysis.name","Normalisation of vitamin D levels (vitamin D level at end of follow-up) – any-treatment-dose vitamin D versus supplemental-dose vitamin D (mixed measures)"
"CD011806_pub2_data","Analysis.name","Normalisation of vitamin D levels (change in vitamin D levels) – any-treatment-dose vitamin D versus supplemental-dose vitamin D (mixed measures)"
"CD011806_pub2_data","Subgroup","Ulcerative colitis"
"CD011806_pub2_data","Subgroup","Any-treatment-dose-vitamin D (mixed measures of quality of life – mixed population)"
"CD011806_pub2_data","Subgroup","Any-treatment-dose-vitamin D (mixed measures of QoL – mixed population)"
"CD011806_pub2_data","Subgroup","Low-treatment-dose vitamin D (Crohn's disease)"
"CD011806_pub2_data","Subgroup","Supplemental-dose vitamin D (mixed population)"
"CD011806_pub2_data","Subgroup","Any-treatment-dose vitamin D (mixed population)"
"CD011806_pub2_data","Subgroup","Supplemental-dose vitamin D (Crohn's Disease Activity Index score)"
"CD011806_pub2_data","Subgroup","All-treatment-dose vitamin D (mixed measures at end of treatment)"
"CD011806_pub2_data","Subgroup","Low-treatment-dose vitamin D (change in Crohn's Disease Activity Index score)"
"CD011806_pub2_data","Subgroup","All-treatment-dose vitamin D (mixed scores)"
"CD011806_pub2_data","Subgroup","Supplemental-dose vitamin D (Lichtinger score)"
"CD011806_pub2_data","Subgroup","All -treatment-dose vitamin D (mixed scores)"
"CD011806_pub2_data","Subgroup","All-treatment-dose vitamin D (mixed measures)"
"CD011806_pub2_data","Subgroup","Low-treatment-dose vitamin D (change from start to end of follow-up)"
"CD011806_pub2_data","Subgroup","Low-treatment-dose vitamin D (vitamin D deficiency at end of follow-up)"
"CD011806_pub2_data","Subgroup","All-treatment-dose vitamin D (mixed population)"
"CD011806_pub2_data","Subgroup","Low-treatment-dose vitamin D (mixed population)"
"CD011841_pub3_data","Analysis.group","1"
"CD011841_pub3_data","Analysis.group","2"
"CD011841_pub3_data","Analysis.group","3"
"CD011841_pub3_data","Analysis.group","4"
"CD011841_pub3_data","Analysis.group","5"
"CD011841_pub3_data","Analysis.group","6"
"CD011841_pub3_data","Analysis.group","7"
"CD011841_pub3_data","Analysis.group","8"
"CD011841_pub3_data","Analysis.group","9"
"CD011841_pub3_data","Analysis.group","10"
"CD011841_pub3_data","Analysis.group","11"
"CD011841_pub3_data","Analysis.group","12"
"CD011841_pub3_data","Analysis.group","13"
"CD011841_pub3_data","Analysis.group","14"
"CD011841_pub3_data","Analysis.group","15"
"CD011841_pub3_data","Analysis.group","16"
"CD011841_pub3_data","Analysis.group","17"
"CD011841_pub3_data","Analysis.group","18"
"CD011841_pub3_data","Analysis.group","19"
"CD011841_pub3_data","Analysis.group","20"
"CD011841_pub3_data","Analysis.group","21"
"CD011841_pub3_data","Analysis.group","22"
"CD011841_pub3_data","Analysis.group","23"
"CD011841_pub3_data","Analysis.name","Mean change in BCVA between baseline and 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Recurrence of central serous chorioretinopathy at 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Persistent central serous chorioretinopathy at 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Mean change in central retinal thickness between baseline and 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Recurrent/persistent central serous chorioretinopathy at 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Quality of life at 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Adverse events"
"CD011841_pub3_data","Analysis.name","Mean change in contrast sensitivity between baseline and 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Adverse events (e.g. loss of vision due to treatment, retinal atrophy, CNV, RPE damage)"
"CD011841_pub3_data","Analysis.name","Adverse events (e.g. conjunctival hyperemia)"
"CD011841_pub3_data","Analysis.name","Harms (e.g. loss of vision due to treatment, retinal atrophy, CNV, RPE damage)"
"CD011841_pub3_data","Analysis.name","Mean change in best-corrected visual acuity between baseline and 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Recurrence/persistence of central serous chorioretinopathy at 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Mean change in contrast sensitivity at 12 months (± 6)"
"CD011841_pub3_data","Analysis.name","Adverse events at 12 months"
"CD011841_pub3_data","Subgroup","Recurrence of CSC at 12 months"
"CD011841_pub3_data","Subgroup","Persistent CSC at 12 months"
"CD011841_pub3_data","Subgroup","Pulsed"
"CD011841_pub3_data","Subgroup","Non-pulsed"
"CD011841_pub3_data","Subgroup","Central macular thickness"
"CD011841_pub3_data","Subgroup","Central foveal thickness"
"CD011841_pub3_data","Subgroup","Yellow compared with red"
"CD011841_pub3_data","Subgroup","Yellow compared with green"
"CD011841_pub3_data","Subgroup","Red compared with green"
"CD011841_pub3_data","Subgroup","Central retinal thickness"
"CD011841_pub3_data","Subgroup","Subfoveal choroidal thickness"
"CD011851_pub3_data","Analysis.group","1"
"CD011851_pub3_data","Analysis.name","Fatal cardiovascular events"
"CD011851_pub3_data","Analysis.name","Fatal cardiovascular events: sensitivity analysis using fixed-effect model"
"CD011851_pub3_data","Analysis.name","Low-density lipoprotein cholesterol"
"CD011851_pub3_data","Analysis.name","Low-density lipoprotein cholesterol: sensitivity analysis using fixed-effect model"
"CD011851_pub3_data","Analysis.name","Low-density lipoprotein cholesterol: sensitivity analysis excluding studies with high risk of bias"
"CD011851_pub3_data","Analysis.name","Systolic blood pressure"
"CD011851_pub3_data","Analysis.name","Systolic blood pressure: sensitivity analysis using fixed-effect model"
"CD011851_pub3_data","Analysis.name","Systolic blood pressure: sensitivity of analysis excluding studies with high risk of bias"
"CD011851_pub3_data","Analysis.name"," Systolic blood pressure: sensitivity analysis excluding outlier"
"CD011851_pub3_data","Analysis.name","Diastolic blood pressure"
"CD011851_pub3_data","Analysis.name","Diastolic blood pressure: sensitivity analysis using fixed-effect model"
"CD011851_pub3_data","Analysis.name","Diastolic blood pressure: sensitivity analysis excluding studies with high risk of bias"
"CD011851_pub3_data","Analysis.name","Heart rate"
"CD011851_pub3_data","Analysis.name","Heart rate: sensitivity analysis using fixed-effect model"
"CD011851_pub3_data","Analysis.name","Heart rate: sensitivity analysis excluding studies with high risk of bias"
"CD011858_pub2_data","Analysis.group","1"
"CD011858_pub2_data","Analysis.group","2"
"CD011858_pub2_data","Analysis.group","3"
"CD011858_pub2_data","Analysis.group","4"
"CD011858_pub2_data","Analysis.group","5"
"CD011858_pub2_data","Analysis.group","6"
"CD011858_pub2_data","Analysis.group","7"
"CD011858_pub2_data","Analysis.group","8"
"CD011858_pub2_data","Analysis.group","9"
"CD011858_pub2_data","Analysis.group","10"
"CD011858_pub2_data","Analysis.group","11"
"CD011858_pub2_data","Analysis.group","12"
"CD011858_pub2_data","Analysis.group","13"
"CD011858_pub2_data","Analysis.group","14"
"CD011858_pub2_data","Analysis.group","15"
"CD011858_pub2_data","Analysis.group","16"
"CD011858_pub2_data","Analysis.group","17"
"CD011858_pub2_data","Analysis.group","18"
"CD011858_pub2_data","Analysis.name","Extracorporeal circuit thrombosis"
"CD011858_pub2_data","Analysis.name","Activated partial thromboplastin time"
"CD011858_pub2_data","Analysis.name","Platelet count"
"CD011858_pub2_data","Analysis.name","Dialysis vascular access thrombosis"
"CD011858_pub2_data","Analysis.name","Dialysis adequacy (Kt/V)"
"CD011858_pub2_data","Analysis.name","Death (any cause)"
"CD011858_pub2_data","Analysis.name","Plasma anti-Xa level"
"CD011858_pub2_data","Analysis.name","Potassium"
"CD011858_pub2_data","Analysis.name","Major bleeding"
"CD011858_pub2_data","Analysis.name","Minor bleeding"
"CD011858_pub2_data","Analysis.name","Subcutaneous bleeding"
"CD011858_pub2_data","Analysis.name","Subconjunctival bleeding"
"CD011858_pub2_data","Analysis.name","Haemorrhoid bleeding"
"CD011858_pub2_data","Analysis.name","Vascular access bleeding"
"CD011858_pub2_data","Analysis.name","Activated clotting time"
"CD011858_pub2_data","Analysis.name","Thrombin antithrombin complex "
"CD011858_pub2_data","Analysis.name","Thrombin time"
"CD011858_pub2_data","Analysis.name","Prothrombin time"
"CD011858_pub2_data","Analysis.name","Time to stop bleeding"
"CD011858_pub2_data","Analysis.name","Dialysis access (urea reduction ratio)"
"CD011858_pub2_data","Analysis.name","Extracorporeal circuit thrombosis (clotting bloodlines)"
"CD011858_pub2_data","Analysis.name","Any bleeding"
"CD011858_pub2_data","Analysis.name","Worsening haemorrhage"
"CD011858_pub2_data","Analysis.name","Cardiovascular adverse events"
"CD011858_pub2_data","Analysis.name","Cost per treatment"
"CD011858_pub2_data","Analysis.name","Cardiovascular death"
"CD011858_pub2_data","Analysis.name","Blood transfusion"
"CD011858_pub2_data","Analysis.name","Clotting leading to discontinuation"
"CD011858_pub2_data","Analysis.name","Gastrointestinal bleeding"
"CD011858_pub2_data","Analysis.name","Cerebral haemorrhage"
"CD011858_pub2_data","Analysis.name","Vascular access site haemorrhage"
"CD011858_pub2_data","Analysis.name","Vascular access thrombosis"
"CD011858_pub2_data","Analysis.name","Vascular access site haematoma"
"CD011858_pub2_data","Analysis.name","Vascular access complication"
"CD011858_pub2_data","Analysis.name","Cardiorespiratory arrest"
"CD011858_pub2_data","Analysis.name","Pain"
"CD011858_pub2_data","Subgroup","Enoxaparin vs nadroparin"
"CD011858_pub2_data","Subgroup","Tinzaparin versus dalteparin"
"CD011858_pub2_data","Subgroup","Tinzaparin vs dalteparin"
"CD011858_pub2_data","Subgroup","Enoxaparin vs dalteparin"
"CD011858_pub2_data","Subgroup","Fraxiparin vs domestically manufactured LMWH"
"CD011858_pub2_data","Subgroup","Hypotension"
"CD011858_pub2_data","Subgroup","Chest tightness"
"CD011866_pub3_data","Analysis.group","1"
"CD011866_pub3_data","Analysis.group","2"
"CD011866_pub3_data","Analysis.group","3"
"CD011866_pub3_data","Analysis.group","4"
"CD011866_pub3_data","Analysis.name","Dropouts"
"CD011866_pub3_data","Analysis.name","Point abstinence, end of treatment"
"CD011866_pub3_data","Analysis.name","Point abstinence, longest follow-up"
"CD011866_pub3_data","Analysis.name","Continuous abstinence, end of treatment"
"CD011866_pub3_data","Analysis.name","Continuous abstinence, longest follow-up"
"CD011866_pub3_data","Analysis.name","Frequency of drug intake, end of treatment"
"CD011866_pub3_data","Analysis.name","Longest period of abstinence"
"CD011866_pub3_data","Analysis.name","Craving"
"CD011866_pub3_data","Analysis.name","Severity of dependence"
"CD011866_pub3_data","Analysis.name","Depression"
"CD011866_pub3_data","Analysis.name","Point abstinence, longest follow up"
"CD011866_pub3_data","Analysis.name","Severity of dependence (ASI)"
"CD011866_pub3_data","Subgroup","CBT"
"CD011866_pub3_data","Subgroup","Contingency management"
"CD011866_pub3_data","Subgroup","Motivational interviewing"
"CD011866_pub3_data","Subgroup","12-step facilitation"
"CD011866_pub3_data","Subgroup","Psychodynamic therapy"
"CD011866_pub3_data","Subgroup","CBT + contingency management"
"CD011866_pub3_data","Subgroup","Motivational interviewing + CBT"
"CD011866_pub3_data","Subgroup","Interpersonal therapy"
"CD011866_pub3_data","Subgroup","Acceptance and commitment therapy"
"CD011885_pub2_data","Analysis.group","1"
"CD011885_pub2_data","Analysis.group","2"
"CD011885_pub2_data","Analysis.name","Clinically relevant response, as defined by study authors"
"CD011885_pub2_data","Analysis.name","Tolerability: leaving study early due to adverse effects"
"CD011885_pub2_data","Analysis.name","Quality of life: SF-36 score change (higher is better)"
"CD011885_pub2_data","Analysis.name","Exacerbations of psychosis, as defined by study authors"
"CD011885_pub2_data","Analysis.name","Acceptability: leaving study early for any reason"
"CD011885_pub2_data","Analysis.name","Efficacy: leaving study early due to inefficacy of treatment"
"CD011885_pub2_data","Analysis.name","General mental state: clinically important change in PANSS total score"
"CD011885_pub2_data","Analysis.name","General mental state: average endpoint or change PANSS total score (lower is better)"
"CD011885_pub2_data","Analysis.name","General mental state: average endpoint BPRS total score (lower is better)"
"CD011885_pub2_data","Analysis.name","Remission as defined by Andreasen (2005)"
"CD011885_pub2_data","Analysis.name","Global state: CGI-Severity endpoint or change score (lower is better)"
"CD011885_pub2_data","Analysis.name","Global state: CGI-Improvement endpoint score (lower is better)"
"CD011885_pub2_data","Analysis.name","Positive symptoms: clinically important change in PANSS positive subscore"
"CD011885_pub2_data","Analysis.name","Positive symptoms: average endpoint or change PANSS positive subscore (lower is better)"
"CD011885_pub2_data","Analysis.name","Negative symptoms: clinically important change in PANSS negative subscore"
"CD011885_pub2_data","Analysis.name","Negative symptoms: average endpoint or change in PANSS negative subscore (lower is better)"
"CD011885_pub2_data","Analysis.name","Negative symptoms: average endpoint SANS score (lower is better)"
"CD011885_pub2_data","Analysis.name","Depressive symptoms: clinically relevant response, as defined by study authors"
"CD011885_pub2_data","Analysis.name","Depressive symptoms: average endpoint PANSS G6 item (depression) score (lower is better)"
"CD011885_pub2_data","Analysis.name","Depressive symptoms: average change in MADRS score (lower is better)"
"CD011885_pub2_data","Analysis.name","Anxiety: average endpoint m-COVI score (lower is better)"
"CD011885_pub2_data","Analysis.name","Aggressive behaviour: clinically important change in PANSS-Excited Component subscore"
"CD011885_pub2_data","Analysis.name","Aggressive behaviour: average endpoint PANSS-Excited Component subscore (lower is better)"
"CD011885_pub2_data","Analysis.name","Duration of hospitalisation in days (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: number of participants experiencing at least one adverse effect"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – akathisia as a dichotomous outcome"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – akathisia measured by mean score change in BAS (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – akathisia measured by mean score change in ESRS-A (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – dyskinesia as a dichotomous outcome"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – dyskinesia measured by mean score change in AIMS (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – dyskinesia measured by mean score change in ESRS-A (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – dystonia measured by mean score change in ESRS-A (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – extrapyramidal disorder as a dichotomous outcome"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – parkinsonism as a dichotomous outcome"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – parkinsonism measured by mean score change in SAS (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: extrapyramidal – parkinsonism measured by mean score change in ESRS-A (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: agitation"
"CD011885_pub2_data","Analysis.name","Adverse effects: anxiety"
"CD011885_pub2_data","Analysis.name","Adverse effects: diarrhoea"
"CD011885_pub2_data","Analysis.name","Adverse effects: dry mouth"
"CD011885_pub2_data","Analysis.name","Adverse effects: fatigue"
"CD011885_pub2_data","Analysis.name","Adverse effects: headache"
"CD011885_pub2_data","Analysis.name","Adverse effects: increased appetite"
"CD011885_pub2_data","Analysis.name","Adverse effects: insomnia"
"CD011885_pub2_data","Analysis.name","Adverse effects: lethargy"
"CD011885_pub2_data","Analysis.name","Adverse effects: prolactin – high levels"
"CD011885_pub2_data","Analysis.name","Adverse effects: prolactin – mean change in ng/dL (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: restlessness"
"CD011885_pub2_data","Analysis.name","Adverse effects: sedation"
"CD011885_pub2_data","Analysis.name","Adverse effects: somnolence"
"CD011885_pub2_data","Analysis.name","Adverse effects: suicidal ideation"
"CD011885_pub2_data","Analysis.name","Adverse effects: triglycerides average change in mg/dL (lower is better)"
"CD011885_pub2_data","Analysis.name","Adverse effects: weight – clinically important increase in weight (≥ 7%)"
"CD011885_pub2_data","Analysis.name","Adverse effects: weight – average change in kg (lower is better)"
"CD011885_pub2_data","Analysis.name","Functioning: average change in PSP score (high is better)"
"CD011885_pub2_data","Analysis.name","Quality of life: average endpoint SF-36 score (higher is better)"
"CD011885_pub2_data","Analysis.name","Quality of life: average change in SWN score (higher is better)"
"CD011885_pub2_data","Analysis.name","Satisfaction with care: clinically important change in MSQ score"
"CD011885_pub2_data","Analysis.name","Satisfaction with care: average change in DAI-10 score (higher is better)"
"CD011885_pub2_data","Analysis.name","Satisfaction with care: average endpoint MSQ score (higher is better)"
"CD011885_pub2_data","Analysis.name","Response: exclusion of studies with unclear randomisation and allocation concealment methods"
"CD011885_pub2_data","Analysis.name","Tolerability: exclusion of studies with unclear randomisation and allocation concealment methods"
"CD011885_pub2_data","Analysis.name","Response: exclusion of studies with a high risk of bias regarding blinding of participants and personnel"
"CD011885_pub2_data","Analysis.name","Tolerability: exclusion of studies with a high risk of bias regarding blinding of participants and personnel"
"CD011885_pub2_data","Analysis.name","Response: exclusion of studies with a high risk of bias in selective reporting"
"CD011885_pub2_data","Analysis.name","Tolerability: exclusion of studies with a high risk of bias in selective reporting "
"CD011885_pub2_data","Analysis.name","Response: fixed-effect model"
"CD011885_pub2_data","Analysis.name","Tolerability: fixed-effect model"
"CD012067_pub3_data","Analysis.group","1"
"CD012067_pub3_data","Analysis.group","2"
"CD012067_pub3_data","Analysis.group","3"
"CD012067_pub3_data","Analysis.group","4"
"CD012067_pub3_data","Analysis.group","5"
"CD012067_pub3_data","Analysis.group","6"
"CD012067_pub3_data","Analysis.group","8"
"CD012067_pub3_data","Analysis.group","9"
"CD012067_pub3_data","Analysis.group","11"
"CD012067_pub3_data","Analysis.group","13"
"CD012067_pub3_data","Analysis.group","14"
"CD012067_pub3_data","Analysis.group","15"
"CD012067_pub3_data","Analysis.group","16"
"CD012067_pub3_data","Analysis.group","17"
"CD012067_pub3_data","Analysis.group","18"
"CD012067_pub3_data","Analysis.group","19"
"CD012067_pub3_data","Analysis.group","20"
"CD012067_pub3_data","Analysis.group","21"
"CD012067_pub3_data","Analysis.group","22"
"CD012067_pub3_data","Analysis.group","23"
"CD012067_pub3_data","Analysis.group","24"
"CD012067_pub3_data","Analysis.group","25"
"CD012067_pub3_data","Analysis.group","26"
"CD012067_pub3_data","Analysis.group","27"
"CD012067_pub3_data","Analysis.group","28"
"CD012067_pub3_data","Analysis.group","29"
"CD012067_pub3_data","Analysis.name","Serum creatinine [mg/dL]"
"CD012067_pub3_data","Analysis.name","Doubling of serum creatinine"
"CD012067_pub3_data","Analysis.name","Mean change in eGFR [mL/min/1.73 m2]"
"CD012067_pub3_data","Analysis.name","Death"
"CD012067_pub3_data","Analysis.name","Pain"
"CD012067_pub3_data","Analysis.name","Systolic blood pressure [mm Hg]"
"CD012067_pub3_data","Analysis.name","Diastolic blood pressure [mm Hg]"
"CD012067_pub3_data","Analysis.name","Total kidney volume [mL/cm]"
"CD012067_pub3_data","Analysis.name","Height-adjusted total kidney volume [mL/cm]"
"CD012067_pub3_data","Analysis.name","Albuminuria [mg/mmol]"
"CD012067_pub3_data","Analysis.name","Spot urine osmolality [mOsm/kg]"
"CD012067_pub3_data","Analysis.name","Urine specific gravity [mOsm/kg]"
"CD012067_pub3_data","Analysis.name","Serious adverse events"
"CD012067_pub3_data","Analysis.name","Adverse events"
"CD012067_pub3_data","Analysis.name","Withdrawal due to adverse events"
"CD012067_pub3_data","Analysis.name","eGFR change [mL/min/1.73 m2/month]"
"CD012067_pub3_data","Analysis.name","Quality of life scores"
"CD012067_pub3_data","Analysis.name","Urinary albumin-creatinine ratio [mg/g]"
"CD012067_pub3_data","Analysis.name","GFR [mL/min/1.73 m2]"
"CD012067_pub3_data","Analysis.name","Change in GFR [mL/min/1.73 m²]"
"CD012067_pub3_data","Analysis.name","Kidney failure"
"CD012067_pub3_data","Analysis.name","Kidney failure or doubling of serum creatinine"
"CD012067_pub3_data","Analysis.name","30% or more decrease in GFR or kidney failure"
"CD012067_pub3_data","Analysis.name","Acute kidney injury"
"CD012067_pub3_data","Analysis.name","Back or flank pain"
"CD012067_pub3_data","Analysis.name","Health-related quality of life"
"CD012067_pub3_data","Analysis.name","Depression and anxiety"
"CD012067_pub3_data","Analysis.name","Mean arterial pressure [mm Hg]"
"CD012067_pub3_data","Analysis.name","Total kidney volume [L]"
"CD012067_pub3_data","Analysis.name","Total kidney volume (TKV), height-adjusted TKV and absolute change (pooled)"
"CD012067_pub3_data","Analysis.name","Cyst volume [L]"
"CD012067_pub3_data","Analysis.name","Parenchymal volume [mL]"
"CD012067_pub3_data","Analysis.name","Proteinuria [g/24 hours]"
"CD012067_pub3_data","Analysis.name","Albuminuria [g/24 hours]"
"CD012067_pub3_data","Analysis.name","GFR [mL/min/1.73 m²]"
"CD012067_pub3_data","Analysis.name","Received transplantation"
"CD012067_pub3_data","Analysis.name","Percent change in total kidney volume [L]"
"CD012067_pub3_data","Analysis.name","Cyst volume [mL]"
"CD012067_pub3_data","Analysis.name","Proteinuria"
"CD012067_pub3_data","Analysis.name","Doubling of proteinuria"
"CD012067_pub3_data","Analysis.name","Albuminuria"
"CD012067_pub3_data","Analysis.name","GFR"
"CD012067_pub3_data","Analysis.name","Change in eGFR [mL/min/1.73 m2]"
"CD012067_pub3_data","Analysis.name","Rate of eGFR decline"
"CD012067_pub3_data","Analysis.name","Annual rate of eGFR decline"
"CD012067_pub3_data","Analysis.name","Quality of life score"
"CD012067_pub3_data","Analysis.name","Percent change in height-adjusted total kidney volume"
"CD012067_pub3_data","Analysis.name","Mean annual percent change in height-adjusted total kidney volume"
"CD012067_pub3_data","Analysis.name","Absolute change in height-adjusted total kidney volume"
"CD012067_pub3_data","Analysis.name","Height-adjusted liver volume"
"CD012067_pub3_data","Analysis.name","Dose completion"
"CD012067_pub3_data","Analysis.name","C-reactive protein"
"CD012067_pub3_data","Analysis.name","eGFR change from baseline [%]"
"CD012067_pub3_data","Analysis.name","Total kidney volume [mL]"
"CD012067_pub3_data","Analysis.name","Albuminuria [mg/g]"
"CD012067_pub3_data","Analysis.name","eGFR [mL/min/1.73 m2]"
"CD012067_pub3_data","Analysis.name","Annual change in eGFR [mL/min/1.73 m2]"
"CD012067_pub3_data","Analysis.name","Cardiovascular events"
"CD012067_pub3_data","Analysis.name","Total kidney volume change [%]"
"CD012067_pub3_data","Analysis.name","Hospitalisations"
"CD012067_pub3_data","Analysis.name","Need for kidney replacement therapy"
"CD012067_pub3_data","Analysis.name","Proteinuria [mg/day]"
"CD012067_pub3_data","Analysis.name","Albuminuria [mg/day]"
"CD012067_pub3_data","Analysis.name","Change in eGFR"
"CD012067_pub3_data","Analysis.name","Change in eGFR [mL/min/1.7 3 m2]"
"CD012067_pub3_data","Analysis.name","Per cent annual change in total kidney volume [mL/cm]"
"CD012067_pub3_data","Analysis.name","All cause hospitalisation "
"CD012067_pub3_data","Analysis.name","Albuminuria [mg/24 hours]"
"CD012067_pub3_data","Analysis.name","Albuminuria [µg/min]"
"CD012067_pub3_data","Analysis.name","Creatinine clearance [mL/min/1.73 m2]"
"CD012067_pub3_data","Analysis.name","Change in height-adjusted total kidney volume"
"CD012067_pub3_data","Analysis.name","Urinary albumin excretion: > 20% increase"
"CD012067_pub3_data","Analysis.name","Annual rate of eGFR"
"CD012067_pub3_data","Analysis.name","Decrease in eGFR: > 25%"
"CD012067_pub3_data","Analysis.name","ADPKD disease progression"
"CD012067_pub3_data","Analysis.name","Height-adjusted total kidney volume [mL]"
"CD012067_pub3_data","Analysis.name","Annual rate of height-adjusted total kidney volume [%]"
"CD012067_pub3_data","Analysis.name","UACR [mg/g]"
"CD012067_pub3_data","Analysis.name","Urine volume [mL]"
"CD012067_pub3_data","Analysis.name","Urine osmolality [mOsmol/Kg]"
"CD012067_pub3_data","Analysis.name","Adherence"
"CD012067_pub3_data","Analysis.name","Change in urine osmolality [mOsm/kg]"
"CD012067_pub3_data","Analysis.name","Serum creatinine [µmol/L]"
"CD012067_pub3_data","Analysis.name","GFR [mL/min]"
"CD012067_pub3_data","Analysis.name","Frequency scale of back or abdominal pain"
"CD012067_pub3_data","Subgroup","Studies > 1 year"
"CD012067_pub3_data","Subgroup","Studies ≤ 1 year"
"CD012067_pub3_data","Subgroup","Kidney pain"
"CD012067_pub3_data","Subgroup","Back pain"
"CD012067_pub3_data","Subgroup","Pain in extremity"
"CD012067_pub3_data","Subgroup","4-11 year olds"
"CD012067_pub3_data","Subgroup","12-17 year olds"
"CD012067_pub3_data","Subgroup","One month"
"CD012067_pub3_data","Subgroup","One week"
"CD012067_pub3_data","Subgroup","Headache"
"CD012067_pub3_data","Subgroup","Diarrhoea"
"CD012067_pub3_data","Subgroup","Dizziness"
"CD012067_pub3_data","Subgroup","Dry mouth"
"CD012067_pub3_data","Subgroup","Nausea"
"CD012067_pub3_data","Subgroup","Thirst"
"CD012067_pub3_data","Subgroup","Fatigue"
"CD012067_pub3_data","Subgroup","Polyuria"
"CD012067_pub3_data","Subgroup","Liver enzyme elevation"
"CD012067_pub3_data","Subgroup","Hypertension"
"CD012067_pub3_data","Subgroup","Upper respiratory tract infection"
"CD012067_pub3_data","Subgroup","Nocturia"
"CD012067_pub3_data","Subgroup","Urinary tract infection"
"CD012067_pub3_data","Subgroup","Pollakiuria"
"CD012067_pub3_data","Subgroup","Increased creatinine"
"CD012067_pub3_data","Subgroup","Any adverse event"
"CD012067_pub3_data","Subgroup","SF-36 mental component summary"
"CD012067_pub3_data","Subgroup","SF-36 physical component summary"
"CD012067_pub3_data","Subgroup","KDQOL overall health rating"
"CD012067_pub3_data","Subgroup","Duration ≤ 1 year"
"CD012067_pub3_data","Subgroup","Duration > 1 year"
"CD012067_pub3_data","Subgroup","Alopecia"
"CD012067_pub3_data","Subgroup","Anaemia"
"CD012067_pub3_data","Subgroup","Renal cyst infection"
"CD012067_pub3_data","Subgroup","Infection"
"CD012067_pub3_data","Subgroup","Fever"
"CD012067_pub3_data","Subgroup","Chest pain"
"CD012067_pub3_data","Subgroup","Epigastric pain"
"CD012067_pub3_data","Subgroup","Gastrointestinal symptoms"
"CD012067_pub3_data","Subgroup","Diarrhoea or abnormal faeces"
"CD012067_pub3_data","Subgroup","Angioedema"
"CD012067_pub3_data","Subgroup","Hyperlipidaemia"
"CD012067_pub3_data","Subgroup","Peripheral oedema"
"CD012067_pub3_data","Subgroup","Oral ulcers"
"CD012067_pub3_data","Subgroup","Haematuria"
"CD012067_pub3_data","Subgroup","Dysmenorrhea"
"CD012067_pub3_data","Subgroup","Arrhythmias"
"CD012067_pub3_data","Subgroup","Dermatitis"
"CD012067_pub3_data","Subgroup","High-dose mTORi"
"CD012067_pub3_data","Subgroup","Low-dose mTORi"
"CD012067_pub3_data","Subgroup","ARB + mTORi"
"CD012067_pub3_data","Subgroup","Abdominal fullness"
"CD012067_pub3_data","Subgroup","Pain interference on sleep"
"CD012067_pub3_data","Subgroup","Pain during strenuous physical activity"
"CD012067_pub3_data","Subgroup","Gastrointestinal tract symptoms"
"CD012067_pub3_data","Subgroup","Hypoglycaemia < 70 mg/dL"
"CD012067_pub3_data","Subgroup","Urinary tract infection or cyst rupture"
"CD012067_pub3_data","Subgroup","Sustained oedema refractory to diuretics"
"CD012067_pub3_data","Subgroup","Completed full dose"
"CD012067_pub3_data","Subgroup","Completed 50% dose"
"CD012067_pub3_data","Subgroup","400 mg/d"
"CD012067_pub3_data","Subgroup","200 mg/d"
"CD012067_pub3_data","Subgroup","400 + 200 mg/d"
"CD012067_pub3_data","Subgroup","Two years"
"CD012067_pub3_data","Subgroup","Eight years"
"CD012067_pub3_data","Subgroup","One year"
"CD012067_pub3_data","Subgroup","Cardiovascular disorder"
"CD012067_pub3_data","Subgroup","Cancer"
"CD012067_pub3_data","Subgroup","Renal haemorrhage or haematuria"
"CD012067_pub3_data","Subgroup","Stroke"
"CD012067_pub3_data","Subgroup","Gastrointestinal disorder"
"CD012067_pub3_data","Subgroup","Hyperkalaemia"
"CD012067_pub3_data","Subgroup","Acute kidney injury"
"CD012067_pub3_data","Subgroup","Nephrolithiasis or renal colic"
"CD012067_pub3_data","Subgroup","Vision changes"
"CD012067_pub3_data","Subgroup","Increased urination"
"CD012067_pub3_data","Subgroup","Increased thirst"
"CD012067_pub3_data","Subgroup","Muscle cramping/soreness"
"CD012067_pub3_data","Subgroup","Elevated AST/ALT"
"CD012067_pub3_data","Subgroup","Elevated AST"
"CD012067_pub3_data","Subgroup","Cyst infection"
"CD012067_pub3_data","Subgroup","Hyponatraemia"
"CD012067_pub3_data","Subgroup","Nephrolithiasis"
"CD012067_pub3_data","Subgroup","Dysuria"
"CD012067_pub3_data","Subgroup","Cyst rupture"
"CD012067_pub3_data","Subgroup","Diarrhea"
"CD012079_pub2_data","Analysis.group","1"
"CD012079_pub2_data","Analysis.group","2"
"CD012079_pub2_data","Analysis.group","3"
"CD012079_pub2_data","Analysis.group","4"
"CD012079_pub2_data","Analysis.group","5"
"CD012079_pub2_data","Analysis.name","Awareness of prolapse (0.5 to 7 years)"
"CD012079_pub2_data","Analysis.name","Repeat surgery (0.5 to 7 years)"
"CD012079_pub2_data","Analysis.name","Recurrent prolapse on examination (any compartment) "
"CD012079_pub2_data","Analysis.name","Recurrent prolapse on examination (anterior compartment) "
"CD012079_pub2_data","Analysis.name","Recurrent prolapse on examination (posterior compartment) "
"CD012079_pub2_data","Analysis.name","Visceral injury "
"CD012079_pub2_data","Analysis.name","Mesh exposure"
"CD012079_pub2_data","Analysis.name","POP-Q assessment "
"CD012079_pub2_data","Analysis.name","POP-Q assessment Total Vaginal Length (TVL)"
"CD012079_pub2_data","Analysis.name","Bladder function: de novo stress urinary incontinence (0.5 to 7 years)"
"CD012079_pub2_data","Analysis.name","Bladder function: de novo urge incontinence or voiding dysfunction "
"CD012079_pub2_data","Analysis.name","Painful intercourse - de novo dyspareunia "
"CD012079_pub2_data","Analysis.name","Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire 12 (PISQ-12) (0-48)"
"CD012079_pub2_data","Analysis.name","Quality of life"
"CD012079_pub2_data","Analysis.name","Quality of life (combined) "
"CD012079_pub2_data","Analysis.name","Patient Global Impression of Improvement (PGI-I) (better or very much better)"
"CD012079_pub2_data","Analysis.name","Operating time (minutes)"
"CD012079_pub2_data","Analysis.name","Length of stay in hospital (days)"
"CD012079_pub2_data","Analysis.name","Blood transfusion"
"CD012079_pub2_data","Analysis.name","Any repeat surgery (0.5 to 7 years)"
"CD012079_pub2_data","Analysis.name","Awareness of prolapse (0.5 to 7 years) including trials at high risk of bias "
"CD012079_pub2_data","Analysis.name","Repeat surgery (0.5 to 7 years) including trials at high risk of bias"
"CD012079_pub2_data","Analysis.name","Recurrent prolapse on examination (any compartment) including trials at high risk of bias"
"CD012079_pub2_data","Analysis.name","Any repeat surgery (0.5 to 7 years) including trials at high risk of bias"
"CD012079_pub2_data","Analysis.name","Awareness of prolapse (2 years)"
"CD012079_pub2_data","Analysis.name","Repeat surgery (2 years) "
"CD012079_pub2_data","Analysis.name","Recurrent prolapse on examination (any)"
"CD012079_pub2_data","Analysis.name","Bladder function: de novo stress urinary incontinence "
"CD012079_pub2_data","Analysis.name","Awareness of prolapse (1 to 3 years)"
"CD012079_pub2_data","Analysis.name","Repeat surgery (1 to 2 years)"
"CD012079_pub2_data","Analysis.name","Recurrent prolapse on examination (posterior compartment)"
"CD012079_pub2_data","Analysis.name","Bladder function: de novo stress urinary incontinence"
"CD012079_pub2_data","Analysis.name","Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire 12 (PISQ-12) (0-48) "
"CD012079_pub2_data","Analysis.name","Quality of life "
"CD012079_pub2_data","Analysis.name","Length of stay (days)"
"CD012079_pub2_data","Analysis.name","Repeat surgery "
"CD012079_pub2_data","Subgroup","Multi-compartment mesh"
"CD012079_pub2_data","Subgroup","Anterior compartment mesh"
"CD012079_pub2_data","Subgroup","Surgery for recurrent prolapse "
"CD012079_pub2_data","Subgroup","Surgery for mesh exposure "
"CD012079_pub2_data","Subgroup","Surgery for urinary incontinence"
"CD012079_pub2_data","Subgroup","Multi-compartment mesh "
"CD012079_pub2_data","Subgroup","Anterior compartment mesh "
"CD012079_pub2_data","Subgroup","Bladder injury"
"CD012079_pub2_data","Subgroup","Bowel injury"
"CD012079_pub2_data","Subgroup","Point C"
"CD012079_pub2_data","Subgroup","Point Bp"
"CD012079_pub2_data","Subgroup","Point Ba "
"CD012079_pub2_data","Subgroup","De novo voiding dysfunction "
"CD012079_pub2_data","Subgroup","De novo urgency, urge incontinence or bladder overactivity "
"CD012079_pub2_data","Subgroup","Prolapse Quality of Life Questionnaire (P-QoL) 0-100"
"CD012079_pub2_data","Subgroup","Pelvic Floor Impact Questionnaire-7 (PFIQ-7) 0-300"
"CD012079_pub2_data","Subgroup","International Consultation on Incontinence Questionnaire Vaginal Symptoms (ICIQ-VS)"
"CD012079_pub2_data","Subgroup","Anterior compartment repair"
"CD012079_pub2_data","Subgroup","Multi-compartment repair"
"CD012079_pub2_data","Subgroup","Posterior compartment repair"
"CD012079_pub2_data","Subgroup","Multi-compartment repair "
"CD012079_pub2_data","Subgroup","De novo urgency, urge incontinence or bladder overactivity"
"CD012079_pub2_data","Subgroup","Surgery for urinary incontinence "
"CD012079_pub2_data","Subgroup","Pelvic Floor Impact Questionnaire 7 (PFIQ-7) 0-300"
"CD012079_pub2_data","Subgroup","Pelvic Floor Distress Inventory (PFDI-20) 0-300"
"CD012079_pub2_data","Subgroup","Bladder injury "
"CD012152_pub4_data","Analysis.group","1"
"CD012152_pub4_data","Analysis.name","Hypoglycaemia"
"CD012152_pub4_data","Analysis.name","Major neurological disability at two years of age "
"CD012152_pub4_data","Analysis.name","Major neurological disability at six to seven years of age"
"CD012152_pub4_data","Analysis.name","Major neurological disability at two years of age - by risk factor"
"CD012152_pub4_data","Analysis.name","Receipt of treatment for hypoglycaemia during initial hospital stay"
"CD012152_pub4_data","Analysis.name","Separation from mother for treatment of hypoglycaemia (admission to NICU for hypoglycaemia)"
"CD012152_pub4_data","Analysis.name","Receipt of intravenous treatment for hypoglycaemia"
"CD012152_pub4_data","Analysis.name","Adverse effects (e.g. choking or vomiting at time of administration)"
"CD012152_pub4_data","Analysis.name","Developmental disability at two years of age"
"CD012152_pub4_data","Analysis.name","Developmental disability at six to seven years of age"
"CD012152_pub4_data","Analysis.name","Any neurological disability at two years of age - by risk factor"
"CD012152_pub4_data","Analysis.name","Any neurological disability at six to seven years of age - by risk factor"
"CD012152_pub4_data","Analysis.name","Any neurological disability at six to seven years of age - by single or multiple gel dose "
"CD012152_pub4_data","Analysis.name","Receipt of oral dextrose gel treatment for hypoglycaemia"
"CD012152_pub4_data","Analysis.name","Receipt of any medications for hypoglycaemia such as glucagon or corticosteroids"
"CD012152_pub4_data","Analysis.name","Number of episodes of hypoglycaemia (glucose oxidase method) (total number per infant)"
"CD012152_pub4_data","Analysis.name","Neonatal seizures"
"CD012152_pub4_data","Analysis.name","Duration of initial hospital stay (days)"
"CD012152_pub4_data","Analysis.name","Breastfeeding (any) after discharge "
"CD012152_pub4_data","Analysis.name","Visual impairment at two years of age"
"CD012152_pub4_data","Analysis.name","Hearing impairment at two years of age"
"CD012152_pub4_data","Analysis.name","Cerebral palsy at two years of age"
"CD012152_pub4_data","Analysis.name","Developmental delay/intellectual impairment at two years of age"
"CD012152_pub4_data","Analysis.name","Developmental delay/intellectual impairment at two years of age - mild (70 to 84)"
"CD012152_pub4_data","Analysis.name","Developmental delay/intellectual impairment at two years of age - moderate or severe (< 70)"
"CD012152_pub4_data","Analysis.name","Developmental delay/intellectual impairment at six to seven years of age"
"CD012152_pub4_data","Analysis.name","Developmental delay/intellectual impairment at two years of age - by risk factor"
"CD012152_pub4_data","Analysis.name","Executive dysfunction at two years of age"
"CD012152_pub4_data","Analysis.name","Executive dysfunction at six to seven years of age"
"CD012152_pub4_data","Analysis.name","Executive dysfunction at six to seven years of age - by single or multiple gel dose "
"CD012152_pub4_data","Analysis.name","Executive dysfunction at two years of age - by risk factor"
"CD012152_pub4_data","Analysis.name","Executive dysfunction at six to seven years of age - by risk factor"
"CD012152_pub4_data","Analysis.name","Emotional-behavioural difficulty at six to seven years of age"
"CD012152_pub4_data","Analysis.name","Emotional-behavioural difficulty at six to seven years of age - by risk factor"
"CD012152_pub4_data","Analysis.name","Emotional-behavioural difficulty at six to seven years of age - by single or multiple gel dose"
"CD012152_pub4_data","Subgroup","Major neurological disability at two years of age"
"CD012152_pub4_data","Subgroup","Child of mother with diabetes "
"CD012152_pub4_data","Subgroup","Other risk factor"
"CD012152_pub4_data","Subgroup","Developmental disability at two years of age"
"CD012152_pub4_data","Subgroup","Developmental disability at six to seven years of age"
"CD012152_pub4_data","Subgroup","Other risk factor "
"CD012152_pub4_data","Subgroup","Multiple dose"
"CD012152_pub4_data","Subgroup","Single dose"
"CD012152_pub4_data","Subgroup","Breastfeeding (full or exclusive) after discharge "
"CD012152_pub4_data","Subgroup","Developmental delay/intellectual impairment at two years of age"
"CD012152_pub4_data","Subgroup","Developmental delay/intellectual impairment at six to seven years of age - language impairment"
"CD012152_pub4_data","Subgroup","Developmental delay/intellectual impairment at six to seven years of age - motor impairment"
"CD012152_pub4_data","Subgroup","Child of mother with diabetes"
"CD012152_pub4_data","Subgroup","Executive dysfunction at two years of age"
"CD012152_pub4_data","Subgroup","Executive dysfunction at six to seven years of age"
"CD012152_pub4_data","Subgroup","Child of mother with diabetes - at two years of age"
"CD012152_pub4_data","Subgroup","Other risk factor - at two years of age"
"CD012152_pub4_data","Subgroup","Other risk factor - at six to seven years of age"
"CD012152_pub4_data","Subgroup","Child of mother with diabetes - at six to seven years of age"
"CD012170_pub2_data","Analysis.group","1"
"CD012170_pub2_data","Analysis.group","2"
"CD012170_pub2_data","Analysis.group","3"
"CD012170_pub2_data","Analysis.group","4"
"CD012170_pub2_data","Analysis.group","5"
"CD012170_pub2_data","Analysis.group","6"
"CD012170_pub2_data","Analysis.group","7"
"CD012170_pub2_data","Analysis.name","Amount of physical activity"
"CD012170_pub2_data","Analysis.name","Minutes of sedentary behaviour"
"CD012170_pub2_data","Analysis.name","Fruit and vegetable consumption"
"CD012170_pub2_data","Analysis.name","Sugary drink consumption"
"CD012170_pub2_data","Analysis.name","Alcohol consumption in the last week"
"CD012170_pub2_data","Analysis.name","Weight"
"CD012170_pub2_data","Analysis.name","Body mass index"
"CD012170_pub2_data","Analysis.name","Systolic blood pressure"
"CD012170_pub2_data","Analysis.name","Diastolic blood pressure"
"CD012170_pub2_data","Analysis.name","Total quality of life"
"CD012170_pub2_data","Analysis.name","Mental health quality of life"
"CD012170_pub2_data","Analysis.name","Physical health quality of life"
"CD012170_pub2_data","Analysis.name","Mental health literacy"
"CD012178_pub2_data","Analysis.group","1"
"CD012178_pub2_data","Analysis.name","Incidence of ROP at any stage"
"CD012178_pub2_data","Analysis.name","Incidence of ROP stage 3 and above"
"CD012178_pub2_data","Analysis.name","Mortality assessed throughout NICU stay"
"CD012178_pub2_data","Analysis.name","Incidence of IVH (all grades of IVH and severe IVH grades III and IV)"
"CD012178_pub2_data","Analysis.name","Incidence of NEC"
"CD012178_pub2_data","Analysis.name","Any reported adverse effects"
"CD012186_pub2_data","Analysis.group","1"
"CD012186_pub2_data","Analysis.name","SAEs"
"CD012186_pub2_data","Analysis.name","Withdrawals due to AEs"
"CD012186_pub2_data","Subgroup","Interferon beta-1b versus placebo"
"CD012186_pub2_data","Subgroup","Interferon beta-1a (Avonex) versus placebo"
"CD012186_pub2_data","Subgroup","Interferon beta-1a (Rebif) versus placebo"
"CD012186_pub2_data","Subgroup","Glatiramer acetate versus placebo"
"CD012186_pub2_data","Subgroup","Natalizumab versus placebo"
"CD012186_pub2_data","Subgroup","Azathioprine versus placebo"
"CD012186_pub2_data","Subgroup","Immunoglobulins versus placebo"
"CD012186_pub2_data","Subgroup","Fingolimod versus placebo"
"CD012186_pub2_data","Subgroup","Teriflunomide versus placebo"
"CD012186_pub2_data","Subgroup","Dimethyl fumarate versus placebo"
"CD012186_pub2_data","Subgroup","Daclizumab versus placebo"
"CD012186_pub2_data","Subgroup","Laquinimod versus placebo"
"CD012186_pub2_data","Subgroup","Pegylated interferon beta-1a versus placebo"
"CD012186_pub2_data","Subgroup","Cladribine versus placebo"
"CD012186_pub2_data","Subgroup","Rituximab versus placebo"
"CD012186_pub2_data","Subgroup","Ocrelizumab versus placebo"
"CD012186_pub2_data","Subgroup","Azathioprine versus interferons"
"CD012186_pub2_data","Subgroup","Natalizumab versus fingolimod"
"CD012186_pub2_data","Subgroup","Fingolimod versus interferon beta-1b"
"CD012186_pub2_data","Subgroup","Ofatumumab versus teriflunomide"
"CD012186_pub2_data","Subgroup","Diroximel fumarate versus dimethyl fumarate"
"CD012186_pub2_data","Subgroup","Dimethyl fumarate versus glatiramer acetate"
"CD012186_pub2_data","Subgroup","Ocrelizumab versus interferon beta 1a (Rebif)"
"CD012186_pub2_data","Subgroup","Ozanimod versus interferon beta-1a (Avonex)"
"CD012186_pub2_data","Subgroup","Fingolimod versus glatiramer acetate"
"CD012186_pub2_data","Subgroup","Rituximab versus glatiramer acetate"
"CD012186_pub2_data","Subgroup","Interferon beta 1a (Rebif) versus interferon beta-1b"
"CD012186_pub2_data","Subgroup","Siponimod versus placebo"
"CD012186_pub2_data","Subgroup","Cyclophosphamide versus corticosteroids"
"CD012186_pub2_data","Subgroup","Alemtuzumab versus interferon beta-1a (Rebif)"
"CD012186_pub2_data","Subgroup","Glatiramer acetate versus interferon beta-1a (Avonex)"
"CD012186_pub2_data","Subgroup","Laquinimod versus interferon beta-1a (Avonex)"
"CD012186_pub2_data","Subgroup","Daclizumab versus interferon beta-1a (Avonex)"
"CD012186_pub2_data","Subgroup","Glatiramer acetate versus interferon beta-1b"
"CD012186_pub2_data","Subgroup","Teriflunomide versus interferon beta-1a (Rebif)"
"CD012186_pub2_data","Subgroup","Ofatumumab versus placebo"
"CD012186_pub2_data","Subgroup","Glatiramer acetate versus interferon beta-1a (Rebif)"
"CD012186_pub2_data","Subgroup","Ocrelizumab versus interferon beta-1a (Avonex)"
"CD012186_pub2_data","Subgroup","Fingolimod versus interferon beta-1a (Avonex)"
"CD012186_pub2_data","Subgroup","Interferon beta-1a(Rebif) versus interferon beta-1a (Avonex)"
"CD012186_pub2_data","Subgroup","Mitoxantrone versus placebo"
"CD012186_pub2_data","Subgroup","Methotrexate versus placebo"
"CD012186_pub2_data","Subgroup","Interferon beta-1a (Avonex) versus interferon beta-1b"
"CD012186_pub2_data","Subgroup","Interferon beta-1a (Rebif) versus interferon beta-1a (Avonex)"
"CD012186_pub2_data","Subgroup","Mitoxantrone versus corticosteroids"
"CD012186_pub2_data","Subgroup","Ocrelizumab versus interferon beta-1a (Rebif)"
"CD012186_pub2_data","Subgroup","Fingolimod versus dimethyl fumarate"
"CD012214_pub3_data","Analysis.group","1"
"CD012214_pub3_data","Analysis.group","2"
"CD012214_pub3_data","Analysis.group","3"
"CD012214_pub3_data","Analysis.name","Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium"
"CD012214_pub3_data","Analysis.name","Progression of endometrial hyperplasia to endometrial cancer"
"CD012214_pub3_data","Analysis.name","Hysterectomy rate"
"CD012214_pub3_data","Analysis.name","Abnormal uterine bleeding"
"CD012214_pub3_data","Analysis.name","Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory or atrophic endometrium"
"CD012214_pub3_data","Analysis.name","Recurrence of endometrial hyperplasia"
"CD012214_pub3_data","Analysis.name","Adverse effects during treatment"
"CD012214_pub3_data","Subgroup","Nausea"
"CD012214_pub3_data","Subgroup","Pain in abdomen"
"CD012214_pub3_data","Subgroup","Heaviness in lower abdomen"
"CD012214_pub3_data","Subgroup","All effects"
"CD012265_pub2_data","Analysis.group","1"
"CD012265_pub2_data","Analysis.name","Proven sepsis"
"CD012265_pub2_data","Analysis.name","Time to full enteral feeds"
"CD012265_pub2_data","Analysis.name","Duration of hospital admission"
"CD012265_pub2_data","Analysis.name","Non-pathogenic intestinal microflora"
"CD012268_pub2_data","Analysis.group","1"
"CD012268_pub2_data","Analysis.name","Body weight"
"CD012268_pub2_data","Analysis.name","BMI"
"CD012268_pub2_data","Analysis.name","Waist circumference"
"CD012268_pub2_data","Analysis.name","Fat mass"
"CD012268_pub2_data","Analysis.name","Subgroup analysis: body weight by menopausal status"
"CD012268_pub2_data","Analysis.name","Subgroup analysis: body weight by sex"
"CD012268_pub2_data","Analysis.name","Subgroup analysis: body weight by baseline BMI"
"CD012268_pub2_data","Analysis.name","Subgroup analysis: body weight by dose"
"CD012268_pub2_data","Analysis.name","Subgroup analysis: body weight by co-intervention"
"CD012268_pub2_data","Analysis.name","Subgroup analysis: body weight by trial duration"
"CD012268_pub2_data","Analysis.name","Subgroup analysis: body weight by trial size"
"CD012268_pub2_data","Analysis.name","Subgroup analysis: intention-to-treat"
"CD012268_pub2_data","Subgroup","Mean change in weight [kg]"
"CD012268_pub2_data","Subgroup","Final body weight [kg]"
"CD012268_pub2_data","Subgroup","Final BMI"
"CD012268_pub2_data","Subgroup","Mean change in BMI"
"CD012268_pub2_data","Subgroup","Change in waist circumference"
"CD012268_pub2_data","Subgroup","Final waist circumference"
"CD012268_pub2_data","Subgroup","Final fat mass (kg)"
"CD012268_pub2_data","Subgroup","Mean change in fat mass"
"CD012268_pub2_data","Subgroup","Premenopausal"
"CD012268_pub2_data","Subgroup","Postmenopausal"
"CD012268_pub2_data","Subgroup","Women and men"
"CD012268_pub2_data","Subgroup","Women "
"CD012268_pub2_data","Subgroup","Obese"
"CD012268_pub2_data","Subgroup","Overweight"
"CD012268_pub2_data","Subgroup","Overweight or obese "
"CD012268_pub2_data","Subgroup","Dose of 0.5 g/day to less than 1 g/day "
"CD012268_pub2_data","Subgroup","Dose of less than 0.5 g/day"
"CD012268_pub2_data","Subgroup","Dose of 1 g/day or more"
"CD012268_pub2_data","Subgroup","With co-intervention"
"CD012268_pub2_data","Subgroup","No co-intervention"
"CD012268_pub2_data","Subgroup","Trial duration of 2 months to less than 6 months"
"CD012268_pub2_data","Subgroup","Trial duration of 6 months or more "
"CD012268_pub2_data","Subgroup","100 participants or more"
"CD012268_pub2_data","Subgroup","Fewer than 100 participants "
"CD012268_pub2_data","Subgroup","Intention-to-treat analysis "
"CD012268_pub2_data","Subgroup","No intention-to-treat analysis "
"CD012335_pub2_data","Analysis.group","1"
"CD012335_pub2_data","Analysis.name","All‐cause mortality"
"CD012335_pub2_data","Analysis.name","Overall survival"
"CD012335_pub2_data","Analysis.name","Cancer-related mortality"
"CD012335_pub2_data","Analysis.name","Disease-free survival"
"CD012335_pub2_data","Analysis.name","Rate of cancer recurrence: overall"
"CD012335_pub2_data","Analysis.name","Rate of cancer recurrence: pelvic recurrence"
"CD012335_pub2_data","Analysis.name","Rate of cancer recurrence: extrapelvic recurrence"
"CD012335_pub2_data","Analysis.name","Overall perioperative adverse event"
"CD012335_pub2_data","Analysis.name","Lymphovascular adverse event: all grades"
"CD012335_pub2_data","Analysis.name","Genitourinary adverse events: all grades"
"CD012335_pub2_data","Analysis.name","Direct surgical adverse events: all grades"
"CD012335_pub2_data","Analysis.name","Severe perioperative adverse events (grade 3 or higher)"
"CD012335_pub2_data","Analysis.name","Quality of life outcomes"
"CD012335_pub2_data","Subgroup","Physical functioning at 6-month"
"CD012335_pub2_data","Subgroup","Role functioning at 6-month"
"CD012335_pub2_data","Subgroup","Emotional functioning at 6-month"
"CD012335_pub2_data","Subgroup","Cognitive functioning at 6-month"
"CD012335_pub2_data","Subgroup","Social functioning at 6-month"
"CD012335_pub2_data","Subgroup","Global Health Status at 6-month"
"CD012335_pub2_data","Subgroup","Fatigue at 6-month"
"CD012335_pub2_data","Subgroup","Nausea and vomiting at 6-month"
"CD012335_pub2_data","Subgroup","Pain at 6-month"
"CD012335_pub2_data","Subgroup","Dyspnea at 6-month"
"CD012335_pub2_data","Subgroup","Insomnia at 6-month"
"CD012335_pub2_data","Subgroup","Appetite loss at 6-month"
"CD012335_pub2_data","Subgroup","Constipation at 6-month"
"CD012335_pub2_data","Subgroup","Diarrhea at 6-month"
"CD012335_pub2_data","Subgroup","Financial difficulties at 6-month"
"CD012397_pub2_data","Analysis.group","1"
"CD012397_pub2_data","Analysis.name","Specific behaviours: aggression – clinically important change in aggressive/violent behaviour, as defined by the individual studies (fixed-effect)"
"CD012397_pub2_data","Analysis.name","Specific behaviours: aggression – clinically important change in aggressive/violent behaviour, as defined by the individual studies (random-effects)"
"CD012397_pub2_data","Analysis.name","Use of coercive measures: use of seclusion room (time, days)"
"CD012397_pub2_data","Analysis.name","Use of coercive measures: use of seclusion room (participants)"
"CD012397_pub2_data","Analysis.name","Use of coercive measures: use of seclusion room (incidents)"
"CD012397_pub2_data","Analysis.name","Self-harm, including suicide"
"CD012397_pub2_data","Analysis.name","Specific behaviours: aggression, other episode of aggression (incidents per treatment days)"
"CD012397_pub2_data","Analysis.name","Specific behaviours: aggression, other episode of aggression (participants)"
"CD012397_pub2_data","Analysis.name","Specific behaviours: average endpoint in aggression score"
"CD012397_pub2_data","Analysis.name","Adverse event (escape)"
"CD012397_pub2_data","Analysis.name","Adverse event (fall down)"
"CD012397_pub2_data","Analysis.name","Adverse event (choking)"
"CD012397_pub2_data","Subgroup","Uncorrected"
"CD012397_pub2_data","Subgroup","Corrected for design effect"
"CD012426_pub2_data","Analysis.group","1"
"CD012426_pub2_data","Analysis.group","2"
"CD012426_pub2_data","Analysis.name","Unfavourable functional outcome at 90 days"
"CD012426_pub2_data","Analysis.name","All-cause mortality at 90 days"
"CD012426_pub2_data","Analysis.name","Improvement of stroke severity at 90 days"
"CD012426_pub2_data","Analysis.name","Serious adverse events at 90 days"
"CD012426_pub2_data","Analysis.name","Adverse events at 90 days"
"CD012426_pub2_data","Analysis.name","Unfavourable functional outcome at 90 days: Sensitivity analysis to remove studies with results at high risk of bias"
"CD012426_pub2_data","Analysis.name","Improvement of stroke severity at 90 days: Sensitivity analysis to remove studies with results at high risk of bias"
"CD012426_pub2_data","Analysis.name","Serious adverse events at 90 days: Sensitivity analysis to remove studies with results at high risk of bias"
"CD012426_pub2_data","Analysis.name","Serious adverse events at 90 days: Sensitivity analysis to remove Hacke 2014"
"CD012429_pub2_data","Analysis.group","1"
"CD012429_pub2_data","Analysis.group","2"
"CD012429_pub2_data","Analysis.group","3"
"CD012429_pub2_data","Analysis.group","4"
"CD012429_pub2_data","Analysis.group","5"
"CD012429_pub2_data","Analysis.name","Change in mental state (BPRS)"
"CD012429_pub2_data","Analysis.name","Change in mental state (PANNS)"
"CD012429_pub2_data","Analysis.name","Change in global state (CGI-S)"
"CD012429_pub2_data","Analysis.name","Need for additional benzodiazpines"
"CD012429_pub2_data","Analysis.name","Any change in general symptoms (MADRS)"
"CD012429_pub2_data","Analysis.name","Total serious adverse events/effects"
"CD012429_pub2_data","Analysis.name","Severe adverse events/effects"
"CD012429_pub2_data","Analysis.name","Sedation"
"CD012429_pub2_data","Analysis.name","Constipation"
"CD012429_pub2_data","Analysis.name","Headache"
"CD012429_pub2_data","Analysis.name","Somnolence"
"CD012429_pub2_data","Analysis.name","Fatigue"
"CD012429_pub2_data","Analysis.name","Agitation"
"CD012429_pub2_data","Analysis.name","Insomnia"
"CD012429_pub2_data","Analysis.name","Akathisia"
"CD012429_pub2_data","Analysis.name","Extrapyramidal disorder"
"CD012429_pub2_data","Analysis.name","Dystonia"
"CD012429_pub2_data","Analysis.name","Dizziness"
"CD012429_pub2_data","Analysis.name","Tremor"
"CD012429_pub2_data","Analysis.name","Change in movement disorders (BARS)"
"CD012429_pub2_data","Analysis.name","Change in movement disorders (AIMS)"
"CD012429_pub2_data","Analysis.name","Change in movement disorders (SAS)"
"CD012429_pub2_data","Analysis.name","Abdominal discomfort"
"CD012429_pub2_data","Analysis.name","Diarrhea"
"CD012429_pub2_data","Analysis.name","Dyspepsia"
"CD012429_pub2_data","Analysis.name","Nausea"
"CD012429_pub2_data","Analysis.name","Toothache"
"CD012429_pub2_data","Analysis.name","Vomiting"
"CD012429_pub2_data","Analysis.name","Diabetes mellitus"
"CD012429_pub2_data","Analysis.name","Dry mouth"
"CD012429_pub2_data","Analysis.name","Stiffness in jaw"
"CD012429_pub2_data","Analysis.name","Leaving the study early for any reason"
"CD012429_pub2_data","Analysis.name","Due to adverse events/effects"
"CD012429_pub2_data","Analysis.name","Due to loss to follow-up"
"CD012429_pub2_data","Analysis.name","Due to lack of efficacy of treatment"
"CD012429_pub2_data","Subgroup","Lurasidone 20 mg/d"
"CD012429_pub2_data","Subgroup","Lurasidone 40 mg/d"
"CD012429_pub2_data","Subgroup","Lurasidone 80 mg/d"
"CD012429_pub2_data","Subgroup","Lurasidone 40 mg/d"
"CD012429_pub2_data","Subgroup","Lurasidone 80 mg/d"
"CD012445_pub2_data","Analysis.group","1"
"CD012445_pub2_data","Analysis.group","2"
"CD012445_pub2_data","Analysis.name","Child emotional and behavioural adjustment – postintervention"
"CD012445_pub2_data","Analysis.name","Child emotional and behavioural adjustment – latest follow-up"
"CD012445_pub2_data","Analysis.name","Parenting skills – postintervention"
"CD012445_pub2_data","Analysis.name","Parenting skills – latest follow-up"
"CD012445_pub2_data","Analysis.name","Parental depression/anxiety – postintervention"
"CD012445_pub2_data","Analysis.name","Parental depression or anxiety – latest follow-up"
"CD012445_pub2_data","Analysis.name","Parenting stress – postintervention"
"CD012445_pub2_data","Analysis.name","Parenting stress – latest follow-up"
"CD012445_pub2_data","Analysis.name","Parent mindfulness – postintervention"
"CD012445_pub2_data","Analysis.name","Parent mindfulness – latest follow-up"
"CD012445_pub2_data","Analysis.name","Parental depression/anxiety – latest follow-up"
"CD012503_pub3_data","Analysis.group","1"
"CD012503_pub3_data","Analysis.group","2"
"CD012503_pub3_data","Analysis.group","3"
"CD012503_pub3_data","Analysis.group","4"
"CD012503_pub3_data","Analysis.group","5"
"CD012503_pub3_data","Analysis.group","6"
"CD012503_pub3_data","Analysis.group","7"
"CD012503_pub3_data","Analysis.group","8"
"CD012503_pub3_data","Analysis.name","Mortality during follow-up (for all studies)"
"CD012503_pub3_data","Analysis.name","Recurrence of ischemic stroke at the endpoint (for all studies)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on unilateral or bilateral limb RIC intervention)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention with reperfusion therapy)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on RIC intervention timing)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, recurrence of ischemic stroke at the endpoint (based on the duration of RIC intervention)"
"CD012503_pub3_data","Analysis.name","Excellent functional outcomes (mRS 0-1) at 90 days (for all studies)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, excellent functional outcomes (mRS 0-1) at 90 days (based on unilateral or bilateral limb RIC intervention)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention with reperfusion therapy)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on RIC intervention timing)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, &nbsp;excellent functional outcomes (mRS 0-1) at 90 days (based on the duration of RIC intervention)"
"CD012503_pub3_data","Analysis.name","Treatment-related adverse events"
"CD012503_pub3_data","Analysis.name","Functional independence (mRS 0-2) at 90 days (for all studies)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on unilateral or bilateral limb RIC intervention)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention with reperfusion therapy)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on RIC intervention timing)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, functional independence (mRS 0-2) at 90 days (based on the duration of RIC intervention)"
"CD012503_pub3_data","Analysis.name","Intracerebral haemorrhagic events during follow-up"
"CD012503_pub3_data","Analysis.name","&nbsp;Improvement in neurological impairment at the endpoint (for all studies)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, &nbsp;improvement in neurological impairment at the endpoint (based on unilateral or bilateral limb RIC intervention)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention with reperfusion therapy)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, improvement in neurological impairment at the endpoint (based on RIC intervention timing)"
"CD012503_pub3_data","Analysis.name","Subgroup analysis, improvement in neurological impairment at the endpoint (based on the duration of RIC intervention)"
"CD012503_pub3_data","Analysis.name","Cardiovascular events during follow-up (for all studies)"
"CD012503_pub3_data","Analysis.name","Cardiovascular events during follow-up (based on unilateral or bilateral limb RIC intervention)"
"CD012503_pub3_data","Analysis.name","Cardiovascular events during follow-up ( based on RIC intervention with reperfusion therapy)"
"CD012503_pub3_data","Analysis.name","Cardiovascular events during follow-up (based on RIC intervention timing)"
"CD012503_pub3_data","Analysis.name","Cardiovascular events during follow-up( based on the duration of RIC intervention)"
"CD012503_pub3_data","Subgroup","unilateral limb"
"CD012503_pub3_data","Subgroup","bilateral limb"
"CD012503_pub3_data","Subgroup","RIC with reperfusion therapy"
"CD012503_pub3_data","Subgroup","RIC without reperfusion therapy"
"CD012503_pub3_data","Subgroup","acute RIC"
"CD012503_pub3_data","Subgroup","delayed RIC"
"CD012503_pub3_data","Subgroup","chronic RIC"
"CD012503_pub3_data","Subgroup","short-duration RIC"
"CD012503_pub3_data","Subgroup","medium-duration RIC"
"CD012503_pub3_data","Subgroup","long-duration RIC"
"CD012503_pub3_data","Subgroup","RIC with reperfusion theraphy"
"CD012503_pub3_data","Subgroup","RIC without reperfusion theraphy"
"CD012503_pub3_data","Subgroup","short-duration"
"CD012503_pub3_data","Subgroup","medium-duration"
"CD012503_pub3_data","Subgroup","long-duration"
"CD012532_pub2_data","Analysis.group","1"
"CD012532_pub2_data","Analysis.group","2"
"CD012532_pub2_data","Analysis.group","3"
"CD012532_pub2_data","Analysis.group","4"
"CD012532_pub2_data","Analysis.group","5"
"CD012532_pub2_data","Analysis.group","6"
"CD012532_pub2_data","Analysis.group","7"
"CD012532_pub2_data","Analysis.name","Overall Survival"
"CD012532_pub2_data","Analysis.name","Progression-free survival"
"CD012532_pub2_data","Analysis.name","Overall survival"
"CD012570_pub2_data","Analysis.group","1"
"CD012570_pub2_data","Analysis.name","All-cause mortality"
"CD012570_pub2_data","Analysis.name","Withdrawal due to adverse effects (WDAE)"
"CD012570_pub2_data","Analysis.name","Serious adverse events"
"CD012570_pub2_data","Analysis.name","Adverse events"
"CD012570_pub2_data","Analysis.name","Systolic blood pressure"
"CD012570_pub2_data","Analysis.name","Diastolic blood pressure"
"CD012570_pub2_data","Analysis.name","Heart rate"
"CD012572_pub3_data","Analysis.group","1"
"CD012572_pub3_data","Analysis.name","All-cause mortality"
"CD012572_pub3_data","Analysis.name","Cardiovascular mortality"
"CD012572_pub3_data","Analysis.name","Myocardial infarction (fatal and non-fatal)"
"CD012572_pub3_data","Analysis.name","Hospitalisation"
"CD012572_pub3_data","Analysis.name","Stroke (fatal + non-fatal + transient ischaemic attack)"
"CD012572_pub3_data","Analysis.name","Systolic blood pressure"
"CD012572_pub3_data","Analysis.name","Systolic blood pressure subgrouped on duration"
"CD012572_pub3_data","Analysis.name","Systolic blood pressure subgrouped on drug type"
"CD012572_pub3_data","Analysis.name","Diastolic blood pressure"
"CD012572_pub3_data","Analysis.name","Diastolic blood pressure subgrouped on duration"
"CD012572_pub3_data","Analysis.name","Diastolic blood pressure subgrouped on drug type"
"CD012572_pub3_data","Analysis.name","Quality of life"
"CD012572_pub3_data","Analysis.name","Success rate – withdrawal/resumption due to hypertension or other clinical reason"
"CD012572_pub3_data","Subgroup","Less than 12 months"
"CD012572_pub3_data","Subgroup","12 months or longer"
"CD012572_pub3_data","Subgroup","Diuretics"
"CD012572_pub3_data","Subgroup","Other"
"CD012586_pub2_data","Analysis.group","1"
"CD012586_pub2_data","Analysis.group","2"
"CD012586_pub2_data","Analysis.group","3"
"CD012586_pub2_data","Analysis.group","4"
"CD012586_pub2_data","Analysis.group","5"
"CD012586_pub2_data","Analysis.group","6"
"CD012586_pub2_data","Analysis.group","7"
"CD012586_pub2_data","Analysis.group","8"
"CD012586_pub2_data","Analysis.group","9"
"CD012586_pub2_data","Analysis.group","10"
"CD012586_pub2_data","Analysis.group","11"
"CD012586_pub2_data","Analysis.group","12"
"CD012586_pub2_data","Analysis.group","13"
"CD012586_pub2_data","Analysis.group","14"
"CD012586_pub2_data","Analysis.group","15"
"CD012586_pub2_data","Analysis.group","16"
"CD012586_pub2_data","Analysis.group","17"
"CD012586_pub2_data","Analysis.group","18"
"CD012586_pub2_data","Analysis.group","19"
"CD012586_pub2_data","Analysis.group","20"
"CD012586_pub2_data","Analysis.group","21"
"CD012586_pub2_data","Analysis.group","22"
"CD012586_pub2_data","Analysis.group","23"
"CD012586_pub2_data","Analysis.group","24"
"CD012586_pub2_data","Analysis.group","25"
"CD012586_pub2_data","Analysis.group","26"
"CD012586_pub2_data","Analysis.group","27"
"CD012586_pub2_data","Analysis.group","28"
"CD012586_pub2_data","Analysis.group","29"
"CD012586_pub2_data","Analysis.group","30"
"CD012586_pub2_data","Analysis.group","31"
"CD012586_pub2_data","Analysis.group","32"
"CD012586_pub2_data","Analysis.group","33"
"CD012586_pub2_data","Analysis.group","34"
"CD012586_pub2_data","Analysis.group","35"
"CD012586_pub2_data","Analysis.group","36"
"CD012586_pub2_data","Analysis.group","37"
"CD012586_pub2_data","Analysis.group","38"
"CD012586_pub2_data","Analysis.group","39"
"CD012586_pub2_data","Analysis.group","40"
"CD012586_pub2_data","Analysis.group","41"
"CD012586_pub2_data","Analysis.group","42"
"CD012586_pub2_data","Analysis.group","43"
"CD012586_pub2_data","Analysis.group","44"
"CD012586_pub2_data","Analysis.group","45"
"CD012586_pub2_data","Analysis.group","46"
"CD012586_pub2_data","Analysis.group","47"
"CD012586_pub2_data","Analysis.name","Live birth or ongoing pregnancy"
"CD012586_pub2_data","Analysis.name","OHSS"
"CD012586_pub2_data","Analysis.name","Clinical pregnancy"
"CD012586_pub2_data","Analysis.name","Multiple pregnancy"
"CD012586_pub2_data","Analysis.name","Miscarriage"
"CD012586_pub2_data","Analysis.name","Ectopic"
"CD012586_pub2_data","Analysis.name","Cancellation"
"CD012586_pub2_data","Analysis.name","Oocyte number"
"CD012586_pub2_data","Analysis.name","Blastocyst number"
"CD012586_pub2_data","Analysis.name","Frozen embryo number"
"CD012586_pub2_data","Analysis.name","Cleavage embryo number"
"CD012586_pub2_data","Subgroup","Normal response"
"CD012586_pub2_data","Subgroup","High response"
"CD012586_pub2_data","Subgroup","Low response"
"CD012594_pub2_data","Analysis.group","1"
"CD012594_pub2_data","Analysis.name","Number of unexpected (previously unknown) adverse drug reaction reports"
"CD012609_pub2_data","Analysis.group","1"
"CD012609_pub2_data","Analysis.group","2"
"CD012609_pub2_data","Analysis.group","3"
"CD012609_pub2_data","Analysis.group","4"
"CD012609_pub2_data","Analysis.group","5"
"CD012609_pub2_data","Analysis.group","6"
"CD012609_pub2_data","Analysis.name","Clinical relapse"
"CD012609_pub2_data","Analysis.name","Loss of clinical response"
"CD012609_pub2_data","Analysis.name","Loss of clinical response in patients with exclusively fistulating disease"
"CD012609_pub2_data","Analysis.name","Withdrawal due to adverse events "
"CD012609_pub2_data","Analysis.name","Serious adverse events "
"CD012609_pub2_data","Analysis.name","Total adverse events "
"CD012609_pub2_data","Analysis.name","Endoscopic relapse"
"CD012609_pub2_data","Analysis.name","Withdrawal due to adverse events"
"CD012609_pub2_data","Analysis.name","Serious adverse events"
"CD012623_pub2_data","Analysis.group","1"
"CD012623_pub2_data","Analysis.group","2"
"CD012623_pub2_data","Analysis.group","3"
"CD012623_pub2_data","Analysis.name","Macular hole closure"
"CD012623_pub2_data","Analysis.name","Visual outcome gained following intervention in ETDRS letters"
"CD012623_pub2_data","Analysis.name","Vision gained following intervention in ETDRS letters"
"CD012623_pub2_data","Analysis.name","Macular hole closure "
"CD012623_pub2_data","Subgroup","3 days positioning"
"CD012623_pub2_data","Subgroup","5 days positioning"
"CD012623_pub2_data","Subgroup","10 days positioning"
"CD012623_pub2_data","Subgroup","Size less than 400 μm"
"CD012623_pub2_data","Subgroup","Size 400 μm or larger"
"CD012635_pub2_data","Analysis.group","1"
"CD012635_pub2_data","Analysis.group","2"
"CD012635_pub2_data","Analysis.group","3"
"CD012635_pub2_data","Analysis.group","4"
"CD012635_pub2_data","Analysis.name","All-cause mortality at 24 hours"
"CD012635_pub2_data","Analysis.name","All-cause mortality at 30 days"
"CD012635_pub2_data","Analysis.name","Total thromboembolic events in the first 30 days after injury"
"CD012635_pub2_data","Analysis.name","Arterial thromboembolic events in the first 30 days after injury"
"CD012635_pub2_data","Analysis.name","Venous thromboembolic events in the first 30 days after injury"
"CD012635_pub2_data","Analysis.name","Requirement for surgery or interventional procedure within first 24 hours "
"CD012635_pub2_data","Analysis.name","All cause mortality at 24 hours "
"CD012635_pub2_data","Analysis.name","All-cause mortality at 24 hours "
"CD012635_pub2_data","Analysis.name","All-cause mortality at 30 days "
"CD012635_pub2_data","Analysis.name","Mortality due to haemorrhage within 24 hours"
"CD012635_pub2_data","Subgroup","Cryoprecipitate plus major haemorrhage protcol versus major haemorrhage protcol alone "
"CD012635_pub2_data","Subgroup"," Blood products (plasma:platelets:RBCs) transfused in 1:1:1 ratio versus a 1:1:2 ratio"
"CD012635_pub2_data","Subgroup","Blood products (RBC:FFP) transfused in 1:1 ratio versus transfusion according to coagulation and full blood count results "
"CD012635_pub2_data","Subgroup","Lyophilised (FlyP) plasma versus fresh frozen plasma "
"CD012635_pub2_data","Subgroup","Lyophilised (FlyP) plasma versus fresh frozen plasma"
"CD012635_pub2_data","Subgroup","Blood products (Plasma:Platelets:RBCs) transfused in 1:1:1 ratio versus standard MHP"
"CD012635_pub2_data","Subgroup","Leucoreduced red blood cells versus standard red blood cells "
"CD012635_pub2_data","Subgroup","Blood products (plasma:platelets:RBCs) transfused in 1:1:1 ratio versus standard MHP"
"CD012635_pub2_data","Subgroup","Restrictive (target haemoglobin levels: 7–9 g/dL) versus liberal (target haemoglobin levels: 10–12 g/dL) transfusion strategy "
"CD012635_pub2_data","Subgroup","Blood products (plasma:platelets:RBCs) transfused in 1:1:1 ratio versus standard major haemorrhage protocol"
"CD012635_pub2_data","Subgroup","Modified (leucoreduced) whole blood versus blood products (RBCs:plasma) transfused in 1:1 ratio "
"CD012635_pub2_data","Subgroup","Modified (leucoreduced) whole blood versus blood products (RBCs:Plasma) in 1:1 ratio "
"CD012635_pub2_data","Subgroup","Modified (leucoreduced) whole blood versus blood products (RBCs:Plasma)transfused  in 1:1 ratio "
"CD012642_pub2_data","Analysis.group","1"
"CD012642_pub2_data","Analysis.group","2"
"CD012642_pub2_data","Analysis.group","3"
"CD012642_pub2_data","Analysis.group","4"
"CD012642_pub2_data","Analysis.group","5"
"CD012642_pub2_data","Analysis.group","6"
"CD012642_pub2_data","Analysis.group","8"
"CD012642_pub2_data","Analysis.group","9"
"CD012642_pub2_data","Analysis.group","10"
"CD012642_pub2_data","Analysis.group","11"
"CD012642_pub2_data","Analysis.name","Mortality (latest time reported up to hospital discharge)"
"CD012642_pub2_data","Analysis.name","Hyponatraemia (< 130 mmol/L)"
"CD012642_pub2_data","Analysis.name","Hypernatraemia (≥ 150 mmol/L)"
"CD012642_pub2_data","Analysis.name","Necrotising enterocolitis"
"CD012642_pub2_data","Analysis.name","Patent ductus arteriosus"
"CD012642_pub2_data","Analysis.name","Bronchopulmonary dysplasia (≥ 28 days age)"
"CD012642_pub2_data","Analysis.name","Intraventricular haemorrhage (any)"
"CD012642_pub2_data","Analysis.name","Periventricular leukomalacia"
"CD012642_pub2_data","Analysis.name","Maximal weight loss %"
"CD012642_pub2_data","Analysis.name","Postnatal growth failure (weight < 10th percentile)"
"CD012642_pub2_data","Analysis.name","Chronic lung disease (36 weeks' PMA)"
"CD012642_pub2_data","Analysis.name","Weight gain"
"CD012642_pub2_data","Analysis.name","Linear growth cm/week"
"CD012642_pub2_data","Analysis.name","Percent weight change from birth to 2 weeks"
"CD012642_pub2_data","Subgroup","≥ 3 mmol/kg/day to < 5 mmol/kg/day"
"CD012642_pub2_data","Subgroup","g/day: sodium ≥ 5 mmol/kg/day"
"CD012642_pub2_data","Subgroup","g/kg/day: sodium ≥ 3 mmol/kg/day to < 5 mmol/kg/day"
"CD012642_pub2_data","Subgroup","≥ 5 mmol/kg/day"
"CD012642_pub2_data","Subgroup","≥ 3mmol/kg/day to < 5 mmol/kg/day"
"CD012642_pub2_data","Subgroup","< 28 weeks or 1000g"
"CD012642_pub2_data","Subgroup","<32 weeks or 1500 g"
"CD012642_pub2_data","Subgroup","<37 weeks or 2500 g"
"CD012642_pub2_data","Subgroup","< 32 weeks or 1500 g"
"CD012642_pub2_data","Subgroup","< 37 weeks or 2500 g"
"CD012642_pub2_data","Subgroup","< 32 weeks aor 1500 g"
"CD012642_pub2_data","Subgroup","Lower fluid intake"
"CD012642_pub2_data","Subgroup","Higher fluid intake"
"CD012642_pub2_data","Subgroup","Sick infants"
"CD012642_pub2_data","Subgroup","Stable infants"
"CD012642_pub2_data","Subgroup","Parenteral"
"CD012642_pub2_data","Subgroup","Parenteral and enteral"
"CD012642_pub2_data","Subgroup","Enteral"
"CD012693_pub3_data","Analysis.group","1"
"CD012693_pub3_data","Analysis.group","2"
"CD012693_pub3_data","Analysis.group","3"
"CD012693_pub3_data","Analysis.group","4"
"CD012693_pub3_data","Analysis.group","5"
"CD012693_pub3_data","Analysis.group","6"
"CD012693_pub3_data","Analysis.group","7"
"CD012693_pub3_data","Analysis.name","Live birth or ongoing pregnancy"
"CD012693_pub3_data","Analysis.name","Severe OHSS"
"CD012693_pub3_data","Analysis.name","Clinical pregnancy"
"CD012693_pub3_data","Analysis.name","Moderate or severe OHSS"
"CD012693_pub3_data","Analysis.name","Multiple pregnancy in randomised women"
"CD012693_pub3_data","Analysis.name","Log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes"
"CD012693_pub3_data","Analysis.name","Poor response to stimulation"
"CD012693_pub3_data","Analysis.name","Normal response to stimulation"
"CD012693_pub3_data","Analysis.name","Hyper-response to stimulation"
"CD012693_pub3_data","Analysis.name","Cycle cancellations for poor response"
"CD012693_pub3_data","Analysis.name","Cycle cancellations for hyper-response"
"CD012693_pub3_data","Analysis.name","Cycle cancellations for poor or hyper-response"
"CD012693_pub3_data","Analysis.name","Women with at least one transferable embryo"
"CD012693_pub3_data","Analysis.name","Total dose of FSH"
"CD012693_pub3_data","Analysis.name","Duration of FSH administration"
"CD012693_pub3_data","Analysis.name","Cumulative live birth: 1 cycle (fresh + frozen)"
"CD012693_pub3_data","Analysis.name","Cumulative live birth: 18 months"
"CD012693_pub3_data","Analysis.name","Multiple pregnancy in women with clinical pregnancy"
"CD012693_pub3_data","Analysis.name","Dose-response: live birth or ongoing pregnancy"
"CD012693_pub3_data","Analysis.name","Dose-response: cumulative live birth: 1 cycle (fresh + frozen)"
"CD012693_pub3_data","Analysis.name","Dose-response: clinical pregnancy"
"CD012693_pub3_data","Analysis.name","Dose-response: log(N oocytes retrieved); data presented on the log scale - cannot interpret pooled estimates as N of oocytes"
"CD012693_pub3_data","Analysis.name","Dose-response: poor response to stimulation"
"CD012693_pub3_data","Analysis.name","Dose-response: normal response to stimulation"
"CD012693_pub3_data","Analysis.name","Dose-response: hyper-response to stimulation"
"CD012693_pub3_data","Analysis.name","Dose-response: cycle cancellations for poor response"
"CD012693_pub3_data","Analysis.name","Dose-response: women with at least one transferable embryo"
"CD012693_pub3_data","Analysis.name","Dose-response: total dose of FSH"
"CD012693_pub3_data","Analysis.name","Dose-response: duration of FSH administration"
"CD012693_pub3_data","Analysis.name","Cost per woman randomised"
"CD012693_pub3_data","Analysis.name","Dose-response: severe OHSS"
"CD012693_pub3_data","Analysis.name","Dose-response: moderate or severe OHSS"
"CD012693_pub3_data","Analysis.name","Dose-response: cycle cancellations for hyper-response"
"CD012693_pub3_data","Analysis.name","Dose-response: cycle cancellations for poor or hyper-response"
"CD012693_pub3_data","Analysis.name","Live birth or ongoing pregnancy (including FET for freeze-all)"
"CD012693_pub3_data","Subgroup","300/450 IU vs 150 IU"
"CD012693_pub3_data","Subgroup","400/450 IU vs 300 IU"
"CD012693_pub3_data","Subgroup","600 IU vs 450 IU"
"CD012693_pub3_data","Subgroup","450 IU vs 300 IU"
"CD012693_pub3_data","Subgroup","225 IU vs 150 IU"
"CD012693_pub3_data","Subgroup","200 IU vs 100 IU"
"CD012693_pub3_data","Subgroup","225/200 IU vs 150 IU"
"CD012693_pub3_data","Subgroup","300 IU vs 225 IU"
"CD012693_pub3_data","Subgroup","300 IU vs 150 IU"
"CD012693_pub3_data","Subgroup","12.1μg vs 10.3μg"
"CD012693_pub3_data","Subgroup","10.3μg vs 8.6μg"
"CD012693_pub3_data","Subgroup","8.6μg vs 6.9μg"
"CD012693_pub3_data","Subgroup","6.9μg vs 5.2μg"
"CD012693_pub3_data","Subgroup","12μg vs 9μg"
"CD012693_pub3_data","Subgroup","9 μg vs 6μg"
"CD012693_pub3_data","Subgroup","9μg vs 6μg"
"CD012693_pub3_data","Subgroup","12 μg vs 9 μg"
"CD012693_pub3_data","Subgroup","9 μg vs 6 μg"
"CD012693_pub3_data","Subgroup","12 μg/d vs 9 μg/d"
"CD012693_pub3_data","Subgroup","9 μg/d vs 6 μg/d"
"CD012693_pub3_data","Subgroup","150 IU vs 100 IU"
"CD012693_pub3_data","Subgroup","9μg vs 6 μg"
"CD012693_pub3_data","Subgroup","Control group: standard dose 150 IU"
"CD012693_pub3_data","Subgroup","Control group: non-ORT algorithm"
"CD012712_pub2_data","Analysis.group","1"
"CD012712_pub2_data","Analysis.group","2"
"CD012712_pub2_data","Analysis.group","3"
"CD012712_pub2_data","Analysis.group","4"
"CD012712_pub2_data","Analysis.group","5"
"CD012712_pub2_data","Analysis.group","6"
"CD012712_pub2_data","Analysis.group","7"
"CD012712_pub2_data","Analysis.group","8"
"CD012712_pub2_data","Analysis.group","9"
"CD012712_pub2_data","Analysis.group","10"
"CD012712_pub2_data","Analysis.name","Mortality before hospital discharge"
"CD012712_pub2_data","Analysis.name","Duration of respiratory support, days"
"CD012712_pub2_data","Analysis.name","Chronic lung disease at 36 weeks"
"CD012712_pub2_data","Analysis.name","Pulmonary air leak syndromes"
"CD012712_pub2_data","Analysis.name","Length of hospital stay, days"
"CD012712_pub2_data","Analysis.name","Endotracheal intubation"
"CD012712_pub2_data","Analysis.name","Trauma to the nostrils and upper airway"
"CD012712_pub2_data","Analysis.name","Failure of respiratory support"
"CD012712_pub2_data","Analysis.name","Duration of oxygen therapy, days"
"CD012712_pub2_data","Analysis.name","Death or chronic lung disease at 36 weeks"
"CD012712_pub2_data","Analysis.name","Patent ductus arteriosus"
"CD012712_pub2_data","Analysis.name","Proven sepsis"
"CD012712_pub2_data","Analysis.name","Necrotising enterocolitis"
"CD012712_pub2_data","Analysis.name","Necrotising enterocolitis (NEC) (Bell stage ≥ 2)"
"CD012712_pub2_data","Analysis.name","Spontaneous intestinal perforation"
"CD012712_pub2_data","Analysis.name","Intraventricular haemorrhage, any"
"CD012712_pub2_data","Analysis.name","Intraventricular haemorrhage, Papile grade 3/4"
"CD012712_pub2_data","Analysis.name","Periventricular leukomalacia"
"CD012712_pub2_data","Analysis.name","Retinopathy of prematurity, any"
"CD012712_pub2_data","Analysis.name","Retinopathy of prematurity, stage ≥ 3"
"CD012712_pub2_data","Analysis.name","Endotracheal reintubation"
"CD012712_pub2_data","Analysis.name","Failure of extubation"
"CD012712_pub2_data","Analysis.name","Necrotising enterocolitis, Bell stage ≥ 2"
"CD012712_pub2_data","Analysis.name","Neurodevelopmental disability at least 18 months' postnatal age or later"
"CD012712_pub2_data","Subgroup","nHFV versus nCPAP"
"CD012712_pub2_data","Subgroup","nHFV versus nIPPV"
"CD012712_pub2_data","Subgroup","nHFV versus HFNC "
"CD012712_pub2_data","Subgroup","nHFV vs nCPAP"
"CD012712_pub2_data","Subgroup","nHFV versus nCPAP - preterm infants"
"CD012712_pub2_data","Subgroup","nHFV versus nCPAP - nHFV MAP < 10 cm H2O"
"CD012712_pub2_data","Subgroup","nHFV versus nCPAP - nHFV Hz ≥ 10"
"CD012712_pub2_data","Subgroup","nHFV versus nCPAP - nHFV Hz < 10"
"CD012712_pub2_data","Subgroup","nHFV versus nCPAP - term or near-term infants"
"CD012712_pub2_data","Subgroup","nHFV versus nIPPV - preterm infants"
"CD012712_pub2_data","Subgroup","nHFV versus nIPPV - nHFV MAP < 10 cm H2O"
"CD012712_pub2_data","Subgroup","nHFV versus nIPPV - nHFV Hz ≥ 10"
"CD012712_pub2_data","Subgroup","nHFV versus nIPPV - term or near-term infants"
"CD012712_pub2_data","Subgroup","nHFV versus nIPPV- preterm infants"
"CD012712_pub2_data","Subgroup","nHFV versus nCPAP - nHFV MAP ≥ 10 cm H2O"
"CD012712_pub2_data","Subgroup","nHFV versus nIPPV- nHFV Hz < 10"
"CD012712_pub2_data","Subgroup","nHFV versus nIPPV - nHFV MAP ≥ 10 cm H2O"
"CD012718_pub2_data","Analysis.group","1"
"CD012718_pub2_data","Analysis.group","2"
"CD012718_pub2_data","Analysis.group","3"
"CD012718_pub2_data","Analysis.group","4"
"CD012718_pub2_data","Analysis.group","5"
"CD012718_pub2_data","Analysis.group","6"
"CD012718_pub2_data","Analysis.group","7"
"CD012718_pub2_data","Analysis.group","8"
"CD012718_pub2_data","Analysis.group","9"
"CD012718_pub2_data","Analysis.group","10"
"CD012718_pub2_data","Analysis.name","Primary caries prevention (at end of study follow-up)"
"CD012718_pub2_data","Analysis.name","Caries arrest (at end of study follow-up)"
"CD012718_pub2_data","Analysis.name","Secondary prevention of caries (at end of study follow-up; analysed with OR)"
"CD012718_pub2_data","Analysis.name","Secondary prevention of caries (at end of study follow-up; analysed using Peto OR)"
"CD012718_pub2_data","Analysis.name","Secondary prevention of caries (at end of study follow-up)"
"CD012718_pub2_data","Analysis.name","Secondary prevention of caries (end of study follow-up)"
"CD012718_pub2_data","Analysis.name","Adverse effects"
"CD012718_pub2_data","Analysis.name","Pain (at end of study follow-up)"
"CD012718_pub2_data","Analysis.name","Aesthetics (end of study follow-up)"
"CD012718_pub2_data","Analysis.name","Dental pain or sensitivity (number of people with tooth sensitivity; end of study follow-up)"
"CD012718_pub2_data","Subgroup","Primary dentition"
"CD012718_pub2_data","Subgroup","Permanent dentition - coronal caries"
"CD012718_pub2_data","Subgroup","Permanent dentition - root caries"
"CD012718_pub2_data","Subgroup","Primary dentition "
"CD012718_pub2_data","Subgroup","Primary dentition - coronal caries"
"CD012718_pub2_data","Subgroup","Primary and permanent coronal caries"
"CD012757_pub2_data","Analysis.group","1"
"CD012757_pub2_data","Analysis.name","Mortality at longest follow-up"
"CD012757_pub2_data","Analysis.name","Mortality at 12 months' follow-up"
"CD012757_pub2_data","Analysis.name","Mortality at 24 months' follow-up"
"CD012757_pub2_data","Analysis.name","Mortality at 36 months' follow-up"
"CD012757_pub2_data","Analysis.name","Mortality at 50 months' follow-up"
"CD012757_pub2_data","Analysis.name","Tumour response measures after treatment (overall response rate = complete response + partial response)"
"CD012757_pub2_data","Analysis.name","Tumour response measures after treatment (complete response)"
"CD012757_pub2_data","Analysis.name","Tumour response measures after treatment (partial response)"
"CD012757_pub2_data","Analysis.name","Tumour response measures after treatment (stable disease)"
"CD012757_pub2_data","Analysis.name","Tumour response measures after treatment (progressive disease)"
"CD012850_pub2_data","Analysis.group","1"
"CD012850_pub2_data","Analysis.group","2"
"CD012850_pub2_data","Analysis.group","3"
"CD012850_pub2_data","Analysis.group","4"
"CD012850_pub2_data","Analysis.group","5"
"CD012850_pub2_data","Analysis.group","6"
"CD012850_pub2_data","Analysis.name","Self-reported joint pain at rest (dichotomous data)"
"CD012850_pub2_data","Analysis.name","Self-reported joint pain at rest (continuous data)"
"CD012850_pub2_data","Analysis.name","Clinically assessed joint pain at rest"
"CD012850_pub2_data","Analysis.name","Self-reported joint pain at mastication (dichotomous data)"
"CD012850_pub2_data","Analysis.name","Muscle pain at rest (dichotomous data)"
"CD012850_pub2_data","Analysis.name","Muscle pain at rest (continuous data)"
"CD012850_pub2_data","Analysis.name","Muscle pain at mastication (dichotomous data)"
"CD012850_pub2_data","Analysis.name","Muscle pain at mastication (continuous data)"
"CD012850_pub2_data","Analysis.name","Severity of joint noise"
"CD012850_pub2_data","Analysis.name","Frequency of joint noise"
"CD012850_pub2_data","Analysis.name","Range of mandibular motion (maximum unassisted (mandibular) opening"
"CD012850_pub2_data","Analysis.name","Range of mandibular motion (unassisted (mandibular) opening without pain)"
"CD012850_pub2_data","Analysis.name","Range of mandibular motion (maximum assisted (mandibular opening)"
"CD012850_pub2_data","Analysis.name","Depression"
"CD012850_pub2_data","Analysis.name","Self-reported joint pain at rest"
"CD012850_pub2_data","Analysis.name","Participant satisfaction or quality of life"
"CD012850_pub2_data","Analysis.name","Muscle pain at rest (dichotomous)"
"CD012850_pub2_data","Analysis.name","Muscle pain at rest"
"CD012850_pub2_data","Analysis.name","Muscle pain at mastication"
"CD012850_pub2_data","Analysis.name","Somatisation"
"CD012850_pub2_data","Analysis.name","Range of mandibular motion (unassisted opening without pain)"
"CD012850_pub2_data","Analysis.name","Range of mandibular motion (maximum assisted opening)"
"CD012850_pub2_data","Analysis.name","Clinically assessed joint pain at rest (dichotomous)"
"CD012850_pub2_data","Analysis.name","Clinically assessed joint pain at rest (continuous)"
"CD012850_pub2_data","Analysis.name","Self-reported joint pain at mastication"
"CD012850_pub2_data","Analysis.name","Range of mandibular motion (maximum unassisted opening)"
"CD012850_pub2_data","Subgroup","Short term"
"CD012850_pub2_data","Subgroup","Long term"
"CD012886_pub3_data","Analysis.group","1"
"CD012886_pub3_data","Analysis.group","2"
"CD012886_pub3_data","Analysis.group","3"
"CD012886_pub3_data","Analysis.group","4"
"CD012886_pub3_data","Analysis.group","5"
"CD012886_pub3_data","Analysis.name","Outcome 1 Newly diagnosed musculoskeletal disorders or symptoms (new onset of musculoskeletal pain - neck)"
"CD012886_pub3_data","Analysis.name","Outcome 2 Newly diagnosed musculoskeletal disorders or symptoms (new onset of musculoskeletal pain - back)"
"CD012886_pub3_data","Analysis.name","Outcome 3 Intensity of musculoskeletal symptoms (pain - overall)"
"CD012886_pub3_data","Analysis.name","Outcome 4 Intensity of musculoskeletal symptoms (pain - neck)"
"CD012886_pub3_data","Analysis.name","Outcome 5 Intensity of musculoskeletal symptoms (pain - back)"
"CD012886_pub3_data","Analysis.name","Outcome 6 Intensity of musculoskeletal symptoms (discomfort - neck)"
"CD012886_pub3_data","Analysis.name","Outcome 7 Intensity of musculoskeletal symptoms (discomfort - back)"
"CD012886_pub3_data","Analysis.name","Outcome 8 Intensity of musculoskeletal symptoms (discomfort - shoulders)"
"CD012886_pub3_data","Analysis.name","Outcome 9 Intensity of musculoskeletal symptoms (discomfort - right shoulder/upper arm)"
"CD012886_pub3_data","Analysis.name","Outcome 10 Intensity of musculoskeletal symptoms (discomfort - left shoulder/upper arm)"
"CD012886_pub3_data","Analysis.name","Outcome 11 Intensity of musculoskeletal symptoms (discomfort - right elbow)"
"CD012886_pub3_data","Analysis.name","Outcome 12 Intensity of musculoskeletal symptoms (discomfort - left elbow)"
"CD012886_pub3_data","Analysis.name","Outcome 13 Intensity of musculoskeletal symptoms (discomfort - forearms/wrists)"
"CD012886_pub3_data","Analysis.name","Outcome 14 Intensity of musculoskeletal symptoms (discomfort - right forearm/wrist/hand)"
"CD012886_pub3_data","Analysis.name","Outcome 15 Intensity of musculoskeletal symptoms (discomfort - left forearm/wrist/hand)"
"CD012886_pub3_data","Analysis.name","Outcome 16 Intensity of musculoskeletal symptoms (discomfort - buttocks)"
"CD012886_pub3_data","Analysis.name","Outcome 17 Intensity of musculoskeletal symptoms (discomfort - legs)"
"CD012886_pub3_data","Analysis.name","Outcome 18 Productivity or work performance (productivity - keystrokes per hour)"
"CD012886_pub3_data","Analysis.name","Outcome 19 Productivity or work performance (productivity - entered documents per day)"
"CD012886_pub3_data","Analysis.name","Outcome 20 Productivity or work performance (productivity - words types per three hours (compared to baseline))"
"CD012886_pub3_data","Analysis.name","Outcome 21 Productivity or work performance (work performance - functioning)"
"CD012886_pub3_data","Analysis.name","Outcome 22 Productivity or work performance (work performance - manual precision)"
"CD012886_pub3_data","Analysis.name","Outcome 1 Intensity of musculoskeletal symptoms (discomfort - neck)"
"CD012886_pub3_data","Analysis.name","Outcome 2 Intensity of musculoskeletal symptoms (discomfort - back)"
"CD012886_pub3_data","Analysis.name","Outcome 3 Intensity of musculoskeletal symptoms (discomfort - shoulders)"
"CD012886_pub3_data","Analysis.name","Outcome 4 Intensity of musculoskeletal symptoms (discomfort - forearms/wrists)"
"CD012886_pub3_data","Analysis.name","Outcome 5 Productivity or work performance (productivity - words typed per three hours)"
"CD012886_pub3_data","Analysis.name","Outcome 1 Intensity of musculoskeletal symptoms (fatigue - overall)"
"CD012891_pub2_data","Analysis.group","1"
"CD012891_pub2_data","Analysis.group","3"
"CD012891_pub2_data","Analysis.group","4"
"CD012891_pub2_data","Analysis.name","Standard controlled ovarian hyperstimulation with gonadotropins versus controlled ovarian hyperstimulation with gonadotropins + letrozole: number of oocytes retrieved after ovarian stimulation"
"CD012891_pub2_data","Analysis.name","Standard controlled ovarian hyperstimulation with gonadotropins versus controlled ovarian hyperstimulation with gonadotropins + tamoxifen: number of oocytes retrieved after ovarian stimulation"
"CD012891_pub2_data","Analysis.name","Standard controlled ovarian hyperstimulation with gonadotropins + letrozole versus standard controlled ovarian hyperstimulation with gonadotropins + tamoxifen: number of oocytes retrieved after ovarian stimulation"
"CD012891_pub2_data","Analysis.name","Ovarian insufficiency grouped by strict or broad definition"
"CD012891_pub2_data","Analysis.name","Ovarian insufficiency grouped by receptor status"
"CD012891_pub2_data","Analysis.name","Live birth"
"CD012891_pub2_data","Analysis.name","Overall survival at 5 years"
"CD012891_pub2_data","Analysis.name","Overall survival at 12 years"
"CD012891_pub2_data","Analysis.name","Overall survival at 12 years grouped by receptor status"
"CD012891_pub2_data","Analysis.name","Clinical pregnancy"
"CD012891_pub2_data","Analysis.name","Clinical pregnancy grouped by receptor status"
"CD012891_pub2_data","Analysis.name","Disease-free survival at 5 years"
"CD012891_pub2_data","Analysis.name","Disease-free survival at 12 years"
"CD012891_pub2_data","Analysis.name","Disease-free survival grouped by receptor status"
"CD012891_pub2_data","Analysis.name","Overall survival"
"CD012891_pub2_data","Analysis.name","Clinical pregnancy grouped by age"
"CD012891_pub2_data","Analysis.name","Disease-free survival"
"CD012891_pub2_data","Subgroup","Ovarian insufficiency, strict definition"
"CD012891_pub2_data","Subgroup","Ovarian insufficiency, broad definition"
"CD012891_pub2_data","Subgroup","Ovarian insufficiency in hormone-receptor-positive patients"
"CD012891_pub2_data","Subgroup","Ovarian insufficiency in hormone-receptor-negative patients"
"CD012891_pub2_data","Subgroup","Overall survival in hormone-receptor-positive patients"
"CD012891_pub2_data","Subgroup","Overall survival in hormone-receptor-negative patients"
"CD012891_pub2_data","Subgroup","Clinical pregnancy in hormone-receptor-positive patients"
"CD012891_pub2_data","Subgroup","Clinical pregnancy in hormone-receptor-negative patients"
"CD012891_pub2_data","Subgroup","Disease-free survival in hormone-receptor-positive patients"
"CD012891_pub2_data","Subgroup","Disease-free survival in hormone-receptor-negative patients"
"CD012891_pub2_data","Subgroup","Ovarian insufficiency, any definition"
"CD012891_pub2_data","Subgroup","At 5 years"
"CD012891_pub2_data","Subgroup","Age < 35 years"
"CD012891_pub2_data","Subgroup","Age ≥ 35 years"
"CD012905_pub2_data","Analysis.group","1"
"CD012905_pub2_data","Analysis.group","2"
"CD012905_pub2_data","Analysis.group","3"
"CD012905_pub2_data","Analysis.group","4"
"CD012905_pub2_data","Analysis.name","Development of AKI"
"CD012905_pub2_data","Analysis.name","Need for kidney replacement therapy"
"CD012905_pub2_data","Analysis.name","Death"
"CD012905_pub2_data","Analysis.name","Change in serum creatinine from baseline"
"CD012905_pub2_data","Analysis.name","Change in urine output from baseline"
"CD012905_pub2_data","Analysis.name","Duration of ICU stay [days]"
"CD012905_pub2_data","Analysis.name","Adverse events"
"CD012905_pub2_data","Analysis.name","Sensitivity analysis: development of AKI based on risk of attrition bias"
"CD012905_pub2_data","Analysis.name","Change in serum creatinine from baseline [mg/dL]"
"CD012905_pub2_data","Subgroup","All populations"
"CD012905_pub2_data","Subgroup","Patients undergoing cardiac surgery"
"CD012905_pub2_data","Subgroup","Hypotension"
"CD012905_pub2_data","Subgroup","Myocardial infarction"
"CD012905_pub2_data","Subgroup","Drug intolerence"
"CD012905_pub2_data","Subgroup","Cardiac arrythymias"
"CD012905_pub2_data","Subgroup","Low risk of attrition bias"
"CD012905_pub2_data","Subgroup","High risk of attrition bias"
"CD012905_pub2_data","Subgroup","Excluding Caimmi 2003"
"CD012905_pub2_data","Subgroup","All studies"
"CD012925_pub2_data","Analysis.group","1"
"CD012925_pub2_data","Analysis.group","2"
"CD012925_pub2_data","Analysis.group","3"
"CD012925_pub2_data","Analysis.name","Provider adherence to recommended practice (dichotomous outcomes)"
"CD012925_pub2_data","Analysis.name","Provider adherence to recommended practice (continuous outcomes)"
"CD012925_pub2_data","Analysis.name","Client's health behaviour"
"CD012925_pub2_data","Analysis.name","Patient/client health status and well-being (desirable outcomes)"
"CD012925_pub2_data","Analysis.name","Patient/client health status and well-being (undesirable outcomes)"
"CD012925_pub2_data","Analysis.name","Client utilisation of primary healthcare and/or services (risk ratio)"
"CD012925_pub2_data","Analysis.name","Client utilisation of primary healthcare and/or services (risk difference)"
"CD012925_pub2_data","Analysis.name","Client utilisation of primary health care and/or services (odds ratio)"
"CD012925_pub2_data","Analysis.name","Patient/client health status and well-being (dichotomous outcomes)"
"CD012925_pub2_data","Analysis.name","Patient/client health status and well-being (inverse variance)"
"CD012925_pub2_data","Analysis.name","Patient/client health status and well-being (continuous outcomes)"
"CD012925_pub2_data","Analysis.name","Client utilisation of primary healthcare and/or services - hospitalisations for stroke"
"CD012925_pub2_data","Analysis.name","Provider adherence to recommended practice"
"CD012925_pub2_data","Analysis.name","Quality of data about services provided"
"CD012925_pub2_data","Analysis.name","Client utilisation of primary healthcare and/or services (odds ratio)"
"CD012925_pub2_data","Analysis.name","Client utilisation of primary healthcare and/or services (odds ratio) - never-missed early infant diagnosis visit"
"CD012925_pub2_data","Analysis.name","Client utilisation of primary healthcare and/or services (dichotomous)"
"CD012925_pub2_data","Analysis.name","Patient/client acceptability/satisfaction with the intervention"
"CD012925_pub2_data","Subgroup","Counselled to initiate complementary food at six months"
"CD012925_pub2_data","Subgroup","Home visit within 24 hours of delivery"
"CD012925_pub2_data","Subgroup","Home visit in the first week after delivery"
"CD012925_pub2_data","Subgroup","Immediate referral to ED or hospital for asthma management"
"CD012925_pub2_data","Subgroup","Blood pressure measurement during antenatal care visit"
"CD012925_pub2_data","Subgroup","Blood test during antenatal care visit"
"CD012925_pub2_data","Subgroup","Weight measurement during antenatal care visit"
"CD012925_pub2_data","Subgroup","Urine test during antenatal care visit"
"CD012925_pub2_data","Subgroup","Counselled to initiate complementary food at six months (non-randomised)"
"CD012925_pub2_data","Subgroup","Number of home visits in first month after delivery"
"CD012925_pub2_data","Subgroup","Early initiation of breastfeeding"
"CD012925_pub2_data","Subgroup","Kangaroo Mother Care"
"CD012925_pub2_data","Subgroup","Exclusive breastfeeding for 6 months"
"CD012925_pub2_data","Subgroup","Skin-to-skin care"
"CD012925_pub2_data","Subgroup","Bath delayed at least 2 days"
"CD012925_pub2_data","Subgroup","Nothing applied to the umbilical cord"
"CD012925_pub2_data","Subgroup","At least 90 iron-folic acid tablets consumed during pregnancy - non-randomised (Prinja)"
"CD012925_pub2_data","Subgroup","At least 90 iron-folic acid tablets consumed during pregnancy (RCTs)"
"CD012925_pub2_data","Subgroup","Improved asthma severity during office visit"
"CD012925_pub2_data","Subgroup","Stillbirths"
"CD012925_pub2_data","Subgroup","Neonatal deaths"
"CD012925_pub2_data","Subgroup","Infant deaths"
"CD012925_pub2_data","Subgroup","Low birth weight (≤ 2kg)"
"CD012925_pub2_data","Subgroup","Pneumonia/fever in the last two weeks"
"CD012925_pub2_data","Subgroup","HIV-positive following test"
"CD012925_pub2_data","Subgroup","At least two tetanus injections during pregnancy (non-randomised) - Prinja"
"CD012925_pub2_data","Subgroup","Emergency department visit within one week of the doctor's office visit for asthma"
"CD012925_pub2_data","Subgroup","Number of HIV tests performed in antenatal women"
"CD012925_pub2_data","Subgroup","Hospitalisation within one week of the doctor's office visit for asthma"
"CD012925_pub2_data","Subgroup","At least two tetanus injections during pregnancy (RCTs)"
"CD012925_pub2_data","Subgroup","Full childhood immunisation (non-randomised) - Prinja"
"CD012925_pub2_data","Subgroup","Women gave birth in a health facility"
"CD012925_pub2_data","Subgroup","Current use of any modern method of contraception"
"CD012925_pub2_data","Subgroup","Full childhood immunisation (RCTs)"
"CD012925_pub2_data","Subgroup","At least three antenatal care visits"
"CD012925_pub2_data","Subgroup","Women giving birth in a health facility - randomised (Hacket)"
"CD012925_pub2_data","Subgroup","Women giving birth in a health facility non randomised  (Prinja, Ilozumba)"
"CD012925_pub2_data","Subgroup","Medication adherence (antihypertensives)"
"CD012925_pub2_data","Subgroup","Women who gave birth at home"
"CD012925_pub2_data","Subgroup","Deaths in stroke patients over 12 months"
"CD012925_pub2_data","Subgroup","Change in systolic blood pressure"
"CD012925_pub2_data","Subgroup","Change in health-related quality of life"
"CD012925_pub2_data","Subgroup","Infants received Nevirapine Prophylaxis"
"CD012925_pub2_data","Subgroup","Screening and management of abnormal foetal growth"
"CD012925_pub2_data","Subgroup","Screening and management of anaemia"
"CD012925_pub2_data","Subgroup","Screening and management of diabetes"
"CD012925_pub2_data","Subgroup","Screening and management of hypertension"
"CD012925_pub2_data","Subgroup"," Data missing for gestational age at delivery"
"CD012925_pub2_data","Subgroup"," Data missing for birthweight at delivery"
"CD012925_pub2_data","Subgroup"," Data missing for haemoglobin at delivery"
"CD012925_pub2_data","Subgroup"," Data missing for blood pressure at delivery"
"CD012925_pub2_data","Subgroup","HIV+ve women exclusive breastfeeding at 6 months"
"CD012925_pub2_data","Subgroup","HIV+ve women on ART at delivery"
"CD012925_pub2_data","Subgroup","Physical activity levels"
"CD012925_pub2_data","Subgroup","High-risk individuals achieving optimal BP levels (systolic blood pressure < 140 mmHg)"
"CD012925_pub2_data","Subgroup","Deaths"
"CD012925_pub2_data","Subgroup","Severe hypertension"
"CD012925_pub2_data","Subgroup","Adverse pregnancy outcome"
"CD012925_pub2_data","Subgroup","Large-for-gestational-age baby"
"CD012925_pub2_data","Subgroup","Hypertensive individuals whose BP is controlled (< 140/90)"
"CD012925_pub2_data","Subgroup","Moderate or severe anaemia"
"CD012925_pub2_data","Subgroup","Infant mortality before the baby reaches 18 months"
"CD012925_pub2_data","Subgroup","Maternal mortality (before the baby reached 18 months) in HIV+ve mothers"
"CD012925_pub2_data","Subgroup","New cardiovascular disease events during follow-up"
"CD012925_pub2_data","Subgroup","Change in fasting plasma glucose"
"CD012925_pub2_data","Subgroup","Change in total cholesterol"
"CD012925_pub2_data","Subgroup","Change in predicted 10-year risk of CVD"
"CD012925_pub2_data","Subgroup","Change in tobacco use"
"CD012925_pub2_data","Subgroup","Change in alcohol use"
"CD012925_pub2_data","Subgroup","Change in depression score"
"CD012925_pub2_data","Subgroup","Change in diastolic blood pressure (DBP)"
"CD012925_pub2_data","Subgroup","Change in quality of life"
"CD012925_pub2_data","Subgroup","Mean change in body mass index (BMI)"
"CD012925_pub2_data","Subgroup","Mean change in systolic blood pressure (SBP)"
"CD012925_pub2_data","Subgroup","Mean change in glycated haemoglobin (HbA1c)"
"CD012925_pub2_data","Subgroup","Women who gave birth at a health facility"
"CD012925_pub2_data","Subgroup","Postnatal care in a health facility"
"CD012925_pub2_data","Subgroup","At least four antenatal care visits"
"CD012925_pub2_data","Subgroup","Linkage to care"
"CD012925_pub2_data","Subgroup","Never missed early infant diagnosis visit"
"CD012925_pub2_data","Subgroup","Fully vaccinated- rural"
"CD012925_pub2_data","Subgroup","Fully vaccinated - urban"
"CD012925_pub2_data","Subgroup","Reported ""slightly/much better"" change in quality of care"
"CD012942_pub2_data","Analysis.group","1"
"CD012942_pub2_data","Analysis.group","2"
"CD012942_pub2_data","Analysis.group","3"
"CD012942_pub2_data","Analysis.group","4"
"CD012942_pub2_data","Analysis.group","5"
"CD012942_pub2_data","Analysis.group","6"
"CD012942_pub2_data","Analysis.group","7"
"CD012942_pub2_data","Analysis.group","8"
"CD012942_pub2_data","Analysis.group","9"
"CD012942_pub2_data","Analysis.group","10"
"CD012942_pub2_data","Analysis.group","11"
"CD012942_pub2_data","Analysis.group","12"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A"
"CD012942_pub2_data","Analysis.name","Comparison 3 Agomelatine versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A"
"CD012942_pub2_data","Analysis.name","Comparison 4 Duloxetine versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A"
"CD012942_pub2_data","Analysis.name","Comparison 5 Escitalopram versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A"
"CD012942_pub2_data","Analysis.name","Comparison 6 Sertraline versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A"
"CD012942_pub2_data","Analysis.name","Comparison 7 Venlafaxine versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A"
"CD012942_pub2_data","Analysis.name","Comparison 8 Vilazodone versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A"
"CD012942_pub2_data","Analysis.name","Comparison 9 Vortioxetine versus placebo, Outcome 1 Rate of treatment response measured as a reduction of at least 50% on the HAM-A"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 3 Agomelatine versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 4 Duloxetine versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 5 Escitalopram versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 6 Paroxetine versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 7 Sertraline versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 8 Venlafaxine versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 9 Vilazodone versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 10 Vortioxetine versus placebo, Outcome 2 Acceptability"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 3 Rate of treatment response (defined by study authors)"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 3 Rate of treatment response (defined by study authors)"
"CD012942_pub2_data","Analysis.name","Comparison 3 Duloxetine versus placebo, Outcome 3 Rate of treatment response (defined by study authors)"
"CD012942_pub2_data","Analysis.name","Comparison 4 Escitalopram versus placebo, Outcome 3 Rate of treatment response (defined by study authors)"
"CD012942_pub2_data","Analysis.name","Comparison 5 Paroxetine versus placebo, Outcome 3 Rate of treatment response (defined by study authors)"
"CD012942_pub2_data","Analysis.name","Comparison 6 Sertraline versus placebo, Outcome 3 Rate of treatment response (defined by study authors)"
"CD012942_pub2_data","Analysis.name","Comparison 7 Venlafaxine versus placebo, Outcome 3 Rate of treatment response (defined by study authors)"
"CD012942_pub2_data","Analysis.name","Comparison 8 Vilazodone versus placebo, Outcome 3 Rate of treatment response (defined by study authors)"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 4 Remission rate"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 4 Remission rate"
"CD012942_pub2_data","Analysis.name","Comparison 3 Agomelatine versus placebo, Outcome 4 Remission rate"
"CD012942_pub2_data","Analysis.name","Comparison 4 Duloxetine versus placebo, Outcome 4 Remission rate"
"CD012942_pub2_data","Analysis.name","Comparison 5 Escitalopram versus placebo, Outcome 4 Remission rate"
"CD012942_pub2_data","Analysis.name","Comparison 6 Paroxetine versus placebo, Outcome 4 Remission rate"
"CD012942_pub2_data","Analysis.name","Comparison 7 Sertraline versus placebo, Outcome 4 Remission rate"
"CD012942_pub2_data","Analysis.name","Comparison 8 Venlafaxine versus placebo, Outcome 4 Remission rate"
"CD012942_pub2_data","Analysis.name","Comparison 8 Vortioxetine versus placebo, Outcome 4 Remission rate"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 5 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 5 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 4 Agomelatine versus placebo, Outcome 4 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 5 Duloxetine versus placebo, Outcome 4 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 6 Escitalopram versus placebo, Outcome 4 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 7 Imipramine versus placebo, Outcome 4 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 8 Paroxetine versus placebo, Outcome 4 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 9 Sertraline versus placebo, Outcome 4 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 10 Venlafaxine versus placebo, Outcome 4 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 11 Vilazodone versus placebo, Outcome 4 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 12 Vortioxetine versus placebo, Outcome 4 Change in symptom levels"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 3 Agomelatine versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 4 Duloxetine versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 5 Escitalopram versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 6 Paroxetine versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 7 Sertraline versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 8 Venlafaxine versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 9 Vilazodone versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 10 Vortioxetine versus placebo, Outcome 6 Total number of participants reporting adverse events"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 3 Agomelatine versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 4 Duloxetine versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 5 Escitalopram versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 6 Paroxetine versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 7 Sertraline versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 8 Venlafaxine versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 9 Vilazodone versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 10 Vortioxetine versus placebo, Outcome 7 Sleepiness/drowsiness"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 8 Agitation/anxiety"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 8 Agitation/anxiety "
"CD012942_pub2_data","Analysis.name","Comparison 3 Escitalopram versus placebo, Outcome 8 Agitation/anxiety"
"CD012942_pub2_data","Analysis.name","Comparison 4 Paroxetine versus placebo, Outcome 8 Agitation/anxiety"
"CD012942_pub2_data","Analysis.name","Comparison 5 Sertraline versus placebo, Outcome 8 Agitation/anxiety"
"CD012942_pub2_data","Analysis.name","Comparison 6 Venlafaxine versus placebo, Outcome 8 Agitation/anxiety"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 9 Suicide wishes/gestures/attempts"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 9 Suicide wishes/gestures/attempts"
"CD012942_pub2_data","Analysis.name","Comparison 3 Duloxetine versus placebo, Outcome 9 Suicide wishes/gestures/attempts"
"CD012942_pub2_data","Analysis.name","Comparison 4 Paroxetine versus placebo, Outcome 9 Suicide wishes/gestures/attempts"
"CD012942_pub2_data","Analysis.name","Comparison 5 Vilazodone versus placebo, Outcome 9 Suicide wishes/gestures/attempts"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 10 Average score/change in quality of life/satisfaction"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 10 Average score/change in quality of life/satisfaction"
"CD012942_pub2_data","Analysis.name","Comparison 3 Escitalopram versus placebo, Outcome 10 Average score/change in quality of life/satisfaction"
"CD012942_pub2_data","Analysis.name","Comparison 4 Paroxetine versus placebo, Outcome 10 Average score/change in quality of life/satisfaction"
"CD012942_pub2_data","Analysis.name","Comparison 5 Sertraline versus placebo, Outcome 10 Average score/change in quality of life/satisfaction"
"CD012942_pub2_data","Analysis.name","Comparison 6 Venlafaxine versus placebo, Outcome 10 Average score/change in quality of life/satisfaction"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 3 Agomelatine versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 4 Duloxetine versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 5 Escitalopram versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 6 Paroxetine versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 7 Sertraline versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 8 Venlafaxine versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 9 Vilazodone versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 10 Vortioxetine versus placebo, Outcome 11 Dropouts due to a lack of efficacy"
"CD012942_pub2_data","Analysis.name","Comparison 1 All antidepressants versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Analysis.name","Comparison 2 Each class of antidepressant versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Analysis.name","Comparison 3 Agomelatine versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Analysis.name","Comparison 4 Duloxetine versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Analysis.name","Comparison 5 Escitalopram versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Analysis.name","Comparison 6 Paroxetine versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Analysis.name","Comparison 7 Sertraline versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Analysis.name","Comparison 8 Venlafaxine versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Analysis.name","Comparison 9 Vilazodone versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Analysis.name","Comparison 10 Vortioxetine versus placebo, Outcome 12 Dropouts due to adverse effects"
"CD012942_pub2_data","Subgroup","SSRIs"
"CD012942_pub2_data","Subgroup","SNRIs"
"CD012942_pub2_data","Subgroup","Other"
"CD012942_pub2_data","Subgroup","TCAs"
"CD012967_pub2_data","Analysis.group","1"
"CD012967_pub2_data","Analysis.name","Change in validated symptom score at 6 months"
"CD012967_pub2_data","Analysis.name","Change in validated symptom score at 24 months"
"CD012967_pub2_data","Analysis.name","Change in impairment score at 6 months"
"CD012967_pub2_data","Analysis.name","Change in impairment score at 24 months"
"CD012967_pub2_data","Analysis.name","Adverse events leading to cessation of treatment"
"CD012993_pub2_data","Analysis.group","1"
"CD012993_pub2_data","Analysis.group","2"
"CD012993_pub2_data","Analysis.group","3"
"CD012993_pub2_data","Analysis.group","4"
"CD012993_pub2_data","Analysis.group","5"
"CD012993_pub2_data","Analysis.group","6"
"CD012993_pub2_data","Analysis.name","Change in 6MWT from baseline"
"CD012993_pub2_data","Analysis.name","Change in FVC from baseline"
"CD012993_pub2_data","Analysis.name","Infusion reactions"
"CD012993_pub2_data","Analysis.name","Quality of life (measured by PCS in SF-36)"
"CD012993_pub2_data","Analysis.name","Treatment-related adverse events"
"CD012993_pub2_data","Analysis.name","Adverse events"
"CD012993_pub2_data","Analysis.name","Infusion-associated reactions"
"CD012993_pub2_data","Analysis.name","Change in 6MWD from baseline"
"CD012993_pub2_data","Analysis.name","Change in sitting FVC (% predicted) from baseline to 52 weeks"
"CD012993_pub2_data","Analysis.name","Change in % predicted SNIP from baseline to 52 weeks"
"CD012993_pub2_data","Analysis.name","Infusion reactions - total"
"CD012993_pub2_data","Analysis.name","Quality of life - PROMIS - physical function score"
"CD012993_pub2_data","Analysis.name","Quality of life - PROMIS - fatigue score"
"CD012993_pub2_data","Analysis.name","Treatment-emergent adverse events - total"
"CD012993_pub2_data","Analysis.name","Treatment-emergent adverse events (breakdown 1)"
"CD012993_pub2_data","Analysis.name","Treatment-emergent adverse events (breakdown 2)"
"CD012993_pub2_data","Analysis.name","Change in 6MWT"
"CD012993_pub2_data","Analysis.name","Change in % predicted 6MWT"
"CD012993_pub2_data","Analysis.name","Change in EQ-5D-5L (from baseline to 49 weeks)"
"CD012993_pub2_data","Analysis.name","Change in health-related quality of life (from baseline to 49 weeks)"
"CD012993_pub2_data","Analysis.name","Treatment-emergent adverse events"
"CD012993_pub2_data","Analysis.name","Treatment-emergent adverse events - breakdown"
"CD012993_pub2_data","Subgroup","To 78 weeks"
"CD012993_pub2_data","Subgroup","At 78 weeks"
"CD012993_pub2_data","Subgroup","To 18 weeks"
"CD012993_pub2_data","Subgroup","To 52 weeks"
"CD012993_pub2_data","Subgroup","To 6 weeks"
"CD012993_pub2_data","Subgroup","To 30 weeks"
"CD012993_pub2_data","Subgroup","At 26 weeks"
"CD012993_pub2_data","Subgroup","At 52 weeks"
"CD012993_pub2_data","Subgroup","Serious treatment-emergent adverse events potentially related to treatment"
"CD012993_pub2_data","Subgroup","Serious treatment-emergent adverse events"
"CD012993_pub2_data","Subgroup","Treatment-emergent adverse events potentially related to treatment"
"CD012993_pub2_data","Subgroup","Nausea"
"CD012993_pub2_data","Subgroup","Myalgia"
"CD012993_pub2_data","Subgroup","Nasopharyngitis"
"CD012993_pub2_data","Subgroup","Arthralgia"
"CD012993_pub2_data","Subgroup","Urinary tract infection"
"CD012993_pub2_data","Subgroup","Diarrhoea"
"CD012993_pub2_data","Subgroup","Pain in extremity"
"CD012993_pub2_data","Subgroup","Oropharyngeal pain"
"CD012993_pub2_data","Subgroup","Musculoskeletal pain"
"CD012993_pub2_data","Subgroup","Back pain"
"CD012993_pub2_data","Subgroup","Fatigue"
"CD012993_pub2_data","Subgroup","Fall"
"CD012993_pub2_data","Subgroup","Headache"
"CD012993_pub2_data","Subgroup","At 49 weeks"
"CD012993_pub2_data","Subgroup","Mobility"
"CD012993_pub2_data","Subgroup","Self-care"
"CD012993_pub2_data","Subgroup","Anxiety/depression"
"CD012993_pub2_data","Subgroup","Usual activities"
"CD012993_pub2_data","Subgroup","Pain/discomfort"
"CD012993_pub2_data","Subgroup","Visual Analogue Scale"
"CD012993_pub2_data","Subgroup","Change in SF-12 MCS"
"CD012993_pub2_data","Subgroup","Change in SF-12 PCS"
"CD012997_pub3_data","Analysis.group","1"
"CD012997_pub3_data","Analysis.group","2"
"CD012997_pub3_data","Analysis.group","3"
"CD012997_pub3_data","Analysis.group","4"
"CD012997_pub3_data","Analysis.name","Incidence of HUS"
"CD012997_pub3_data","Analysis.name","Adverse events"
"CD012997_pub3_data","Analysis.name","Adverse events: treatment emergent"
"CD012997_pub3_data","Analysis.name","Neurological complications"
"CD012997_pub3_data","Analysis.name","Death (any cause)"
"CD012997_pub3_data","Subgroup","Urtoxazumab 3.0 mg/kg versus placebo"
"CD012997_pub3_data","Subgroup","Urtoxazumab 1.0 mg/kg versus placebo"
"CD013023_pub2_data","Analysis.group","1"
"CD013023_pub2_data","Analysis.group","2"
"CD013023_pub2_data","Analysis.group","3"
"CD013023_pub2_data","Analysis.group","4"
"CD013023_pub2_data","Analysis.group","5"
"CD013023_pub2_data","Analysis.group","6"
"CD013023_pub2_data","Analysis.group","7"
"CD013023_pub2_data","Analysis.group","8"
"CD013023_pub2_data","Analysis.group","9"
"CD013023_pub2_data","Analysis.group","10"
"CD013023_pub2_data","Analysis.group","11"
"CD013023_pub2_data","Analysis.name","Arterial catheter failure"
"CD013023_pub2_data","Analysis.name","Dislodgement"
"CD013023_pub2_data","Analysis.name","Occlusion"
"CD013023_pub2_data","Analysis.name","Adverse events"
"CD013023_pub2_data","Analysis.name","Incidence of catheter-related bloodstream infection"
"CD013038_pub3_data","Analysis.group","1"
"CD013038_pub3_data","Analysis.name","Time to reach full sucking feeds (days)"
"CD013038_pub3_data","Analysis.name","Time to reach full sucking feeds (days) – by type of exposure"
"CD013038_pub3_data","Analysis.name","Duration of parenteral nutrition (days)"
"CD013038_pub3_data","Analysis.name","Time to reach full enteral feeds (days)"
"CD013038_pub3_data","Analysis.name","Time to reach full enteral feeds (days) – by type of exposure"
"CD013038_pub3_data","Analysis.name","Necrotising enterocolitis during hospitalisation"
"CD013038_pub3_data","Analysis.name","Late infection during hospitalisation"
"CD013038_pub3_data","Analysis.name","Time to first discharge home (days)"
"CD013038_pub3_data","Analysis.name","Time to first discharge home (postmenstrual age in weeks)"
"CD013038_pub3_data","Analysis.name","Time to first discharge home (days) – by type of exposure"
"CD013038_pub3_data","Analysis.name","Time to first discharge home (postmenstrual age in weeks) – by type of exposure"
"CD013038_pub3_data","Subgroup","After receiving smell and taste of milk"
"CD013038_pub3_data","Subgroup","After receiving only smell of milk"
"CD013042_pub2_data","Analysis.group","1"
"CD013042_pub2_data","Analysis.group","2"
"CD013042_pub2_data","Analysis.group","3"
"CD013042_pub2_data","Analysis.group","4"
"CD013042_pub2_data","Analysis.group","5"
"CD013042_pub2_data","Analysis.group","6"
"CD013042_pub2_data","Analysis.group","7"
"CD013042_pub2_data","Analysis.group","8"
"CD013042_pub2_data","Analysis.group","9"
"CD013042_pub2_data","Analysis.group","10"
"CD013042_pub2_data","Analysis.group","11"
"CD013042_pub2_data","Analysis.name","Mean pain (0 to 10, 0 is no pain)"
"CD013042_pub2_data","Analysis.name","Mean disability (0 to 100, 0 is no disability)"
"CD013042_pub2_data","Analysis.name","Mean grip strength (lb/in2)"
"CD013042_pub2_data","Analysis.name","Health-related quality of life (SMD)"
"CD013042_pub2_data","Analysis.name","Participant reported treatment success"
"CD013042_pub2_data","Analysis.name","Proportion of overall withdrawals"
"CD013042_pub2_data","Analysis.name","Proportion with any adverse event"
"CD013042_pub2_data","Analysis.name","Pain-free grip strength (SMD)"
"CD013042_pub2_data","Analysis.name","Proportion on sick leave"
"CD013042_pub2_data","Analysis.name","Mean health related quality of life"
"CD013042_pub2_data","Analysis.name","Pain free grip strength (SMD)"
"CD013042_pub2_data","Analysis.name","Mean pain free grip strength (kg)"
"CD013042_pub2_data","Analysis.name","Mean health-related quality of life"
"CD013042_pub2_data","Analysis.name","Participant-reported treatment success"
"CD013042_pub2_data","Analysis.name","Mean grip strength (kg)"
"CD013042_pub2_data","Analysis.name","Mean health-related quality of life (1 to 3, 1 = perfect health)"
"CD013042_pub2_data","Analysis.name","Mean grip strength (pain-free, kg)"
"CD013042_pub2_data","Analysis.name","Mean elbow disability (0 to 100, 0 is no disability)"
"CD013042_pub2_data","Analysis.name","Mean health-related quality of life (EQ-5D utility score)"
"CD013042_pub2_data","Analysis.name","Mean grip strength (affected side/unaffected side x 100)"
"CD013042_pub2_data","Analysis.name","Subgroup analysis: pain end of intervention"
"CD013042_pub2_data","Analysis.name","Subgroup analysis: disability end of intervention"
"CD013042_pub2_data","Subgroup","End of intervention (2 to 3 weeks)"
"CD013042_pub2_data","Subgroup","End of intervention (3 weeks)"
"CD013042_pub2_data","Subgroup","First time point (3 to 6 weeks)"
"CD013042_pub2_data","Subgroup","End of intervention (4 weeks to 3 months)"
"CD013042_pub2_data","Subgroup","Last time point (8 weeks to 12 months)"
"CD013042_pub2_data","Subgroup","First time point (3 weeks)"
"CD013042_pub2_data","Subgroup","End of intervention (6 weeks to 3 months)"
"CD013042_pub2_data","Subgroup","Last time point (12 months)"
"CD013042_pub2_data","Subgroup","End of intervention (6 to 8 weeks)"
"CD013042_pub2_data","Subgroup","End of intervention (6 weeks)"
"CD013042_pub2_data","Subgroup","End of intervention (4 to 6 weeks)"
"CD013042_pub2_data","Subgroup","Last time point (8 weeks to 3 months)"
"CD013042_pub2_data","Subgroup","Last time point (8 weeks)"
"CD013042_pub2_data","Subgroup","End of intervention (4 weeks)"
"CD013042_pub2_data","Subgroup","End of intervention (7 weeks to 3 months)"
"CD013042_pub2_data","Subgroup","First time point (6 weeks)"
"CD013042_pub2_data","Subgroup","End of intervention (3 months)"
"CD013042_pub2_data","Subgroup","End of intervention (8 weeks to 3 months)"
"CD013042_pub2_data","Subgroup","Last time point (3 to 12 months)"
"CD013042_pub2_data","Subgroup","First time point (2 to 4 weeks)"
"CD013042_pub2_data","Subgroup","Last time point (3 months)"
"CD013042_pub2_data","Subgroup","End of treatment (4 to 6 weeks)"
"CD013042_pub2_data","Subgroup","First time point (2 weeks)"
"CD013042_pub2_data","Subgroup","First time point (2 to 3 weeks)"
"CD013042_pub2_data","Subgroup","Last time point (6 months)"
"CD013042_pub2_data","Subgroup","End of intervention (6 weeks to 6 months)"
"CD013042_pub2_data","Subgroup","First time point (4 weeks)"
"CD013042_pub2_data","Subgroup","End of intervention (3 to 6 months)"
"CD013042_pub2_data","Subgroup","End of intervention (6 months)"
"CD013042_pub2_data","Subgroup","Last follow-up (12 months)"
"CD013042_pub2_data","Subgroup","End of intervention (6 to 7 weeks)"
"CD013042_pub2_data","Subgroup","Average symptom duration more than 6 months"
"CD013042_pub2_data","Subgroup","Average symptom duration for 3 months or less"
"CD013042_pub2_data","Subgroup","Average symptom duration for more than 3 months up to 6 months"
"CD013042_pub2_data","Subgroup","Symptom duration more than 6 months"
"CD013051_pub3_data","Analysis.group","1"
"CD013051_pub3_data","Analysis.group","2"
"CD013051_pub3_data","Analysis.group","3"
"CD013051_pub3_data","Analysis.group","4"
"CD013051_pub3_data","Analysis.name","Resolution of ear discharge"
"CD013051_pub3_data","Analysis.name","Subgroup analysis: CSOM diagnosis"
"CD013051_pub3_data","Analysis.name","Resolution of ear discharge (1 to up to 2 weeks)"
"CD013051_pub3_data","Analysis.name","Resolution of ear discharge (2 to up to 4 weeks)"
"CD013051_pub3_data","Analysis.name","Ear pain/discomfort/local irritation"
"CD013051_pub3_data","Subgroup","Measured at 1–2 weeks"
"CD013051_pub3_data","Subgroup","Measured at 2–4 weeks"
"CD013051_pub3_data","Subgroup","Chronic ear discharge"
"CD013051_pub3_data","Subgroup","CSOM"
"CD013051_pub3_data","Subgroup","Quinolones versus aminoglycosides"
"CD013051_pub3_data","Subgroup","Quinolones versus neomycin/polymixin B"
"CD013051_pub3_data","Subgroup","Mild irritation to EAM"
"CD013052_pub3_data","Analysis.group","1"
"CD013052_pub3_data","Analysis.group","2"
"CD013052_pub3_data","Analysis.group","3"
"CD013052_pub3_data","Analysis.group","4"
"CD013052_pub3_data","Analysis.group","5"
"CD013052_pub3_data","Analysis.group","6"
"CD013052_pub3_data","Analysis.group","7"
"CD013052_pub3_data","Analysis.group","8"
"CD013052_pub3_data","Analysis.name","Resolution of ear discharge at 1 to 2 weeks "
"CD013052_pub3_data","Analysis.name","Resolution of ear discharge (1 to 2 weeks)"
"CD013052_pub3_data","Analysis.name","Resolution of ear discharge (2 to 4 weeks)"
"CD013052_pub3_data","Analysis.name","Subgroup analysis: CSOM diagnosis"
"CD013052_pub3_data","Analysis.name","Ear pain"
"CD013052_pub3_data","Analysis.name","Ototoxicity"
"CD013052_pub3_data","Analysis.name","Resolution of ear discharge (after 4 weeks)"
"CD013052_pub3_data","Analysis.name","Serious complications"
"CD013052_pub3_data","Analysis.name","Resolution of ear discharge at 2 to 4 weeks"
"CD013052_pub3_data","Analysis.name","Resolution of ear discharge after 4 weeks"
"CD013052_pub3_data","Analysis.name","Sensitivity analysis: resolution of ear discharge at 2 to 4 weeks"
"CD013052_pub3_data","Analysis.name","Sensitivity analysis: resolution of ear discharge after 4 weeks"
"CD013052_pub3_data","Analysis.name","Suspected ototoxicity"
"CD013052_pub3_data","Subgroup","Any antibiotic (mezlocillin or ceftazidime)"
"CD013052_pub3_data","Subgroup","Mezlocillin"
"CD013052_pub3_data","Subgroup","Ceftazidime"
"CD013052_pub3_data","Subgroup","Chronic ear discharge"
"CD013052_pub3_data","Subgroup","CSOM"
"CD013052_pub3_data","Subgroup","Dizziness/vertigo/balance"
"CD013052_pub3_data","Subgroup","Metronidazole plus gentamicin-steroid drops compared to gentamicin-steroid alone"
"CD013052_pub3_data","Subgroup","Cotrimoxazole for 6 weeks: 6-week follow-up"
"CD013052_pub3_data","Subgroup","Mastoid abscess (follow-up: 12 weeks)"
"CD013052_pub3_data","Subgroup","No correction"
"CD013052_pub3_data","Subgroup","ICC used in primary analysis (0.015)"
"CD013052_pub3_data","Subgroup","High ICC (0.03)"
"CD013052_pub3_data","Subgroup","Pipemidic acid versus aminobenzylpenicillin"
"CD013052_pub3_data","Subgroup","Norfloxacin versus aminobenzylpenicillin"
"CD013052_pub3_data","Subgroup","Levofloxacin versus co-amoxiclav"
"CD013052_pub3_data","Subgroup","Dizziness or vertigo"
"CD013052_pub3_data","Subgroup","Tinnitus"
"CD013052_pub3_data","Subgroup","Other beta-lactam versus cephalosporin"
"CD013052_pub3_data","Subgroup","Lincomycin versus metronidazole"
"CD013052_pub3_data","Subgroup","Clindamycin versus metronidazole"
"CD013053_pub3_data","Analysis.group","1"
"CD013053_pub3_data","Analysis.group","2"
"CD013053_pub3_data","Analysis.group","3"
"CD013053_pub3_data","Analysis.name","Resolution of ear discharge"
"CD013053_pub3_data","Analysis.name","Subgroup analyses: diagnosis of chronic suppurative otitis media (CSOM)"
"CD013053_pub3_data","Analysis.name","Resolution of ear discharge – sensitivity analysis, re-including excluded case"
"CD013053_pub3_data","Subgroup","At 1–2 weeks"
"CD013053_pub3_data","Subgroup","At 2–4 weeks"
"CD013053_pub3_data","Subgroup","Chronic ear discharge"
"CD013053_pub3_data","Subgroup","CSOM"
"CD013054_pub3_data","Analysis.group","1"
"CD013054_pub3_data","Analysis.group","2"
"CD013054_pub3_data","Analysis.group","3"
"CD013054_pub3_data","Analysis.group","4"
"CD013054_pub3_data","Analysis.group","5"
"CD013054_pub3_data","Analysis.group","7"
"CD013054_pub3_data","Analysis.group","8"
"CD013054_pub3_data","Analysis.group","9"
"CD013054_pub3_data","Analysis.group","10"
"CD013054_pub3_data","Analysis.group","11"
"CD013054_pub3_data","Analysis.group","12"
"CD013054_pub3_data","Analysis.group","13"
"CD013054_pub3_data","Analysis.name","Resolution of ear discharge 2 to 4 weeks"
"CD013054_pub3_data","Analysis.name","Resolution of ear discharge 1 to 2 weeks"
"CD013054_pub3_data","Analysis.name","Ear pain or discomfort"
"CD013054_pub3_data","Analysis.name","Sensitivity analysis: unpublished - resolution of ear discharge 1 to 2 weeks"
"CD013054_pub3_data","Analysis.name","Resolution of ear discharge after 4 weeks"
"CD013054_pub3_data","Analysis.name","Dizziness/vertigo/balance"
"CD013054_pub3_data","Analysis.name","Subgroup analysis: resolution of ear discharge - CSOM diagnosis"
"CD013054_pub3_data","Analysis.name","Subgroup analysis: resolution of ear discharge - age"
"CD013054_pub3_data","Analysis.name","Ear pain or discomfort at 2 to 4 weeks"
"CD013054_pub3_data","Subgroup","Aminoglycosides plus steroids"
"CD013054_pub3_data","Subgroup","Quinolones"
"CD013054_pub3_data","Subgroup","Aminoglycosides"
"CD013054_pub3_data","Subgroup","Neomycin-polymixin B-steroids"
"CD013054_pub3_data","Subgroup","Framycetin-gramicidin-dexamethasone"
"CD013054_pub3_data","Subgroup","All studies (published and unpublished)"
"CD013054_pub3_data","Subgroup","Published only"
"CD013054_pub3_data","Subgroup","CSOM"
"CD013054_pub3_data","Subgroup","Ear discharge"
"CD013054_pub3_data","Subgroup","Less than 6 years old"
"CD013054_pub3_data","Subgroup","6 years or older"
"CD013054_pub3_data","Subgroup","Aminoglycosides with steroids"
"CD013054_pub3_data","Subgroup","CSOM diagnosis"
"CD013055_pub3_data","Analysis.group","1"
"CD013055_pub3_data","Analysis.group","2"
"CD013055_pub3_data","Analysis.group","3"
"CD013055_pub3_data","Analysis.group","4"
"CD013055_pub3_data","Analysis.name","Resolution of ear discharge (2 to 4 weeks)"
"CD013055_pub3_data","Analysis.name","Resolution of ear discharge (after 4 weeks)"
"CD013055_pub3_data","Analysis.name","Resolution of ear discharge (3 to 4 months)"
"CD013055_pub3_data","Analysis.name","Resolution of ear discharge (1 to 2 weeks)"
"CD013055_pub3_data","Analysis.name","Ear pain, discomfort, irritation"
"CD013055_pub3_data","Subgroup","No correction"
"CD013055_pub3_data","Subgroup","ICC used in primary analysis (0.015)"
"CD013055_pub3_data","Subgroup","High ICC (0.03)"
"CD013056_pub3_data","Analysis.group","1"
"CD013056_pub3_data","Analysis.group","2"
"CD013056_pub3_data","Analysis.group","3"
"CD013056_pub3_data","Analysis.group","5"
"CD013056_pub3_data","Analysis.group","7"
"CD013056_pub3_data","Analysis.name","Resolution of ear discharge (1–2 weeks)"
"CD013056_pub3_data","Analysis.name","Resolution of ear discharge (2–4 weeks)"
"CD013056_pub3_data","Analysis.name","Ear pain, discomfort, irritation"
"CD013056_pub3_data","Analysis.name","Change in hearing"
"CD013056_pub3_data","Analysis.name","Resolution of ear discharge (after 4 weeks)"
"CD013056_pub3_data","Subgroup","Aminoglycosides"
"CD013056_pub3_data","Subgroup","Quinolones"
"CD013056_pub3_data","Subgroup","Aminoglycosides plus steroid"
"CD013057_pub3_data","Analysis.group","1"
"CD013057_pub3_data","Analysis.group","2"
"CD013057_pub3_data","Analysis.name","Resolution of ear discharge (after 4 weeks)"
"CD013057_pub3_data","Analysis.name","Resolution of ear discharge (1–2 weeks)"
"CD013057_pub3_data","Analysis.name","Vertigo/dizziness/tinnitus"
"CD013059_pub2_data","Analysis.group","1"
"CD013059_pub2_data","Analysis.group","2"
"CD013059_pub2_data","Analysis.group","3"
"CD013059_pub2_data","Analysis.group","4"
"CD013059_pub2_data","Analysis.group","5"
"CD013059_pub2_data","Analysis.group","6"
"CD013059_pub2_data","Analysis.group","7"
"CD013059_pub2_data","Analysis.group","8"
"CD013059_pub2_data","Analysis.group","9"
"CD013059_pub2_data","Analysis.group","10"
"CD013059_pub2_data","Analysis.group","11"
"CD013059_pub2_data","Analysis.group","12"
"CD013059_pub2_data","Analysis.group","13"
"CD013059_pub2_data","Analysis.group","14"
"CD013059_pub2_data","Analysis.group","15"
"CD013059_pub2_data","Analysis.name","Depressive symptomatology"
"CD013059_pub2_data","Analysis.name","Treatment non-acceptability"
"CD013059_pub2_data","Analysis.name","Quality of life and psychological well-being"
"CD013059_pub2_data","Analysis.name","Anxious symptomatology"
"CD013059_pub2_data","Analysis.name","Depressive symptomatology (end-of-intervention)"
"CD013059_pub2_data","Analysis.name","Depressive symptomatology, therapeutic contact (weeks)"
"CD013059_pub2_data","Analysis.name","Depressive symptomatology, therapeutic contact (number of sessions)"
"CD013059_pub2_data","Analysis.name","Depressive symptomatology, therapeutic contact (total treatment dose)"
"CD013059_pub2_data","Subgroup","Short-term"
"CD013059_pub2_data","Subgroup","End-of-intervention"
"CD013059_pub2_data","Subgroup","Medium-term"
"CD013059_pub2_data","Subgroup","Long-term"
"CD013059_pub2_data","Subgroup","> 54.8 points on a standardised 100-point scale"
"CD013059_pub2_data","Subgroup","< 54.8 points on a standardised 100-point scale"
"CD013059_pub2_data","Subgroup","BT"
"CD013059_pub2_data","Subgroup","RT"
"CD013059_pub2_data","Subgroup","CBT"
"CD013059_pub2_data","Subgroup","Treatment as usual"
"CD013059_pub2_data","Subgroup","Non-specific attentional control"
"CD013059_pub2_data","Subgroup","Low cognitive impairment"
"CD013059_pub2_data","Subgroup","High cognitive impairment"
"CD013059_pub2_data","Subgroup","Professional therapist without LTC staff involvement"
"CD013059_pub2_data","Subgroup","Professional therapist with LTC staff involvement"
"CD013059_pub2_data","Subgroup","> 8.5 weeks"
"CD013059_pub2_data","Subgroup","< 8.5 weeks"
"CD013059_pub2_data","Subgroup","< 9.5 total sessions"
"CD013059_pub2_data","Subgroup","> 9.5 total sessions"
"CD013059_pub2_data","Subgroup","> 6.5 total hours"
"CD013059_pub2_data","Subgroup","< 6.5 total hours"
"CD013071_pub2_data","Analysis.group","1"
"CD013071_pub2_data","Analysis.group","2"
"CD013071_pub2_data","Analysis.group","3"
"CD013071_pub2_data","Analysis.group","4"
"CD013071_pub2_data","Analysis.name","Erectile function (AMS sexual)"
"CD013071_pub2_data","Analysis.name","Erectile function (IIEF)"
"CD013071_pub2_data","Analysis.name","Erectile function (conversion to IIEF-EF)"
"CD013071_pub2_data","Analysis.name","Sexual quality of life (AMS total)"
"CD013071_pub2_data","Analysis.name","Sexual quality of life (IIEF-overall satisfaction)"
"CD013071_pub2_data","Analysis.name","Cardiovascular mortality"
"CD013071_pub2_data","Analysis.name","Treatment withdrawal due to adverse events"
"CD013071_pub2_data","Analysis.name","Prostate-related events"
"CD013071_pub2_data","Analysis.name","Lower urinary tract symptoms"
"CD013071_pub2_data","Analysis.name","Erectile function (subgroup: age and testosterone level, conversion to IIEF-EF)"
"CD013071_pub2_data","Analysis.name","Cardiovascular mortality (subgroup: age and testosterone level)"
"CD013071_pub2_data","Analysis.name","Erectile function (subgroup: metabolic syndrome (MS), conversion to IIEF-EF)"
"CD013071_pub2_data","Analysis.name","Sexual quality of life (subgroup: metabolic syndrome (MS), AMS total)"
"CD013071_pub2_data","Analysis.name","Sexual quality of life (subgroup: metabolic syndrome (MS), IIEF - overall satisfaction)"
"CD013071_pub2_data","Analysis.name","Cardiovascular mortality (subgroup: metabolic syndrome (MS))"
"CD013071_pub2_data","Analysis.name","Erectile function (conversion to IIEF-EF; sensitivity analysis)"
"CD013071_pub2_data","Analysis.name","Sexual quality of life (AMS total; sensitivity analysis)"
"CD013071_pub2_data","Analysis.name","Sexual quality of life (IIEF-overall satisfaction; sensitivity analysis)"
"CD013071_pub2_data","Analysis.name","Treatment withdrawal due to adverse events (sensitivity analysis)"
"CD013071_pub2_data","Analysis.name","Prostate-related events (sensitivity analysis)"
"CD013071_pub2_data","Analysis.name","Lower urinary tract symptoms (sensitivity analysis)"
"CD013071_pub2_data","Analysis.name","Erectile function (IIEF-EF)"
"CD013071_pub2_data","Analysis.name","Erectile function (IIEF-5)"
"CD013071_pub2_data","Analysis.name","Erectile function"
"CD013071_pub2_data","Analysis.name","Sexual quality of life (IIEF - overall satisfaction)"
"CD013071_pub2_data","Subgroup","IIEF-EF"
"CD013071_pub2_data","Subgroup","IIEF-5"
"CD013071_pub2_data","Subgroup","All ages over 18 years/testosterone ≤ 12 nmol/L"
"CD013071_pub2_data","Subgroup","Age ≥ 65 years/testosterone < 8 nmol/L"
"CD013071_pub2_data","Subgroup","MS: not reported"
"CD013071_pub2_data","Subgroup","MS: participants with MS"
"CD013071_pub2_data","Subgroup","MS: participants without MS"
"CD013071_pub2_data","Subgroup","MS: participants with DM"
"CD013078_pub2_data","Analysis.group","1"
"CD013078_pub2_data","Analysis.group","2"
"CD013078_pub2_data","Analysis.group","3"
"CD013078_pub2_data","Analysis.group","4"
"CD013078_pub2_data","Analysis.name","Pain intensity at the end of the treatment (6 months)"
"CD013078_pub2_data","Analysis.name","Function at the end of treatment"
"CD013078_pub2_data","Analysis.name","Function at 6 months' follow-up"
"CD013078_pub2_data","Analysis.name","Pain intensity at the end of treatment"
"CD013078_pub2_data","Analysis.name","Pain intensity at 6 months"
"CD013078_pub2_data","Analysis.name","Pain intensity at 12 months' follow-up"
"CD013078_pub2_data","Analysis.name","Function at end of treatment"
"CD013078_pub2_data","Analysis.name","Function at 12 months' follow-up"
"CD013078_pub2_data","Analysis.name","Global assessment treatment success at the end of treatment"
"CD013078_pub2_data","Analysis.name","Global assessment treatment success at 6 months' follow-up"
"CD013078_pub2_data","Analysis.name","Global assessment treatment success at 12 months' follow-up"
"CD013078_pub2_data","Analysis.name","Return to sport at 12 months' follow-up"
"CD013078_pub2_data","Analysis.name","Muscle strength at the end of treatment"
"CD013105_pub2_data","Analysis.group","1"
"CD013105_pub2_data","Analysis.group","2"
"CD013105_pub2_data","Analysis.group","3"
"CD013105_pub2_data","Analysis.group","5"
"CD013105_pub2_data","Analysis.group","6"
"CD013105_pub2_data","Analysis.group","7"
"CD013105_pub2_data","Analysis.group","8"
"CD013105_pub2_data","Analysis.group","9"
"CD013105_pub2_data","Analysis.group","10"
"CD013105_pub2_data","Analysis.group","11"
"CD013105_pub2_data","Analysis.group","12"
"CD013105_pub2_data","Analysis.group","13"
"CD013105_pub2_data","Analysis.name","Awareness of prolapse "
"CD013105_pub2_data","Analysis.name","Repeat surgery for recurrent prolapse"
"CD013105_pub2_data","Analysis.name","Objective failure at any site "
"CD013105_pub2_data","Analysis.name","POP-Q assessment "
"CD013105_pub2_data","Analysis.name","Adverse events "
"CD013105_pub2_data","Analysis.name","Patient-reported outcome measures "
"CD013105_pub2_data","Analysis.name","Perioperative outcomes "
"CD013105_pub2_data","Analysis.name","Bladder function "
"CD013105_pub2_data","Analysis.name","Perioperative outcomes"
"CD013105_pub2_data","Analysis.name","Awareness of prolapse  "
"CD013105_pub2_data","Analysis.name","Bowel function "
"CD013105_pub2_data","Analysis.name","Postoperative pain "
"CD013105_pub2_data","Analysis.name","Patient Global impression of Improvement (PGI-I)"
"CD013105_pub2_data","Analysis.name","Awareness of prolapse"
"CD013105_pub2_data","Analysis.name","Objective failure at any site"
"CD013105_pub2_data","Subgroup","Surgery for recurrent prolapse"
"CD013105_pub2_data","Subgroup","Point Ba (mid anterior vaginal wall) "
"CD013105_pub2_data","Subgroup","Point Bp (mid posterior vaginal wall) "
"CD013105_pub2_data","Subgroup","Point C (vaginal apex) "
"CD013105_pub2_data","Subgroup","Bladder injury "
"CD013105_pub2_data","Subgroup","Pelvic Floor Distress Inventory-20 ( PFDI-20) higher the score greater dysfunction (range 0-300)"
"CD013105_pub2_data","Subgroup","Urinary Distress Inventory (UDI) range 0-100"
"CD013105_pub2_data","Subgroup","Pelvic Organ Prolapse - Distress inventory (POP-DI range 0-100)"
"CD013105_pub2_data","Subgroup","Colorectal Anal Distress Inventory (CRADI 0-100)"
"CD013105_pub2_data","Subgroup","Prolapse/urinary Incontinence Sexual Questionanire (PISQ) 0-48: higher score better function "
"CD013105_pub2_data","Subgroup","Pelvic Organ Prolapse Symptoms Score (POP SS) 0-28: higher score greater dysfunction "
"CD013105_pub2_data","Subgroup","Operating time (mins) "
"CD013105_pub2_data","Subgroup","Estimated blood loss "
"CD013105_pub2_data","Subgroup","Length of hospital stay (days) "
"CD013105_pub2_data","Subgroup","Urinary tract infections "
"CD013105_pub2_data","Subgroup","Discharge with catheter"
"CD013105_pub2_data","Subgroup","Visual analogue scale for pain (0-10): 0 no pain and 10 worst imaginable pain "
"CD013105_pub2_data","Subgroup","Length of stay (days) "
"CD013105_pub2_data","Subgroup","Total catheter days"
"CD013105_pub2_data","Subgroup","Visual analog score for pain (0-10): 0 no pain and 10 worst imaginable pain "
"CD013105_pub2_data","Subgroup","Awareness of Prolapse"
"CD013105_pub2_data","Subgroup","Bowel injury "
"CD013105_pub2_data","Subgroup","Readmission to hospital (within 30 days "
"CD013105_pub2_data","Subgroup","Surgeons satisfaction with surgical field "
"CD013105_pub2_data","Subgroup","Estimated blood loss (mL) "
"CD013105_pub2_data","Subgroup","Units of narcotic utilised during admission "
"CD013105_pub2_data","Subgroup","Readmission to hospital (within 30 days)"
"CD013105_pub2_data","Subgroup","Blood transfusion "
"CD013105_pub2_data","Subgroup","Point Ba (mid-anterior vaginal wall) "
"CD013105_pub2_data","Subgroup","Pelvic Floor Distress Inventory -20 ( PFDI-20)"
"CD013105_pub2_data","Subgroup","Pelvic Floor Impact Questionnaire-7 ( PFIO-7)"
"CD013105_pub2_data","Subgroup","Visual analogue scale for pain (range 0-10): 0 no pain and 10 worst imaginable pain "
"CD013105_pub2_data","Subgroup","Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ)"
"CD013111_pub2_data","Analysis.group","1"
"CD013111_pub2_data","Analysis.group","2"
"CD013111_pub2_data","Analysis.group","3"
"CD013111_pub2_data","Analysis.name","Metformin plus progestin compared to progestin. Live birth rate. RCTs"
"CD013111_pub2_data","Analysis.name","Metformin plus progestin compared to progestin. Complete pathological response rate (12-16 weeks). RCTs"
"CD013111_pub2_data","Analysis.name","Metformin plus progestin compared to progestin.  Pregnancy rate. RCTs"
"CD013111_pub2_data","Analysis.name","Metformin plus progestin compared to progestin. Surgery for persistent/progressive disease (hysterectomy). RCTs"
"CD013111_pub2_data","Analysis.name","Metformin plus progestin compared to progestin. Severe adverse events grade 3-4."
"CD013111_pub2_data","Analysis.name","Levonorgestrel intrauterine system compared to oral progestin. Live birth rate"
"CD013111_pub2_data","Analysis.name","Levonorgestrel intrauterine system compared to oral progestin.Complete pathological response rate. "
"CD013111_pub2_data","Analysis.name","Levonorgestrel intrauterine system compared to oral progestin.Severe adverse events (weight gain)"
"CD013111_pub2_data","Analysis.name","Levonorgestrel intrauterine system compared to oral progestin. Complete pathological response rate. "
"CD013111_pub2_data","Analysis.name","Oral progestin plus levonorgestrel intrauterine system compared to oral progestin. Live birth rate."
"CD013111_pub2_data","Analysis.name","Oral progestin plus levonorgestrel intrauterine system compared to oral progestin. Complete pathological response rate"
"CD013111_pub2_data","Analysis.name","Oral progestin plus levonorgestrel intrauterine system compared to oral progestin. Severe adverse events (weight gain)"
"CD013111_pub2_data","Analysis.name","Oral progestin plus levonorgestrel intrauterine system compared to oral progestin. Surgery  for persistent/progressive disease (hysterectomy)"
"CD013111_pub2_data","Analysis.name","Oral progestin plus levonorgestrel intrauterine system compared to oral progestin. (EC) Live birth rate"
"CD013111_pub2_data","Analysis.name","Oral progestin plus levonorgestrel intrauterine system compared to oral progestin.(EC) Complete pathological response rate"
"CD013111_pub2_data","Analysis.name","Oral progestin plus levonorgestrel intrauterine system compared to oral progestin.(EC). Severe adverse event (weight gain)"
"CD013111_pub2_data","Analysis.name","Oral progestin plus levonorgestrel intrauterine system compared to oral progestin.(EC) Surgery for persistent/progressive disease (Hysterectomy)"
"CD013158_pub2_data","Analysis.group","1"
"CD013158_pub2_data","Analysis.name","Mortality prior to hospital discharge"
"CD013158_pub2_data","Analysis.name","Bronchopulmonary dysplasia"
"CD013158_pub2_data","Analysis.name","Surfactant utilization (number of infants receiving surfactant)"
"CD013158_pub2_data","Analysis.name","Any pneumothorax"
"CD013158_pub2_data","Analysis.name","Retinopathy of prematurity (all grades)"
"CD013166_pub3_data","Analysis.group","1"
"CD013166_pub3_data","Analysis.group","2"
"CD013166_pub3_data","Analysis.group","3"
"CD013166_pub3_data","Analysis.group","4"
"CD013166_pub3_data","Analysis.group","5"
"CD013166_pub3_data","Analysis.group","6"
"CD013166_pub3_data","Analysis.name","Erectile function "
"CD013166_pub3_data","Analysis.name","Discontinuation from treatment"
"CD013166_pub3_data","Analysis.name","Treatment-related adverse events"
"CD013166_pub3_data","Analysis.name","Penile rigidity"
"CD013166_pub3_data","Analysis.name","Subgroup analysis by PDE-5i response status: erectile function"
"CD013166_pub3_data","Analysis.name","Subgroup analysis by PDE-5i response status: discontinuation from treatment"
"CD013166_pub3_data","Analysis.name","Subgroup analysis by PDE-5i response status: treatment-related adverse events"
"CD013166_pub3_data","Analysis.name","Erectile function"
"CD013166_pub3_data","Subgroup","PDE-5i responders"
"CD013166_pub3_data","Subgroup","PDE-5i non-responders"
"CD013197_pub2_data","Analysis.group","1"
"CD013197_pub2_data","Analysis.group","2"
"CD013197_pub2_data","Analysis.name","All-cause mortality short-term"
"CD013197_pub2_data","Analysis.name","Health-related quality of life short-term"
"CD013197_pub2_data","Analysis.name","Health-related quality of life medium-term"
"CD013197_pub2_data","Analysis.name","Serious adverse events (SAEs) start of surgery until eight hours after surgery"
"CD013197_pub2_data","Analysis.name","Serious adverse events (SAEs) short-term"
"CD013197_pub2_data","Analysis.name","Non-serious adverse events (nSAEs) start of surgery until eight hours after surgery"
"CD013197_pub2_data","Analysis.name","Non-serious adverse events (nSAEs) short-term"
"CD013197_pub2_data","Analysis.name","Readmissions within three months after surgery"
"CD013197_pub2_data","Analysis.name","Postoperative pain one hour after surgery or at postanaesthesia care unit (PACU)"
"CD013197_pub2_data","Analysis.name","Postoperative pain 24 hours after surgery"
"CD013197_pub2_data","Analysis.name","Postoperative pain one week after surgery"
"CD013197_pub2_data","Analysis.name","Measures of early postoperative recovery: length of hospital stay"
"CD013197_pub2_data","Analysis.name","Operating time"
"CD013197_pub2_data","Analysis.name","Postoperative pain one hour after surgery or at PACU: subgroup BMI"
"CD013197_pub2_data","Analysis.name","Postoperative pain 24 hours after surgery: subgroup BMI"
"CD013197_pub2_data","Analysis.name","Postoperative pain one hour after surgery or at PACU: subgroup intra-abdominal pressure"
"CD013197_pub2_data","Analysis.name","Postoperative pain 24 hours after surgery: subgroup intra-abdominal pressure"
"CD013197_pub2_data","Analysis.name","Serious adverse events (sensitivity analysis)"
"CD013197_pub2_data","Analysis.name","Non-serious adverse events (sensitivity analysis)"
"CD013197_pub2_data","Subgroup","Normal BMI"
"CD013197_pub2_data","Subgroup","High BMI"
"CD013197_pub2_data","Subgroup","Standard-pressure pneumoperitoneum"
"CD013197_pub2_data","Subgroup","Low-pressure pneumoperitoneum"
"CD013197_pub2_data","Subgroup","Worst-best case short-term"
"CD013197_pub2_data","Subgroup","Best-worst case short-term"
"CD013197_pub2_data","Subgroup","Best-worst case start of surgery until 8 hours after surgery"
"CD013197_pub2_data","Subgroup","Worst-best case start of surgery until 8 hours after surgery"
"CD013197_pub2_data","Subgroup","Worst-best short-term"
"CD013197_pub2_data","Subgroup","Best-worst short-term"
"CD013232_pub2_data","Analysis.group","1"
"CD013232_pub2_data","Analysis.group","2"
"CD013232_pub2_data","Analysis.group","3"
"CD013232_pub2_data","Analysis.group","4"
"CD013232_pub2_data","Analysis.group","5"
"CD013232_pub2_data","Analysis.group","6"
"CD013232_pub2_data","Analysis.group","7"
"CD013232_pub2_data","Analysis.group","8"
"CD013232_pub2_data","Analysis.group","9"
"CD013232_pub2_data","Analysis.group","10"
"CD013232_pub2_data","Analysis.group","11"
"CD013232_pub2_data","Analysis.group","12"
"CD013232_pub2_data","Analysis.group","13"
"CD013232_pub2_data","Analysis.group","14"
"CD013232_pub2_data","Analysis.group","15"
"CD013232_pub2_data","Analysis.name","Irritability"
"CD013232_pub2_data","Analysis.name","Relapse"
"CD013232_pub2_data","Analysis.name","Improvement"
"CD013232_pub2_data","Analysis.name","Aggression"
"CD013232_pub2_data","Analysis.name","Self-injury"
"CD013232_pub2_data","Analysis.name","Adverse effects: cardiovascular"
"CD013232_pub2_data","Analysis.name","Adverse effects: gastrointestinal"
"CD013232_pub2_data","Analysis.name","Adverse effects: immune system"
"CD013232_pub2_data","Analysis.name","Adverse effects: metabolic (dichotomous)"
"CD013232_pub2_data","Analysis.name","Adverse effects: metabolic (continuous)"
"CD013232_pub2_data","Analysis.name","Adverse effects: musculoskeletal"
"CD013232_pub2_data","Analysis.name","Adverse effects: neurological"
"CD013232_pub2_data","Analysis.name","Adverse effects: psychological"
"CD013232_pub2_data","Analysis.name","Adverse effects: respiratory"
"CD013232_pub2_data","Analysis.name","Adverse effects: skin"
"CD013232_pub2_data","Analysis.name","Adverse effects: urinary"
"CD013232_pub2_data","Analysis.name","Quality of life"
"CD013232_pub2_data","Analysis.name","Tolerability/acceptability: loss to follow-up"
"CD013232_pub2_data","Analysis.name","Subgroup analysis: age - irritability"
"CD013232_pub2_data","Analysis.name","Subgroup analysis: age - aggression"
"CD013232_pub2_data","Analysis.name","Subgroup analysis: cognitive ability - irritability"
"CD013232_pub2_data","Analysis.name","Adverse effects: skin "
"CD013232_pub2_data","Analysis.name","Adverse effects: other"
"CD013232_pub2_data","Analysis.name","Subgroup analyses: gender - irritability"
"CD013232_pub2_data","Analysis.name","Adverse effects: neurological (dichotomous)"
"CD013232_pub2_data","Analysis.name","Adverse effects: neurological (continuous)"
"CD013232_pub2_data","Analysis.name","Adverse effects: psychological (dichotomous)"
"CD013232_pub2_data","Analysis.name","Subgroup analyses: age - irritability"
"CD013232_pub2_data","Analysis.name","Adverse effect: immune system"
"CD013232_pub2_data","Analysis.name","Adverse effects: metabolic"
"CD013232_pub2_data","Analysis.name","Adverse effect: musculoskeletal"
"CD013232_pub2_data","Analysis.name","Serious adverse events"
"CD013232_pub2_data","Analysis.name","Adverse effects: cardiovascular (tachycardia)"
"CD013232_pub2_data","Analysis.name","Tolerability"
"CD013232_pub2_data","Analysis.name","Adverse Effects: neurological"
"CD013232_pub2_data","Analysis.name","Irritability (continuous)"
"CD013232_pub2_data","Analysis.name","Irritability (dichotomous)"
"CD013232_pub2_data","Analysis.name","Adverse events: metabolic"
"CD013232_pub2_data","Analysis.name","Adverse effects: musculoskeletal pain"
"CD013232_pub2_data","Analysis.name","Adverse events: other"
"CD013232_pub2_data","Analysis.name","Adverse events: psychological"
"CD013232_pub2_data","Analysis.name","Adverse events: respiratory"
"CD013232_pub2_data","Analysis.name","Subgroup analysis: age - irritability (continuous)"
"CD013232_pub2_data","Analysis.name","Irritabilty (continuous)"
"CD013232_pub2_data","Analysis.name","Adverse effects: immune System"
"CD013232_pub2_data","Analysis.name","Adverse effects: respiratory system"
"CD013232_pub2_data","Analysis.name","Other adverse effects"
"CD013232_pub2_data","Analysis.name","Subgroup analyses: age - irritability (option 1)"
"CD013232_pub2_data","Analysis.name","Subgroup analyses: age - irritability (option 2)"
"CD013232_pub2_data","Analysis.name","Subgroup analyses: age - self-injury (option 1)"
"CD013232_pub2_data","Analysis.name","Subgroup analyses: age - self-injury (option 2)"
"CD013232_pub2_data","Analysis.name","Tolerability/acceptabiity: loss to follow-up"
"CD013232_pub2_data","Subgroup","Aripiprazole vs placebo"
"CD013232_pub2_data","Subgroup","Risperidone vs placebo"
"CD013232_pub2_data","Subgroup","Lurasidone vs placebo"
"CD013232_pub2_data","Subgroup","Ariprazole vs placebo"
"CD013232_pub2_data","Subgroup","Tachycardia"
"CD013232_pub2_data","Subgroup","Drooling"
"CD013232_pub2_data","Subgroup","Stomach ache"
"CD013232_pub2_data","Subgroup","Dyspepsia (indigestion)"
"CD013232_pub2_data","Subgroup","Abdominal pain"
"CD013232_pub2_data","Subgroup","Constipation"
"CD013232_pub2_data","Subgroup","Diarrhoea"
"CD013232_pub2_data","Subgroup","Dry mouth"
"CD013232_pub2_data","Subgroup","Vomiting/nausea"
"CD013232_pub2_data","Subgroup","Nausea"
"CD013232_pub2_data","Subgroup","Hypersalivation"
"CD013232_pub2_data","Subgroup","Sore throat"
"CD013232_pub2_data","Subgroup","Earache"
"CD013232_pub2_data","Subgroup","Cough"
"CD013232_pub2_data","Subgroup","Pyrexia"
"CD013232_pub2_data","Subgroup","Flu-like symptoms"
"CD013232_pub2_data","Subgroup","Decreased appetite"
"CD013232_pub2_data","Subgroup","Weight gain"
"CD013232_pub2_data","Subgroup","Increased appetite"
"CD013232_pub2_data","Subgroup","Thirst"
"CD013232_pub2_data","Subgroup","Weight gain (kg)"
"CD013232_pub2_data","Subgroup","Dyskinesia"
"CD013232_pub2_data","Subgroup","Rigidity"
"CD013232_pub2_data","Subgroup","Movement disorder"
"CD013232_pub2_data","Subgroup","Restlessness (akathisia)"
"CD013232_pub2_data","Subgroup","Insomnia"
"CD013232_pub2_data","Subgroup","Agitation/excitation"
"CD013232_pub2_data","Subgroup","Drowsiness"
"CD013232_pub2_data","Subgroup","Dizziness"
"CD013232_pub2_data","Subgroup","Fatigue"
"CD013232_pub2_data","Subgroup","Aggression"
"CD013232_pub2_data","Subgroup","Apathy"
"CD013232_pub2_data","Subgroup","Tremor"
"CD013232_pub2_data","Subgroup","Sedation"
"CD013232_pub2_data","Subgroup","Presyncope"
"CD013232_pub2_data","Subgroup","Lethargy"
"CD013232_pub2_data","Subgroup","Headache"
"CD013232_pub2_data","Subgroup","Extrapyramidal disorder"
"CD013232_pub2_data","Subgroup","Hyperactivity"
"CD013232_pub2_data","Subgroup","Hypersomnia"
"CD013232_pub2_data","Subgroup","Somnolence"
"CD013232_pub2_data","Subgroup","Anxiety"
"CD013232_pub2_data","Subgroup","Depression"
"CD013232_pub2_data","Subgroup","Epistaxis"
"CD013232_pub2_data","Subgroup","Ear infection"
"CD013232_pub2_data","Subgroup","Rhinitis"
"CD013232_pub2_data","Subgroup","Upper respiratory tract infection"
"CD013232_pub2_data","Subgroup","Nasal congestion"
"CD013232_pub2_data","Subgroup","Nasopharyngitis"
"CD013232_pub2_data","Subgroup","Pharyngolaryngeal pain"
"CD013232_pub2_data","Subgroup","Bruise"
"CD013232_pub2_data","Subgroup","Rash"
"CD013232_pub2_data","Subgroup","Enuresis"
"CD013232_pub2_data","Subgroup","Adults only"
"CD013232_pub2_data","Subgroup","Children only"
"CD013232_pub2_data","Subgroup","Mixed IQ"
"CD013232_pub2_data","Subgroup","Oxytocin"
"CD013232_pub2_data","Subgroup","Vasopressin"
"CD013232_pub2_data","Subgroup","ACTH"
"CD013232_pub2_data","Subgroup","Secretin"
"CD013232_pub2_data","Subgroup","Endpoint"
"CD013232_pub2_data","Subgroup","Three month follow-up"
"CD013232_pub2_data","Subgroup","Cardiac disorders"
"CD013232_pub2_data","Subgroup","Vascular disorders"
"CD013232_pub2_data","Subgroup","Palpitations"
"CD013232_pub2_data","Subgroup","Gastrointestinal disorders"
"CD013232_pub2_data","Subgroup","Abdominal pain or discomfort"
"CD013232_pub2_data","Subgroup","Encopresis"
"CD013232_pub2_data","Subgroup","Stomatitis"
"CD013232_pub2_data","Subgroup","Salivary hypersecretion"
"CD013232_pub2_data","Subgroup","Vomiting"
"CD013232_pub2_data","Subgroup","infections and infestations"
"CD013232_pub2_data","Subgroup","Metabolism and nutrition disorders"
"CD013232_pub2_data","Subgroup","Weight loss"
"CD013232_pub2_data","Subgroup","Mean change in weight (kg)"
"CD013232_pub2_data","Subgroup","Muscle spasms"
"CD013232_pub2_data","Subgroup","Musculoskeletal and connective tissue disorders"
"CD013232_pub2_data","Subgroup","Rhabdomyolysis"
"CD013232_pub2_data","Subgroup","Absence seizures"
"CD013232_pub2_data","Subgroup","Decreased attention"
"CD013232_pub2_data","Subgroup","Agitation"
"CD013232_pub2_data","Subgroup","Leg shaking"
"CD013232_pub2_data","Subgroup","Restlessness"
"CD013232_pub2_data","Subgroup","Forgetfulness"
"CD013232_pub2_data","Subgroup","Seizure"
"CD013232_pub2_data","Subgroup","Excessive talking"
"CD013232_pub2_data","Subgroup","Dysphoria"
"CD013232_pub2_data","Subgroup","Tics"
"CD013232_pub2_data","Subgroup","Oppositional"
"CD013232_pub2_data","Subgroup","Nervous systems disorders"
"CD013232_pub2_data","Subgroup","Irritability"
"CD013232_pub2_data","Subgroup","Panic attack"
"CD013232_pub2_data","Subgroup","Psychiatric"
"CD013232_pub2_data","Subgroup","Self-injury"
"CD013232_pub2_data","Subgroup","Nasal irritation/runny nose"
"CD013232_pub2_data","Subgroup","Sinusitis"
"CD013232_pub2_data","Subgroup","Respiratory, thoracic and mediastinal disorders"
"CD013232_pub2_data","Subgroup","Croup"
"CD013232_pub2_data","Subgroup","Cold symptoms"
"CD013232_pub2_data","Subgroup","Skin and subcutaneous tissue disorders"
"CD013232_pub2_data","Subgroup","Skin rash"
"CD013232_pub2_data","Subgroup","General/systemic disorders and administration site conditions"
"CD013232_pub2_data","Subgroup","Renal and urinary disorders"
"CD013232_pub2_data","Subgroup","Injury, poisoning, and procedural complications"
"CD013232_pub2_data","Subgroup","Troponin I increased"
"CD013232_pub2_data","Subgroup","Neoplasms: benign, malignant, and unspecified"
"CD013232_pub2_data","Subgroup","Lymphadenopathy"
"CD013232_pub2_data","Subgroup","Investigations"
"CD013232_pub2_data","Subgroup","Balovaptan"
"CD013232_pub2_data","Subgroup","Male and female participants"
"CD013232_pub2_data","Subgroup","Male participants only"
"CD013232_pub2_data","Subgroup","Irritability: stimulant ADHD-related drugs"
"CD013232_pub2_data","Subgroup","Irritability: non-stimulant ADHD-related drugs"
"CD013232_pub2_data","Subgroup","Bradycardia"
"CD013232_pub2_data","Subgroup","Stomachache"
"CD013232_pub2_data","Subgroup","Stomach or abdominal discomfort"
"CD013232_pub2_data","Subgroup","Fever"
"CD013232_pub2_data","Subgroup","Myalgia"
"CD013232_pub2_data","Subgroup","Influenza"
"CD013232_pub2_data","Subgroup","Weakness"
"CD013232_pub2_data","Subgroup","Increased energy"
"CD013232_pub2_data","Subgroup","Restless"
"CD013232_pub2_data","Subgroup","Repetitive behaviour"
"CD013232_pub2_data","Subgroup","Emotional / tearful"
"CD013232_pub2_data","Subgroup","Increased motor activity"
"CD013232_pub2_data","Subgroup","Nightmares"
"CD013232_pub2_data","Subgroup","Motor tics"
"CD013232_pub2_data","Subgroup","Sleep disturbance"
"CD013232_pub2_data","Subgroup","Talking excessively"
"CD013232_pub2_data","Subgroup","Waking"
"CD013232_pub2_data","Subgroup","Decreased activity"
"CD013232_pub2_data","Subgroup","Social withdrawal"
"CD013232_pub2_data","Subgroup","Silly behaviour"
"CD013232_pub2_data","Subgroup","Mood change"
"CD013232_pub2_data","Subgroup","Skin picking"
"CD013232_pub2_data","Subgroup","ADHD-related drugs: loss to follow-up"
"CD013232_pub2_data","Subgroup","Adults and children "
"CD013232_pub2_data","Subgroup","Dibenzoxazepine"
"CD013232_pub2_data","Subgroup","SSRIs"
"CD013232_pub2_data","Subgroup","Flushing"
"CD013232_pub2_data","Subgroup","Nausea/abdominal pain"
"CD013232_pub2_data","Subgroup","Gastrointestinal disturbance"
"CD013232_pub2_data","Subgroup","Allergies"
"CD013232_pub2_data","Subgroup","Cold, flu or other systemic infection"
"CD013232_pub2_data","Subgroup","Infections"
"CD013232_pub2_data","Subgroup","Appetite disturbance"
"CD013232_pub2_data","Subgroup","Decreased energy"
"CD013232_pub2_data","Subgroup","Motor disturbance"
"CD013232_pub2_data","Subgroup","Neck pain"
"CD013232_pub2_data","Subgroup","Anger/irritability"
"CD013232_pub2_data","Subgroup","Aggression or hostility"
"CD013232_pub2_data","Subgroup","Activation syndrome"
"CD013232_pub2_data","Subgroup","Autonomic disturbance"
"CD013232_pub2_data","Subgroup","CNS disturbance"
"CD013232_pub2_data","Subgroup","Drowsiness/fatigue"
"CD013232_pub2_data","Subgroup","Diaphoresis (sweating)"
"CD013232_pub2_data","Subgroup","Increased speech"
"CD013232_pub2_data","Subgroup","Mood disturbance"
"CD013232_pub2_data","Subgroup","Vertigo"
"CD013232_pub2_data","Subgroup","Twitching"
"CD013232_pub2_data","Subgroup","Numbness"
"CD013232_pub2_data","Subgroup","Mood lability"
"CD013232_pub2_data","Subgroup","Anorexia"
"CD013232_pub2_data","Subgroup","Vivid or bad dreams"
"CD013232_pub2_data","Subgroup","Verbal aggression"
"CD013232_pub2_data","Subgroup","Silliness"
"CD013232_pub2_data","Subgroup","Impulsive/intrusive behaviour"
"CD013232_pub2_data","Subgroup","Suicidal ideation"
"CD013232_pub2_data","Subgroup","Unstable mood"
"CD013232_pub2_data","Subgroup","Stereotypy"
"CD013232_pub2_data","Subgroup","Anxiety/nervousness"
"CD013232_pub2_data","Subgroup","Upper respiratory infection (URI)"
"CD013232_pub2_data","Subgroup","Respiratory"
"CD013232_pub2_data","Subgroup","Rash or skin irritation"
"CD013232_pub2_data","Subgroup","Urinary tract infection (UTI)"
"CD013232_pub2_data","Subgroup","Polyuria"
"CD013232_pub2_data","Subgroup","Trembling (mild)"
"CD013232_pub2_data","Subgroup","Salty taste"
"CD013232_pub2_data","Subgroup","Hospitalisation for dehydration"
"CD013232_pub2_data","Subgroup","Severe diarrhoea"
"CD013232_pub2_data","Subgroup","Nausea/vomiting"
"CD013232_pub2_data","Subgroup","Ataxia"
"CD013232_pub2_data","Subgroup","Blunted effect"
"CD013232_pub2_data","Subgroup","Respiratory tract infection"
"CD013232_pub2_data","Subgroup","Muscle rigidity"
"CD013232_pub2_data","Subgroup","Nervousness"
"CD013232_pub2_data","Subgroup","Difficulty sleeping"
"CD013232_pub2_data","Subgroup","Increased salivation"
"CD013232_pub2_data","Subgroup","Increased hyperactivity"
"CD013232_pub2_data","Subgroup","Agitation/excitement"
"CD013232_pub2_data","Subgroup","Chills"
"CD013232_pub2_data","Subgroup","Hypersomnolence"
"CD013232_pub2_data","Subgroup","Echolalia"
"CD013232_pub2_data","Subgroup","Paraesthesia"
"CD013232_pub2_data","Subgroup","Impulsivity"
"CD013232_pub2_data","Subgroup","Complete response (≥ 50% reduction in irritability score)"
"CD013232_pub2_data","Subgroup","Partial response (≥ 25% reduction in irritability score)"
"CD013232_pub2_data","Subgroup","Gastroenteritis"
"CD013232_pub2_data","Subgroup","Daytime drowsiness"
"CD013232_pub2_data","Subgroup","Morning drowsiness"
"CD013232_pub2_data","Subgroup","Increased infections"
"CD013232_pub2_data","Subgroup","Mood changes"
"CD013232_pub2_data","Subgroup","Emotional lability"
"CD013232_pub2_data","Subgroup","Anger"
"CD013232_pub2_data","Subgroup","Skin irritation"
"CD013232_pub2_data","Subgroup","Affective disorder"
"CD013232_pub2_data","Subgroup","Adverse behaviour"
"CD013232_pub2_data","Subgroup","Anxiolytics vs placebo"
"CD013232_pub2_data","Subgroup","Response rate (> 25% decrease in irritability score)"
"CD013232_pub2_data","Subgroup","Increased aggression"
"CD013232_pub2_data","Subgroup","Rhinorrhoea"
"CD013232_pub2_data","Subgroup","Sinus congestion"
"CD013232_pub2_data","Subgroup","Eye disorders"
"CD013232_pub2_data","Subgroup","Ear and labyrinth disorders"
"CD013232_pub2_data","Subgroup","Dextromethorphan"
"CD013232_pub2_data","Subgroup","Celecoxib"
"CD013232_pub2_data","Subgroup","Simvastatin "
"CD013232_pub2_data","Subgroup","Riluzole"
"CD013232_pub2_data","Subgroup","Baclofen"
"CD013232_pub2_data","Subgroup","Pregnenolone"
"CD013232_pub2_data","Subgroup","Bumetanide"
"CD013232_pub2_data","Subgroup","Arbaclofen"
"CD013232_pub2_data","Subgroup","Dextromethorphan/quinidine"
"CD013232_pub2_data","Subgroup","Tetrahydrobiopterin"
"CD013232_pub2_data","Subgroup","Sulforaphane"
"CD013232_pub2_data","Subgroup","Lofexedine"
"CD013232_pub2_data","Subgroup","Naltrexone"
"CD013232_pub2_data","Subgroup","N-acetylcysteine"
"CD013232_pub2_data","Subgroup","L-carnosine"
"CD013232_pub2_data","Subgroup","Nicotine"
"CD013232_pub2_data","Subgroup","Resveratol"
"CD013232_pub2_data","Subgroup","Folinic acid"
"CD013232_pub2_data","Subgroup","Minocycline"
"CD013232_pub2_data","Subgroup","Pioglitazone"
"CD013232_pub2_data","Subgroup","Palmitoylethanolamide"
"CD013232_pub2_data","Subgroup","Prednisolone (steroid)"
"CD013232_pub2_data","Subgroup","Propentofylline"
"CD013232_pub2_data","Subgroup","Trichuris suris ova"
"CD013232_pub2_data","Subgroup","Change in bowel habits"
"CD013232_pub2_data","Subgroup","Flatulance"
"CD013232_pub2_data","Subgroup","Dyspepsia"
"CD013232_pub2_data","Subgroup","Hypokalemia"
"CD013232_pub2_data","Subgroup","Weight loss (0.45-2.19 kg)"
"CD013232_pub2_data","Subgroup","Hyponatremia"
"CD013232_pub2_data","Subgroup","Hypoglycemia"
"CD013232_pub2_data","Subgroup","Weight loss (0.12-0.67 kg)"
"CD013232_pub2_data","Subgroup","Change in weight (kg)"
"CD013232_pub2_data","Subgroup","Arthralgia"
"CD013232_pub2_data","Subgroup","Difficulty walking"
"CD013232_pub2_data","Subgroup","Stiffness"
"CD013232_pub2_data","Subgroup","Impaired balance"
"CD013232_pub2_data","Subgroup","Slow movement"
"CD013232_pub2_data","Subgroup","Dazed"
"CD013232_pub2_data","Subgroup","Syncope"
"CD013232_pub2_data","Subgroup","Difficulty concentrating"
"CD013232_pub2_data","Subgroup","Increased irritability"
"CD013232_pub2_data","Subgroup","Increased stereotypies"
"CD013232_pub2_data","Subgroup","Migraine"
"CD013232_pub2_data","Subgroup","New onset seizures"
"CD013232_pub2_data","Subgroup","Rocking"
"CD013232_pub2_data","Subgroup","Hypoactivity"
"CD013232_pub2_data","Subgroup","Increased self-injurious behaviour"
"CD013232_pub2_data","Subgroup","Worsening of temper tantrums"
"CD013232_pub2_data","Subgroup","Mental symptoms"
"CD013232_pub2_data","Subgroup","Congestion/cold"
"CD013232_pub2_data","Subgroup","Lung congestion"
"CD013232_pub2_data","Subgroup","Aggravation of asthma"
"CD013232_pub2_data","Subgroup","Respiratory adverse effects"
"CD013232_pub2_data","Subgroup","Hives"
"CD013232_pub2_data","Subgroup","Itches"
"CD013232_pub2_data","Subgroup","Skin lesion"
"CD013232_pub2_data","Subgroup","Skin adverse effects"
"CD013232_pub2_data","Subgroup","Urinary retention"
"CD013232_pub2_data","Subgroup","Urinary tract infection"
"CD013232_pub2_data","Subgroup","Diuresis"
"CD013232_pub2_data","Subgroup","Dilated pupils"
"CD013232_pub2_data","Subgroup","Blurred vision"
"CD013232_pub2_data","Subgroup","Sweating"
"CD013232_pub2_data","Subgroup","Vision: conjunctivitis"
"CD013232_pub2_data","Subgroup","Children and adults"
"CD013232_pub2_data","Subgroup","Dextromethorphan: children only"
"CD013232_pub2_data","Subgroup","N-acetylcysteine: children only"
"CD013232_pub2_data","Subgroup","Resveratol: children only"
"CD013232_pub2_data","Subgroup","Mecamylamine: children only"
"CD013232_pub2_data","Subgroup","D-cycloserine: children only"
"CD013232_pub2_data","Subgroup","Riluzole: children only"
"CD013232_pub2_data","Subgroup","Pioglitazone: children only"
"CD013232_pub2_data","Subgroup","Trichuris suis ova: adults only"
"CD013232_pub2_data","Subgroup","Celecoxib: children only"
"CD013232_pub2_data","Subgroup","Tetrahydrobiopterin: children only"
"CD013232_pub2_data","Subgroup","Riluzole: children and adults"
"CD013232_pub2_data","Subgroup","Lofexedine: children only"
"CD013232_pub2_data","Subgroup","Palmitoylethanolamide: children only"
"CD013232_pub2_data","Subgroup","Minocycline: children only"
"CD013232_pub2_data","Subgroup","Propentofylline: children only"
"CD013232_pub2_data","Subgroup","Baclofen: children only"
"CD013232_pub2_data","Subgroup","Naltrexone: adults only"
"CD013232_pub2_data","Subgroup","Sulforaphane: children only"
"CD013232_pub2_data","Subgroup","Folinic acid: children only"
"CD013232_pub2_data","Subgroup","L-carnosine: children only"
"CD013232_pub2_data","Subgroup","Prednisolone (steroid): children only"
"CD013232_pub2_data","Subgroup","Dextromethorphan/quinidine: adults only"
"CD013232_pub2_data","Subgroup","Pregnenolone: children only"
"CD013232_pub2_data","Subgroup","Bumetanide: children only"
"CD013232_pub2_data","Subgroup","Arbaclofen: children and adults"
"CD013232_pub2_data","Subgroup","Dystonia"
"CD013232_pub2_data","Subgroup","Fatigue/lethargy"
"CD013232_pub2_data","Subgroup","Behaviour problems"
"CD013255_pub2_data","Analysis.group","1"
"CD013255_pub2_data","Analysis.group","2"
"CD013255_pub2_data","Analysis.group","3"
"CD013255_pub2_data","Analysis.group","4"
"CD013255_pub2_data","Analysis.group","5"
"CD013255_pub2_data","Analysis.group","6"
"CD013255_pub2_data","Analysis.group","7"
"CD013255_pub2_data","Analysis.group","8"
"CD013255_pub2_data","Analysis.group","9"
"CD013255_pub2_data","Analysis.group","10"
"CD013255_pub2_data","Analysis.group","11"
"CD013255_pub2_data","Analysis.group","12"
"CD013255_pub2_data","Analysis.group","13"
"CD013255_pub2_data","Analysis.group","14"
"CD013255_pub2_data","Analysis.name","Sinus rhythm until hospital discharge or end of study follow-up (paroxysmal AF)"
"CD013255_pub2_data","Analysis.name","Acute procedural success (paroxysmal AF)"
"CD013255_pub2_data","Analysis.name","Sinus rhythm until hospital discharge or end of study follow-up (persistent AF)"
"CD013255_pub2_data","Analysis.name","30-day all-cause mortality"
"CD013255_pub2_data","Analysis.name","30-day cardiovascular mortality"
"CD013255_pub2_data","Analysis.name","Stroke or systemic embolism at 30 days"
"CD013255_pub2_data","Analysis.name","Sinus rhythm until hospital discharge or end of study follow-up (atrial flutter)"
"CD013255_pub2_data","Analysis.name","Acute procedural success (atrial flutter)"
"CD013255_pub2_data","Analysis.name","Acute procedural success (persistent AF)"
"CD013278_pub3_data","Analysis.group","1"
"CD013278_pub3_data","Analysis.group","2"
"CD013278_pub3_data","Analysis.name","All-cause mortality during hospital stay"
"CD013278_pub3_data","Analysis.name","Surgical PDA ligation or transcatheter occlusion"
"CD013278_pub3_data","Analysis.name","Receipt of any pharmacotherapy for a hs-PDA"
"CD013278_pub3_data","Analysis.name","Receipt of rescue medical treatment for a hs-PDA"
"CD013278_pub3_data","Analysis.name","Chronic lung disease (CLD)"
"CD013278_pub3_data","Analysis.name","Duration of ventilator support (days)"
"CD013278_pub3_data","Analysis.name","Duration of need for supplementary oxygen (days)"
"CD013278_pub3_data","Analysis.name","Postnatal corticosteroid use for CLD any time during hospital stay"
"CD013278_pub3_data","Analysis.name","Pneumothorax"
"CD013278_pub3_data","Analysis.name","Intraventricular hemorrhage (IVH; grades I to IV)"
"CD013278_pub3_data","Analysis.name","Severe IVH (grades III and IV)"
"CD013278_pub3_data","Analysis.name","Periventricular leukomalacia (PVL; any grade)"
"CD013278_pub3_data","Analysis.name","Necrotizing enterocolitis (NEC; stage 2 or greater)"
"CD013278_pub3_data","Analysis.name","Spontaneous intestinal perforation"
"CD013278_pub3_data","Analysis.name","Time to full enteral feeds (postnatal age at time of achieving full enteral feeds)"
"CD013278_pub3_data","Analysis.name","Time to regain birth weight (days)"
"CD013278_pub3_data","Analysis.name","Severe retinopathy of prematurity (ROP)"
"CD013278_pub3_data","Analysis.name","Definite sepsis"
"CD013278_pub3_data","Analysis.name","Oliguria"
"CD013278_pub3_data","Analysis.name","Receipt of repeat courses of pharmacotherapy for a persistent hs-PDA"
"CD013278_pub3_data","Analysis.name","Pulmonary hemorrhage"
"CD013278_pub3_data","Analysis.name","Pulmonary hypertension"
"CD013278_pub3_data","Analysis.name","IVH (grades I to IV)"
"CD013278_pub3_data","Analysis.name","PVL (any grade)"
"CD013278_pub3_data","Analysis.name","NEC (stage 2 or greater)"
"CD013278_pub3_data","Analysis.name","Gastrointestinal bleeding within seven days of the first dose of pharmacotherapy"
"CD013278_pub3_data","Analysis.name","Severe ROP"
"CD013278_pub3_data","Analysis.name","Duration of hospitalization"
"CD013278_pub3_data","Analysis.name","Moderate/severe neurodevelopmental impairment at 18 to 24 months"
"CD013278_pub3_data","Analysis.name","Moderate/severe cognitive delay at 18 to 24 months"
"CD013278_pub3_data","Analysis.name","Moderate/severe motor delay at 18 to 24 months"
"CD013278_pub3_data","Analysis.name","Moderate/severe language delay at 18 to 24 months"
"CD013278_pub3_data","Analysis.name","Moderate/severe cerebral palsy at 18 to 24 months"
"CD013278_pub3_data","Subgroup","Intravenous/oral indomethacin"
"CD013278_pub3_data","Subgroup","Intravenous/oral ibuprofen"
"CD013278_pub3_data","Subgroup","Intravenous/oral indomethacin or intravenous/oral ibuprofen"
"CD013278_pub3_data","Subgroup","Intravenous/oral acetaminophen"
"CD013278_pub3_data","Subgroup","Rectal ibuprofen or intravenous acetaminophen"
"CD013284_pub2_data","Analysis.group","1"
"CD013284_pub2_data","Analysis.group","2"
"CD013284_pub2_data","Analysis.name","Rate of moderate or severe exacerbations"
"CD013284_pub2_data","Analysis.name","Rate of moderate or severe exacerbations (stratified by baseline 25(OH)D)"
"CD013284_pub2_data","Analysis.name","Rate of moderate or severe exacerbations (stratified by baseline FEV1, % predicted)"
"CD013284_pub2_data","Analysis.name","Rate of moderate or severe exacerbations (stratified by baseline corticosteroid use)"
"CD013284_pub2_data","Analysis.name","Proportion of participants experiencing one or more exacerbations (moderate or severe)"
"CD013284_pub2_data","Analysis.name","Time to first exacerbation"
"CD013284_pub2_data","Analysis.name","Rate of severe exacerbation, requiring ED attendance or hospitalisation"
"CD013284_pub2_data","Analysis.name","Rate of moderate exacerbation"
"CD013284_pub2_data","Analysis.name","Incidence of study defined exacerbation"
"CD013284_pub2_data","Analysis.name","Inter-arm difference in mean change in FEV1 (% predicted)"
"CD013284_pub2_data","Analysis.name","Inter-arm difference in mean change in FVC (% predicted)"
"CD013284_pub2_data","Analysis.name","Proportion of participants with one or more serious adverse event of any cause"
"CD013284_pub2_data","Analysis.name","Mortality (all-cause)"
"CD013284_pub2_data","Analysis.name","Mortality (all-cause), risk difference"
"CD013284_pub2_data","Analysis.name","Mortality (respiratory)"
"CD013284_pub2_data","Analysis.name","Mortality (respiratory), risk difference"
"CD013284_pub2_data","Analysis.name","Inter-arm difference in mean change in FEV1 (% predicted), excluding studies at high risk of bias"
"CD013284_pub2_data","Subgroup","Baseline 25(OH)D 25 to 49.9 nmol/L"
"CD013284_pub2_data","Subgroup","Baseline 25(OH)D < 25 nmol/L"
"CD013284_pub2_data","Subgroup","Baseline 25(OH)D 50 to 74.9 nmol/L"
"CD013284_pub2_data","Subgroup","Baseline 25(OH)D ≥ 75 nmol/L"
"CD013284_pub2_data","Subgroup","Baseline FEV1 < 50% predicted"
"CD013284_pub2_data","Subgroup","Baseline FEV1 ≥ 50% predicted"
"CD013284_pub2_data","Subgroup","No baseline corticosteroid use"
"CD013284_pub2_data","Subgroup","Any baseline corticosteroid use"
"CD013294_pub2_data","Analysis.group","1"
"CD013294_pub2_data","Analysis.group","2"
"CD013294_pub2_data","Analysis.group","3"
"CD013294_pub2_data","Analysis.name","Time (%) in target oxygen saturation range"
"CD013294_pub2_data","Analysis.name","Severe retinopathy of prematurity"
"CD013294_pub2_data","Analysis.name","Chronic lung disease or bronchopulmonary dysplasia"
"CD013294_pub2_data","Analysis.name","Time (%) above alarm limit or desired oxygen saturation range, regardless of fraction of inspired oxygen received"
"CD013294_pub2_data","Analysis.name","Time (%) above alarm limit or desired oxygen saturation range, excluding time in room air"
"CD013294_pub2_data","Analysis.name","Time (%) below alarm limit or desired oxygen saturation range"
"CD013294_pub2_data","Analysis.name","Hypoxic episodes during study period"
"CD013294_pub2_data","Analysis.name","Time (%) with oxygen saturation below 80%"
"CD013294_pub2_data","Analysis.name","Time with oxygen saturation between 97% and 100%, excluding time in room air"
"CD013294_pub2_data","Analysis.name","Periventricular leukomalacia"
"CD013294_pub2_data","Analysis.name","Average oxygen saturation (%)"
"CD013294_pub2_data","Analysis.name","Average fraction of inspired oxygen"
"CD013294_pub2_data","Analysis.name","Number of manual adjustments during study"
"CD013294_pub2_data","Analysis.name","Time (%) in desired oxygen saturation range"
"CD013294_pub2_data","Analysis.name","Time (%) below alarm limits or desired oxygen saturation range"
"CD013294_pub2_data","Analysis.name","Time (%) with oxygen saturation between 97% and 100%, excluding time in room air"
"CD013294_pub2_data","Subgroup","Invasive respiratory support"
"CD013294_pub2_data","Subgroup","Non-invasive respiratory support"
"CD013295_pub2_data","Analysis.group","1"
"CD013295_pub2_data","Analysis.group","2"
"CD013295_pub2_data","Analysis.group","3"
"CD013295_pub2_data","Analysis.group","4"
"CD013295_pub2_data","Analysis.group","5"
"CD013295_pub2_data","Analysis.group","6"
"CD013295_pub2_data","Analysis.group","7"
"CD013295_pub2_data","Analysis.group","8"
"CD013295_pub2_data","Analysis.group","9"
"CD013295_pub2_data","Analysis.group","10"
"CD013295_pub2_data","Analysis.group","11"
"CD013295_pub2_data","Analysis.group","12"
"CD013295_pub2_data","Analysis.group","13"
"CD013295_pub2_data","Analysis.group","14"
"CD013295_pub2_data","Analysis.group","15"
"CD013295_pub2_data","Analysis.group","16"
"CD013295_pub2_data","Analysis.group","17"
"CD013295_pub2_data","Analysis.group","18"
"CD013295_pub2_data","Analysis.group","19"
"CD013295_pub2_data","Analysis.group","20"
"CD013295_pub2_data","Analysis.group","21"
"CD013295_pub2_data","Analysis.group","22"
"CD013295_pub2_data","Analysis.group","23"
"CD013295_pub2_data","Analysis.group","24"
"CD013295_pub2_data","Analysis.group","25"
"CD013295_pub2_data","Analysis.group","26"
"CD013295_pub2_data","Analysis.group","27"
"CD013295_pub2_data","Analysis.group","28"
"CD013295_pub2_data","Analysis.group","29"
"CD013295_pub2_data","Analysis.group","30"
"CD013295_pub2_data","Analysis.group","31"
"CD013295_pub2_data","Analysis.group","32"
"CD013295_pub2_data","Analysis.group","33"
"CD013295_pub2_data","Analysis.name","Need for allogeneic blood transfusion (only trials included in the NMA)"
"CD013295_pub2_data","Analysis.name","Units of red blood cells transfused (only trials included in the NMA)"
"CD013295_pub2_data","Analysis.name","Risk of experiencing DVT (only trials included in the NMA)"
"CD013295_pub2_data","Analysis.name","Length of hospital stay (only trials included in the NMA)"
"CD013295_pub2_data","Analysis.name","Need for allogeneic blood transfusion"
"CD013295_pub2_data","Analysis.name","All-cause mortality"
"CD013295_pub2_data","Analysis.name","Units of red blood cells transfused"
"CD013295_pub2_data","Analysis.name","Reoperation"
"CD013295_pub2_data","Analysis.name","Length of hospital stay"
"CD013295_pub2_data","Analysis.name","Risk of experiencing DVT"
"CD013295_pub2_data","Analysis.name","Risk of experiencing PE"
"CD013295_pub2_data","Analysis.name","Risk of experiencing MI"
"CD013295_pub2_data","Analysis.name","Risk of experiencing CVA"
"CD013295_pub2_data","Analysis.name","Risk of having suspected serious drug reactions"
"CD013295_pub2_data","Analysis.name","Risk of allogeneic blood transfusion"
"CD013295_pub2_data","Analysis.name","Risk of transfusion reactions"
"CD013295_pub2_data","Analysis.name","Risk of suspected serious drug reactions"
"CD013295_pub2_data","Subgroup","EACA vs placebo"
"CD013295_pub2_data","Subgroup","Aprotinin vs placebo"
"CD013295_pub2_data","Subgroup","Aprotinin vs EACA"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_intra_post vs TXA_oral_grt_than_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_preI vs TXA_IV_2g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_preI vs TXA_IV_IA_2g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_preI vs TXA_oral_2g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_preI_intra vs TXA_IV_IA_2g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_intra vs TXA_IV_oral_grt_than_3g_intra_post"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_intra_post vs TXA_IV_oral_grt_than_3g_intra_post"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_preI vs TXA_IV_1g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_preI vs TXA_IV_2g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_preI_intra vs TXA_oral_2g_preI"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_preI_intra vs TXA_oral_2g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_preI_post vs TXA_IV_IA_grt_than_3g_preI_intra_post"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_preI_post vs TXA_IV_oral_grt_than_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_3g_intra_post vs TXA_oral_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_IA_2g_preI_intra vs TXA_oral_2g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_oral_grt_than_3g_intra_post vs TXA_oral_grt_than_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_preI_post vs TXA_oral_2g_preI_post"
"CD013295_pub2_data","Subgroup","TXA topical 2 g intraoperatively vs TXA IV 2 g pre-incision"
"CD013295_pub2_data","Subgroup","TXA IV 1 g intraoperatively vs TXA IV 1 g pre-incision"
"CD013295_pub2_data","Subgroup","TXA IV total dose 1 g, pre-incision, intraoperatively and postoperatively vs placebo"
"CD013295_pub2_data","Subgroup","EACA vs TXA oral total dose > 3 g, pre-incision and postoperatively"
"CD013295_pub2_data","Subgroup","TXA IV 2 g pre-incision vs placebo"
"CD013295_pub2_data","Subgroup","TXA IV 1 g intraoperatively vs TXA IV + TXA topical total dose 2 g, intraoperatively"
"CD013295_pub2_data","Subgroup","TXA IV 1 g pre-incision vs placebo"
"CD013295_pub2_data","Subgroup","TXA IV + TXA topical total dose 2 g, intraoperatively vs placebo"
"CD013295_pub2_data","Subgroup","TXA oral total dose 2 g, pre-incision and postoperatively vs placebo"
"CD013295_pub2_data","Subgroup","TXA IV total dose > 3 g, intraoperatively and postoperatively vs placebo"
"CD013295_pub2_data","Subgroup","Desmopressin vs TXA IV total dose 1 g, pre-incision and intraoperatively"
"CD013295_pub2_data","Subgroup","TXA topical 1 g intraoperatively vs placebo"
"CD013295_pub2_data","Subgroup","TXA IV 1 g intraoperatively vs placebo"
"CD013295_pub2_data","Subgroup","TXA IV total dose 1 g, intraoperatively and postoperatively vs placebo"
"CD013295_pub2_data","Subgroup","TXA IV total dose 1 g, pre-incision and postoperatively vs placebo"
"CD013295_pub2_data","Subgroup","TXA IV total dose 2 g, intraoperatively and postoperatively vs placebo"
"CD013295_pub2_data","Subgroup","TXA IV total dose 2 g, pre-incision and postoperatively vs placebo"
"CD013295_pub2_data","Subgroup","Fibrin topical vs TXA IV 1 g intraoperatively"
"CD013295_pub2_data","Subgroup","TXA IV total dose 3 g, intraoperatively and postoperatively vs placebo"
"CD013295_pub2_data","Subgroup","TXA IV + TXA topical total dose > 3 g, pre-incision, intraoperatively and postoperatively vs placebo"
"CD013295_pub2_data","Subgroup","EACA vs TXA IV total dose 2 g, intraoperatively and postoperatively"
"CD013295_pub2_data","Subgroup","TXA topical 1 g, intraoperatively vs TXA oral + TXA topical total dose > 3 g, pre-incision, intraoperatively and postoperatively"
"CD013295_pub2_data","Subgroup","TXA IV 1 g intraoperatively vs TXA IV total dose 1 g, pre-incision and intraoperatively"
"CD013295_pub2_data","Subgroup","Fibrin topical vs placebo"
"CD013295_pub2_data","Subgroup","Desmopressin vs placebo"
"CD013295_pub2_data","Subgroup","EACA vs TXA_IV_2g_intra_post"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_preI vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_preI_intra_post vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_3g_intra_post vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_preI_post vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_intra_post vs placebo"
"CD013295_pub2_data","Subgroup","Aprotinin vs TXA_IV_1g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IA_1g_intra vs TXA_oral_IA_grt_than_3g_preI_intra_post"
"CD013295_pub2_data","Subgroup","TXA_IV_IA_2g_preI_intra vs TXA_IV_IA_grt_than_3g_preI_intra_post"
"CD013295_pub2_data","Subgroup","TXA_IA_1g_intra vs TXA_IV_1g_preI"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_intra vs TXA_IV_1g_preI"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_post vs TXA_IV_2g_post"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_intra vs TXA_IV_1g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_preI_intra vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_post vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IA_2g_intra vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_intra vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_post vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_grt_than_3g_intra_post vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_preI_post vs TXA_IV_grt_than_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_3g_preI_intra vs TXA_IV_grt_than_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_grt_than_3g_preI_post vs TXA_IV_oral_grt_than_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_IA_3g_preI_intra vs TXA_IV_IA_grt_than_3g_preI_intra_post"
"CD013295_pub2_data","Subgroup","Fibrin_top vs TXA_IA_3g_intra"
"CD013295_pub2_data","Subgroup","TXA_IV_1g_intra vs TXA_IV_IA_2g_intra"
"CD013295_pub2_data","Subgroup","TXA_IV_2g_preI_post vs TXA_IV_3g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IV_IA_3g_preI_intra_post vs TXA_IV_oral_grt_than_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_oral_2g_preI vs TXA_oral_grt_than_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IA_3g_intra vs TXA_IV_2g_intra"
"CD013295_pub2_data","Subgroup","EACA vs TXA_IV_2g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IA_3g_intra vs TXA_IV_3g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IV_grt_than_3g_preI_post vs TXA_IV_IA_3g_preI_intra_post"
"CD013295_pub2_data","Subgroup","TXA_IV_IA_oral_grt_than_3g_intra_post vs TXA_oral_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_oral_2g_preI vs TXA_oral_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_oral_3g_preI_post vs TXA_oral_grt_than_3g_preI_post"
"CD013295_pub2_data","Subgroup","TXA_IV_IA_grt_than_3g_preI_intra_post vs placebo"
"CD013295_pub2_data","Subgroup","Desmopressin vs TXA_IV_1g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA_IA_3g_intra vs placebo"
"CD013295_pub2_data","Subgroup","Fibrin_top vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IV_IA_2g_intra vs placebo"
"CD013295_pub2_data","Subgroup","TXA_oral_2g_preI_post vs placebo"
"CD013295_pub2_data","Subgroup","TXA_IA_3g_intra vs TXA_IV_1g_preI_intra"
"CD013295_pub2_data","Subgroup","TXA, IV more than 3 g"
"CD013295_pub2_data","Subgroup","TXA, IV 3 g"
"CD013295_pub2_data","Subgroup","TXA, IV 2 g"
"CD013295_pub2_data","Subgroup","TXA, IV 1 g"
"CD013295_pub2_data","Subgroup","More than 3 g"
"CD013295_pub2_data","Subgroup","TXA, oral 1 g"
"CD013295_pub2_data","Subgroup","TXA, oral 2 g"
"CD013295_pub2_data","Subgroup","TXA, oral 3 g"
"CD013295_pub2_data","Subgroup","TXA, oral more than 3 g"
"CD013295_pub2_data","Subgroup","TXA, topical 2 g"
"CD013295_pub2_data","Subgroup","TXA, topical 1 g"
"CD013295_pub2_data","Subgroup","TXA, topical 3 g"
"CD013295_pub2_data","Subgroup","TXA, topical more than 3 g"
"CD013295_pub2_data","Subgroup","TXA, Topical 2g"
"CD013295_pub2_data","Subgroup","TXA, Topical 3g"
"CD013295_pub2_data","Subgroup","TXA, Topical More than 3g"
"CD013295_pub2_data","Subgroup","TXA, IV + TXA, topical 2 g"
"CD013295_pub2_data","Subgroup","TXA, IV 1g vs TXA, IV 3g"
"CD013295_pub2_data","Subgroup","TXA, IV 2g vs TXA, IV More than 3g"
"CD013295_pub2_data","Subgroup","TXA, IV 3g vs TXA, IV 4g"
"CD013295_pub2_data","Subgroup","TXA, IV 3g vs TXA, IV 5g"
"CD013295_pub2_data","Subgroup","TXA, IV 4g vs TXA, IV 5g"
"CD013295_pub2_data","Subgroup","TXA, IV 2g vs TXA, IV 3g"
"CD013295_pub2_data","Subgroup","TXA, IV 3g vs TXA, IV More than 3g"
"CD013295_pub2_data","Subgroup","TXA, IV 3.5g vs TXA, IV 5.5g"
"CD013295_pub2_data","Subgroup","TXA, IV 5.5g vs TXA, IV 6.5g"
"CD013295_pub2_data","Subgroup","TXA, IV 3.5g vs TXA, IV 6.5g"
"CD013295_pub2_data","Subgroup","TXA, IV 5g vs TXA, IV More than 5g"
"CD013295_pub2_data","Subgroup","TXA, IV 4g vs TXA, IV More than 5g"
"CD013295_pub2_data","Subgroup","TXA, IV 1 g vs TXA, IV 2 g"
"CD013295_pub2_data","Subgroup","TXA, IV 5g vs TXA, IV more than 5 g"
"CD013295_pub2_data","Subgroup","TXA, IV 1 g vs TXA, IV 3 g"
"CD013295_pub2_data","Subgroup","TXA, IV 2 g vs TXA, IV more than 3 g"
"CD013295_pub2_data","Subgroup","TXA, IV 5 g vs TXA, IV more than 5 g"
"CD013295_pub2_data","Subgroup","TXA, IV 3 g vs TXA, IV 5 g"
"CD013295_pub2_data","Subgroup","TXA, IV 2 g vs TXA, IV 3 g"
"CD013295_pub2_data","Subgroup","TXA, IV 3 g vs TXA, IV more than 3 g"
"CD013295_pub2_data","Subgroup","TXA, IV 3 g vs TXA, IV 4 g"
"CD013295_pub2_data","Subgroup","TXA, IV 4 g vs TXA, IV 5 g"
"CD013295_pub2_data","Subgroup","TXA, IV 4 g vs TXA, IV more than 5 g"
"CD013295_pub2_data","Subgroup","TXA, IV 5.5 g vs TXA, IV 6.5 g"
"CD013295_pub2_data","Subgroup","TXA, IV 3.5 g vs TXA, IV 5.5 g"
"CD013295_pub2_data","Subgroup","TXA, IV 3.5 g vs TXA, IV 6.5 g"
"CD013295_pub2_data","Subgroup","TXA, IV 1g"
"CD013295_pub2_data","Subgroup","TXA, IV vs TXA, topical 1200 mg"
"CD013295_pub2_data","Subgroup","TXA, IV vs TXA, topical 400 mg"
"CD013295_pub2_data","Subgroup","TXA, IV vs TXA, topical 1 g"
"CD013295_pub2_data","Subgroup","TXA, IV vs TXA, topical 2 g"
"CD013295_pub2_data","Subgroup","TXA, IV vs TXA, topical 3 g"
"CD013295_pub2_data","Subgroup","TXA, IV vs TXA, topical 800 mg"
"CD013295_pub2_data","Subgroup","TXA, oral 2 g vs TXA, oral 4 g"
"CD013295_pub2_data","Subgroup","TXA, oral 2 g vs TXA, oral more than 4 g"
"CD013295_pub2_data","Subgroup","TXA, oral 4 g vs TXA, oral more than 4 g"
"CD013295_pub2_data","Subgroup","TXA, oral 2 g vs TXA, oral 3 g"
"CD013295_pub2_data","Subgroup","TXA, oral 1 g vs TXA, oral 2 g"
"CD013295_pub2_data","Subgroup","TXA, oral 1 g vs TXA, oral 3 g"
"CD013295_pub2_data","Subgroup","TXA, Oral 1g vs TXA, Oral 3g"
"CD013295_pub2_data","Subgroup","TXA, Oral 2g vs TXA, Oral 3g"
"CD013295_pub2_data","Subgroup","TXA, oral 4 g vs TXA, oral, more than 4 g"
"CD013295_pub2_data","Subgroup","TXA, topical 800 mg vs TXA, topical 1200 mg"
"CD013295_pub2_data","Subgroup","TXA, topical 400 mg vs TXA, topical 800 mg"
"CD013295_pub2_data","Subgroup","TXA, topical 400 mg vs TXA, topical 1200 mg"
"CD013295_pub2_data","Subgroup","TXA IV + TXA oral days 1 to 14 vs TXA IV"
"CD013295_pub2_data","Subgroup","TXA, IV + TXA oral days 1 to 2 vs TXA, IV"
"CD013295_pub2_data","Subgroup","TXA, IV + TXA oral days 1 to 5 vs TXA, IV"
"CD013295_pub2_data","Subgroup","TXA, topical vs TXA, oral + TXA, topical 6 g"
"CD013295_pub2_data","Subgroup","TXA, topical vs TXA, oral + TXA, topical 5 g"
"CD013295_pub2_data","Subgroup","TXA, topical vs TXA, oral + TXA, topical 4 g"
"CD013295_pub2_data","Subgroup","TXA, topical vs TXA, oral + TXA, topical 7 g"
"CD013295_pub2_data","Subgroup","TXA, IV + TXA, IA 3 g vs TXA, IV + TXA, IA more than 4 g"
"CD013295_pub2_data","Subgroup","TXA, IV + TXA, IA 3 g vs TXA, IV + TXA, IA more than 3 g"
"CD013295_pub2_data","Subgroup","TXA, IV + TXA, IA more than 3 g vs TXA, IV + TXA, IA more than 4 g"
"CD013295_pub2_data","Subgroup","TXA, IV + TXA, IA 3g vs TXA, IV + TXA, IA More than 4g"
"CD013295_pub2_data","Subgroup","TXA, IV + TXA, IA More than 3g vs TXA, IV + TXA, IA More than 4g"
"CD013295_pub2_data","Subgroup","TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7 g"
"CD013295_pub2_data","Subgroup","TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 6 g"
"CD013295_pub2_data","Subgroup","TXA, oral + TXA, topical 6 g vs TXA, oral + TXA, topical 7 g"
"CD013295_pub2_data","Subgroup","TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 5 g"
"CD013295_pub2_data","Subgroup","TXA, oral + TXA, topical 5 g vs TXA, oral + TXA, topical 7 g"
"CD013295_pub2_data","Subgroup","TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 6 g"
"CD013295_pub2_data","Subgroup","TXA, oral + TXA, tpical 4 g vs TXA, oral + TXA, topical 5 g"
"CD013295_pub2_data","Subgroup","TXA, oral + TXA, topical 4 g vs TXA, oral, + TXA, topical 5 g"
"CD013295_pub2_data","Subgroup","TXA, oral + TXA, topical 4 g vs TXA, oral + TXA, topical 7g"
"CD013303_pub2_data","Analysis.group","1"
"CD013303_pub2_data","Analysis.group","2"
"CD013303_pub2_data","Analysis.group","3"
"CD013303_pub2_data","Analysis.group","4"
"CD013303_pub2_data","Analysis.group","5"
"CD013303_pub2_data","Analysis.group","6"
"CD013303_pub2_data","Analysis.group","7"
"CD013303_pub2_data","Analysis.group","8"
"CD013303_pub2_data","Analysis.group","9"
"CD013303_pub2_data","Analysis.name","HIV health literacy: understanding HIV terms (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","HIV health literacy: recognition of HIV terms (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health-related knowledge: HIV global disease/treatment knowledge, 0 to 100 (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health-related knowledge: HIV knowledge, risk of getting sicker (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health outcomes: subjective health status (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: blood glucose self-monitoring 2 times per day (capped at 2), self-report (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: physical activity, average daily steps (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: physical activity, average daily steps (short-term: three months post-intervention)"
"CD013303_pub2_data","Analysis.name","Self-efficacy to manage one's disease (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Generic health literacy: health numeracy, NVS (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Generic health literacy: print literacy, REALM (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Any disease-specific health literacy (short-term: immediately post-intervention) - all studies"
"CD013303_pub2_data","Analysis.name","Any disease-specific health literacy (short-term: immediately post-intervention - by subgroup length of programme)"
"CD013303_pub2_data","Analysis.name","Any disease-specific health literacy (short-term: immediately post-intervention) - studies without high risk of bias"
"CD013303_pub2_data","Analysis.name","Any disease-specific health literacy (short-term: immediately post-intervention) - without Kaur 2019"
"CD013303_pub2_data","Analysis.name","High blood pressure health literacy, HBP health literacy scale (medium-term: 6 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy - appraise: decisional balance for using mammography and Pap testing (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Diabetes-related quality of life, DQOL (short-term: immediately post-intervention) - all studies"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - all studies"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - by subgroup length of programme"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - studies without high risk of bias"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (short-term: immediately post-intervention) - without Kaur 2019"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (medium-term: up to 6 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health outcome: any depression (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health outcome: any depression (medium-term: up to 6 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: diabetes self-care activities (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: oral hygiene self-care behaviour (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: screening adherence (mammogram and Pap test), medical record review (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: non-adherence to blood pressure medication (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: non-adherence to blood pressure medication (medium-term: 6 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: blood glucose self-monitoring 2 times per day (capped at 2), self-report (medium-term: 4 1/2 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Self-efficacy to manage one's disease (short-term: immediately post-intervention) - all studies"
"CD013303_pub2_data","Analysis.name","Self-efficacy to manage one's disease (short-term: immediately post-intervention) - studies without high risk of bias"
"CD013303_pub2_data","Analysis.name","Self-efficacy to manage one's disease (medium-term: 6 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Any generic health literacy (short-term: up to 1 month post-intervention)"
"CD013303_pub2_data","Analysis.name","Depression literacy, D-Lit (short-term: outcome assessment immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (short-term: up to 1 month post-intervention) - all studies"
"CD013303_pub2_data","Analysis.name","Hepatitis B knowledge (medium-term: 6 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: fat-related dietary habits, self-report (short-term: 1-month post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: any screening adherence, odds ratio short-/medium-term: up to 6 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy - appraise: decisional conflict (long-term: approx. 7 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy - apply: prostate cancer screening intention (long-term: approx. 7 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Prostate cancer knowledge, 0 to 100 (long-term: approx. 7 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: prostate cancer testing (long-term: 2 years post-intervention)"
"CD013303_pub2_data","Analysis.name","Adverse events: anxiety (long-term: approx. 7 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy: depression literacy, D-Lit (short-term: at 1-week post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy: apply - intent to seek treatment (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (short-term: immediately up to 3 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health outcome: any depression (short-term: up to 1 week post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: child's up-to-date immunisation (short-term: immediately up to 3 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Self-efficacy to identify need for treatment (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health service use: emergency room visits, medical record review (short-term: immediately up to 3 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Diabetes health literacy, DHLS (short-term: immediately post-intervention )"
"CD013303_pub2_data","Analysis.name","Health literacy - competencies: inhaler use technique, checklist 0 to 10 (medium-term: 3 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy - understanding physician's instructions (medium-term: 3 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy - appraise: decisional conflict (short-term: 1 month post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy - apply: informed decision against HPV vaccination (short-term: 1 month post-intervention)"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (short-term: up to 1 month post-intervention) - by subgroup audiovisual (multimedia)/visual (print only)"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (medium-term: 3 to 6 months post-intervention) - all studies"
"CD013303_pub2_data","Analysis.name","Any health-related knowledge, 0 to 100 (medium-term: 3 to 6 months post-intervention) - by subgroup audiovisual (multimedia)/visual (print only)"
"CD013303_pub2_data","Analysis.name","Health outcome: depression, PHQ-8 (long-term: 12 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: any cancer screening uptake (medium-term: up to 6-month follow-up)"
"CD013303_pub2_data","Analysis.name","Health behaviour: new documentation of advance care planning (long-term: 12 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Breast cancer self-efficacy (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Cancer-related self-efficacy (medium-term: at 3-month follow-up)"
"CD013303_pub2_data","Analysis.name","Self-efficacy regarding Pap testing (medium-term: at 6-month follow-up)"
"CD013303_pub2_data","Analysis.name","Adverse event: anxiety, GAD-7 (long-term: 12 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy - understanding physician's instruction (medium-term: 3 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health literacy - apply: Pap testing intention, self-report (medium-term: 6 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Cervical cancer knowledge, 0 to 100 (medium-term: 6 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Asthma knowledge (medium-term: 3 months post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: cervical cancer screening (medium-term: at 6-month follow-up)"
"CD013303_pub2_data","Analysis.name","Understand: medication understanding (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Generic health literacy, TOFHLA (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Diabetes health literacy, DHLS (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Cardiovascular health behaviour (short-term: immediately post-intervention)"
"CD013303_pub2_data","Analysis.name","Health behaviour: new documentation of advance care planning (long-term: approx. 12 months post-intervention)"
"CD013303_pub2_data","Subgroup","12 months"
"CD013303_pub2_data","Subgroup","Up to 6 months"
"CD013303_pub2_data","Subgroup","Audiovisual format (multimedia)"
"CD013303_pub2_data","Subgroup","Visual format (print only)"
"CD013329_pub2_data","Analysis.group","1"
"CD013329_pub2_data","Analysis.name","Child health, functioning, and quality of life (effect size estimate functional status)"
"CD013329_pub2_data","Analysis.name","Child and family satisfaction (CAHPS healthcare quality rating)"
"CD013329_pub2_data","Analysis.name","Child and family satisfaction (CAHPS help with coordinating multiple providers)"
"CD013329_pub2_data","Analysis.name","Child and family satisfaction (CAHPS getting needed care quickly)"
"CD013329_pub2_data","Analysis.name","Child and family satisfaction (family-centred care)"
"CD013329_pub2_data","Analysis.name","Child and family satisfaction (child health care)"
"CD013329_pub2_data","Analysis.name","Child and family satisfaction (care coordination)"
"CD013329_pub2_data","Analysis.name","Child and family satisfaction (getting care quickly)"
"CD013329_pub2_data","Analysis.name","Number of healthcare encounters (ED visits per child year)"
"CD013329_pub2_data","Analysis.name","Number of hospitalised days per child-year"
"CD013329_pub2_data","Analysis.name","Costs to healthcare system (health plan and clinic costs)"
"CD013331_pub2_data","Analysis.group","1"
"CD013331_pub2_data","Analysis.group","2"
"CD013331_pub2_data","Analysis.group","3"
"CD013331_pub2_data","Analysis.group","4"
"CD013331_pub2_data","Analysis.group","5"
"CD013331_pub2_data","Analysis.name","Pain relief: high-frequency TENS versus placebo or no treatment"
"CD013331_pub2_data","Analysis.name","Adverse effects: high-frequency TENS versus placebo or no treatment"
"CD013331_pub2_data","Analysis.name","Requirements for additional analgesics - number of tablets: high-frequency TENS versus placebo or no treatment"
"CD013331_pub2_data","Analysis.name","Requirements for additional analgesics - number of women: high-frequency TENS versus placebo or no treatment"
"CD013331_pub2_data","Analysis.name","Limitation of daily activities: high-frequency TENS versus placebo or no treatment"
"CD013331_pub2_data","Analysis.name","Absence from work or school: high-frequency TENS versus placebo or no treatment"
"CD013331_pub2_data","Analysis.name","Pain relief: low-frequency TENS versus placebo or no treatment"
"CD013331_pub2_data","Analysis.name","Requirements for additional analgesics - number of tablets: low-frequency TENS versus placebo or no treatment"
"CD013331_pub2_data","Analysis.name","Absence from work or school: low-frequency TENS versus placebo or no treatment"
"CD013331_pub2_data","Analysis.name","Pain relief: high-frequency TENS versus low-frequency TENS"
"CD013331_pub2_data","Analysis.name","Adverse effects: high-frequency TENS versus low-frequency TENS"
"CD013331_pub2_data","Analysis.name","Requirements of additional analgesics - number of tablets: high-frequency TENS versus low-frequency TENS"
"CD013331_pub2_data","Analysis.name","Absence from work or school: high-frequency TENS versus low-frequency TENS"
"CD013331_pub2_data","Analysis.name","Pain relief: high-frequency TENS versus acupressure"
"CD013331_pub2_data","Analysis.name","Pain relief: high-frequency TENS versus acetaminophen"
"CD013331_pub2_data","Analysis.name","Pain relief: high-frequency TENS versus interferential current therapy"
"CD013331_pub2_data","Analysis.name","Adverse effects: high-frequency TENS versus NSAIDs"
"CD013331_pub2_data","Analysis.name","Requirements for additional analgesics - number of women: high-frequency TENS versus NSAIDs"
"CD013331_pub2_data","Analysis.name","Requirements for additional analgesics - number of women: high-frequency TENS versus interferential current therapy"
"CD013331_pub2_data","Analysis.name","Pain relief: low-frequency TENS versus other treatment"
"CD013331_pub2_data","Subgroup","Sham TENS"
"CD013331_pub2_data","Subgroup","No treatment"
"CD013331_pub2_data","Subgroup","Placebo pill"
"CD013331_pub2_data","Subgroup","Acetaminophen"
"CD013332_pub2_data","Analysis.group","1"
"CD013332_pub2_data","Analysis.group","2"
"CD013332_pub2_data","Analysis.group","3"
"CD013332_pub2_data","Analysis.group","4"
"CD013332_pub2_data","Analysis.group","5"
"CD013332_pub2_data","Analysis.group","6"
"CD013332_pub2_data","Analysis.group","7"
"CD013332_pub2_data","Analysis.group","8"
"CD013332_pub2_data","Analysis.group","9"
"CD013332_pub2_data","Analysis.name","SSI"
"CD013332_pub2_data","Analysis.name","All-cause mortality"
"CD013332_pub2_data","Analysis.name","Hospital length of stay"
"CD013332_pub2_data","Analysis.name","Adverse effects: Hypoglycaemia"
"CD013332_pub2_data","Subgroup","Diabetic and non-diabetic patients"
"CD013332_pub2_data","Subgroup","Non-diabetic patients"
"CD013332_pub2_data","Subgroup","Diabetic patients only"
"CD013332_pub2_data","Subgroup","Diabetic only patients"
"CD013332_pub2_data","Subgroup","Superficial sternal wound infection"
"CD013332_pub2_data","Subgroup","Deep sternal wound infection"
"CD013332_pub2_data","Subgroup","Superficial SSI"
"CD013332_pub2_data","Subgroup","Deep SSI"
"CD013332_pub2_data","Subgroup","All-cause mortality"
"CD013342_pub2_data","Analysis.group","1"
"CD013342_pub2_data","Analysis.group","2"
"CD013342_pub2_data","Analysis.group","3"
"CD013342_pub2_data","Analysis.group","4"
"CD013342_pub2_data","Analysis.group","5"
"CD013342_pub2_data","Analysis.group","6"
"CD013342_pub2_data","Analysis.group","7"
"CD013342_pub2_data","Analysis.group","8"
"CD013342_pub2_data","Analysis.name","Mean overall pain (0 to 10, 0 is no pain)"
"CD013342_pub2_data","Analysis.name","Mean overall pain by cell origin (0 to 10, 0 is no pain)"
"CD013342_pub2_data","Analysis.name","Mean function (0 to 100, 0 is best function)"
"CD013342_pub2_data","Analysis.name","Mean function by cell origin (0 to 100, 0 is best function)"
"CD013342_pub2_data","Analysis.name","Mean quality of life (SF-36 mental health)"
"CD013342_pub2_data","Analysis.name","Participant-reported global assessment of success"
"CD013342_pub2_data","Analysis.name","Withdrawals due to adverse events"
"CD013342_pub2_data","Analysis.name","Serious adverse events"
"CD013342_pub2_data","Analysis.name","Total adverse events"
"CD013342_pub2_data","Analysis.name","Treatment failure"
"CD013342_pub2_data","Analysis.name","Mean overall pain (0 to 10 points, 0 is no pain)"
"CD013342_pub2_data","Analysis.name","MRI joint progression (bone marrow lesions)"
"CD013342_pub2_data","Analysis.name","Mean pain (0 to 10, 0 is no pain)"
"CD013342_pub2_data","Analysis.name","Mean quality of life (0 to 100, 100 is best score)"
"CD013342_pub2_data","Analysis.name","Mean quality of life (0 to 100, 100 is best quality of life)"
"CD013342_pub2_data","Analysis.name","MRI measure of joint pathology (e.g. cartilage volume, bone marrow lesions, synovitis)"
"CD013342_pub2_data","Analysis.name","Radiographic joint progression"
"CD013342_pub2_data","Analysis.name","MRI cartilage loss (Whole-Organ Magnetic Resonance Imaging (WORMS score))"
"CD013342_pub2_data","Subgroup","Up to 3 months"
"CD013342_pub2_data","Subgroup","> 3 months to 6 months"
"CD013342_pub2_data","Subgroup","> 6 months to 1 year"
"CD013342_pub2_data","Subgroup","Autologous (> 3 months to 6 months)"
"CD013342_pub2_data","Subgroup","Allogeneic (> 3 months to 6 months)"
"CD013342_pub2_data","Subgroup","Autologous"
"CD013342_pub2_data","Subgroup","Allogeneic"
"CD013342_pub2_data","Subgroup","12 months"
"CD013342_pub2_data","Subgroup","> 1 year to 2 years"
"CD013342_pub2_data","Subgroup","> 2 years to < 5 years"
"CD013342_pub2_data","Subgroup","5 years"
"CD013342_pub2_data","Subgroup","> 1 year to < 2 years"
"CD013342_pub2_data","Subgroup","> 6 months to 12 months"
"CD013342_pub2_data","Subgroup","6 months"
"CD013342_pub2_data","Subgroup","3 months"
"CD013342_pub2_data","Subgroup","24 months"
"CD013344_pub2_data","Analysis.group","1"
"CD013344_pub2_data","Analysis.group","2"
"CD013344_pub2_data","Analysis.group","3"
"CD013344_pub2_data","Analysis.group","4"
"CD013344_pub2_data","Analysis.group","5"
"CD013344_pub2_data","Analysis.group","6"
"CD013344_pub2_data","Analysis.group","7"
"CD013344_pub2_data","Analysis.group","8"
"CD013344_pub2_data","Analysis.group","9"
"CD013344_pub2_data","Analysis.group","10"
"CD013344_pub2_data","Analysis.group","11"
"CD013344_pub2_data","Analysis.name","Graft loss"
"CD013344_pub2_data","Analysis.name","Persistence of decoy cells/viraemia at 12 months"
"CD013344_pub2_data","Analysis.name","Acute rejection"
"CD013344_pub2_data","Analysis.name","Serum creatinine [µmol/L]"
"CD013344_pub2_data","Analysis.name","BK viraemia at end of study (8 to 12 months)"
"CD013344_pub2_data","Analysis.name","Sustained BK viraemia"
"CD013344_pub2_data","Analysis.name","BK viruria"
"CD013344_pub2_data","Analysis.name","Viral load reduction at 6 months"
"CD013344_pub2_data","Analysis.name","Viral load > 10,000 copies/mL"
"CD013344_pub2_data","Analysis.name","Initial BK titre copies/L"
"CD013344_pub2_data","Analysis.name","BK virus-associated nephropathy (BKVAN)"
"CD013344_pub2_data","Analysis.name","Donor-specific antibodies"
"CD013344_pub2_data","Analysis.name","Death"
"CD013344_pub2_data","Analysis.name","Malignancy"
"CD013344_pub2_data","Analysis.name","Infection"
"CD013344_pub2_data","Analysis.name","Therapy-related adverse events: tendonitis"
"CD013344_pub2_data","Analysis.name","Rejection"
"CD013344_pub2_data","Analysis.name","Serum creatinine [mg/dL]"
"CD013344_pub2_data","Analysis.name","eGFR [mL/min]"
"CD013344_pub2_data","Analysis.name","BK viraemia"
"CD013344_pub2_data","Analysis.name","Patient survival at 5 years"
"CD013344_pub2_data","Analysis.name","Therapy-related adverse events: new-onset diabetes after transplantation (NODAT)"
"CD013344_pub2_data","Analysis.name","BK viraemia at 12 months"
"CD013344_pub2_data","Analysis.name","Reduction of BK viruria by 50%"
"CD013344_pub2_data","Analysis.name","BK virus-associated nepropathy (BKVAN)"
"CD013344_pub2_data","Analysis.name","BK viral load < 600 copies/mL"
"CD013344_pub2_data","Analysis.name","Change in serum creatinine [mg/dL]"
"CD013344_pub2_data","Analysis.name","Serum creatinine increase"
"CD013344_pub2_data","Analysis.name","Change in creatinine clearance [mL/min]"
"CD013344_pub2_data","Analysis.name","Change in plasma BK viral load [copies/µL]"
"CD013344_pub2_data","Analysis.name","Change in urine BK viral load [copies/µL]"
"CD013344_pub2_data","Analysis.name","Biopsy-confirmed acute rejection (BKVAN)"
"CD013344_pub2_data","Analysis.name","Malignancy: skin cancer"
"CD013344_pub2_data","Analysis.name","Therapy-related adverse events"
"CD013344_pub2_data","Subgroup","12 months"
"CD013344_pub2_data","Subgroup","6 months"
"CD013344_pub2_data","Subgroup","3 months"
"CD013344_pub2_data","Subgroup","Urinary tract infection"
"CD013344_pub2_data","Subgroup","Clostridium difficile"
"CD013344_pub2_data","Subgroup","Cardiac death"
"CD013344_pub2_data","Subgroup","Any cause"
"CD013344_pub2_data","Subgroup","Upper respiratory tract infection"
"CD013344_pub2_data","Subgroup","Bacterial urinary tract infection"
"CD013344_pub2_data","Subgroup","Peripheral oedema"
"CD013344_pub2_data","Subgroup","Hypokalaemia"
"CD013344_pub2_data","Subgroup","Hypertension aggravated"
"CD013344_pub2_data","Subgroup","Abnormal liver function at 6 months"
"CD013344_pub2_data","Subgroup","Diarrhoea"
"CD013344_pub2_data","Subgroup","Anaemia"
"CD013353_pub2_data","Analysis.group","1"
"CD013353_pub2_data","Analysis.group","2"
"CD013353_pub2_data","Analysis.group","3"
"CD013353_pub2_data","Analysis.group","4"
"CD013353_pub2_data","Analysis.group","5"
"CD013353_pub2_data","Analysis.name","PIPP during endotracheal suctioning"
"CD013353_pub2_data","Analysis.name","ALPS-Neo Scale during endotracheal suctioning"
"CD013353_pub2_data","Analysis.name","Heart rate during endotracheal suctioning (bpm)"
"CD013353_pub2_data","Analysis.name","Oxygen saturation during endotracheal suctioning (%)"
"CD013353_pub2_data","Analysis.name","Stress and defence behaviours (SDB) during endotracheal suctioning"
"CD013353_pub2_data","Analysis.name","Self-regulatory behaviours (SRB) during endotracheal suctioning"
"CD013353_pub2_data","Subgroup","Facilitated tucking / four-handed care / gentle human touch versus white noise"
"CD013353_pub2_data","Subgroup","Facilitated tucking / four-handed care / gentle human touch versus standard care"
"CD013353_pub2_data","Subgroup","Facilitated tucking / four-handed care / gentle human touch versus familiar odour (breast milk smell)"
"CD013353_pub2_data","Subgroup","Familiar odour (breast milk smell) versus white noise"
"CD013353_pub2_data","Subgroup","Familiar odour (breast milk smell) versus standard care"
"CD013353_pub2_data","Subgroup","Expressed breast milk versus oral sucrose"
"CD013353_pub2_data","Subgroup","Expressed breast milk versus swaddling"
"CD013355_pub2_data","Analysis.group","1"
"CD013355_pub2_data","Analysis.name","PIPP during endotracheal suctioning"
"CD013355_pub2_data","Analysis.name","Pulmonary outcome: chronic lung disease"
"CD013355_pub2_data","Analysis.name","Haemodynamic outcome: arterial hypotension"
"CD013355_pub2_data","Analysis.name","Neurological outcome: periventricular leukomalacia"
"CD013355_pub2_data","Analysis.name","Neurological outcome: overall intraventricular haemorrhage"
"CD013355_pub2_data","Analysis.name","Neurological outcome: severe intraventricular haemorrhage"
"CD013355_pub2_data","Analysis.name","28-day mortality"
"CD013358_pub2_data","Analysis.group","1"
"CD013358_pub2_data","Analysis.group","2"
"CD013358_pub2_data","Analysis.group","3"
"CD013358_pub2_data","Analysis.group","4"
"CD013358_pub2_data","Analysis.group","5"
"CD013358_pub2_data","Analysis.group","6"
"CD013358_pub2_data","Analysis.name","Systolic blood pressure (mmHg), change from baseline"
"CD013358_pub2_data","Analysis.name","Diastolic blood pressure (mmHg), change from baseline"
"CD013358_pub2_data","Analysis.name","Anxiety, change from baseline"
"CD013358_pub2_data","Analysis.name","Depression, change from baseline"
"CD013358_pub2_data","Analysis.name","Perceived stress, change from baseline"
"CD013358_pub2_data","Analysis.name","Well-being"
"CD013358_pub2_data","Analysis.name","Total cholesterol (mmol/L), change from baseline"
"CD013358_pub2_data","Analysis.name","LDL cholesterol (mmol/L), change from baseline"
"CD013358_pub2_data","Analysis.name","HDL cholesterol (mmol/L), change from baseline"
"CD013358_pub2_data","Analysis.name","Triglycerides (mmol/L), change from baseline"
"CD013358_pub2_data","Analysis.name","Fasting blood glucose (mmol/L), change from baseline"
"CD013358_pub2_data","Analysis.name","HbA1c (%), change from baseline"
"CD013358_pub2_data","Analysis.name","Weight (kg), change from baseline"
"CD013358_pub2_data","Analysis.name","BMI (kg/m2), change from baseline"
"CD013358_pub2_data","Analysis.name","Smoking cessation"
"CD013358_pub2_data","Analysis.name","Quality of life, change from baseline"
"CD013358_pub2_data","Analysis.name","Self-efficacy, change from baseline"
"CD013358_pub2_data","Analysis.name","Clinical CVD events (CVD mortality and non-fatal MI)"
"CD013358_pub2_data","Analysis.name","Adverse events"
"CD013358_pub2_data","Analysis.name","Coping strategies, change from baseline"
"CD013358_pub2_data","Analysis.name","Self-management, change from baseline"
"CD013358_pub2_data","Analysis.name","Clinical CVD events (CVD mortality, non-fatal MI and stroke, revascularisations)"
"CD013358_pub2_data","Subgroup","Primary prevention"
"CD013358_pub2_data","Subgroup","Secondary prevention"
"CD013366_pub2_data","Analysis.group","1"
"CD013366_pub2_data","Analysis.group","2"
"CD013366_pub2_data","Analysis.group","3"
"CD013366_pub2_data","Analysis.group","4"
"CD013366_pub2_data","Analysis.group","5"
"CD013366_pub2_data","Analysis.group","6"
"CD013366_pub2_data","Analysis.group","7"
"CD013366_pub2_data","Analysis.group","8"
"CD013366_pub2_data","Analysis.group","9"
"CD013366_pub2_data","Analysis.name","Venous thromboembolism"
"CD013366_pub2_data","Analysis.name","Venous thromboembolism (subgroup analysis - age)"
"CD013366_pub2_data","Analysis.name","Venous thromboembolism (sensitivity analysis)"
"CD013366_pub2_data","Analysis.name","PICC-associated BSI"
"CD013366_pub2_data","Analysis.name","Occlusion"
"CD013366_pub2_data","Analysis.name","Occlusion (subgroup analyses - age)"
"CD013366_pub2_data","Analysis.name","Occlusion (sensitivity analyses)"
"CD013366_pub2_data","Analysis.name","All-cause mortality"
"CD013366_pub2_data","Analysis.name","Catheter failure"
"CD013366_pub2_data","Analysis.name","Catheter failure (sensitivity analyses)"
"CD013366_pub2_data","Analysis.name","Incidence of PICC-related BSI"
"CD013366_pub2_data","Analysis.name","Catheter breakage"
"CD013366_pub2_data","Analysis.name","Catheter breakage (sensitivity analyses)"
"CD013366_pub2_data","Analysis.name","PICC dwell time"
"CD013366_pub2_data","Analysis.name","Skin reaction"
"CD013366_pub2_data","Analysis.name","PICC-related BSI "
"CD013366_pub2_data","Analysis.name","Occlusion - sensitivity analysis"
"CD013366_pub2_data","Analysis.name","Catheter failure - sensitivity analysis"
"CD013366_pub2_data","Analysis.name","Occlusion (subgroup analysis - age)"
"CD013366_pub2_data","Analysis.name","Catheter failure (subgroup analysis - age)"
"CD013366_pub2_data","Analysis.name","Venous thromboembolism "
"CD013366_pub2_data","Analysis.name","PICC-related BSI"
"CD013366_pub2_data","Subgroup","Paediatric patients"
"CD013366_pub2_data","Subgroup","Adult patients"
"CD013366_pub2_data","Subgroup","Patient unit of randomisation"
"CD013366_pub2_data","Subgroup","Not terminated early"
"CD013377_pub2_data","Analysis.group","1"
"CD013377_pub2_data","Analysis.group","2"
"CD013377_pub2_data","Analysis.group","3"
"CD013377_pub2_data","Analysis.group","4"
"CD013377_pub2_data","Analysis.group","5"
"CD013377_pub2_data","Analysis.group","6"
"CD013377_pub2_data","Analysis.group","7"
"CD013377_pub2_data","Analysis.group","8"
"CD013377_pub2_data","Analysis.name","Overall survival"
"CD013377_pub2_data","Analysis.name","Progression-free survival "
"CD013377_pub2_data","Analysis.name","Adverse events grades 3 to 5 (Participants with at least one serious adverse event)"
"CD013377_pub2_data","Analysis.name","Survival rates at 3 years"
"CD013377_pub2_data","Analysis.name","Survival rates at 5 years"
"CD013377_pub2_data","Analysis.name","Health-related quality of life"
"CD013377_pub2_data","Analysis.name","Survival rates at 40 months"
"CD013377_pub2_data","Analysis.name","Adverse events grade 3-5 (Participants with at least one serious adverse event)"
"CD013377_pub2_data","Analysis.name","Quality of life: mean change from baseline in Global Health Status score"
"CD013377_pub2_data","Subgroup","Epidermal growth factor"
"CD013377_pub2_data","Subgroup","Global health status. EORTC QLQ-C30. Score at six months."
"CD013396_pub2_data","Analysis.group","1"
"CD013396_pub2_data","Analysis.group","2"
"CD013396_pub2_data","Analysis.group","3"
"CD013396_pub2_data","Analysis.group","4"
"CD013396_pub2_data","Analysis.group","5"
"CD013396_pub2_data","Analysis.name","Asthma"
"CD013396_pub2_data","Analysis.name","Wheeze"
"CD013396_pub2_data","Analysis.name","Atopic dermatitis"
"CD013396_pub2_data","Analysis.name","Adverse events"
"CD013396_pub2_data","Analysis.name","Any airway infection"
"CD013396_pub2_data","Analysis.name","Lower respiratory tract infection"
"CD013396_pub2_data","Analysis.name","Upper respiratory tract infection"
"CD013396_pub2_data","Analysis.name","Allergic sensitisation – total IgE (continuous)"
"CD013396_pub2_data","Analysis.name","Allergic sensitisation – skin prick against common allergens"
"CD013396_pub2_data","Analysis.name","Airway inflammation – eosinophil counts (continuous)"
"CD013396_pub2_data","Analysis.name","Airway inflammation – exhaled nitric oxide (continuous)"
"CD013396_pub2_data","Analysis.name","Allergic sensitisation – specific IgE against common allergens (dichotomous)"
"CD013396_pub2_data","Analysis.name","Airway inflammation – elevated eosinophil counts (dichotomous)"
"CD013396_pub2_data","Analysis.name","Asthma (6-year follow-up data)"
"CD013396_pub2_data","Analysis.name","Asthma – as defined by trial authors"
"CD013396_pub2_data","Analysis.name","Wheeze – as defined by trial authors"
"CD013396_pub2_data","Subgroup","Infant elevated 25OHD"
"CD013396_pub2_data","Subgroup","Infant hypercalcaemia"
"CD013396_pub2_data","Subgroup","Maternal hypercalcaemia"
"CD013396_pub2_data","Subgroup","Infant death"
"CD013396_pub2_data","Subgroup","Intrauterine death"
"CD013396_pub2_data","Subgroup","Congenital malformations"
"CD013396_pub2_data","Subgroup","Preterm delivery"
"CD013396_pub2_data","Subgroup","Maternal hypertension"
"CD013396_pub2_data","Subgroup","Infant/child death"
"CD013396_pub2_data","Subgroup","Maternal death"
"CD013396_pub2_data","Subgroup","Preterm delivery < 32 weeks"
"CD013396_pub2_data","Subgroup","Pre-eclampsia"
"CD013396_pub2_data","Subgroup","Maternal hospitalisation"
"CD013408_pub2_data","Analysis.group","1"
"CD013408_pub2_data","Analysis.name","All-cause mortality"
"CD013408_pub2_data","Analysis.name","All-cause mortality - sensitivity analysis"
"CD013408_pub2_data","Analysis.name","All-cause hospitalisation"
"CD013408_pub2_data","Analysis.name","All-cause hospitalisation - sensitivity analysis"
"CD013408_pub2_data","Analysis.name","Cardiovascular mortality"
"CD013408_pub2_data","Analysis.name","Cardiovascular mortality - sensitivity analysis"
"CD013408_pub2_data","Analysis.name","Cardiovascular hospitalisation"
"CD013408_pub2_data","Analysis.name","Cardiovascular hospitalisation - sensitivity analysis"
"CD013408_pub2_data","Analysis.name","AF-related emergency department visits"
"CD013408_pub2_data","Analysis.name","AF-related emergency department visits - sensitivity analysis"
"CD013408_pub2_data","Analysis.name","Thromboembolic complications"
"CD013408_pub2_data","Analysis.name","Thromboembolic complications - sensitivity analysis"
"CD013408_pub2_data","Analysis.name","Major cerebrovascular bleeding events"
"CD013408_pub2_data","Analysis.name","Major cerebrovascular bleeding events - sensitivity analysis"
"CD013408_pub2_data","Analysis.name","All bleeding events"
"CD013408_pub2_data","Analysis.name","All bleeding events - sensitivity analysis"
"CD013408_pub2_data","Analysis.name","AF symptom burden"
"CD013408_pub2_data","Subgroup","Fatigue"
"CD013408_pub2_data","Subgroup","Dyspnoea"
"CD013408_pub2_data","Subgroup","Palpitations"
"CD013408_pub2_data","Subgroup","Chest pain"
"CD013408_pub2_data","Subgroup","Dizziness/Syncope"
"CD013414_pub2_data","Analysis.group","1"
"CD013414_pub2_data","Analysis.group","2"
"CD013414_pub2_data","Analysis.group","3"
"CD013414_pub2_data","Analysis.group","4"
"CD013414_pub2_data","Analysis.name","eGFR: change"
"CD013414_pub2_data","Analysis.name","eGFR: final measure"
"CD013414_pub2_data","Analysis.name","All-cause death"
"CD013414_pub2_data","Analysis.name","Kidney failure"
"CD013414_pub2_data","Analysis.name","Adverse events"
"CD013414_pub2_data","Analysis.name","Withdrawal due to intolerance"
"CD013414_pub2_data","Analysis.name","Quality of life"
"CD013414_pub2_data","Analysis.name","Vitamin B12 deficiency"
"CD013414_pub2_data","Analysis.name","Withdrawal due to adverse events"
"CD013414_pub2_data","Analysis.name","UACR: % change"
"CD013414_pub2_data","Analysis.name","Progression to UACR > 30 mg/g"
"CD013414_pub2_data","Analysis.name","Death: ADPKD subgroup analysis"
"CD013414_pub2_data","Analysis.name","eGFR change: ADPKD subgroup analysis"
"CD013414_pub2_data","Analysis.name","Death: age subgroup analysis"
"CD013414_pub2_data","Analysis.name","eGFR change: duration of study subgroup analysis"
"CD013414_pub2_data","Analysis.name","Death: duration of study subgroup analysis"
"CD013414_pub2_data","Analysis.name","Change in UACR (%): age subgroup analysis"
"CD013414_pub2_data","Subgroup","B12 deficient"
"CD013414_pub2_data","Subgroup","Raised lactate"
"CD013414_pub2_data","Subgroup","Serious adverse events"
"CD013414_pub2_data","Subgroup","Nausea"
"CD013414_pub2_data","Subgroup","Vomiting"
"CD013414_pub2_data","Subgroup","Diarrhoea"
"CD013414_pub2_data","Subgroup","Hypoglycaemia"
"CD013414_pub2_data","Subgroup","Gastrointestinal"
"CD013414_pub2_data","Subgroup","Mental component "
"CD013414_pub2_data","Subgroup","Physical component"
"CD013414_pub2_data","Subgroup","No ADPKD patients"
"CD013414_pub2_data","Subgroup","ADPKD patients"
"CD013414_pub2_data","Subgroup","ADPKD"
"CD013414_pub2_data","Subgroup","No ADPKD"
"CD013414_pub2_data","Subgroup","Age ≤ 60 years"
"CD013414_pub2_data","Subgroup","Age > 60 years"
"CD013414_pub2_data","Subgroup","Duration ≤ 2 years"
"CD013414_pub2_data","Subgroup","Duration > 2 years"
"CD013421_pub2_data","Analysis.group","1"
"CD013421_pub2_data","Analysis.group","2"
"CD013421_pub2_data","Analysis.group","3"
"CD013421_pub2_data","Analysis.group","4"
"CD013421_pub2_data","Analysis.group","5"
"CD013421_pub2_data","Analysis.group","6"
"CD013421_pub2_data","Analysis.group","7"
"CD013421_pub2_data","Analysis.name","Mean time to hemostasis"
"CD013421_pub2_data","Analysis.name","Proportion achieving hemostasis at time points"
"CD013421_pub2_data","Analysis.name","Failure of hemostatic intervention"
"CD013421_pub2_data","Analysis.name","Intraoperative blood loss"
"CD013421_pub2_data","Analysis.name","Operating time"
"CD013421_pub2_data","Analysis.name","Postoperative bleeding"
"CD013421_pub2_data","Analysis.name","Unplanned return to operating room for bleeding complications"
"CD013421_pub2_data","Analysis.name","Mean time to hemostasis - studies combining multiple surgery indications"
"CD013421_pub2_data","Analysis.name","Proportion achieving hemostasis at time points - studies combining multiple surgery indications"
"CD013421_pub2_data","Analysis.name","Failure of hemostatic intervention - studies combining multiple surgery indications"
"CD013421_pub2_data","Analysis.name","Intraoperative blood loss - studies combining multiple surgery indications"
"CD013421_pub2_data","Analysis.name","Operating time - studies combining multiple surgery indications"
"CD013421_pub2_data","Analysis.name","Postoperative bleeding up to 30 days - studies combining multiple surgery indications"
"CD013421_pub2_data","Analysis.name","Unplanned return to operating room for bleeding complications up to 30 days - studies combining multiple surgery indications"
"CD013421_pub2_data","Subgroup","Time to hemostasis - 5 minutes"
"CD013421_pub2_data","Subgroup","Time to hemostasis - 4 minutes"
"CD013421_pub2_data","Subgroup","Time to hemostasis - 10 minutes"
"CD013425_pub2_data","Analysis.group","1"
"CD013425_pub2_data","Analysis.group","2"
"CD013425_pub2_data","Analysis.name","Global state: clinically important change"
"CD013425_pub2_data","Analysis.name","Global state: relapse"
"CD013425_pub2_data","Analysis.name","Mental state: overall - clinically important change in overall mental state (≥ 50% reduction in PANSS endpoint score)"
"CD013425_pub2_data","Analysis.name","Mental state: overall - average endpoint score (PANSS, BPRS total scores, SMD, high = poor)"
"CD013425_pub2_data","Analysis.name","Adverse effects/events: specific - extrapyramidal - any effect"
"CD013425_pub2_data","Analysis.name","Adverse effects/events: specific - metabolic - weight increase"
"CD013425_pub2_data","Analysis.name","Quality of life: clinically important change in quality of life (≥ 20% increase in QLS endpoint score)"
"CD013425_pub2_data","Analysis.name","Quality of life: overall - average endpoint total score (various scales, SMD, high = good)"
"CD013425_pub2_data","Analysis.name","Leaving the study early: adverse effects"
"CD013425_pub2_data","Analysis.name","Global state: clinically important change; sensitivity analysis (inadequate randomised, high attrition rate data excluded)"
"CD013425_pub2_data","Analysis.name","Global state: clinically important change; sensitivity analysis (fixed-effect model applied)"
"CD013425_pub2_data","Analysis.name","Global state: relapse: sensitivity analysis (inadequate randomised, high attrition rate data excluded)"
"CD013425_pub2_data","Analysis.name","Global state: relapse: sensitivity analysis (fixed-effect model applied)"
"CD013425_pub2_data","Analysis.name","Mental state: overall - clinically important change in overall mental state (≥ 50% reduction in PANSS endpoint score): sensitivity analysis (inadequate randomised, high attrition rate data excluded)"
"CD013425_pub2_data","Analysis.name","Mental state: overall - clinically important change in overall mental state (≥ 50% reduction in PANSS endpoint score): sensitivity analysis (fixed-effect model applied)"
"CD013425_pub2_data","Analysis.name","Adverse effects/events: specific - extrapyramidal - any effect: sensitivity analysis (inadequate randomised, high attrition rate data excluded)"
"CD013425_pub2_data","Analysis.name","Adverse effects/events: specific - extrapyramidal - any effect: sensitivity analysis (fixed-effect model applied)"
"CD013425_pub2_data","Analysis.name","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (inadequate randomised trials excluded)"
"CD013425_pub2_data","Analysis.name","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (high attrition rate data excluded)"
"CD013425_pub2_data","Analysis.name","Adverse effects/events: specific - metabolic - weight increase: sensitivity analysis (fixed-effect model applied)"
"CD013425_pub2_data","Analysis.name","Leaving the study early: adverse effects: sensitivity analysis (inadequate randomised trials excluded)"
"CD013425_pub2_data","Analysis.name","Leaving the study early: adverse effects: sensitivity analysis (fixed-effect model applied)"
"CD013425_pub2_data","Subgroup","Medium-term"
"CD013425_pub2_data","Subgroup","Short-term"
"CD013425_pub2_data","Subgroup","Long-term"
"CD013425_pub2_data","Subgroup","Medium-term (PANSS, BPRS total scores)"
"CD013425_pub2_data","Subgroup","Long-term (PANSS total score only)"
"CD013425_pub2_data","Subgroup","Short-term (PANSS, BPRS total scores)"
"CD013425_pub2_data","Subgroup","Increase - short-term"
"CD013425_pub2_data","Subgroup","Increase - medium-term"
"CD013425_pub2_data","Subgroup","Increase - long-term"
"CD013425_pub2_data","Subgroup","Short-term - GQOLT, Q-LES-Q, QLS, SF-36 scales, high = good"
"CD013425_pub2_data","Subgroup","Medium-term - MANSA, QoL, S-QoL scales (high = good)"
"CD013429_pub2_data","Analysis.group","1"
"CD013429_pub2_data","Analysis.group","2"
"CD013429_pub2_data","Analysis.group","3"
"CD013429_pub2_data","Analysis.group","4"
"CD013429_pub2_data","Analysis.group","5"
"CD013429_pub2_data","Analysis.group","6"
"CD013429_pub2_data","Analysis.group","7"
"CD013429_pub2_data","Analysis.group","8"
"CD013429_pub2_data","Analysis.name","Primary: Obstructive Eustachian tube dysfunction symptoms - severity (patient-reported): change in ETDQ-7: 0 to 3 months"
"CD013429_pub2_data","Analysis.name","Primary: Obstructive Eustachian tube dysfunction symptoms - severity (patient-reported): change in ETDQ-7: > 3 months"
"CD013429_pub2_data","Analysis.name","Primary: Eustachian tube function measured by an objective or semi-objective test: improvement of tympanometry (by ear)"
"CD013429_pub2_data","Analysis.name","Primary: Eustachian tube function measured by an objective or semi-objective test: ability to perform positive Valsalva/Toynbee (by ear)"
"CD013429_pub2_data","Analysis.name","Primary: Eustachian tube function measured by an objective or semi-objective test: Eustachian Tube Score"
"CD013429_pub2_data","Analysis.name","Secondary: Hearing: air-bone gap 0-3 months"
"CD013429_pub2_data","Analysis.name","Secondary: Hearing: air-bone gap over 3 months"
"CD013429_pub2_data","Analysis.name","Secondary: Tympanic membrane abnormalities: normalisation of TM position"
"CD013429_pub2_data","Analysis.name","Secondary: Quality of life: ear stuffiness VAS"
"CD013429_pub2_data","Analysis.name","Secondary: Quality of life: COMOT-15"
"CD013429_pub2_data","Analysis.name","Secondary: Hearing: air-bone gap"
"CD013429_pub2_data","Analysis.name","Primary: Obstructive Eustachian tube dysfunction symptoms - severity (patient-reported): change in ETDQ-7"
"CD013429_pub2_data","Analysis.name","Secondary: Tympanic membrane abnormalities: Normalisation of TM position"
"CD013429_pub2_data","Analysis.name","Primary: Eustachian tube function measured by an objective or semi-objective test: Improvement of tympanometry (by ear)"
"CD013429_pub2_data","Analysis.name","Primary: Obstructive Eustachian tube dysfunction symptoms - severity (patient-reported): ETDQ-7"
"CD013429_pub2_data","Analysis.name","Primary: Eustachian tube function measured by an objective or semi-objective test: Ability to perform positive Valsalva/Toynbee (by ear)"
"CD013429_pub2_data","Subgroup","Change from baseline"
"CD013429_pub2_data","Subgroup","Data at follow-up"
"CD013429_pub2_data","Subgroup","3 to < 12 months"
"CD013429_pub2_data","Subgroup","Sensitivity analysis"
"CD013429_pub2_data","Subgroup","0 to 3 months"
"CD013429_pub2_data","Subgroup","12 to < 24 months"
"CD013429_pub2_data","Subgroup","> 3 to 12 months"
"CD013429_pub2_data","Subgroup","2 to 5 years"
"CD013429_pub2_data","Subgroup","12 to 24 months"
"CD013445_pub2_data","Analysis.group","1"
"CD013445_pub2_data","Analysis.name","Stone-free rate"
"CD013445_pub2_data","Analysis.name","Major complications"
"CD013445_pub2_data","Analysis.name","Secondary interventions"
"CD013445_pub2_data","Analysis.name","Length of hospital stay"
"CD013445_pub2_data","Analysis.name","Minor complications"
"CD013445_pub2_data","Analysis.name","Blood transfusions"
"CD013445_pub2_data","Analysis.name","Procedure time"
"CD013445_pub2_data","Analysis.name","Postprocedure drainage tube or stent"
"CD013445_pub2_data","Analysis.name","Duration of postprocedure drainage tube or stent"
"CD013445_pub2_data","Analysis.name","Ureteral stricture or injury"
"CD013445_pub2_data","Analysis.name","Pain on postoperative day 0"
"CD013445_pub2_data","Analysis.name","Pain on postoperative day 1"
"CD013445_pub2_data","Analysis.name","Pain on postoperative days 2 to 7"
"CD013445_pub2_data","Analysis.name","Narcotic analgesic use"
"CD013445_pub2_data","Analysis.name","Primary treatment failure"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by access size: stone-free rate"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by stone burden: stone-free rate"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by stone location: stone-free rate"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by stone size: stone-free rate"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by access size: major complications"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by stone burden: major complications"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by stone location: major complications"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by stone size: major complications"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by access size: secondary interventions"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by stone burden: secondary interventions"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by stone location: secondary intervention"
"CD013445_pub2_data","Analysis.name","Subgroup analysis by stone size: secondary intervention"
"CD013445_pub2_data","Analysis.name","Sensitivity analysis for stone-free rate by definition of stone freedom (≤ 4 mm by any imaging modality)"
"CD013445_pub2_data","Analysis.name","Sensitivity analysis for stone-free rate by definition of stone freedom (≤ 2 mm by any imaging modality)"
"CD013445_pub2_data","Analysis.name","Sensitivity analysis for stone-free rate by definition of stone freedom (totally stone-free by CT scan)"
"CD013445_pub2_data","Analysis.name","Sensitivity analysis for major complications by definition of stone freedom (≤ 4 mm by any imaging modality)"
"CD013445_pub2_data","Analysis.name","Sensitivity analysis for major complications by definition of stone freedom (≤ 2 mm by any imaging modality)"
"CD013445_pub2_data","Analysis.name","Sensitivity analysis for major complications by definition of stone freedom (totally stone-free by CT scan)"
"CD013445_pub2_data","Analysis.name","Sensitivity analysis for secondary interventions by definition of stone freedom (≤ 4 mm by any imaging modality)"
"CD013445_pub2_data","Analysis.name","Sensitivity analysis for secondary interventions by definition of stone freedom (≤  2 mm by any imaging modality)"
"CD013445_pub2_data","Analysis.name","Sensitivity analysis for secondary interventions by definition of stone freedom (totally stone-free by CT scan)"
"CD013445_pub2_data","Subgroup","Access size < 15 Fr"
"CD013445_pub2_data","Subgroup","Access size ≥ 24 Fr"
"CD013445_pub2_data","Subgroup","Access size 15–23 Fr"
"CD013445_pub2_data","Subgroup","Solitary stone"
"CD013445_pub2_data","Subgroup","Multiple stones"
"CD013445_pub2_data","Subgroup","Non-lower pole stone"
"CD013445_pub2_data","Subgroup","Lower pole stone"
"CD013445_pub2_data","Subgroup","≤ 20 mm"
"CD013445_pub2_data","Subgroup","> 20 mm"
"CD013445_pub2_data","Subgroup","Multi-stone"
"CD013456_pub2_data","Analysis.group","1"
"CD013456_pub2_data","Analysis.group","2"
"CD013456_pub2_data","Analysis.name","Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, post-treatment"
"CD013456_pub2_data","Analysis.name","Psychosocial interventions versus inactive control; outcome 1: PTSD symptoms, 3 months"
"CD013456_pub2_data","Analysis.name","Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, post-treatment"
"CD013456_pub2_data","Analysis.name","Psychosocial interventions versus inactive control; outcome 2: Depressive symptoms, 3 months"
"CD013456_pub2_data","Analysis.name","Psychosocial interventions versus inactive control; outcome 3: Dropout from treatment"
"CD013456_pub2_data","Analysis.name","Psychosocial interventions versus inactive control; outcome 4: Adverse events"
"CD013456_pub2_data","Analysis.name","Psychosocial interventions versus inactive control; outcome 5: Anxiety symptoms, post-treatment"
"CD013456_pub2_data","Analysis.name","Psychosocial interventions versus inactive control; outcome 5: Anxiety symptoms, 3 months"
"CD013456_pub2_data","Analysis.name","Psychosocial interventions versus inactive control; outcome 6: Global mental health/distress, post-treatment"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 1: PTSD symptoms, post-treatment"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 1: PTSD symptoms, 3 months"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 1: PTSD symptoms, 6 months"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 2: Depressive symptoms, post-treatment"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 2: Depressive symptoms, 3 months"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 2: Depressive symptoms, 6 months"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 3: Dropout from treatment"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 4: Adverse events"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 5: Anxiety symptoms, post-treatment"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 5: Anxiety symptoms, 3 months"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 5: Anxiety symptoms, 6 months"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non-trauma focused interventions; outcome 7: Trauma-related beliefs, post-treatment"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 7: Global mental health/distress, post-treatment"
"CD013456_pub2_data","Analysis.name","Trauma-focused versus non trauma-focused interventions; outcome 7: Global mental health/distress, 3 months"
"CD013456_pub2_data","Subgroup","Cognitive Behavioural Therapy"
"CD013456_pub2_data","Subgroup","Behavioural Therapy"
"CD013456_pub2_data","Subgroup","Psychosocial (low-intensity) interventions"
"CD013462_pub3_data","Analysis.group","1"
"CD013462_pub3_data","Analysis.group","2"
"CD013462_pub3_data","Analysis.group","3"
"CD013462_pub3_data","Analysis.group","4"
"CD013462_pub3_data","Analysis.group","5"
"CD013462_pub3_data","Analysis.group","6"
"CD013462_pub3_data","Analysis.group","7"
"CD013462_pub3_data","Analysis.group","8"
"CD013462_pub3_data","Analysis.name","Rate of postoperative pancreatic fistula (grade B or C defined according to the 2005 ISGPF definition)"
"CD013462_pub3_data","Analysis.name","Postoperative mortality"
"CD013462_pub3_data","Analysis.name","Rate of surgical reintervention"
"CD013462_pub3_data","Analysis.name","Rate of postoperative bleeding"
"CD013462_pub3_data","Analysis.name","Overall rate of surgical complications"
"CD013462_pub3_data","Analysis.name","Length of hospital stay"
"CD013462_pub3_data","Analysis.name","Rate of postoperative pancreatic fistula (grade B or C defined according to the 2016 ISGPS definition)"
"CD013462_pub3_data","Analysis.name","Adverse events"
"CD013462_pub3_data","Analysis.name","Rate of POPF (grade B or C defined according to the 2005 ISGPF definition)"
"CD013462_pub3_data","Subgroup","Grade B"
"CD013462_pub3_data","Subgroup","Grade C"
"CD013462_pub3_data","Subgroup","Soft pancreas"
"CD013462_pub3_data","Subgroup","Firm pancreas"
"CD013462_pub3_data","Subgroup","Pancreatic duct stents"
"CD013462_pub3_data","Subgroup","No stents"
"CD013462_pub3_data","Subgroup","Prophylactic somatostatin"
"CD013462_pub3_data","Subgroup","No somatostatin"
"CD013468_pub2_data","Analysis.group","1"
"CD013468_pub2_data","Analysis.group","2"
"CD013468_pub2_data","Analysis.group","3"
"CD013468_pub2_data","Analysis.group","4"
"CD013468_pub2_data","Analysis.group","5"
"CD013468_pub2_data","Analysis.group","6"
"CD013468_pub2_data","Analysis.group","7"
"CD013468_pub2_data","Analysis.group","8"
"CD013468_pub2_data","Analysis.group","9"
"CD013468_pub2_data","Analysis.group","11"
"CD013468_pub2_data","Analysis.group","12"
"CD013468_pub2_data","Analysis.group","13"
"CD013468_pub2_data","Analysis.group","14"
"CD013468_pub2_data","Analysis.group","15"
"CD013468_pub2_data","Analysis.group","16"
"CD013468_pub2_data","Analysis.group","17"
"CD013468_pub2_data","Analysis.group","18"
"CD013468_pub2_data","Analysis.group","19"
"CD013468_pub2_data","Analysis.group","20"
"CD013468_pub2_data","Analysis.group","21"
"CD013468_pub2_data","Analysis.name","Change in burn‐related pruritus"
"CD013468_pub2_data","Analysis.name","Adverse events"
"CD013468_pub2_data","Analysis.name","Change in burn-related pruritus"
"CD013468_pub2_data","Analysis.name","Adverse events (somnolence)"
"CD013468_pub2_data","Analysis.name","Change in burn-related pruritus (visual analogue JW pruritic score)"
"CD013468_pub2_data","Analysis.name","Change in burn-related pruritus "
"CD013468_pub2_data","Analysis.name","Pain"
"CD013468_pub2_data","Analysis.name","Participant health-related quality of life"
"CD013468_pub2_data","Analysis.name","Change in burn-related pruritus (VAS)"
"CD013474_pub2_data","Analysis.group","1"
"CD013474_pub2_data","Analysis.group","2"
"CD013474_pub2_data","Analysis.group","3"
"CD013474_pub2_data","Analysis.name","Overall survival (time to event)"
"CD013474_pub2_data","Analysis.name","Overall survival (time to event): type of drug"
"CD013474_pub2_data","Analysis.name","Health-related quality of life"
"CD013474_pub2_data","Analysis.name","Grade 3 and 4 adverse events"
"CD013474_pub2_data","Analysis.name","Grade 3 and 4 adverse events: type of drug"
"CD013474_pub2_data","Analysis.name","Progression-free survival (time to event)"
"CD013474_pub2_data","Analysis.name","Progression-free survival (time to event): type of drug"
"CD013474_pub2_data","Analysis.name","Treatment-related mortality"
"CD013474_pub2_data","Analysis.name","Treatment-related mortality: type of drug"
"CD013474_pub2_data","Analysis.name","Treatment discontinuation"
"CD013474_pub2_data","Analysis.name","Treatment discontinuation: type of drug"
"CD013474_pub2_data","Analysis.name","All adverse events"
"CD013474_pub2_data","Analysis.name","All adverse events: type of drug"
"CD013474_pub2_data","Analysis.name","Complete response rate"
"CD013474_pub2_data","Analysis.name","Overall response rate"
"CD013474_pub2_data","Subgroup","Rituximab"
"CD013474_pub2_data","Subgroup","Ofatumumab"
"CD013476_pub2_data","Analysis.group","1"
"CD013476_pub2_data","Analysis.name","Disease-specific health-related quality of life scores at 6 months follow-up (SNOT-score)"
"CD013476_pub2_data","Analysis.name","Disease-specific health-related quality of life scores at 6 months follow-up (SNOT-score) (excluding high risk of bias studies)"
"CD013476_pub2_data","Analysis.name","Disease-specific health-related quality of life scores at 36 months follow-up (Rhinosinusitis Disability Index) (all studies)"
"CD013476_pub2_data","Analysis.name","Asthma control at 6 months follow-up (Asthma Control Questionnaire) "
"CD013476_pub2_data","Analysis.name","Asthma control at 6 months follow-up (Asthma Control Test)"
"CD013476_pub2_data","Analysis.name","Significant adverse events during maintenance therapy up to 6 months follow-up"
"CD013476_pub2_data","Analysis.name","Mean change from baseline in peak nasal inspiratory flow (PNIF) at 6 months follow-up (L/min)"
"CD013476_pub2_data","Analysis.name","Nasal endoscopy score at 36 months follow-up  (Lildholdt score)"
"CD013476_pub2_data","Analysis.name","Change in dosage of inhaled corticosteroids at 6 months follow-up (µg)"
"CD013476_pub2_data","Analysis.name","Change in dosage of nasal corticosteroids at 6 months follow-up (µg)"
"CD013476_pub2_data","Analysis.name","Change in medication score at 6 months follow-up (dosage of inhaled/intranasal corticosteroid) "
"CD013476_pub2_data","Analysis.name","Symptom score after 6 months follow-up"
"CD013476_pub2_data","Analysis.name","Asthma exacerbations after 6 months follow-up"
"CD013476_pub2_data","Analysis.name","Chronic rhinosinusitis exacerbations after 36 months follow-up"
"CD013476_pub2_data","Subgroup","Disease-specific health-related quality of life scores at 6 months follow-up (all studies)"
"CD013476_pub2_data","Subgroup","Disease-specific health-related quality of life scores at 6 months follow-up (excluding high risk of bias studies)"
"CD013476_pub2_data","Subgroup","Significant adverse events during maintenance therapy up to 6 months follow-up (all studies)"
"CD013476_pub2_data","Subgroup","Smell score"
"CD013476_pub2_data","Subgroup","Nasal blockage"
"CD013476_pub2_data","Subgroup","Sneezing"
"CD013508_pub3_data","Analysis.group","1"
"CD013508_pub3_data","Analysis.name","Depression"
"CD013508_pub3_data","Analysis.name","HADS-D "
"CD013508_pub3_data","Analysis.name","BDI-II"
"CD013508_pub3_data","Analysis.name","PHQ-9"
"CD013508_pub3_data","Analysis.name","Anxiety"
"CD013508_pub3_data","Analysis.name","HADS-A"
"CD013508_pub3_data","Analysis.name","GAD-7"
"CD013508_pub3_data","Analysis.name","BAI"
"CD013508_pub3_data","Analysis.name","HRQoL (PCS)"
"CD013508_pub3_data","Analysis.name","SF12/36 (PCS)"
"CD013508_pub3_data","Analysis.name","HRQoL (MCS)"
"CD013508_pub3_data","Analysis.name","SF12/36 (MCS)"
"CD013508_pub3_data","Analysis.name","Self-efficacy"
"CD013508_pub3_data","Analysis.name","Mortality (all-cause)"
"CD013508_pub3_data","Analysis.name","MACE"
"CD013539_pub2_data","Analysis.group","1"
"CD013539_pub2_data","Analysis.group","2"
"CD013539_pub2_data","Analysis.group","3"
"CD013539_pub2_data","Analysis.name","Progression-free survival"
"CD013539_pub2_data","Analysis.name","Duration of response"
"CD013539_pub2_data","Analysis.name","Overall survival"
"CD013539_pub2_data","Analysis.name","Serious adverse events"
"CD013539_pub2_data","Analysis.name","Objective response rate"
"CD013539_pub2_data","Analysis.name","Mortality"
"CD013539_pub2_data","Analysis.name","Neutralising antibodies"
"CD013539_pub2_data","Analysis.name","Antidrug antibodies"
"CD013539_pub2_data","Analysis.name","Any adverse events"
"CD013539_pub2_data","Analysis.name","Event-free survival"
"CD013539_pub2_data","Analysis.name","Antidrug antibodies "
"CD013539_pub2_data","Analysis.name","Pathological complete response"
"CD013539_pub2_data","Subgroup","Lung cancer"
"CD013539_pub2_data","Subgroup","Colorectal cancer"
"CD013539_pub2_data","Subgroup","Antidrug antibodies at baseline"
"CD013539_pub2_data","Subgroup","Antidrug antibodies at end of study"
"CD013541_pub2_data","Analysis.group","1"
"CD013541_pub2_data","Analysis.group","2"
"CD013541_pub2_data","Analysis.group","3"
"CD013541_pub2_data","Analysis.group","4"
"CD013541_pub2_data","Analysis.group","5"
"CD013541_pub2_data","Analysis.group","6"
"CD013541_pub2_data","Analysis.group","7"
"CD013541_pub2_data","Analysis.group","8"
"CD013541_pub2_data","Analysis.group","12"
"CD013541_pub2_data","Analysis.group","13"
"CD013541_pub2_data","Analysis.group","14"
"CD013541_pub2_data","Analysis.group","16"
"CD013541_pub2_data","Analysis.group","17"
"CD013541_pub2_data","Analysis.group","19"
"CD013541_pub2_data","Analysis.name","Relapse (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Relapse (≤ 1 month postintervention, completer)"
"CD013541_pub2_data","Analysis.name","Relapse (> 6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Relapse (> 6 months postintervention, completer)"
"CD013541_pub2_data","Analysis.name","Caregiver burden (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Caregiver burden (1-6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Caregiver burden (> 6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Number of people shifting to low expressed emotion (positive outcome)"
"CD013541_pub2_data","Analysis.name","Number of people shifting to low expressed emotion (completer, positive outcome)"
"CD013541_pub2_data","Analysis.name","Expressed emotion (1-6 months, negative outcome)"
"CD013541_pub2_data","Analysis.name","Adverse effects"
"CD013541_pub2_data","Analysis.name","Global state (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Service use: hospital admission (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Service use: hospital admission (> 6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Service use: average number of hospital admissions (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Service use: average number of hospital admissions (1-6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Service use: average number of hospital admissions (> 6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Service use: days in hospital (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Service use: days in hospital (1-6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Service use: days in hospital (> 6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Mental state: overall (≤ 1 month postintervention, negative outcome)"
"CD013541_pub2_data","Analysis.name","Mental state: overall (> 6 months postintervention, negative outcome)"
"CD013541_pub2_data","Analysis.name","Mental state: positive symptoms (≤ 1 month postintervention, negative outcome)"
"CD013541_pub2_data","Analysis.name","Mental state: positive symptoms (1-6 months postintervention, negative outcome)"
"CD013541_pub2_data","Analysis.name","Mental state: positive symptoms (> 6 months postintervention, negative outcome)"
"CD013541_pub2_data","Analysis.name","Mental state: negative symptoms (≤ 1 month postintervention, negative outcome)"
"CD013541_pub2_data","Analysis.name","Mental state: general psychopathology (≤ 1 month postintervention, negative outcome)"
"CD013541_pub2_data","Analysis.name","Mental state: mania-hostility symptoms (≤ 1 month postintervention, negative outcome)"
"CD013541_pub2_data","Analysis.name","Mental state: insight (≤ 1 month postintervention, positive outcome)"
"CD013541_pub2_data","Analysis.name","Functioning: overall (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Functioning: overall (> 6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Functioning: social functioning (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Caregiving: competence (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Caregiving: competence (1-6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Caregiving: competence (> 6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Social support (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Social support (1-6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Social support (> 6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Family outcomes: family service usage (≤ 1 month postintervention, positive outcome)"
"CD013541_pub2_data","Analysis.name","Family outcomes: family service usage (1-6 months postintervention, positive outcome)"
"CD013541_pub2_data","Analysis.name","Family outcomes: family service usage (> 6 months postintervention, positive outcome)"
"CD013541_pub2_data","Analysis.name","Family outcomes: family functioning (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Family outcomes: family functioning (> 6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Family members' satisfaction with care"
"CD013541_pub2_data","Analysis.name","Leaving the study early (≤ 1 month postintervention)"
"CD013541_pub2_data","Analysis.name","Leaving the study early (1-6 months postintervention)"
"CD013541_pub2_data","Analysis.name","Leaving the study early (6-12 months postintervention)"
"CD013541_pub2_data","Analysis.name","Leaving the study early (> 12 months postintervention)"
"CD013541_pub2_data","Analysis.name","Family members' knowledge (≤ 1 month postintervention)"
"CD013541_pub2_data","Subgroup","Pre- to post-intervention mean change"
"CD013541_pub2_data","Subgroup","Postintervention mean"
"CD013541_pub2_data","Subgroup","Other cause"
"CD013541_pub2_data","Subgroup","Suicide "
"CD013541_pub2_data","Subgroup","Post-intervention mean"
"CD013541_pub2_data","Subgroup","Pre- to postintervention mean change"
"CD013541_pub2_data","Subgroup","Postintervention mean "
"CD013561_pub2_data","Analysis.group","1"
"CD013561_pub2_data","Analysis.group","2"
"CD013561_pub2_data","Analysis.name","Adverse events"
"CD013561_pub2_data","Analysis.name","Biochemical remission according to normalisation of IGF-1 and GH"
"CD013561_pub2_data","Analysis.name","Disease-related complications"
"CD013561_pub2_data","Analysis.name","Biochemical remission according to IGF-1 normalisation and GH < 1 ug/L"
"CD013561_pub2_data","Analysis.name","Biochemical remission according to normalisation of IGF-1"
"CD013561_pub2_data","Analysis.name","Biochemical remission according to normalisation of GH < 1 ug/L"
"CD013561_pub2_data","Analysis.name","Surgery for recurrent or persistent disease"
"CD013561_pub2_data","Analysis.name","Non-surgical therapy for recurrent or persistent disease"
"CD013571_pub2_data","Analysis.group","1"
"CD013571_pub2_data","Analysis.group","2"
"CD013571_pub2_data","Analysis.group","3"
"CD013571_pub2_data","Analysis.group","4"
"CD013571_pub2_data","Analysis.name","Participant-reported cure or improvement: immediately after treatment"
"CD013571_pub2_data","Analysis.name","Participant-reported cure or improvement: long-term effect (> 2 months after treatment)"
"CD013571_pub2_data","Analysis.name","Number of incontinence episodes per 24 hours: immediately after treatment"
"CD013571_pub2_data","Analysis.name","Symptom-related quality of life (QoL): immediately after treatment"
"CD013571_pub2_data","Analysis.name","Symptom-related QoL: long-term effect (> 2 months after treatment)"
"CD013571_pub2_data","Analysis.name","Adverse events: immediately after treatment"
"CD013571_pub2_data","Analysis.name","Adverse events: long-term effect (> 2 months after treatment)"
"CD013571_pub2_data","Analysis.name","Number of incontinence episodes per 24 hours: long-term effect (> 2 months after treatment)"
"CD013571_pub2_data","Analysis.name","Number of urgency episodes per 24 hours: immediately after treatment"
"CD013571_pub2_data","Analysis.name","Number of urgency episodes per 24 hours: long-term effect (> 2 months after treatment)"
"CD013571_pub2_data","Analysis.name","Number of micturition episodes per 24 hours: immediately after treatment"
"CD013571_pub2_data","Analysis.name","Number of micturition episodes per 24 hours: long-term effect (> 2 months after treatment)"
"CD013571_pub2_data","Analysis.name","Symptom-related QOL: long-term effect (> 2 months after treatment)"
"CD013571_pub2_data","Analysis.name","Participant-reported satisfaction: immediately after treatment"
"CD013571_pub2_data","Analysis.name","Participant-reported satisfaction: long-term effect (> 2 months after treatment)"
"CD013590_pub2_data","Analysis.group","1"
"CD013590_pub2_data","Analysis.group","2"
"CD013590_pub2_data","Analysis.group","3"
"CD013590_pub2_data","Analysis.group","4"
"CD013590_pub2_data","Analysis.group","5"
"CD013590_pub2_data","Analysis.group","6"
"CD013590_pub2_data","Analysis.group","7"
"CD013590_pub2_data","Analysis.group","8"
"CD013590_pub2_data","Analysis.group","9"
"CD013590_pub2_data","Analysis.group","10"
"CD013590_pub2_data","Analysis.group","11"
"CD013590_pub2_data","Analysis.group","12"
"CD013590_pub2_data","Analysis.group","13"
"CD013590_pub2_data","Analysis.group","14"
"CD013590_pub2_data","Analysis.group","15"
"CD013590_pub2_data","Analysis.group","16"
"CD013590_pub2_data","Analysis.group","17"
"CD013590_pub2_data","Analysis.name","Frequency of crisis (mean number of pain crises)"
"CD013590_pub2_data","Analysis.name","Frequency of hospitalisation"
"CD013590_pub2_data","Analysis.name","SCD-related complications (number of participants)"
"CD013590_pub2_data","Analysis.name","Frequency of crisis (number of participants with pain crisis)"
"CD013590_pub2_data","Analysis.name","Severity of pain "
"CD013590_pub2_data","Analysis.name","Adverse events"
"CD013590_pub2_data","Analysis.name","Frequency of crisis (number of VOC episodes)"
"CD013590_pub2_data","Analysis.name","QoL of participants living with SCD and their caregivers"
"CD013590_pub2_data","Analysis.name","Frequency of hospitalization"
"CD013590_pub2_data","Analysis.name","SCD-related complications (sq mm per day)"
"CD013590_pub2_data","Analysis.name","Frequency of SCD-related complications (number of participants with infections) at 6 months"
"CD013590_pub2_data","Analysis.name","SCD-related complications (other)"
"CD013590_pub2_data","Analysis.name","Haemoglobin status (g/dL) (at up to 6 months)"
"CD013590_pub2_data","Analysis.name","Haemoglobin % (at over 12 months)"
"CD013590_pub2_data","Analysis.name","Laboratory markers of haemolysis and inflammation"
"CD013590_pub2_data","Analysis.name","Frequency of crisis (mean change from baseline: number of vaso-occlusive crises (at up to 12 months))"
"CD013590_pub2_data","Analysis.name"," Frequency of hospitalization (mean change from baseline)"
"CD013590_pub2_data","Analysis.name","Frequency of SCD-related complications (mean change from baseline)"
"CD013590_pub2_data","Analysis.name"," Laboratory markers of haemolysis and inflammation"
"CD013590_pub2_data","Analysis.name","Frequency of SCD-related complications"
"CD013590_pub2_data","Analysis.name","Frequency of crisis"
"CD013590_pub2_data","Analysis.name","Frequency of crisis "
"CD013590_pub2_data","Analysis.name","Pain severity (pain intensity)"
"CD013590_pub2_data","Analysis.name","Pain severity (home analgesia)"
"CD013590_pub2_data","Analysis.name","QoL of participants living with SCD and their caregivers (measured using SF-36 scoring system)"
"CD013590_pub2_data","Analysis.name","Adverse effects"
"CD013590_pub2_data","Analysis.name"," Frequency of hospitalization"
"CD013590_pub2_data","Analysis.name","Haemoglobin status (g/dL)"
"CD013590_pub2_data","Analysis.name","Frequency of crises"
"CD013590_pub2_data","Analysis.name","Severity of pain"
"CD013590_pub2_data","Analysis.name","Haemoglobin status"
"CD013590_pub2_data","Analysis.name","Severity of pain crises"
"CD013590_pub2_data","Analysis.name","Frequency of SCD-related complications "
"CD013590_pub2_data","Analysis.name","Frequency of SCD-related complications (improvement in leg ulcer size)"
"CD013590_pub2_data","Analysis.name","Frequency of SCD-related complications (leg ulcer healing rate) "
"CD013590_pub2_data","Subgroup","At up to 12 months"
"CD013590_pub2_data","Subgroup","Mean cumulative number days in hospital (at up to 12 months) "
"CD013590_pub2_data","Subgroup","Mean number of days in hospital (up to 12 months)"
"CD013590_pub2_data","Subgroup","Mean number of emergency clinic visits (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Acute chest syndrome (at up to 12  months)"
"CD013590_pub2_data","Subgroup","Number of participants who experienced pain crisis at up to 6 months"
"CD013590_pub2_data","Subgroup","Number of participants using NSAIDs (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of participants using opioid analgesics (at up to 6 months)"
"CD013590_pub2_data","Subgroup","At up to 6 months (number of participants experiencing AEs)"
"CD013590_pub2_data","Subgroup","Leg ulcer (at up to six months)"
"CD013590_pub2_data","Subgroup","Acute chest syndrome (at up to six months)"
"CD013590_pub2_data","Subgroup","Stroke (at up to six months)"
"CD013590_pub2_data","Subgroup","Blood transfusion (at up to six months)"
"CD013590_pub2_data","Subgroup","Priapism (at up to six months)"
"CD013590_pub2_data","Subgroup","Number of vaso-occlusive crises (at over 12 months)"
"CD013590_pub2_data","Subgroup","Total episodes of crisis (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Frequency of crisis (number of sickle pain episodes at over six months )"
"CD013590_pub2_data","Subgroup","At over 12 months (mean frequency of crisis)"
"CD013590_pub2_data","Subgroup","Loss of work days/crisis (at over 12 months)"
"CD013590_pub2_data","Subgroup","At over 12 months (mean hospital stay/crisis)"
"CD013590_pub2_data","Subgroup","Complete healing of leg ulcer  (sq mm per day) at up to 6 months"
"CD013590_pub2_data","Subgroup","Number of participants with improved leg ulcer (sq mm per day) at up to 6 months"
"CD013590_pub2_data","Subgroup","Sequestration (at over 12 months)"
"CD013590_pub2_data","Subgroup","Aplastic crisis (at over 12 months)"
"CD013590_pub2_data","Subgroup","Haemolytic crisis (at over 12 months)"
"CD013590_pub2_data","Subgroup","White blood cells 103/L  (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Reticulocyte % (at over 12 months) (mean difference post intervention)"
"CD013590_pub2_data","Subgroup","Platelets 103/L (at up to 6 months) (mean change from baseline)"
"CD013590_pub2_data","Subgroup","Reticulocytes (%) at up to six months (mean change from baseline)"
"CD013590_pub2_data","Subgroup","Reticulocytes (%) at up to 12 months (mean change from baseline)"
"CD013590_pub2_data","Subgroup","Mean number of days in short-stay medical unit (haematology acute care unit) (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Mean number of emergency visits (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Mean number of hospitalizations at up to 12 months (days)"
"CD013590_pub2_data","Subgroup","Mean number of episodes of acute chest syndrome (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Reticulocytes % (mean) at up to 12 months"
"CD013590_pub2_data","Subgroup","Mean number of hospitalizations (days) (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Reticulocytes % (at up to 12 months) mean change from baseline"
"CD013590_pub2_data","Subgroup","Number of vaso-occlusive episodes (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Vaso-occlusive crises at up to six months (event rate per patient year)"
"CD013590_pub2_data","Subgroup","Number of episodes of vaso-occlusive crises (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Pain days at up to six months (event rate per patient year)"
"CD013590_pub2_data","Subgroup","Mean pain intensity on pain days at up to 6 months (lower is better)"
"CD013590_pub2_data","Subgroup","Days with home analgesic (event rate per patient-year at up to six months)"
"CD013590_pub2_data","Subgroup","Mean change in physical component scale (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Mean change in mental component scale (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of participants experiencing any adverse effect at up to 6 months"
"CD013590_pub2_data","Subgroup","Event rate of hospitalization (per patient year)"
"CD013590_pub2_data","Subgroup","Priapism"
"CD013590_pub2_data","Subgroup","Acute chest syndrome"
"CD013590_pub2_data","Subgroup","Sequestration"
"CD013590_pub2_data","Subgroup","Mean change from baseline (at up to six months)"
"CD013590_pub2_data","Subgroup","LDH U/L (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","CRP mg/L (mean change from baseline at up to six months)"
"CD013590_pub2_data","Subgroup","Platelet count x103/L (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","Total white blood cells x109/L (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","Reticulocytes x103/L (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of vaso-occlusive crises (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Number of participants experiencing daily pain (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of participants experiencing monthly pain (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of participants experiencing yearly pain (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of participants experiencing weekly pain (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Dose of opioid use mg/kg (mean difference post intervention at up to 6 months)"
"CD013590_pub2_data","Subgroup","Rate of decline of worst pain score at up to six months (mean difference post intervention) (more is better)"
"CD013590_pub2_data","Subgroup","Mean change from baseline in pain scores using a 10-cm visual analogue scale, at up to 6 months (lower score is better )"
"CD013590_pub2_data","Subgroup","Mean length of hospitalization in days (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Mean change from baseline in g/dL (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Reticulocytes % (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","Platelets (x 109/L) (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","Total white blood cells (X 109/L) (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","HbF (g/dL) (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of pain episodes (rate ratio at up to 12 months)"
"CD013590_pub2_data","Subgroup","Number of participants who had any adverse effect (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Number of participants with any adverse effect (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of participants who had serious adverse effects (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of participants who had severe anaemia (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Number of participants who had sequestration crisis (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Number of participants who had stroke (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Number of participants who recieved blood transfusion (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Number of participants who had avascular necrosis (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Mean change from baseline in haemoglobin (g/L) (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Mean change from baseline in haemoglobin (g/L) (at up to 6 months)"
"CD013590_pub2_data","Subgroup"," Total white blood cells 103/µL (mean count at 6 months)"
"CD013590_pub2_data","Subgroup","Platelet count 103/µL (mean count at up to 6 months)"
"CD013590_pub2_data","Subgroup","Reticulocytes % (mean count at up to 6 months)"
"CD013590_pub2_data","Subgroup","Lactic acid dehydrogenase U/L(mean value at up to 12 months)"
"CD013590_pub2_data","Subgroup","Reticulocytes % (mean count at up to 12 months)"
"CD013590_pub2_data","Subgroup","Lactic acid dehydrogenase U/L (mean value at up to 6 months)"
"CD013590_pub2_data","Subgroup","Total white blood cells 103/μL (mean count at up to 12 months)"
"CD013590_pub2_data","Subgroup","Platelet count 103/μL (mean count at up to 12 months)"
"CD013590_pub2_data","Subgroup","Number of participants experiencing painful crisis (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Number of hospitalization episodes (clinic visits/child) (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Splenic sequestration (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Major infections (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Dactylitis (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Minor infections (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Haemoglobin level g/dL (mean change from baseline at up to six months)"
"CD013590_pub2_data","Subgroup","Total white blood cells K/μL (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","Reticulocytes K/μL (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","Leg ulcers area - change in size in cm (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Mean number of vaso-occlusive crises  (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Mean number hospitalizations (measured as the number of hospitalizations at up to 12 months)"
"CD013590_pub2_data","Subgroup","Acute chest events ( mean change from baseline at up to 12 months)"
"CD013590_pub2_data","Subgroup","Reticulocyte count % (mean change from baseline at up to 12 months)"
"CD013590_pub2_data","Subgroup","Mean reduction in leg ulcer areas (cm) (change from baseline at up to six months)"
"CD013590_pub2_data","Subgroup","Number of completely-healed leg ulcers (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of partially-healed leg ulcers (at up to 6 months)"
"CD013590_pub2_data","Subgroup","Haemoglobin (g/dL) mean change from baseline at up to 6 months"
"CD013590_pub2_data","Subgroup","Foetal haemoglobin % (mean change from baseline at up to 6 months)"
"CD013590_pub2_data","Subgroup","Number of VOC episodes (at up to 12 months)"
"CD013590_pub2_data","Subgroup","Mean change from baseline at up to 6 months"
"CD013591_pub2_data","Analysis.group","1"
"CD013591_pub2_data","Analysis.group","2"
"CD013591_pub2_data","Analysis.group","3"
"CD013591_pub2_data","Analysis.name","Physical activity (moderate to vigorous physical activity)"
"CD013591_pub2_data","Analysis.name","Physical activity (other measures)"
"CD013591_pub2_data","Analysis.name","Anthropometric measures (BMI)"
"CD013591_pub2_data","Analysis.name","Anthropometric measures (body weight)"
"CD013591_pub2_data","Analysis.name","Self-efficacy (scores)"
"CD013591_pub2_data","Analysis.name","Dietary behaviour (fruit/vegetable intake)"
"CD013591_pub2_data","Analysis.name","Dietary behaviour (energy intake)"
"CD013591_pub2_data","Analysis.name","Dietary behaviour (other measures - unhealthy)"
"CD013591_pub2_data","Analysis.name","Dietary behaviour (other measures - healthy)"
"CD013591_pub2_data","Analysis.name","Dietary behaviour (other measures -  healthy)"
"CD013591_pub2_data","Analysis.name","Anthropometric measures (BMI z-score)"
"CD013591_pub2_data","Subgroup","Medium-term: 8 months (MVPA in min/day - measured by accelerometer)"
"CD013591_pub2_data","Subgroup","Long-term: 12 months (MVPA in min/week)"
"CD013591_pub2_data","Subgroup","Short-term: 3 to 4 months (MVPA in min/day - measured by accelerometer)"
"CD013591_pub2_data","Subgroup","Short-term: 3 to 4 months (MVPA in min/week)"
"CD013591_pub2_data","Subgroup","Estimated energy expenditure (MET-minutes/week) - medium-term: 8 months"
"CD013591_pub2_data","Subgroup","Total activity time (minutes/week) - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Cardiorespiratory fitness (mL/kg/minutes) - medium-term: 8 months"
"CD013591_pub2_data","Subgroup","Leisure time physical activity (kcal/week) - long-term: 24 months"
"CD013591_pub2_data","Subgroup","Total activity time (minutes/week) - long-term: 12 months"
"CD013591_pub2_data","Subgroup","Cardiorespiratory fitness (mL/kg/minutes) - short-term: 4 months"
"CD013591_pub2_data","Subgroup","Health enhancing physical activity (score) - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Walking (minutes/week) - short-term: 4 months"
"CD013591_pub2_data","Subgroup","Leisure time physical activity (kcal/week) - medium-term: 6 months"
"CD013591_pub2_data","Subgroup","Leisure time physical activity (kcal/week) - long-term: 12 months"
"CD013591_pub2_data","Subgroup","Physical component summary score (SF-12 Health Survey) - short-term: 4 months"
"CD013591_pub2_data","Subgroup","Estimated energy expenditure (MET-minutes/week) - short term: 4 months"
"CD013591_pub2_data","Subgroup","Accelerometer-measured step count (steps/day) - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Long-term: 12 months (BMI)"
"CD013591_pub2_data","Subgroup","Medium-term: 6 to 8 months (BMI)"
"CD013591_pub2_data","Subgroup","Short-term: 3 to 4 months (BMI)"
"CD013591_pub2_data","Subgroup","Short-term: 3 to 4 months (BMI) - only change data"
"CD013591_pub2_data","Subgroup","Long-term: 24 months"
"CD013591_pub2_data","Subgroup","Short-term: 3 to 4 months"
"CD013591_pub2_data","Subgroup","Long-term: 12 months"
"CD013591_pub2_data","Subgroup","Medium-term: 6 months"
"CD013591_pub2_data","Subgroup","Self-efficacy for physical activity (Exercise Confidence Survey) - medium term: 8 months"
"CD013591_pub2_data","Subgroup","Self-efficacy for physical activity (Exercise Confidence Survey) - short-term: 4 months"
"CD013591_pub2_data","Subgroup","Short-term: 3 months"
"CD013591_pub2_data","Subgroup","Sweet snacks intake (occasions/day) - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Sugary sweetened drinks intake (occassions/day) - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Food Frequency Questionnaire (snack score) - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Food Frequency Questionnaire (drink score) - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Food Frequency Questionnaire (total score) - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Healthy Eating Index score change - long-term: 24 months"
"CD013591_pub2_data","Subgroup","Healthy Eating Index score change - medium-term: 6 months"
"CD013591_pub2_data","Subgroup","Overall nutrition score pattern - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Adherence to Mediterranean diet - short-term: 3 months"
"CD013591_pub2_data","Subgroup","Healthy Eating Index score change - long-term: 12 months"
"CD013591_pub2_data","Subgroup","Adherence to Mediterranean diet - long-term: 12 months"
"CD013591_pub2_data","Subgroup","Short-term: 3 months (MVPA in min/week - measured by accelerometer)"
"CD013591_pub2_data","Subgroup","Short term: 3 months"
"CD013591_pub2_data","Subgroup","Overall Score Nutrition Pattern - short-term: 3 months"
"CD013595_pub2_data","Analysis.group","1"
"CD013595_pub2_data","Analysis.group","2"
"CD013595_pub2_data","Analysis.group","3"
"CD013595_pub2_data","Analysis.group","4"
"CD013595_pub2_data","Analysis.group","5"
"CD013595_pub2_data","Analysis.group","6"
"CD013595_pub2_data","Analysis.group","7"
"CD013595_pub2_data","Analysis.group","8"
"CD013595_pub2_data","Analysis.name","Overall survival"
"CD013595_pub2_data","Analysis.name","Overall survival - cytogenetic profile at study entry"
"CD013595_pub2_data","Analysis.name","Overall survival - International Staging System disease stage"
"CD013595_pub2_data","Analysis.name","Progression-free survival"
"CD013595_pub2_data","Analysis.name","EORTC 3 month"
"CD013595_pub2_data","Analysis.name","EORTC 9 month"
"CD013595_pub2_data","Analysis.name","EORTC 12 month"
"CD013595_pub2_data","Analysis.name","EQ-5D 3 month"
"CD013595_pub2_data","Analysis.name","EQ-5D 9 month"
"CD013595_pub2_data","Analysis.name","EQ-5D 12 month"
"CD013595_pub2_data","Analysis.name","On-study mortality"
"CD013595_pub2_data","Analysis.name","Serious adverse events"
"CD013595_pub2_data","Analysis.name","Adverse events (CTCAE grade ≥ 3)"
"CD013595_pub2_data","Analysis.name","Infections"
"CD013595_pub2_data","Analysis.name","Neutropenia"
"CD013595_pub2_data","Analysis.name","Thrombocytopenia"
"CD013595_pub2_data","Analysis.name","Anaemia"
"CD013595_pub2_data","Analysis.name","Leukopenia"
"CD013595_pub2_data","Analysis.name","Lymphopenia"
"CD013595_pub2_data","Analysis.name","Diarrhoea"
"CD013595_pub2_data","Analysis.name","Pneumonia"
"CD013595_pub2_data","Analysis.name","Nausea"
"CD013595_pub2_data","Analysis.name","Complete response"
"CD013595_pub2_data","Analysis.name","Minimal residual disease negativity"
"CD013595_pub2_data","Subgroup","Standard risk at study entry"
"CD013595_pub2_data","Subgroup","High risk at study entry"
"CD013595_pub2_data","Subgroup","International Staging System disease stage I"
"CD013595_pub2_data","Subgroup","International Staging System disease stage II"
"CD013595_pub2_data","Subgroup","International Staging System disease stage III"
"CD013613_pub2_data","Analysis.group","1"
"CD013613_pub2_data","Analysis.group","2"
"CD013613_pub2_data","Analysis.group","3"
"CD013613_pub2_data","Analysis.group","4"
"CD013613_pub2_data","Analysis.name","PTSD severity at three months"
"CD013613_pub2_data","Analysis.name","PTSD severity at study endpoint"
"CD013613_pub2_data","Analysis.name","Dropouts due to adverse events at three months"
"CD013613_pub2_data","Analysis.name","Dropouts due to adverse events at study endpoint"
"CD013613_pub2_data","Analysis.name","PTSD rate at three months"
"CD013613_pub2_data","Analysis.name","Sensitivity analysis: PTSD rate at three months (cases out of randomised)"
"CD013613_pub2_data","Analysis.name","PTSD rate at study endpoint"
"CD013613_pub2_data","Analysis.name","Sensitivity analysis: PTSD rate at study endpoint (cases out of randomised)"
"CD013613_pub2_data","Analysis.name","Depression severity at three months"
"CD013613_pub2_data","Analysis.name","Depression severity at study endpoint"
"CD013613_pub2_data","Analysis.name","Anxiety severity at three months"
"CD013613_pub2_data","Analysis.name","Anxiety severity at study endpoint"
"CD013613_pub2_data","Analysis.name","Functional disability at study endpoint"
"CD013613_pub2_data","Analysis.name","Dropout for any reason at three months"
"CD013613_pub2_data","Analysis.name","Dropout for any reason at study endpoint"
"CD013613_pub2_data","Analysis.name","Quality of life at three months"
"CD013614_pub2_data","Analysis.group","1"
"CD013614_pub2_data","Analysis.group","2"
"CD013614_pub2_data","Analysis.group","3"
"CD013614_pub2_data","Analysis.group","4"
"CD013614_pub2_data","Analysis.group","5"
"CD013614_pub2_data","Analysis.group","6"
"CD013614_pub2_data","Analysis.group","7"
"CD013614_pub2_data","Analysis.group","8"
"CD013614_pub2_data","Analysis.group","9"
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks"
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks"
"CD013614_pub2_data","Analysis.name","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks"
"CD013614_pub2_data","Analysis.name","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks"
"CD013614_pub2_data","Analysis.name","Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks"
"CD013614_pub2_data","Analysis.name","MCID in HAQ proportion of patients at 12 weeks"
"CD013614_pub2_data","Analysis.name","Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks"
"CD013614_pub2_data","Analysis.name","MCID in HAQ proportion of patients at 24 weeks"
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). "
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS)."
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). "
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). "
"CD013614_pub2_data","Analysis.name","Radiographic progression (change from baseline) at 24 weeks"
"CD013614_pub2_data","Analysis.name","Number of patients with serious adverse events at any time "
"CD013614_pub2_data","Analysis.name","(OR) Number of patients with serious adverse events at any time "
"CD013614_pub2_data","Analysis.name","Withdrawal due to adverse events"
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks"
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks."
"CD013614_pub2_data","Analysis.name","Enthesitis: resolution as LEI=0 at 12 weeks"
"CD013614_pub2_data","Analysis.name","Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 12 weeks"
"CD013614_pub2_data","Analysis.name","Enthesitis: resolution as LEI=0 at 24 weeks"
"CD013614_pub2_data","Analysis.name","Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 24 weeks."
"CD013614_pub2_data","Analysis.name","Resolution of dactylitis as no dactylitis at 12 weeks"
"CD013614_pub2_data","Analysis.name","Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks."
"CD013614_pub2_data","Analysis.name","Resolution of dactylitis as no dactylitis at 24 weeks"
"CD013614_pub2_data","Analysis.name","Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 24 weeks."
"CD013614_pub2_data","Analysis.name","Improvement in pain as measured by VAS or NRS at week 12."
"CD013614_pub2_data","Analysis.name","Improvement in pain as measured by VAS or NRS at week 24."
"CD013614_pub2_data","Analysis.name","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks."
"CD013614_pub2_data","Analysis.name","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks."
"CD013614_pub2_data","Analysis.name","Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks."
"CD013614_pub2_data","Analysis.name","Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 24 weeks."
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 52 weeks"
"CD013614_pub2_data","Analysis.name","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 52 Weeks"
"CD013614_pub2_data","Analysis.name","Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 52 weeks"
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS) "
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks (SF-36 PCS) "
"CD013614_pub2_data","Analysis.name","Radiographic progression (change from baseline) at 52 weeks"
"CD013614_pub2_data","Analysis.name","Number of patients with serious adverse events at any time"
"CD013614_pub2_data","Analysis.name","(OR) Number of patients with serious adverse events at any time"
"CD013614_pub2_data","Analysis.name","Withdrawal due to adverse events at any time"
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks"
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks"
"CD013614_pub2_data","Analysis.name","Resolution of dactylitis as no dactylitis at 52 weeks"
"CD013614_pub2_data","Analysis.name","Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 52 weeks."
"CD013614_pub2_data","Analysis.name","Improvement in pain as measured by VAS or NRS at week 52."
"CD013614_pub2_data","Analysis.name","Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 52 weeks"
"CD013614_pub2_data","Analysis.name","Proportion of patients achieving MCID in HAQ at 12 weeks"
"CD013614_pub2_data","Analysis.name","Proportion of patients achieving MCID in HAQ at 24 weeks"
"CD013614_pub2_data","Analysis.name","Proportion of patients achieving MCID in HAQ at 52 weeks"
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS). "
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks (SF-36 MCS). "
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks (SF-36 PCS). "
"CD013614_pub2_data","Analysis.name","Enthesitis: resolution as LEI=0 at 52 weeks"
"CD013614_pub2_data","Analysis.name","Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 52 weeks."
"CD013614_pub2_data","Analysis.name","Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 52 weeks."
"CD013614_pub2_data","Analysis.name","Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 52 weeks."
"CD013614_pub2_data","Analysis.name","MCID in HAQ proportion of patients at 52 weeks"
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks. (SF-36 MCS). "
"CD013614_pub2_data","Analysis.name","Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks. (SF-36 PCS). "
"CD013614_pub2_data","Analysis.name","Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 12 weeks."
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks."
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks stratified for sex"
"CD013614_pub2_data","Analysis.name","Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks stratified for sex"
"CD013614_pub2_data","Analysis.name","Number of patients with serious adverse events at any time stratified for sex"
"CD013614_pub2_data","Subgroup","Adalimumab vs Placebo"
"CD013614_pub2_data","Subgroup","Certolizumab pegol vs Placebo"
"CD013614_pub2_data","Subgroup","Etanercept vs Placebo"
"CD013614_pub2_data","Subgroup","Golimumab vs Placebo"
"CD013614_pub2_data","Subgroup","Infliximab vs Placebo"
"CD013614_pub2_data","Subgroup","Etanercept (+ Methotrexate) vs Methotrexate "
"CD013614_pub2_data","Subgroup","Etanercept vs Methotrexate"
"CD013614_pub2_data","Subgroup","Golimumab (+ Methotrexate) vs Methotrexate"
"CD013614_pub2_data","Subgroup","Infliximab (+ Methotrexate) vs Methotrexate"
"CD013614_pub2_data","Subgroup","Etanercept (+MTX) vs Methotrexate"
"CD013614_pub2_data","Subgroup","Etanercept (+ Methotrexate) vs  Methotrexate"
"CD013614_pub2_data","Subgroup","Etanercept (+ Methotrexate) vs Methotrexate"
"CD013614_pub2_data","Subgroup","Golimumab (+ Methotreate) vs Methotrexate "
"CD013614_pub2_data","Subgroup","Etanercept (+Methotrexate) vs Methotrexate "
"CD013614_pub2_data","Subgroup","Golimumab (+Methotrexate) vs Methotrexate"
"CD013614_pub2_data","Subgroup","Golimumab (+ Methotrexate) vs Methotrexate (+ Placebo)"
"CD013614_pub2_data","Subgroup","Etanercept (+ Methotrexate vs Methotrexate)"
"CD013614_pub2_data","Subgroup","Etenercept (+ Methotrexate) vs Methotrexate"
"CD013614_pub2_data","Subgroup","Infliximab (+ Methotrexate) vs Methotrexate (+ Placebo)"
"CD013614_pub2_data","Subgroup","Etanercept (+ Methotrexate) vs csDMARDs"
"CD013614_pub2_data","Subgroup","Infliximab (+Methotrexate) vs Methotrexate"
"CD013614_pub2_data","Subgroup","Etanercept vs Ustekinumab"
"CD013614_pub2_data","Subgroup","Adalimumab vs Ixekizumab"
"CD013614_pub2_data","Subgroup","Adalimumab vs Secukinumab"
"CD013614_pub2_data","Subgroup","Adalimumab vs Bimekizumab"
"CD013614_pub2_data","Subgroup","TNFi vs Ustekinumab"
"CD013614_pub2_data","Subgroup","Adalimumab vs bimekizumab"
"CD013614_pub2_data","Subgroup","Adalimumab vs Ixekiumab"
"CD013614_pub2_data","Subgroup","Adalimumab vs Tofacitinib"
"CD013614_pub2_data","Subgroup","Adalimumab vs Upadacitinib"
"CD013614_pub2_data","Subgroup","Golimumab vs Placebo in female patients"
"CD013614_pub2_data","Subgroup","Golimumab vs Placebo in male patients"
"CD013631_pub2_data","Analysis.group","1"
"CD013631_pub2_data","Analysis.group","2"
"CD013631_pub2_data","Analysis.group","3"
"CD013631_pub2_data","Analysis.group","4"
"CD013631_pub2_data","Analysis.group","5"
"CD013631_pub2_data","Analysis.group","6"
"CD013631_pub2_data","Analysis.group","7"
"CD013631_pub2_data","Analysis.group","8"
"CD013631_pub2_data","Analysis.name","Patient-reported outcomes: HRQoL at 12 weeks"
"CD013631_pub2_data","Analysis.name","Kidney function: eGFR at 4 weeks"
"CD013631_pub2_data","Analysis.name","Kidney function: serum creatinine at 8 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: urea at 4 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: indoxyl sulfate at 4 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: p-cresol sulfate at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: change in any GI upset or intolerance (prevalence of borborygmi) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: change in any GI upset or intolerance (GSRS Total Index at 12 months)"
"CD013631_pub2_data","Analysis.name","GI function: faecal pH at 7 weeks"
"CD013631_pub2_data","Analysis.name","GI function: faecal characteristics (Bristol Stool Chart) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: faecal characteristics (Bristol Stool Chart) at 12 months"
"CD013631_pub2_data","Analysis.name","Patient-reported outcomes: HRQoL at 24 weeks"
"CD013631_pub2_data","Analysis.name","Adverse events: any adverse event"
"CD013631_pub2_data","Analysis.name","Withdrawals due to adverse events"
"CD013631_pub2_data","Analysis.name","Kidney function: eGFR at 12 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: indoxyl sulfate at 6 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: p-cresol sulfate at 6 weeks"
"CD013631_pub2_data","Analysis.name","GI function: change in any GI upset or intolerance (burping) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: change in any GI upset or intolerance (cramping) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: change in any GI upset or intolerance (distension) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: change in any GI upset or intolerance (flatulence) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: change in any GI upset or intolerance (nausea) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: change in any GI upset or intolerance (reflux) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: change in any GI upset or intolerance (rumblings) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Actinobacteria) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Bacteriodetes) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Proteobacteria) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Firmicutes) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Synergistetes) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Verrucomicrobia) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (faecal acetate) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (faecal propionate) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (faecal butyrate) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (faecal total short-chain fatty acids) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (faecal indoles) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (faecal p-cresol) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: faecal characteristics (bowel movements) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: faecal characteristics (ease of passage) at 4 weeks"
"CD013631_pub2_data","Analysis.name","GI function: faecal characteristics (consistency) at 4 weeks"
"CD013631_pub2_data","Analysis.name","Adverse events: number participants reporting an event"
"CD013631_pub2_data","Analysis.name","Dialysis outcomes: peritonitis at 24 weeks"
"CD013631_pub2_data","Analysis.name","Kidney function: GFR at 8 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: urea at 8 weeks"
"CD013631_pub2_data","Analysis.name","Kidney function: eGFR at 6 or 12 weeks"
"CD013631_pub2_data","Analysis.name","Kidney function: SrCr at 6 or 12 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: urea at 6 or 12 weeks"
"CD013631_pub2_data","Analysis.name","GI function: GSRS Item 6 (rumbling) at 12 weeks"
"CD013631_pub2_data","Analysis.name","GI function: GSRS Item 13 (hard stools) at 12 weeks"
"CD013631_pub2_data","Analysis.name","GI function: abdominal pain at 12 weeks"
"CD013631_pub2_data","Analysis.name","GI function: constipation syndrome at 12 weeks"
"CD013631_pub2_data","Analysis.name","Kidney function: serum creatinine at 8 or 12 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: urea at 12 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: indoxyl sulfate at 8 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: p-cresyl sulfate at 8 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Facealibacterium) at 8 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Parabacteroides) at 8 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Bifidobacteria) at 8 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Ruminococcus) at 8 weeks"
"CD013631_pub2_data","Analysis.name","GI function: microbiota composition (Prevotella) at 8 weeks"
"CD013631_pub2_data","Analysis.name","Adverse events: any adverse event (number of participants)"
"CD013631_pub2_data","Analysis.name","Kidney function: GFR at 8, 12 or 15 weeks"
"CD013631_pub2_data","Analysis.name","Kidney function: serum creatinine at 8, 12 or 24 weeks"
"CD013631_pub2_data","Analysis.name","Kidney function: albuminuria at 12 or 24 weeks"
"CD013631_pub2_data","Analysis.name","Kidney function: proteinuria at 12 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: urea at 12 or 24 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: indoxyl sulfate at 12 or 24 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: p-cresyl sulfate at 4, 12 or 24 weeks"
"CD013631_pub2_data","Analysis.name","Uraemic toxins: indole-3-acetic acid acid at 12 weeks"
"CD013631_pub2_data","Analysis.name","GI function: any GI upset or intolerance (abdominal pain/diarrhoea) at 12 weeks"
"CD013631_pub2_data","Analysis.name","GI function: any GI upset or intolerance (constipation) at 12 weeks"
"CD013631_pub2_data","Analysis.name","GI function: faecal pH at 12 weeks"
"CD013631_pub2_data","Subgroup","CKD stage G5D with diabetes and hypertension"
"CD013631_pub2_data","Subgroup","CKD stage 3Ga (transplant)"
"CD013631_pub2_data","Subgroup","CKD stage G5D"
"CD013631_pub2_data","Subgroup","CKD Stage 3 to 4"
"CD013631_pub2_data","Subgroup","CKD stage 3 to 4"
"CD013631_pub2_data","Subgroup","CKD stage G3a (transplant)"
"CD013631_pub2_data","Subgroup","CKD stage 5GD"
"CD013631_pub2_data","Subgroup","CKD stage 3 to 5 (non-dialysis)"
"CD013631_pub2_data","Subgroup","CKD stage G5D with diabetes"
"CD013631_pub2_data","Subgroup","CKD stage G3 to G4"
"CD013631_pub2_data","Subgroup","CKD stage G3b"
"CD013631_pub2_data","Subgroup","CKD stage 3b"
"CD013631_pub2_data","Subgroup","CKD stage A2 with diabetic nephropathy"
"CD013631_pub2_data","Subgroup","CKD stage 3A with diabetes and hypertension"
"CD013631_pub2_data","Subgroup","CKD stage 1 and type 2 diabetes"
"CD013631_pub2_data","Subgroup","Diabetic nephropathy all CKD stages"
"CD013643_pub2_data","Analysis.group","1"
"CD013643_pub2_data","Analysis.group","2"
"CD013643_pub2_data","Analysis.name","Number of continent women (objective measure as reported by the trialists), short term (< 1 year)"
"CD013643_pub2_data","Analysis.name","Number of continent women (objective measure as reported by the trialists), medium term (1 to 5 years)"
"CD013643_pub2_data","Analysis.name","Improvement in patient-reported incontinence, short term (< 1 year)"
"CD013643_pub2_data","Analysis.name","Improvement in patient-reported incontinence, medium term (1 to 5 years)"
"CD013643_pub2_data","Analysis.name","Number of major adverse events (Clavien-Dindo III-V), short term (< 1 year)"
"CD013643_pub2_data","Analysis.name","Number of continent women by patient-reported measures, short term (< 1 year)"
"CD013643_pub2_data","Analysis.name","Number of continent women by patient-reported measures, medium term (1 to 5 years)"
"CD013643_pub2_data","Analysis.name","Improvement in incontinence-specific quality of life, short term (< 1 year)"
"CD013643_pub2_data","Analysis.name","Improvement in incontinence-specific quality of life, medium term (1 to 5 years)"
"CD013643_pub2_data","Analysis.name","Improvement in clinical measures of urinary incontinence (mean number of voids on 3-day voiding diary), short term (< 1 year)"
"CD013643_pub2_data","Analysis.name","Improvement in clinical measures of urinary incontinence (mean number of voids on 3-day voiding diary), medium term (1 to 5 years)"
"CD013643_pub2_data","Analysis.name","Improvement in patient-reported sexual function, short term (< 1 year)"
"CD013643_pub2_data","Analysis.name","Improvement in patient-reported sexual function, medium term (1 to 5 years)"
"CD013643_pub2_data","Analysis.name","Number of minor adverse events (Clavien-Dindo I, II), short term (< 1 year) "
"CD013643_pub2_data","Analysis.name","Number of minor adverse events (Clavien-Dindo I, II), short term (< 1 year)"
"CD013643_pub2_data","Subgroup","CO2 Laser"
"CD013643_pub2_data","Subgroup","Er:YAG Laser"
"CD013643_pub2_data","Subgroup","ER: YAG"
"CD013643_pub2_data","Subgroup","ER:YAG Laser"
"CD013672_pub2_data","Analysis.group","1"
"CD013672_pub2_data","Analysis.group","2"
"CD013672_pub2_data","Analysis.group","3"
"CD013672_pub2_data","Analysis.group","4"
"CD013672_pub2_data","Analysis.name","Treatment retention"
"CD013672_pub2_data","Analysis.name","Treatment retention, subgroup analysis: buprenorphine versus methadone"
"CD013672_pub2_data","Analysis.name","Treatment retention, subgroup analysis: single provider primary care setting versus availability of a primary care team"
"CD013672_pub2_data","Analysis.name","Treatment retention, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care"
"CD013672_pub2_data","Analysis.name","Treatment retention, subgroup analysis: DSM diagnostic criteria used versus DSM diagnostic criteria not used"
"CD013672_pub2_data","Analysis.name","Abstinence from non-prescribed opioids"
"CD013672_pub2_data","Analysis.name","Abstinence from non-prescribed opioids, subgroup analysis: buprenorphine versus methadone"
"CD013672_pub2_data","Analysis.name","Abstinence from non-prescribed opioids, subgroup analysis: single-provider primary care settings versus availability of a primary care team"
"CD013672_pub2_data","Analysis.name","Abstinence from non-prescribed opioids, subgroup analysis: maintenance of existing OAT versus initiation of OAT in primary care"
"CD013672_pub2_data","Analysis.name","Abstinence from non-prescribed opioids, subgroup analysis: DSM diagnostic criteria used versus DSM diagnostic criteria not used"
"CD013672_pub2_data","Analysis.name","Major adverse events"
"CD013672_pub2_data","Analysis.name","Quality of life"
"CD013672_pub2_data","Subgroup","Buprenorphine maintenance"
"CD013672_pub2_data","Subgroup","Methadone maintenance"
"CD013672_pub2_data","Subgroup","Single-provider treatment settings"
"CD013672_pub2_data","Subgroup","Team-based treatment settings"
"CD013672_pub2_data","Subgroup","OAT maintenance in primary care"
"CD013672_pub2_data","Subgroup","OAT initiation in primary care"
"CD013672_pub2_data","Subgroup","Using DSM criteria to identify patients"
"CD013672_pub2_data","Subgroup","No mention of DSM criteria"
"CD013707_pub2_data","Analysis.group","1"
"CD013707_pub2_data","Analysis.group","2"
"CD013707_pub2_data","Analysis.group","3"
"CD013707_pub2_data","Analysis.name","All-cause mortality within 30 days"
"CD013707_pub2_data","Analysis.name","Low cardiac output syndrome"
"CD013707_pub2_data","Analysis.name","Length of intensive care stay"
"CD013707_pub2_data","Analysis.name","Length of hospital stay"
"CD013707_pub2_data","Analysis.name","Duration of mechanical ventilation"
"CD013707_pub2_data","Analysis.name","Inotrope score"
"CD013707_pub2_data","Analysis.name","Number of patients requiring mechanical circulatory support"
"CD013707_pub2_data","Analysis.name","Arrhythmia"
"CD013707_pub2_data","Analysis.name","Hypokalaemia"
"CD013707_pub2_data","Analysis.name","Reduced left ventricular ejection fraction (< 50%) or shortening fraction (< 28%)"
"CD013707_pub2_data","Analysis.name","Renal failure requiring replacement therapy"
"CD013707_pub2_data","Analysis.name","Hypotension"
"CD013707_pub2_data","Analysis.name","Thrombocytopaenia"
"CD013715_pub2_data","Analysis.group","1"
"CD013715_pub2_data","Analysis.group","2"
"CD013715_pub2_data","Analysis.name","PedACR70 at up to 16 weeks "
"CD013715_pub2_data","Analysis.name","PedACR70 at 17 to 26 weeks"
"CD013715_pub2_data","Analysis.name","PedACR70 at 27 to 52 weeks "
"CD013715_pub2_data","Analysis.name","Pain at up to 16 weeks "
"CD013715_pub2_data","Analysis.name","Pain at 17 to 26 weeks "
"CD013715_pub2_data","Analysis.name","Mean CHAQ at up to 16 weeks "
"CD013715_pub2_data","Analysis.name","Participant global assessment of disease activity at up to 16 weeks "
"CD013715_pub2_data","Analysis.name","Participant global assessment of disease activity at 27 to 52 weeks "
"CD013715_pub2_data","Analysis.name","Disease remission at 17 to 26 weeks "
"CD013715_pub2_data","Analysis.name","Disease remission at 27 to 52 weeks "
"CD013715_pub2_data","Analysis.name","Withdrawals due to adverse events at up to 16 weeks"
"CD013715_pub2_data","Analysis.name","Withdrawals due to adverse events at 17 to 26 weeks"
"CD013715_pub2_data","Analysis.name","Withdrawals due to adverse events at 27 to 52 weeks"
"CD013715_pub2_data","Analysis.name","Withdrawals due to adverse events at end of study"
"CD013715_pub2_data","Analysis.name","Serious adverse events at up to 16 weeks"
"CD013715_pub2_data","Analysis.name","Serious adverse events at 17 to 26 weeks"
"CD013715_pub2_data","Analysis.name","Serious adverse events at 27 to 52 weeks"
"CD013715_pub2_data","Analysis.name","Serious adverse events at the end of study"
"CD013715_pub2_data","Analysis.name","PedACR50 at up to 16 weeks "
"CD013715_pub2_data","Analysis.name","PedACR50 at 17 to 26 weeks"
"CD013715_pub2_data","Analysis.name","PedACR50 at 27 to 52 weeks "
"CD013715_pub2_data","Analysis.name","Total adverse events"
"CD013715_pub2_data","Analysis.name","Sensitivity analysis: pedACR70 at the latest time point"
"CD013715_pub2_data","Analysis.name","PedACR70 at up to 16 weeks"
"CD013715_pub2_data","Analysis.name","PedACR70 at up to 52 weeks"
"CD013715_pub2_data","Analysis.name","Remission at up 16 weeks"
"CD013715_pub2_data","Analysis.name","Remission at 17 to 26 weeks"
"CD013715_pub2_data","Analysis.name","Remission at up to 52 weeks"
"CD013715_pub2_data","Analysis.name","Withdrawals due to adverse events up to 26 weeks"
"CD013715_pub2_data","Analysis.name","Withdrawals due to adverse events up to 52 weeks"
"CD013715_pub2_data","Analysis.name","Withdrawals due to adverse events at any time"
"CD013715_pub2_data","Analysis.name","Serious adverse events up to 26 weeks"
"CD013715_pub2_data","Analysis.name","Serious adverse events up to 52 weeks"
"CD013715_pub2_data","Analysis.name","Serious adverse events at any time"
"CD013715_pub2_data","Analysis.name","PedACR50 at up to 16 weeks"
"CD013715_pub2_data","Analysis.name","PedACR50 at up to 52 weeks"
"CD013715_pub2_data","Analysis.name","Health economics concerning the estimation of direct costs of the treatment"
"CD013715_pub2_data","Subgroup","Adalimumab vs Placebo"
"CD013715_pub2_data","Subgroup","Infliximab vs Placebo"
"CD013715_pub2_data","Subgroup","Etanercept vs Placebo"
"CD013715_pub2_data","Subgroup","Golimumab vs Placebo"
"CD013715_pub2_data","Subgroup","Etanercept"
"CD013715_pub2_data","Subgroup","Adalimumab"
"CD013715_pub2_data","Subgroup","Infliximab "
"CD013715_pub2_data","Subgroup","Golimumab"
"CD013715_pub2_data","Subgroup","Infliximab"
"CD013715_pub2_data","Subgroup","Adalimumab vs Placebo "
"CD013715_pub2_data","Subgroup","Adalimumab vs placebo"
"CD013715_pub2_data","Subgroup","Etanercept vs placebo"
"CD013715_pub2_data","Subgroup","Infliximab vs placebo"
"CD013715_pub2_data","Subgroup","Golimumab vs placebo"
"CD013715_pub2_data","Subgroup","IFX+MTX vs MTX"
"CD013715_pub2_data","Subgroup","ETN+MTX vs MTX+PBO"
"CD013715_pub2_data","Subgroup","Etanercept (+ Methotrexate) vs Methotrexate"
"CD013715_pub2_data","Subgroup","IFX (+Methotrexate) vs Methotrexate"
"CD013715_pub2_data","Subgroup","Infliximab + MTX vs MTX"
"CD013715_pub2_data","Subgroup","Infliximab (+ Methotrexate) vs Methotrexate"
"CD013715_pub2_data","Subgroup","Total medication costs original infliximab"
"CD013715_pub2_data","Subgroup","Total costs Intra-articular injections"
"CD013715_pub2_data","Subgroup","Total health care costs original infliximab"
"CD013715_pub2_data","Subgroup","Costs for health care outpatient visits"
"CD013715_pub2_data","Subgroup","Total costs Intra-venous administration"
"CD013715_pub2_data","Subgroup","Costs for check-up and imaging"
"CD013715_pub2_data","Subgroup","Total health care costs biosimilar infliximab"
"CD013715_pub2_data","Subgroup","Total medication costs biosimilar infliximab"
"CD013715_pub2_data","Subgroup","Etanercept+MTX vs MTX+ placebo"
"CD013719_pub2_data","Analysis.group","1"
"CD013719_pub2_data","Analysis.group","2"
"CD013719_pub2_data","Analysis.group","3"
"CD013719_pub2_data","Analysis.group","4"
"CD013719_pub2_data","Analysis.group","5"
"CD013719_pub2_data","Analysis.group","6"
"CD013719_pub2_data","Analysis.group","7"
"CD013719_pub2_data","Analysis.group","8"
"CD013719_pub2_data","Analysis.group","9"
"CD013719_pub2_data","Analysis.group","10"
"CD013719_pub2_data","Analysis.group","11"
"CD013719_pub2_data","Analysis.group","12"
"CD013719_pub2_data","Analysis.group","13"
"CD013719_pub2_data","Analysis.name","Short-term hair regrowth ≥ 75%"
"CD013719_pub2_data","Analysis.name","Incidence of serious adverse events"
"CD013719_pub2_data","Analysis.name","Health-related quality of life"
"CD013719_pub2_data","Analysis.name","Long-term hair regrowth ≥ 75%"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Oral classical immunosuppressants vs placebo: short-term hair regrowth"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Betamethasone vs azathioprine or prednisolone: short-term hair regrowth"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Intralesional classical immunosuppressants vs placebo: short-term hair regrowth"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Subcutaneous biologics vs placebo: short-term hair regrowth"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Oral small molecule inhibitors: baricitinib vs placebo"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Oral small molecule inhibitors: ruxolitinib vs tofacitinib"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Topical small molecule inhibitors: short-term hair regrowth"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Contact immunotherapy vs placebo: short-term hair regrowth"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Contact immunotherapy vs minoxidil: short-term hair regrowth"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Contact immunotherapy + hair growth stimulants vs contact immunotherapy: short term hair regrowth"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Topical hair growth stimulants vs placebo: short-term hair-regrowth"
"CD013719_pub2_data","Analysis.name","Sensitivity analysis. Cryotherapy vs fractional CO2 laser: short-term hair regrowth"
"CD013719_pub2_data","Subgroup","Short-term hair regrowth"
"CD013719_pub2_data","Subgroup","Long-term hair regrowth"
"CD013726_pub2_data","Analysis.group","1"
"CD013726_pub2_data","Analysis.group","2"
"CD013726_pub2_data","Analysis.group","3"
"CD013726_pub2_data","Analysis.name","Pain"
"CD013726_pub2_data","Analysis.name","Function"
"CD013726_pub2_data","Analysis.name","Quality of life"
"CD013726_pub2_data","Analysis.name","Participant global assessment of treatment success"
"CD013726_pub2_data","Analysis.name","Reoperation (treatment failure)"
"CD013726_pub2_data","Analysis.name","Adverse events"
"CD013726_pub2_data","Analysis.name","Serious adverse events"
"CD013726_pub2_data","Analysis.name","Radiological measurement of the hallux valgus angle"
"CD013726_pub2_data","Subgroup","Mild to moderate (intermetatarsal angle < 16 degrees)"
"CD013726_pub2_data","Subgroup","Mild to severe (any preoperative intermetatarsal angle)"
"CD013726_pub2_data","Subgroup","Moderate to severe (intermetatarsal angle > 12 degrees)"
"CD013726_pub2_data","Subgroup","Moderate to severe (hallux valgus angle > 20 degrees)"
"CD013729_pub2_data","Analysis.group","1"
"CD013729_pub2_data","Analysis.group","2"
"CD013729_pub2_data","Analysis.group","3"
"CD013729_pub2_data","Analysis.name","Change in systolic blood pressure (medium-term follow-up)"
"CD013729_pub2_data","Analysis.name","Change in systolic blood pressure: sensitivity analysis (low risk of bias for random sequence generation, allocation concealment, and incomplete outcome data)"
"CD013729_pub2_data","Analysis.name","Change in diastolic blood pressure (medium-term follow-up)"
"CD013729_pub2_data","Analysis.name","Change in total cholesterol (medium-term follow-up)"
"CD013729_pub2_data","Analysis.name","Change in low-density lipoprotein (LDL) cholesterol (medium-term follow-up)"
"CD013729_pub2_data","Analysis.name","Change in high-density lipoprotein (HDL) cholesterol (medium-term follow-up)"
"CD013729_pub2_data","Analysis.name","Change in triglycerides (medium-term follow-up)"
"CD013729_pub2_data","Analysis.name","Myocardial infarction (medium-term follow-up)"
"CD013729_pub2_data","Analysis.name","Change in systolic blood pressure (long-term follow-up)"
"CD013729_pub2_data","Analysis.name","Change in diastolic blood pressure (long-term follow-up)"
"CD013729_pub2_data","Analysis.name","Change in health-related quality of life (medium-term follow-up)"
"CD013729_pub2_data","Analysis.name","Change in health-related quality of life (long-term follow-up)"
"CD013729_pub2_data","Analysis.name","Adverse effects (medium-term follow-up)"
"CD013729_pub2_data","Analysis.name","All-cause mortality (medium-term follow-up)"
"CD013731_pub2_data","Analysis.group","1"
"CD013731_pub2_data","Analysis.group","2"
"CD013731_pub2_data","Analysis.group","3"
"CD013731_pub2_data","Analysis.group","4"
"CD013731_pub2_data","Analysis.group","5"
"CD013731_pub2_data","Analysis.group","6"
"CD013731_pub2_data","Analysis.name","Overall survival at censored observation (measured at end of treatment, i.e. 20 months)"
"CD013731_pub2_data","Analysis.name","Serious adverse events (Intention-to-treat) (measured at end of treatment, i.e. 20 months)"
"CD013731_pub2_data","Analysis.name","Disease progression (measured at end of treatment, i.e. 20 months)"
"CD013731_pub2_data","Analysis.name","Any adverse events considered non-serious (number of participants) (during 20 months of  treatment)"
"CD013731_pub2_data","Analysis.name","All-cause mortality (measured at 1-year follow-up)"
"CD013731_pub2_data","Analysis.name","All-cause mortality (measured at 2-year follow-up)"
"CD013731_pub2_data","Analysis.name","Any adverse events considered non-serious (number of participants)"
"CD013731_pub2_data","Analysis.name","All-cause mortality (measured at 3-year follow-up)"
"CD013731_pub2_data","Analysis.name","All-cause mortality (measured at 5-year follow-up) (primary time point)"
"CD013731_pub2_data","Analysis.name","Overall survival (measured at 6 months)"
"CD013731_pub2_data","Analysis.name","Overall survival (measured at 12 months)"
"CD013731_pub2_data","Analysis.name","Disease progression (measured at 6 months)"
"CD013731_pub2_data","Analysis.name","Disease progression at median 12.8 months"
"CD013731_pub2_data","Analysis.name","Disease progression at 2 weeks"
"CD013731_pub2_data","Analysis.name","Any adverse events considered non-serious (number of events)"
"CD013731_pub2_data","Analysis.name","Proportion of people without improvement in liver function tests at 2 weeks"
"CD013745_pub2_data","Analysis.group","1"
"CD013745_pub2_data","Analysis.group","2"
"CD013745_pub2_data","Analysis.group","3"
"CD013745_pub2_data","Analysis.group","4"
"CD013745_pub2_data","Analysis.group","5"
"CD013745_pub2_data","Analysis.group","6"
"CD013745_pub2_data","Analysis.group","7"
"CD013745_pub2_data","Analysis.group","8"
"CD013745_pub2_data","Analysis.group","9"
"CD013745_pub2_data","Analysis.name","Rivaroxaban versus antiplatelet therapy"
"CD013745_pub2_data","Analysis.name","Apixaban versus antiplatelet therapy"
"CD013745_pub2_data","Analysis.name","Edoxaban versus antiplatelet therapy"
"CD013745_pub2_data","Analysis.name","NOACs versus antiplatelet therapy"
"CD013745_pub2_data","Analysis.name","Apixaban versus VKA"
"CD013745_pub2_data","Analysis.name","Edoxaban versus VKA"
"CD013745_pub2_data","Analysis.name","NOACs versus VKA"
"CD013748_pub2_data","Analysis.group","1"
"CD013748_pub2_data","Analysis.group","2"
"CD013748_pub2_data","Analysis.name","Poor functional outcome"
"CD013748_pub2_data","Analysis.name","Case fatality"
"CD013748_pub2_data","Analysis.name","Haemorrhagic complications"
"CD013748_pub2_data","Analysis.name","Cerebral artery vasospasm"
"CD013748_pub2_data","Analysis.name","Delayed cerebral ischaemia"
"CD013748_pub2_data","Analysis.name","Cerebral infarction"
"CD013748_pub2_data","Analysis.name","Hydrocephalus"
"CD013757_pub3_data","Analysis.group","1"
"CD013757_pub3_data","Analysis.name","Hospitalisation due to RSV infection"
"CD013757_pub3_data","Analysis.name","Mortality"
"CD013757_pub3_data","Analysis.name","Adverse events"
"CD013757_pub3_data","Analysis.name","Hospitalisation due to respiratory‐related illness"
"CD013757_pub3_data","Analysis.name","Subgroup analysis: hospitalisation due to respiratory‐related illness"
"CD013757_pub3_data","Analysis.name","Length of hospital stay"
"CD013757_pub3_data","Analysis.name","RSV infection"
"CD013757_pub3_data","Analysis.name","Days of supplemental oxygen"
"CD013757_pub3_data","Analysis.name","Intensive care unit length of stay"
"CD013757_pub3_data","Analysis.name","Mechanical ventilation days"
"CD013757_pub3_data","Subgroup","Systemic (intramuscular/intravenous)"
"CD013757_pub3_data","Subgroup","Intranasal"
"CD013757_pub3_data","Subgroup","High-income countries"
"CD013757_pub3_data","Subgroup","Low- and middle-income countries"
"CD013758_pub2_data","Analysis.group","1"
"CD013758_pub2_data","Analysis.group","2"
"CD013758_pub2_data","Analysis.name","Underweight (weight-for-age z-score)"
"CD013758_pub2_data","Analysis.name","Underweight (weight-for-age z-score): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","Stunting (height-for-age z-score)"
"CD013758_pub2_data","Analysis.name","Stunting (height-for-age z-score): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","Wasting (weight-for-height z-score)"
"CD013758_pub2_data","Analysis.name","Wasting (weight-for-height z-score): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","Overweight"
"CD013758_pub2_data","Analysis.name","Overweight (formula with complementary foods): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","Obesity"
"CD013758_pub2_data","Analysis.name","Obesity (formula with complementary foods): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","Any adverse event"
"CD013758_pub2_data","Analysis.name","Adverse events (sole feeding method)"
"CD013758_pub2_data","Analysis.name","Adverse events (formula with complementary foods)"
"CD013758_pub2_data","Analysis.name","Weight (kg)"
"CD013758_pub2_data","Analysis.name","Weight (kg): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","Height (cm)"
"CD013758_pub2_data","Analysis.name","Height (cm): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","BMI (z-score)"
"CD013758_pub2_data","Analysis.name","BMI (z-score): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","BMI (kg/m2)"
"CD013758_pub2_data","Analysis.name","BMI (kg/m2): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","Head circumference (z-score)"
"CD013758_pub2_data","Analysis.name","Head circumference (z-score): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","Head circumference (cm)"
"CD013758_pub2_data","Analysis.name","Head circumference (cm): subgroup analysis by duration of treatment"
"CD013758_pub2_data","Analysis.name","Adverse events: subgroup analysis by type"
"CD013758_pub2_data","Subgroup","Sole feeding method"
"CD013758_pub2_data","Subgroup","With complementary foods"
"CD013758_pub2_data","Subgroup","2 months"
"CD013758_pub2_data","Subgroup","4 months"
"CD013758_pub2_data","Subgroup","6 months"
"CD013758_pub2_data","Subgroup","> 5 years"
"CD013758_pub2_data","Subgroup","1 year"
"CD013758_pub2_data","Subgroup","5 years"
"CD013758_pub2_data","Subgroup","2 years"
"CD013758_pub2_data","Subgroup","8 years"
"CD013758_pub2_data","Subgroup","11 years"
"CD013758_pub2_data","Subgroup","Milk hypersensitivity"
"CD013758_pub2_data","Subgroup","Vomiting"
"CD013758_pub2_data","Subgroup","Diarrhea"
"CD013758_pub2_data","Subgroup","3 years"
"CD013758_pub2_data","Subgroup","3years"
"CD013763_pub3_data","Analysis.group","1"
"CD013763_pub3_data","Analysis.group","2"
"CD013763_pub3_data","Analysis.group","3"
"CD013763_pub3_data","Analysis.group","4"
"CD013763_pub3_data","Analysis.group","5"
"CD013763_pub3_data","Analysis.group","6"
"CD013763_pub3_data","Analysis.group","7"
"CD013763_pub3_data","Analysis.group","8"
"CD013763_pub3_data","Analysis.group","9"
"CD013763_pub3_data","Analysis.group","10"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS)"
"CD013763_pub3_data","Analysis.name","Rates of block-related adverse events"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity during activity (24 hours postoperatively) (VAS)"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity at rest - 2 hours (VAS)"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity at rest - 48 hours (VAS)"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity during activity - 2 hours (VAS)"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity during activity - 48 hours (VAS)"
"CD013763_pub3_data","Analysis.name","Rate of chronic post-surgical pain after 3 months"
"CD013763_pub3_data","Analysis.name","Rate of chronic post-surgical pain after 6 months"
"CD013763_pub3_data","Analysis.name","Cumulative mean oral morphine requirement in mg - 2 hours"
"CD013763_pub3_data","Analysis.name","Cumulative mean oral morphine requirement in mg - 24 hours"
"CD013763_pub3_data","Analysis.name","Cumulative mean oral morphine requirement in mg - 48 hours"
"CD013763_pub3_data","Analysis.name","Rates of opioid-related adverse events (PONV)"
"CD013763_pub3_data","Analysis.name","Rates of opioid-related adverse events (pruritus)"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity at rest - 48 hours"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity during activity - 2 hours"
"CD013763_pub3_data","Analysis.name","Rates of block-related adverse outcomes"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity during activity (24 hours postoperatively)"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of surgery"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Type of local anaesthetic"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Volume of local anaesthetic"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Fixed multimodal analgesia"
"CD013763_pub3_data","Analysis.name","Mean difference in postoperative pain intensity at rest (24 hours postoperatively) (VAS) - Baseline non-opioid analgesia"
"CD013763_pub3_data","Subgroup","Spine surgery"
"CD013763_pub3_data","Subgroup","Abdominal surgery"
"CD013763_pub3_data","Subgroup","Breast surgery"
"CD013763_pub3_data","Subgroup","Hip surgery"
"CD013763_pub3_data","Subgroup","Thoracic surgery"
"CD013763_pub3_data","Subgroup","Bupivacaine 0.25% to 0.5%"
"CD013763_pub3_data","Subgroup","Ropivacaine 0.3% to 0.5%"
"CD013763_pub3_data","Subgroup","15 mL to 19 mL"
"CD013763_pub3_data","Subgroup","20 mL to 24 mL"
"CD013763_pub3_data","Subgroup","25 mL to 30 mL"
"CD013763_pub3_data","Subgroup","Non-opioid + PCA"
"CD013763_pub3_data","Subgroup","Non-opioid + rescue opioids"
"CD013763_pub3_data","Subgroup","No specified multimodal analgesia"
"CD013763_pub3_data","Subgroup","NSAID"
"CD013763_pub3_data","Subgroup","Paracetamol"
"CD013763_pub3_data","Subgroup","Not specified"
"CD013763_pub3_data","Subgroup","Both paracetamol + NSAID"
"CD013764_pub2_data","Analysis.group","1"
"CD013764_pub2_data","Analysis.group","2"
"CD013764_pub2_data","Analysis.name","Successful abortion"
"CD013764_pub2_data","Analysis.name","Continued pregnancy"
"CD013764_pub2_data","Analysis.name","Blood transfusion"
"CD013764_pub2_data","Analysis.name","Hospitalisation"
"CD013764_pub2_data","Analysis.name","Emergency visit"
"CD013764_pub2_data","Analysis.name","Adherence"
"CD013764_pub2_data","Analysis.name","Satisfaction"
"CD013764_pub2_data","Analysis.name","Continuing pregnancy"
"CD013773_pub2_data","Analysis.group","1"
"CD013773_pub2_data","Analysis.name","Refractive error (D)"
"CD013773_pub2_data","Analysis.name","Incidence of myopia"
"CD013773_pub2_data","Analysis.name","Axial length (mm)"
"CD013773_pub2_data","Subgroup","At 1 year"
"CD013773_pub2_data","Subgroup","At 3 years"
"CD013773_pub2_data","Subgroup","At 2 years"
"CD013774_pub2_data","Analysis.group","1"
"CD013774_pub2_data","Analysis.group","2"
"CD013774_pub2_data","Analysis.name","Time to death from any cause"
"CD013774_pub2_data","Analysis.name","Health-related quality of life"
"CD013774_pub2_data","Analysis.name","Adverse events grade 3 to 5"
"CD013774_pub2_data","Analysis.name","Time to disease progression"
"CD013774_pub2_data","Analysis.name","Discontinuation due to adverse events"
"CD013774_pub2_data","Analysis.name","Time to death from any cause – subgroup analysis: atezolizumab vs pembrolizumab vs durvalumab"
"CD013774_pub2_data","Analysis.name","Adverse events grade 3 to 5 – subgroup analysis: atezolizumab vs pembrolizumab vs durvalumab"
"CD013774_pub2_data","Analysis.name","Time to death from any cause – subgroup analysis: ECOG PS of 0 versus 1 versus ≧ 2"
"CD013774_pub2_data","Analysis.name","Time to death from any cause – subgroup analysis: cisplatin-eligible vs cisplatin-ineligible participants"
"CD013774_pub2_data","Analysis.name","Time to death from any cause – subgroup analysis: positive versus negative PD-L1 status"
"CD013774_pub2_data","Analysis.name","Time to death from any cause – subgroup analysis: atezolizumab vs pembrolizumab "
"CD013774_pub2_data","Analysis.name","Health-related quality of life – subgroup analysis: atezolizumab vs pembrolizumab "
"CD013774_pub2_data","Analysis.name","Adverse events grade 3 to 5 – subgroup analysis: atezolizumab vs pembrolizumab "
"CD013774_pub2_data","Analysis.name","Time to death from any cause – subgroup analysis: ECOG PS of 0 versus 1"
"CD013774_pub2_data","Subgroup","atezolizumab"
"CD013774_pub2_data","Subgroup","pembrolizumab"
"CD013774_pub2_data","Subgroup","durvalumab"
"CD013774_pub2_data","Subgroup","ECOG 0"
"CD013774_pub2_data","Subgroup","ECOG 1"
"CD013774_pub2_data","Subgroup","ECOG ≧ 2"
"CD013774_pub2_data","Subgroup","Cisplatin-ineligible"
"CD013774_pub2_data","Subgroup","Cisplatin eligible"
"CD013774_pub2_data","Subgroup","PD-L1 positive (CPS > 10)"
"CD013774_pub2_data","Subgroup","PD-L1 negative (CPS < 10)"
"CD013781_pub2_data","Analysis.group","1"
"CD013781_pub2_data","Analysis.group","2"
"CD013781_pub2_data","Analysis.group","3"
"CD013781_pub2_data","Analysis.group","4"
"CD013781_pub2_data","Analysis.group","5"
"CD013781_pub2_data","Analysis.group","6"
"CD013781_pub2_data","Analysis.group","7"
"CD013781_pub2_data","Analysis.group","8"
"CD013781_pub2_data","Analysis.group","9"
"CD013781_pub2_data","Analysis.group","10"
"CD013781_pub2_data","Analysis.name","Secondary outcome: cardiac index (postoperative nadir)"
"CD013781_pub2_data","Analysis.name","Primary outcome: incidence of LCOS"
"CD013781_pub2_data","Analysis.name","Primary outcome: adverse events - atrial fibrillation"
"CD013781_pub2_data","Analysis.name","Primary outcome: adverse events - perioperative myocardial infarction"
"CD013781_pub2_data","Analysis.name","Secondary outcome: length of hospital stay (days)"
"CD013781_pub2_data","Analysis.name","Secondary outcome: mean arterial pressure (24 hours after surgery)"
"CD013781_pub2_data","Analysis.name","Secondary outcome: duration of mechanical ventilation (hours)"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs - dopamine"
"CD013781_pub2_data","Analysis.name","Secondary outcome: proportion of renal failure"
"CD013781_pub2_data","Analysis.name","Primary outcome: all-cause mortality"
"CD013781_pub2_data","Analysis.name","Primary outcome: adverse events - cardiogenic shock"
"CD013781_pub2_data","Analysis.name","Primary outcome: adverse events - non-embolic stroke or transient ischaemic attack"
"CD013781_pub2_data","Analysis.name","Secondary outcome: length of ICU stay (days)"
"CD013781_pub2_data","Analysis.name","Secondary outcome: cardiac index"
"CD013781_pub2_data","Analysis.name","Secondary outcome: mean arterial pressure"
"CD013781_pub2_data","Analysis.name","Secondary outcome: PCWP"
"CD013781_pub2_data","Analysis.name","Secondary outcome: proportion of weaning failure within 48 hours of extubation"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring mechanical circulatory support"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs - epinephrine"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs - norepinephrine"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs - dobutamine"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs - phenylephrine"
"CD013781_pub2_data","Analysis.name","Secondary analysis: cardiac index"
"CD013781_pub2_data","Analysis.name","Secondary analysis: PCWP"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring  additional inotropic drugs"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring cardiac transplantation"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring cardiopulmonary resuscitation"
"CD013781_pub2_data","Analysis.name","Primary outcome: adverse events - non-embolic stroke or transient ischaemic attack "
"CD013781_pub2_data","Analysis.name","Secondary outcome: proportion of weaning failure within 48 hours after extubation"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs - enoximone"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs - milrinone"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs - nitroprusside"
"CD013781_pub2_data","Analysis.name","Secondary outcome: number of participants requiring additional inotropic drugs - ephedrine"
"CD013781_pub2_data","Analysis.name","Secondary outcome: proportion of renal failure "
"CD013781_pub2_data","Analysis.name","Adverse event: atrial fibrillation"
"CD013781_pub2_data","Analysis.name","All-cause mortality"
"CD013781_pub2_data","Analysis.name","Incidence of LCOS"
"CD013781_pub2_data","Analysis.name","Adverse events: atrial fibrillation"
"CD013781_pub2_data","Analysis.name","Adverse events: perioperative myocardial infarction"
"CD013781_pub2_data","Analysis.name","Adverse events: non-embolic stroke or transient ischaemic attack"
"CD013781_pub2_data","Analysis.name","Adverse events: Perioperative myocardial infarction"
"CD013781_pub2_data","Subgroup","Cardiac index 6 hours after surgery"
"CD013781_pub2_data","Subgroup","Cardiac index 12 hours after surgery"
"CD013781_pub2_data","Subgroup","End of surgery cardiac index"
"CD013781_pub2_data","Subgroup","Mean arterial pressure 6 hours after surgery"
"CD013781_pub2_data","Subgroup","Baseline mean arterial pressure"
"CD013781_pub2_data","Subgroup","Mean arterial pressure 12 hours after surgery"
"CD013781_pub2_data","Subgroup","End of surgery mean arterial pressure"
"CD013781_pub2_data","Subgroup","PCWP 12 hours after surgery"
"CD013781_pub2_data","Subgroup","PCWP 6 hours after surgery"
"CD013781_pub2_data","Subgroup","End of surgery PCWP"
"CD013781_pub2_data","Subgroup","Baseline cardiac index"
"CD013781_pub2_data","Subgroup","Cardiac index after 24 hours"
"CD013781_pub2_data","Subgroup","Cardiac index after 6 hours"
"CD013781_pub2_data","Subgroup","Cardiac index after 12 hours"
"CD013781_pub2_data","Subgroup","Mean arterial pressure after 6 hours"
"CD013781_pub2_data","Subgroup","Mean arterial pressure after 12 hours"
"CD013781_pub2_data","Subgroup","Mean arterial pressure after 24 hours"
"CD013781_pub2_data","Subgroup","Baseline PCWP"
"CD013781_pub2_data","Subgroup","PCWP after 6 hours"
"CD013781_pub2_data","Subgroup","PCWP after 12 hours"
"CD013781_pub2_data","Subgroup","PCWP after 24 hours"
"CD013781_pub2_data","Subgroup","End-of-surgery cardiac index"
"CD013781_pub2_data","Subgroup","Cardiac index 24 hours after surgery"
"CD013781_pub2_data","Subgroup","Mean arterial pressure 24 hours after surgery"
"CD013781_pub2_data","Subgroup","PCWP 24 hours after surgery"
"CD013781_pub2_data","Subgroup","Levosimendan vs active controlled"
"CD013781_pub2_data","Subgroup","Levosimendan vs passive controlled"
"CD013781_pub2_data","Subgroup","Preoperative period"
"CD013781_pub2_data","Subgroup","Perioperative/anaesthesia induction period"
"CD013781_pub2_data","Subgroup","Perioperative/anaesthesia induction period "
"CD013781_pub2_data","Subgroup","With bolus"
"CD013781_pub2_data","Subgroup","Without bolus"
"CD013789_pub2_data","Analysis.group","1"
"CD013789_pub2_data","Analysis.name","Scar improvement (VSS) (PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar improvement (POSAS) (participant/caregiver, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar improvement (POSAS) (observer, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Pain (POSAS participant/caregiver, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Pruritus (POSAS participant/caregiver, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar thickness (ultrasound, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar thickness (POSAS, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar thickness (ultrasound, high vs low pressure)"
"CD013789_pub2_data","Analysis.name","Scar pigmentation (VSS, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar pigmentation (POSAS observer, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar colour (POSAS participant/caregiver, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar colour – lightness (PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar colour – redness (PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar colour – redness (high vs low pressure)"
"CD013789_pub2_data","Analysis.name","Scar colour – yellowness (PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar pliability (VSS, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar pliability (POSAS participant/caregiver, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar pliability (POSAS observer, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar texture (POSAS participant/caregiver, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar relief (POSAS observer, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Scar height (VSS, PGT vs other scar management therapy)"
"CD013789_pub2_data","Analysis.name","Vascularity (POSAS observer, PGT vs other scar management therapy)"
"CD013789_pub2_data","Subgroup","PGT vs silicone"
"CD013789_pub2_data","Subgroup","PGT + silicone vs silicone"
"CD013789_pub2_data","Subgroup","PGT vs no treatment/lanolin"
"CD013789_pub2_data","Subgroup","PGT + silicone vs no treatment/lanolin"
"CD013789_pub2_data","Subgroup","PGT + scar management therapy (including silicone) vs scar management therapy (including silicone)"
"CD013789_pub2_data","Subgroup","PGT + scar management therapy including silicone vs scar management therapy including silicone"
"CD013789_pub2_data","Subgroup","PGT vs silicone, observer rated"
"CD013789_pub2_data","Subgroup","PGT vs silicone, caregiver rated"
"CD013789_pub2_data","Subgroup","PGT + scar management therapy including silicone vs scar management therapy including silicone, caregiver rated"
"CD013789_pub2_data","Subgroup","PGT + silicone vs silicone, caregiver rated"
"CD013789_pub2_data","Subgroup","PGT + silicone vs silicone, observer rated"
"CD013789_pub2_data","Subgroup","PGT + scar management therapy including silicone vs scar management therapy including silicone, observer rated"
"CD013789_pub2_data","Subgroup","PGT + standard care (including silicone) vs standard care (including silicone)"
"CD013789_pub2_data","Subgroup","Burns, adults, measured with Minolta Chromameter"
"CD013789_pub2_data","Subgroup","Mixed population, adults, measured with Spectrocolorimeter"
"CD013800_pub2_data","Analysis.group","1"
"CD013800_pub2_data","Analysis.name","Residual kidney function at 6 months [mL/min/1.73 m2]"
"CD013800_pub2_data","Analysis.name","Residual kidney function at 12 months [mL/min/1.73 m2]"
"CD013800_pub2_data","Analysis.name","Residual kidney function at 24 months [mL/min/1.73 m2]"
"CD013800_pub2_data","Analysis.name","Residual urine volume at 12 months [mL/day]"
"CD013800_pub2_data","Analysis.name","Loss of residual kidney function (number who became anuric) at approximately 12-month follow-up"
"CD013800_pub2_data","Analysis.name","All-cause death"
"CD013800_pub2_data","Analysis.name","Cardiovascular death"
"CD013800_pub2_data","Analysis.name","Infection-related death"
"CD013800_pub2_data","Analysis.name","Bacteraemia/bloodstream infection "
"CD013800_pub2_data","Analysis.name","Infection episodes (all types)"
"CD013800_pub2_data","Analysis.name","Bacteraemia/bloodstream infection episodes"
"CD013800_pub2_data","Analysis.name","Acute myocardial infarction"
"CD013800_pub2_data","Analysis.name","Coronary artery disease"
"CD013800_pub2_data","Analysis.name","Ischaemic heart disease"
"CD013800_pub2_data","Analysis.name","Congestive heart failure"
"CD013800_pub2_data","Analysis.name","Stroke"
"CD013800_pub2_data","Analysis.name","Hospitalisation"
"CD013800_pub2_data","Analysis.name","All-cause hospitalisation events"
"CD013800_pub2_data","Analysis.name","Employed patients 1 year after dialysis initiation"
"CD013800_pub2_data","Subgroup","Adults"
"CD013800_pub2_data","Subgroup","Paediatric"
"CD013800_pub2_data","Subgroup","Adult"
"CD013801_pub2_data","Analysis.group","1"
"CD013801_pub2_data","Analysis.group","2"
"CD013801_pub2_data","Analysis.group","3"
"CD013801_pub2_data","Analysis.name","Physician-evaluated change in severity of symptoms and signs (short-term)"
"CD013801_pub2_data","Analysis.name","Physician-evaluated change in severity of symptoms and signs (medium-term)"
"CD013801_pub2_data","Analysis.name","Physician-evaluated change in severity of symptoms and signs (medium-term) (sensitivity analysis)"
"CD013801_pub2_data","Analysis.name","Physician-evaluated change in severity of symptoms and signs (long-term)"
"CD013801_pub2_data","Analysis.name","Patient-reported change in functional capacity (medium-term)"
"CD013801_pub2_data","Analysis.name","Patient-reported change in functional capacity (medium-term) (sensitivity analysis)"
"CD013801_pub2_data","Analysis.name","Patient-reported change in functional capacity (long-term)"
"CD013801_pub2_data","Analysis.name","Changes in measures that incorporate both physician-evaluated and patient-reported items (medium-term)"
"CD013801_pub2_data","Analysis.name","Length of hospitalization"
"CD013801_pub2_data","Analysis.name","Incidence of myasthenia gravis-related hospitalizations"
"CD013801_pub2_data","Analysis.name","Incidence of headache"
"CD013801_pub2_data","Analysis.name","Incidence of hemolysis"
"CD013801_pub2_data","Analysis.name","Incidence of acute renal failure"
"CD013801_pub2_data","Analysis.name","Incidence of all-cause mortality"
"CD013801_pub2_data","Analysis.name","Incidence of treatment discontinuation due to adverse events"
"CD013801_pub2_data","Analysis.name","Physician-evaluated change in severity of symptoms and signs (short-term) (sensitivity analysis)"
"CD013801_pub2_data","Analysis.name","Patient-reported change in functional capacity (short-term)"
"CD013801_pub2_data","Analysis.name","Incidence of hypotension requiring vascular expansion"
"CD013801_pub2_data","Analysis.name","Incidence of allergic reaction"
"CD013801_pub2_data","Analysis.name","Incidence of fever (temperature greater than 38 ºC)"
"CD013801_pub2_data","Analysis.name","Incidence of bleeding"
"CD013801_pub2_data","Subgroup","Active MG"
"CD013801_pub2_data","Subgroup","Periprocedural"
"CD013801_pub2_data","Subgroup","Steroid Tapering"
"CD013810_pub2_data","Analysis.group","1"
"CD013810_pub2_data","Analysis.group","2"
"CD013810_pub2_data","Analysis.name","Sleepiness (Epworth Sleepiness Scale)"
"CD013810_pub2_data","Analysis.name","Quality of life (Functional Outcomes of Sleep Questionnaire)"
"CD013810_pub2_data","Analysis.name","Quality of life (Assessment of Quality of Life – 8 Dimensions – Psychosocial Superdimension)"
"CD013810_pub2_data","Analysis.name","Quality of life (Assessment of Quality of Life – 8 Dimensions – Physical Superdimension)"
"CD013810_pub2_data","Analysis.name","Quality of life (Assessment of Quality of Life – 8 Dimensions – Global Utility)"
"CD013810_pub2_data","Analysis.name","Quality of life (EuroQol 5-Dimensions)"
"CD013810_pub2_data","Analysis.name","Quality of life (EuroQol Thermometer)"
"CD013810_pub2_data","Analysis.name","Quality of life (36-Item Short Form – Physical Component Summary)"
"CD013810_pub2_data","Analysis.name","Quality of life (36-Item Short Form – Mental Component Summary)"
"CD013810_pub2_data","Analysis.name","Quality of life (Visual Analogical Well-being Scale)"
"CD013810_pub2_data","Analysis.name","Cardiovascular event incident rate per 100 participants per year"
"CD013810_pub2_data","Analysis.name","Cardiovascular risk factor (body mass index)"
"CD013810_pub2_data","Analysis.name","Cardiovascular risk factor (24-hour blood pressure)"
"CD013810_pub2_data","Analysis.name","Cardiovascular risk factor (24-hour systolic blood pressure)"
"CD013810_pub2_data","Analysis.name","Cardiovascular risk factor (24-hour diastolic blood pressure)"
"CD013810_pub2_data","Analysis.name","Continuous positive airway pressure adherence"
"CD013810_pub2_data","Analysis.name","Quality of life (Assessment of Quality of Life – 8 Dimensions – Global Utility; EuroQol 5-Dimensions)"
"CD013810_pub2_data","Analysis.name","Cardiovascular risk factor (systolic blood pressure)"
"CD013810_pub2_data","Analysis.name","Cardiovascular risk factor (diastolic blood pressure)"
"CD013816_pub2_data","Analysis.group","1"
"CD013816_pub2_data","Analysis.group","2"
"CD013816_pub2_data","Analysis.name","Thromboembolic events (composite)"
"CD013816_pub2_data","Analysis.name","Device-pocket hematoma"
"CD013816_pub2_data","Analysis.name","Transient ischemic attack"
"CD013816_pub2_data","Analysis.name","Ischemic stroke"
"CD013816_pub2_data","Analysis.name","Deep vein thrombosis"
"CD013816_pub2_data","Analysis.name","Pulmonary embolism"
"CD013816_pub2_data","Analysis.name","Peripheral embolism"
"CD013816_pub2_data","Analysis.name","Valve thrombosis"
"CD013816_pub2_data","Analysis.name","Bleeding events (composite)"
"CD013816_pub2_data","Analysis.name","Hemothorax"
"CD013816_pub2_data","Analysis.name","Cardiac tamponade"
"CD013816_pub2_data","Analysis.name","Non-tamponade pericardial effusion"
"CD013816_pub2_data","Analysis.name","All-cause mortality"
"CD013816_pub2_data","Analysis.name","Adverse events"
"CD013816_pub2_data","Analysis.name","Adverse events - Bleeding (clinically significant bleeding that does not qualify as device-pocket hematoma, hemothorax, cardiac tamponade, or non-tamponade pericardial effusion)"
"CD013816_pub2_data","Analysis.name","Adverse events - Pneumothorax"
"CD013816_pub2_data","Analysis.name","Adverse events - Infection"
"CD013816_pub2_data","Analysis.name","General health status (QoL)"
"CD013816_pub2_data","Analysis.name","Economic costs - Days of hospitalization"
"CD013816_pub2_data","Analysis.name","Ischemic stroke "
"CD013816_pub2_data","Analysis.name","Adverse events - Hematoma (clinically non-significant device-pocket hematoma)"
"CD013821_pub2_data","Analysis.group","1"
"CD013821_pub2_data","Analysis.name","Postoperative psychosocial well-being"
"CD013821_pub2_data","Analysis.name","Postoperative physical well-being"
"CD013821_pub2_data","Analysis.name","Postoperative sexual well-being"
"CD013821_pub2_data","Analysis.name","Satisfaction with breast"
"CD013821_pub2_data","Analysis.name","Satisfaction with reconstruction"
"CD013821_pub2_data","Analysis.name","Short-term complications"
"CD013821_pub2_data","Analysis.name","Long-term complications"
"CD013821_pub2_data","Analysis.name","Locoregional recurrence"
"CD013821_pub2_data","Analysis.name","Reintervention"
"CD013821_pub2_data","Analysis.name","Duration of surgery (minutes)"
"CD013821_pub2_data","Analysis.name","Length of postoperative stay (days)"
"CD013822_pub2_data","Analysis.group","1"
"CD013822_pub2_data","Analysis.group","2"
"CD013822_pub2_data","Analysis.group","3"
"CD013822_pub2_data","Analysis.name","Knowledge"
"CD013822_pub2_data","Analysis.name","Confidence - decisional conflict - continuous"
"CD013822_pub2_data","Analysis.name","Confidence - decisional conflict - dichotomous"
"CD013822_pub2_data","Analysis.name","Confidence - regret/anticipated regret"
"CD013822_pub2_data","Analysis.name","Knowledge - continuous"
"CD013822_pub2_data","Analysis.name","Knowledge - informed choice (composite of knowledge, attitudes and intentions)"
"CD013822_pub2_data","Analysis.name","Knowledge - dichotomous (correct answers)"
"CD013822_pub2_data","Analysis.name","Anxiety - continuous"
"CD013822_pub2_data","Analysis.name","Anxiety - dichotomous"
"CD013822_pub2_data","Analysis.name","Confidence"
"CD013822_pub2_data","Analysis.name","Confidence - long-term follow-up"
"CD013822_pub2_data","Analysis.name","Knowledge - continuous - long term"
"CD013822_pub2_data","Analysis.name","Anxiety and depression"
"CD013822_pub2_data","Analysis.name","Anxiety and depression - long term"
"CD013822_pub2_data","Analysis.name","Cancer worry"
"CD013822_pub2_data","Analysis.name","Cancer worry - long term"
"CD013822_pub2_data","Subgroup","Knowledge - frequency of testing"
"CD013822_pub2_data","Subgroup","Knowledge - age to start screening"
"CD013822_pub2_data","Subgroup","Decisional conflict scale (0 to 100) - higher scores/more conflict"
"CD013822_pub2_data","Subgroup","SURE scale (0 to 4)"
"CD013822_pub2_data","Subgroup","Anticipated regret"
"CD013822_pub2_data","Subgroup","Regret"
"CD013822_pub2_data","Subgroup","Scale 0 to 10"
"CD013822_pub2_data","Subgroup","Scale 0 to 7"
"CD013822_pub2_data","Subgroup","Scale 0 to 5"
"CD013822_pub2_data","Subgroup","Scale 0 to 100"
"CD013822_pub2_data","Subgroup","Decisional conflict - post intervention to 2 weeks"
"CD013822_pub2_data","Subgroup","Anticipated regret - 2 weeks"
"CD013822_pub2_data","Subgroup","Decisional regret - 6 months"
"CD013822_pub2_data","Subgroup","Decisional conflict - post intervention to 2 weeks - sensitivity analysis"
"CD013822_pub2_data","Subgroup","24 months - Anticipated regret"
"CD013822_pub2_data","Subgroup","12 months - Decisional regret"
"CD013822_pub2_data","Subgroup","Analysis with all included studies"
"CD013822_pub2_data","Subgroup","Sensitivity analysis (excluding studies at high risk of bias)"
"CD013822_pub2_data","Subgroup","12 months"
"CD013822_pub2_data","Subgroup","24 months"
"CD013822_pub2_data","Subgroup","All studies"
"CD013822_pub2_data","Subgroup","12 month follow-up"
"CD013822_pub2_data","Subgroup","Post intervention"
"CD013822_pub2_data","Subgroup","24 month follow-up"
"CD013822_pub2_data","Subgroup","2 weeks"
"CD013822_pub2_data","Subgroup","Anxiety ≤ 1 month"
"CD013822_pub2_data","Subgroup","Depression"
"CD013822_pub2_data","Subgroup","Anxiety ≤ 1 month - sensitivity analysis"
"CD013822_pub2_data","Subgroup","Anxiety - 12 months"
"CD013822_pub2_data","Subgroup","Anxiety - 24 months"
"CD013822_pub2_data","Subgroup","Sensitivity analysis"
"CD013822_pub2_data","Subgroup","Cancer worry - 12 months"
"CD013822_pub2_data","Subgroup","Cancer worry - 24 months"
"CD013823_pub2_data","Analysis.group","1"
"CD013823_pub2_data","Analysis.name","Maternal anaemia"
"CD013823_pub2_data","Analysis.name","Maternal vitamin B12 deficiency or insufficiency"
"CD013823_pub2_data","Analysis.name","Low birthweight (< 2500 g)"
"CD013823_pub2_data","Analysis.name","Preterm birth (< 37 weeks)"
"CD013823_pub2_data","Analysis.name","Maternal total vitamin B12 concentrations"
"CD013823_pub2_data","Analysis.name","Maternal haemoglobin concentrations"
"CD013823_pub2_data","Analysis.name","Maternal hyperhomocysteinaemia"
"CD013823_pub2_data","Analysis.name","Infant total vitamin B12 concentrations"
"CD013823_pub2_data","Analysis.name","Infant homocysteine concentrations"
"CD013823_pub2_data","Analysis.name","Infant haemoglobin concentrations"
"CD013823_pub2_data","Analysis.name","Infant anaemia"
"CD013827_pub2_data","Analysis.group","1"
"CD013827_pub2_data","Analysis.group","2"
"CD013827_pub2_data","Analysis.group","3"
"CD013827_pub2_data","Analysis.group","4"
"CD013827_pub2_data","Analysis.name","Live birth or ongoing pregnancy"
"CD013827_pub2_data","Analysis.name","Oocyte pick-up cancellation"
"CD013827_pub2_data","Analysis.name","Clinical pregnancy"
"CD013827_pub2_data","Analysis.name","Cumulative pregnancy rate"
"CD013827_pub2_data","Analysis.name","Miscarriage"
"CD013827_pub2_data","Analysis.name","Multiple pregnancy"
"CD013827_pub2_data","Analysis.name","Premature LH surge"
"CD013827_pub2_data","Analysis.name","Total oocytes"
"CD013827_pub2_data","Analysis.name","MII oocytes"
"CD013827_pub2_data","Analysis.name","Duration of stimulation (days)"
"CD013827_pub2_data","Analysis.name","Total dose of gonadotropins (IU)"
"CD013827_pub2_data","Analysis.name","Moderate or severe OHSS"
"CD013827_pub2_data","Analysis.name","Live birth or ongoing pregnancy sensitivity analysis"
"CD013827_pub2_data","Analysis.name","Oocyte pick-up cancellation sensitivity analysis"
"CD013827_pub2_data","Analysis.name","Clinical Pregnancy"
"CD013827_pub2_data","Analysis.name","Cumulative pregnancy"
"CD013827_pub2_data","Analysis.name","Duration of stimulation"
"CD013827_pub2_data","Analysis.name","Total dose of gonadotropins"
"CD013827_pub2_data","Subgroup","Poor-responders (MPA 10 mg versus GnRH antagonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normoresponders (MPA 10 mg versus GnRH antagonists) - Donor oocytes  - Early phase stimulation protocol - Fresh embryo transfer"
"CD013827_pub2_data","Subgroup","Normoresponders  (micronised progesterone 200 mg versus GnRH antagonists) - Own oocytes - Early phase stimulation protocol - Fresh embryo transfer"
"CD013827_pub2_data","Subgroup","Miscarriage per clinical pregnancy - Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per randomised woman - Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per randomised woman - Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per clinical pregnancy - Poor Ovarian Reserve (MPA 10 mg versus GnRH antagonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Own oocytes - PCOS (high-responders) - Early phase stimulation protocol - Frozen embryo transfer"
"CD013827_pub2_data","Subgroup","Donor oocytes - Normoresponders - Early phase stimulation protocol - Fresh embryo transfer"
"CD013827_pub2_data","Subgroup","Own oocytes - Normoresponders - Early phase stimulation protocol - Fresh embryo transfer"
"CD013827_pub2_data","Subgroup","Poor-responders"
"CD013827_pub2_data","Subgroup","Normoresponders - Own oocytes - Early phase stimulation protocol - Fresh embryo transfer (Micronised progesterone versus GnRH antagonists)"
"CD013827_pub2_data","Subgroup","PCOS (high-responders) - Own oocytes - Early phase stimulation protocol - Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists)"
"CD013827_pub2_data","Subgroup","Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists)"
"CD013827_pub2_data","Subgroup","Oocyte freezing - random start (Dydrogesterone 10 mg versus GnRH antagonists)"
"CD013827_pub2_data","Subgroup","Normoresponders - Donor oocytes - Early phase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) "
"CD013827_pub2_data","Subgroup","PCOS (high-responders) - Own oocytes - Early phase stimulation protocol - Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) "
"CD013827_pub2_data","Subgroup","Oocyte freezing - Random start (Dydrogesterone 10 mg versus GnRH antagonists)"
"CD013827_pub2_data","Subgroup","Normoresponders - Donor oocytes - Early ophase stimulation protocol - Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists"
"CD013827_pub2_data","Subgroup","PCOS (high-responders) - Own oocytes - Early phase stumulation protocol - Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists)"
"CD013827_pub2_data","Subgroup","Poor responders (MPA 10 mg versus GNrH antagoninsts - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","PCOS (high-responders) - own oocytes - early phase stimulation protocol - frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists)"
"CD013827_pub2_data","Subgroup","PCOS (high-responders)(micronised progesterone 100 mg versus GnRH antagonists) - Own oocytes - Early phase stimulation protocol - Frozen embryo transfer"
"CD013827_pub2_data","Subgroup","Normo-responders (MPA 4 mg versus GnRH agonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo responders (MPA 4 mg versus GnRH agonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage rate per randomised woman - Normo responders (MPA 4 mg versus GnRH agonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage rate per clinical pregnancy - Normo responders (MPA 4 mg versus GnRH agonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per randomised woman - Normo responders (MPA 4 mg versus GnRH agonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per clinical pregnancy - Normo responders (MPA 4 mg versus GnRH agonists) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders (MPA 4 mg versus MPA 10 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders with endometriosis (MPA 4 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders with endometriosis (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders with endometriosis (MPA 4 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders (Micronised progesterone 100 mg versus Micronised progesterone 200mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders (MPA 4 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders (MPA 4 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders (MPA 10 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders (Dydrogesterone 20 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Normo-responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per clinical pregnancy - Normo-responders (MPA 4 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per randomised woman - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per randomised woman - Normo-responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per clinical pregnancy - Normo-responders (MPA 4 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per randomised woman - Normo-responders (MPA 10 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per randomised woman - Normo-responders (MPA 4 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per randomised woman - Normo-responders (MPA 4 mg versus MPA 10 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per clinical pregnancy - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per randomised woman - Normo-responders (MPA 4 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per clinical pregnancy - Normo-responders (MPA 4 mg versus MPA 10 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per clinical pregnancy - Normo-responders (MPA 10 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Miscarriage per clinical pregnancy - Normo-responders (Micronised progesterone 100 mg versus Micronised progesterone 200 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per randomised woman - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per clinical pregnancy - Normo-responders (MPA 4 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per clinical pregnancy - Normo-responders (Micronised progesterone 100 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per clinical pregnancy - Normo-responders (MPA 4 mg versus MPA 10 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per clinical pregnancy - Normo-responders (MPA 10 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per randomised woman - Normo-responders (MPA 4 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per clinical pregnancy - Normo-responders (MPA 4 mg versus Micronised progesterone 100 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per randomised woman - Normo-responders (MPA 4 mg versus MPA 10 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per randomised woman - Normo-responders (MPA 4 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Multiple pregnancy per randomised woman - Normo-responders (MPA 10 mg versus Dydrogesterone 20 mg) - Own oocytes - Early phase stimulation protocol"
"CD013827_pub2_data","Subgroup","Oocyte donors (MPA 10 mg versus nothing) - Luteal phase in a double stimulation protocol"
"CD013830_pub2_data","Analysis.group","1"
"CD013830_pub2_data","Analysis.group","2"
"CD013830_pub2_data","Analysis.group","3"
"CD013830_pub2_data","Analysis.group","4"
"CD013830_pub2_data","Analysis.group","5"
"CD013830_pub2_data","Analysis.name","Death or major neurodevelopmental disability"
"CD013830_pub2_data","Analysis.name","Death at hospital discharge"
"CD013830_pub2_data","Analysis.name","Major neurodevelopmental disability"
"CD013830_pub2_data","Analysis.name","Cerebral palsy or gross motor disability"
"CD013830_pub2_data","Analysis.name","Cognitive delay"
"CD013830_pub2_data","Analysis.name","Any apneic episodes"
"CD013830_pub2_data","Analysis.name","Failed apnea reduction"
"CD013830_pub2_data","Analysis.name","Positive-pressure ventilation after institution of treatment"
"CD013830_pub2_data","Analysis.name","Duration of positive-pressure ventilation after institution of treatment (hours)"
"CD013830_pub2_data","Analysis.name","Duration of oxygen therapy (days)"
"CD013830_pub2_data","Analysis.name","Patent ductus arteriosus (PDA) requiring any treatment"
"CD013830_pub2_data","Analysis.name","Patent ductus arteriosus (PDA) requiring ligation"
"CD013830_pub2_data","Analysis.name","Any intraventricular hemorrhage (IVH)"
"CD013830_pub2_data","Analysis.name","Severe intraventricular hemorrhage (grades 3 and 4)"
"CD013830_pub2_data","Analysis.name","Periventricular leukomalacia (PVL)"
"CD013830_pub2_data","Analysis.name","Necrotizing enterocolitis (NEC) (Bell's stage II or greater OR any grade; requiring surgery)"
"CD013830_pub2_data","Analysis.name","Retinopathy of prematurity (ROP) in infants examined (any stage)"
"CD013830_pub2_data","Analysis.name","Severe retinopathy of prematurity (ROP) in infants examined (stage 2 or greater)"
"CD013830_pub2_data","Analysis.name","Oxygen therapy at 28 to 30 days"
"CD013830_pub2_data","Analysis.name","Chronic lung disease (CLD) defined as use of supplemental oxygen at 36 weeks' postmenstrual age"
"CD013830_pub2_data","Analysis.name","Tachycardia leading to cessation of treatment"
"CD013830_pub2_data","Analysis.name","Five-year follow-up"
"CD013830_pub2_data","Analysis.name","Corrected gestational age at last use of positive-pressure ventilation"
"CD013830_pub2_data","Analysis.name","Corrected gestational age at last use of oxygen therapy"
"CD013830_pub2_data","Analysis.name","Failed extubation"
"CD013830_pub2_data","Analysis.name","Failure to extubate within seven days"
"CD013830_pub2_data","Subgroup","Caffeine"
"CD013830_pub2_data","Subgroup","Aminophylline"
"CD013830_pub2_data","Subgroup","Theophylline"
"CD013830_pub2_data","Subgroup","Death or disability"
"CD013830_pub2_data","Subgroup","Death before 5 years of age"
"CD013830_pub2_data","Subgroup","Motor impairment"
"CD013830_pub2_data","Subgroup","Cognitive impairment"
"CD013830_pub2_data","Subgroup","Poor general health"
"CD013830_pub2_data","Subgroup","Behavior problem"
"CD013830_pub2_data","Subgroup","Severe hearing loss"
"CD013830_pub2_data","Subgroup","Bilateral blindness"
"CD013830_pub2_data","Subgroup","Caffeine or theophylline"
"CD013830_pub2_data","Subgroup","Methylxanthine to prevent re-intubation in preterm infants"
"CD013834_pub2_data","Analysis.group","1"
"CD013834_pub2_data","Analysis.group","2"
"CD013834_pub2_data","Analysis.group","3"
"CD013834_pub2_data","Analysis.group","4"
"CD013834_pub2_data","Analysis.group","5"
"CD013834_pub2_data","Analysis.group","6"
"CD013834_pub2_data","Analysis.group","7"
"CD013834_pub2_data","Analysis.group","8"
"CD013834_pub2_data","Analysis.group","9"
"CD013834_pub2_data","Analysis.group","10"
"CD013834_pub2_data","Analysis.group","11"
"CD013834_pub2_data","Analysis.name","TUG"
"CD013834_pub2_data","Analysis.name","MS Walking Scale - 12"
"CD013834_pub2_data","Analysis.name","Walking endurance"
"CD013834_pub2_data","Analysis.name","Gait speed"
"CD013834_pub2_data","Analysis.name","BBS"
"CD013834_pub2_data","Analysis.name","9HPT"
"CD013834_pub2_data","Analysis.name","TUG - cognitive"
"CD013834_pub2_data","Analysis.name","Symbol Digit Modalities Test"
"CD013834_pub2_data","Analysis.name","ABC scale"
"CD013834_pub2_data","Analysis.name","BDI"
"CD013834_pub2_data","Analysis.name","MS International QoL"
"CD013834_pub2_data","Analysis.name","Tinetti Test"
"CD013834_pub2_data","Analysis.name","FSST"
"CD013834_pub2_data","Analysis.name","FES-1"
"CD013834_pub2_data","Analysis.name","Fatigue"
"CD013834_pub2_data","Analysis.name","PASAT"
"CD013835_pub2_data","Analysis.group","1"
"CD013835_pub2_data","Analysis.name","All-cause mortality at 30 days"
"CD013835_pub2_data","Analysis.name","PE-related mortality at 30 days"
"CD013844_pub2_data","Analysis.group","1"
"CD013844_pub2_data","Analysis.group","2"
"CD013844_pub2_data","Analysis.group","3"
"CD013844_pub2_data","Analysis.name","Acceptability (dropouts)"
"CD013844_pub2_data","Analysis.name","Self-harm at short term (1-3 months) follow-up"
"CD013844_pub2_data","Analysis.name","Self-harm at medium-term (4-12 months) follow-up"
"CD013844_pub2_data","Analysis.name","Self-harm at long-term (> 12 months) follow-up"
"CD013844_pub2_data","Analysis.name","Suicidal ideation at postintervention follow-up"
"CD013844_pub2_data","Analysis.name","Suicidal ideation postintervention: sensitivity analysis (ICC 0.01)"
"CD013844_pub2_data","Analysis.name","Suicidal ideation postintervention: sensitivity analysis (ICC 0.05)"
"CD013844_pub2_data","Analysis.name","Suicidal ideation postintervention: sensitivity analysis (ICC 0.1)"
"CD013844_pub2_data","Analysis.name","Suicidal ideation at short-term (1-3 months) follow-up"
"CD013844_pub2_data","Analysis.name","Hopelessness at postintervention follow-up"
"CD013844_pub2_data","Analysis.name","Self-harm at postintervention follow-up"
"CD013844_pub2_data","Analysis.name","Self-harm postintervention: sensitivity analysis (ICC 0.01)"
"CD013844_pub2_data","Analysis.name","Self-harm postintervention: sensitivity analysis (ICC 0.05)"
"CD013844_pub2_data","Analysis.name","Self-harm post intervention: sensitivity analysis (ICC 0.1)"
"CD013844_pub2_data","Analysis.name","Self-harm at short-term (1-3 months) follow-up"
"CD013844_pub2_data","Analysis.name","Non-suicidal self-injury at postintervention follow-up"
"CD013844_pub2_data","Analysis.name","Self-harm frequency at postintervention follow-up"
"CD013844_pub2_data","Analysis.name","Suicide ideation at medium-term (4-12 months) follow-up"
"CD013844_pub2_data","Analysis.name","Suicidal ideation at the longest follow-up"
"CD013844_pub2_data","Analysis.name","Hopelessness postintervention"
"CD013844_pub2_data","Analysis.name","Hopelessness at short-term (1-3 months) follow-up"
"CD013844_pub2_data","Subgroup","Psychoeducation"
"CD013844_pub2_data","Subgroup","Psychological"
"CD013844_pub2_data","Subgroup","Other"
"CD013844_pub2_data","Subgroup","Screening"
"CD013844_pub2_data","Subgroup","Others"
"CD013844_pub2_data","Subgroup","Gatekeeper training"
"CD013844_pub2_data","Subgroup","CBT-type"
"CD013844_pub2_data","Subgroup","DBT-type"
"CD013844_pub2_data","Subgroup","Interpersonal psychotherapy"
"CD013853_pub2_data","Analysis.group","1"
"CD013853_pub2_data","Analysis.group","2"
"CD013853_pub2_data","Analysis.group","3"
"CD013853_pub2_data","Analysis.group","7"
"CD013853_pub2_data","Analysis.group","8"
"CD013853_pub2_data","Analysis.group","9"
"CD013853_pub2_data","Analysis.name","Exergaming vs control at the end of treatment: change in global physical functioning (composite)"
"CD013853_pub2_data","Analysis.name","Exergaming vs control at the end of treatment: change in global cognitive functioning (composite)"
"CD013853_pub2_data","Analysis.name","Exergaming vs control at the end of treatment: change in activities for daily living (ADL)"
"CD013853_pub2_data","Analysis.name","Exergaming vs alternative treatment at the end of treatment: change in global physical functioning (composite)"
"CD013853_pub2_data","Analysis.name","Exergaming vs alternative treatment at the end of treatment: change in functional status and physical performance"
"CD013853_pub2_data","Analysis.name","Exergaming vs alternative treatment at the end of treatment: change in global cognitive functioning (composite)"
"CD013853_pub2_data","Analysis.name","Exergaming vs alternative treatment at the end of treatment: change in lower limb functioning"
"CD013853_pub2_data","Analysis.name","Exergaming vs control at the end of treatment: change in activities of daily living (ADL)"
"CD013853_pub2_data","Analysis.name","Exergaming vs control at the end of treatment: change in lower limb functioning"
"CD013853_pub2_data","Analysis.name","Exergaming vs control at the end of treatment: change in general cognition"
"CD013853_pub2_data","Analysis.name","Exergaming vs control at the end of treatment: change in attention, processing speed, working memory"
"CD013853_pub2_data","Analysis.name","Exergaming vs control at follow-up: change in global cognitive functioning (composite)"
"CD013853_pub2_data","Analysis.name","Exergaming vs control at follow-up: change in general cognition"
"CD013853_pub2_data","Analysis.name","Exergaming vs alternative treatment for people with dementia "
"CD013853_pub2_data","Analysis.name","Number of dropouts at the end of treatment (exergaming vs control intervention) for people with dementia"
"CD013853_pub2_data","Analysis.name","Number of dropouts at the end of treatment (exergaming vs alternative treatment) for people with dementia"
"CD013853_pub2_data","Analysis.name","Number of dropouts at the end of treatment (exergaming vs control intervention) for people with mild cognitive impairment (MCI)"
"CD013853_pub2_data","Analysis.name","Number of dropouts at the end of treatment (exergaming vs alternative treatment) for people with mild cognitive impairment (MCI)"
"CD013853_pub2_data","Analysis.name","Number of dropouts at follow-up (exergame vs control intervention) for people with dementia"
"CD013853_pub2_data","Analysis.name","Number of dropouts at follow-up (exergame vs control intervention) for people with mild cognitive impairment (MCI)"
"CD013857_pub2_data","Analysis.group","1"
"CD013857_pub2_data","Analysis.name","Incidence of new localised tissue injury"
"CD013857_pub2_data","Analysis.name","Incidence of new major amputation of the CLL"
"CD013857_pub2_data","Analysis.name","Survival"
"CD013874_pub3_data","Analysis.group","1"
"CD013874_pub3_data","Analysis.group","2"
"CD013874_pub3_data","Analysis.group","3"
"CD013874_pub3_data","Analysis.group","4"
"CD013874_pub3_data","Analysis.group","5"
"CD013874_pub3_data","Analysis.group","6"
"CD013874_pub3_data","Analysis.group","7"
"CD013874_pub3_data","Analysis.group","8"
"CD013874_pub3_data","Analysis.group","9"
"CD013874_pub3_data","Analysis.group","10"
"CD013874_pub3_data","Analysis.group","11"
"CD013874_pub3_data","Analysis.name","Disability worsening over 24 months"
"CD013874_pub3_data","Analysis.name","Time to relapse over 24 months"
"CD013874_pub3_data","Analysis.name","Relapse over 24 months"
"CD013874_pub3_data","Analysis.name","Total serious adverse events (SAEs)"
"CD013874_pub3_data","Analysis.name","Upper respiratory tract infection "
"CD013874_pub3_data","Analysis.name","Urinary tract infections "
"CD013874_pub3_data","Analysis.name","Skin infections   "
"CD013874_pub3_data","Analysis.name","Viral infections     "
"CD013874_pub3_data","Analysis.name","Annualised relapse rate"
"CD013874_pub3_data","Analysis.name","T2 or gadolinium MRI lesions over 24 months"
"CD013874_pub3_data","Analysis.name","Treatment discontinuation due to adverse events"
"CD013874_pub3_data","Analysis.name","Any adverse event"
"CD013874_pub3_data","Analysis.name","Time to relapse over 24 months "
"CD013874_pub3_data","Analysis.name","Serious adverse events assessed with Grades 3/4 CTCAE over 24 months "
"CD013874_pub3_data","Analysis.name","Gadolinium magnetic resonance imaging (MRI) lesions "
"CD013874_pub3_data","Analysis.name","Disability worsening over 24 months "
"CD013874_pub3_data","Analysis.name","Relapse over 24 months "
"CD013874_pub3_data","Analysis.name","Serious adverse events over 24 months "
"CD013874_pub3_data","Analysis.name","Common infections over 24 months "
"CD013874_pub3_data","Analysis.name","Cancer over 24 months "
"CD013874_pub3_data","Analysis.name","Mortality over 24 months "
"CD013874_pub3_data","Analysis.name","First infusion reactions"
"CD013874_pub3_data","Analysis.name","Second infusion reactions"
"CD013874_pub3_data","Analysis.name","Relapse over 12 months"
"CD013874_pub3_data","Analysis.name","Serious adverse events (SAEs)"
"CD013874_pub3_data","Analysis.name","Common infections"
"CD013874_pub3_data","Analysis.name","Cancer"
"CD013874_pub3_data","Analysis.name","Mortality"
"CD013874_pub3_data","Analysis.name","Annualised relapse rate "
"CD013874_pub3_data","Analysis.name","Gadolinium MRI lesions over 12 months"
"CD013874_pub3_data","Analysis.name","Cardiovascular events"
"CD013874_pub3_data","Analysis.name","Time to disability worsening over 24 months' follow-up"
"CD013874_pub3_data","Analysis.name","Time to relapse over 18 to 24 months' follow-up"
"CD013874_pub3_data","Analysis.name","Serious adverse events assessed with Grades 3/4 CTCAE over 18 to 24 months' follow-up"
"CD013874_pub3_data","Analysis.name","Common infections over 18 to 72 months' follow-up"
"CD013874_pub3_data","Analysis.name","Time to cancer over 24 to 36 months' follow-up"
"CD013874_pub3_data","Analysis.name","Mortality over 24 months' follow-up"
"CD013874_pub3_data","Analysis.name","Time to mortality over 24 months' follow-up"
"CD013874_pub3_data","Analysis.name","Annualised relapse rate (change from baseline) – by type of DMT"
"CD013874_pub3_data","Analysis.name","Annualised relapse rate (end point) – by type of DMT"
"CD013874_pub3_data","Analysis.name","MRI gadolinium-enhancing lesions over 18 to 24 months' follow-up"
"CD013874_pub3_data","Analysis.name","MRI gadolinium-enhancing lesions or new T2 lesions over 12 to 24 months' follow-up"
"CD013874_pub3_data","Analysis.name","Treatment discontinuation due to adverse events  over 12 to 24 months' follow-up – by type of DMT"
"CD013874_pub3_data","Analysis.name","Cardiovascular events over 18 to 24 months' follow-up – by type of DMT"
"CD013874_pub3_data","Analysis.name","Time to cardiovascular events over 24 months' follow-up"
"CD013874_pub3_data","Analysis.name","Time to depression or antidepressant use over 96 months' follow-up"
"CD013874_pub3_data","Analysis.name","Serious adverse events"
"CD013874_pub3_data","Analysis.name","Serious adverse events "
"CD013874_pub3_data","Analysis.name","Common infections – by different DMTs"
"CD013874_pub3_data","Analysis.name","Gadolinium MRI lesions "
"CD013874_pub3_data","Analysis.name","Treatment discontinuation due to adverse events "
"CD013874_pub3_data","Analysis.name","Opportunistic infections"
"CD013874_pub3_data","Analysis.name","Time to disability worsening over 36 months' follow-up"
"CD013874_pub3_data","Analysis.name","Time to disability worsening over 18 months' follow-up"
"CD013874_pub3_data","Analysis.name","Relapse over 24 months – by type of DMT (unadjusted data)"
"CD013874_pub3_data","Analysis.name","Common infections – by type of DMT"
"CD013874_pub3_data","Analysis.name","Cancer – by type of DMT"
"CD013874_pub3_data","Analysis.name","T2 MRI lesions – by DMT (unadjusted data)"
"CD013874_pub3_data","Analysis.name","Gadolinium MRI lesions (unadjusted data)"
"CD013874_pub3_data","Analysis.name","Discontinuation due to adverse events – by type of DMT"
"CD013874_pub3_data","Analysis.name","Cardiovascular events – by DMT"
"CD013874_pub3_data","Analysis.name","First infusion reaction"
"CD013874_pub3_data","Analysis.name","Difference in two-year relapse rate"
"CD013874_pub3_data","Subgroup","Rituximab vs fingolimod"
"CD013874_pub3_data","Subgroup","Rituximab vs natalizumab"
"CD013874_pub3_data","Subgroup","Rituximab vs interferons beta or glatiramer acetate"
"CD013874_pub3_data","Subgroup","Rituximab vs dimethyl fumarate"
"CD013874_pub3_data","Subgroup","Rituximab vs interferon beta or glatiramer acetate"
"CD013874_pub3_data","Subgroup","SAEs over 12 months in relapsing MS"
"CD013874_pub3_data","Subgroup","Common infections over 24 months in secondary progressive MS"
"CD013874_pub3_data","Subgroup","Common infections over 12 months in relapsing MS"
"CD013874_pub3_data","Subgroup","Relapsing MS over 12 months"
"CD013874_pub3_data","Subgroup","Rituximab when switching from another DMT in relapsing MS"
"CD013874_pub3_data","Subgroup","Rituximab when switching from another DMT in secondary progressive MS"
"CD013874_pub3_data","Subgroup","Rituximab vs interferons or glatiramer"
"CD013874_pub3_data","Subgroup","Rituximab vs alemtuzumab"
"CD013874_pub3_data","Subgroup","Rituximab vs ocrelizumab"
"CD013874_pub3_data","Subgroup","Rituximab versus fingolimod"
"CD013874_pub3_data","Subgroup","Rituximab versus natalizumab"
"CD013874_pub3_data","Subgroup","Rituximab versus dimethyl fumarate"
"CD013874_pub3_data","Subgroup","Rituximab versus ocrelizumab"
"CD013874_pub3_data","Subgroup","Rituximab versus cladribine"
"CD013874_pub3_data","Subgroup","Rituximab versus interferons"
"CD013874_pub3_data","Subgroup","Rituximab versus glatiramer acetate"
"CD013874_pub3_data","Subgroup","Rituximab vs glatiramer acetate"
"CD013874_pub3_data","Subgroup","Rituximab vs cyclophosphamide"
"CD013874_pub3_data","Subgroup","Rituximab vs glatiramer acetate "
"CD013874_pub3_data","Subgroup","Rituximab vs other DMTs"
"CD013874_pub3_data","Subgroup","Rituximab versus ocrelizuman"
"CD013875_pub2_data","Analysis.group","1"
"CD013875_pub2_data","Analysis.group","2"
"CD013875_pub2_data","Analysis.group","3"
"CD013875_pub2_data","Analysis.name","Live birth (or ongoing pregnancy) – low risk of bias"
"CD013875_pub2_data","Analysis.name","Live birth (or ongoing pregnancy) – all studies"
"CD013875_pub2_data","Analysis.name","Live birth (or ongoing pregnancy) – sensitivity analysis (risk ratio)"
"CD013875_pub2_data","Analysis.name","Live birth (or ongoing pregnancy) – sensitivity analysis (live birth only)"
"CD013875_pub2_data","Analysis.name","Miscarriage – low risk of bias"
"CD013875_pub2_data","Analysis.name","Miscarriage – all studies"
"CD013875_pub2_data","Analysis.name","Miscarriage – sensitivity analysis (risk ratio)"
"CD013875_pub2_data","Analysis.name","Miscarriage – sensitivity analysis (per clinical pregnancy)"
"CD013875_pub2_data","Analysis.name","Clinical pregnancy – low risk of bias"
"CD013875_pub2_data","Analysis.name","Clinical pregnancy – all studies"
"CD013875_pub2_data","Analysis.name","Clinical pregnancy – sensitivity analysis (risk ratio)"
"CD013875_pub2_data","Analysis.name","Clinical pregnancy – sensitivity analysis (full text only)"
"CD013875_pub2_data","Analysis.name","Multiple pregnancy – all studies"
"CD013875_pub2_data","Analysis.name","Multiple pregnancy – sensitivity analysis (risk ratio)"
"CD013875_pub2_data","Analysis.name","Ectopic pregnancy – low risk of bias"
"CD013875_pub2_data","Analysis.name","Ectopic pregnancy – sensitivity analysis (risk ratio)"
"CD013875_pub2_data","Analysis.name","Preterm delivery"
"CD013875_pub2_data","Analysis.name","Preterm delivery – sensitivity analysis (risk ratio)"
"CD013875_pub2_data","Analysis.name","Live birth"
"CD013875_pub2_data","Analysis.name","Live birth – sensitivity analysis (risk ratio)"
"CD013875_pub2_data","Analysis.name","Miscarriage"
"CD013875_pub2_data","Analysis.name","Clinical pregnancy"
"CD013875_pub2_data","Analysis.name","Ongoing pregnancy"
"CD013875_pub2_data","Analysis.name","Ongoing pregnancy – sensitivity analysis (risk ratio)"
"CD014040_pub2_data","Analysis.group","1"
"CD014040_pub2_data","Analysis.group","2"
"CD014040_pub2_data","Analysis.name","Live birth per participant randomized (low risk of bias studies)"
"CD014040_pub2_data","Analysis.name","Live birth per participant randomized (all studies)"
"CD014040_pub2_data","Analysis.name","Miscarriage rate per participant (low risk of bias studies)"
"CD014040_pub2_data","Analysis.name","Miscarriage per participant randomized (all studies)"
"CD014040_pub2_data","Analysis.name","Clinical pregnancy rate per participant (low risk of bias studies)"
"CD014040_pub2_data","Analysis.name","Clinical pregnancy per participant randomized (all studies)"
"CD014040_pub2_data","Analysis.name","Multiple pregnancy per participant randomized (low risk of bias studies)"
"CD014040_pub2_data","Analysis.name","Total fertilization failure rate per participant randomized (low risk of bias studies)"
"CD014040_pub2_data","Analysis.name","Total fertilization failure per participant (all studies)"
"CD014040_pub2_data","Analysis.name","Still birth rate per participant randomized (low risk of bias studies)"
"CD014040_pub2_data","Analysis.name","Fertilization rate "
"CD014040_pub2_data","Analysis.name","Cleavage rate"
"CD014040_pub2_data","Analysis.name","Blastocyst development rate"
"CD014040_pub2_data","Subgroup","Male factor"
"CD014040_pub2_data","Subgroup","Low or no fertilization"
"CD014040_pub2_data","Subgroup","Previous low or no fertilization"
"CD014040_pub2_data","Subgroup","Unselected population"
"CD014040_pub2_data","Subgroup","Male factor "
"CD014089_data","Analysis.group","1"
"CD014089_data","Analysis.group","2"
"CD014089_data","Analysis.group","3"
"CD014089_data","Analysis.group","4"
"CD014089_data","Analysis.group","5"
"CD014089_data","Analysis.group","6"
"CD014089_data","Analysis.name","Frequency of attacks (average per week)"
"CD014089_data","Analysis.name","Duration of attacks (average attack duration, minutes)"
"CD014089_data","Analysis.name","Severity of attacks (0 to 10 VAS)"
"CD014089_data","Analysis.name","Pain (0 to 10 VAS)"
"CD014089_data","Analysis.name","Patient global assessment"
"CD014089_data","Analysis.name","Function"
"CD014089_data","Analysis.name","Raynaud's Condition Score "
"CD014089_data","Analysis.name","Physician global assessment"
"CD014089_data","Analysis.name","Number of people with healed digital ulcers"
"CD014089_data","Analysis.name","Number of people with new digital ulcers"
"CD014089_data","Analysis.name","Adverse effects"
"CD014089_data","Analysis.name","Duration of attacks (minutes)"
"CD014089_data","Subgroup","Cross-over: endline changes"
"CD014089_data","Subgroup","Cross-over: change of changes"
"CD014089_data","Subgroup","Parallel RCTs"
"CD014089_data","Subgroup","Headache"
"CD014089_data","Subgroup","Myalgia"
"CD014089_data","Subgroup","Dizziness"
"CD014089_data","Subgroup","Primary Raynaud's phenomenon"
"CD014089_data","Subgroup","Secondary Raynaud's phenomenon"
"CD014089_data","Subgroup","Tadalafil"
"CD014089_data","Subgroup","Sildenafil"
"CD014089_data","Subgroup","Vardenafil"
"CD014089_data","Subgroup","PF-00489791"
"CD014089_data","Subgroup","Sildenafil 100 mg/day"
"CD014089_data","Subgroup","Sildenafil 200 mg/day"
"CD014145_pub2_data","Analysis.group","1"
"CD014145_pub2_data","Analysis.group","2"
"CD014145_pub2_data","Analysis.name","Failed apnea reduction after 2 to 7 days"
"CD014145_pub2_data","Analysis.name","Need for positive pressure ventilation after initiation of treatment"
"CD014145_pub2_data","Analysis.name","Side effects causing cessation of therapy"
"CD014145_pub2_data","Analysis.name","'Clinical apnea' after initiation of treatment"
"CD014145_pub2_data","Analysis.name","Failed extubation (unable to wean from (intermittent positive pressure ventilation) IPPV and extubate or reintubation for IPPV within 1 week)"
"CD014145_pub2_data","Analysis.name","Duration of positive pressure ventilation after initiation of treatment"
"CD014145_pub2_data","Analysis.name","Duration of oxygen therapy (days)"
"CD014145_pub2_data","Analysis.name","Necrotizing enterocolitis (NEC) stage 2 or greater"
"CD014145_pub2_data","Analysis.name","Retinopathy of prematurity (ROP) (any stages)"
"CD014145_pub2_data","Analysis.name","Oxygen at 28 to 30 days"
"CD014145_pub2_data","Analysis.name","Death (at any time during initial hospitalization)"
"CD014145_pub2_data","Subgroup","Doxapram compared to no treatment for the treatment of apnea"
"CD014145_pub2_data","Subgroup","Doxapram compared to alternative treatment for the treatment of apnea"
"CD014145_pub2_data","Subgroup","Doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea"
"CD014145_pub2_data","Subgroup","Doxapram plus methylxanthine compared to methylxanthine alone for the prevention of reintubation"
"CD014145_pub2_data","Subgroup","Doxapram compared to alternative treatment for the prevention of reintubation in preterm infants"
"CD014145_pub2_data","Subgroup","Doxapram plus methylxanthine compared to methylxanthine alone for the prevention of reintubation in preterm infants"
"CD014145_pub2_data","Subgroup","Doxapram plus methylxanthine compared to methylxanthine alone for prevention of reintubation in preterm infants"
"CD014160_pub2_data","Analysis.group","1"
"CD014160_pub2_data","Analysis.name","Duration of any pharmacological treatment for neonatal abstinence syndrome"
"CD014160_pub2_data","Analysis.name","Adverse events (e.g. local irritation, vital sign instability)"
"CD014160_pub2_data","Analysis.name","Length of hospital stay"
"CD014160_pub2_data","Analysis.name","Duration of oral morphine therapy for neonatal abstinence syndrome, during hospital admission"
"CD014160_pub2_data","Analysis.name","Duration of oral phenobarbital therapy for neonatal abstinence syndrome, during hospital admission"
"CD014300_pub2_data","Analysis.group","1"
"CD014300_pub2_data","Analysis.name","Mental well-being at study endpoint: children"
"CD014300_pub2_data","Analysis.name","Mental well-being at follow-up: children"
"CD014300_pub2_data","Analysis.name","Mental well-being at study endpoint: adults"
"CD014300_pub2_data","Analysis.name","Mental well-being at follow-up: adults"
"CD014300_pub2_data","Analysis.name","Functioning at study endpoint: children"
"CD014300_pub2_data","Analysis.name","Functioning at follow-up: children"
"CD014300_pub2_data","Analysis.name","Resilience at study endpoint: children"
"CD014300_pub2_data","Analysis.name","Resilience at follow-up: children"
"CD014300_pub2_data","Analysis.name","Coping at study endpoint: children"
"CD014300_pub2_data","Analysis.name","Hope at study endpoint: children"
"CD014300_pub2_data","Analysis.name","Prosocial behaviour at study endpoint: children"
"CD014300_pub2_data","Analysis.name","Prosocial behaviour at follow-up: children"
"CD014300_pub2_data","Analysis.name","Acceptability at study endpoint: children"
"CD014300_pub2_data","Analysis.name","Acceptability at study endpoint: adults"
"CD014300_pub2_data","Subgroup","Girls First Resilience Curriculum"
"CD014300_pub2_data","Subgroup","Teaching Recovery Techniques (TRT)"
"CD014300_pub2_data","Subgroup","Qaderoon intervention"
"CD014300_pub2_data","Subgroup","International Child Development Program (ICDP)"
"CD014300_pub2_data","Subgroup","Caregiver Support Intervention (CSI)"
"CD014300_pub2_data","Subgroup","ERSAE-Stress-Prosocial (ESPS)"
"CD014300_pub2_data","Subgroup","Advancing Adolescents"
"CD014300_pub2_data","Subgroup","Life Skills Training (LST)"
"CD014300_pub2_data","Subgroup","ERSAE-Stress-Prosocial (ESP)"
"CD014300_pub2_data","Subgroup","Teaching recovery techniques"
"CD014300_pub2_data","Subgroup","Psychosocial intervention"
"CD014300_pub2_data","Subgroup","FRIENDS program"
"CD014428_pub2_data","Analysis.group","1"
"CD014428_pub2_data","Analysis.group","2"
"CD014428_pub2_data","Analysis.group","3"
"CD014428_pub2_data","Analysis.group","4"
"CD014428_pub2_data","Analysis.group","5"
"CD014428_pub2_data","Analysis.group","6"
"CD014428_pub2_data","Analysis.name","Pain intensity"
"CD014428_pub2_data","Analysis.name","Function"
"CD014428_pub2_data","Analysis.name","Anxiety (Anxiety Component Summary)"
"CD014428_pub2_data","Analysis.name","Depression (Depression Component Summary)"
"CD014428_pub2_data","Analysis.name","Health-related quality of life (total summary)"
"CD014428_pub2_data","Analysis.name","Health-related quality of life (Physical Component Summary)"
"CD014428_pub2_data","Analysis.name","Health-related quality of life (Mental Component Summary)"
"CD014428_pub2_data","Analysis.name","Fear avoidance (Physical Activity Component Summary)"
"CD014428_pub2_data","Analysis.name","Fear avoidance (Work Component Summary)"
"CD014428_pub2_data","Analysis.name","Adherence"
"CD014428_pub2_data","Analysis.name","Anxiety"
"CD014428_pub2_data","Analysis.name","Depression"
"CD014428_pub2_data","Subgroup","Short-term (≤ 3 months after randomisation)"
"CD014428_pub2_data","Subgroup","Intermediate-term (> 3 months to < 12 months after randomisation)"
"CD014428_pub2_data","Subgroup","Long-term (≥ 12 months after randomisation)"
"CD014428_pub2_data","Subgroup","Immediate-term (≤ 2 weeks after randomisation)"
"CD014428_pub2_data","Subgroup","Short-term (≤ 3 months after randomisation; assessed with: training frequency)"
"CD014497_pub2_data","Analysis.group","1"
"CD014497_pub2_data","Analysis.name","Induction of clinical Remision"
"CD014497_pub2_data","Analysis.name","Endoscopic remision"
"CD014541_pub2_data","Analysis.group","1"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: short-term (45 days or fewer)"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: short-term (45 days or fewer); random-effects sensitivity anaysis"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: short-term (45 days or fewer); COVID-19 sensitivity analysis"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: short-term (45 days or fewer); same extended agent sensitivity analysis"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: long-term (more than 45 days)"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: short-term (45 days or fewer); men versus women subgroup analysis"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: short-term (45 days or fewer); ≥ 75 years versus < 75 years of age subgroup analysis"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: short-term (45 days or fewer); history of cancer versus no history of cancer subgroup analysis"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: short-term (45 days or fewer); positive D-dimer test versus no positive D-dimer test subgroup analysis"
"CD014541_pub2_data","Analysis.name","Symptomatic VTE: short-term (45 days or fewer); admitting diagnosis of acute infection versus no acute infection subgroup analysis"
"CD014541_pub2_data","Analysis.name","Major bleeding: short-term (45 days or fewer)"
"CD014541_pub2_data","Analysis.name","Major bleeding: short-term (45 days or fewer); COVID-19 sensitivty analysis"
"CD014541_pub2_data","Analysis.name","Major bleeding: short-term (45 days or fewer); same extended agent sensitivity analysis"
"CD014541_pub2_data","Analysis.name","Major bleeding: short-term (45 days or fewer); men versus women subgroup analysis"
"CD014541_pub2_data","Analysis.name","Major bleeding: short-term (45 days or less); ≥ 75 years versus < 75 years of age subgroup analysis"
"CD014541_pub2_data","Analysis.name","Major bleeding: short-term (45 days or fewer); history of cancer versus no history of cancer subgroup analysis"
"CD014541_pub2_data","Analysis.name","Major bleeding: short-term (45 days or fewer); positive D-dimer test versus no positive D-dimer test subgroup analysis"
"CD014541_pub2_data","Analysis.name","Major bleeding: short-term (45 days or fewer); admitting diagnosis of acute infection versus no acute infection subgroup analysis"
"CD014541_pub2_data","Analysis.name","All-cause mortality: short-term (45 days or fewer)"
"CD014541_pub2_data","Analysis.name","All-cause mortality: short-term (45 days or fewer); same extended agent sensitivity analysis"
"CD014541_pub2_data","Analysis.name","All-cause mortality: long-term (more than 45 days)"
"CD014541_pub2_data","Analysis.name","Total VTE: short-term (45 days or fewer)"
"CD014541_pub2_data","Analysis.name","Total VTE: long-term (more than 45 days)"
"CD014541_pub2_data","Analysis.name","Composite of fatal and irreversible vascular events: short-term (45 days or fewer)"
"CD014541_pub2_data","Analysis.name","Composite of fatal and irreversible vascular events: long-term (more than 45 days)"
"CD014541_pub2_data","Analysis.name","Fatal bleeding: short-term (45 days or fewer)"
"CD014541_pub2_data","Analysis.name","VTE-related mortality: short-term (45 days or fewer)"
"CD014541_pub2_data","Analysis.name","VTE-related mortality: long-term (more than 45 days)"
"CD014541_pub2_data","Subgroup","Men"
"CD014541_pub2_data","Subgroup","Women"
"CD014541_pub2_data","Subgroup","< 75 years"
"CD014541_pub2_data","Subgroup","≥ 75 years"
"CD014541_pub2_data","Subgroup","History of cancer"
"CD014541_pub2_data","Subgroup","No history of cancer"
"CD014541_pub2_data","Subgroup","Positive D-dimer test"
"CD014541_pub2_data","Subgroup","Negative D-dimer test"
"CD014541_pub2_data","Subgroup","No acute infection"
"CD014541_pub2_data","Subgroup","Acute infection"
"CD014544_pub2_data","Analysis.group","1"
"CD014544_pub2_data","Analysis.group","2"
"CD014544_pub2_data","Analysis.group","3"
"CD014544_pub2_data","Analysis.group","4"
"CD014544_pub2_data","Analysis.group","5"
"CD014544_pub2_data","Analysis.group","6"
"CD014544_pub2_data","Analysis.group","7"
"CD014544_pub2_data","Analysis.name","Annualized Bleeding Rates (ABR)"
"CD014544_pub2_data","Analysis.name","Proportion with zero bleeds (risk ratio)"
"CD014544_pub2_data","Analysis.name","HRQoL—Haem-A-QoL"
"CD014544_pub2_data","Analysis.name","HRQoL—EQ-5D-5L VAS"
"CD014544_pub2_data","Analysis.name","HRQoL—EQ-5D-5L Utility Index Score"
"CD014544_pub2_data","Analysis.name","Adverse events"
"CD014544_pub2_data","Analysis.name","Bleeding rates"
"CD014544_pub2_data","Analysis.name","HRQoL—SF-36v2"
"CD014544_pub2_data","Analysis.name","Bleeding rates (fixed effects model)"
"CD014544_pub2_data","Analysis.name","Proportion of participants with zero bleeds (risk ratio)"
"CD014544_pub2_data","Analysis.name","Proportion of participants with zero bleeds "
"CD014544_pub2_data","Analysis.name","Proportion of participants with zero bleeds"
"CD014544_pub2_data","Analysis.name","Change in HRQoL—Haem-A-QoL"
"CD014544_pub2_data","Subgroup","Annualized spontaneous bleeding rate (AsBR)"
"CD014544_pub2_data","Subgroup","ABR - All treated bleeds "
"CD014544_pub2_data","Subgroup","Annualized target joint Bleeding Rates (AtjBR) "
"CD014544_pub2_data","Subgroup","Annualized Bleeding Rates (ABR) - all bleeds"
"CD014544_pub2_data","Subgroup","Annualized joint Bleeding Rates (AjBR)"
"CD014544_pub2_data","Subgroup","Emicizumab"
"CD014544_pub2_data","Subgroup","Change from baseline in total score"
"CD014544_pub2_data","Subgroup","Change from baseline in physical health score"
"CD014544_pub2_data","Subgroup","EQ-5D-5L Visual Analog Scale Scores"
"CD014544_pub2_data","Subgroup","EQ-5D-5L Index utility score"
"CD014544_pub2_data","Subgroup","Serious adverse events "
"CD014544_pub2_data","Subgroup","Serious infections"
"CD014544_pub2_data","Subgroup","Other infections"
"CD014544_pub2_data","Subgroup","Adverse events - All"
"CD014544_pub2_data","Subgroup","Injection site reactions"
"CD014544_pub2_data","Subgroup","Other adverse events (not including serious adverse events)"
"CD014544_pub2_data","Subgroup","Upper respiratory tract infections"
"CD014544_pub2_data","Subgroup","All treated bleeds "
"CD014544_pub2_data","Subgroup","Annualized joint bleeding rate (AjBR)"
"CD014544_pub2_data","Subgroup","Annualized bleeding rate (ABR) - All bleeds"
"CD014544_pub2_data","Subgroup","Annualized spontaneous bleeding rate (AsBR)  "
"CD014544_pub2_data","Subgroup","Fitusiran"
"CD014544_pub2_data","Subgroup","Annualized Bleeding Rate (ABR), Treated Bleeds - Concizumab"
"CD014544_pub2_data","Subgroup","Annualized spontaneous bleeding rate (AsBR) - Concizumab"
"CD014544_pub2_data","Subgroup","Annualized joint bleeding rate (AjBR) - Concizumab"
"CD014544_pub2_data","Subgroup","Annualized target joint bleeding rate (AtjBR) - Concizumab"
"CD014544_pub2_data","Subgroup","Annualized bleeding rates (ABR), All bleeds - Concizumab"
"CD014544_pub2_data","Subgroup","Concizumab"
"CD014544_pub2_data","Subgroup","Change from baseline in SF-36 mental component score"
"CD014544_pub2_data","Subgroup","Change from baseline in SF-36 physical component score"
"CD014544_pub2_data","Subgroup","All adverse events"
"CD014544_pub2_data","Subgroup","Serious adverse events"
"CD014544_pub2_data","Subgroup","Upper respiratory tract infection"
"CD014544_pub2_data","Subgroup","Injection site reaction"
"CD014544_pub2_data","Subgroup","Annualized bleeding rate (ABR) - All treated bleeds"
"CD014544_pub2_data","Subgroup","Annualized target joint bleeding rate (AtjBR)"
"CD014544_pub2_data","Subgroup","Annualized bleeding rates (ABR) - All bleeds"
"CD014544_pub2_data","Subgroup","Proportion with zero bleeds (risk ratio)"
"CD014544_pub2_data","Subgroup","Haem-A-QoL physical health score, adjusted for baseline score"
"CD014544_pub2_data","Subgroup","Haem-A-QoL total score, adjusted for baseline score "
"CD014544_pub2_data","Subgroup","EQ-5D-5L Visual Analog Scale scores, adjusted for baseline score"
"CD014544_pub2_data","Subgroup","EQ-5D-5L index utility score, adjusted for baseline score"
"CD014544_pub2_data","Subgroup","Proportion with zero bleeds"
"CD014544_pub2_data","Subgroup","Proportion with zero bleeds "
"CD014544_pub2_data","Subgroup","Difference in Haem-A-QoL total score, adjusted for baseline score (Emicizumab)"
"CD014544_pub2_data","Subgroup","Difference in Haem-A-QoL physical health score, adjusted for baseline score (Emicizumab)"
"CD014544_pub2_data","Subgroup","Change from baseline in Haem-A-QoL, total health score"
"CD014544_pub2_data","Subgroup","Change from baseline in Haem-A-QoL, physical health score"
"CD014573_data","Analysis.group","1"
"CD014573_data","Analysis.group","2"
"CD014573_data","Analysis.name","Cases of cholera (2 doses + booster dose; 2-year follow-up; per-protocol analysis)"
"CD014573_data","Analysis.name","Cases of cholera (2 doses ± booster dose; 5-month and 2-year follow-up; per-protocol analysis)"
"CD014573_data","Analysis.name","Cases of cholera (2 doses; 1-year follow-up; per-protocol analysis)"
"CD014573_data","Analysis.name","Cases of cholera (2 doses; 2-year follow-up; per-protocol analysis)"
"CD014573_data","Analysis.name","Cases of cholera (2 doses; 5-year follow-up; per-protocol analysis)"
"CD014573_data","Analysis.name","Cases of cholera (1 dose; 6-month follow-up; per-protocol analysis)"
"CD014573_data","Analysis.name","Cases of severe dehydrating cholera (1 dose; 6-month follow-up; per-protocol analysis)"
"CD014573_data","Analysis.name","Cases of cholera (1 dose; 2-year follow-up; per-protocol analysis)"
"CD014573_data","Analysis.name","Cases of severe dehydrating cholera (1 dose; 2-year follow-up; per-protocol analysis)"
"CD014574_pub2_data","Analysis.group","1"
"CD014574_pub2_data","Analysis.group","2"
"CD014574_pub2_data","Analysis.group","3"
"CD014574_pub2_data","Analysis.name","Improvement in symptom severity: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","Improvement in functional ability: long term  (> 9 months)"
"CD014574_pub2_data","Analysis.name","Steroid sparing effect: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","Relapse requiring rescue therapy: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","Serious adverse events: long term "
"CD014574_pub2_data","Analysis.name","Improvement in symptom severity: medium term (2-9 months)"
"CD014574_pub2_data","Analysis.name","Improvement in symptom severity: short term (< 2 months)"
"CD014574_pub2_data","Analysis.name","Improvement in functional ability: medium term (2-9 months)"
"CD014574_pub2_data","Analysis.name","Improvement in functional ability: short term (< 2 months)"
"CD014574_pub2_data","Analysis.name","Clinically significant improvement in QMG: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","Clinically significant improvement in QMG: medium term  (2-9 months)"
"CD014574_pub2_data","Analysis.name","Clinically significant improvement in QMG: short term (< 2 months)"
"CD014574_pub2_data","Analysis.name","Clinically significant improvement in MG-ADL: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","Clinially significant improvement in MG-ADL: medium term (2-9 months)"
"CD014574_pub2_data","Analysis.name","Clinically significant improvement in MG-ADL: short term (< 2 months)"
"CD014574_pub2_data","Analysis.name","MGC score: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","MGC score: medium term (2-9 months)"
"CD014574_pub2_data","Analysis.name","MGC score: short term (< 2 months)"
"CD014574_pub2_data","Analysis.name","Clinically significant improvement in MGC score: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","Clinically significant improvement in MGC: medium term (2-9 months)"
"CD014574_pub2_data","Analysis.name","Clinically significant improvement in MGC: short term (< 2 months)"
"CD014574_pub2_data","Analysis.name","Steroid sparing effect: medium term (2-9 months)"
"CD014574_pub2_data","Analysis.name","Steroid sparing effect: short term (< 2 months)"
"CD014574_pub2_data","Analysis.name","Relapse requiring rescue therapy: medium term (2-9 months)"
"CD014574_pub2_data","Analysis.name","Quality of life: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","Quality of life: medium term (2-9 months)"
"CD014574_pub2_data","Analysis.name","Quality of life: short term (< 2 months)"
"CD014574_pub2_data","Analysis.name","Hospital admissions: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","Antibody titre: long term (> 9 months)"
"CD014574_pub2_data","Analysis.name","Antibody titre: medium term (2-9 months)"
"CD014574_pub2_data","Analysis.name","Any adverse event: long term"
"CD014574_pub2_data","Analysis.name","Treatment-related adverse events: long term"
"CD014574_pub2_data","Analysis.name","Adverse events leading to discontinuation of treatment: long term"
"CD014574_pub2_data","Analysis.name","Improvement in symptom severity (long term; > 9 months)"
"CD014574_pub2_data","Analysis.name","Improvement in functional ability (long term; > 9 months)"
"CD014574_pub2_data","Analysis.name","Steroid sparing effect (long term; > 9 months)"
"CD014574_pub2_data","Analysis.name","Relapse requiring rescue therapy (long term; > 9 months)"
"CD014574_pub2_data","Analysis.name","Serious adverse events"
"CD014574_pub2_data","Subgroup","Treatment Naive"
"CD014574_pub2_data","Subgroup","Refractory"
"CD014580_pub2_data","Analysis.group","1"
"CD014580_pub2_data","Analysis.group","2"
"CD014580_pub2_data","Analysis.group","3"
"CD014580_pub2_data","Analysis.group","4"
"CD014580_pub2_data","Analysis.group","5"
"CD014580_pub2_data","Analysis.group","6"
"CD014580_pub2_data","Analysis.group","7"
"CD014580_pub2_data","Analysis.name","Treatment success"
"CD014580_pub2_data","Analysis.name","Stool consistency"
"CD014580_pub2_data","Analysis.name","Painful defecation"
"CD014580_pub2_data","Analysis.name","Faecal incontinence"
"CD014580_pub2_data","Analysis.name","Adverse events"
"CD014580_pub2_data","Analysis.name","Abdominal pain"
"CD014580_pub2_data","Analysis.name","Non-fulfilment of Rome criteria"
"CD014580_pub2_data","Analysis.name","Frequency of defecation"
"CD014580_pub2_data","Analysis.name","Quality of life"
"CD014580_pub2_data","Analysis.name","Quality of life (child-reported)"
"CD014580_pub2_data","Analysis.name","Quality of life (parent-reported)"
"CD014585_pub2_data","Analysis.group","1"
"CD014585_pub2_data","Analysis.group","2"
"CD014585_pub2_data","Analysis.group","3"
"CD014585_pub2_data","Analysis.group","4"
"CD014585_pub2_data","Analysis.group","5"
"CD014585_pub2_data","Analysis.name","Global symptoms of dyspepsia (dichotomous)"
"CD014585_pub2_data","Analysis.name","Global symptoms of dyspepsia (continuous)"
"CD014585_pub2_data","Analysis.name","Incident ulcer"
"CD014585_pub2_data","Analysis.name","Adverse events"
"CD014585_pub2_data","Analysis.name","Ulcer complications "
"CD014585_pub2_data","Analysis.name","Quality of life"
"CD014585_pub2_data","Analysis.name","Global symptoms of dyspepsia (Dichotomous)"
"CD014585_pub2_data","Subgroup","Non-selective NSAID"
"CD014585_pub2_data","Subgroup","Selective NSAID"
"CD014585_pub2_data","Subgroup","Selective"
"CD014585_pub2_data","Subgroup","Non-selective"
"CD014585_pub2_data","Subgroup","Omeprazole"
"CD014585_pub2_data","Subgroup","Esomeprazole"
"CD014585_pub2_data","Subgroup","Pantoprazole"
"CD014585_pub2_data","Subgroup","Lansoprazole"
"CD014594_pub2_data","Analysis.group","1"
"CD014594_pub2_data","Analysis.group","2"
"CD014594_pub2_data","Analysis.group","3"
"CD014594_pub2_data","Analysis.group","4"
"CD014594_pub2_data","Analysis.group","5"
"CD014594_pub2_data","Analysis.group","6"
"CD014594_pub2_data","Analysis.group","7"
"CD014594_pub2_data","Analysis.group","8"
"CD014594_pub2_data","Analysis.group","9"
"CD014594_pub2_data","Analysis.group","10"
"CD014594_pub2_data","Analysis.group","11"
"CD014594_pub2_data","Analysis.group","12"
"CD014594_pub2_data","Analysis.group","13"
"CD014594_pub2_data","Analysis.name","First-pass success"
"CD014594_pub2_data","Analysis.name","Sensitivity analysis: first-pass success excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","Time to successful CFA access"
"CD014594_pub2_data","Analysis.name","Time to successful CFA access: sensitivity analysis from local anesthetic"
"CD014594_pub2_data","Analysis.name","Time to successful CFA access: sensitivity analysis from fluoroscopy table movement or US probe application"
"CD014594_pub2_data","Analysis.name","Time to successful CFA access: sensitivity analysis from skin penetration"
"CD014594_pub2_data","Analysis.name","Time to successful CFA access: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","Major bleeding"
"CD014594_pub2_data","Analysis.name","Minor bleeding"
"CD014594_pub2_data","Analysis.name","Minor bleeding: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","Major bleeding: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","Overall cannulation success"
"CD014594_pub2_data","Analysis.name","Venipuncture"
"CD014594_pub2_data","Analysis.name","Venipuncture: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","VAS pain score"
"CD014594_pub2_data","Analysis.name","Additional analgesia"
"CD014594_pub2_data","Analysis.name","Number of attempts"
"CD014594_pub2_data","Analysis.name","Number of attempts: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","Retroperitoneal hematoma"
"CD014594_pub2_data","Analysis.name","Retroperitoneal hematoma: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","Pseudoaneurysm formation"
"CD014594_pub2_data","Analysis.name","Pseudoaneurysm formation: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","Dissection"
"CD014594_pub2_data","Analysis.name","Dissection: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","AV fistula"
"CD014594_pub2_data","Analysis.name","AV fistula: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","Target vessel occlusion"
"CD014594_pub2_data","Analysis.name","Target vessel occlusion: sensitivity analysis excluding rescue U/S"
"CD014594_pub2_data","Analysis.name","Infection"
"CD014617_pub3_data","Analysis.group","1"
"CD014617_pub3_data","Analysis.group","2"
"CD014617_pub3_data","Analysis.name","Risk of ocular infection within one month of corneal abrasion"
"CD014617_pub3_data","Analysis.name","Proportion of eyes healed within 48 hours"
"CD014617_pub3_data","Analysis.name","Proportion of eyes healed within 48 hours - Chung 1996"
"CD014617_pub3_data","Analysis.name","Adverse events"
"CD014617_pub3_data","Subgroup","Ocular signs"
"CD014617_pub3_data","Subgroup","Conjunctivitis"
"CD014617_pub3_data","Subgroup","1% fusidic acid versus 1% chloramphenicol"
"CD014617_pub3_data","Subgroup","6% sulphacetamide sodium versus 1% chloramphenicol"
"CD014623_pub2_data","Analysis.group","1"
"CD014623_pub2_data","Analysis.name","Impairment"
"CD014623_pub2_data","Analysis.name","Symptoms of peripheral neuropathy"
"CD014623_pub2_data","Analysis.name","Quality of life"
"CD014623_pub2_data","Analysis.name","Corneal nerve fibre length (mm/mm<sup>2</sup>)"
"CD014623_pub2_data","Analysis.name","Sural sensory nerve action potential (SNAP) amplitudes (μV)"
"CD014623_pub2_data","Analysis.name","Any adverse events"
"CD014623_pub2_data","Analysis.name","Serious adverse events"
"CD014624_pub2_data","Analysis.group","1"
"CD014624_pub2_data","Analysis.group","2"
"CD014624_pub2_data","Analysis.group","3"
"CD014624_pub2_data","Analysis.name","Depression response (early phase)"
"CD014624_pub2_data","Analysis.name","Depression remission (early phase)"
"CD014624_pub2_data","Analysis.name","Adverse events (mother)"
"CD014624_pub2_data","Analysis.name","Depression severity according to HAMD (early phase)"
"CD014624_pub2_data","Analysis.name","Treatment acceptability (measured by dropouts)"
"CD014624_pub2_data","Analysis.name","Depression response (acute phase)"
"CD014624_pub2_data","Analysis.name","Depression remission (acute phase)"
"CD014624_pub2_data","Analysis.name","Depression severity (early phase)"
"CD014624_pub2_data","Analysis.name","Depression severity (acute phase)"
"CD014624_pub2_data","Analysis.name","Treatment acceptability"
"CD014624_pub2_data","Analysis.name"," Barkin Index of Maternal Functioning (early phase)"
"CD014624_pub2_data","Analysis.name"," Barkin Index of Maternal Functioning (acute phase)"
"CD014624_pub2_data","Subgroup","2 hours post-infusion"
"CD014624_pub2_data","Subgroup","4 hours post-infusion"
"CD014624_pub2_data","Subgroup","8 hours post-infusion"
"CD014624_pub2_data","Subgroup","12 hours post-infusion"
"CD014624_pub2_data","Subgroup","24 hours post-infusion"
"CD014624_pub2_data","Subgroup","36 hours post-infusion"
"CD014624_pub2_data","Subgroup","48 hours post-infusion"
"CD014624_pub2_data","Subgroup","60 hours post-infusion"
"CD014624_pub2_data","Subgroup","72 hours post-infusion"
"CD014624_pub2_data","Subgroup","7 days post-infusion"
"CD014624_pub2_data","Subgroup","30 days post-infusion"
"CD014624_pub2_data","Subgroup","Any adverse event"
"CD014624_pub2_data","Subgroup","Severe adverse event"
"CD014624_pub2_data","Subgroup","Serious adverse event"
"CD014624_pub2_data","Subgroup","Day 3"
"CD014624_pub2_data","Subgroup","Day 8"
"CD014624_pub2_data","Subgroup","Day 15"
"CD014624_pub2_data","Subgroup","Day 21"
"CD014624_pub2_data","Subgroup","Day 28"
"CD014624_pub2_data","Subgroup","Any adverse events"
"CD014624_pub2_data","Subgroup","Severe adverse events"
"CD014624_pub2_data","Subgroup","Serious adverse events"
"CD014624_pub2_data","Subgroup","Deaths"
"CD014666_pub2_data","Analysis.group","1"
"CD014666_pub2_data","Analysis.group","2"
"CD014666_pub2_data","Analysis.group","3"
"CD014666_pub2_data","Analysis.group","4"
"CD014666_pub2_data","Analysis.name","Fear of falling: subgrouped according to intervention approach"
"CD014666_pub2_data","Analysis.name","Fear of falling: subgrouped according to mean age"
"CD014666_pub2_data","Analysis.name","Fear of falling: subgrouped according to control"
"CD014666_pub2_data","Analysis.name","Fear of falling: subgrouped according to ""A Matter of Balance"" (AMB) versus non-AMB based interventions"
"CD014666_pub2_data","Analysis.name","Fear of falling: subgrouped according to group versus individual interventions"
"CD014666_pub2_data","Analysis.name","Fear of falling: subgrouped according to  AMB versus non-AMB based interventions"
"CD014666_pub2_data","Analysis.name","Activity avoidance: immediate postintervention "
"CD014666_pub2_data","Analysis.name","Occurrence of falls: immediate postintervention"
"CD014666_pub2_data","Analysis.name","Depression: immediate postintervention"
"CD014666_pub2_data","Analysis.name","Anxiety: immediate postintervention"
"CD014666_pub2_data","Analysis.name","Quality of life: immediate postintervention"
"CD014666_pub2_data","Subgroup","CBT with exercise interventions"
"CD014666_pub2_data","Subgroup","CBT only"
"CD014666_pub2_data","Subgroup","< 75 years "
"CD014666_pub2_data","Subgroup","≥ 75 years"
"CD014666_pub2_data","Subgroup","Placebo"
"CD014666_pub2_data","Subgroup","Usual care"
"CD014666_pub2_data","Subgroup","Non AMB-based interventions"
"CD014666_pub2_data","Subgroup","AMB-based interventions"
"CD014666_pub2_data","Subgroup","Individual intervention"
"CD014666_pub2_data","Subgroup","Group intervention"
"CD014666_pub2_data","Subgroup","Sustainability of effects, CBT only"
"CD014666_pub2_data","Subgroup","Sustainability of effects, CBT with exercise"
"CD014666_pub2_data","Subgroup","CBT with exercise intervention"
"CD014666_pub2_data","Subgroup","CBT with exercise"
"CD014678_pub2_data","Analysis.group","1"
"CD014678_pub2_data","Analysis.group","2"
"CD014678_pub2_data","Analysis.group","3"
"CD014678_pub2_data","Analysis.group","4"
"CD014678_pub2_data","Analysis.group","5"
"CD014678_pub2_data","Analysis.group","6"
"CD014678_pub2_data","Analysis.group","7"
"CD014678_pub2_data","Analysis.group","8"
"CD014678_pub2_data","Analysis.group","9"
"CD014678_pub2_data","Analysis.group","10"
"CD014678_pub2_data","Analysis.group","11"
"CD014678_pub2_data","Analysis.group","12"
"CD014678_pub2_data","Analysis.group","13"
"CD014678_pub2_data","Analysis.group","14"
"CD014678_pub2_data","Analysis.group","15"
"CD014678_pub2_data","Analysis.group","16"
"CD014678_pub2_data","Analysis.group","17"
"CD014678_pub2_data","Analysis.group","18"
"CD014678_pub2_data","Analysis.group","19"
"CD014678_pub2_data","Analysis.name","All-cause mortality (apixaban versus placebo)"
"CD014678_pub2_data","Analysis.name","All-cause mortality (rivaroxaban versus placebo)"
"CD014678_pub2_data","Analysis.name","All-cause mortality (dabigatran versus placebo)"
"CD014678_pub2_data","Analysis.name","Cardiovascular mortality (apixaban versus placebo)"
"CD014678_pub2_data","Analysis.name","Cardiovascular mortality (rivaroxaban versus placebo)"
"CD014678_pub2_data","Analysis.name","Cardiovascular mortality (dabigatran versus placebo)"
"CD014678_pub2_data","Analysis.name","Major bleeding (apixaban versus placebo)"
"CD014678_pub2_data","Analysis.name","Major bleeding (rivaroxaban versus placebo)"
"CD014678_pub2_data","Analysis.name","Major bleeding (dabigatran versus placebo)"
"CD014678_pub2_data","Analysis.name","All-cause mortality"
"CD014678_pub2_data","Analysis.name","Cardiovascular mortality"
"CD014678_pub2_data","Analysis.name","Major bleeding"
"CD014678_pub2_data","Analysis.name","Myocardial infarction"
"CD014678_pub2_data","Analysis.name","Stroke"
"CD014678_pub2_data","Analysis.name","Stent thrombosis"
"CD014678_pub2_data","Analysis.name","Non-major bleeding"
"CD014678_pub2_data","Analysis.name","Systemic embolism"
"CD014678_pub2_data","Subgroup","Apixaban 10 mg versus placebo"
"CD014678_pub2_data","Subgroup","Apixaban 5 mg versus placebo"
"CD014678_pub2_data","Subgroup","Apixaban total versus placebo"
"CD014678_pub2_data","Subgroup","apixaban 10mg versus placebo"
"CD014678_pub2_data","Subgroup","apixaban total versus placebo"
"CD014678_pub2_data","Subgroup","Rivaroxaban 20 mg versus placebo"
"CD014678_pub2_data","Subgroup","Rivaroxaban total versus placebo"
"CD014678_pub2_data","Subgroup","Rivaroxaban 5 mg versus placebo "
"CD014678_pub2_data","Subgroup","Rivaroxaban 10 mg versus placebo"
"CD014678_pub2_data","Subgroup","Rivaroxaban 15 mg versus placebo"
"CD014678_pub2_data","Subgroup","Rivaroxaban 5 mg versus placebo"
"CD014678_pub2_data","Subgroup","Dabigatran total versus placebo"
"CD014678_pub2_data","Subgroup","Dabigatran 150 mg BD versus placebo"
"CD014678_pub2_data","Subgroup","Dabigatran 110 mg BD versus placebo"
"CD014678_pub2_data","Subgroup","Dabigatran 75 mg BD versus placebo"
"CD014678_pub2_data","Subgroup","Dabigatran 50 mg BD versus placebo"
"CD014678_pub2_data","Subgroup","Dabigatran versus placebo"
"CD014687_pub2_data","Analysis.group","1"
"CD014687_pub2_data","Analysis.group","2"
"CD014687_pub2_data","Analysis.group","3"
"CD014687_pub2_data","Analysis.group","4"
"CD014687_pub2_data","Analysis.group","5"
"CD014687_pub2_data","Analysis.group","6"
"CD014687_pub2_data","Analysis.group","7"
"CD014687_pub2_data","Analysis.group","8"
"CD014687_pub2_data","Analysis.group","9"
"CD014687_pub2_data","Analysis.group","10"
"CD014687_pub2_data","Analysis.group","11"
"CD014687_pub2_data","Analysis.group","12"
"CD014687_pub2_data","Analysis.group","13"
"CD014687_pub2_data","Analysis.name","Pain: VAS (0-100) (final values): short term (up to 1 month)"
"CD014687_pub2_data","Analysis.name","Function: AOFAS (0-100) (final values): short term (up to 1 month)"
"CD014687_pub2_data","Analysis.name","Satisfaction (short term)"
"CD014687_pub2_data","Analysis.name","Adverse events: short term"
"CD014687_pub2_data","Analysis.name","Pain: VAS (0-100) meta-analysis (change from baseline and final values) short-term results"
"CD014687_pub2_data","Analysis.name","Pain: VAS (0-100) meta-analysis (change from baseline and final values) intermediate-term results"
"CD014687_pub2_data","Analysis.name","Pain: VAS (0-100) (final values) long-term results"
"CD014687_pub2_data","Analysis.name","Function: AOFAS (0-100) and MFPDS (0-100) meta-analysis (final values) short term"
"CD014687_pub2_data","Analysis.name","Function: AOFAS (0-100) and MFPDS (0-100) meta-analysis (final values) intermediate term"
"CD014687_pub2_data","Analysis.name","Function: MFPDS (0-100) (final values) long term"
"CD014687_pub2_data","Analysis.name","HRQoL: EQ-5D (0-1) (final values) short term"
"CD014687_pub2_data","Analysis.name","HRQoL: EQ-5D (0-1) (final values) intermediate term"
"CD014687_pub2_data","Analysis.name","HRQoL: EQ-5D (0-1) (final values) long term"
"CD014687_pub2_data","Analysis.name","Satisfaction: intermediate time point (6 months)"
"CD014687_pub2_data","Analysis.name","Adverse events: intermediate term"
"CD014687_pub2_data","Analysis.name","Pain: VAS (0-100) (final values) short term"
"CD014687_pub2_data","Analysis.name","Pain: VAS (0-100) meta-analysis (final values) intermediate term"
"CD014687_pub2_data","Analysis.name","Pain: VAS (0-100) meta-analysis (final values) long term"
"CD014687_pub2_data","Analysis.name","Function: MFPDS (17-51) (final values) short term"
"CD014687_pub2_data","Analysis.name","Function: MOXFQ (0-100) and MFPDS (17-51) meta-analysis (final values) intermediate term"
"CD014687_pub2_data","Analysis.name","Function: MOXFQ (0-100) and MFPDS (17-51) meta-analysis (final values) long term"
"CD014687_pub2_data","Analysis.name","Satisfaction: short term"
"CD014687_pub2_data","Analysis.name","Satisfaction: meta-analysis intermediate term"
"CD014687_pub2_data","Analysis.name","Satisfaction: long term"
"CD014687_pub2_data","Analysis.name","Adverse events: long term"
"CD014688_pub2_data","Analysis.group","1"
"CD014688_pub2_data","Analysis.group","2"
"CD014688_pub2_data","Analysis.group","3"
"CD014688_pub2_data","Analysis.group","4"
"CD014688_pub2_data","Analysis.name","Child/adolescent quality of life between baseline and 12 months (self-reported) "
"CD014688_pub2_data","Analysis.name","Child/adolescent quality of life between baseline and 12 months (parent proxy-reported)"
"CD014688_pub2_data","Analysis.name","Parent quality of life between baseline and 24 months "
"CD014688_pub2_data","Analysis.name","Hospitalisation rates between baseline and 12 months"
"CD014688_pub2_data","Analysis.name","Rates of emergency department attendance between baseline and 12 months"
"CD014713_pub2_data","Analysis.group","1"
"CD014713_pub2_data","Analysis.group","2"
"CD014713_pub2_data","Analysis.name","Unplanned hospital presentation rates - unplanned hospital admissions within one month (30 days)"
"CD014713_pub2_data","Analysis.name","Unplanned hospital presentation rates - unplanned hospital admissions within 12 months (365 days)"
"CD014713_pub2_data","Analysis.name","Unplanned hospital presentation rates - emergency department presentations within one month (30 days)"
"CD014713_pub2_data","Analysis.name","Unplanned hospital presentation rates - emergency department presentations within 12 months (365 days)"
"CD014713_pub2_data","Analysis.name","Utilisation of community services - hospital outpatient appointments within one month (30 days)"
"CD014722_pub2_data","Analysis.group","1"
"CD014722_pub2_data","Analysis.group","2"
"CD014722_pub2_data","Analysis.group","3"
"CD014722_pub2_data","Analysis.group","4"
"CD014722_pub2_data","Analysis.group","5"
"CD014722_pub2_data","Analysis.group","6"
"CD014722_pub2_data","Analysis.group","7"
"CD014722_pub2_data","Analysis.group","8"
"CD014722_pub2_data","Analysis.group","9"
"CD014722_pub2_data","Analysis.group","10"
"CD014722_pub2_data","Analysis.name","Diagnosis of mental disorders at 1-6 months "
"CD014722_pub2_data","Analysis.name","Diagnosis of mental disorders at 7-24 months"
"CD014722_pub2_data","Analysis.name","Quality of life at 0-1 months"
"CD014722_pub2_data","Analysis.name","Quality of life at 7-24 months "
"CD014722_pub2_data","Analysis.name","Depressive symptoms at 0-1 months"
"CD014722_pub2_data","Analysis.name","Depressive symptoms at 1-6 months"
"CD014722_pub2_data","Analysis.name","Depressive symptoms at 7-24 months"
"CD014722_pub2_data","Analysis.name","Anxiety symptoms at 0-1 months"
"CD014722_pub2_data","Analysis.name","Distress/PTSD symptoms at 0-1 months"
"CD014722_pub2_data","Analysis.name","Social outcomes at 0-1 months"
"CD014722_pub2_data","Analysis.name","Quality of life at 1-6 months "
"CD014722_pub2_data","Analysis.name","Anxiety symptoms at 1-6 months"
"CD014722_pub2_data","Analysis.name","Distress/PTSD symptoms at 0-1 months"
"CD014722_pub2_data","Analysis.name","Distress/PTSD symptoms at 1-6 months"
"CD014722_pub2_data","Analysis.name","Distress/PTSD symptoms at 7-24 months"
"CD014722_pub2_data","Analysis.name","Social outcomes at 1-6 months"
"CD014722_pub2_data","Analysis.name","Social outcomes at 7-24 months"
"CD014722_pub2_data","Analysis.name","Diagnosis of mental disorders at 0-1 months"
"CD014722_pub2_data","Analysis.name","Quality of life at 7-24  months "
"CD014722_pub2_data","Analysis.name","Adverse events at 0-1 months"
"CD014722_pub2_data","Analysis.name","Psychological functioning and impairment at 0-1 months"
"CD014722_pub2_data","Analysis.name","Psychological functioning and impairment at 1-6 months "
"CD014722_pub2_data","Analysis.name","Psychological functioning and impairment at 7-24 months"
"CD014722_pub2_data","Analysis.name","Anxiety symptoms at 1-6 months "
"CD014722_pub2_data","Analysis.name","Anxiety symptoms at 7-24 months"
"CD014722_pub2_data","Analysis.name","Distress/PTSD symptoms at 1-6 months "
"CD014722_pub2_data","Analysis.name","Distress/PTSD symptoms at 7-24 months"
"CD014722_pub2_data","Analysis.name","Psychological functioning and impairment at 7-24 months "
"CD014722_pub2_data","Analysis.name","Distress/PTSD  symptoms at 0-1 months"
"CD014722_pub2_data","Analysis.name","Social outcomes at 1-6 months "
"CD014722_pub2_data","Analysis.name","Diagnosis of mental disorders at 1 to 6 months "
"CD014722_pub2_data","Analysis.name","Diagnosis of mental disorders at 0-1 months—indicated prevention adults"
"CD014722_pub2_data","Analysis.name","Quality of life at 0-1 months—selective prevention adults"
"CD014722_pub2_data","Analysis.name","Quality of life at 1-6 months—selective prevention adults"
"CD014722_pub2_data","Analysis.name","Psychological functioning and impairment at 0-1 months—indicated prevention adults"
"CD014722_pub2_data","Analysis.name","Depressive symptoms at 0-1 months—indicated prevention adults"
"CD014722_pub2_data","Analysis.name","Distress/PTSD symptoms at 0-1 months—indicated prevention adults"
"CD014722_pub2_data","Analysis.name","Depressive symptoms at 1-6 months—indicated prevention adults"
"CD014722_pub2_data","Subgroup","Primary healthcare workers"
"CD014722_pub2_data","Subgroup","Community workers"
"CD014722_pub2_data","Subgroup","Community setting"
"CD014722_pub2_data","Subgroup","Refugee camp"
"CD014722_pub2_data","Subgroup","Other"
"CD014722_pub2_data","Subgroup","School"
"CD014736_pub2_data","Analysis.group","1"
"CD014736_pub2_data","Analysis.group","2"
"CD014736_pub2_data","Analysis.name","Maximum Walking Distance (metres)"
"CD014736_pub2_data","Analysis.name","Six-minute walk test (metres)"
"CD014736_pub2_data","Analysis.name","Pain-free walking distance at end of follow-up (change from baseline, metres)"
"CD014736_pub2_data","Analysis.name","Ankle-brachial index (ABI) - Absolute values at end of follow-up"
"CD014736_pub2_data","Analysis.name","Mortality by end of follow-up"
"CD014736_pub2_data","Analysis.name","Health-related quality of life: SF-36 Physical component - Absolute values at end of follow-up"
"CD014736_pub2_data","Analysis.name","Health-related quality of life: SF-36 Mental component - Absolute values at end of follow-up"
"CD014736_pub2_data","Analysis.name","Walking Impairment Questionnaire - Total score - Absolute values at end of follow-up"
"CD014736_pub2_data","Analysis.name","Reintervention by end of follow-up"
"CD014736_pub2_data","Subgroup","Final maximum walking distance at end of follow-up"
"CD014736_pub2_data","Subgroup","Final maximum walking distance at 6 months"
"CD014736_pub2_data","Subgroup","Change in distance from baseline to end of follow-up"
"CD014736_pub2_data","Subgroup","Absolute distance at end of follow-up"
"CD014736_pub2_data","Subgroup","Change from baseline at end of follow-up"
"CD014741_pub2_data","Analysis.group","1"
"CD014741_pub2_data","Analysis.group","2"
"CD014741_pub2_data","Analysis.group","3"
"CD014741_pub2_data","Analysis.group","4"
"CD014741_pub2_data","Analysis.group","5"
"CD014741_pub2_data","Analysis.group","6"
"CD014741_pub2_data","Analysis.name","All-cause mortality"
"CD014741_pub2_data","Analysis.name","Myocardial infarction (fatal or non-fatal)"
"CD014741_pub2_data","Analysis.name","Unstable angina"
"CD014741_pub2_data","Analysis.name","Adverse events"
"CD014741_pub2_data","Analysis.name","Adverse events (by patients)"
"CD014741_pub2_data","Analysis.name","Adverse events (any infections)"
"CD014741_pub2_data","Analysis.name","Stroke (fatal or non-fatal)"
"CD014741_pub2_data","Analysis.name","Heart failure"
"CD014741_pub2_data","Analysis.name","Myocardial Infarction (fatal or non-fatal)"
"CD014741_pub2_data","Analysis.name","Adverse events (incidence rate)"
"CD014741_pub2_data","Analysis.name","Adverse event: any infection (incidence rate)"
"CD014741_pub2_data","Analysis.name","Peripheral vascular disease"
"CD014741_pub2_data","Analysis.name","Adverse events any infection (incidence rate)"
"CD014741_pub2_data","Analysis.name","Adverse events (serious infections)"
"CD014741_pub2_data","Analysis.name","Adverse events by incidence rate"
"CD014741_pub2_data","Analysis.name","Adverse events: serious infections by incidence rate "
"CD014741_pub2_data","Analysis.name","Adverse events (any infection) incidence rate"
"CD014741_pub2_data","Analysis.name","Adverse events: incidence rate for serious infection"
"CD014741_pub2_data","Analysis.name","Quality of life"
"CD014741_pub2_data","Subgroup","Anakinra"
"CD014741_pub2_data","Subgroup","Canakinumab"
"CD014741_pub2_data","Subgroup","Tocilizumab"
"CD014741_pub2_data","Subgroup","Infliximab"
"CD014741_pub2_data","Subgroup","Etanercept"
"CD014741_pub2_data","Subgroup","All-cause mortality"
"CD014755_pub2_data","Analysis.group","1"
"CD014755_pub2_data","Analysis.group","2"
"CD014755_pub2_data","Analysis.name","Number of chemotherapy cycles to remission"
"CD014755_pub2_data","Analysis.name","Treatment success rate"
"CD014755_pub2_data","Analysis.name","Relapse "
"CD014755_pub2_data","Analysis.name","Disease-specific mortality"
"CD014755_pub2_data","Analysis.name","Death due to treatment"
"CD014755_pub2_data","Analysis.name","Pregnancy rate"
"CD014755_pub2_data","Analysis.name","Any adverse events "
"CD014755_pub2_data","Analysis.name","Adverse events (grade 3 or 4)"
"CD014755_pub2_data","Analysis.name","Emergency hysterectomy"
"CD014758_pub3_data","Analysis.group","1"
"CD014758_pub3_data","Analysis.group","2"
"CD014758_pub3_data","Analysis.group","3"
"CD014758_pub3_data","Analysis.group","4"
"CD014758_pub3_data","Analysis.group","5"
"CD014758_pub3_data","Analysis.group","6"
"CD014758_pub3_data","Analysis.group","7"
"CD014758_pub3_data","Analysis.group","8"
"CD014758_pub3_data","Analysis.group","9"
"CD014758_pub3_data","Analysis.group","10"
"CD014758_pub3_data","Analysis.group","11"
"CD014758_pub3_data","Analysis.name","Change in refractive error from baseline"
"CD014758_pub3_data","Analysis.name","Change in axial length from baseline"
"CD014758_pub3_data","Analysis.name","Change in axial length from baseline "
"CD014758_pub3_data","Analysis.name","Change in refractive error following cessation of treatment "
"CD014758_pub3_data","Analysis.name","Change in refractive error from baseline "
"CD014758_pub3_data","Analysis.name","Change in axial length following cessation of treatment "
"CD014758_pub3_data","Analysis.name","Change in refractive error from baseline (1 year)"
"CD014758_pub3_data","Analysis.name","Change in axial length from baseline (1 year)"
"CD014758_pub3_data","Analysis.name","Change in refractive error from baseline (2 years)"
"CD014758_pub3_data","Analysis.name","Change in axial length from baseline (2 years)"
"CD014758_pub3_data","Analysis.name","Change in refractive error from baseline (3 years)"
"CD014758_pub3_data","Analysis.name","Change in axial length from baseline (3 years)"
"CD014758_pub3_data","Analysis.name","Change in refractive error  from baseline (5 years)"
"CD014758_pub3_data","Analysis.name","Change in axial length from baseline (5 years)"
"CD014758_pub3_data","Analysis.name","Change in axial length"
"CD014758_pub3_data","Analysis.name","Change in axial length following cessation of treatment"
"CD014758_pub3_data","Subgroup","At 1 year"
"CD014758_pub3_data","Subgroup","At 2 years"
"CD014758_pub3_data","Subgroup","At 3 years"
"CD014758_pub3_data","Subgroup","At 1 year after cessation of treatment"
"CD014758_pub3_data","Subgroup","Atropine (high dose)"
"CD014758_pub3_data","Subgroup","Atropine eyedrops (low dose)"
"CD014758_pub3_data","Subgroup","Pirenzepine 2% gel"
"CD014758_pub3_data","Subgroup","Atropine eyedrops (high dose)"
"CD014758_pub3_data","Subgroup","Pirenzepine eyedrops 2% gel"
"CD014758_pub3_data","Subgroup","Atropine (low dose)"
"CD014758_pub3_data","Subgroup","At 1 year after cessation of treatment (low dose)"
"CD014758_pub3_data","Subgroup","At 1 year after cessation of treatment (high dose)"
"CD014758_pub3_data","Subgroup","Low dose atropine (Asian studies)"
"CD014758_pub3_data","Subgroup","Atropine (low dose). Non-Asian studies"
"CD014758_pub3_data","Subgroup","Low dose atropine (non-Asian studies)"
"CD014758_pub3_data","Subgroup","Low dose atropine  (Asian studies)"
"CD014758_pub3_data","Subgroup","Atropine eyedrops (low dose). Asian studies"
"CD014758_pub3_data","Subgroup","Low dose atropine"
"CD014758_pub3_data","Subgroup","At 1-year"
"CD014762_pub2_data","Analysis.group","1"
"CD014762_pub2_data","Analysis.group","2"
"CD014762_pub2_data","Analysis.name","Short-term resolution of symptoms (days 1 to 4 after randomisation)"
"CD014762_pub2_data","Analysis.name","Medium-term resolution of symptoms (days 5 to 10 after randomisation)"
"CD014762_pub2_data","Analysis.name","Adverse events (to day 30 after randomisation)"
"CD014762_pub2_data","Analysis.name","Duration of symptoms [days]"
"CD014762_pub2_data","Analysis.name","Severity of symptoms"
"CD014762_pub2_data","Analysis.name","Microbiological resolution (by day 10 after randomisation)"
"CD014762_pub2_data","Analysis.name","Use of rescue antibiotic treatment (by day 30 after randomisation)"
"CD014762_pub2_data","Analysis.name","Emergence of antibiotic resistant bacteria"
"CD014762_pub2_data","Subgroup","NSAIDs versus antibiotics"
"CD014762_pub2_data","Subgroup","NSAIDs + antibiotics vs antibiotics"
"CD014762_pub2_data","Subgroup","NSAIDs vs antibiotics"
"CD014762_pub2_data","Subgroup","NSAIDs vs placebo"
"CD014762_pub2_data","Subgroup","NSAIDs vs Uva-Ursi (herbal product)"
"CD014763_pub2_data","Analysis.group","1"
"CD014763_pub2_data","Analysis.group","2"
"CD014763_pub2_data","Analysis.group","3"
"CD014763_pub2_data","Analysis.name","Surgical site infection"
"CD014763_pub2_data","Analysis.name","Participant satisfaction (very satisfied or satisfied)"
"CD014763_pub2_data","Analysis.name","Participant satisfaction (unsatisfied or very unsatisfied)"
"CD014763_pub2_data","Analysis.name","Incisional hernia"
"CD014763_pub2_data","Analysis.name","Anastomotic leak"
"CD014763_pub2_data","Analysis.name","Intestinal obstruction"
"CD014763_pub2_data","Analysis.name","Operative time (minutes)"
"CD014763_pub2_data","Analysis.name","Length of hospital stay (days)"
"CD014763_pub2_data","Subgroup","Very satisfied"
"CD014763_pub2_data","Subgroup","Satisfied"
"CD014763_pub2_data","Subgroup","Satisfied or very satisfied"
"CD014763_pub2_data","Subgroup","Unsatisfied"
"CD014763_pub2_data","Subgroup","Very unsatisfied"
"CD014763_pub2_data","Subgroup","Unsatisfied or very unsatisfied"
"CD014763_pub2_data","Subgroup","Very satisfied or satisfied"
"CD014769_pub2_data","Analysis.group","1"
"CD014769_pub2_data","Analysis.name","Any VTE"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for any VTE stratified by provoked status"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for any VTE stratified by age"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for any VTE stratified by sex"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for any VTE stratified by disease"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for any VTE stratified by type of statin"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for any VTE statified by different doses of rosuvstatin"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for any VTE stratified by different doses of atorvastatin"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for any VTE stratified by treatment duration"
"CD014769_pub2_data","Analysis.name","Sensitivity analysis for any VTE excluding unpublished data"
"CD014769_pub2_data","Analysis.name","Sensitivity analysis for any VTE excluding studies with high risk of bias"
"CD014769_pub2_data","Analysis.name","Sensitivity analysis for any VTE excluding data from  > 15% missing outcome data"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for DVT stratified by type of statin"
"CD014769_pub2_data","Analysis.name","DVT: sensitivity analysis"
"CD014769_pub2_data","Analysis.name","PE"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for any serious adverse event stratified by type of statin"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for myopathy stratified by type of statin"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for rhabdomyolysis stratified by type of statin"
"CD014769_pub2_data","Analysis.name","Bleeding"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for muscular weakness, stiffness, or pain, stratified by type of statin"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for gastrointestinal disorders stratified by type of statin"
"CD014769_pub2_data","Analysis.name","Sensitivity analysis for gastrointestinal disorders"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for hepatic disorders stratified by type of statin"
"CD014769_pub2_data","Analysis.name","Sensitivity analysis for hepatic disorders"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for renal disorders stratified by types of statins"
"CD014769_pub2_data","Analysis.name","Subgroup analysis for mortality stratified by types of statins"
"CD014769_pub2_data","Analysis.name","Mortality after PE"
"CD014769_pub2_data","Analysis.name","Sensitivity analysis for mortality after PE"
"CD014769_pub2_data","Subgroup","Provoked VTE"
"CD014769_pub2_data","Subgroup","Unprovoked VTE"
"CD014769_pub2_data","Subgroup","Age 70 to 97 years"
"CD014769_pub2_data","Subgroup","Age 50 to 69 years"
"CD014769_pub2_data","Subgroup","Men"
"CD014769_pub2_data","Subgroup","Women"
"CD014769_pub2_data","Subgroup","Chronic kidney disease"
"CD014769_pub2_data","Subgroup","Cerebrovascular disease"
"CD014769_pub2_data","Subgroup","Heart failure"
"CD014769_pub2_data","Subgroup","Other"
"CD014769_pub2_data","Subgroup","Aortic valve stenosis"
"CD014769_pub2_data","Subgroup","Vascular disease"
"CD014769_pub2_data","Subgroup","Diabetes mellitus"
"CD014769_pub2_data","Subgroup","Hypercholesterolaemia"
"CD014769_pub2_data","Subgroup","Healthy"
"CD014769_pub2_data","Subgroup","Atorvastatin"
"CD014769_pub2_data","Subgroup","Fluvastatin"
"CD014769_pub2_data","Subgroup","Lovastatin"
"CD014769_pub2_data","Subgroup","Pravastatin"
"CD014769_pub2_data","Subgroup","Rosuvastatin"
"CD014769_pub2_data","Subgroup","Simvastation"
"CD014769_pub2_data","Subgroup","10-20 mg/day"
"CD014769_pub2_data","Subgroup","40 mg/day"
"CD014769_pub2_data","Subgroup","20 mg/day"
"CD014769_pub2_data","Subgroup","80 mg/day"
"CD014769_pub2_data","Subgroup","10 mg/day"
"CD014769_pub2_data","Subgroup","Short term"
"CD014769_pub2_data","Subgroup","Long-term"
"CD014769_pub2_data","Subgroup","Medium-term"
"CD014769_pub2_data","Subgroup","Simvastatin"
"CD014785_pub2_data","Analysis.group","1"
"CD014785_pub2_data","Analysis.group","2"
"CD014785_pub2_data","Analysis.group","3"
"CD014785_pub2_data","Analysis.name","Proportion of children with normal nutrition status"
"CD014785_pub2_data","Analysis.name","Proportion of children who had eaten beta-carotene rich foods (paw-paw) the day before interview"
"CD014785_pub2_data","Analysis.name","Proportion of children experiencing vomiting in the past 2 weeks"
"CD014785_pub2_data","Analysis.name","Mean weight-for-age z-score at 6 months"
"CD014785_pub2_data","Analysis.name","Mean height-for-age z-score at 6 months"
"CD014785_pub2_data","Analysis.name","Mean weight-for-height z-score at 6 months"
"CD014785_pub2_data","Analysis.name","Energy intake (kcal) at 12 months"
"CD014785_pub2_data","Analysis.name","Mean length gain (cm per month) after 24 months"
"CD014792_pub2_data","Analysis.group","1"
"CD014792_pub2_data","Analysis.group","2"
"CD014792_pub2_data","Analysis.group","3"
"CD014792_pub2_data","Analysis.name","Mortality (Grade V Clavien-Dindo)"
"CD014792_pub2_data","Analysis.name","Length of hospital stay"
"CD014792_pub2_data","Analysis.name","Major complications"
"CD014792_pub2_data","Analysis.name","Minor complications"
"CD014792_pub2_data","Analysis.name","Complications related to nutritional support"
"CD014792_pub2_data","Analysis.name","Postoperative pancreatic fistula"
"CD014792_pub2_data","Analysis.name","Delayed gastric emptying"
"CD014792_pub2_data","Analysis.name","Post pancreatectomy haemorrhage"
"CD014792_pub2_data","Analysis.name","Major postoperative complications as defined by the Clavien-Dindo classification (III-IV)"
"CD014792_pub2_data","Analysis.name","Minor postoperative complications as defined by the Clavien-Dindo classification (I-II)"
"CD014792_pub2_data","Analysis.name","Mesenteric ischaemia"
"CD014792_pub2_data","Subgroup","Abdominal abscess"
"CD014792_pub2_data","Subgroup","Anastomotic leak"
"CD014792_pub2_data","Subgroup","Biliary fistula"
"CD014792_pub2_data","Subgroup","Pneumonia"
"CD014792_pub2_data","Subgroup","Wound infection"
"CD014792_pub2_data","Subgroup","Discontinuation"
"CD014792_pub2_data","Subgroup","Pancreaticojejunostomy leak"
"CD014792_pub2_data","Subgroup","Intra-abdominal fluid collection"
"CD014792_pub2_data","Subgroup","Chyle abdomen"
"CD014792_pub2_data","Subgroup","Intra-abdominal abscess"
"CD014792_pub2_data","Subgroup","Respiratory tract infection"
"CD014792_pub2_data","Subgroup","Bacteraemia"
"CD014802_pub2_data","Analysis.group","1"
"CD014802_pub2_data","Analysis.name","Functional outcome, measured by mRS (0 to 4), at 90 days"
"CD014802_pub2_data","Analysis.name","Functional outcome, measured by mRS (0 to 4), at 12 months (participants ≤ 70 years)"
"CD014802_pub2_data","Analysis.name","Death at 30 days"
"CD014802_pub2_data","Analysis.name","Death at more than 90 days (90 days, or up to 4 years + 11 months)"
"CD014802_pub2_data","Analysis.name","Quality of life: EuroQol group 5-dimension (EQ-5D) at 90 days"
"CD014802_pub2_data","Analysis.name","Quality of life: EuroQol group 5-dimension (EQ-5D) at 6 months"
"CD014802_pub2_data","Analysis.name","Quality of life: EuroQol group 5-dimension (EQ-5D) at 12 months"
"CD014802_pub2_data","Analysis.name","Serious adverse events (up to 4 years + 11 months)"
"CD014802_pub2_data","Analysis.name","Adverse events: hypoglycaemia (88 hours after drug bolus, or up to 4 years + 11 months)"
"CD014802_pub2_data","Analysis.name","Adverse events: cardiac events (7 days, or discharge, or up to 4 years + 11 months)"
"CD014802_pub2_data","Analysis.name","Complications: neurological deterioration (3 days)"
"CD014802_pub2_data","Analysis.name","Complications: nervous system hemorrhage and infarction (7 days, or up to 4 years + 11 months)"
"CD014802_pub2_data","Analysis.name","Complications: pneumonia (up to 4 years + 11 months)"
"CD014803_pub2_data","Analysis.group","1"
"CD014803_pub2_data","Analysis.group","2"
"CD014803_pub2_data","Analysis.name","Self-reported depression symptoms (continuous measure)"
"CD014803_pub2_data","Analysis.name","Depression remission (dichotomous measure)"
"CD014803_pub2_data","Analysis.name","Attrition (dropouts)"
"CD014811_pub2_data","Analysis.group","1"
"CD014811_pub2_data","Analysis.group","2"
"CD014811_pub2_data","Analysis.name","Net weight loss (kg)"
"CD014811_pub2_data","Analysis.name","All-cause mortality"
"CD014811_pub2_data","Analysis.name","Length of hospital stay (days)"
"CD014811_pub2_data","Analysis.name","Readmission to hospital following discharge for the longest available follow-up stated in the trials "
"CD014811_pub2_data","Analysis.name","Acute kidney injury (adverse event)"
"CD014820_pub2_data","Analysis.group","1"
"CD014820_pub2_data","Analysis.group","2"
"CD014820_pub2_data","Analysis.group","3"
"CD014820_pub2_data","Analysis.group","4"
"CD014820_pub2_data","Analysis.group","5"
"CD014820_pub2_data","Analysis.group","6"
"CD014820_pub2_data","Analysis.group","7"
"CD014820_pub2_data","Analysis.group","8"
"CD014820_pub2_data","Analysis.group","9"
"CD014820_pub2_data","Analysis.name","Acute kidney injury"
"CD014820_pub2_data","Analysis.name","Death (any cause)"
"CD014820_pub2_data","Analysis.name","Dialysis"
"CD014820_pub2_data","Analysis.name","Change in serum creatinine [mg/dL]"
"CD014820_pub2_data","Analysis.name","Change in serum cystatin C [mg/L]"
"CD014820_pub2_data","Analysis.name","Length of hospital stay [days]"
"CD014820_pub2_data","Analysis.name","Adverse events: myocardial infarction"
"CD014820_pub2_data","Analysis.name","Adverse events: stroke"
"CD014820_pub2_data","Analysis.name","Adverse events: thrombosis"
"CD014820_pub2_data","Analysis.name","Adverse events: hypertension"
"CD014820_pub2_data","Analysis.name","AKI: KDIGO or AKIN or RIFLE"
"CD014820_pub2_data","Analysis.name","AKI: KDIGO"
"CD014820_pub2_data","Analysis.name","AKI: AKIN"
"CD014820_pub2_data","Analysis.name","AKI: RIFLE"
"CD014820_pub2_data","Analysis.name","AKI: severe AKI"
"CD014820_pub2_data","Analysis.name","Death"
"CD014820_pub2_data","Subgroup","Subcutaneous"
"CD014820_pub2_data","Subgroup","Intravenous"
"CD014820_pub2_data","Subgroup","Subcutaneous and intravenous"
"CD014820_pub2_data","Subgroup","intravenous"
"CD014820_pub2_data","Subgroup","Subctaneous"
"CD014820_pub2_data","Subgroup","Miscellaneous"
"CD014820_pub2_data","Subgroup","Children/neonates"
"CD014820_pub2_data","Subgroup","Cardiac surgeries"
"CD014820_pub2_data","Subgroup","Long-acting"
"CD014820_pub2_data","Subgroup","Short-acting"
"CD014833_pub2_data","Analysis.group","1"
"CD014833_pub2_data","Analysis.group","2"
"CD014833_pub2_data","Analysis.name","Incidence of depression immediately post-intervention"
"CD014833_pub2_data","Analysis.name","Incidence of depression short-term 1 to 3 months post-intervention"
"CD014833_pub2_data","Analysis.name","Incidence of depression medium-term 4 to 6 months post-intervention"
"CD014833_pub2_data","Analysis.name","Depressive symptoms immediately post-intervention"
"CD014833_pub2_data","Analysis.name","Depressive symptoms short-term 1 to 3 months post-intervention"
"CD014833_pub2_data","Analysis.name","Anxiety immediately post-intervention"
"CD014833_pub2_data","Analysis.name","Breastfeeding exclusivity immediately post-intervention"
"CD014833_pub2_data","Analysis.name","Breastfeeding exclusivity short-term 1 to 3 months post-intervention"
"CD014833_pub2_data","Analysis.name","Breastfeeding exclusivity medium-term 4 to 6 months post-intervention"
"CD014833_pub2_data","Analysis.name","Breastfeeding exclusivity long-term 7 to 12 months post-intervention"
"CD014833_pub2_data","Analysis.name","Breastfeeding duration immediately post-intervention"
"CD014833_pub2_data","Analysis.name","Breastfeeding duration short-term 3 months post-intervention"
"CD014833_pub2_data","Analysis.name","Breastfeeding duration long-term 7 to 12 months post-intervention"
"CD014833_pub2_data","Analysis.name","Stress immediately post-intervention"
"CD014844_pub2_data","Analysis.group","1"
"CD014844_pub2_data","Analysis.name","Uterine infection"
"CD014844_pub2_data","Analysis.name","Adverse event – vomiting"
"CD014844_pub2_data","Analysis.name","Adverse event – diarrhoea"
"CD014844_pub2_data","Analysis.name","Adverse event – allergy"
"CD014844_pub2_data","Analysis.name","Adverse event – anaphylaxis"
"CD014844_pub2_data","Analysis.name","Antibiotics to treat infection after uterine evacuation procedure for miscarriage"
"CD014844_pub2_data","Analysis.name","Hospitalisation for treatment of infection"
"CD014844_pub2_data","Analysis.name","Sensitivity analysis: uterine infection – studies at low risk of bias"
"CD014844_pub2_data","Analysis.name","Subgroup: uterine infection by gestation"
"CD014844_pub2_data","Analysis.name","Subgroup: uterine infection by antibiotic class"
"CD014844_pub2_data","Analysis.name","Subgroup: uterine infection by length of treatment course"
"CD014844_pub2_data","Analysis.name","Subgroup: uterine infection by administration route"
"CD014844_pub2_data","Subgroup","Gestation < 12 weeks"
"CD014844_pub2_data","Subgroup","Gestation ≥ 12 weeks"
"CD014844_pub2_data","Subgroup","Uterine infection (tetracyclines)"
"CD014844_pub2_data","Subgroup","Uterine infection (other antibiotic classes)"
"CD014844_pub2_data","Subgroup","Uterine infection (short-course treatment)"
"CD014844_pub2_data","Subgroup","Uterine infection (long-course treatment)"
"CD014844_pub2_data","Subgroup","Uterine infection (oral route)"
"CD014844_pub2_data","Subgroup","Uterine infection (intravenous route)"
"CD014845_pub2_data","Analysis.group","1"
"CD014845_pub2_data","Analysis.group","2"
"CD014845_pub2_data","Analysis.name","Food selection/purchasing (kcal)"
"CD014845_pub2_data","Analysis.name","Subgroup analysis: food selection/purchasing by setting (kcal)"
"CD014845_pub2_data","Analysis.name","Subgroup analysis: food selection/purchasing by label type (kcal)"
"CD014845_pub2_data","Analysis.name","Subgroup analysis: food selection/purchasing by socioeconomic status (kcal)"
"CD014845_pub2_data","Analysis.name","Additional exploratory subgroup analysis: food selection/purchasing by placement of labels"
"CD014845_pub2_data","Analysis.name","Sensitivity analysis: food selection/purchasing by low risk of bias (kcal)"
"CD014845_pub2_data","Analysis.name","Sensitivity analysis: food selection/purchasing excluding Reynolds 2022, Vasiljevic 2018, Vasiljevic 2019"
"CD014845_pub2_data","Analysis.name","Food consumption (kcal)"
"CD014845_pub2_data","Analysis.name","Subgroup analysis: food consumption by setting (kcal)"
"CD014845_pub2_data","Analysis.name","Subgroup analysis: food consumption by label type (kcal)"
"CD014845_pub2_data","Analysis.name","Subgroup analysis: food consumption by socioeconomic status (kcal)"
"CD014845_pub2_data","Analysis.name","Sensitivity analysis: food consumption by low risk of bias (kcal)"
"CD014845_pub2_data","Analysis.name","Alcohol selection/purchasing of energy (kcal)"
"CD014845_pub2_data","Analysis.name","Alcohol selection/purchasing of alcohol (units)"
"CD014845_pub2_data","Subgroup","Restaurant"
"CD014845_pub2_data","Subgroup","Store"
"CD014845_pub2_data","Subgroup","Naturalistic"
"CD014845_pub2_data","Subgroup","Laboratory"
"CD014845_pub2_data","Subgroup","Calorie with PACE"
"CD014845_pub2_data","Subgroup","Calorie and nutrient"
"CD014845_pub2_data","Subgroup","Simple calorie"
"CD014845_pub2_data","Subgroup","High"
"CD014845_pub2_data","Subgroup","Both low and high"
"CD014845_pub2_data","Subgroup","On product packaging "
"CD014845_pub2_data","Subgroup","Adjacent to product packaging"
"CD014845_pub2_data","Subgroup","On menus"
"CD014845_pub2_data","Subgroup","Both adjacent to and on product packaging"
"CD014845_pub2_data","Subgroup","Low risk of bias"
"CD014845_pub2_data","Subgroup","Some concerns or high risk of bias"
"CD014845_pub2_data","Subgroup","Calorie"
"CD014845_pub2_data","Subgroup","Some concerns or high risk of bias "
"CD014852_pub2_data","Analysis.group","1"
"CD014852_pub2_data","Analysis.group","2"
"CD014852_pub2_data","Analysis.group","3"
"CD014852_pub2_data","Analysis.group","4"
"CD014852_pub2_data","Analysis.group","5"
"CD014852_pub2_data","Analysis.group","6"
"CD014852_pub2_data","Analysis.group","7"
"CD014852_pub2_data","Analysis.group","8"
"CD014852_pub2_data","Analysis.group","9"
"CD014852_pub2_data","Analysis.group","10"
"CD014852_pub2_data","Analysis.group","11"
"CD014852_pub2_data","Analysis.group","12"
"CD014852_pub2_data","Analysis.group","13"
"CD014852_pub2_data","Analysis.group","14"
"CD014852_pub2_data","Analysis.group","15"
"CD014852_pub2_data","Analysis.group","16"
"CD014852_pub2_data","Analysis.group","17"
"CD014852_pub2_data","Analysis.name","Disability (modified Rankin Scale 0 to 2, good status) at follow‐up "
"CD014852_pub2_data","Analysis.name","Activities of daily living (Functional Independence Measure, Motor score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: activities of daily living "
"CD014852_pub2_data","Analysis.name","Neurological impairment (change in NIHSS score) during intervention phase"
"CD014852_pub2_data","Analysis.name","Walking capacity (2-minute walk test) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Walking capacity (6-minute walk test) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Muscle strength (grip strength) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status change (body weight ) during intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: nutritional status (body weight ) "
"CD014852_pub2_data","Analysis.name","Subgroup analysis – nutritional status at baseline: nutritional status (body weight ) "
"CD014852_pub2_data","Analysis.name","Nutritional status (triceps skinfold thickness) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","All-cause mortality at follow-up"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: all-cause mortality "
"CD014852_pub2_data","Analysis.name","Subgroup analysis – nutritional status at baseline: all-cause mortality "
"CD014852_pub2_data","Analysis.name","Stroke recurrence at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Change in cognitive function score (Mini-Mental State Examination) during intervention phase"
"CD014852_pub2_data","Analysis.name","Complication (pressure sores) during intervention phase"
"CD014852_pub2_data","Analysis.name","Complications (infections: pneumonia, urinary tract, and septicaemias) during intervention phase"
"CD014852_pub2_data","Analysis.name","Complication (pneumonia) during intervention phase"
"CD014852_pub2_data","Analysis.name","Complication (urinary tract infection) during intervention phase"
"CD014852_pub2_data","Analysis.name","Complication (hyper/hypoglycaemia) during intervention phase"
"CD014852_pub2_data","Analysis.name","Complication (gastrointestinal haemorrhage) during intervention phase"
"CD014852_pub2_data","Analysis.name","Complication (diarrhoea) during intervention phase"
"CD014852_pub2_data","Analysis.name","Disability (modified Rankin Scale 0 to 2, good status) at end of intervention"
"CD014852_pub2_data","Analysis.name","Activities of daily living  (change in Barthel Index or Functional Independence Measure) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Sensitivity analysis: Activities of daily living (change in Barthel Index or Functional Independence Measure) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: activities of daily living  (Barthel Index and Functional Independence Measure) "
"CD014852_pub2_data","Analysis.name","Nutritional status (change in calf circumference) during intervention phase"
"CD014852_pub2_data","Analysis.name","All-cause mortality at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Muscle strength (change in grip strength) during intervention phase"
"CD014852_pub2_data","Analysis.name","Disability (modified Rankin Scale) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (proportion of skeletal muscle atrophy) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (change in lean mass) during intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (short-form NeuroQoL measurement tool, fatigue) at end of follow-up "
"CD014852_pub2_data","Analysis.name","Quality of life (short-form NeuroQoL measurement tool, lower extremity mobility) at end of follow-up "
"CD014852_pub2_data","Analysis.name","Quality of life (short-form NeuroQoL measurement tool, cognition) at end of follow-up"
"CD014852_pub2_data","Analysis.name","Physical performance (Fugl-Meyer Assessment, lower extremity function) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Physical performance (Timed Up & Go test) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Physical performance (Berg Balance Scale) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Neurological impairment (change in NIHSS score) during intervention phase "
"CD014852_pub2_data","Analysis.name","Activities of daily living (Functional Independence Measure, Motor score) at end of intervention phase "
"CD014852_pub2_data","Analysis.name","Gait speed (10-metre walk test) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (skeletal muscle index) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (cross-sectional area of total thigh muscle area: paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (cross-sectional area of total thigh muscle area: non-paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (cross-sectional area of normal thigh muscle area: paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (cross-sectional area of normal thigh muscle area: non-paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (cross-sectional area of thigh muscle area with fat infiltration: paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (cross-sectional area of thigh muscle area with fat infiltration: non-paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Nutritional status (body weight) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Muscle strength (grip strength, paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Muscle strength (grip strength, non-paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Muscle strength (knee-extensor strength, paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Muscle strength (knee-extensor strength, non-paretic side) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Physical performance (30-second chair test) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Stroke recurrence at follow-up"
"CD014852_pub2_data","Analysis.name","Neurological impairment (NIHSS score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, physical component scale) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, mental component scale) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Disability: modified Rankin Scale (mRS 0 to 3, good status) at follow‐up"
"CD014852_pub2_data","Analysis.name","Activities of daily living (Barthel Index score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: activities of daily living (Barthel Index score)"
"CD014852_pub2_data","Analysis.name","Activity of daily living (independent) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Neurological impairment (NIHSS score) at and of intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: neurological impairment (NIHSS)"
"CD014852_pub2_data","Analysis.name","Neurological improvement (NIHSS score, ≥ 90% decrease ) at and of intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: nutritional status (triceps skinfold thickness) "
"CD014852_pub2_data","Analysis.name","Nutritional status (arm muscular circumference) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: nutritional status (arm muscular circumference) "
"CD014852_pub2_data","Analysis.name","Swallowing function (water swallow test score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: mortality "
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: pneumonia"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: urinary tract infection"
"CD014852_pub2_data","Analysis.name","Complication (intestinal infection) during intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: intestinal infection"
"CD014852_pub2_data","Analysis.name","Complication (sepsis) during intervention phase"
"CD014852_pub2_data","Analysis.name","Complication (vomiting) during intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: gastrointestinal haemorrhage"
"CD014852_pub2_data","Analysis.name","Complication (renal problems) during intervention phase"
"CD014852_pub2_data","Analysis.name","Activity of daily living (ADL score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – type of stroke: NIHSS score"
"CD014852_pub2_data","Analysis.name","Physical performance (Fugl-Meyer Assessment score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, Physiological Function score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, Role Function score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, Physical Pain score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, General Health score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, Mental Health score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, Energy score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, Social Function score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Quality of life (SF-36, Emotional Function score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Activities of daily living (Functional Independence Measure, total score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Swallowing function (Dysphagia Outcome and Severity Scale score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Swallowing function (improvement in Dysphagia Outcome and Severity Scale score) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Activities of daily living (Functional Independence Measure, motor score) at follow-up"
"CD014852_pub2_data","Analysis.name","Nutritional status (change in body weight) during follow-up or intervention phase"
"CD014852_pub2_data","Analysis.name","Subgroup analysis – nutritional status at baseline: change in body weight"
"CD014852_pub2_data","Analysis.name","Nutritional status (thigh circumference, paretic side) at follow-up"
"CD014852_pub2_data","Analysis.name","Nutritional status (thigh circumference, non-paretic side) at follow-up"
"CD014852_pub2_data","Analysis.name","Nutritional status (calf circumference, paretic side) at follow-up"
"CD014852_pub2_data","Analysis.name","Nutritional status (calf circumference, non-paretic side) at follow-up"
"CD014852_pub2_data","Analysis.name","Nutritional status (arm circumference, paretic side) at follow-up"
"CD014852_pub2_data","Analysis.name","Nutritional status (arm circumference, non-paretic side) at follow-up"
"CD014852_pub2_data","Analysis.name","Nutritional status (arm circumference, dominant or non-dominant arm) at end of intervention phase"
"CD014852_pub2_data","Analysis.name","Cognitive function (Functional Independence Measure, cognition score) at follow-up"
"CD014852_pub2_data","Analysis.name","Quality of life (EQ-5D questionnaire, improvement in mobility) at follow-up"
"CD014852_pub2_data","Analysis.name","Quality of life (EQ-5D questionnaire, improvement in self-care) at follow-up"
"CD014852_pub2_data","Analysis.name","Quality of life (EQ-5D questionnaire, improvement in usual activities) at follow-up"
"CD014852_pub2_data","Analysis.name","Quality of life (EQ-5D questionnaire, improvement in pain/discomfort) at follow-up"
"CD014852_pub2_data","Analysis.name","Quality of life (EQ-5D questionnaire, improvement in anxiety/depression) at follow-up"
"CD014852_pub2_data","Analysis.name","Muscle strength (change in grip strength) at follow-up"
"CD014852_pub2_data","Analysis.name","Nutritional status (decreased nutritional status) during intervention phase"
"CD014852_pub2_data","Analysis.name","Disability (Glasgow Outcome Scale Extended score 1 to 4, poor status) at follow-up"
"CD014852_pub2_data","Subgroup","Acute phase"
"CD014852_pub2_data","Subgroup","Acute and subacute phase "
"CD014852_pub2_data","Subgroup","Subacute phase "
"CD014852_pub2_data","Subgroup","Mixed: ischaemic stroke and intracerebral and subarachnoid haemorrhage"
"CD014852_pub2_data","Subgroup","Mixed: ischaemic and haemorrhagic stroke"
"CD014852_pub2_data","Subgroup","Acute phase "
"CD014852_pub2_data","Subgroup","Acute or subacute phase"
"CD014852_pub2_data","Subgroup","Acute and subacute "
"CD014852_pub2_data","Subgroup","Subacute phase"
"CD014852_pub2_data","Subgroup","Acute and subacute phase"
"CD014852_pub2_data","Subgroup","Ischaemic stroke"
"CD014852_pub2_data","Subgroup","Inclusion criteria with malnutrition or malnutrition risk"
"CD014852_pub2_data","Subgroup","No inclusion criteria with malnutrition or malnutrition risk"
"CD014852_pub2_data","Subgroup","Mixed: ischaemic stroke and intracerebral haemorrhage"
"CD014852_pub2_data","Subgroup","Mixed: intracerebral and subarachnoid haemorrhage"
"CD014852_pub2_data","Subgroup","Acute phese"
"CD014852_pub2_data","Subgroup","Mixed: ischemic and hemorrhagic stroke"
"CD014852_pub2_data","Subgroup","Chronic phase"
"CD014852_pub2_data","Subgroup","Chronic group"
"CD014852_pub2_data","Subgroup","Chronic phase "
"CD014852_pub2_data","Subgroup","Haemorrhagic stroke"
"CD014852_pub2_data","Subgroup","Mixed: ischaemic or haemorrhagic stroke"
"CD014855_pub2_data","Analysis.group","1"
"CD014855_pub2_data","Analysis.group","2"
"CD014855_pub2_data","Analysis.group","3"
"CD014855_pub2_data","Analysis.name","Intraperitoneal abscess"
"CD014855_pub2_data","Analysis.name","Wound infection"
"CD014855_pub2_data","Analysis.name","Morbidity"
"CD014855_pub2_data","Analysis.name","Mortality"
"CD014855_pub2_data","Analysis.name","Hospital stay"
"CD014855_pub2_data","Analysis.name","Hospital costs (VND)"
"CD014855_pub2_data","Subgroup","Open appendectomy"
"CD014855_pub2_data","Subgroup","Laparoscopic appendectomy"
"CD014855_pub2_data","Subgroup","Laparoscopic appendectomy "
"CD014855_pub2_data","Subgroup","Children"
"CD014855_pub2_data","Subgroup","Adults"
"CD014861_pub2_data","Analysis.group","1"
"CD014861_pub2_data","Analysis.group","2"
"CD014861_pub2_data","Analysis.name","Adverse events (proportion of participants with at least one AE)"
"CD014861_pub2_data","Analysis.name","Hospital inpatient admission within 48 hours of administration of anti-cancer therapy (mean number of visits)"
"CD014861_pub2_data","Analysis.name","Hospital attendance within 48 hours of administration of anti-cancer therapy (mean number of visits)"
"CD014861_pub2_data","Analysis.name","Hospital attendance within 48 hours of treatment administration (proportion of participants with a visit)"
"CD014861_pub2_data","Analysis.name","Participant preference for future treatment location"
"CD014861_pub2_data","Analysis.name","Cost (healthcare system perspective: 2022 AUD values)"
"CD014861_pub2_data","Analysis.name","Cost-effectiveness (quality-adjusted life years, Corrie 2013)"
"CD014861_pub2_data","Analysis.name","Health-related quality of life (EORTC QLQC30 all domains)"
"CD014861_pub2_data","Analysis.name","Health-related quality of life (EORTC QOL-C30)"
"CD014861_pub2_data","Analysis.name","Participant satisfaction (Borras 2001)"
"CD014861_pub2_data","Analysis.name","Proportion of participants completing treatment regimen as planned"
"CD014861_pub2_data","Analysis.name","Hospital attendance within 48 hours of treatment administration (proportion of participants with at least one visit)"
"CD014861_pub2_data","Analysis.name","Cost (healthcare system perspective: 2022 AUD value)"
"CD014861_pub2_data","Analysis.name","Health-related quality of life (EORTC QLQC30 all domain and unit scores)"
"CD014869_pub2_data","Analysis.group","1"
"CD014869_pub2_data","Analysis.name"," All-cause mortality (between  1 and 5 years)"
"CD014869_pub2_data","Analysis.name","Serious adverse events (number of participants) (end of 1 year)"
"CD014869_pub2_data","Analysis.name","Quality of life at 9 months' follow-up"
"CD014869_pub2_data","Analysis.name","Disease progression (between 1 and 5 years)"
"CD014869_pub2_data","Analysis.name","Adverse events considered non-serious (number of participants) (between 1 and 3 years)"
"CD014869_pub2_data","Analysis.name","Sensitivity analysis: all-cause mortality between 1 and 5 years (best-worst case scenario)"
"CD014869_pub2_data","Analysis.name","Sensitivity analysis: all-cause mortality between 1 and 5 years (worst-best case scenario)"
"CD014869_pub2_data","Subgroup","at 5 years"
"CD014869_pub2_data","Subgroup","at 1 year"
"CD014869_pub2_data","Subgroup","between 2 and 3 years"
"CD014869_pub2_data","Subgroup","At 5 -year"
"CD014871_pub2_data","Analysis.group","1"
"CD014871_pub2_data","Analysis.name","Walking energy cost"
"CD014871_pub2_data","Analysis.name","Perceived intensity of exertion on different terrains (range 6 to 20)"
"CD014871_pub2_data","Analysis.name","Self-selected comfortable walking speed"
"CD014871_pub2_data","Analysis.name","Self-selected comfortable walking speed on uneven terrain"
"CD014871_pub2_data","Analysis.name","Sit-to-stand five times test"
"CD014871_pub2_data","Analysis.name","Four-square step test"
"CD014871_pub2_data","Analysis.name","Timed stair ascent"
"CD014871_pub2_data","Analysis.name","Forty-yard dash"
"CD014871_pub2_data","Analysis.name","Cadence"
"CD014871_pub2_data","Analysis.name","Step time"
"CD014871_pub2_data","Analysis.name","Stride length"
"CD014871_pub2_data","Analysis.name","Step length"
"CD014871_pub2_data","Analysis.name","Step width"
"CD014871_pub2_data","Analysis.name","Double support time"
"CD014871_pub2_data","Analysis.name","Forward centre of pressure progression during midstance"
"CD014871_pub2_data","Analysis.name","Heel off timing"
"CD014871_pub2_data","Analysis.name","Step length variability"
"CD014871_pub2_data","Analysis.name","Step width variability"
"CD014871_pub2_data","Analysis.name","Step time variability"
"CD014871_pub2_data","Analysis.name","Peak ankle dorsiflexion angle in midstance"
"CD014871_pub2_data","Analysis.name","Peak ankle dorsiflexion angle in terminal stance"
"CD014871_pub2_data","Analysis.name","Peak ankle dorsiflexion angle in swing"
"CD014871_pub2_data","Analysis.name","Ankle range of motion (plantarflexion - dorsiflexion)"
"CD014871_pub2_data","Analysis.name","Ankle range of motion (valgus-varus)"
"CD014871_pub2_data","Analysis.name","Peak knee flexion angle in midstance"
"CD014871_pub2_data","Analysis.name","Peak knee flexion angle in terminal stance"
"CD014871_pub2_data","Analysis.name","Knee range of motion (flexion - extension)"
"CD014871_pub2_data","Analysis.name","Knee range of motion (valgus-varus)"
"CD014871_pub2_data","Analysis.name","Peak hip flexion angle in the swing phase"
"CD014871_pub2_data","Analysis.name","Hip range of motion (flexion - extension)"
"CD014871_pub2_data","Analysis.name","Hip range of motion (adduction-abduction)"
"CD014871_pub2_data","Analysis.name","Peak pelvis elevation in the swing phase"
"CD014871_pub2_data","Analysis.name","Mean ankle dorsiflexion moment during midstance"
"CD014871_pub2_data","Analysis.name","Peak ankle dorsiflexion moment in terminal stance"
"CD014871_pub2_data","Analysis.name","Peak ankle dorsiflexion moment (whole gait cycle)"
"CD014871_pub2_data","Analysis.name","Peak ankle varus moment"
"CD014871_pub2_data","Analysis.name","Mean knee flexion moment during midstance"
"CD014871_pub2_data","Analysis.name","Mean knee flexion moment during terminal stance"
"CD014871_pub2_data","Analysis.name","Peak knee flexion moment (whole gait cycle)"
"CD014871_pub2_data","Analysis.name","Minimal knee extension moment in the stance phase"
"CD014871_pub2_data","Analysis.name","Peak knee varus moment"
"CD014871_pub2_data","Analysis.name","Peak hip flexion moment (whole gait cycle)"
"CD014871_pub2_data","Analysis.name","Peak hip flexion moment in pre-swing"
"CD014871_pub2_data","Analysis.name","Peak hip adduction moment"
"CD014871_pub2_data","Analysis.name","Peak ankle power in terminal stance"
"CD014871_pub2_data","Analysis.name","Peak ankle power (whole gait cycle)"
"CD014871_pub2_data","Analysis.name","Peak knee power (whole gait cycle)"
"CD014871_pub2_data","Analysis.name","Peak hip power in pre-swing"
"CD014871_pub2_data","Analysis.name","Peak hip power (whole gait cycle)"
"CD014871_pub2_data","Analysis.name","Ground reaction force (GRF) impulse"
"CD014871_pub2_data","Analysis.name","Peak impact force contralateral leg"
"CD014871_pub2_data","Analysis.name","Peak impact force affected leg"
"CD014871_pub2_data","Analysis.name","Peak push-off force contralateral leg"
"CD014871_pub2_data","Analysis.name","Peak push-off force affected leg"
"CD014871_pub2_data","Analysis.name","Peak knee adduction moment during loading response contralateral leg"
"CD014871_pub2_data","Analysis.name","Peak knee adduction moment during loading response affected leg"
"CD014871_pub2_data","Analysis.name","Knee adduction impulse contralateral leg"
"CD014871_pub2_data","Analysis.name","Knee adduction impulse affected leg"
"CD014871_pub2_data","Analysis.name","Knee adduction impulse corrected for stride length contralateral leg"
"CD014871_pub2_data","Analysis.name","Knee adduction impulse corrected for stride length affected leg"
"CD014871_pub2_data","Analysis.name","Peak knee flexion moment during loading response contralateral leg"
"CD014871_pub2_data","Analysis.name","Peak knee flexion moment during loading response affected leg"
"CD014871_pub2_data","Analysis.name","Knee flexion impulse contralateral leg"
"CD014871_pub2_data","Analysis.name","Knee flexion impulse affected leg"
"CD014871_pub2_data","Analysis.name","Knee flexion impulse corrected for stride leg contralateral leg"
"CD014871_pub2_data","Analysis.name","Knee flexion impulse corrected for stride leg affected leg"
"CD014871_pub2_data","Subgroup","Carbon (custom-made)"
"CD014871_pub2_data","Subgroup","Polypropylene"
"CD014871_pub2_data","Subgroup","Silicone"
"CD014871_pub2_data","Subgroup","Elastic"
"CD014871_pub2_data","Subgroup","Leather combined with other materials"
"CD014871_pub2_data","Subgroup","Carbon"
"CD014871_pub2_data","Subgroup","Leather and unknown materials"
"CD014871_pub2_data","Subgroup","leather and unknown materials"
"CD014872_pub2_data","Analysis.group","1"
"CD014872_pub2_data","Analysis.group","2"
"CD014872_pub2_data","Analysis.group","3"
"CD014872_pub2_data","Analysis.group","4"
"CD014872_pub2_data","Analysis.name","Progression-free survival"
"CD014872_pub2_data","Analysis.name","Progression-free survival (solid cancer vs haematological cancer)"
"CD014872_pub2_data","Analysis.name","Progression-free survival (standard-of-care chemotherapy vs hormonal therapy)"
"CD014872_pub2_data","Analysis.name","Progression-free survival (FDA/EMA approved vs not approved)"
"CD014872_pub2_data","Analysis.name","Overall survival"
"CD014872_pub2_data","Analysis.name","Overall survival (solid cancer vs haematological cancer)"
"CD014872_pub2_data","Analysis.name","Overall survival (standard-of-care chemotherapy vs hormonal therapy)"
"CD014872_pub2_data","Analysis.name","Overall survival (FDA/EMA-approved vs not approved)"
"CD014872_pub2_data","Analysis.name","Overall response rate"
"CD014872_pub2_data","Analysis.name","Overall response rate (solid cancer vs haematological cancer)"
"CD014872_pub2_data","Analysis.name","Overall response rate (standard-of-care chemotherapy vs hormonal therapy)"
"CD014872_pub2_data","Analysis.name","Overall response rate (FDA/EMA-approved vs not approved)"
"CD014872_pub2_data","Analysis.name","Severe adverse events"
"CD014872_pub2_data","Analysis.name","Severe adverse events (haematological vs non-haematological events)"
"CD014872_pub2_data","Analysis.name","Quality of life "
"CD014872_pub2_data","Analysis.name","Progression-free survival (standard-of-care-chemotherapy vs hormonal therapy)"
"CD014872_pub2_data","Analysis.name","Progression-free survival (FDA/EMA-approved vs not approved)"
"CD014872_pub2_data","Analysis.name","Sensitivity analysis: Progression-free survival"
"CD014872_pub2_data","Analysis.name","Sensitivity analysis: Overall survival"
"CD014872_pub2_data","Analysis.name","Quality of life"
"CD014872_pub2_data","Analysis.name","Progression-free survival "
"CD014872_pub2_data","Analysis.name","Overall survival "
"CD014872_pub2_data","Subgroup","Haematological cancer"
"CD014872_pub2_data","Subgroup","Solid cancer"
"CD014872_pub2_data","Subgroup","Standard-of-care hormonal therapy"
"CD014872_pub2_data","Subgroup","Standard-of-care chemotherapy"
"CD014872_pub2_data","Subgroup","FDA/EMA approved"
"CD014872_pub2_data","Subgroup","FDA/EMA not approved"
"CD014872_pub2_data","Subgroup","FDA/EMA-approved"
"CD014872_pub2_data","Subgroup","FDA/EMA-not approved"
"CD014872_pub2_data","Subgroup","Hormonal therapy"
"CD014872_pub2_data","Subgroup","Chemotherapy"
"CD014872_pub2_data","Subgroup","Non-haematological"
"CD014872_pub2_data","Subgroup","Haematological"
"CD014872_pub2_data","Subgroup","Pain (higher scores represent worse symptoms)"
"CD014872_pub2_data","Subgroup","Appetite loss (higher scores represent worse symptoms)"
"CD014872_pub2_data","Subgroup","Physical functioning (higher scores represent better functioning)"
"CD014889_pub2_data","Analysis.group","1"
"CD014889_pub2_data","Analysis.name","All-cause mortality"
"CD014889_pub2_data","Analysis.name","Serious adverse events"
"CD014889_pub2_data","Analysis.name","Anastomosis leakage"
"CD014889_pub2_data","Analysis.name","Sepsis or mediastinitis"
"CD014889_pub2_data","Analysis.name","Esophageal stricture"
"CD014891_pub2_data","Analysis.group","1"
"CD014891_pub2_data","Analysis.name","Uncorrected distance visual acuity worse than 6/6"
"CD014891_pub2_data","Analysis.name","Corrected distance visual acuity worse than 6/6 "
"CD014891_pub2_data","Analysis.name","Uncorrected distance visual acuity (logMAR)"
"CD014891_pub2_data","Analysis.name","Corrected distance visual acuity (logMAR) "
"CD014891_pub2_data","Analysis.name","Uncorrected near visual acuity worse than J2"
"CD014891_pub2_data","Analysis.name","Uncorrected near visual acuity (logMAR)"
"CD014891_pub2_data","Analysis.name","Corrected near visual acuity (logMAR) "
"CD014891_pub2_data","Analysis.name","Uncorrected intermediate visual acuity worse than 6/9 "
"CD014891_pub2_data","Analysis.name","Uncorrected intermediate visual acuity (logMAR)"
"CD014891_pub2_data","Analysis.name","Corrected intermediate visual acuity (logMAR) "
"CD014891_pub2_data","Analysis.name","Modulation transfer function (MTF) at 40 cycles per degree, 3 mm pupil diameter"
"CD014891_pub2_data","Analysis.name","Contrast sensitivity under photopic and mesopic conditions"
"CD014891_pub2_data","Analysis.name","Defocus curve: 0.0 D (far), LogMAR visual acuity"
"CD014891_pub2_data","Analysis.name","Defocus curve: -1.5 D (intermediate), LogMAR visual acuity"
"CD014891_pub2_data","Analysis.name","Defocus curve: -3.0 D (intermediate), LogMAR visual acuity"
"CD014891_pub2_data","Analysis.name","Any adverse outcome: posterior capsular opacification (PCO)"
"CD014891_pub2_data","Analysis.name","LASEK after all visits for residual refractive error or astigmatism"
"CD014891_pub2_data","Analysis.name","Consideration of excimer laser augmentation at end of study "
"CD014891_pub2_data","Subgroup","12 months"
"CD014914_pub2_data","Analysis.group","1"
"CD014914_pub2_data","Analysis.group","2"
"CD014914_pub2_data","Analysis.group","3"
"CD014914_pub2_data","Analysis.group","4"
"CD014914_pub2_data","Analysis.group","5"
"CD014914_pub2_data","Analysis.group","6"
"CD014914_pub2_data","Analysis.group","7"
"CD014914_pub2_data","Analysis.group","8"
"CD014914_pub2_data","Analysis.group","9"
"CD014914_pub2_data","Analysis.group","10"
"CD014914_pub2_data","Analysis.group","11"
"CD014914_pub2_data","Analysis.group","12"
"CD014914_pub2_data","Analysis.group","13"
"CD014914_pub2_data","Analysis.group","14"
"CD014914_pub2_data","Analysis.group","15"
"CD014914_pub2_data","Analysis.group","16"
"CD014914_pub2_data","Analysis.name","Proportion of participants developing colds/URTI: primary analysis"
"CD014914_pub2_data","Analysis.name","Mean number of colds/URTIs developed: primary analysis"
"CD014914_pub2_data","Analysis.name","Mean duration of colds/URTIs (prevention): primary analysis "
"CD014914_pub2_data","Analysis.name","Adverse events (prevention): primary analysis"
"CD014914_pub2_data","Analysis.name","Serious adverse events (prevention): primary analysis"
"CD014914_pub2_data","Analysis.name","Standardised mean global symptom severity (prevention)"
"CD014914_pub2_data","Analysis.name","Severity of nasal congestion (prevention)"
"CD014914_pub2_data","Analysis.name","Severity of nasal drainage (prevention)"
"CD014914_pub2_data","Analysis.name","Severity of nasal symptoms (prevention)"
"CD014914_pub2_data","Analysis.name","Cough (continuous) (prevention)"
"CD014914_pub2_data","Analysis.name","Nasal drainage (continuous) (prevention)"
"CD014914_pub2_data","Analysis.name","Fever (continuous) (prevention)"
"CD014914_pub2_data","Analysis.name","Headache (continuous) (prevention)"
"CD014914_pub2_data","Analysis.name","Hoarseness (continuous) (prevention)"
"CD014914_pub2_data","Analysis.name","Muscle aches (continuous) (prevention)"
"CD014914_pub2_data","Analysis.name","Nasal congestion (continuous) (prevention)"
"CD014914_pub2_data","Analysis.name","Sneezing (continuous) (prevention)"
"CD014914_pub2_data","Analysis.name","Sore throat (continuous) (prevention)"
"CD014914_pub2_data","Analysis.name","Proportion of participants missing days from work or school (prevention)"
"CD014914_pub2_data","Analysis.name","Mean days missed from work or school (prevention)"
"CD014914_pub2_data","Analysis.name","Mean duration of colds/URTIs (treatment): primary analysis"
"CD014914_pub2_data","Analysis.name","Subgroup analysis (treatment): all administration routes"
"CD014914_pub2_data","Analysis.name","Subgroup analysis (treatment): daily dose of zinc"
"CD014914_pub2_data","Analysis.name","Risk of ongoing cold/URTIs at end of study (treatment): primary analysis"
"CD014914_pub2_data","Analysis.name","Adverse events (treatment): primary analysis"
"CD014914_pub2_data","Analysis.name","Subgroup analysis (treatment): intranasal vs lozenge"
"CD014914_pub2_data","Analysis.name","Subgroup analysis (treatment): zinc acetate vs zinc gluconate"
"CD014914_pub2_data","Analysis.name","Subgroup analysis (treatment): age groupings"
"CD014914_pub2_data","Analysis.name","Standardised mean global symptom severity (treatment)"
"CD014914_pub2_data","Analysis.name","Proportion with changes in global symptom severity (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of cough (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of headache (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of hoarseness (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of malaise (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of muscle aches (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of nasal congestion (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of nasal drainage (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of scratchy throat (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of sneezing (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of sore throat (treatment)"
"CD014914_pub2_data","Analysis.name","Severity of fever (treatment)"
"CD014914_pub2_data","Analysis.name","Cough (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Fever (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Headache (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Hoarseness (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Malaise (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Muscle aches (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Nasal congestion (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Nasal drainage (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Scratchy throat (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Sneezing (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Sore throat (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Nasal symptoms (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Throat symptoms (continuous) (treatment)"
"CD014914_pub2_data","Analysis.name","Cough (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Fever (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Headache (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Hoarseness (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Muscle aches (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Nasal congestion (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Nasal drainage (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Scratchy throat (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Sneezing (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Sore throat (dichotomous) (treatment)"
"CD014914_pub2_data","Analysis.name","Proportion of participants missing days from work or school (treatment)"
"CD014914_pub2_data","Analysis.name","Proportion of days absent from work or school (treatment)"
"CD014914_pub2_data","Subgroup","Intranasal"
"CD014914_pub2_data","Subgroup","Lozenge"
"CD014914_pub2_data","Subgroup","> 85 mg/d"
"CD014914_pub2_data","Subgroup","< 85 mg/d"
"CD014914_pub2_data","Subgroup","Zinc acetate"
"CD014914_pub2_data","Subgroup","Zinc gluconate"
"CD014914_pub2_data","Subgroup","< 18 yo"
"CD014914_pub2_data","Subgroup","> 18 yo"
"CD014920_pub2_data","Analysis.group","1"
"CD014920_pub2_data","Analysis.name","Acute myocardial infarction (short term < 30 days)"
"CD014920_pub2_data","Analysis.name","Acute myocardial infarction (long term > 30 days)"
"CD014920_pub2_data","Analysis.name","All-cause mortality (perioperative)"
"CD014920_pub2_data","Analysis.name","All-cause mortality (long term)"
"CD014920_pub2_data","Analysis.name","Cardiovascular mortality"
"CD014920_pub2_data","Analysis.name","Length of hospital stay"
"CD014923_pub2_data","Analysis.group","1"
"CD014923_pub2_data","Analysis.group","2"
"CD014923_pub2_data","Analysis.group","3"
"CD014923_pub2_data","Analysis.group","4"
"CD014923_pub2_data","Analysis.group","5"
"CD014923_pub2_data","Analysis.name","Gait speed - unpaired, parallel assessment < 12 months"
"CD014923_pub2_data","Analysis.name","Gait speed -  paired assessment < 12 months"
"CD014923_pub2_data","Analysis.name","Unpaired parallel assessment < 12 months"
"CD014923_pub2_data","Analysis.name","Paired assessment longitudinal < 12 months"
"CD014923_pub2_data","Analysis.name","Patient disability - number of participants who improved (unpaired, parallel assessment < 12 months)"
"CD014923_pub2_data","Analysis.name","Patient disability - functionally independent (unpaired, parallel assessment < 12 months)"
"CD014923_pub2_data","Analysis.name","Patient disability - number of participants who improved  (paired assessment < 12 months)"
"CD014923_pub2_data","Analysis.name","Patient disability - functionally independent (paired assessment < 12 months)"
"CD014923_pub2_data","Analysis.name","Adverse events < 3 months post-surgery"
"CD014923_pub2_data","Analysis.name","General cognitive screening - unpaired, parallel assessment < 6 months"
"CD014923_pub2_data","Analysis.name","General cognitive screening - paired assessment < 12 months"
"CD014923_pub2_data","Analysis.name","Symbol Digit Tests - unpaired, parallel assessment < 6 months"
"CD014923_pub2_data","Analysis.name","Symbol Digit Tests - paired assessment < 12 months"
"CD014932_pub2_data","Analysis.group","1"
"CD014932_pub2_data","Analysis.group","2"
"CD014932_pub2_data","Analysis.group","3"
"CD014932_pub2_data","Analysis.group","4"
"CD014932_pub2_data","Analysis.group","5"
"CD014932_pub2_data","Analysis.group","6"
"CD014932_pub2_data","Analysis.group","7"
"CD014932_pub2_data","Analysis.name","Reduction in disease severity, as measured by clinical signs (SCORAD)"
"CD014932_pub2_data","Analysis.name","Long-term reduction in disease severity, as measured by clinical signs (SCORAD) across all age groups"
"CD014932_pub2_data","Analysis.name","Short-term reduction in disease severity, as measured by clinical signs (SCORAD)"
"CD014932_pub2_data","Analysis.name","Reduction in disease severity, as measured by patient-reported symptoms"
"CD014932_pub2_data","Analysis.name","Improvement in quality-of-life measures (DLQI): all scales, infants, children, and family"
"CD014932_pub2_data","Analysis.name","Improvement in quality-of-life measures: family impact"
"CD014932_pub2_data","Analysis.name","Improvement in psychological well-being measures"
"CD014932_pub2_data","Analysis.name","Change in concordance with standard treatment: Parents’ Self-Efficacy with Eczema Care Index"
"CD014932_pub2_data","Analysis.name","Reduction in disease severity, as measured by patient-reported symptoms (POEM)"
"CD014932_pub2_data","Analysis.name","Improvement in quality-of-life measures"
"CD014932_pub2_data","Analysis.name","Improvement in long-term control of eczema symptoms (RECAP)"
"CD014932_pub2_data","Analysis.name","Improvement in psychological well-being measures: one-item overall stress-rating scale"
"CD014932_pub2_data","Analysis.name","Improvement in quality-of-life measures: children (CDLQI)"
"CD014932_pub2_data","Analysis.name","Reduction in disease severity, as measured by clinical signs (EASI)"
"CD014932_pub2_data","Analysis.name","Improvement in psychological measures: State Anxiety"
"CD014932_pub2_data","Analysis.name","Improvement in psychological well-being measures: State Anxiety"
"CD014932_pub2_data","Analysis.name","Reduction in disease severity, as measured by patient-reported symptoms (VAS)"
"CD014932_pub2_data","Analysis.name","Improvement in quality-of-life measures (DFI)"
"CD014932_pub2_data","Subgroup","Short Term Reduction in disease severity, as measured by clinical signs, unspecified age- SCORAD"
"CD014932_pub2_data","Subgroup","Improvement in Quality of Life Measures -Children-CDLQI"
"CD014932_pub2_data","Subgroup","Improvement in Quality of Life Measures- Infants-IDLQI"
"CD014932_pub2_data","Subgroup"," Improvement in quality-of-life measures-Family-impact"
"CD014932_pub2_data","Subgroup","Improvement in psychological measures-State Anxiety"
"CD014932_pub2_data","Subgroup","Improvement in psychological measures-Perceived Stress Scale"
"CD014932_pub2_data","Subgroup","Long Term Reduction in disease severity as measured by patient (0-12 years)-POEM "
"CD014932_pub2_data","Subgroup","Long term reduction in disease severity as measured by patient (13 -25 years)-POEM"
"CD014932_pub2_data","Subgroup","Reduction in disease severity as measured by patient-POEM-unspecified age"
"CD014932_pub2_data","Subgroup","Improvment in quality of life measures-DLQI "
"CD014932_pub2_data","Subgroup","Improvement in quality of life measures (0-12 years)-Health related quality of life"
"CD014932_pub2_data","Subgroup","Improvement in quality of life measures (13-25 years)-Health related quality of life"
"CD014932_pub2_data","Subgroup","Improvement in quality of life measures- Health related quality of life-unspecified age"
"CD014932_pub2_data","Subgroup","Improvement in long-term control in eczema symptoms (0-12 years)-RECAP at 24 wks"
"CD014932_pub2_data","Subgroup","Improvement in long-term control in eczema symptoms (0-12 years)-RECAP at 52 wks"
"CD014932_pub2_data","Subgroup","Improvement in long-term control in eczema symptoms (13-25 years)-RECAP at 24 wks"
"CD014932_pub2_data","Subgroup","Improvement in long-term control in eczema symptoms (13-25 years)-RECAP at 52 wks"
"CD014932_pub2_data","Subgroup","Improvment in psychological well-being measures- State Anxiety-STAXI-S)"
"CD014932_pub2_data","Subgroup","Anxiety Carer -Anxiety (GAD7) Intervention"
"CD014932_pub2_data","Subgroup","Perceived Stress- Carers-Perceived Stress (PSS) Intervention"
"CD014932_pub2_data","Subgroup","Depression - Carer-Depression (PHQ-9) Intervention"
"CD014935_pub2_data","Analysis.group","1"
"CD014935_pub2_data","Analysis.name","All-cause mortality"
"CD014935_pub2_data","Analysis.name","All-cause mortality - Sensitivity analysis (best-case scenario)"
"CD014935_pub2_data","Analysis.name","All-cause mortality - Sensitivity analysis (worst-case scenario)"
"CD014935_pub2_data","Analysis.name","Serious adverse events"
"CD014935_pub2_data","Analysis.name","Serious adverse events - Sensitivity Analysis (fixed-effect model)"
"CD014935_pub2_data","Analysis.name","Serious adverse events - Sensitivity Analysis (best-case scenario)"
"CD014935_pub2_data","Analysis.name","Serious adverse events - Sensitivity Analysis (worst-case scenario)"
"CD014935_pub2_data","Analysis.name","Non-serious adverse events"
"CD014935_pub2_data","Analysis.name","Days of hospitalisation"
"CD014935_pub2_data","Analysis.name","Days of hospitalisation - Sensitivity analysis (fixed-effect model)"
"CD014935_pub2_data","Analysis.name","Jarisch-Herxheimer reaction"
"CD014937_pub2_data","Analysis.group","1"
"CD014937_pub2_data","Analysis.group","2"
"CD014937_pub2_data","Analysis.name","Acute kidney injury"
"CD014937_pub2_data","Analysis.name","Any use of kidney replacement therapy"
"CD014937_pub2_data","Analysis.name","Death"
"CD014937_pub2_data","Analysis.name","Permanent dialysis"
"CD014937_pub2_data","Analysis.name","Adverse events"
"CD014937_pub2_data","Analysis.name","Changes in serum creatinine within 30 days (mg/dL]"
"CD014937_pub2_data","Analysis.name","Urinary output"
"CD014937_pub2_data","Analysis.name","Sensitivity analysis: acute kidney injury (low overall risk of bias)"
"CD014937_pub2_data","Analysis.name","Sensitivity analysis: acute kidney injury (overall risk of bias 'some concerns' or 'low')"
"CD014937_pub2_data","Analysis.name","Sensitivity analysis: acute kidney injury (placebo-controlled studies)"
"CD014937_pub2_data","Analysis.name","Sensitivity analysis: acute kidney injury (excluding kidney transplantation)"
"CD014937_pub2_data","Analysis.name","Subgroup analysis: acute kidney injury by population"
"CD014937_pub2_data","Analysis.name","Subgroup analysis: acute kidney injury by type of diuretic"
"CD014937_pub2_data","Analysis.name","Subgroup analysis: acute kidney injury by definition"
"CD014937_pub2_data","Analysis.name","Subgroup analysis: acute kidney injury by age"
"CD014937_pub2_data","Analysis.name","Sensitivity analysis: any use of KRT (only studies with a ""low"" overall risk of bias)"
"CD014937_pub2_data","Analysis.name","Sensitivity analysis: any use of KRT (only studies with ""some concerns""  or a ""low"" overall risk of bias)"
"CD014937_pub2_data","Analysis.name","Sensitivity analysis: any use of KRT (placebo-controlled studies)"
"CD014937_pub2_data","Analysis.name","Sensitivity analysis: any use of KRT (excluding kidney transplantation)"
"CD014937_pub2_data","Analysis.name","Subgroup analysis: any use of KRT by population"
"CD014937_pub2_data","Analysis.name","Subgroup analysis: any use of KRT by type of diuretic"
"CD014937_pub2_data","Analysis.name","Subgroup analysis: any use of KRT by age"
"CD014937_pub2_data","Analysis.name","Sensitivity analysis: any use of KRT (studies with ""some concerns"" or a ""low"" overall risk of bias)"
"CD014937_pub2_data","Subgroup","Hypokalaemia"
"CD014937_pub2_data","Subgroup","Arrhythmia"
"CD014937_pub2_data","Subgroup","Hypotension"
"CD014937_pub2_data","Subgroup","Surgery"
"CD014937_pub2_data","Subgroup","Procedures with contrast media"
"CD014937_pub2_data","Subgroup","Critical care"
"CD014937_pub2_data","Subgroup","Non-cardiac-related procedures"
"CD014937_pub2_data","Subgroup","Cardiac-related procedures"
"CD014937_pub2_data","Subgroup","Mannitol"
"CD014937_pub2_data","Subgroup","Furosemide"
"CD014937_pub2_data","Subgroup","Natriuretic peptide"
"CD014937_pub2_data","Subgroup","Spironolactone"
"CD014937_pub2_data","Subgroup","Acetazolamide"
"CD014937_pub2_data","Subgroup","Thiazide"
"CD014937_pub2_data","Subgroup","Furosemide without RenalGuard"
"CD014937_pub2_data","Subgroup","Furosemide with RenalGuard"
"CD014937_pub2_data","Subgroup","AKIN"
"CD014937_pub2_data","Subgroup","KDIGO"
"CD014937_pub2_data","Subgroup","RIFLE"
"CD014937_pub2_data","Subgroup","Acute kidney injury (≤ 16 years)"
"CD014937_pub2_data","Subgroup","Acute kidney injury (≥ 16 years)"
"CD014937_pub2_data","Subgroup","Age < 16 years"
"CD014937_pub2_data","Subgroup","Age ≥ 16 years"
"CD014937_pub2_data","Subgroup","Arrhythmias"
"CD014941_pub2_data","Analysis.group","1"
"CD014941_pub2_data","Analysis.name","50% responder rate"
"CD014941_pub2_data","Analysis.name","Seizure freedom"
"CD014941_pub2_data","Analysis.name","Any adverse event"
"CD014941_pub2_data","Analysis.name"," ≥ 75% seizure reduction/month during the maintenance treatment period compared to baseline"
"CD014941_pub2_data","Analysis.name","≥ 90% seizure reduction/month during the maintenance treatment period compared to baseline"
"CD014941_pub2_data","Analysis.name","Withdrawal from the study due to adverse events"
"CD014941_pub2_data","Analysis.name","Withdrawal rate"
"CD014941_pub2_data","Analysis.name","Any treatment-related adverse events"
"CD014941_pub2_data","Analysis.name","Any serious adverse event"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - subgroup analysis, 50% responder rate"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - subgroup analysis, seizure freedom"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - subgroup analysis, any adverse event"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - subgroup analysis, ≥ 75% seizure reduction/month during the maintenance treatment period compared to baseline"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - subgroup analysis, ≥ 90% seizure reduction/month during the maintenance treatment period compared to baseline"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - subgroup analysis, withdrawal from the study due to adverse events"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - subgroup analysis, withdrawal rate"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - subgroup analysis, any treatment-related adverse events"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - subgroup analysis, any serious adverse event"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - sensitivity analysis, 50% responder rate (random-effects model)"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - sensitivity analysis, seizure freedom (random-effects model)"
"CD014941_pub2_data","Analysis.name","Cenobamate versus placebo - sensitivity analysis, any adverse event (random-effects model) "
"CD014941_pub2_data","Subgroup","Cenobamate (any dose)"
"CD014941_pub2_data","Subgroup","Cenobamate 200 mg"
"CD014941_pub2_data","Subgroup","Cenobamate 100 mg"
"CD014941_pub2_data","Subgroup","Cenobamate 400 mg"
"CD014941_pub2_data","Subgroup","Cenobatame 200 mg"
"CD014944_pub2_data","Analysis.group","1"
"CD014944_pub2_data","Analysis.group","2"
"CD014944_pub2_data","Analysis.group","3"
"CD014944_pub2_data","Analysis.group","4"
"CD014944_pub2_data","Analysis.group","5"
"CD014944_pub2_data","Analysis.name","Proportion of participants without treatment success at the longest follow-up (1–4 years)"
"CD014944_pub2_data","Analysis.name","Proportion of participants with serious adverse events (pancreatitis, at 1 year)"
"CD014944_pub2_data","Analysis.name","Health-related quality of life (measured with SF-36 Physical scale at 1 year)"
"CD014944_pub2_data","Analysis.name","Health-related quality of life (measured with SF-36 Mental scale at 1 year)"
"CD014944_pub2_data","Analysis.name","Proportion of participants without improvement in liver function tests"
"CD014944_pub2_data","Analysis.name","Proportion of participants with serious adverse events (recurrent common bile duct stones, at 1 year)"
"CD014944_pub2_data","Analysis.name","Proportion of participants without treatment success (at 1 year)"
"CD014944_pub2_data","Analysis.name","Risk of bias. Proportion of participants without treatment success at the longest follow-up (1–4 years)"
"CD014944_pub2_data","Analysis.name","Best-worst case scenario analysis"
"CD014944_pub2_data","Analysis.name","Worst-best case scenario analysis"
"CD014944_pub2_data","Subgroup","Trials at some concern and at high risk of bias"
"CD014944_pub2_data","Subgroup","Trials at low risk of bias"
"CD014959_pub2_data","Analysis.group","1"
"CD014959_pub2_data","Analysis.group","2"
"CD014959_pub2_data","Analysis.name","All-cause mortality"
"CD014959_pub2_data","Analysis.name","Proportion of people with laboratory-confirmed leptospirosis regardless of the presence of an identified clinical syndrome (inclusive of asymptomatic cases) "
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: laboratory-confirmed leptospirosis (best-case scenario)"
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: laboratory-confirmed leptospirosis (worst-case scenario)"
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: laboratory-confirmed leptospirosis (only pre-exposure prophylaxis)"
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: laboratory-confirmed leptospirosis (only postexposure prophylaxis)"
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: laboratory-confirmed leptospirosis (including only endemic community)"
"CD014959_pub2_data","Analysis.name","Proportion of people with clinical diagnosis of leptospirosis regardless of the presence of laboratory confirmation "
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: clinical diagnosis of leptospirosis regardless of the presence of laboratory confirmation (best-case scenario)"
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: clinical diagnosis of leptospirosis regardless of the presence of laboratory confirmation (worst-case scenario)"
"CD014959_pub2_data","Analysis.name","Proportion of people with clinical diagnosis of leptospirosis confirmed by laboratory diagnosis (exclusive of asymptomatic cases)"
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: clinical diagnosis confirmed by laboratory diagnosis (best-case scenario)"
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: clinical diagnosis confirmed by laboratory diagnosis (worst-case scenario)"
"CD014959_pub2_data","Analysis.name","Proportion of people with non-serious adverse events"
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: non-serious adverse events (best-case scenario)"
"CD014959_pub2_data","Analysis.name","Sensitivity analysis: non-serious adverse events (worst-case scenario)"
"CD014960_pub2_data","Analysis.group","1"
"CD014960_pub2_data","Analysis.group","2"
"CD014960_pub2_data","Analysis.name","All-cause mortality"
"CD014960_pub2_data","Analysis.name","Proportion of people with adverse events considered non-serious"
"CD014960_pub2_data","Analysis.name","Days of hospitalisation "
"CD014960_pub2_data","Analysis.name","All-cause mortality (penicillin versus cefotaxime or ceftriaxone)"
"CD014960_pub2_data","Analysis.name","All-cause mortality (penicillin versus doxycycline)"
"CD014960_pub2_data","Analysis.name","All-cause mortality (cefotaxime versus doxycycline)"
"CD014960_pub2_data","Analysis.name","Serious adverse event (nosocomial infection) (penicillin versus cefotaxime)"
"CD014960_pub2_data","Analysis.name","Serious adverse event (nosocomial infection) (penicillin versus doxycycline)"
"CD014960_pub2_data","Analysis.name","Serious adverse event (nosocomial infection) (doxycycline versus cefotaxime)"
"CD014960_pub2_data","Analysis.name","Proportion of people with adverse events considered non-serious (penicillin versus cefotaxime)"
"CD014960_pub2_data","Analysis.name","Proportion of people with adverse events considered non-serious (penicillin versus doxycycline)"
"CD014960_pub2_data","Analysis.name","Proportion of people with adverse events considered non-serious (penicillin versus chloramphenicol)"
"CD014964_pub2_data","Analysis.group","1"
"CD014964_pub2_data","Analysis.group","2"
"CD014964_pub2_data","Analysis.group","3"
"CD014964_pub2_data","Analysis.group","4"
"CD014964_pub2_data","Analysis.group","5"
"CD014964_pub2_data","Analysis.group","6"
"CD014964_pub2_data","Analysis.group","7"
"CD014964_pub2_data","Analysis.group","8"
"CD014964_pub2_data","Analysis.name","Number of attempts until success or procedure termination"
"CD014964_pub2_data","Analysis.name","Procedure time (needling time)"
"CD014964_pub2_data","Analysis.name","Participant satisfaction during the procedure"
"CD014964_pub2_data","Analysis.name","First‐attempt success"
"CD014964_pub2_data","Analysis.name","Technical failure of neuraxial anaesthesia"
"CD014964_pub2_data","Analysis.name","Pain during the procedure"
"CD014964_pub2_data","Analysis.name","Any adverse events"
"CD014964_pub2_data","Analysis.name","Number of attempts (Difficulty of palpating landmarks)"
"CD014964_pub2_data","Analysis.name","Number of attempts (Experience of operators)"
"CD014964_pub2_data","Analysis.name","Number of attempts (Types of ultrasound guidance: preprocedural versus real‐time)"
"CD014964_pub2_data","Analysis.name","Number of attempts (Types of neuraxial anaesthesia)"
"CD014964_pub2_data","Analysis.name","Number of attempts (Definition of outcome: used 'number of insertions through the skin')"
"CD014964_pub2_data","Analysis.name","Number of attempts (Including only studies that were judged 'low risk of bias')"
"CD014964_pub2_data","Analysis.name","Number of attempts (Including only studies that reported both the mean and standard deviation)"
"CD014964_pub2_data","Analysis.name","Procedure time (Difficulty of palpating landmarks)"
"CD014964_pub2_data","Analysis.name","Procedure time (Experience of operators)"
"CD014964_pub2_data","Analysis.name","Procedure time (Types of ultrasound guidance: preprocedural versus real‐time)"
"CD014964_pub2_data","Analysis.name","Procedure time (Types of neuraxial anaesthesia)"
"CD014964_pub2_data","Analysis.name","Procedure time (Including only studies that were judged 'low risk of bias')"
"CD014964_pub2_data","Analysis.name","Procedure time (Including only studies that reported both the mean and standard deviation)"
"CD014964_pub2_data","Analysis.name","Participant satisfaction (Difficulty of palpating landmarks)"
"CD014964_pub2_data","Analysis.name","Participant satisfaction (Experience of operators)"
"CD014964_pub2_data","Analysis.name","Participant satisfaction (Types of ultrasound guidance: preprocedural versus real‐time)"
"CD014964_pub2_data","Analysis.name","Participant satisfaction (Types of neuraxial anaesthesia)"
"CD014964_pub2_data","Analysis.name","Participant satisfaction (Including only studies that were judged 'low risk of bias')"
"CD014964_pub2_data","Analysis.name","Participant satisfaction (Including only studies that reported both the mean and standard deviation)"
"CD014964_pub2_data","Analysis.name","First-attempt success (Difficulty of palpating landmarks)"
"CD014964_pub2_data","Analysis.name","First-attempt success  (Experience of operators)"
"CD014964_pub2_data","Analysis.name","First-attempt success (Types of ultrasound guidance: preprocedural versus real‐time)"
"CD014964_pub2_data","Analysis.name","First-attempt success (Types of neuraxial anaesthesia)"
"CD014964_pub2_data","Analysis.name","First-attempt success (Definition of outcome: used 'first skin insertion')"
"CD014964_pub2_data","Analysis.name","First-attempt success (Including only studies that were judged 'low risk of bias')"
"CD014964_pub2_data","Analysis.name","Technical failure (Difficulty of palpating landmarks)"
"CD014964_pub2_data","Analysis.name","Technical failure (Types of ultrasound guidance: preprocedural versus real‐time)"
"CD014964_pub2_data","Analysis.name","Technical failure (Types of neuraxial anaesthesia)"
"CD014964_pub2_data","Analysis.name","Technical failure (Including only studies that were judged 'low risk of bias')"
"CD014964_pub2_data","Analysis.name","Pain (Difficulty of palpating landmarks)"
"CD014964_pub2_data","Analysis.name","Pain (Experience of operators)"
"CD014964_pub2_data","Analysis.name","Pain (Types of neuraxial anaesthesia)"
"CD014964_pub2_data","Analysis.name","Pain (Including only studies that were judged 'low risk of bias')"
"CD014964_pub2_data","Analysis.name","Pain (Including only studies that reported both the mean and standard deviation)"
"CD014964_pub2_data","Analysis.name","Adverse events (Difficulty of palpating landmarks)"
"CD014964_pub2_data","Analysis.name","Adverse events (Experience of operators)"
"CD014964_pub2_data","Analysis.name","Adverse events (Types of ultrasound guidance: preprocedural versus real‐time)"
"CD014964_pub2_data","Analysis.name","Adverse events (Types of neuraxial anaesthesia)"
"CD014964_pub2_data","Analysis.name","Adverse events (Including only studies that were judged 'low risk of bias')"
"CD014964_pub2_data","Subgroup","Difficut"
"CD014964_pub2_data","Subgroup","Not difficult"
"CD014964_pub2_data","Subgroup","Experienced"
"CD014964_pub2_data","Subgroup","Inexperienced"
"CD014964_pub2_data","Subgroup","Ultrasound preprocedure"
"CD014964_pub2_data","Subgroup","Ultrasound real-time"
"CD014964_pub2_data","Subgroup","Spinal"
"CD014964_pub2_data","Subgroup","Lumbar epidural"
"CD014964_pub2_data","Subgroup","Thoracic epidural"
"CD014964_pub2_data","Subgroup","No"
"CD014964_pub2_data","Subgroup","Yes"
"CD014965_pub2_data","Analysis.group","1"
"CD014965_pub2_data","Analysis.group","2"
"CD014965_pub2_data","Analysis.group","3"
"CD014965_pub2_data","Analysis.group","4"
"CD014965_pub2_data","Analysis.group","5"
"CD014965_pub2_data","Analysis.group","6"
"CD014965_pub2_data","Analysis.name","Irritability"
"CD014965_pub2_data","Analysis.name","Aggression"
"CD014965_pub2_data","Analysis.name","Weight gain above clinically relevant thresholds"
"CD014965_pub2_data","Analysis.name","Weight gain as a continuous measure (in kilograms)"
"CD014965_pub2_data","Analysis.name","Extrapyramidal side effects: any extrapyramidal symptom"
"CD014965_pub2_data","Analysis.name","Obsessive-compulsive behaviours"
"CD014965_pub2_data","Analysis.name","Inappropriate speech"
"CD014965_pub2_data","Analysis.name","Metabolic side effects: triglyceride levels as a continuous measure"
"CD014965_pub2_data","Analysis.name","Metabolic side effects: triglyceride levels above clinically relevant thresholds"
"CD014965_pub2_data","Analysis.name","Metabolic side effects: total cholesterol levels as a continuous measure"
"CD014965_pub2_data","Analysis.name","Metabolic side effects: total cholesterol levels above clinically relevant thresholds"
"CD014965_pub2_data","Analysis.name","Other side effects: any adverse event"
"CD014965_pub2_data","Analysis.name","Other side effects: somnolence"
"CD014965_pub2_data","Analysis.name","Other side effects: sedation"
"CD014965_pub2_data","Analysis.name","Other side effects: headache"
"CD014965_pub2_data","Analysis.name","Other side effects: constipation"
"CD014965_pub2_data","Analysis.name","Other side effects: self-injurious behaviour"
"CD014965_pub2_data","Analysis.name","Other side effects: hypersalivation"
"CD014965_pub2_data","Analysis.name","Other side effects: tremor"
"CD014965_pub2_data","Analysis.name","Other side effects: akathisia"
"CD014965_pub2_data","Analysis.name","Other side effects: dyskinesia"
"CD014965_pub2_data","Analysis.name","Other side effects: rigidity"
"CD014965_pub2_data","Analysis.name","Other side effects: insomnia"
"CD014965_pub2_data","Analysis.name","Lethargy/withdrawal"
"CD014965_pub2_data","Analysis.name","Hyperactivity"
"CD014965_pub2_data","Analysis.name","Stereotypy"
"CD014965_pub2_data","Analysis.name","Clinical improvement"
"CD014965_pub2_data","Analysis.name","Weight gain as a continuous measure"
"CD014965_pub2_data","Analysis.name","Social-communication adaptive functioning"
"CD014965_pub2_data","Analysis.name","Irritability: posology (fixed-dose scheme versus flexible-dose scheme)"
"CD014965_pub2_data","Analysis.name","Weight gain above clinically relevant thresholds: posology (fixed-dose scheme versus flexible-dose scheme)"
"CD014965_pub2_data","Subgroup","Risperidone"
"CD014965_pub2_data","Subgroup","Aripiprazole"
"CD014965_pub2_data","Subgroup","Lurasidone"
"CD014965_pub2_data","Subgroup","Olanzapine"
"CD014965_pub2_data","Subgroup","Fixed-dose scheme"
"CD014965_pub2_data","Subgroup","Flexible-dose scheme"
"CD014966_pub2_data","Analysis.group","1"
"CD014966_pub2_data","Analysis.group","2"
"CD014966_pub2_data","Analysis.group","3"
"CD014966_pub2_data","Analysis.group","4"
"CD014966_pub2_data","Analysis.group","5"
"CD014966_pub2_data","Analysis.name","Kidney graft loss"
"CD014966_pub2_data","Analysis.name","Kidney graft loss: time-to-event analysis"
"CD014966_pub2_data","Analysis.name","Kidney graft loss: female donor"
"CD014966_pub2_data","Analysis.name","Kidney graft loss: male donor"
"CD014966_pub2_data","Analysis.name","Pancreatic graft loss"
"CD014966_pub2_data","Analysis.name","Death"
"CD014966_pub2_data","Analysis.name","Cancer incidence"
"CD014966_pub2_data","Analysis.name","Rejection: acute and chronic"
"CD014966_pub2_data","Subgroup","End of study: 1 to 10 years"
"CD014966_pub2_data","Subgroup","Up to 1 year"
"CD014966_pub2_data","Subgroup","Up to 5 years "
"CD014966_pub2_data","Subgroup","Up to 10 years "
"CD014966_pub2_data","Subgroup","Death up to 30 years"
"CD014966_pub2_data","Subgroup","Late death (> 5 years)"
"CD014966_pub2_data","Subgroup","Early death (≤ 5 years)"
"CD014966_pub2_data","Subgroup","Acute and/or chronic rejection"
"CD014966_pub2_data","Subgroup","Chronic rejection "
"CD014966_pub2_data","Subgroup","Acute rejection"
"CD014967_pub2_data","Analysis.group","1"
"CD014967_pub2_data","Analysis.group","2"
"CD014967_pub2_data","Analysis.group","3"
"CD014967_pub2_data","Analysis.group","4"
"CD014967_pub2_data","Analysis.group","5"
"CD014967_pub2_data","Analysis.group","6"
"CD014967_pub2_data","Analysis.group","7"
"CD014967_pub2_data","Analysis.group","8"
"CD014967_pub2_data","Analysis.group","9"
"CD014967_pub2_data","Analysis.group","10"
"CD014967_pub2_data","Analysis.name","Proportion of infants who achieve seizure control after the first loading dose of ASM"
"CD014967_pub2_data","Analysis.name","Proportion of infants who achieve seizure control after the the maximal loading dose of ASM"
"CD014967_pub2_data","Analysis.name","Mortality before hospital discharge"
"CD014967_pub2_data","Analysis.name","Requirement for mechanical ventilation"
"CD014967_pub2_data","Analysis.name","Proportion of infants who develop sedation or drowsiness"
"CD014967_pub2_data","Analysis.name","Bradycardia"
"CD014967_pub2_data","Analysis.name","Hypotension requiring volume or inotropes"
"CD014967_pub2_data","Analysis.name","Shock requiring volume or inotropes"
"CD014967_pub2_data","Analysis.name","Recurrence of seizure before hospital discharge"
"CD014967_pub2_data","Analysis.name","Proportion of infants with epilepsy post-discharge"
"CD014967_pub2_data","Analysis.name","Proportion of infants who achieve seizure control after the maximal loading dose of ASM"
"CD014967_pub2_data","Analysis.name","Proportion of infants with an abnormal background pattern in EEG during ASM treatment"
"CD014967_pub2_data","Analysis.name","Proportion of infants with an abnormal background pattern in EEG after stopping ASM"
"CD014967_pub2_data","Analysis.name","Duration of hospital stay"
"CD014967_pub2_data","Analysis.name","Proportion of infants with persistent seizures and/or requiring ASM at discharge"
"CD014967_pub2_data","Analysis.name","Proportion of infants discharged on gavage feeds"
"CD014967_pub2_data","Analysis.name","Proportion of infants with an abnormal neurological examination at discharge"
"CD014967_pub2_data","Analysis.name","Proportion of infants who develop epilepsy post discharge"
"CD014967_pub2_data","Analysis.name","Arrythmias causing circulatory disturbance"
"CD014967_pub2_data","Analysis.name","Requirement of mechanical ventilation"
"CD014967_pub2_data","Analysis.name","Proportion of infants with cognitive impairment at 18-24 months"
"CD014967_pub2_data","Analysis.name","Seizure burden during hospitalisation"
"CD014967_pub2_data","Analysis.name","Hypotension  requiring volume or inotropes"
"CD014967_pub2_data","Analysis.name","Mortality or neurodevelopmental disability at 12 months' corrected age"
"CD014967_pub2_data","Analysis.name","Neurodevelopmental disability at 12 months' corrected age"
"CD014967_pub2_data","Analysis.name","Proportion of infants with repeat seizure before hospital discharge"
"CD014967_pub2_data","Analysis.name","Mortality at 18 to 24 months"
"CD014967_pub2_data","Analysis.name","Neurodevelopmental disability at 18 to 24 months' corrected age"
"CD014967_pub2_data","Analysis.name","Abnormal background pattern in EEG after achieving  seizure control"
"CD014967_pub2_data","Analysis.name","Abnormal neurological examination at discharge"
"CD014967_pub2_data","Analysis.name","Proportion of infants who develop epilepsy post-discharge"
"CD014999_pub2_data","Analysis.group","1"
"CD014999_pub2_data","Analysis.group","2"
"CD014999_pub2_data","Analysis.name","Rebleeding"
"CD014999_pub2_data","Analysis.name","Reintervention (events)"
"CD014999_pub2_data","Analysis.name","Reintervention (patients)"
"CD014999_pub2_data","Analysis.name","30-day bleeding-related mortality"
"CD014999_pub2_data","Analysis.name","30-day all-cause mortality"
"CD014999_pub2_data","Analysis.name","Duration of hospitalization"
"CD014999_pub2_data","Analysis.name","Rebleeding: sensitivity analysis, Forrest Ia–IIa"
"CD014999_pub2_data","Analysis.name","Reintervention (events): sensitivity analysis, Forrest Ia–IIa"
"CD014999_pub2_data","Analysis.name","Reintervention (patients): sensitivity analysis, Forrest Ia–IIa"
"CD014999_pub2_data","Analysis.name","30-day all-cause mortality: sensitivity analysis, Forrest Ia–IIa"
"CD014999_pub2_data","Analysis.name","Duration of hospitalization: sensitivity analysis, Forrest Ia–IIa"
"CD015003_pub2_data","Analysis.group","1"
"CD015003_pub2_data","Analysis.group","2"
"CD015003_pub2_data","Analysis.group","3"
"CD015003_pub2_data","Analysis.name","All-cause mortality"
"CD015003_pub2_data","Analysis.name","Non-fatal myocardial infarction"
"CD015003_pub2_data","Analysis.name","Stroke"
"CD015003_pub2_data","Analysis.name","Adverse events"
"CD015003_pub2_data","Analysis.name","Cardiovascular mortality"
"CD015003_pub2_data","Analysis.name","Post-cardiac procedure atrial fibrillation"
"CD015003_pub2_data","Subgroup","Gastrointestinal (diarrhoea)"
"CD015003_pub2_data","Subgroup","Neurological (seizure, confusion)"
"CD015014_pub2_data","Analysis.group","1"
"CD015014_pub2_data","Analysis.name","ED visits (proportion of residents with at least one ED visit)"
"CD015014_pub2_data","Analysis.name","ED visits (proportion of residents with at least one ED visit): sensitivity analysis by risk of bias"
"CD015014_pub2_data","Analysis.name","ED visits (mean number of ED visits per resident)"
"CD015014_pub2_data","Analysis.name","ED visits: logarithm of rate ratio per person-time"
"CD015014_pub2_data","Analysis.name","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission)"
"CD015014_pub2_data","Analysis.name","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by EPOC category"
"CD015014_pub2_data","Analysis.name","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by type of care provided"
"CD015014_pub2_data","Analysis.name","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): subgroup analysis by resident's condition"
"CD015014_pub2_data","Analysis.name","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by risk of bias"
"CD015014_pub2_data","Analysis.name","Unplanned hospital admissions (proportion of residents with at least one unplanned hospital admission): sensitivity analysis by timing of effect"
"CD015014_pub2_data","Analysis.name","Unplanned hospital admissions (mean number of unplanned hospital admissions per resident)"
"CD015014_pub2_data","Analysis.name","Unplanned hospital admissions (logarithm of rate ratio)"
"CD015014_pub2_data","Analysis.name","Adverse events/falls (proportion of residents with a fall)"
"CD015014_pub2_data","Analysis.name","Adverse events/falls (proportion of residents with a fall): subgroup analysis by type of care provided"
"CD015014_pub2_data","Analysis.name","Adverse events/falls (proportion of residents with a fall): sensitivity analysis by risk of bias"
"CD015014_pub2_data","Analysis.name","Adverse events/falls (proportion of residents with a fall): sensitivity analysis by timing of effects"
"CD015014_pub2_data","Analysis.name","Adverse events/falls (mean number of falls per resident)"
"CD015014_pub2_data","Analysis.name","Adverse events/falls (logarithm of rate ratio)"
"CD015014_pub2_data","Analysis.name","Adverse events/injurious falls (proportion of residents with an injurious fall)"
"CD015014_pub2_data","Analysis.name","Adverse events/injurious falls (mean number of injurious falls per resident)"
"CD015014_pub2_data","Analysis.name","Adverse events/infections (proportion of residents with an infection)"
"CD015014_pub2_data","Analysis.name","Adherence to clinical guideline-recommended care (proportion of residents with adequate antidepressant therapy)"
"CD015014_pub2_data","Analysis.name","Adherence to clinical guideline-recommended care (proportion of residents with adequate antidepressant therapy, two intervention arms combined)"
"CD015014_pub2_data","Analysis.name","Adherence to clinical guideline-recommended care (proportion of residents with adequate antipsychotic therapy)"
"CD015014_pub2_data","Analysis.name","Adherence to clinical guideline-recommended care (proportion of residents with adequate antipsychotic therapy, two arms combined)"
"CD015014_pub2_data","Analysis.name","Adherence to clinical guideline-recommended care (proportion of residents with adequate antibiotic therapy)"
"CD015014_pub2_data","Analysis.name","Adherence to clinical guidelines (MAI)"
"CD015014_pub2_data","Analysis.name","Quality of life (standardised mean difference)"
"CD015014_pub2_data","Analysis.name","Quality of life (standardised mean difference): sensitivity analysis by risk of bias"
"CD015014_pub2_data","Analysis.name","Quality of life (standardised mean difference): sensitivity analysis by timing of effect"
"CD015014_pub2_data","Analysis.name","Quality of life (no meta-analysis, calculations for individual studies)"
"CD015014_pub2_data","Analysis.name","Mortality (proportion of residents who died)"
"CD015014_pub2_data","Analysis.name","Mortality (proportion of residents who died): sensitivity analyses by risk of bias"
"CD015014_pub2_data","Analysis.name","Mortality (proportion of residents who died): sensitivity analysis by timing of effect"
"CD015014_pub2_data","Analysis.name","Any hospital admission (proportion of residents with at least one hospital admission)"
"CD015014_pub2_data","Analysis.name","Any hospital admission (proportion of residents with at least one hospital admission): sensitivity analysis by risk of bias"
"CD015014_pub2_data","Analysis.name","Any hospital admission (proportion of residents with at least one hospital admission): sensitivity by timing of effect"
"CD015014_pub2_data","Analysis.name","Any hospital admission (mean number of hospital admissions per resident)"
"CD015014_pub2_data","Analysis.name","Any hospital admission (logarithm of rate ratio)"
"CD015014_pub2_data","Analysis.name","Length of hospital stay (mean number of days per resident)"
"CD015014_pub2_data","Analysis.name","Length of hospital stay (mean number of days per resident): subgroup analysis by type of care provided"
"CD015014_pub2_data","Analysis.name","Length of hospital stay (mean number of days per resident): sensitivity analysis by risk of bias"
"CD015014_pub2_data","Analysis.name","Length of hospital stay (mean number of days per resident): sensitivity analysis by timing of effect"
"CD015014_pub2_data","Analysis.name","Length of hospital stay (mean number of days per resident): no meta-analysis, calculations for individual studies "
"CD015014_pub2_data","Analysis.name","Length of hospital stay (mean number of days per admission/admitted resident) "
"CD015014_pub2_data","Analysis.name","Residents’ satisfaction with the health care received (mean satisfaction score)"
"CD015014_pub2_data","Analysis.name","Proportion of residents’ satisfied with the health care received "
"CD015014_pub2_data","Analysis.name","'Next of kin' satisfaction with the health care received"
"CD015014_pub2_data","Subgroup","Low risk of bias"
"CD015014_pub2_data","Subgroup","High or unclear risk of bias"
"CD015014_pub2_data","Subgroup","Who provides care"
"CD015014_pub2_data","Subgroup","Co-ordination of care"
"CD015014_pub2_data","Subgroup","Primary care"
"CD015014_pub2_data","Subgroup","Primary and secondary care"
"CD015014_pub2_data","Subgroup","Recently discharged"
"CD015014_pub2_data","Subgroup","Residents with infections"
"CD015014_pub2_data","Subgroup","Mixed health residents"
"CD015014_pub2_data","Subgroup","Mental/behavioural issues"
"CD015014_pub2_data","Subgroup","Short term < 12 months"
"CD015014_pub2_data","Subgroup","Long term > 12 months"
"CD015014_pub2_data","Subgroup","Short-term"
"CD015014_pub2_data","Subgroup","Longer-term"
"CD015014_pub2_data","Subgroup","EQ-5D"
"CD015014_pub2_data","Subgroup","SF-36"
"CD015014_pub2_data","Subgroup","SF-12"
"CD015014_pub2_data","Subgroup","QUALIDEM"
"CD015014_pub2_data","Subgroup","Minimum data set"
"CD015014_pub2_data","Subgroup","QoL in late-stage dementia scale"
"CD015014_pub2_data","Subgroup","Minimum Data Set Health Status Index"
"CD015014_pub2_data","Subgroup","Unclear or high risk of bias"
"CD015014_pub2_data","Subgroup","Short-term "
"CD015014_pub2_data","Subgroup","Short term"
"CD015014_pub2_data","Subgroup","Longer term"
"CD015033_pub2_data","Analysis.group","1"
"CD015033_pub2_data","Analysis.group","2"
"CD015033_pub2_data","Analysis.group","3"
"CD015033_pub2_data","Analysis.name","All-cause mortality (range from18 months to 24 months)"
"CD015033_pub2_data","Analysis.name","All-cause mortality. Best-worst case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","All-cause mortality. Worst-best case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Serious adverse events (24 months)"
"CD015033_pub2_data","Analysis.name","Serious adverse events. Best-worst case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Serious adverse events. Worst-best case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Health-related quality of life (physical health, 24 months)"
"CD015033_pub2_data","Analysis.name","Health-related quality of life (psychosocial health, 24 months)"
"CD015033_pub2_data","Analysis.name","Non-serious adverse events (number of events, 24 months)"
"CD015033_pub2_data","Analysis.name","Non-serious averse events. Best-worst case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Non-serious averse events. Worst-best case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Liver enzyme levels. Serum ALT levels (range from 2 months to 24 months)"
"CD015033_pub2_data","Analysis.name","Liver enzyme levels. Serum AST levels (range from 2 months to 24 months)"
"CD015033_pub2_data","Analysis.name","Liver enzyme levels. Serum ALP levels (range from 2 months to 24 months)"
"CD015033_pub2_data","Analysis.name","Liver enzyme levels. Serum GGT levels (range from 12 months to 24 months)"
"CD015033_pub2_data","Analysis.name","Imaging response. No-improvement in steatosis on ultrasound (range from 5 months to 12 months)"
"CD015033_pub2_data","Analysis.name","Imaging response. No-improvement in steatosis on ultrasound. Best-worst case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Imaging response. No-improvement in steatosis on ultrasound. Worst-best case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Imaging response. Proportion of participants without a normal ultrasound (range from 5 months to 12 months)"
"CD015033_pub2_data","Analysis.name","Imaging response. Proportion of participants without a normal ultrasound. Best-worst case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Imaging response. Proportion of participants without a normal ultrasound. Worst-best case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Liver enzyme levels. Serum ALT levels (range from 6 months to 12 months)"
"CD015033_pub2_data","Analysis.name","Liver enzyme levels. Serum AST levels (12 months)"
"CD015033_pub2_data","Analysis.name","Liver enzyme levels. Serum GGT levels (12 months)"
"CD015033_pub2_data","Analysis.name","Imaging response. No-improvements in steatosis on ultrasound (12 months)"
"CD015033_pub2_data","Analysis.name","Imaging response. No-improvements in steatosis on ultrasound. Best-worst case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Imaging response. No-improvements in steatosis on ultrasound. Worst-best case scenario sensitivity analysis"
"CD015033_pub2_data","Analysis.name","Imaging response. Proportion of participants without a normal ultrasound (12 months)"
"CD015033_pub2_data","Analysis.name","Serum ALT levels (for treatment time)"
"CD015033_pub2_data","Analysis.name","Serum ALT levels (for daily dosage)"
"CD015033_pub2_data","Analysis.name","Serum ALT levels (for profit support)"
"CD015033_pub2_data","Analysis.name","Serum AST levels (for treatment time)"
"CD015033_pub2_data","Analysis.name","Serum AST levels (for daily dosage)"
"CD015033_pub2_data","Analysis.name","Serum AST levels (for profit support)"
"CD015033_pub2_data","Subgroup","≥ 1 year"
"CD015033_pub2_data","Subgroup","＜ 1 year"
"CD015033_pub2_data","Subgroup","≥ 400 IU"
"CD015033_pub2_data","Subgroup","＜ 400 IU"
"CD015033_pub2_data","Subgroup","without for profit"
"CD015033_pub2_data","Subgroup","for profit"
"CD015038_pub2_data","Analysis.group","1"
"CD015038_pub2_data","Analysis.group","2"
"CD015038_pub2_data","Analysis.name","Mortality"
"CD015038_pub2_data","Analysis.name","Success of treatment"
"CD015038_pub2_data","Analysis.name","Clostridium difficile diarrhoea"
"CD015038_pub2_data","Analysis.name","Wound infection"
"CD015038_pub2_data","Analysis.name","Pneumonia"
"CD015038_pub2_data","Analysis.name","Venous thromboembolism"
"CD015038_pub2_data","Analysis.name","Intra-abdominal abscess or collection"
"CD015038_pub2_data","Analysis.name","Ileus"
"CD015038_pub2_data","Analysis.name","Reoperation"
"CD015038_pub2_data","Analysis.name","Complicated appendicitis at surgery"
"CD015038_pub2_data","Analysis.name","Pain score (acute)"
"CD015038_pub2_data","Analysis.name","Pain score (chronic)"
"CD015038_pub2_data","Analysis.name","Length of hospital stay"
"CD015038_pub2_data","Analysis.name","Period of sick leave"
"CD015038_pub2_data","Analysis.name","Negative appendectomy rate (normal histology)"
"CD015038_pub2_data","Analysis.name","Postoperative quality of life"
"CD015038_pub2_data","Subgroup","At > 4 weeks"
"CD015038_pub2_data","Subgroup","At < 2 weeks"
"CD015040_pub2_data","Analysis.group","1"
"CD015040_pub2_data","Analysis.group","2"
"CD015040_pub2_data","Analysis.group","4"
"CD015040_pub2_data","Analysis.group","6"
"CD015040_pub2_data","Analysis.group","7"
"CD015040_pub2_data","Analysis.name","PTSD symptom severity: immediately after treatment, SMD (ITT, endpoint)"
"CD015040_pub2_data","Analysis.name","PTSD symptom severity: immediately after treatment, SMD (ITT, endpoint; with data imputation)"
"CD015040_pub2_data","Analysis.name","PTSD symptom severity: change from baseline to immediately after treatment, SMD (ITT, with data imputation)"
"CD015040_pub2_data","Analysis.name","PTSD symptom severity: immediately after treatment, SMD (per-protocol, endpoint)"
"CD015040_pub2_data","Analysis.name","Stimulation frequency: low versus high frequency"
"CD015040_pub2_data","Analysis.name","Combination treatment status: rTMS alone versus rTMS paired with exposure/psychotherapy"
"CD015040_pub2_data","Analysis.name","PTSD symptom severity: change from baseline to 4 to 12 weeks after treatment (ITT)"
"CD015040_pub2_data","Analysis.name","Depression severity: immediately after treatment, SMD (ITT, endpoint)"
"CD015040_pub2_data","Analysis.name","Depression severity: immediately after treatment, SMD (ITT, endpoint, with data imputation)"
"CD015040_pub2_data","Analysis.name","Depression severity: change from baseline to immediately after treatment, SMD (ITT, with data imputation)"
"CD015040_pub2_data","Analysis.name","Anxiety severity: immediately after treatment, SMD (ITT, endpoint)"
"CD015040_pub2_data","Analysis.name","Anxiety severity: change from baseline to immediately after treatment, SMD (ITT, with data imputation)"
"CD015040_pub2_data","Subgroup","Low frequency (1 Hz)"
"CD015040_pub2_data","Subgroup","High frequency (10 Hz to 50 Hz)"
"CD015040_pub2_data","Subgroup","rTMS stand-alone treatment"
"CD015040_pub2_data","Subgroup","rTMS combined with exposure/psychotherapy"
"CD015042_pub2_data","Analysis.group","1"
"CD015042_pub2_data","Analysis.name","Number of continuously abstinent women"
"CD015042_pub2_data","Analysis.name","Number of drinks per day"
"CD015042_pub2_data","Analysis.name","Number of women who completed treatment"
"CD015046_pub2_data","Analysis.group","1"
"CD015046_pub2_data","Analysis.group","2"
"CD015046_pub2_data","Analysis.group","3"
"CD015046_pub2_data","Analysis.group","4"
"CD015046_pub2_data","Analysis.name","Adverse events&nbsp;"
"CD015046_pub2_data","Analysis.name","Change in severity of ICBs&nbsp;"
"CD015046_pub2_data","Analysis.name","Adverse events - dizziness&nbsp;"
"CD015046_pub2_data","Analysis.name","Adverse events - nausea"
"CD015046_pub2_data","Analysis.name","Adverse events - headache&nbsp;"
"CD015046_pub2_data","Analysis.name","Adverse events - blood pressure changes&nbsp;"
"CD015046_pub2_data","Analysis.name","Change in frequency of ICBs&nbsp;"
"CD015046_pub2_data","Analysis.name","Change in severity of ICBs"
"CD015046_pub2_data","Analysis.name","Change in quality of life"
"CD015046_pub2_data","Analysis.name","Change in neuropsychiatric symptoms - depression"
"CD015046_pub2_data","Analysis.name","Change in neuropsychiatric symptoms - anxiety"
"CD015046_pub2_data","Analysis.name","Adverse events - sleepiness"
"CD015046_pub2_data","Analysis.name","Adverse events - fall (without orthostatic hypotension)"
"CD015046_pub2_data","Analysis.name","Adverse events - orthostatic hypotension"
"CD015046_pub2_data","Analysis.name","Adverse events - restless legs syndrome"
"CD015046_pub2_data","Analysis.name","Adverse events - fatigue&nbsp;"
"CD015046_pub2_data","Analysis.name","Adverse events - asymptomatic bradycardia (51 to 59 bpm)"
"CD015060_pub2_data","Analysis.group","1"
"CD015060_pub2_data","Analysis.group","2"
"CD015060_pub2_data","Analysis.group","3"
"CD015060_pub2_data","Analysis.group","4"
"CD015060_pub2_data","Analysis.group","5"
"CD015060_pub2_data","Analysis.group","6"
"CD015060_pub2_data","Analysis.group","7"
"CD015060_pub2_data","Analysis.group","8"
"CD015060_pub2_data","Analysis.group","9"
"CD015060_pub2_data","Analysis.group","10"
"CD015060_pub2_data","Analysis.name","Proteinuria: > 50% increase from baseline"
"CD015060_pub2_data","Analysis.name","eGFR: ≥ 60% decline from baseline at 3 years"
"CD015060_pub2_data","Analysis.name","Haematuria resolution"
"CD015060_pub2_data","Analysis.name","Proteinuria: ≥ 50% increase from baseline or ≥ 1 g/d"
"CD015060_pub2_data","Analysis.name","Final proteinuria "
"CD015060_pub2_data","Analysis.name","Proteinuria: > 1 g/d"
"CD015060_pub2_data","Analysis.name","eGFR decline or kidney failure"
"CD015060_pub2_data","Analysis.name","Worsening proteinuria: > 1 g/1.73 m2/d"
"CD015060_pub2_data","Analysis.name","Final proteinuria"
"CD015060_pub2_data","Analysis.name","eGFR: ≥ 50% decline from baseline"
"CD015060_pub2_data","Analysis.name","Final GFR"
"CD015060_pub2_data","Analysis.name","Proteinuria change "
"CD015060_pub2_data","Analysis.name","eGFR change"
"CD015060_pub2_data","Analysis.name","Proteinuria improvement "
"CD015060_pub2_data","Analysis.name","eGFR at end of treatment"
"CD015060_pub2_data","Analysis.name","Proteinuria at end of treatment"
"CD015060_pub2_data","Analysis.name","Worsening proteinuria: > 50% increase from baseline"
"CD015060_pub2_data","Analysis.name","eGFR: > 50% decline from baseline"
"CD015060_pub2_data","Analysis.name","Proteinuria remission "
"CD015060_pub2_data","Analysis.name","Final proteinuria  "
"CD015060_pub2_data","Subgroup","6 months therapy"
"CD015060_pub2_data","Subgroup","12 months therapy"
"CD015064_pub2_data","Analysis.group","1"
"CD015064_pub2_data","Analysis.group","2"
"CD015064_pub2_data","Analysis.group","3"
"CD015064_pub2_data","Analysis.group","4"
"CD015064_pub2_data","Analysis.group","5"
"CD015064_pub2_data","Analysis.name","Pimecrolimus 1% versus vehicle"
"CD015064_pub2_data","Analysis.name","Topical corticosteroids versus topical calcineurin inhibitors"
"CD015066_pub2_data","Analysis.group","1"
"CD015066_pub2_data","Analysis.group","2"
"CD015066_pub2_data","Analysis.name","Personal attenuation rating (PAR; dB) (immediate, short-term, long-term)"
"CD015066_pub2_data","Analysis.name","Personal attenuation rating (PAR; dB) (immediate)"
"CD015066_pub2_data","Analysis.name","Earplugs, PAR pass rate (%) (immediate)"
"CD015066_pub2_data","Subgroup","Extensive instructions versus no instructions, earplugs, immediate follow-up"
"CD015066_pub2_data","Subgroup","Simple instructions versus no instructions, earplugs, short-term follow-up (1 and 4 months)"
"CD015066_pub2_data","Subgroup","Simple instructions versus no instructions, earplugs, long-term follow-up"
"CD015066_pub2_data","Subgroup","Earplugs"
"CD015083_pub2_data","Analysis.group","1"
"CD015083_pub2_data","Analysis.group","2"
"CD015083_pub2_data","Analysis.group","3"
"CD015083_pub2_data","Analysis.group","4"
"CD015083_pub2_data","Analysis.group","5"
"CD015083_pub2_data","Analysis.group","6"
"CD015083_pub2_data","Analysis.group","7"
"CD015083_pub2_data","Analysis.group","8"
"CD015083_pub2_data","Analysis.name","Referral for or receipt of any lumbar spine imaging at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Prescription or use of opioid medication at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Referral to surgeon or lumbar spine surgery at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Admission to hospital for non-specific LBP at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Pain at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Back-related function at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Adverse events at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Referral for or receipt of advanced lumbar spine imaging at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Referral or use of any injection to the lumbar spine at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Health-related quality of life at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Participant satisfaction with care at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Referral for or receipt of any lumbar spine imaging"
"CD015083_pub2_data","Analysis.name","Prescription or use of opioid medication"
"CD015083_pub2_data","Analysis.name","Referral to surgeon or lumbar spine surgery"
"CD015083_pub2_data","Analysis.name","Admission to hospital for non-specific LBP"
"CD015083_pub2_data","Analysis.name","Pain"
"CD015083_pub2_data","Analysis.name","Back-related function"
"CD015083_pub2_data","Analysis.name","Adverse events"
"CD015083_pub2_data","Analysis.name","Referral for or receipt of advanced lumbar spine imaging"
"CD015083_pub2_data","Analysis.name","Prescription or use of anti-epileptics, benzodiazepines, or muscle relaxants"
"CD015083_pub2_data","Analysis.name","Referral or use of any injection to the lumbar spine"
"CD015083_pub2_data","Analysis.name","Health-related quality of life"
"CD015083_pub2_data","Analysis.name","Participant satisfaction with care"
"CD015083_pub2_data","Analysis.name","Referral for or receipt of any lumbar spin imaging at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Back-related function at last follow-up within 12 months "
"CD015083_pub2_data","Analysis.name","Prescription or use of anti-epileptic, benzodiazepines, or muscle relaxants at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Referral or receipt of any lumbar spine imaging at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Referral to a surgeon or lumbar spine surgery at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Referral for or use of any injection to the lumbar spine at last follow-up within 12 months"
"CD015083_pub2_data","Analysis.name","Patient satisfaction with care at last follow-up within 12 months"
"CD015083_pub2_data","Subgroup","> 6 months up to 12 months"
"CD015083_pub2_data","Subgroup","Up to 6 months"
"CD015083_pub2_data","Subgroup","> 12 months"
"CD015083_pub2_data","Subgroup","How and when care is delivered/Co-ordination of care and management of care processes"
"CD015083_pub2_data","Subgroup","Who provides care and how the healthcare workforce is managed/Co-ordination of care and management of care processes/Information and communication technology"
"CD015083_pub2_data","Subgroup","How and when care is delivered/Who provides care and how the healthcare workforce is managed"
"CD015083_pub2_data","Subgroup","Coordination of care and management of care processes/Information and communication technology"
"CD015083_pub2_data","Subgroup","Co-ordination of care and management of care processes"
"CD015083_pub2_data","Subgroup","How and when care is delivered/Who provides care and how healthcare workforce is managed/Co-ordination of care and management of care processes"
"CD015083_pub2_data","Subgroup","Co-ordination of care and management of care processes/Information and communication technology"
"CD015083_pub2_data","Subgroup","Information and communication technology"
"CD015083_pub2_data","Subgroup","Who provides care and how the healthcare workforces is managed/Co-ordination of care and management of care processes/Information and communication technology"
"CD015083_pub2_data","Subgroup","How and when care is delivered"
"CD015083_pub2_data","Subgroup","Where care is provided and changes to the healthcare environment/Information and communication technology"
"CD015083_pub2_data","Subgroup","Where care is provided and changes to the healthcare environment"
"CD015083_pub2_data","Subgroup","Where care is provided and changes in healthcare environment/Co-ordination of care and management of care processes/Information and communication technology"
"CD015083_pub2_data","Subgroup","Who provides care and how the healthcare workforce is managed"
"CD015083_pub2_data","Subgroup","Where care is provided and changes to the healthcare environment/Co-ordination of care and management of care processes/Information and communication technology "
"CD015083_pub2_data","Subgroup","Military/veterans affairs healthcare system"
"CD015083_pub2_data","Subgroup","Occupational health clinic"
"CD015083_pub2_data","Subgroup","General practice"
"CD015083_pub2_data","Subgroup","Emergency department"
"CD015083_pub2_data","Subgroup","Primary care and physiotherapy clinic"
"CD015083_pub2_data","Subgroup","Physiotherapy practices"
"CD015083_pub2_data","Subgroup","Primary care and veterans affairs healthcare system"
"CD015083_pub2_data","Subgroup","Primary care and physiotherapy"
"CD015083_pub2_data","Subgroup","Non-specific"
"CD015083_pub2_data","Subgroup","Veterans affairs healthcare system"
"CD015083_pub2_data","Subgroup","General practices"
"CD015083_pub2_data","Subgroup","Outpatient spine clinic"
"CD015083_pub2_data","Subgroup","Chiropractic"
"CD015083_pub2_data","Subgroup","Rheumatology"
"CD015083_pub2_data","Subgroup","Chronic symptoms"
"CD015083_pub2_data","Subgroup","Not stated"
"CD015083_pub2_data","Subgroup","Acute symptoms"
"CD015083_pub2_data","Subgroup","Acute and chronic symptoms"
"CD015083_pub2_data","Subgroup","Low risk of bias"
"CD015083_pub2_data","Subgroup","High or unclear risk of bias"
"CD015083_pub2_data","Subgroup","No missing/imputed data"
"CD015083_pub2_data","Subgroup","Missing/imputed data"
"CD015084_pub2_data","Analysis.group","1"
"CD015084_pub2_data","Analysis.group","2"
"CD015084_pub2_data","Analysis.group","3"
"CD015084_pub2_data","Analysis.group","4"
"CD015084_pub2_data","Analysis.group","5"
"CD015084_pub2_data","Analysis.group","6"
"CD015084_pub2_data","Analysis.name","Clinical remission"
"CD015084_pub2_data","Analysis.name","Disease improvement: clinical activity scale (Rachmilewitz index)"
"CD015084_pub2_data","Analysis.name","Disease improvement: biochemical markers of inflammation (faecal calprotectin)"
"CD015084_pub2_data","Analysis.name","Disease improvement: biochemical markers of inflammation (IL-8 in rectal dialysis fluid)"
"CD015084_pub2_data","Analysis.name","Disease improvement: biochemical markers of inflammation (PGE-2 in rectal dialysis fluid)"
"CD015084_pub2_data","Analysis.name","Withdrawals due to adverse events"
"CD015084_pub2_data","Analysis.name","Disease improvement: clinical activity scale (Mayo score)"
"CD015084_pub2_data","Analysis.name","Number of adverse events"
"CD015084_pub2_data","Analysis.name","Disease improvement: clinical activity scale (Lichtiger index)"
"CD015084_pub2_data","Analysis.name","Disease improvement: biochemical markers of inflammation (serum CRP)"
"CD015084_pub2_data","Analysis.name","Clinical relapse"
"CD015084_pub2_data","Analysis.name","Disease improvement: clinical activity scale (partial Mayo score)"
"CD015084_pub2_data","Analysis.name","Disease improvement: quality of life score (IBDQ)"
"CD015084_pub2_data","Analysis.name","Disease improvement: quality of life score (bowel component of IBDQ)"
"CD015084_pub2_data","Analysis.name","Disease improvement: quality of life score (systemic component of IBDQ)"
"CD015084_pub2_data","Analysis.name","Disease improvement: quality of life score (emotional component of IBDQ)"
"CD015084_pub2_data","Analysis.name","Disease improvement: quality of life score (social component of IBDQ)"
"CD015084_pub2_data","Subgroup","Short-chain fatty acids"
"CD015084_pub2_data","Subgroup","Prebiotics"
"CD015087_pub2_data","Analysis.group","1"
"CD015087_pub2_data","Analysis.group","2"
"CD015087_pub2_data","Analysis.group","3"
"CD015087_pub2_data","Analysis.group","4"
"CD015087_pub2_data","Analysis.group","5"
"CD015087_pub2_data","Analysis.group","7"
"CD015087_pub2_data","Analysis.group","8"
"CD015087_pub2_data","Analysis.group","9"
"CD015087_pub2_data","Analysis.group","10"
"CD015087_pub2_data","Analysis.group","11"
"CD015087_pub2_data","Analysis.name","Adverse events"
"CD015087_pub2_data","Analysis.name","Pain intensity as reported by a third party (0 to 2 hours)"
"CD015087_pub2_data","Analysis.name","Pain intensity as reported by a third party (2 to 24 hours)"
"CD015087_pub2_data","Analysis.name","Pain intensity as reported by a third party (1 to 7 days)"
"CD015087_pub2_data","Analysis.name","Opioid consumption (2 to 24 hours)"
"CD015087_pub2_data","Analysis.name","Opioid consumption (1 to 7 days)"
"CD015087_pub2_data","Analysis.name","Nausea and/or vomiting"
"CD015087_pub2_data","Analysis.name","Any bleeding"
"CD015087_pub2_data","Analysis.name","Requiring rescue medication (0 to 2 hours)"
"CD015087_pub2_data","Analysis.name","Requiring rescue medication (2 to 24 hours)"
"CD015087_pub2_data","Analysis.name","Time to rescue medication reported by a third party"
"CD015087_pub2_data","Analysis.name","Nausea and/or vomiting - risk difference analysis"
"CD015087_pub2_data","Analysis.name","Any bleeding - risk difference analysis"
"CD015087_pub2_data","Analysis.name","Pain intensity reported by the child (0 to 2 hours)"
"CD015087_pub2_data","Analysis.name","Pain intensity reported by the child (2 to 24 hours)"
"CD015087_pub2_data","Analysis.name","Serious adverse events"
"CD015087_pub2_data","Analysis.name","Requiring rescue medication (1 to 7 days)"
"CD015087_pub2_data","Analysis.name","Return to activities of daily living"
"CD015087_pub2_data","Analysis.name","Pain intensity reported by a third party (0 to 2 hours)"
"CD015087_pub2_data","Analysis.name","Pain intensity reported by a third party (2 to 24 hours)"
"CD015087_pub2_data","Analysis.name","Pain intensity reported by the child (1 to 7 days)"
"CD015101_data","Analysis.group","1"
"CD015101_data","Analysis.group","2"
"CD015101_data","Analysis.group","3"
"CD015101_data","Analysis.group","4"
"CD015101_data","Analysis.group","5"
"CD015101_data","Analysis.name","All symptoms"
"CD015101_data","Analysis.name","GSS"
"CD015101_data","Analysis.name","VAS (symptoms)"
"CD015101_data","Analysis.name","BCTQ (SSS)"
"CD015101_data","Analysis.name","All function"
"CD015101_data","Analysis.name","VAS (function)"
"CD015101_data","Analysis.name","BCTQ (FSS)"
"CD015101_data","Analysis.name","Median DML"
"CD015101_data","Analysis.name","Median SCV"
"CD015101_data","Analysis.name","Quality of life"
"CD015101_data","Analysis.name","Adverse events"
"CD015101_data","Subgroup","Baseline to ≤ 3 months' follow-up"
"CD015101_data","Subgroup","Baseline to > 3 months' follow-up"
"CD015101_data","Subgroup","End of study"
"CD015112_pub3_data","Analysis.group","1"
"CD015112_pub3_data","Analysis.name","Rates of symptomatic PCR-positive SARS‐CoV‐2 infection"
"CD015112_pub3_data","Analysis.name","Rates of any positive PCR SARS‐CoV‐2 infection"
"CD015112_pub3_data","Analysis.name","Absenteeism"
"CD015120_pub2_data","Analysis.group","1"
"CD015120_pub2_data","Analysis.group","2"
"CD015120_pub2_data","Analysis.group","3"
"CD015120_pub2_data","Analysis.group","4"
"CD015120_pub2_data","Analysis.group","5"
"CD015120_pub2_data","Analysis.group","6"
"CD015120_pub2_data","Analysis.group","7"
"CD015120_pub2_data","Analysis.group","8"
"CD015120_pub2_data","Analysis.group","9"
"CD015120_pub2_data","Analysis.group","10"
"CD015120_pub2_data","Analysis.group","11"
"CD015120_pub2_data","Analysis.group","12"
"CD015120_pub2_data","Analysis.group","13"
"CD015120_pub2_data","Analysis.group","14"
"CD015120_pub2_data","Analysis.group","15"
"CD015120_pub2_data","Analysis.group","16"
"CD015120_pub2_data","Analysis.group","17"
"CD015120_pub2_data","Analysis.group","18"
"CD015120_pub2_data","Analysis.group","19"
"CD015120_pub2_data","Analysis.group","20"
"CD015120_pub2_data","Analysis.group","21"
"CD015120_pub2_data","Analysis.group","22"
"CD015120_pub2_data","Analysis.group","23"
"CD015120_pub2_data","Analysis.group","24"
"CD015120_pub2_data","Analysis.group","25"
"CD015120_pub2_data","Analysis.group","26"
"CD015120_pub2_data","Analysis.group","27"
"CD015120_pub2_data","Analysis.group","28"
"CD015120_pub2_data","Analysis.group","29"
"CD015120_pub2_data","Analysis.group","30"
"CD015120_pub2_data","Analysis.group","31"
"CD015120_pub2_data","Analysis.group","32"
"CD015120_pub2_data","Analysis.group","33"
"CD015120_pub2_data","Analysis.group","34"
"CD015120_pub2_data","Analysis.group","35"
"CD015120_pub2_data","Analysis.name","Smoking cessation"
"CD015120_pub2_data","Analysis.name","Smoking cessation (lozenge comparator)"
"CD015120_pub2_data","Analysis.name","Smoking cessation (patch comparator)"
"CD015120_pub2_data","Subgroup","Upper-middle-income country economic classification"
"CD015120_pub2_data","Subgroup","High-income country economic classification"
"CD015120_pub2_data","Subgroup","Education"
"CD015120_pub2_data","Subgroup","Income level"
"CD015120_pub2_data","Subgroup","Level of deprivation"
"CD015122_pub2_data","Analysis.group","1"
"CD015122_pub2_data","Analysis.group","2"
"CD015122_pub2_data","Analysis.name","Blood transfusion"
"CD015122_pub2_data","Analysis.name","Stone-free rate"
"CD015122_pub2_data","Analysis.name","Thromboembolic events"
"CD015122_pub2_data","Analysis.name","Adverse events"
"CD015122_pub2_data","Analysis.name","Secondary interventions"
"CD015122_pub2_data","Analysis.name","Major Surgical complications"
"CD015122_pub2_data","Analysis.name","Minor surgical complications"
"CD015122_pub2_data","Analysis.name","Unplanned hospitalizations or readmissions"
"CD015122_pub2_data","Analysis.name","Hospital length of stay (days)"
"CD015122_pub2_data","Analysis.name","Blood transfusion (Sensitivity analysis & Risk of bias)"
"CD015122_pub2_data","Analysis.name","Stone-free rate (Sensitivity analysis & Risk of bias)"
"CD015122_pub2_data","Analysis.name","Thromboembolic events (Sensitivity analysis & Risk of bias)"
"CD015122_pub2_data","Analysis.name","Secondary interventions (Sensitivity analysis & Risk of bias)"
"CD015122_pub2_data","Analysis.name","Major surgical Complications (Sensitivity analysis & Risk of bias)"
"CD015122_pub2_data","Analysis.name","Minor Surgical complications (Sensitivity analysis & Risk of bias)"
"CD015122_pub2_data","Analysis.name","Unplanned hospitalizations or readmissions (Sensitivity analysis & Risk of bias)"
"CD015122_pub2_data","Analysis.name","Hospital length ofsStay (days) (Sensitivity analysis & Risk of bias)"
"CD015122_pub2_data","Analysis.name","Blood transfusion (Sensitivity analysis & definition of stone freedom)"
"CD015122_pub2_data","Analysis.name","Stone-free rate (Sensitivity analysis & definition of stone freedom)"
"CD015122_pub2_data","Analysis.name","Thromboembolic events (Sensitivity analysis & definition of stone freedom)"
"CD015122_pub2_data","Analysis.name","Adverse Eeents (Sensitivity analysis & definition of stone freedom)"
"CD015122_pub2_data","Analysis.name","Secondary interventions (Sensitivity analysis & definition of stone freedom)"
"CD015122_pub2_data","Analysis.name","Major surgical complications (Sensitivity analysis & definition of stone freedom)"
"CD015122_pub2_data","Analysis.name","Minor surgical complications (Sensitivity analysis & definition of stone freedom)"
"CD015122_pub2_data","Analysis.name","Unplanned hospitalizations or readmissions (Sensitivity analysis & definition of stone freedom)"
"CD015122_pub2_data","Analysis.name","Hospital length of stay (days) (Sensitivity analysis & definition of Stone freedom)"
"CD015122_pub2_data","Analysis.name","Adverse event"
"CD015122_pub2_data","Analysis.name","Major surgical complications"
"CD015123_pub2_data","Analysis.group","1"
"CD015123_pub2_data","Analysis.group","2"
"CD015123_pub2_data","Analysis.group","3"
"CD015123_pub2_data","Analysis.group","4"
"CD015123_pub2_data","Analysis.name","Time to first relapse"
"CD015123_pub2_data","Analysis.name","Time to sustained disability progression"
"CD015123_pub2_data","Analysis.name","Number of participants with at least one SAE"
"CD015123_pub2_data","Analysis.name","Number of participants with at least one SAE (sensitivity analysis: MS relapses excluded) "
"CD015123_pub2_data","Analysis.name","Quality of life: PCS in SF-36"
"CD015123_pub2_data","Analysis.name","Quality of life: MCS in SF-36"
"CD015123_pub2_data","Analysis.name","Number of participants with new or enlarging T2-weighted MRI lesions"
"CD015123_pub2_data","Analysis.name","Number of participants with Gd+ T1-weighted MRI lesions"
"CD015123_pub2_data","Analysis.name","Number of participants experiencing treatment discontinuation caused by AE"
"CD015123_pub2_data","Analysis.name","Number of participants with at least one AE"
"CD015123_pub2_data","Analysis.name","Number of participants with new Gd+ T1-weighted MRI lesions"
"CD015123_pub2_data","Analysis.name","Number of participants who experienced at least one relapse"
"CD015123_pub2_data","Analysis.name","Number of participants with sustained disability that worsened during the study"
"CD015123_pub2_data","Analysis.name","Quality of life: MSIS-29 physical score"
"CD015123_pub2_data","Subgroup","Natalizumab vs Placebo"
"CD015123_pub2_data","Subgroup","Natalizumab + IFN-β vs Placebo + IFN-β"
"CD015124_pub2_data","Analysis.group","1"
"CD015124_pub2_data","Analysis.group","2"
"CD015124_pub2_data","Analysis.group","3"
"CD015124_pub2_data","Analysis.group","4"
"CD015124_pub2_data","Analysis.group","5"
"CD015124_pub2_data","Analysis.name","Assessment of prognostic factors around breast cancer diagnosis"
"CD015124_pub2_data","Subgroup","Adjusted results"
"CD015124_pub2_data","Subgroup","Unadjusted results"
"CD015124_pub2_data","Subgroup","Unadjusted"
"CD015134_pub2_data","Analysis.group","1"
"CD015134_pub2_data","Analysis.name","Infant hospitalisation with laboratory-confirmed RSV disease"
"CD015134_pub2_data","Analysis.name","Intrauterine growth restriction"
"CD015134_pub2_data","Analysis.name","Stillbirth"
"CD015134_pub2_data","Analysis.name","Maternal death"
"CD015134_pub2_data","Analysis.name","Preterm birth"
"CD015134_pub2_data","Analysis.name","Congenital abnormalities"
"CD015134_pub2_data","Analysis.name","Infant death"
"CD015140_pub2_data","Analysis.group","1"
"CD015140_pub2_data","Analysis.group","2"
"CD015140_pub2_data","Analysis.name","Overall survival (OS) - fixed-effect model"
"CD015140_pub2_data","Analysis.name","Overall survival (OS) - random-effects model"
"CD015140_pub2_data","Analysis.name","Disease-free survival (DFS) - fixed-effect model"
"CD015140_pub2_data","Analysis.name","Disease-free survival (DFS) - random-effects model"
"CD015140_pub2_data","Analysis.name","Disease-free survival (DFS) in stage IB"
"CD015140_pub2_data","Analysis.name","Adverse events ≥ grade 3"
"CD015140_pub2_data","Analysis.name","Adverse events grades 1 and 2"
"CD015140_pub2_data","Analysis.name","Health-related quality of life (HRQoL) - mixed model of repeated measures (MMRM) of mean change from baseline up to Week 96 in SF-36 PCS, MCS, and health domain scores"
"CD015140_pub2_data","Analysis.name","Health-related quality of life (HRQoL) - time to deterioration (TTD) analysis from baseline up to Week 96 of the SF-36 PCS, MCS, and health domain scores"
"CD015140_pub2_data","Analysis.name","Risk of relapse in drug-off time - fixed-effect model"
"CD015140_pub2_data","Analysis.name","Risk of relapse in drug-off time - random-effects model"
"CD015140_pub2_data","Analysis.name","Risk of relapse in drug-on time - fixed-effect model"
"CD015140_pub2_data","Analysis.name","Risk of relapse in drug-on time - random-effects model"
"CD015140_pub2_data","Analysis.name","Risk of brain relapse"
"CD015140_pub2_data","Analysis.name","Overall survival (OS)"
"CD015140_pub2_data","Analysis.name","Overall survival (OS) by EGFR type mutation"
"CD015140_pub2_data","Analysis.name","Overall survival (OS) by age"
"CD015140_pub2_data","Analysis.name","Overall survival (OS) by smoking status"
"CD015140_pub2_data","Analysis.name","Overall survival (OS) by gender"
"CD015140_pub2_data","Analysis.name","Disease-free survival (DFS)"
"CD015140_pub2_data","Analysis.name","Disease-free survival (DFS) by EGFR type mutation"
"CD015140_pub2_data","Analysis.name","Disease-free survival (DFS) by stage"
"CD015140_pub2_data","Analysis.name","Disease-free survival (DFS) by age"
"CD015140_pub2_data","Analysis.name","Disease-free survival (DFS) by smoking status"
"CD015140_pub2_data","Analysis.name","Disease-free survival (DFS) by gender"
"CD015140_pub2_data","Analysis.name","Health-related quality of life (HRQoL) - FACT-L"
"CD015140_pub2_data","Analysis.name","Health-related quality of life (HRQoL) - LCSS"
"CD015140_pub2_data","Analysis.name","Risk of relapse in drug-off time"
"CD015140_pub2_data","Analysis.name","Risk of relapse in drug-on time"
"CD015140_pub2_data","Subgroup","PCS"
"CD015140_pub2_data","Subgroup","MCS"
"CD015140_pub2_data","Subgroup","Physical functioning"
"CD015140_pub2_data","Subgroup","Role-physical"
"CD015140_pub2_data","Subgroup","Bodily pain"
"CD015140_pub2_data","Subgroup","General health"
"CD015140_pub2_data","Subgroup","Vitality"
"CD015140_pub2_data","Subgroup","Social functioning"
"CD015140_pub2_data","Subgroup","Role-emotional"
"CD015140_pub2_data","Subgroup","Mental health"
"CD015140_pub2_data","Subgroup","PCS "
"CD015140_pub2_data","Subgroup","EGFR Del 19"
"CD015140_pub2_data","Subgroup","EGFR L858R"
"CD015140_pub2_data","Subgroup","Age < 65"
"CD015140_pub2_data","Subgroup","Age ≥ 65"
"CD015140_pub2_data","Subgroup","Smokers"
"CD015140_pub2_data","Subgroup","Non-smokers"
"CD015140_pub2_data","Subgroup","Male"
"CD015140_pub2_data","Subgroup","Female"
"CD015140_pub2_data","Subgroup","Stage II"
"CD015140_pub2_data","Subgroup","Stage IIIA"
"CD015140_pub2_data","Subgroup","<65"
"CD015140_pub2_data","Subgroup","≥ 65"
"CD015140_pub2_data","Subgroup","FACT- L "
"CD015145_pub2_data","Analysis.group","1"
"CD015145_pub2_data","Analysis.group","2"
"CD015145_pub2_data","Analysis.group","3"
"CD015145_pub2_data","Analysis.name","Postoperative pain (VAS) 24 hours"
"CD015145_pub2_data","Analysis.name","Nausea and vomiting"
"CD015145_pub2_data","Analysis.name","Opioid use (MME) 0 to 24 hours after surgery"
"CD015145_pub2_data","Analysis.name","Opioid use (MME) 0 to 48 hours after surgery"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 2 hours"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 6 hours"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 12 hours"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 48 hours"
"CD015145_pub2_data","Analysis.name","Time to discharge (hours)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (surgery covariate)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (technique covariate)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (approach)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (timing covariate)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (formulation)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (adjuvant)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (control pain score)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) during movement 24 hrs"
"CD015145_pub2_data","Analysis.name","Time to first postoperative opioid (minutes)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (surgery)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (technique)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) 24 hours (timing)"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) at rest 24 hours"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) during movement 24 hours"
"CD015145_pub2_data","Analysis.name","Sedation"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) at rest 2 hours"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) at rest 6 hours"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) during movement 2 hours"
"CD015145_pub2_data","Analysis.name","Postoperative pain score (VAS) during movement 6 hours"
"CD015145_pub2_data","Subgroup","Other"
"CD015145_pub2_data","Subgroup","Hysterectomy"
"CD015145_pub2_data","Subgroup","Ultrasound"
"CD015145_pub2_data","Subgroup","Laparoscopic"
"CD015145_pub2_data","Subgroup","Subcostal"
"CD015145_pub2_data","Subgroup","Unspecified"
"CD015145_pub2_data","Subgroup","Lateral"
"CD015145_pub2_data","Subgroup","Before"
"CD015145_pub2_data","Subgroup","After"
"CD015145_pub2_data","Subgroup","Levobupivacaine"
"CD015145_pub2_data","Subgroup","Ropivacaine"
"CD015145_pub2_data","Subgroup","Bupivacaine"
"CD015145_pub2_data","Subgroup","Bupivacaine + liposomal bupivacaine"
"CD015145_pub2_data","Subgroup","With adjuvant"
"CD015145_pub2_data","Subgroup","Without adjuvant"
"CD015145_pub2_data","Subgroup","Control group mean pain score < 30"
"CD015145_pub2_data","Subgroup","Control group mean pain score > or = to 30"
"CD015145_pub2_data","Subgroup","Posterior"
"CD015158_pub2_data","Analysis.group","1"
"CD015158_pub2_data","Analysis.name","Forced expiratory volume in 1 second (FEV1) (absolute z score)"
"CD015158_pub2_data","Analysis.name","Forced expiratory volume in 1 second (FEV1) (change in z score)"
"CD015158_pub2_data","Analysis.name","Forced vital capacity (FVC) (absolute z score)"
"CD015158_pub2_data","Analysis.name","Lung Clearance Index (LCI) (absolute change)"
"CD015158_pub2_data","Analysis.name","Total CF-CT score (Brody-II)"
"CD015158_pub2_data","Analysis.name","Individual CF-CT scores (at 5 years)"
"CD015158_pub2_data","Analysis.name","Change in proportion of total disease on chest CT scan"
"CD015158_pub2_data","Analysis.name","Change in proportion of trapped air on CT scan"
"CD015158_pub2_data","Analysis.name","Weight (z score)"
"CD015158_pub2_data","Analysis.name","Body mass index (BMI) (z score)"
"CD015158_pub2_data","Analysis.name","Change in body mass index (BMI)"
"CD015158_pub2_data","Analysis.name","Positive P aeruginosa isolates per participant per year"
"CD015158_pub2_data","Analysis.name","Prevalence of P aeruginosa in BAL at 5 years of age"
"CD015158_pub2_data","Analysis.name","Sensitivity analysis - prevalence of P aeruginosa in BAL at 5 years of age (40% versus 5%)"
"CD015158_pub2_data","Analysis.name","Sensitivity analysis - prevalence of P aeruginosa in BAL at 5 years of age (5% versus 40%)"
"CD015158_pub2_data","Analysis.name","Clearance of P aeruginosa after 1 or 2 eradication treatments"
"CD015158_pub2_data","Analysis.name","Age at first acquisition of P aeruginosa infection"
"CD015158_pub2_data","Analysis.name"," Quality of life: Cystic Fibrosis Questionnaire Revised (CFQ-R) score (child self-report)"
"CD015158_pub2_data","Analysis.name","Quality of life: Cystic Fibrosis Questionnaire Revised (CFQ-R) score (parent proxy report)"
"CD015158_pub2_data","Analysis.name","Quality of life: Cystic Fibrosis Questionnaire Revised (CFQ-R) score (respiratory symptom score, change from baseline)"
"CD015158_pub2_data","Analysis.name","Pediatric Quality of Life Inventory (PedsQL) total score"
"CD015158_pub2_data","Analysis.name","Number of hospital admissions per participant per year"
"CD015158_pub2_data","Analysis.name","Number of hospitalisations per person per year due to non-P aeruginosa exacerbations"
"CD015158_pub2_data","Analysis.name","Days as a hospital inpatient per participant per year"
"CD015158_pub2_data","Analysis.name","Duration of hospital admissions due to non-P aeruginosa exacerbations"
"CD015158_pub2_data","Analysis.name","Mean hospital admissions cost per participant (in Australian dollars)"
"CD015158_pub2_data","Analysis.name","Total cost of care per participant (in Australian dollars)"
"CD015158_pub2_data","Analysis.name","Number of pulmonary exacerbations (requiring oral or intravenous antibiotics) per participant per year"
"CD015158_pub2_data","Subgroup","At 5 years"
"CD015158_pub2_data","Subgroup","At 2 years"
"CD015158_pub2_data","Subgroup","Bronchiectstasis"
"CD015158_pub2_data","Subgroup","Parencymal disease"
"CD015158_pub2_data","Subgroup","Mucus plugging"
"CD015158_pub2_data","Subgroup","Airway wall thickening"
"CD015158_pub2_data","Subgroup","Air trapping"
"CD015158_pub2_data","Subgroup","Eating disturbances"
"CD015158_pub2_data","Subgroup","Emotional functioning"
"CD015158_pub2_data","Subgroup","Physical functioning"
"CD015158_pub2_data","Subgroup","Body image"
"CD015158_pub2_data","Subgroup","Respiratory symptoms"
"CD015158_pub2_data","Subgroup","Digestion"
"CD015158_pub2_data","Subgroup","Treatment burden"
"CD015158_pub2_data","Subgroup","Social functioning"
"CD015158_pub2_data","Subgroup","School"
"CD015158_pub2_data","Subgroup","Health perceptions"
"CD015158_pub2_data","Subgroup","Weight"
"CD015158_pub2_data","Subgroup","Vitality"
"CD015158_pub2_data","Subgroup","Child self-report"
"CD015158_pub2_data","Subgroup","Parent proxy report"
"CD015160_pub2_data","Analysis.group","1"
"CD015160_pub2_data","Analysis.group","2"
"CD015160_pub2_data","Analysis.group","3"
"CD015160_pub2_data","Analysis.group","4"
"CD015160_pub2_data","Analysis.group","5"
"CD015160_pub2_data","Analysis.group","6"
"CD015160_pub2_data","Analysis.name","Surgical site infections (as defined by the included studies) within 30 days of repair"
"CD015160_pub2_data","Analysis.name","Mortality (defined as all‐cause mortality) within 30 days of repair"
"CD015160_pub2_data","Analysis.name","Surgical site infections (as defined by the included studies) within 90 days of repair"
"CD015160_pub2_data","Analysis.name","Clinical recurrence or reoperation for recurrence within 30 days of repair"
"CD015160_pub2_data","Analysis.name","Clinical recurrence or reoperation for recurrence within one year of repair"
"CD015160_pub2_data","Analysis.name","Mesh removal within 30 days of repair"
"CD015160_pub2_data","Analysis.name","Mesh removal within 90 days of repair"
"CD015160_pub2_data","Analysis.name","Mortality (defined as all-cause mortality) within 30 days of repair"
"CD015160_pub2_data","Subgroup","Femoral hernia"
"CD015160_pub2_data","Subgroup","Inguinal hernia"
"CD015160_pub2_data","Subgroup","Clean to clean-contaminated surgical field"
"CD015160_pub2_data","Subgroup","Contaminated surgical field"
"CD015160_pub2_data","Subgroup","Dirty surgical field"
"CD015160_pub2_data","Subgroup","Contaminated to dirty surgical field"
"CD015160_pub2_data","Subgroup","Male sex"
"CD015160_pub2_data","Subgroup","Female sex"
"CD015160_pub2_data","Subgroup","Bowel resection"
"CD015160_pub2_data","Subgroup","No bowel resection"
"CD015160_pub2_data","Subgroup","Best-case scenario"
"CD015160_pub2_data","Subgroup","Worst-case scenario"
"CD015192_pub2_data","Analysis.group","1"
"CD015192_pub2_data","Analysis.group","2"
"CD015192_pub2_data","Analysis.group","3"
"CD015192_pub2_data","Analysis.group","4"
"CD015192_pub2_data","Analysis.group","5"
"CD015192_pub2_data","Analysis.group","6"
"CD015192_pub2_data","Analysis.group","7"
"CD015192_pub2_data","Analysis.group","8"
"CD015192_pub2_data","Analysis.group","9"
"CD015192_pub2_data","Analysis.group","10"
"CD015192_pub2_data","Analysis.group","11"
"CD015192_pub2_data","Analysis.group","12"
"CD015192_pub2_data","Analysis.group","13"
"CD015192_pub2_data","Analysis.group","14"
"CD015192_pub2_data","Analysis.group","15"
"CD015192_pub2_data","Analysis.name","Graft infection rate"
"CD015192_pub2_data","Analysis.name","All-cause mortality"
"CD015192_pub2_data","Analysis.name","Re-intervention rate"
"CD015192_pub2_data","Analysis.name","Surgical site infection rate"
"CD015192_pub2_data","Analysis.name","Amputation rate"
"CD015192_pub2_data","Analysis.name","Adverse events resulting from the interventions for prevention of infection"
"CD015192_pub2_data","Analysis.name","Arterial reconstruction failure rate"
"CD015192_pub2_data","Subgroup","Cefuroxime"
"CD015192_pub2_data","Subgroup","Methicillin plus netilmicin"
"CD015192_pub2_data","Subgroup","Cefazolin"
"CD015192_pub2_data","Subgroup","Vancomycin"
"CD015192_pub2_data","Subgroup","Intraoperative cefoxitin versus 48 hours cefoxitin"
"CD015192_pub2_data","Subgroup","One day cefuroxime versus three day cefuroxime"
"CD015192_pub2_data","Subgroup","24 hours cefotaxime versus 48 hours cloxacillin plus gentamicin "
"CD015192_pub2_data","Subgroup","Glycopeptide versus cephalosporin"
"CD015192_pub2_data","Subgroup","Second or third generation cephalosporin versus first generation cephalosporin"
"CD015192_pub2_data","Subgroup","Beta-lactam versus cephalosporin"
"CD015213_pub2_data","Analysis.group","1"
"CD015213_pub2_data","Analysis.group","2"
"CD015213_pub2_data","Analysis.group","3"
"CD015213_pub2_data","Analysis.group","4"
"CD015213_pub2_data","Analysis.group","5"
"CD015213_pub2_data","Analysis.group","6"
"CD015213_pub2_data","Analysis.group","7"
"CD015213_pub2_data","Analysis.group","8"
"CD015213_pub2_data","Analysis.group","9"
"CD015213_pub2_data","Analysis.name","Time to wound healing"
"CD015213_pub2_data","Analysis.name","Proportion of wounds healed"
"CD015213_pub2_data","Analysis.name","Recurrence rate"
"CD015213_pub2_data","Analysis.name","Recurrence rate (Subgroup analysis according to follow-up duration)"
"CD015213_pub2_data","Analysis.name","Wound infection"
"CD015213_pub2_data","Analysis.name","Wound infection (Sensitivity analysis according to risk of bias)"
"CD015213_pub2_data","Analysis.name","Wound dehiscence"
"CD015213_pub2_data","Analysis.name","Time to return to work"
"CD015213_pub2_data","Analysis.name","Operative time"
"CD015213_pub2_data","Analysis.name","Length of hospital stay"
"CD015213_pub2_data","Analysis.name","Postoperative or post-procedural pain"
"CD015213_pub2_data","Analysis.name","Proportion of wounds healed at 3 months"
"CD015213_pub2_data","Analysis.name","Proportion of wounds healed at 12 months"
"CD015213_pub2_data","Analysis.name","Recurrence rate (Sensitivity analysis according to risk of bias)"
"CD015213_pub2_data","Analysis.name","Recurrence rate (Sensitivity analysis according to characteristics of tension‐free midline closure)"
"CD015213_pub2_data","Analysis.name","Wound infection (Sensitivity analysis according to characteristics of tension‐free midline closure)"
"CD015213_pub2_data","Analysis.name","Time to wound healing (Sensitivity analysis according to risk of bias)"
"CD015213_pub2_data","Analysis.name","Wound dehiscence (Sensitivity analysis according to risk of bias)"
"CD015213_pub2_data","Analysis.name","Time to return to work (Sensitivity analysis according to risk of bias)"
"CD015213_pub2_data","Subgroup","Limberg flap"
"CD015213_pub2_data","Subgroup","Modified Limberg flap"
"CD015213_pub2_data","Subgroup","Karydakis flap"
"CD015213_pub2_data","Subgroup","Rotational flap"
"CD015213_pub2_data","Subgroup","Follow-up ≥ 12 months"
"CD015213_pub2_data","Subgroup","Follow-up＜12 months"
"CD015213_pub2_data","Subgroup","Limberg flap & Karydakis flap"
"CD015213_pub2_data","Subgroup","Follow-up ≥ 12months"
"CD015213_pub2_data","Subgroup","Follow-up ＜12months"
"CD015213_pub2_data","Subgroup","Limberg Flap"
"CD015213_pub2_data","Subgroup","Follow-up ≥12 months"
"CD015213_pub2_data","Subgroup","Follow-up ＜12 months"
"CD015215_pub2_data","Analysis.group","1"
"CD015215_pub2_data","Analysis.group","2"
"CD015215_pub2_data","Analysis.group","3"
"CD015215_pub2_data","Analysis.group","4"
"CD015215_pub2_data","Analysis.group","5"
"CD015215_pub2_data","Analysis.group","6"
"CD015215_pub2_data","Analysis.group","7"
"CD015215_pub2_data","Analysis.name","Return to normal hearing, randomised by ear (medium-term)"
"CD015215_pub2_data","Analysis.name","Mean final hearing threshold, randomised by ear (medium-term)"
"CD015215_pub2_data","Analysis.name","Change in hearing threshold from baseline, randomised by ear (medium-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: perforation/retraction, randomised by ear (medium-term)"
"CD015215_pub2_data","Analysis.name","Persistence of OME: randomised by child (very short-term)"
"CD015215_pub2_data","Analysis.name","Persistence of OME: randomised by child (medium-term)"
"CD015215_pub2_data","Analysis.name","Persistence of OME: randomised by ear (medium-term)"
"CD015215_pub2_data","Analysis.name","Mean improvement in comprehensive language, randomised by child (medium-term)"
"CD015215_pub2_data","Analysis.name","Mean improvement in expressive language, randomised by child (medium-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: tympanosclerosis, randomised by ear (medium-term)"
"CD015215_pub2_data","Analysis.name","Return to normal hearing, randomised by child (long-term)"
"CD015215_pub2_data","Analysis.name","Mean final hearing threshold, randomised by child (short-term)"
"CD015215_pub2_data","Analysis.name","Mean final hearing threshold (air conduction), randomised by child (medium-term)"
"CD015215_pub2_data","Analysis.name","Mean final hearing threshold (air-bone gap), randomised by child, analysed by ear (medium-term)"
"CD015215_pub2_data","Analysis.name","Mean final hearing threshold, randomised by child (long-term)"
"CD015215_pub2_data","Analysis.name","Hearing in noise test, randomised by child (long-term)"
"CD015215_pub2_data","Analysis.name","Change in hearing threshold from baseline, randomised by child (medium-term)"
"CD015215_pub2_data","Analysis.name","Adjusted mean difference in hearing improvement, randomised by child (medium term)"
"CD015215_pub2_data","Analysis.name","Adverse event: persistent perforation, randomised by child (medium-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: persistent perforation, randomised by child (long-term)"
"CD015215_pub2_data","Analysis.name","Presence/persistence of OME, randomised by child, measured by otoscopy (medium-term)"
"CD015215_pub2_data","Analysis.name","Presence/persistence of OME, randomised by child, measured by tympanometry (medium-term)"
"CD015215_pub2_data","Analysis.name","Presence/persistence of OME, mean percentage of days, randomised by child (medium-term)"
"CD015215_pub2_data","Analysis.name","Presence/persistence of OME, randomised by child (long-term)"
"CD015215_pub2_data","Analysis.name","Presence/persistence of OME, adjusted OR, randomised by child (long-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: tympanosclerosis (long-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: fibrosis (long-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: segmental atrophy (long-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: retraction pocket with other abnormality (long-term)"
"CD015215_pub2_data","Analysis.name","Receptive language development, Reynell test, randomised by child (medium-term)"
"CD015215_pub2_data","Analysis.name","Receptive language development, Reynell test, adjusted MD (medium-term)"
"CD015215_pub2_data","Analysis.name","Receptive language, Reynell test, randomised by child (long-term)"
"CD015215_pub2_data","Analysis.name","Receptive language: Reynell test, long-term, adjusted MD"
"CD015215_pub2_data","Analysis.name","Receptive language: WOLD adjusted OR (long-term)"
"CD015215_pub2_data","Analysis.name","Receptive language, mean difference (months) in improvement in Reynell test score (equivalent age-real age): medium-term"
"CD015215_pub2_data","Analysis.name","Receptive language, adjusted mean difference (months) in improvement in Reynell test score (equivalent age - real age): medium-term"
"CD015215_pub2_data","Analysis.name","Expressive language development: Reynell test (medium-term)"
"CD015215_pub2_data","Analysis.name","Expressive language development: Reynell test, medium-term, adjusted MD"
"CD015215_pub2_data","Analysis.name","Expressive language development: Reynell test (long-term)"
"CD015215_pub2_data","Analysis.name","Expressive language development: Reynell test, long-term, adjusted MD"
"CD015215_pub2_data","Analysis.name","Expressive language: WOLD adjusted OR (long-term)"
"CD015215_pub2_data","Analysis.name","Expressive language, MD (months) in improvement in Schlichting test score (equivalent age-real age): medium-term"
"CD015215_pub2_data","Analysis.name","Expressive language, adjusted mean difference (months) in improvement in Schlichting test score (equivalent age-real age): medium-term"
"CD015215_pub2_data","Analysis.name","Non-word repetition total score, adjusted OR (long-term)"
"CD015215_pub2_data","Analysis.name","Reading , WORD test, adjusted OR (long-term)"
"CD015215_pub2_data","Analysis.name","Spelling, ALSPAC test, adjusted OR (long-term)"
"CD015215_pub2_data","Analysis.name","Phoneme deletion, adjusted OR (long-term)"
"CD015215_pub2_data","Analysis.name","Cognitive development: Griffiths practical reasoning (medium-term)"
"CD015215_pub2_data","Analysis.name","Cognitive development: IQ (WISC-III UK short form) adjusted OR (long-term)"
"CD015215_pub2_data","Analysis.name","Behaviour, Richman score (medium-term)"
"CD015215_pub2_data","Analysis.name","Behaviour, Richman score, dichotomised (medium-term)"
"CD015215_pub2_data","Analysis.name","Behaviour, Richman score, adjusted OR (medium-term)"
"CD015215_pub2_data","Analysis.name","Behaviour, Richman score (long-term)"
"CD015215_pub2_data","Analysis.name","Behaviour, Richman score, dichotomised (long-term)"
"CD015215_pub2_data","Analysis.name","Behaviour: SDQ teacher report, total, adjusted OR (long-term)"
"CD015215_pub2_data","Analysis.name","Parent-child interaction: Erickson child scale (medium-term)"
"CD015215_pub2_data","Analysis.name","Parent-child interaction: Erickson parent scale (medium-term)"
"CD015215_pub2_data","Analysis.name","Generic health-related quality of life: TAIQOL (medium-term)"
"CD015215_pub2_data","Analysis.name","Parental stress, Parental Stress Index, short form (long-term)"
"CD015215_pub2_data","Analysis.name","Literacy (long-term)"
"CD015215_pub2_data","Analysis.name","Phonological awareness (long-term)"
"CD015215_pub2_data","Analysis.name","Attention, impulsivity and psychosocial function, long-term (1): disruptive behaviour disorders, child behaviour and impairment rating"
"CD015215_pub2_data","Analysis.name","Attention, impulsivity and psychosocial function, long-term (2): social skills"
"CD015215_pub2_data","Analysis.name","Attention, impulsivity and psychosocial function, long-term: Visual and auditory continuous performance"
"CD015215_pub2_data","Analysis.name","Intelligence and academic achievement (long-term)"
"CD015215_pub2_data","Analysis.name","Mean final hearing threshold (short-term)"
"CD015215_pub2_data","Analysis.name","Mean final hearing threshold (medium-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: myringosclerosis (long-term)"
"CD015215_pub2_data","Analysis.name","Number of doctor-diagnosed AOM episodes (medium-term)"
"CD015215_pub2_data","Analysis.name","Number of doctor-diagnosed episodes of AOM (long-term)"
"CD015215_pub2_data","Analysis.name","Hearing returned to normal: VT versus laser myringotomy (medium-term)"
"CD015215_pub2_data","Analysis.name","Mean final hearing threshold, randomised by child (short-term). Adjusted for non-independence of within-individual measurements; assumed ICC of 0.5"
"CD015215_pub2_data","Analysis.name","Mean final hearing threshold, randomised by ear (short-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: persistent perforation (medium-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: persistent perforation cold-steel myringotomy (medium-term)"
"CD015215_pub2_data","Analysis.name","Persistence of OME: VT versus laser myringotomy (short-term)"
"CD015215_pub2_data","Analysis.name","Persistence of OME: VT versus thermal myringotomy, randomised by ear (short-term)"
"CD015215_pub2_data","Analysis.name","Persistence of OME: VT versus cold-steel myringotomy (medium-term)"
"CD015215_pub2_data","Analysis.name","Persistence of OME: VT versus laser myringotomy (medium-term)"
"CD015215_pub2_data","Analysis.name","Persistence of OME: VT versus laser myringotomy, randomised by ear (medium-term)"
"CD015215_pub2_data","Analysis.name","Persistence of OME: mean days to first recurrence"
"CD015215_pub2_data","Analysis.name","Persistence of OME (long-term)"
"CD015215_pub2_data","Analysis.name","Adverse events: otorrhoea (long-term)"
"CD015215_pub2_data","Analysis.name","Zero, one or two episodes of AOM in 12 months"
"CD015215_pub2_data","Analysis.name","Three or more episodes of AOM in 12 months"
"CD015215_pub2_data","Analysis.name","Adverse event: retraction of TM: VT versus laser myringotomy (medium-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: hypertrophic scar of TM: VT versus laser myringotomy (medium-term)"
"CD015215_pub2_data","Analysis.name","Adverse event: otorrhoea: VT versus laser myringotomy (medium-term)"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Return to normal hearing, randomised by ear (medium-term); CC = 0.3"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Return to normal hearing, randomised by ear (medium-term); CC = 0.7"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Return to normal hearing, randomised by ear (medium-term). Normal defined as < 25 dB; CC = 0.5"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold, randomised by ear (medium-term); CC = 0.3"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold, randomised by ear (medium-term); CC = 0.7"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Change in hearing threshold from baseline, randomised by ear (medium-term); CC = 0.3"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Change in hearing threshold from baseline, randomised by ear (medium-term); CC = 0.7"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Adverse event: perforation/retraction, randomised by ear (medium-term); CC = 0.3"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Adverse event: perforation/retraction, randomised by ear (medium-term); CC = 0.7"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: randomised by child (medium-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: randomised by child (medium-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: randomised by ear (medium-term); CC = 0.3"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: randomised by ear (medium-term); CC = 0.7"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold (air-bone gap), randomised by child, analysed by ear (medium-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold (air-bone gap), randomised by child, analysed by ear (medium-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold, randomised by child (long-term); CC for Paradise 2007 of 0.3"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold, randomised by child (long-term); CC for Paradise 2007 of 0.7"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistent perforation, randomised by child (long-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistent perforation, randomised by child (long-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME, randomised by child, measured by otoscopy (medium-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME, randomised by child, measured by otoscopy (medium-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Tympanosclerosis (long-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Tympanosclerosis (long-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Adverse event: fibrosis (long-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Adverse event: fibrosis (long-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Segmental atrophy (long-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Segmental atrophy (long-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Retraction pocket with other abnormality (long-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Retraction pocket with other abnormality (long-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Parent-child interaction: Erickson child scale (medium-term); CC = 0.3"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Parent-child interaction: Erickson child scale (medium-term); CC = 0.7"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Parent-child interaction: Erickson parent scale (medium-term); CC = 0.3"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Parent-child interaction: Erickson parent scale (medium-term); CC = 0.7"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Hearing returned to normal: VT versus laser myringotomy (medium-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Hearing returned to normal: VT versus laser myringotomy (medium-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold, randomised by child (short-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold, randomised by child (short-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold (medium-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Mean final hearing threshold (medium-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistent perforation (medium-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistent perforation (medium-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: VT versus laser myringotomy (short-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: VT versus laser myringotomy (short-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: VT versus laser myringotomy (medium-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: VT versus laser myringotomy (medium-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: VT versus laser myringotomy, randomised by ear (medium-term); CC = 0.3"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Persistence of OME: VT versus laser myringotomy, randomised by ear (medium-term); CC = 0.7"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Retraction of TM: VT versus laser myringotomy (medium-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Retraction of TM: VT versus laser myringotomy (medium-term); ICC = zero"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Otorrhoea: VT versus laser myringotomy (medium-term); ICC = 1.0"
"CD015215_pub2_data","Analysis.name","Sensitivity analysis: Otorrhoea: VT versus laser myringotomy (medium-term); ICC = zero"
"CD015215_pub2_data","Subgroup","Randomised by ear: normal defined as < 15 dB; CC = 0.5 (medium-term)"
"CD015215_pub2_data","Subgroup","Correlation coefficient = 0.5"
"CD015215_pub2_data","Subgroup","Correlation coefficient 0.5"
"CD015215_pub2_data","Subgroup","Adjusted for non-independence of within-individual measurements, assuming ICC of 0.5"
"CD015215_pub2_data","Subgroup","Assumed correlation coefficient for Paradise 2007 (left and right ear data combined) of 0.5"
"CD015215_pub2_data","Subgroup","Competing noise from the front (dB)"
"CD015215_pub2_data","Subgroup","Competing noise from the right (dB)"
"CD015215_pub2_data","Subgroup","Competing noise from the left (dB)"
"CD015215_pub2_data","Subgroup","Adjusted for non-independence of within-individual measurements: ICC 0.5"
"CD015215_pub2_data","Subgroup","Adjusted for non-independence of within-individual measurements. Assumed ICC 0.5"
"CD015215_pub2_data","Subgroup","Adjusted for non-independence of within-individual measurements; assumed ICC 0.5"
"CD015215_pub2_data","Subgroup","Vitality"
"CD015215_pub2_data","Subgroup","Appetite"
"CD015215_pub2_data","Subgroup","Communication"
"CD015215_pub2_data","Subgroup","Motoric"
"CD015215_pub2_data","Subgroup","Social"
"CD015215_pub2_data","Subgroup","Anxiety"
"CD015215_pub2_data","Subgroup","Aggression"
"CD015215_pub2_data","Subgroup","Eating"
"CD015215_pub2_data","Subgroup","Sleeping"
"CD015215_pub2_data","Subgroup","Woodcock Reading Mastery Tests: Word Attack subtest"
"CD015215_pub2_data","Subgroup","Woodcock Reading Mastery Tests: Passage Comprehension subtest"
"CD015215_pub2_data","Subgroup","Oral reading fluency test: Children in grade 3"
"CD015215_pub2_data","Subgroup","Oral reading fluency test: Children in grade 4"
"CD015215_pub2_data","Subgroup","Oral reading fluency test: Children in grade 5"
"CD015215_pub2_data","Subgroup","Oral reading fluency test: Children in grade 6"
"CD015215_pub2_data","Subgroup","Woodcock–Johnson III Tests of Achievement: Spelling subtest"
"CD015215_pub2_data","Subgroup","Woodcock–Johnson III Tests of Achievement: Writing Samples subtest"
"CD015215_pub2_data","Subgroup","Woodcock Reading Mastery Tests: Word Identification subtest"
"CD015215_pub2_data","Subgroup","Comprehensive Test of Phonological Processing: Elision subtest"
"CD015215_pub2_data","Subgroup","Comprehensive Test of Phonological Processing: Rapid Letter Naming subtest"
"CD015215_pub2_data","Subgroup","Child Behavior Checklist: Total Problems score, parent’s rating"
"CD015215_pub2_data","Subgroup","Child Behavior Checklist: Total Problems score, teacher’s rating"
"CD015215_pub2_data","Subgroup","Impairment Rating Scales: Overall functioning, parent’s rating"
"CD015215_pub2_data","Subgroup","Impairment Rating Scales: Overall functioning, teacher’s rating"
"CD015215_pub2_data","Subgroup","Disruptive Behavior Disorders Rating Scale: Oppositional defiant factor: Teacher's rating"
"CD015215_pub2_data","Subgroup","Disruptive Behavior Disorders Rating Scale: Impulsivity and overactivity factor: Parent's rating"
"CD015215_pub2_data","Subgroup","Disruptive Behavior Disorders Rating Scale: Oppositional defiant factor: Parent's rating"
"CD015215_pub2_data","Subgroup","Disruptive Behavior Disorders Rating Scale: Inattention factor: Teacher's rating"
"CD015215_pub2_data","Subgroup","Disruptive Behavior Disorders Rating Scale: Inattention factor: Parent's rating"
"CD015215_pub2_data","Subgroup","Disruptive Behavior Disorders Rating Scale: Impulsivity and overactivity factor: Teacher's rating"
"CD015215_pub2_data","Subgroup","Attention, impulsivity and psychosocial function: Social Skills Rating System: parent version"
"CD015215_pub2_data","Subgroup","Attention, impulsivity and psychosocial function: Social Skills Rating System: teacher version"
"CD015215_pub2_data","Subgroup","Visual Continuous Performance Test: Inattention"
"CD015215_pub2_data","Subgroup","Visual Continuous Performance Test: Impulsivity"
"CD015215_pub2_data","Subgroup","Auditory Continuous Performance Test: Inattention"
"CD015215_pub2_data","Subgroup","Auditory Continuous Performance Test: Impulsivity"
"CD015215_pub2_data","Subgroup","Wechsler Abbreviated Scale of Intelligence"
"CD015215_pub2_data","Subgroup","Calculation subtest of the Woodcock–Johnson III Tests of Achievement"
"CD015215_pub2_data","Subgroup","Adjusted for non-independence of within-individual measurements; assumed ICC of 0.5"
"CD015215_pub2_data","Subgroup","Air-bone gap at 12 months"
"CD015215_pub2_data","Subgroup","Pure tone audiometry at 12 months. Adjusted for non-independence of within-individual measurements; assumed ICC of 0.5"
"CD015215_pub2_data","Subgroup","Adjustment for non-independence of within-individual measurements: assumed ICC of 0.5"
"CD015215_pub2_data","Subgroup","Adjusted for non-independence of within-participant measurements; assumed ICC of 0.5"
"CD015215_pub2_data","Subgroup","Correlation coefficient of 0.5 assumed"
"CD015215_pub2_data","Subgroup","Zero episodes"
"CD015215_pub2_data","Subgroup","One episode"
"CD015215_pub2_data","Subgroup","Two episodes"
"CD015215_pub2_data","Subgroup","Four or more episodes"
"CD015215_pub2_data","Subgroup","Three episodes"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: normal defined as < 15 dB; CC = 0.3"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: normal defined as < 15 dB; CC = 0.7"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: normal defined as < 25 dB; CC = 0.5 (medium-term)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: correlation coefficient = 0.3"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: correlation coefficient = 0.7"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: assuming ICC of 1.0 (complete correlation between ears)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: assuming ICC of 0.0 (no correlation between ears)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: CC for Paradise 2007 (left and right ear data combined) of 0.3"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: CC for Paradise 2007 (left and right ear data combined) of 0.7"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: ICC 1.0 (complete correlation between ears)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: ICC zero (no correlation between ears)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: ICC 1.0 (full correlation between ears)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis ICC zero (no correlation between ears)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: ICC of 1.0 (complete correlation between ears)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: ICC of zero (no correlation between ears)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: ICC = 1 (complete correlation between ears)"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: correlation coefficient of 0.3 assumed"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: correlation coefficient of 0.7 assumed"
"CD015215_pub2_data","Subgroup","Sensitivity analysis: 1.0 (complete correlation between ears)"
"CD015219_pub2_data","Analysis.group","1"
"CD015219_pub2_data","Analysis.group","2"
"CD015219_pub2_data","Analysis.group","3"
"CD015219_pub2_data","Analysis.group","4"
"CD015219_pub2_data","Analysis.group","5"
"CD015219_pub2_data","Analysis.name","All-cause mortality – at 28 to 30 days, or in‐hospital"
"CD015219_pub2_data","Analysis.name","Progression to invasive mechanical ventilation"
"CD015219_pub2_data","Analysis.name","Need for admission to hospital (if ambulatory)"
"CD015219_pub2_data","Analysis.name","Time to clinical improvement (defined as time to a 2-point reduction in participants’ admission status on WHO’s ordinal scale)"
"CD015219_pub2_data","Analysis.name","Progression to oxygen therapy"
"CD015219_pub2_data","Analysis.name","Need for critical or intensive care (any reason)"
"CD015219_pub2_data","Analysis.name","Progression to non‐invasive ventilation"
"CD015219_pub2_data","Analysis.name","Duration of hospitalization"
"CD015219_pub2_data","Analysis.name","Time to negative PCR for SARS‐CoV‐2"
"CD015219_pub2_data","Analysis.name","All adverse events"
"CD015219_pub2_data","Analysis.name","Serious adverse events attributable to the drug"
"CD015219_pub2_data","Analysis.name","Hyperuricaemia"
"CD015219_pub2_data","Analysis.name","Need for admission to hospital (if ambulatory) – fixed-effect model"
"CD015219_pub2_data","Analysis.name","Time to negative PCR for SARS‐CoV‐2 – fixed-effect model"
"CD015219_pub2_data","Analysis.name","All adverse events – fixed-effect model"
"CD015219_pub2_data","Analysis.name","All-cause mortality – at 28 to 30 days, or in-hospital"
"CD015219_pub2_data","Subgroup","Ambulatory, mild"
"CD015219_pub2_data","Subgroup","Moderate, severe or critical"
"CD015219_pub2_data","Subgroup","Moderate, severe, or critical"
"CD015219_pub2_data","Subgroup","Dose < 1600 mg/day"
"CD015219_pub2_data","Subgroup","Dose ≥ 1600 mg/day"
"CD015219_pub2_data","Subgroup","Favipiravir versus active comparator"
"CD015219_pub2_data","Subgroup","Favipiravir versus SOC/placebo"
"CD015219_pub2_data","Subgroup","Favipiravir versus standard care/placebo"
"CD015229_pub2_data","Analysis.group","1"
"CD015229_pub2_data","Analysis.group","2"
"CD015229_pub2_data","Analysis.name","Quality of life at 14 days"
"CD015229_pub2_data","Analysis.name","Pain score at 14 days"
"CD015229_pub2_data","Analysis.name","Pain score at 1 month"
"CD015229_pub2_data","Analysis.name","Pain score at 3 months"
"CD015229_pub2_data","Analysis.name","Opiate consumption at 14 days"
"CD015229_pub2_data","Analysis.name","Opiate consumption at 1 month"
"CD015229_pub2_data","Analysis.name","Opiate consumption at 3 months"
"CD015252_pub2_data","Analysis.group","1"
"CD015252_pub2_data","Analysis.group","2"
"CD015252_pub2_data","Analysis.group","3"
"CD015252_pub2_data","Analysis.group","4"
"CD015252_pub2_data","Analysis.name","Proportion of children whose hearing has returned to normal"
"CD015252_pub2_data","Analysis.name","Serious adverse event: haemorrhage"
"CD015252_pub2_data","Analysis.name","Presence or persistence of OME"
"CD015252_pub2_data","Analysis.name","Sensitivity analysis: presence or persistence of OME (complete correlation between ears)"
"CD015252_pub2_data","Analysis.name","Sensitivity analysis: presence or persistence of OME (no correlation between ears)"
"CD015252_pub2_data","Analysis.name","Time with effusion"
"CD015252_pub2_data","Analysis.name","Number of doctor-diagnosed acute otitis media episodes"
"CD015252_pub2_data","Analysis.name","Return to normal hearing"
"CD015252_pub2_data","Analysis.name","Final hearing threshold"
"CD015252_pub2_data","Analysis.name","Presence/persistence of OME"
"CD015252_pub2_data","Analysis.name","Sensitivity analysis: return to normal hearing ICC 0"
"CD015252_pub2_data","Analysis.name","Sensitivity analysis: return to normal hearing ICC 1"
"CD015252_pub2_data","Analysis.name","Sensitivity analysis: presence/persistence of OME ICC 0"
"CD015252_pub2_data","Analysis.name","Sensitivity analysis: presence/persistence of OME ICC 1"
"CD015252_pub2_data","Analysis.name","Return to normal hearing (medium-term)"
"CD015252_pub2_data","Analysis.name","Hearing threshold"
"CD015252_pub2_data","Analysis.name","Adverse events: tympanosclerosis"
"CD015252_pub2_data","Analysis.name","Adverse events: perforation/retraction"
"CD015252_pub2_data","Subgroup","Up to 12 months"
"CD015252_pub2_data","Subgroup","Up to 3 months"
"CD015252_pub2_data","Subgroup","Over 12 months"
"CD015252_pub2_data","Subgroup","Sensitivity analysis: normal hearing < 25 dB"
"CD015252_pub2_data","Subgroup","Normal hearing ≤ 15 dB"
"CD015252_pub2_data","Subgroup","Up to 12 months. Dempster data from tympanometry"
"CD015252_pub2_data","Subgroup","SENSITIVITY ANALYSIS: Up to 12 months. Dempster data from otoscopy"
"CD015254_pub2_data","Analysis.group","1"
"CD015254_pub2_data","Analysis.group","2"
"CD015254_pub2_data","Analysis.name","Normal hearing (as complete improvement in air-bone gap in worst ear): short-term"
"CD015254_pub2_data","Analysis.name","Hearing threshold: speech reception threshold (short-term). Correction of variance assuming correlation coefficient of 0.5"
"CD015254_pub2_data","Analysis.name","Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.3"
"CD015254_pub2_data","Analysis.name","Sensitivity analysis: speech reception threshold: assuming correlation coefficient of 0.7"
"CD015254_pub2_data","Analysis.name","Hearing threshold: speech awareness threshold (short-term)"
"CD015254_pub2_data","Analysis.name","Persistence of OME (short-term)"
"CD015254_pub2_data","Analysis.name","Sensitivity analysis: persistence (short-term) including cases of acute otitis (Mandel 1987)"
"CD015254_pub2_data","Analysis.name","Sensitivity analysis: persistence (short-term) assuming ICC of 1.0 (complete correlation between ears) (Puhakka 1985)"
"CD015254_pub2_data","Analysis.name","Sensitivity analysis: persistence (short-term) assuming ICC of zero (no correlation between ears) (Puhakka 1985)"
"CD015254_pub2_data","Analysis.name","Persistence of OME (medium-term)"
"CD015254_pub2_data","Analysis.name","Sensitivity analysis: persistence of OME (medium-term); defined as 'OME' or 'AOM without perforation' (Leach 2008)"
"CD015254_pub2_data","Analysis.name","Adverse event: eardrum perforation"
"CD015254_pub2_data","Analysis.name","Adverse event: 'gastrointestinal' "
"CD015254_pub2_data","Analysis.name","Episodes of acute otitis media"
"CD015254_pub2_data","Analysis.name","Hearing returned to normal (very short-term)"
"CD015254_pub2_data","Analysis.name","Final hearing threshold (short-term)"
"CD015254_pub2_data","Analysis.name","Sensitivity analysis 1: persistence of OME (short-term). ICC = zero"
"CD015254_pub2_data","Analysis.name","Sensitivity analysis 2: persistence of OME (short-term). ICC = 1.0"
"CD015254_pub2_data","Analysis.name","Episodes of acute otitis media (short-term)"
"CD015254_pub2_data","Subgroup","Persistence  defined as effusion both ears if bilateral at baseline, and in one/both ears if unilateral"
"CD015254_pub2_data","Subgroup","Persistence defined as effusion in one ear or both"
"CD015254_pub2_data","Subgroup","Persistence defined as effusion in the worst ear"
"CD015254_pub2_data","Subgroup","Persistence defined as effusion in both ears (if bilateral at baseline) and in one or both ears (if unilateral)"
"CD015254_pub2_data","Subgroup","Persistence defined as 'OME' in one or both affected ears"
"CD015254_pub2_data","Subgroup","Persistence defined as effusion in affected ear"
"CD015254_pub2_data","Subgroup","Persistence defined as 'OME or AOM without perforation' in one or both affected ears"
"CD015254_pub2_data","Subgroup","Analysis by child: persistence in any ear"
"CD015254_pub2_data","Subgroup","Analysis by child: persistence in any affected ear"
"CD015254_pub2_data","Subgroup","Analysis by ear. Adjusted for non-independence, assuming ICC of 0.5"
"CD015254_pub2_data","Subgroup","Analysis by ear. Adjusted for non-independence, assuming ICC of 0"
"CD015254_pub2_data","Subgroup","Analysis by ear. Adjusted for non-independence, assuming ICC of 1"
"CD015255_pub2_data","Analysis.group","1"
"CD015255_pub2_data","Analysis.group","2"
"CD015255_pub2_data","Analysis.group","3"
"CD015255_pub2_data","Analysis.group","4"
"CD015255_pub2_data","Analysis.name","Normal hearing (very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Normal hearing (very short-term - up to 6 weeks, adjusted OR)"
"CD015255_pub2_data","Analysis.name","Normal hearing defined as complete improvement in air-bone gap (short-term - up to 3 months)"
"CD015255_pub2_data","Analysis.name","Normal hearing (medium-term - up to 1 year)"
"CD015255_pub2_data","Analysis.name","Hearing threshold (very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Hearing threshold (difference in adjusted mean, very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Disease-specific quality of life (very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Disease-specific quality of life (medium-term - up to 1 year)"
"CD015255_pub2_data","Analysis.name","Persistence of OME (very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Sensitivity analysis: persistence of OME (very short-term); persistence in all affected ears (Berman 1990)"
"CD015255_pub2_data","Analysis.name","Sensitivity analysis: persistence of OME (very short-term); effusion in both ears (Niederman 1984)"
"CD015255_pub2_data","Analysis.name","Persistence of OME (short-term - up to 3 months); ICC = 0.5"
"CD015255_pub2_data","Analysis.name","Sensitivity analysis: persistence of OME (short-term); ICC = 1.0"
"CD015255_pub2_data","Analysis.name","Sensitivity analysis: persistence of OME (short-term); ICC = zero"
"CD015255_pub2_data","Analysis.name","Sensitivity analysis: persistence of OME (short-term); persistence in all affected ears (Macknin 1985)"
"CD015255_pub2_data","Analysis.name","Persistence of OME (medium-term - up to 1 year)"
"CD015255_pub2_data","Analysis.name","Acute otitis media (very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Generic health-related quality of life (PedsQL, very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Generic health-related quality of life (PedsQL, medium-term - up to 1 year)"
"CD015255_pub2_data","Analysis.name","Generic health-related quality of life (HU13, very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Generic health-related quality of life (HU13, medium-term - up to 1 year)"
"CD015255_pub2_data","Analysis.name","Subgroup analysis: normal hearing: allergy versus none (very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Subgroup analysis: persistence of OME: allergy versus none (very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Subgroup analysis: persistence of OME: age < 4 versus ≥ 4 (very short-term - up to 6 weeks)"
"CD015255_pub2_data","Analysis.name","Persistence of OME (short-term - up to 3 months)"
"CD015255_pub2_data","Analysis.name","Change in hearing threshold (short-term - up to 3 months); ICC = 0.5"
"CD015255_pub2_data","Analysis.name","Sensitivity analysis: change in hearing threshold (short-term); ICC = 1.0"
"CD015255_pub2_data","Analysis.name","Sensitivity analysis: change in hearing threshold (short-term); ICC = zero"
"CD015255_pub2_data","Analysis.name","Final hearing threshold (short-term - up to 3 months)"
"CD015255_pub2_data","Analysis.name","Disease-specific quality of life (short-term - up to 3 months)"
"CD015255_pub2_data","Analysis.name","Persistence of OME (very short-term - up to 6 weeks); ICC = 0.5"
"CD015255_pub2_data","Analysis.name","Sensitivity analysis: persistence of OME (very short-term); ICC = 1.0"
"CD015255_pub2_data","Analysis.name","Sensitivity analysis: persistence of OME (very short-term); ICC = zero"
"CD015255_pub2_data","Analysis.name","Adverse event: nasal bleeding (medium-term - up to 1 year)"
"CD015255_pub2_data","Analysis.name","Generic health-related quality of life (medium-term - up to 1 year)"
"CD015255_pub2_data","Analysis.name","Final hearing threshold (very short-term - up to 6 weeks)"
"CD015255_pub2_data","Subgroup","Persistence defined as effusion in either or both ears"
"CD015255_pub2_data","Subgroup","Persistence undefined"
"CD015255_pub2_data","Subgroup","Persistence in one or both affected ears"
"CD015255_pub2_data","Subgroup","Persistence defined as effusion in all affected ears"
"CD015255_pub2_data","Subgroup","Persistence defined as effusion in both ears (whether affected at baseline or not)"
"CD015255_pub2_data","Subgroup","Persistence defined as effusion in the worst ear"
"CD015255_pub2_data","Subgroup","Persistence in any ear"
"CD015255_pub2_data","Subgroup","Persistence defined as effusion in any ear"
"CD015255_pub2_data","Subgroup","Persistence defined as effusion in both affected ears"
"CD015255_pub2_data","Subgroup","Allergy"
"CD015255_pub2_data","Subgroup","No allergy"
"CD015255_pub2_data","Subgroup","Age ≥ 4"
"CD015255_pub2_data","Subgroup","Age < 4"
"CD015255_pub2_data","Subgroup","Persistence in one or both ears"
"CD015255_pub2_data","Subgroup","Analysis per ear"
"CD015255_pub2_data","Subgroup","Analysis per child"
"CD015255_pub2_data","Subgroup","Persistence in both ears"
"CD015255_pub2_data","Subgroup","Persistence in any or both ears"
"CD015255_pub2_data","Subgroup","Persistence in any affected ear"
"CD015255_pub2_data","Subgroup","Persistence in affected ears"
"CD015255_pub2_data","Subgroup","Persistence in affected ears. ICC 1.0"
"CD015255_pub2_data","Subgroup","Persistence in affected ears. ICC zero"
"CD015284_pub2_data","Analysis.group","1"
"CD015284_pub2_data","Analysis.group","2"
"CD015284_pub2_data","Analysis.group","3"
"CD015284_pub2_data","Analysis.group","4"
"CD015284_pub2_data","Analysis.group","5"
"CD015284_pub2_data","Analysis.group","6"
"CD015284_pub2_data","Analysis.name","Seizure frequency per month"
"CD015284_pub2_data","Analysis.name","Quality of Life in Epilepsy Inventory Total score (QOLIE-10)"
"CD015284_pub2_data","Analysis.name","World Health Organization Quality of Life instrument, short version (WHOQOL- BREF) scale"
"CD015284_pub2_data","Analysis.name","Satisfaction With Life Scale (SWLS) scale"
"CD015284_pub2_data","Analysis.name","Geriatric Depression Scale (GDS)"
"CD015284_pub2_data","Analysis.name","Composite International Diagnostic Interview (CIDI): Depression"
"CD015284_pub2_data","Analysis.name","Composite International Diagnostic Interview (CIDI): Dysthymia"
"CD015284_pub2_data","Analysis.name","Washington Psychosocial Seizure Inventory (WPSI): Total score"
"CD015284_pub2_data","Analysis.name","Patient Health Questionnaire – 9 items (PHQ‐9): Depression"
"CD015284_pub2_data","Analysis.name","Neurological Disorders Depression Inventory for Epilepsy (NDDIE)"
"CD015284_pub2_data","Analysis.name","Generalized Anxiety Disorder–7 items (GAD-7)"
"CD015284_pub2_data","Analysis.name","Depression Anxiety Stress Scales–21 items: DASS-21 total score"
"CD015284_pub2_data","Analysis.name","Work and Social Adjustment Scale (WSAS)"
"CD015284_pub2_data","Analysis.name","Change in seizure frequency per month from baseline"
"CD015284_pub2_data","Analysis.name","Change in Liverpool Seizure Severity Scale"
"CD015284_pub2_data","Analysis.name","Quality of Life in Epilepsy Inventory Total score (QOLIE-31-P)"
"CD015284_pub2_data","Analysis.name","Beck Depression Inventory - II (BDI-II)"
"CD015284_pub2_data","Analysis.name","Beck Anxiety Inventory (BAI)"
"CD015284_pub2_data","Analysis.name","Seizure frequency"
"CD015284_pub2_data","Analysis.name","Seizure freedom"
"CD015284_pub2_data","Analysis.name","≥ 50% reduction in seizure frequency&nbsp;"
"CD015284_pub2_data","Analysis.name","Change in seizure frequency from baseline"
"CD015284_pub2_data","Analysis.name","Seizure frequency: &lt; 1 seizure per month"
"CD015284_pub2_data","Analysis.name","Seizure severity"
"CD015284_pub2_data","Analysis.name","Quality of Life in Epilepsy Inventory total score (QOLIE-31 or QOLIE-31-P)"
"CD015284_pub2_data","Analysis.name","Quality of Life in Epilepsy Inventory total score (QOLIE-10)"
"CD015284_pub2_data","Analysis.name","SF-36 Health Survey physical health score"
"CD015284_pub2_data","Analysis.name","SF-36 Health Survey mental health score"
"CD015284_pub2_data","Analysis.name","Epilepsy and Learning Disabilities Quality of Life Scale (ELDQOL)"
"CD015284_pub2_data","Analysis.name","Epilepsy and Learning Disabilities Quality of Life Scale: side effects"
"CD015284_pub2_data","Analysis.name","EQ-5D-5L index score"
"CD015284_pub2_data","Analysis.name","EQ-5D-5L visual analogue scale (VAS)"
"CD015284_pub2_data","Analysis.name","Epilepsy Self-Management Scale"
"CD015284_pub2_data","Analysis.name","Stigma"
"CD015284_pub2_data","Analysis.name","Depressive Mood Scale"
"CD015284_pub2_data","Analysis.name","Rosenberg Self-Esteem Scale"
"CD015284_pub2_data","Analysis.name","Restrictions in daily living"
"CD015284_pub2_data","Analysis.name","Mobility and leisure behaviour"
"CD015284_pub2_data","Analysis.name","Epilepsy-related fear"
"CD015284_pub2_data","Analysis.name","Coping with Epilepsy total score"
"CD015284_pub2_data","Analysis.name","Hospital Anxiety and Depression Scale: Depression (HADS-D)"
"CD015284_pub2_data","Analysis.name","Hospital Anxiety and Depression Scale: Anxiety (HADS-A)"
"CD015284_pub2_data","Analysis.name","Self-mastery and control score"
"CD015284_pub2_data","Analysis.name","Impact of epilepsy score"
"CD015284_pub2_data","Analysis.name","Montgomery-Åsberg Depression Rating Scale (MADRS)"
"CD015284_pub2_data","Analysis.name","Epilepsy Self-Efficacy Scale"
"CD015284_pub2_data","Analysis.name","Morisky Medication Adherence Scale"
"CD015284_pub2_data","Analysis.name","AED tolerability score"
"CD015284_pub2_data","Analysis.name","Knowledge Score"
"CD015284_pub2_data","Analysis.name","Epilepsy Knowledge Scale"
"CD015284_pub2_data","Analysis.name","Multidimensional Scale of Perceived Social Support"
"CD015284_pub2_data","Analysis.name","Percentage change in seizure frequency from baseline"
"CD015284_pub2_data","Analysis.name","Quality of Life in Epilepsy Inventory Total score (QOLIE-31 or QOLIE-89)"
"CD015284_pub2_data","Analysis.name","State-Trait Anxiety Inventory (STAI): State"
"CD015284_pub2_data","Analysis.name","State-Trait Anxiety Inventory (STAI): Trait"
"CD015284_pub2_data","Analysis.name","Perceived Stress Scale (PSS-10)"
"CD015284_pub2_data","Analysis.name","Pittsburgh Sleep Quality Index (PSQI)"
"CD015284_pub2_data","Analysis.name","Profile of Mood States (POMS) scale"
"CD015284_pub2_data","Analysis.name","Adverse Effects Profile (AEP) scale"
"CD015284_pub2_data","Analysis.name","Quality of Life in Epilepsy Inventory total score (QOLIE-31 or QOLIE-89)"
"CD015284_pub2_data","Analysis.name","Restrictions in daily life due to epilepsy"
"CD015284_pub2_data","Analysis.name","Satisfaction scores"
"CD015284_pub2_data","Analysis.name","≥ 50% reduction in seizure frequency"
"CD015284_pub2_data","Analysis.name","Quality of Life in Epilepsy Inventory Total score (QOLIE-31)"
"CD015284_pub2_data","Analysis.name","Severe depression (Beck Depression Inventory score &gt; 16)"
"CD015284_pub2_data","Analysis.name","Severe anxiety (Beck Anxiety Inventory score ≥ 37)"
"CD015284_pub2_data","Subgroup","Post-intervention"
"CD015284_pub2_data","Subgroup","Short term (3-6 months)"
"CD015284_pub2_data","Subgroup","Long term (12 months)"
"CD015284_pub2_data","Subgroup","Short term (3 months)"
"CD015284_pub2_data","Subgroup","Short term (6 months)"
"CD015284_pub2_data","Subgroup","Long term (9 months)"
"CD015284_pub2_data","Subgroup","Long term (12 months)&nbsp;"
"CD015284_pub2_data","Subgroup","Long term (1 year)"
"CD015284_pub2_data","Subgroup","Short term (12 weeks)"
"CD015284_pub2_data","Subgroup","Short term (6 - 8 weeks)"
"CD015284_pub2_data","Subgroup","Short term (10 weeks)"
"CD015284_pub2_data","Subgroup","Short term (6 weeks)"
"CD015284_pub2_data","Subgroup","Short term (20 weeks - 6 months)"
"CD015284_pub2_data","Subgroup","Long term (72 weeks)"
"CD015284_pub2_data","Subgroup","Short term (1 month)"
"CD015284_pub2_data","Subgroup","Short term (24 weeks)"
"CD015284_pub2_data","Subgroup","Long term (12 months to 72 weeks)"
"CD015284_pub2_data","Subgroup","Behaviour: Short term (20 weeks)"
"CD015284_pub2_data","Subgroup","Mood: Short term (20 weeks)"
"CD015284_pub2_data","Subgroup","Short term (20 weeks)"
"CD015284_pub2_data","Subgroup","Short term (4 - 10 weeks)"
"CD015284_pub2_data","Subgroup","Short term (1 week)"
"CD015284_pub2_data","Subgroup","Short term (16 weeks)"
"CD015284_pub2_data","Subgroup","QOLIE-31: Short term (6 months)"
"CD015284_pub2_data","Subgroup","QOLIE-89: Long term (2 years)"
"CD015284_pub2_data","Subgroup","HADS-D score &gt; 8: Short term (6 months)"
"CD015284_pub2_data","Subgroup","HADS-D score &gt; 11: Short term (6 months)"
"CD015284_pub2_data","Subgroup","HADS-A score &gt; 8: Short term (6 months)"
"CD015284_pub2_data","Subgroup","HADS-A score &gt; 11: Short term (6 months)"
"CD015284_pub2_data","Subgroup","Satisfaction with information and advice: Short term (6 months)"
"CD015284_pub2_data","Subgroup","Satisfaction with patient–doctor relationship: Short term (6 months)"
"CD015284_pub2_data","Subgroup","Satisfaction with organization of care: Short term (6 months)"
"CD015284_pub2_data","Subgroup","Long term ( 9 months - 12 months)"
"CD015313_pub2_data","Analysis.group","1"
"CD015313_pub2_data","Analysis.name","Exacerbation rate (per child/year) "
"CD015313_pub2_data","Analysis.name","Improvement in FEV1 % predicted from baseline "
"CD015313_pub2_data","Analysis.name","Improvement in FVC % predicted from baseline "
"CD015314_pub2_data","Analysis.group","1"
"CD015314_pub2_data","Analysis.group","2"
"CD015314_pub2_data","Analysis.group","3"
"CD015314_pub2_data","Analysis.group","4"
"CD015314_pub2_data","Analysis.group","5"
"CD015314_pub2_data","Analysis.group","6"
"CD015314_pub2_data","Analysis.group","7"
"CD015314_pub2_data","Analysis.name","Tobacco cessation at longest follow-up"
"CD015314_pub2_data","Analysis.name","Subgrouped by modality of support"
"CD015314_pub2_data","Analysis.name","Tobacco cessation at longest follow up"
"CD015314_pub2_data","Subgroup","Duration ≤ 1 hour"
"CD015314_pub2_data","Subgroup","Duration 1 to 3 hours"
"CD015314_pub2_data","Subgroup","Duration > 3 hours"
"CD015314_pub2_data","Subgroup","Duration unclear"
"CD015314_pub2_data","Subgroup","Face-to-face individual"
"CD015314_pub2_data","Subgroup","Face-to-face group"
"CD015314_pub2_data","Subgroup","Telephone support"
"CD015326_pub2_data","Analysis.group","1"
"CD015326_pub2_data","Analysis.group","2"
"CD015326_pub2_data","Analysis.group","3"
"CD015326_pub2_data","Analysis.group","4"
"CD015326_pub2_data","Analysis.group","5"
"CD015326_pub2_data","Analysis.name","BMI (Short-term)"
"CD015326_pub2_data","Analysis.name","zBMI (Short-term)"
"CD015326_pub2_data","Analysis.name","zBMI (Medium-term)"
"CD015326_pub2_data","Analysis.name","BMI percentile (Short-term)"
"CD015326_pub2_data","Analysis.name","zBMI (Short-term) - Subgroup analysis: Socioeconomic status"
"CD015326_pub2_data","Analysis.name","zBMI (Medium-term) - Sensitivity Analysis: ICC=0.04"
"CD015326_pub2_data","Analysis.name","BMI (Medium-term)"
"CD015326_pub2_data","Analysis.name","BMI percentile (Medium-term)"
"CD015326_pub2_data","Analysis.name","BMI (Short-term) - Subgroup analysis: Setting of intervention"
"CD015326_pub2_data","Analysis.name","zBMI (Short-term) - Subgroup analysis: Setting of intervention"
"CD015326_pub2_data","Analysis.name","zBMI (Medium-term) - Subgroup analysis: Setting of intervention"
"CD015326_pub2_data","Analysis.name","zBMI (Medium-term) - Subgroup analysis: Socioeconomic status"
"CD015326_pub2_data","Analysis.name","BMI (Short-term) - Sensitivity Analysis: ICC=0.04 "
"CD015326_pub2_data","Analysis.name","BMI (Medium-Term) - Sensitivity Analysis ICC=0.04 "
"CD015326_pub2_data","Analysis.name","zBMI (Short Term) -  Sensitivity Analysis ICC=0.04 "
"CD015326_pub2_data","Analysis.name","zBMI (Medium Term) - Sensitivity Analysis ICC=0.04 "
"CD015326_pub2_data","Analysis.name","BMI percentile (Short-Term) - Sensitivity Analysis ICC=0.04 "
"CD015326_pub2_data","Analysis.name","BMI percentile (Medium Term) - Sensitivity Analysis ICC=0.04 "
"CD015326_pub2_data","Analysis.name","BMI (Medium Term)"
"CD015326_pub2_data","Analysis.name","BMI (Long Term)"
"CD015326_pub2_data","Analysis.name","zBMI (Short Term)"
"CD015326_pub2_data","Analysis.name","zBMI (Medium Term)"
"CD015326_pub2_data","Analysis.name","zBMI (Long Term)"
"CD015326_pub2_data","Analysis.name","BMI percentile (Short Term)"
"CD015326_pub2_data","Analysis.name","BMI percentile (Medium Term)"
"CD015326_pub2_data","Analysis.name","BMI percentile (Long Term)"
"CD015326_pub2_data","Analysis.name","BMI (Short Term) - Subgroup Analysis - Setting of Intervention"
"CD015326_pub2_data","Analysis.name","BMI (Short Term) - Subgroup Analysis- Socioeconomic Status"
"CD015326_pub2_data","Analysis.name","BMI (Medium Term) - Subgroup Analysis- Setting of Intervention"
"CD015326_pub2_data","Analysis.name","BMI (Medium Term) - Subgroup Analysis - Socioeconomic Status"
"CD015326_pub2_data","Analysis.name","BMI (Medium Term) - Subgroup Analysis - Duration of Intervention"
"CD015326_pub2_data","Analysis.name","BMI (Long Term) - Subgroup Analysis - Setting of Intervention"
"CD015326_pub2_data","Analysis.name","BMI (Long Term) - Subgroup Analysis - Socioeconomic Status"
"CD015326_pub2_data","Analysis.name","BMI (Long Term) - Subgroup Analysis - Duration of Intervention"
"CD015326_pub2_data","Analysis.name","zBMI (Short Term) - Subgroup Analysis - Setting of Intervention"
"CD015326_pub2_data","Analysis.name","zBMI (Short Term) - Subgroup Analysis - Socioeconomic Status"
"CD015326_pub2_data","Analysis.name","zBMI (Short Term) - Subgroup Analysis - Duration of Intervention"
"CD015326_pub2_data","Analysis.name","zBMI (Medium Term) - Subgroup Analysis - Setting of Intervention"
"CD015326_pub2_data","Analysis.name","zBMI (Medium Term) - Subgroup Analysis - Socioeconomic Status"
"CD015326_pub2_data","Analysis.name","zBMI (Medium Term) -  Subgroup Analysis - Duration of Intervention"
"CD015326_pub2_data","Analysis.name","zBMI (Long Term) - Subgroup Analysis - Setting of Intervention"
"CD015326_pub2_data","Analysis.name","zBMI (Long Term) - Subgroup Analysis - Socioeconomic Status"
"CD015326_pub2_data","Analysis.name","zBMI (Long Term) - Subgroup Analysis - Duration of Intervention"
"CD015326_pub2_data","Analysis.name","BMI percentile (Short Term) - Subgroup Analysis -  Setting of Intervention"
"CD015326_pub2_data","Analysis.name","BMI percentile (Medium Term) - Subgroup Analysis - Setting of Intervention"
"CD015326_pub2_data","Analysis.name","BMI percentile (Medium Term) - Subgroup Analysis - Socioeconomic Status"
"CD015326_pub2_data","Analysis.name","BMI percentile (Medium Term)- Subgroup Analysis - Duration of Intervention"
"CD015326_pub2_data","Analysis.name","BMI percentile (Long Term) - Subgroup Analysis - Socioeconomic Status"
"CD015326_pub2_data","Analysis.name","BMI (Short Term) - Sensitivity Analysis ICC=0.04"
"CD015326_pub2_data","Analysis.name","BMI (Medium Term) - Sensitivity Analysis ICC=0.04 "
"CD015326_pub2_data","Analysis.name","BMI (Long Term) - Sensitivity Analysis ICC=0.04 "
"CD015326_pub2_data","Analysis.name","BMI-z (Short Term) - Sensitivity Analysis ICC=0.04 "
"CD015326_pub2_data","Analysis.name","zBMI (Long Term) - Sensitivity Analysis ICC=0.04 "
"CD015326_pub2_data","Analysis.name","BMI (Short-Term) "
"CD015326_pub2_data","Analysis.name","BMI (Medium-Term)"
"CD015326_pub2_data","Analysis.name","zBMI (Short-Term)"
"CD015326_pub2_data","Analysis.name","BMI percentile (Medium-Term)"
"CD015326_pub2_data","Analysis.name","BMI percentile (Medium-Term) - Subgroup analysis - socioeconomic status"
"CD015326_pub2_data","Subgroup","Main Analysis"
"CD015326_pub2_data","Subgroup","Subgroup Analysis - Socioeconomic Status - Low"
"CD015326_pub2_data","Subgroup","Subgroup Analysis - Socioeconomic Status - Assumed Mixed"
"CD015326_pub2_data","Subgroup","Childcare"
"CD015326_pub2_data","Subgroup","Home"
"CD015326_pub2_data","Subgroup","Childcare and Home"
"CD015326_pub2_data","Subgroup","Other"
"CD015326_pub2_data","Subgroup","Low"
"CD015326_pub2_data","Subgroup","Assumed Mixed"
"CD015326_pub2_data","Subgroup","Main Setting of Intervention Delivery - Childcare "
"CD015326_pub2_data","Subgroup","Main Setting of Intervention Delivery - Home"
"CD015326_pub2_data","Subgroup","Main Setting of Intervention Delivery - Childcare & Home"
"CD015326_pub2_data","Subgroup","Main Setting of Intervention Delivery - Other "
"CD015326_pub2_data","Subgroup","Socioeconomic Status- Low"
"CD015326_pub2_data","Subgroup","Socioeconomic Status- Assumed Mixed"
"CD015326_pub2_data","Subgroup","Childcare + Home"
"CD015326_pub2_data","Subgroup","Short"
"CD015326_pub2_data","Subgroup","Medium"
"CD015326_pub2_data","Subgroup","Childcare+Home"
"CD015326_pub2_data","Subgroup","Long"
"CD015326_pub2_data","Subgroup","Main Setting of Intervention"
"CD015328_pub2_data","Analysis.group","1"
"CD015328_pub2_data","Analysis.group","2"
"CD015328_pub2_data","Analysis.group","3"
"CD015328_pub2_data","Analysis.group","4"
"CD015328_pub2_data","Analysis.group","5"
"CD015328_pub2_data","Analysis.group","6"
"CD015328_pub2_data","Analysis.name","BMI short-term"
"CD015328_pub2_data","Analysis.name","BMI medium-term"
"CD015328_pub2_data","Analysis.name","BMI long-term"
"CD015328_pub2_data","Analysis.name","zBMI short-term"
"CD015328_pub2_data","Analysis.name","zBMI medium-term"
"CD015328_pub2_data","Analysis.name","zBMI long-term"
"CD015328_pub2_data","Analysis.name","Percentile short-term"
"CD015328_pub2_data","Analysis.name","Percentile medium-term"
"CD015328_pub2_data","Analysis.name","Percentile long-term"
"CD015330_pub2_data","Analysis.group","1"
"CD015330_pub2_data","Analysis.group","2"
"CD015330_pub2_data","Analysis.group","3"
"CD015330_pub2_data","Analysis.group","4"
"CD015330_pub2_data","Analysis.name","BMI short term"
"CD015330_pub2_data","Analysis.name","BMI medium term"
"CD015330_pub2_data","Analysis.name","BMI long term"
"CD015330_pub2_data","Analysis.name","zBMI short term"
"CD015330_pub2_data","Analysis.name","zBMI medium term"
"CD015330_pub2_data","Analysis.name","zBMI long term"
"CD015330_pub2_data","Analysis.name","Percentile short term"
"CD015330_pub2_data","Analysis.name","Percentile medium term"
"CD015330_pub2_data","Analysis.name","Percentile long term"
"CD015331_pub2_data","Analysis.group","1"
"CD015331_pub2_data","Analysis.name","Mental state - general: mean endpoint PANSS total (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - general: mean change PANSS total (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - general: mean endpoint PSYRATS (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - general: mean endpoint BPRS total (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - general: mean endpoint overall symptom scales (high = poor) (combined time points)"
"CD015331_pub2_data","Analysis.name","Mental state - general: mean endpoint overall symptom scales (high = poor) (separated time points)"
"CD015331_pub2_data","Analysis.name","Mental state - general: number of participants with clinically important change in general mental state (combined time points)"
"CD015331_pub2_data","Analysis.name","Mental state - general: number of participants with clinically important change in general mental state (separated time points)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: number of participants with clinically important change in positive symptoms (combined time points)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: number of participants with clinically important change in positive symptoms (separated time points)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint PANSS positive (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean change PANSS positive (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint BPRS positive (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint SAPS (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint positive symptoms scales (high = poor) (combined time points)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint positive symptoms scales (high = poor) (separated time points)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint PANSS negative (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean change PANSS negative (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint BPRS negative (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint SANS (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint BNSS (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint negative symptoms scale (high = poor) (combined time points)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint negative symptoms scale (high = poor) (separated time points)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint BDI short form (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint BDI-II (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint HADS Depression (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint CDS (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean change CDS (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint MADRS (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint Hamilton Depression (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint CESD-R (high = poor)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint depressive symptoms (high = poor) (combined time points)"
"CD015331_pub2_data","Analysis.name","Mental state - specific: mean endpoint depressive symptoms (high = poor) (separated time points)"
"CD015331_pub2_data","Analysis.name","Global state - number of participants with relapse/exacerbations of psychosis (combined time points)"
"CD015331_pub2_data","Analysis.name","Global state - number of participants with relapse/exacerbations of psychosis (separated time points)"
"CD015331_pub2_data","Analysis.name","Global state - number of participants with remission (combined time points)"
"CD015331_pub2_data","Analysis.name","Global state - number of participants with remission (separated time points)"
"CD015331_pub2_data","Analysis.name","Global state - number of participants with clinically important change in global state"
"CD015331_pub2_data","Analysis.name","Global state - mean endpoint CGI (high = poor) (separated time points)"
"CD015331_pub2_data","Analysis.name","Global state - mean endpoint/change CGI-S (high = poor) (separated time points)"
"CD015331_pub2_data","Analysis.name","Global state - mean endpoint CGI-I (high = poor) (separated time points)"
"CD015331_pub2_data","Analysis.name","Global state - mean endpoint/change global state scales (high = poor) (combined time points)"
"CD015331_pub2_data","Analysis.name","Global state - mean endpoint/change global state scales (high = poor) (separated time points)"
"CD015331_pub2_data","Analysis.name","Service use - admission to hospital (combined time points)"
"CD015331_pub2_data","Analysis.name","Service use - admission to hospital (separated time points)"
"CD015331_pub2_data","Analysis.name","Service use - number of days in hospital (combined time points)"
"CD015331_pub2_data","Analysis.name","Service use - number of days in hospital (separated time points)"
"CD015331_pub2_data","Analysis.name","Leaving the study early - for any reason - overall acceptability (combined time points)"
"CD015331_pub2_data","Analysis.name","Leaving the study early - for any reason - overall acceptability (separated time points)"
"CD015331_pub2_data","Analysis.name","Functioning - mean endpoint GAF (high = good)"
"CD015331_pub2_data","Analysis.name","Functioning - mean change GAF (high = good)"
"CD015331_pub2_data","Analysis.name","Functioning - mean endpoint SOFAS (high = good)"
"CD015331_pub2_data","Analysis.name","Functioning - mean endpoint PSP (high = good)"
"CD015331_pub2_data","Analysis.name","Functioning - mean endpoint FAST (high = poor)"
"CD015331_pub2_data","Analysis.name","Functioning - mean endpoint FESFS (high = good)"
"CD015331_pub2_data","Analysis.name","Functioning - mean endpoint functioning scale (high = good) (combined time points)"
"CD015331_pub2_data","Analysis.name","Functioning - mean endpoint functioning scale (high = good) (separated time points)"
"CD015331_pub2_data","Analysis.name","Quality of life - mean endpoint WHO QoL-bref (high = good)"
"CD015331_pub2_data","Analysis.name","Quality of life - mean endpoint EQ5d (WHO) (high = good)"
"CD015331_pub2_data","Analysis.name","Quality of life - mean endpoint QLS (high = good)"
"CD015331_pub2_data","Analysis.name","Quality of life - mean endpoint MSQoL (high = good)"
"CD015331_pub2_data","Analysis.name","Quality of life - mean change MSQoL (high = good)"
"CD015331_pub2_data","Analysis.name","Quality of life - MANSA (high = good)"
"CD015331_pub2_data","Analysis.name","Quality of life - mean endpoint quality of life scale (high = good) (combined time points)"
"CD015331_pub2_data","Analysis.name","Quality of life - mean endpoint quality of life scale (high = good) (separated time points)"
"CD015331_pub2_data","Analysis.name","Behaviour - occurence of violent incidents"
"CD015331_pub2_data","Analysis.name","Behaviour - participants with self-injury"
"CD015331_pub2_data","Analysis.name","Behaviour - participants with suicide attempts"
"CD015331_pub2_data","Analysis.name","Adverse events - participants with at least one adverse event"
"CD015331_pub2_data","Analysis.name","Adverse events - specific: Non Compliance"
"CD015331_pub2_data","Analysis.name","Adverse events - specific: Deterioration of symptoms"
"CD015331_pub2_data","Analysis.name","Mortality - overall mortality (combined time points)"
"CD015331_pub2_data","Analysis.name","Mortality - overall mortality (separated time points)"
"CD015331_pub2_data","Analysis.name","Mortality - due to natural causes"
"CD015331_pub2_data","Analysis.name","Mortality - due to suicide"
"CD015331_pub2_data","Analysis.name","Sensitivity analysis - Blinding of outcome assessor"
"CD015331_pub2_data","Analysis.name","Sensitivity analysis - Assumptions for missing data"
"CD015331_pub2_data","Analysis.name","Sensitivity analysis - Risk of Bias"
"CD015331_pub2_data","Analysis.name","Sensitivity analysis - Imputed values"
"CD015331_pub2_data","Analysis.name","Sensitivity analysis - Fixed-effect"
"CD015331_pub2_data","Analysis.name","Sensitivity analysis excluding outliers"
"CD015331_pub2_data","Analysis.name","Subgroup analysis - Different types of CBT"
"CD015331_pub2_data","Analysis.name","Subgroup analysis - Modality of treatment"
"CD015331_pub2_data","Analysis.name","Subgroup analysis - Method of delivery"
"CD015331_pub2_data","Analysis.name","Subgroup analysis - Control group"
"CD015331_pub2_data","Subgroup","< 6 months"
"CD015331_pub2_data","Subgroup","< 12 months"
"CD015331_pub2_data","Subgroup","> 1 year"
"CD015331_pub2_data","Subgroup","> 12 months"
"CD015331_pub2_data","Subgroup","> 6 months"
"CD015331_pub2_data","Subgroup","CBT and Motivational Interviewing for cannabis use cessation"
"CD015331_pub2_data","Subgroup","CBT integrated with other psychosocial interventions"
"CD015331_pub2_data","Subgroup","Special types of CBT"
"CD015331_pub2_data","Subgroup","CBT"
"CD015331_pub2_data","Subgroup","Group CBT"
"CD015331_pub2_data","Subgroup","Individual CBT"
"CD015331_pub2_data","Subgroup","Face to face"
"CD015331_pub2_data","Subgroup","Smartphone app"
"CD015331_pub2_data","Subgroup","CBT compared to other psychosocial interventions"
"CD015331_pub2_data","Subgroup","CBT compared to TAU"
"CD015332_pub2_data","Analysis.group","1"
"CD015332_pub2_data","Analysis.group","2"
"CD015332_pub2_data","Analysis.group","3"
"CD015332_pub2_data","Analysis.name","Mental state – general: mean endpoint PANSS total (high = poor)"
"CD015332_pub2_data","Analysis.name","Number of participants with clinically important change in general mental state (separated time points)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint PANSS positive (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint PANSS negative (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint BDI (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint BAI (high = poor)"
"CD015332_pub2_data","Analysis.name","Global state – number of participants with relapse/exacerbations of psychosis (separated time points)"
"CD015332_pub2_data","Analysis.name","Service use – readmission to hospital "
"CD015332_pub2_data","Analysis.name","Service use – mean number of days in hospital "
"CD015332_pub2_data","Analysis.name","Leaving the study early – for any reason – overall acceptability (separated time points)"
"CD015332_pub2_data","Analysis.name","Functioning – mean endpoint PSP (high = good)"
"CD015332_pub2_data","Analysis.name","Behaviour – participants with suicide attempts "
"CD015332_pub2_data","Analysis.name","Adverse events – deterioration of symptoms "
"CD015332_pub2_data","Analysis.name","Adverse events – participants with serious adverse events"
"CD015332_pub2_data","Analysis.name","Mortality – overall mortality "
"CD015332_pub2_data","Analysis.name","Mortality – mortality due to natural causes "
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint HADS Depression (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint HADS Anxiety (high = poor)"
"CD015332_pub2_data","Analysis.name","Global state – mean endpoint CGI-Clinician (high = poor)"
"CD015332_pub2_data","Analysis.name","Global state – mean endpoint CGI-Clinician – Improvement (high = poor)"
"CD015332_pub2_data","Analysis.name","Service use – number of days in hospital (separated time points)"
"CD015332_pub2_data","Analysis.name","Functioning – mean endpoint FESFS (high = good)"
"CD015332_pub2_data","Analysis.name","Functioning – mean endpoint functioning scales (high = good)"
"CD015332_pub2_data","Analysis.name","Quality of life – mean endpoint WHOQOL (high = good)"
"CD015332_pub2_data","Analysis.name","Quality of life – mean endpoint EQ-5D-5L (high = good)"
"CD015332_pub2_data","Analysis.name","Quality of life – mean endpoint quality of life scales (high = good)"
"CD015332_pub2_data","Analysis.name","Behaviour – violent incidents (separated time points)"
"CD015332_pub2_data","Analysis.name","Behaviour – self-injury (separated time points)"
"CD015332_pub2_data","Analysis.name","Behaviour – suicide attempts (separated time points)"
"CD015332_pub2_data","Analysis.name","Adverse events – participants with at least 1 adverse event"
"CD015332_pub2_data","Analysis.name","Adverse events – participants with serious adverse events "
"CD015332_pub2_data","Analysis.name","Adverse events – mean endpoint ANNSERS (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – general: mean endpoint BPRS total (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points)"
"CD015332_pub2_data","Analysis.name","Mental state – general: number of participants with clinically important change in general mental state (separated time points)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint BPRS positive (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint positive symptoms scales (high = poor) (separated time points)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint SANS negative (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint negative symptoms scales (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint HAM-D (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint depression scales (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint HAM-A (high = poor)"
"CD015332_pub2_data","Analysis.name","Mental state – specific: mean endpoint anxiety scales (high = poor)"
"CD015332_pub2_data","Analysis.name","Service use – readmission to hospital (separated time points)"
"CD015332_pub2_data","Analysis.name","Leaving the study early due to adverse effects (separated time points)"
"CD015332_pub2_data","Analysis.name","Functioning – mean endpoint SOFAS (high = good)"
"CD015332_pub2_data","Analysis.name","Quality of life – mean endpoint Quality of Life Scale (high = good)"
"CD015332_pub2_data","Analysis.name","Adverse events – participants with at least 1 adverse event (pooled time points)"
"CD015332_pub2_data","Analysis.name","Adverse events – participants with at least 1 adverse event (separated time points)"
"CD015332_pub2_data","Analysis.name","Adverse events – participants with serious adverse events (separated time points)"
"CD015332_pub2_data","Analysis.name","Adverse events – deterioration of symptoms (separated time points)"
"CD015332_pub2_data","Analysis.name","Adverse events – lack of improvement (separated time points)"
"CD015332_pub2_data","Analysis.name","Adverse events – mean endpoint UKU (high = poor)"
"CD015332_pub2_data","Subgroup","< 6 months"
"CD015332_pub2_data","Subgroup","< 12 months"
"CD015332_pub2_data","Subgroup","> 1 year"
"CD015332_pub2_data","Subgroup","< 6 m"
"CD015332_pub2_data","Subgroup","< 12 m"
"CD015350_pub2_data","Analysis.group","1"
"CD015350_pub2_data","Analysis.group","2"
"CD015350_pub2_data","Analysis.group","3"
"CD015350_pub2_data","Analysis.group","4"
"CD015350_pub2_data","Analysis.group","5"
"CD015350_pub2_data","Analysis.group","6"
"CD015350_pub2_data","Analysis.group","7"
"CD015350_pub2_data","Analysis.name","Days to healing"
"CD015350_pub2_data","Analysis.name","Size of infiltrate"
"CD015350_pub2_data","Analysis.name","Distance visual acuity"
"CD015350_pub2_data","Analysis.name","Proportion with visual improvement"
"CD015350_pub2_data","Analysis.name","Proportion cured or with complete corneal healing"
"CD015350_pub2_data","Analysis.name","Proportion with non-serious or non-severe harms/adverse events"
"CD015350_pub2_data","Analysis.name","Proportion with serious/severe harms/adverse events"
"CD015350_pub2_data","Analysis.name","Unaided distance visual acuity"
"CD015350_pub2_data","Analysis.name","Proportion cured or with complete ulcer healing"
"CD015350_pub2_data","Analysis.name","Subjective signs and symptoms"
"CD015350_pub2_data","Subgroup","4th Generation Fluoroquinolones"
"CD015350_pub2_data","Subgroup","2nd/3rd Generation Fluoroquinolones"
"CD015350_pub2_data","Subgroup","Corrected"
"CD015350_pub2_data","Subgroup","Unaided"
"CD015350_pub2_data","Subgroup","Ciprofloxacin control"
"CD015350_pub2_data","Subgroup","Moxifloxacin control"
"CD015373_pub2_data","Analysis.group","1"
"CD015373_pub2_data","Analysis.group","2"
"CD015373_pub2_data","Analysis.group","3"
"CD015373_pub2_data","Analysis.group","4"
"CD015373_pub2_data","Analysis.group","5"
"CD015373_pub2_data","Analysis.group","6"
"CD015373_pub2_data","Analysis.group","7"
"CD015373_pub2_data","Analysis.group","8"
"CD015373_pub2_data","Analysis.group","9"
"CD015373_pub2_data","Analysis.group","10"
"CD015373_pub2_data","Analysis.group","11"
"CD015373_pub2_data","Analysis.group","12"
"CD015373_pub2_data","Analysis.group","13"
"CD015373_pub2_data","Analysis.name","Pain intensity (continuous), immediate-term follow-up"
"CD015373_pub2_data","Analysis.name","Pain intensity (continuous), immediate-term follow-up: duration of administration subgroup analysis"
"CD015373_pub2_data","Analysis.name","Pain intensity (≥ 50% reduction), immediate-term follow-up"
"CD015373_pub2_data","Analysis.name","Pain intensity (continuous), short-term follow-up"
"CD015373_pub2_data","Analysis.name","Pain intensity (continuous), short-term follow-up: clinical condition subgroup analysis"
"CD015373_pub2_data","Analysis.name","Pain intensity (continuous), short-term follow-up: duration of administration subgroup analysis"
"CD015373_pub2_data","Analysis.name","Pain intensity (≥ 50% reduction), short-term follow-up"
"CD015373_pub2_data","Analysis.name","Pain intensity (continuous), medium-term follow-up"
"CD015373_pub2_data","Analysis.name","Adverse events (total)"
"CD015373_pub2_data","Analysis.name","Adverse events (total): clinical condition subgroup analysis"
"CD015373_pub2_data","Analysis.name","Adverse events (total): duration of administration subgroup analysis"
"CD015373_pub2_data","Analysis.name","Psychotomimetic effects"
"CD015373_pub2_data","Analysis.name","Hallucinations"
"CD015373_pub2_data","Analysis.name","Sedation"
"CD015373_pub2_data","Analysis.name","Nausea"
"CD015373_pub2_data","Analysis.name","Vomiting"
"CD015373_pub2_data","Analysis.name","Dizziness"
"CD015373_pub2_data","Analysis.name","Headache"
"CD015373_pub2_data","Analysis.name","Serious adverse events"
"CD015373_pub2_data","Analysis.name","Disability (Radboud Skills Questionnaire), short-term follow-up"
"CD015373_pub2_data","Analysis.name","Health-related quality of life (Fibromyalgia Impact Questionnaire), immediate-term follow-up"
"CD015373_pub2_data","Analysis.name","Health-related quality of life (Fibromyalgia Impact Questionnaire), short-term follow-up"
"CD015373_pub2_data","Analysis.name","Tolerability"
"CD015373_pub2_data","Analysis.name","Ketamine versus ketorolac: pain intensity (continuous), immediate-term follow up"
"CD015373_pub2_data","Analysis.name","Ketamine versus ketorolac: serious adverse events"
"CD015373_pub2_data","Analysis.name","Ketamine versus morphine: adverse events (total)"
"CD015373_pub2_data","Analysis.name","Dissociative symptoms"
"CD015373_pub2_data","Analysis.name","Ketamine (oral) versus methadone: pain intensity (continuous), short-term follow-up"
"CD015373_pub2_data","Analysis.name","Ketamine (oral) versus methadone: hallucinations"
"CD015373_pub2_data","Analysis.name","Ketamine (oral) versus methadone: sedation"
"CD015373_pub2_data","Analysis.name","Ketamine (oral) versus methadone: nausea"
"CD015373_pub2_data","Analysis.name","Ketamine (oral) versus methadone: vomiting"
"CD015373_pub2_data","Analysis.name","Ketamine (oral) versus methadone: dizziness"
"CD015373_pub2_data","Analysis.name","Ketamine (oral) versus methadone: headache"
"CD015373_pub2_data","Analysis.name","Ketamine (oral) versus methadone: tolerability"
"CD015373_pub2_data","Analysis.name","Pain intensity (≥ 30% reduction), short-term follow-up"
"CD015373_pub2_data","Analysis.name","Ketamine (topical) versus amitriptyline: pain intensity (continuous), immediate-term follow-up"
"CD015373_pub2_data","Analysis.name","Ketamine (topical) versus amitriptyline: pain intensity (continuous), short-term follow-up"
"CD015373_pub2_data","Analysis.name","Ketamine (topical) versus amitriptyline: pain intensity (≥30% response), short-term follow-up"
"CD015373_pub2_data","Analysis.name","Ketamine (topical) versus amitriptyline: pain intensity (≥50% response), short-term follow-up"
"CD015373_pub2_data","Analysis.name","Ketamine (topical) versus amitriptyline: adverse events (total)"
"CD015373_pub2_data","Analysis.name","Ketamine (topical) versus amitriptyline: sedation"
"CD015373_pub2_data","Analysis.name","Ketamine (topical) versus amitriptyline: tolerability"
"CD015373_pub2_data","Analysis.name","Pain intensity (continuous), short-term follow-up: medicine dose subgroup analysis"
"CD015373_pub2_data","Analysis.name","Pain intensity (≥ 50% reduction), medium-term follow-up"
"CD015373_pub2_data","Analysis.name","Adverse events (total): medicine dose subgroup analysis"
"CD015373_pub2_data","Analysis.name","Other adverse events"
"CD015373_pub2_data","Analysis.name","Disability (Pain Disability Index), short-term follow up"
"CD015373_pub2_data","Analysis.name","Depressive symptoms, short-term follow up"
"CD015373_pub2_data","Analysis.name","Depressive symptoms (Hospital Anxiety and Depression Scale depression subscale), medium-term follow up"
"CD015373_pub2_data","Analysis.name","Health-related quality of life, short-term follow up"
"CD015373_pub2_data","Analysis.name","Health-related quality of life (EQ-5D Visual Analogue Scale), medium-term follow-up"
"CD015373_pub2_data","Analysis.name","Pain intensity (continuous), short-term follow up"
"CD015373_pub2_data","Analysis.name","Health-related quality of life (SF-36 General Health subscale), short-term follow up"
"CD015373_pub2_data","Analysis.name","Health-related quality of life (SF-12 Physical Component score), short-term follow up"
"CD015373_pub2_data","Analysis.name","Magnesium (oral) versus aspirin: tolerability"
"CD015373_pub2_data","Subgroup",">1 day to ≤7 days"
"CD015373_pub2_data","Subgroup","≤1 day"
"CD015373_pub2_data","Subgroup","Peripheral neuropathic pain"
"CD015373_pub2_data","Subgroup","Fibromyalgia"
"CD015373_pub2_data","Subgroup","Complex regional pain syndrome"
"CD015373_pub2_data","Subgroup",">1 week to ≤1 month"
"CD015373_pub2_data","Subgroup",">1 month"
"CD015373_pub2_data","Subgroup","Standard dose"
"CD015373_pub2_data","Subgroup","Above standard dose"
"CD015383_pub2_data","Analysis.group","1"
"CD015383_pub2_data","Analysis.group","2"
"CD015383_pub2_data","Analysis.name","Anxiety on STAI-T (scale 20 to 80)"
"CD015383_pub2_data","Analysis.name","Anxiety on STAI-S (scale 20 to 80)"
"CD015383_pub2_data","Analysis.name","Depression on BDI (scale 0 to 63)"
"CD015383_pub2_data","Analysis.name","Depression on different scales (BDI, HADS-D), SMD"
"CD015383_pub2_data","Subgroup","Psilocybin versus placebo"
"CD015383_pub2_data","Subgroup","LSD versus placebo"
"CD015383_pub2_data","Subgroup","MDMA versus placebo"
"CD015387_pub2_data","Analysis.group","1"
"CD015387_pub2_data","Analysis.group","2"
"CD015387_pub2_data","Analysis.group","3"
"CD015387_pub2_data","Analysis.group","4"
"CD015387_pub2_data","Analysis.name","Good functional outcome at the end of scheduled follow-up"
"CD015387_pub2_data","Analysis.name","Good functional outcome at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only"
"CD015387_pub2_data","Analysis.name","All-cause mortality at the end of scheduled follow-up"
"CD015387_pub2_data","Analysis.name","All-cause mortality at the end of scheduled follow-up: sensitivity analysis of low risk of bias trials only"
"CD015387_pub2_data","Analysis.name","Thirty-day case fatality"
"CD015387_pub2_data","Analysis.name","Health-related quality of life at the end of scheduled follow-up"
"CD015387_pub2_data","Analysis.name","Good functional outcome at the end of scheduled follow-up: stratified by surgical approach"
"CD015387_pub2_data","Analysis.name","All-cause mortality at the end of scheduled follow-up: stratified by surgical approach"
"CD015387_pub2_data","Analysis.name","Thirty-day case fatality: stratified by surgical approach"
"CD015387_pub2_data","Subgroup","Endoscopic evacuation"
"CD015387_pub2_data","Subgroup","Mixed minimally invasive approaches"
"CD015387_pub2_data","Subgroup","Non-visualised minimally invasive surgery"
"CD015387_pub2_data","Subgroup","Tubular retractor-mediated evacuation"
"CD015395_pub3_data","Analysis.group","1"
"CD015395_pub3_data","Analysis.group","2"
"CD015395_pub3_data","Analysis.name","All-cause mortality at day 28"
"CD015395_pub3_data","Analysis.name","Worsening of clinical status at day 28: admission to hospital or death"
"CD015395_pub3_data","Analysis.name","Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on age)"
"CD015395_pub3_data","Analysis.name","Worsening of clinical status at day 28: admission to hospital or death (subgroup analysis based on ethnicity)"
"CD015395_pub3_data","Analysis.name","Serious adverse events during the study period"
"CD015395_pub3_data","Analysis.name","Any grade treatment-emergent adverse events during the study period"
"CD015395_pub3_data","Analysis.name","Any grade treatment-related adverse events during the study period"
"CD015395_pub3_data","Analysis.name","Discontinuation of study drug due to adverse events during the study period"
"CD015395_pub3_data","Analysis.name","All-cause mortality at day 28 (subgroup analysis based on age)"
"CD015395_pub3_data","Analysis.name","Viral clearance at day 7"
"CD015395_pub3_data","Analysis.name","Viral clearance at day 14"
"CD015395_pub3_data","Subgroup","Age ≥ 65 years"
"CD015395_pub3_data","Subgroup","Aged < 65 years"
"CD015395_pub3_data","Subgroup","Black/African American"
"CD015395_pub3_data","Subgroup","White"
"CD015395_pub3_data","Subgroup","Asian"
"CD015395_pub3_data","Subgroup","Other"
"CD015395_pub3_data","Subgroup","Aged ≤ 65 years"
"CD015395_pub3_data","Subgroup","Aged > 65 years"
"CD015432_pub2_data","Analysis.group","1"
"CD015432_pub2_data","Analysis.group","2"
"CD015432_pub2_data","Analysis.group","3"
"CD015432_pub2_data","Analysis.group","4"
"CD015432_pub2_data","Analysis.group","5"
"CD015432_pub2_data","Analysis.group","6"
"CD015432_pub2_data","Analysis.group","7"
"CD015432_pub2_data","Analysis.name","Pain intensity – as reported by the child, less than 2 hours postintervention"
"CD015432_pub2_data","Analysis.name","Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention"
"CD015432_pub2_data","Analysis.name","Pain intensity – as reported by the child, from 24 hours up to 7 days postintervention"
"CD015432_pub2_data","Analysis.name","Adverse events"
"CD015432_pub2_data","Analysis.name","Pain intensity – as reported by a third party, e.g. parents and caregivers, less than 2 hours postintervention"
"CD015432_pub2_data","Analysis.name","Number of children who required rescue medication less than 2 hours postintervention"
"CD015432_pub2_data","Analysis.name","Number of children who required rescue medication 2 hours to less than 24 hours postintervention"
"CD015432_pub2_data","Analysis.name","Number of children who required rescue medication, from 24 hours up to 7 days"
"CD015432_pub2_data","Analysis.name","Opioid consumption, less than 2 hours postintervention"
"CD015432_pub2_data","Analysis.name","Opioid consumption, 2 hours to less than 24 hours postintervention"
"CD015432_pub2_data","Analysis.name","Opioid consumption, from 24 hours up to 7 days postintervention"
"CD015432_pub2_data","Analysis.name","Time to rescue medication, as reported by a third party, e.g. parents and caregivers"
"CD015432_pub2_data","Analysis.name","Nausea or vomiting "
"CD015432_pub2_data","Analysis.name","Any bleeding, including gastrointestinal bleeding and oral bleeding"
"CD015432_pub2_data","Analysis.name","Renal dysfunction"
"CD015432_pub2_data","Analysis.name","Pain intensity – as reported by the child, from 24 hours up to 7 days"
"CD015432_pub2_data","Analysis.name","Pain intensity – as reported by a third party, e.g. parents and caregivers, 2 hours to less than 24 hours"
"CD015432_pub2_data","Analysis.name","Pain intensity – as reported by a third party, e.g. parents and caregivers, from 24 hours up to 7 days postintervention"
"CD015432_pub2_data","Analysis.name","Nausea or vomiting"
"CD015432_pub2_data","Analysis.name","Number of children who required rescue medication from 24 hours to 7 days postintervention"
"CD015443_pub2_data","Analysis.group","1"
"CD015443_pub2_data","Analysis.group","2"
"CD015443_pub2_data","Analysis.group","3"
"CD015443_pub2_data","Analysis.name","Relapse (12 months)"
"CD015443_pub2_data","Analysis.name","Relapse (24 months)"
"CD015443_pub2_data","Analysis.name","Relapse (36 months)"
"CD015443_pub2_data","Analysis.name","Disability worsening (24 months)"
"CD015443_pub2_data","Analysis.name","Disability worsening (36 months)"
"CD015443_pub2_data","Analysis.name","Serious adverse events"
"CD015443_pub2_data","Analysis.name","Discontinuations due to adverse events"
"CD015443_pub2_data","Analysis.name","New gadolinium-enhancing positive T1-weighted MRI lesions (12 months)"
"CD015443_pub2_data","Analysis.name","New gadolinium-enhancing positive T1-weighted MRI lesions (24 months)"
"CD015443_pub2_data","Analysis.name","New gadolinium-enhancing positive T1-weighted MRI lesions (36 months)"
"CD015443_pub2_data","Analysis.name","New or enlarging T2-weighted MRI lesions (12 months)"
"CD015443_pub2_data","Analysis.name","New or enlarging T2-weighted MRI lesions (24 months)"
"CD015443_pub2_data","Analysis.name","New or enlarging T2-weighted MRI lesions (36 months)"
"CD015443_pub2_data","Analysis.name","QoL total (MSIS-29) "
"CD015443_pub2_data","Analysis.name","QoL Mental (SF-36)"
"CD015443_pub2_data","Analysis.name","QoL physical (SF-36) "
"CD015443_pub2_data","Analysis.name","Mortality"
"CD015443_pub2_data","Subgroup","Immunoglobulins versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Methotrexate versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Rituximab versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Interferon beta 1a (Avonex, Rebif) versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Steroids versus cyclophosphamide"
"CD015443_pub2_data","Subgroup","Interferon beta 1b (Betaferon) versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Azathioprine versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Natalizumab versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Methotrexate versus placebo/no treatement"
"CD015443_pub2_data","Subgroup","Interferon beta1b (Betaferon) versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Glatiramer acetate versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Siponimod versu placebo/no treatment"
"CD015443_pub2_data","Subgroup","Interferon Beta1a (Avonex, Rebif) versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Rituximab versus placebo / no treatment"
"CD015443_pub2_data","Subgroup","Interferon Beta 1a (Avonex, Rebif) versus placebo/no treatement"
"CD015443_pub2_data","Subgroup","Interferon Beta 1b (Betaferon) versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Ocrelizumab versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Interferon beta-1a versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Interferon beta-1b versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Fingolimod versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Siponimod versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Laquinimod versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Interferon Beta 1b versus placebo / no treatment"
"CD015443_pub2_data","Subgroup","Interferon Beta 1a versus placebo/no treatment"
"CD015443_pub2_data","Subgroup","Fingolimod versus placebo / no treatment"
"CD015443_pub2_data","Subgroup","Glatiramer acetate versus placebo / no treatment"
"CD015443_pub2_data","Subgroup","Immunoglobulins versus placebo / no treatements"
"CD015443_pub2_data","Subgroup","Rituximab versus glatiramer acetate"
"CD015443_pub2_data","Subgroup","Siponimod versus placebo / no treatment"
"CD015443_pub2_data","Subgroup","Rituximab versus placebo / no treatment "
"CD015443_pub2_data","Subgroup","Fingolimod versus placebo"
"CD015443_pub2_data","Subgroup","Interferon beta-1a  (Avonex, Rebif) versus placebo"
"CD015443_pub2_data","Subgroup","Natalizumab versus placebo"
"CD015443_pub2_data","Subgroup","Interferon beta-1a (Avonex, Rebif) versus placebo"
"CD015443_pub2_data","Subgroup","Ocrelizumab versu placebo"
"CD015443_pub2_data","Subgroup","Interferon beta-1b versus placebo/no treatment "
"CD015443_pub2_data","Subgroup","Fingolimod versus placebo/no treatment "
"CD015443_pub2_data","Subgroup","Laquinimod versus placebo/no treatment "
"CD015443_pub2_data","Subgroup","Glatiramer acetate versus placebo/no treatment "
"CD015443_pub2_data","Subgroup","Ocrelizumab versus placebo/no treatment "
"CD015448_pub2_data","Analysis.group","1"
"CD015448_pub2_data","Analysis.group","2"
"CD015448_pub2_data","Analysis.group","3"
"CD015448_pub2_data","Analysis.group","4"
"CD015448_pub2_data","Analysis.group","5"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in symptom scores at 4 weeks"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in symptom scores at 6 months"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in meibum quality scores at 4 weeks—SMD"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in meibomian gland atrophy at 3 months"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in tear film breakup time at 4 weeks—SMD"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in non-invasive tear film breakup time at 4 weeks"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in symptom scores at 12 months"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in meibomian gland atrophy at 2 months"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in non-invasive tear film breakup time at 4 weeks—SMD"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in symptom scores at 1 week"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in meibomian gland expression scores at 1 week"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in symptom scores at 42 days"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in meibomian gland expression scores at 42 days"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in meibum quality scores at 42 days"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in symptom scores at 3 months"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in meibomian gland expression scores at 3 months"
"CD015448_pub2_data","Analysis.name","Mean change from baseline in tear film breakup time at 3 months"
"CD015448_pub2_data","Subgroup","SPEED; participant-level"
"CD015448_pub2_data","Subgroup","SPEED; eye-level"
"CD015448_pub2_data","Subgroup","OSDI; participant-level"
"CD015448_pub2_data","Subgroup","OSDI; eye-level"
"CD015448_pub2_data","Subgroup","Participant-level"
"CD015448_pub2_data","Subgroup","Eye-level"
"CD015448_pub2_data","Subgroup","SANDE"
"CD015448_pub2_data","Subgroup","OSDI"
"CD015448_pub2_data","Subgroup","IDEEL-SB"
"CD015462_pub2_data","Analysis.group","1"
"CD015462_pub2_data","Analysis.name","All-cause mortality prior to hospital discharge"
"CD015462_pub2_data","Analysis.name","Moderate to severe neurodevelopmental disability at 18 to 26 months - developmental delay more than two SDs below population mean on a standardized test of development: cognitive"
"CD015462_pub2_data","Analysis.name","Moderate to severe neurodevelopmental disability at 18 to 26 months - developmental delay more than two SDs below population mean on a standardized test of development: language"
"CD015462_pub2_data","Analysis.name","Moderate to severe neurodevelopmental disability at 18 to 26 months - developmental delay more than two SDs below population mean on a standardized test of development: motor"
"CD015462_pub2_data","Analysis.name","Bronchopulmonary dysplasia/chronic lung disease: defined as 28 days of oxygen exposure at 36 weeks' postmenstrual age"
"CD015462_pub2_data","Analysis.name","Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines"
"CD015462_pub2_data","Analysis.name","Failure to extubate within one week of commencing treatment"
"CD015462_pub2_data","Analysis.name","Failed apnea reduction after two to seven days (less than 50% reduction in apnea), for infants treated for apnea"
"CD015462_pub2_data","Analysis.name","Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after 24 hours from commencing treatment over a 24-hour period"
"CD015462_pub2_data","Analysis.name","Apnea: number of episodes (defined as interruption of breathing for more than 20 seconds) after one week"
"CD015462_pub2_data","Analysis.name","Apnea: number of infants with at least one episode (defined as interruption of breathing for more than 20 seconds) after 24 hours of commencing treatment after one week"
"CD015462_pub2_data","Analysis.name","Number of days of respiratory support (mechanical ventilation; continuous positive airway pressure [CPAP]; high-flow nasal cannula; non-invasive positive-pressure ventilation [NIPPV])"
"CD015462_pub2_data","Analysis.name","Number of days of supplemental oxygen"
"CD015462_pub2_data","Analysis.name","Intraventricular hemorrhage on brain ultrasound (any; and severe [Papile grade 3 to 4])"
"CD015462_pub2_data","Analysis.name","Periventricular leukomalacia"
"CD015462_pub2_data","Analysis.name","Necrotizing enterocolitis (proven = Bell stage 2 or greater)"
"CD015462_pub2_data","Analysis.name","Patent ductus arteriosus (PDA) requiring treatment (cyclo-oxygenase inhibitors or surgical ligation)"
"CD015462_pub2_data","Analysis.name","Retinopathy of prematurity (ROP) (any ROP; and severe ROP [stage 3 or greater])"
"CD015476_pub2_data","Analysis.group","1"
"CD015476_pub2_data","Analysis.group","2"
"CD015476_pub2_data","Analysis.group","3"
"CD015476_pub2_data","Analysis.name","Adenoma detection rate"
"CD015476_pub2_data","Analysis.name","Polyp detection rate"
"CD015476_pub2_data","Analysis.name","Sessile serrated lesion detection rate"
"CD015476_pub2_data","Analysis.name","Number of adenomas per participant"
"CD015476_pub2_data","Analysis.name","Number of polyps per participant"
"CD015476_pub2_data","Analysis.name","Number of flat polyps per participant"
"CD015476_pub2_data","Analysis.name","Adenoma detection rate between LASEREO and ELUXEO"
"CD015476_pub2_data","Analysis.name","Adenoma detection rate between pre-2020 and post-2020"
"CD015476_pub2_data","Analysis.name","Adenoma detection rate between lesions <10 mm and ≥10 mm"
"CD015476_pub2_data","Analysis.name","Adenoma detection rate between Western countries and Asia"
"CD015476_pub2_data","Analysis.name","Adenoma detection rate between experienced colonoscopists and trainees"
"CD015476_pub2_data","Analysis.name","Adenoma detection rate excluding studies with a high overall risk of bias"
"CD015476_pub2_data","Analysis.name","Polyp detection rate excluding studies with a high overall risk of bias"
"CD015476_pub2_data","Analysis.name","Number of adenomas per participant excluding studies with a high overall risk of bias"
"CD015476_pub2_data","Analysis.name","Number of polyps per participant excluding studies with a high overall risk of bias"
"CD015476_pub2_data","Analysis.name","Adenoma detection rate excluding studies that included patients with Lynch syndrome"
"CD015476_pub2_data","Analysis.name","Polyp detection rate excluding studies that included patients with Lynch syndrome"
"CD015476_pub2_data","Analysis.name","Serrated adenoma detection rate excluding studies that included patients with Lynch syndrome"
"CD015476_pub2_data","Analysis.name","Number of adenomas per participant excluding studies that included patients with Lynch syndrome"
"CD015476_pub2_data","Analysis.name","Number of polyps per participant excluding studies that included patients with Lynch syndrome"
"CD015476_pub2_data","Analysis.name","Number of flat polyps per participant excluding studies that included patients with Lynch syndrome"
"CD015476_pub2_data","Subgroup","LASEREO"
"CD015476_pub2_data","Subgroup","ELUXEO"
"CD015476_pub2_data","Subgroup","Pre-2020"
"CD015476_pub2_data","Subgroup","Post-2020"
"CD015476_pub2_data","Subgroup","lesions <10 mm"
"CD015476_pub2_data","Subgroup","lesions ≥10 mm"
"CD015476_pub2_data","Subgroup","Western countries"
"CD015476_pub2_data","Subgroup","Asia"
"CD015476_pub2_data","Subgroup","Experienced colonoscopists"
"CD015476_pub2_data","Subgroup","Trainees"
"CD015495_data","Analysis.group","1"
"CD015495_data","Analysis.group","2"
"CD015495_data","Analysis.group","3"
"CD015495_data","Analysis.group","4"
"CD015495_data","Analysis.name","Overall survival (hazard ratio) in people aged 65 years and older, at any time point"
"CD015495_data","Analysis.name","Overall survival (hazard ratio) in people aged 65 to 75 years, inclusive, at any time point"
"CD015495_data","Analysis.name","Overall survival (hazard ratio) in people aged 75 years and older, at any time point"
"CD015495_data","Analysis.name","Treatment-related adverse events ≥ grade 3, in people aged 65 years and older, at any time point"
"CD015495_data","Analysis.name","Treatment-related adverse events ≥ grade 3 for people aged 65 to 75 years, inclusive, at any time point"
"CD015495_data","Analysis.name","Progression-free survival (hazard ratio) in people aged 65 years and older, at any time point"
"CD015495_data","Analysis.name","Progression-free survival (hazard ratio) in people aged 65 to 75 years, inclusive, at any time point"
"CD015495_data","Analysis.name","Progression-free survival (hazard ratio) in people aged 75 years and older, at any time point"
"CD015495_data","Analysis.name","Objective response rate in people aged 65 years and older, at any time point"
"CD015495_data","Analysis.name","Objective response rate for people aged 65 to 75 years, inclusive, at any time point"
"CD015514_pub2_data","Analysis.group","1"
"CD015514_pub2_data","Analysis.name","Proportion of eyes with retinal displacement at 6 months"
"CD015514_pub2_data","Analysis.name","Proportion of eyes with retinal displacement within 3 months"
"CD015514_pub2_data","Analysis.name","Mean change in visual acuity (logMAR) at 3 months"
"CD015514_pub2_data","Analysis.name","Mean change in visual acuity (ETDRS)"
"CD015514_pub2_data","Analysis.name","Objective distortion score"
"CD015514_pub2_data","Analysis.name","Quality of life score - NEI-VFQ"
"CD015514_pub2_data","Analysis.name","Adverse events - outer retinal folds"
"CD015514_pub2_data","Analysis.name","Adverse events - binocular diplopia and elevated intraocular pressure at 6 months"
"CD015514_pub2_data","Subgroup","Without perfluoron"
"CD015514_pub2_data","Subgroup","With perfluoron"
"CD015514_pub2_data","Subgroup","Week 8"
"CD015514_pub2_data","Subgroup","Week 26"
"CD015514_pub2_data","Subgroup","1 month"
"CD015514_pub2_data","Subgroup","3 months"
"CD015514_pub2_data","Subgroup","6 months"
"CD015514_pub2_data","Subgroup","Elevated intraocular pressure"
"CD015514_pub2_data","Subgroup","Binocular diplopia"
"CD015517_data","Analysis.group","1"
"CD015517_data","Analysis.group","2"
"CD015517_data","Analysis.group","3"
"CD015517_data","Analysis.group","4"
"CD015517_data","Analysis.group","5"
"CD015517_data","Analysis.group","6"
"CD015517_data","Analysis.group","7"
"CD015517_data","Analysis.group","8"
"CD015517_data","Analysis.group","9"
"CD015517_data","Analysis.group","10"
"CD015517_data","Analysis.group","11"
"CD015517_data","Analysis.group","12"
"CD015517_data","Analysis.name","CRF at 12 weeks or less after the intervention"
"CD015517_data","Analysis.name","CRF at greater than 12 weeks to less than 6 months after the intervention"
"CD015517_data","Analysis.name","CRF at 6 months or greater after the intervention"
"CD015517_data","Analysis.name","QoL at 12 weeks or less after the intervention"
"CD015517_data","Analysis.name","QoL at greater than 12 weeks to less than 6 months after the intervention"
"CD015517_data","Analysis.name","QoL at 6 months or greater after the intervention"
"CD015517_data","Analysis.name","Anxiety ≤ 12 weeks after the intervention "
"CD015517_data","Analysis.name","Anxiety ≥ 6 months after the intervention"
"CD015517_data","Analysis.name","Depression ≤ 12 weeks after the intervention"
"CD015517_data","Analysis.name","Depression ≥ 6 months after the intervention"
"CD015517_data","Analysis.name","CRF ≤ 12 weeks after the intervention "
"CD015517_data","Analysis.name","QoL ≤ 12 weeks after the intervention"
"CD015517_data","Analysis.name","CRF ≥ 6 months after the intervention"
"CD015517_data","Analysis.name","QoL ≥ 6 months after the intervention"
"CD015517_data","Analysis.name","Adverse events"
"CD015517_data","Analysis.name","Anxiety ≤ 12 weeks after the intervention"
"CD015517_data","Analysis.name","CRF ≤ 12 weeks after the intervention"
"CD015517_data","Analysis.name","QoL ≤ 12 weeks after the intervention "
"CD015517_data","Subgroup","Not reported"
"CD015517_data","Subgroup","Moderate to high"
"CD015517_data","Subgroup","High"
"CD015517_data","Subgroup","Lung"
"CD015517_data","Subgroup","Hodgkin-/Non-Hodgkin lymphoma"
"CD015517_data","Subgroup","Prostate"
"CD015517_data","Subgroup","Breast"
"CD015517_data","Subgroup","Mixed"
"CD015517_data","Subgroup","Hodgkin-/Non-Hodgkin lymphoma "
"CD015517_data","Subgroup","Individual training"
"CD015517_data","Subgroup","Group training"
"CD015517_data","Subgroup","Supervised"
"CD015517_data","Subgroup","Younger than 65 years"
"CD015517_data","Subgroup","65 years or older"
"CD015517_data","Subgroup","Chemotherapy"
"CD015517_data","Subgroup","Moderate"
"CD015517_data","Subgroup","Testicular"
"CD015517_data","Subgroup","Colorectal"
"CD015517_data","Subgroup","Individual and group training"
"CD015517_data","Subgroup","Self-administered"
"CD015518_data","Analysis.group","1"
"CD015518_data","Analysis.group","2"
"CD015518_data","Analysis.group","3"
"CD015518_data","Analysis.group","4"
"CD015518_data","Analysis.group","5"
"CD015518_data","Analysis.group","6"
"CD015518_data","Analysis.group","7"
"CD015518_data","Analysis.group","8"
"CD015518_data","Analysis.group","9"
"CD015518_data","Analysis.group","10"
"CD015518_data","Analysis.group","11"
"CD015518_data","Analysis.group","12"
"CD015518_data","Analysis.name","Cancer-related fatigue ≤ 12 weeks"
"CD015518_data","Analysis.name","Cancer-related fatigue > 12 weeks to < 6 months"
"CD015518_data","Analysis.name","Cancer-related fatigue ≥ 6 months"
"CD015518_data","Analysis.name","Quality of life ≤ 12 weeks"
"CD015518_data","Analysis.name","Quality of life > 12 weeks to < 6 months"
"CD015518_data","Analysis.name","Quality of life ≥ 6 months"
"CD015518_data","Analysis.name","Depression ≤ 12 weeks"
"CD015518_data","Analysis.name","Depression ≥ 6 months"
"CD015518_data","Analysis.name","Anxiety ≤ 12 weeks"
"CD015518_data","Analysis.name","Anxiety ≥ 6 months"
"CD015518_data","Subgroup","Moderate to vigorous intensity"
"CD015518_data","Subgroup","Moderate intensity"
"CD015518_data","Subgroup","Light to vigorous intensity"
"CD015518_data","Subgroup","Near-maximal to maximal intensity"
"CD015518_data","Subgroup","Breast cancer"
"CD015518_data","Subgroup","Haematological malignancies and other conditions"
"CD015518_data","Subgroup","Prostate cancer"
"CD015518_data","Subgroup","Nasopharyngeal carcinoma"
"CD015518_data","Subgroup","Pancreatic cancer"
"CD015518_data","Subgroup","Individual training"
"CD015518_data","Subgroup","Group training"
"CD015518_data","Subgroup","Individual training and group training"
"CD015518_data","Subgroup","Supervised training"
"CD015518_data","Subgroup","Supervised training and self-administered training"
"CD015518_data","Subgroup","Self-administered training"
"CD015518_data","Subgroup","Mixed cancer therapies"
"CD015518_data","Subgroup","Surgery with or without additional therapy"
"CD015518_data","Subgroup","Allogeneic hematopoietic stem cell transplantation"
"CD015518_data","Subgroup","Radiotherapy with or without androgen deprivation therapy"
"CD015518_data","Subgroup","Chemoradiotherapy "
"CD015518_data","Subgroup","Androgen deprivation therapy"
"CD015518_data","Subgroup","Chemoradiotherapy"
"CD015518_data","Subgroup","Endometrial cancer"
"CD015518_data","Subgroup","Haematological malignancies (acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome)"
"CD015518_data","Subgroup","Hematopoietic stem cell transplantation"
"CD015518_data","Subgroup","Radiotherapy and androgen deprivation therapy"
"CD015519_pub2_data","Analysis.group","1"
"CD015519_pub2_data","Analysis.group","2"
"CD015519_pub2_data","Analysis.group","3"
"CD015519_pub2_data","Analysis.group","4"
"CD015519_pub2_data","Analysis.name","Cancer-related fatigue (CRF) ≤ 12 weeks"
"CD015519_pub2_data","Analysis.name","CRF  ≥ 6 months"
"CD015519_pub2_data","Analysis.name","Quality of life (QoL) ≤ 12 weeks"
"CD015519_pub2_data","Analysis.name","QoL ≥ 6 months"
"CD015519_pub2_data","Analysis.name","Depression ≤ 12 weeks"
"CD015519_pub2_data","Analysis.name","Depression ≥ 6 months "
"CD015519_pub2_data","Analysis.name","Anxiety ≤ 12 weeks"
"CD015519_pub2_data","Analysis.name","Anxiety ≥ 6 months"
"CD015519_pub2_data","Analysis.name","Adverse events  ≥ 6 months"
"CD015519_pub2_data","Subgroup","People with breast cancer"
"CD015519_pub2_data","Subgroup","People with prostate cancer"
"CD015519_pub2_data","Subgroup","Treated with chemotherapy"
"CD015519_pub2_data","Subgroup","Treated with radiotherapy"
"CD015520_data","Analysis.group","1"
"CD015520_data","Analysis.group","2"
"CD015520_data","Analysis.group","3"
"CD015520_data","Analysis.group","4"
"CD015520_data","Analysis.group","5"
"CD015520_data","Analysis.group","6"
"CD015520_data","Analysis.group","7"
"CD015520_data","Analysis.group","8"
"CD015520_data","Analysis.group","9"
"CD015520_data","Analysis.name","CRF ≤ 12 weeks "
"CD015520_data","Analysis.name","CRF > 12 weeks to < 6 months"
"CD015520_data","Analysis.name","CRF ≥ 6 months"
"CD015520_data","Analysis.name","QoL ≤ 12 weeks"
"CD015520_data","Analysis.name","QoL > 12 weeks to < 6 months "
"CD015520_data","Analysis.name","Depression ≤ 12 weeks"
"CD015520_data","Analysis.name","Depression > 12 weeks to < 6 months "
"CD015520_data","Analysis.name","Depression ≥  6 months"
"CD015520_data","Analysis.name","Anxiety ≤ 12 weeks"
"CD015520_data","Analysis.name","Anxiety > 12 weeks to < 6 months "
"CD015520_data","Analysis.name","Anxiety  ≥ 6 months"
"CD015520_data","Analysis.name","CRF ≤ 12 weeks"
"CD015520_data","Analysis.name","CRF > 12 weeks to < 6 months "
"CD015520_data","Subgroup","Individual yoga course"
"CD015520_data","Subgroup","Group yoga course"
"CD015520_data","Subgroup","Mixed yoga style"
"CD015520_data","Subgroup","Dru yoga"
"CD015520_data","Subgroup","Supervised yoga"
"CD015520_data","Subgroup","Supervised yoga and self-administered yoga"
"CD015520_data","Subgroup","Mixed yoga styles"
"CD015520_data","Subgroup","Hatha yoga"
"CD015520_data","Subgroup","Breast cancer"
"CD015520_data","Subgroup","Colon cancer"
"CD015520_data","Subgroup","Any type of cancer"
"CD015520_data","Subgroup","Older than 65 years"
"CD015520_data","Subgroup","Younger than 65 years"
"CD015520_data","Subgroup","Age not reported"
"CD015524_pub2_data","Analysis.group","1"
"CD015524_pub2_data","Analysis.group","2"
"CD015524_pub2_data","Analysis.group","3"
"CD015524_pub2_data","Analysis.group","4"
"CD015524_pub2_data","Analysis.name","Analysis 1.1. Outcome 1: Proportion of participants with serious adverse events"
"CD015524_pub2_data","Analysis.name","Analysis 1.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis ‘best-worst’ case scenario"
"CD015524_pub2_data","Analysis.name","Analysis 1.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis ‘worst-best’ case scenario"
"CD015524_pub2_data","Analysis.name","Analysis 1.4. Outcome 2: ALT (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 1.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.6. Outcome 3: AST (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 1.7. Outcome 4: GGT (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 1.8. Outcome 5: Proportion of participants with non-serious adverse events"
"CD015524_pub2_data","Analysis.name","Analysis 1.9. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis on trials at ‘low’ risk of bias"
"CD015524_pub2_data","Analysis.name","Analysis 1.10. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.11. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis ‘best-worst’ case scenario"
"CD015524_pub2_data","Analysis.name","Analysis 1.12. Outcome 5: Proportion of participants with non-serious adverse events: sensitivity analysis ‘worst-best’ case scenario"
"CD015524_pub2_data","Analysis.name","Analysis 1.13. Outcome 6: Proportion of participants without improvement of steatosis"
"CD015524_pub2_data","Analysis.name","Analysis 1.14. Outcome 6: Proportion of participants without improvement of steatosis: sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.15. Outcome 7: Proportion of participants without improvement of lobular inflammation"
"CD015524_pub2_data","Analysis.name","Analysis 1.16. Outcome 7: Proportion of participants without improvement of lobular inflammation: sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.17. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning"
"CD015524_pub2_data","Analysis.name","Analysis 1.18. Outcome 8: Proportion of participants without improvement of hepatocyte ballooning: sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.19. Outcome 9: Proportion of participants without improvement of NAS"
"CD015524_pub2_data","Analysis.name","Analysis 1.20. Outcome 9: Proportion of participants without improvement of NAS: sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.21. Outcome 10: Proportion of participants without improvement of fibrosis"
"CD015524_pub2_data","Analysis.name","Analysis 1.22. Outcome 10: Proportion of participants without improvement of fibrosis: sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.23. Outcome 11: Proportion of participants without normalisation of ALT"
"CD015524_pub2_data","Analysis.name","Analysis 1.24. Outcome 12: Proportion of participants without normalisation of AST"
"CD015524_pub2_data","Analysis.name","Analysis 1.25. Outcome 13: Proportion of participants without improvement of LSM"
"CD015524_pub2_data","Analysis.name","Analysis 1.26. Outcome 14: TC (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 1.27. Outcome 14: TC (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.28. Outcome 15: TG (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 1.29. Outcome 15: TG (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.30. Outcome 16: HDL cholesterol (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 1.31. Outcome 16: HDL cholesterol (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.32. Outcome 17: LDL cholesterol (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 1.33. Outcome 17: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 1.34. Outcome 18: FBS (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 1.35. Outcome 19: BMI (kg/m2)"
"CD015524_pub2_data","Analysis.name","Analysis 1.36. Outcome 19: BMI (kg/m2): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 2.1. Outcome 1: Proportion of participants with serious adverse events"
"CD015524_pub2_data","Analysis.name","Analysis 2.2. Outcome 2: ALT (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 2.3. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 2.4. Outcome 3: AST (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 2.5. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 2.6. Outcome 4: GGT (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 2.7. Outcome 5: Proportion of participants with non-serious adverse events"
"CD015524_pub2_data","Analysis.name","Analysis 2.8. Outcome 6: TC (mmol/L) "
"CD015524_pub2_data","Analysis.name","Analysis 2.9. Outcome 6: TC (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 2.10. Outcome 7: TG (mmol/L) "
"CD015524_pub2_data","Analysis.name","Analysis 2.11. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 2.12. Outcome 8: HDL cholesterol (mmol/L) "
"CD015524_pub2_data","Analysis.name","Analysis 2.13. Outcome 9: LDL cholesterol (mmol/L) "
"CD015524_pub2_data","Analysis.name","Analysis 2.14. Outcome 10: FBS (mmol/L) "
"CD015524_pub2_data","Analysis.name","Analysis 2.15. Outcome 11: HOMA-IR"
"CD015524_pub2_data","Analysis.name","Analysis 2.16. Outcome 12: Insulin (mmol/l)"
"CD015524_pub2_data","Analysis.name","Analysis 2.17. Outcome 13: Weight (kg)"
"CD015524_pub2_data","Analysis.name","Analysis 2.18. Outcome 14: BMI (kg/m2)"
"CD015524_pub2_data","Analysis.name","Analysis 3.1. Outcome 1: Proportion of participants with serious adverse events"
"CD015524_pub2_data","Analysis.name","Analysis 3.2. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis ‘best-worst’ case scenario"
"CD015524_pub2_data","Analysis.name","Analysis 3.3. Outcome 1: Proportion of participants with serious adverse events: sensitivity analysis ‘worst-best’ case scenario"
"CD015524_pub2_data","Analysis.name","Analysis 3.4. Outcome 2: ALT (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 3.5. Outcome 2: ALT (U/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.6. Outcome 3: AST (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 3.7. Outcome 3: AST (U/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.8. Outcome 4: GGT (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 3.9. Outcome 4: GGT (U/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.10. Outcome 5: Proportion of participants with non-serious adverse events"
"CD015524_pub2_data","Analysis.name","Analysis 3.11. Outcome 6: Proportion of participants without normalisation of ALT"
"CD015524_pub2_data","Analysis.name","Analysis 3.12. Outcome 7: Proportion of participants without normalisation of AST"
"CD015524_pub2_data","Analysis.name","Analysis 3.13. Outcome 8: Proportion of participants without improvement of the ultrasound"
"CD015524_pub2_data","Analysis.name","Analysis 3.14. Outcome 9: TC (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 3.15. Outcome 9: TC (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.16. Outcome 10: TG (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 3.17. Outcome 10: TG (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.18. Outcome 11: HDL cholesterol (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 3.19. Outcome 11: HDL cholesterol (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.20. Outcome 12: LDL cholesterol (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 3.21. Outcome 12: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.22. Outcome 13: FBS (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 3.23. Outcome 13: FBS (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.24. Outcome 14: HOMA-IR"
"CD015524_pub2_data","Analysis.name","Analysis 3.25. Outcome 14: HOMA-IR: sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.26. Outcome 15: Insulin (pmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 3.27. Outcome 15: Insulin (pmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.28. Outcome 16: Weight (kg)"
"CD015524_pub2_data","Analysis.name","Analysis 3.29. Outcome 16: Weight (kg): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.30. Outcome 17: BMI (kg/m2)"
"CD015524_pub2_data","Analysis.name","Analysis 3.31. Outcome 17: BMI (kg/m2): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.32. Outcome 18: WC (cm)"
"CD015524_pub2_data","Analysis.name","Analysis 3.33. Outcome 18: WC (cm): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 3.34. Outcome 19: LSM (Kpa)"
"CD015524_pub2_data","Analysis.name","Analysis 3.35. Outcome 20: CAP (dB/m)"
"CD015524_pub2_data","Analysis.name","Analysis 4.1. Outcome 1: Proportion of participants with serious adverse events"
"CD015524_pub2_data","Analysis.name","Analysis 4.2. Outcome 2: ALT (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 4.3. Outcome 3: AST (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 4.4. Outcome 4: GGT (U/L)"
"CD015524_pub2_data","Analysis.name","Analysis 4.5. Outcome 5: Proportion of participants with non-serious adverse events"
"CD015524_pub2_data","Analysis.name","Analysis 4.6. Outcome 6: TC (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 4.7. Outcome 6: TC (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 4.8. Outcome 7: TG (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 4.9. Outcome 7: TG (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 4.10. Outcome 8: HDL cholesterol (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 4.11. Outcome 9: LDL cholesterol (mmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 4.12. Outcome 9: LDL cholesterol (mmol/L): sensitivity analysis fixed-effect model"
"CD015524_pub2_data","Analysis.name","Analysis 4.13. Outcome 10: FBS (mmol/L)"
"CD015524_pub2_data","Analysis.name"," Analysis 4.14. Outcome 11: HOMA-IR"
"CD015524_pub2_data","Analysis.name","Analysis 4.15. Outcome 12: Insulin (pmol/L)"
"CD015524_pub2_data","Analysis.name","Analysis 4.16. Outcome 13: Weight (kg)"
"CD015524_pub2_data","Analysis.name","Analysis 4.17. Outcome 14: BMI (kg/m2)"
"CD015524_pub2_data","Analysis.name","Analysis 4.18. Outcome 15: WC (cm)"
"CD015526_pub2_data","Analysis.group","1"
"CD015526_pub2_data","Analysis.group","2"
"CD015526_pub2_data","Analysis.name","Dialysis dysequilibrium syndrome"
"CD015526_pub2_data","Analysis.name","Severe dialysis dysequilibrium syndrome"
"CD015526_pub2_data","Analysis.name","Death"
"CD015526_pub2_data","Analysis.name","Adverse events"
"CD015526_pub2_data","Analysis.name","Dialysis disequilibrium syndrome"
"CD015530_pub2_data","Analysis.group","1"
"CD015530_pub2_data","Analysis.group","2"
"CD015530_pub2_data","Analysis.group","3"
"CD015530_pub2_data","Analysis.group","4"
"CD015530_pub2_data","Analysis.name","Incidence of herpes zoster (up to 21 months after final dose)"
"CD015530_pub2_data","Analysis.name","All-cause mortality (up to 28 days after final dose)"
"CD015530_pub2_data","Analysis.name","Adverse events of any grade (up to 30 days after final dose)"
"CD015530_pub2_data","Analysis.name","Serious adverse events (up to 12 months after final dose)"
"CD015530_pub2_data","Analysis.name","Serious adverse events (up to 30 days after final dose)"
"CD015530_pub2_data","Analysis.name","Serious adverse events (up to 6 months after final dose)"
"CD015530_pub2_data","Analysis.name","Adverse events of special interest - injection site adverse events (up to 28 days after final dose)"
"CD015530_pub2_data","Analysis.name","Adverse events of special interest - injection site adverse events (up to 7 days post vaccination)"
"CD015530_pub2_data","Analysis.name","Adverse events of special interest - systemic adverse events (up to 28 days after final dose)"
"CD015530_pub2_data","Analysis.name","Adverse events of special interest - systemic adverse events (up to 7 days post vaccination)"
"CD015530_pub2_data","Analysis.name","Incidence of COVID-19 (up to 6 months after second dose) "
"CD015530_pub2_data","Analysis.name","Adverse events of any grade (up to 6 months after second dose)"
"CD015530_pub2_data","Analysis.name","Serious adverse events (up to 6 months after second dose)"
"CD015530_pub2_data","Analysis.name","Incidence of COVID-19 (up to median 3.1 months from vaccination)"
"CD015530_pub2_data","Analysis.name","Incidence of influenza (within the 2015 to 2016 flu season)"
"CD015532_data","Analysis.group","1"
"CD015532_data","Analysis.group","2"
"CD015532_data","Analysis.group","3"
"CD015532_data","Analysis.group","4"
"CD015532_data","Analysis.group","5"
"CD015532_data","Analysis.name","Overall mortality"
"CD015532_data","Analysis.name","Duration to liberation from invasive mechanical ventilation"
"CD015532_data","Analysis.name","Adverse events"
"CD015532_data","Analysis.name","Ventilator-associated pneumonia"
"CD015532_data","Analysis.name","Postoperative bleeding"
"CD015532_data","Analysis.name","Airway obstruction"
"CD015532_data","Analysis.name","ICU length of stay"
"CD015532_data","Analysis.name","28-day (± 2) mortality"
"CD015532_data","Analysis.name","90-day mortality"
"CD015532_data","Analysis.name","Mortality (time to event)"
"CD015532_data","Analysis.name","Duration to decannulation"
"CD015532_data","Analysis.name","Tracheal stenosis"
"CD015532_data","Analysis.name","Ventilatory problems"
"CD015532_data","Analysis.name","In-hospital mortality"
"CD015532_data","Analysis.name","60-day mortality"
"CD015532_data","Analysis.name","Liberation from mechanical ventilation"
"CD015532_data","Analysis.name","Need for renal replacement therapy"
"CD015532_data","Analysis.name","Need for ECMO"
"CD015532_data","Analysis.name","Hospital length of stay"
"CD015532_data","Analysis.name","Overall mortality and in-hospital mortality"
"CD015532_data","Analysis.name","60-day (± 3) mortality"
"CD015532_data","Analysis.name","90-day (± 1) mortality"
"CD015532_data","Analysis.name","Liberation from invasive mechanical ventilation"
"CD015532_data","Analysis.name","Need for ECMO "
"CD015532_data","Analysis.name","Time to liberation from invasive mechanical ventilation"
"CD015532_data","Subgroup","Early ≤ 14 (± 1) days vs late > 14 (± 1) days"
"CD015532_data","Subgroup","Early ≤ 21 days vs late > 21 days"
"CD015532_data","Subgroup","RCT: early ≤ 10 days vs late > 10 days"
"CD015532_data","Subgroup","Early ≤ 7 days vs late > 7 days"
"CD015532_data","Subgroup","Early ≤ 10 days vs late > 10 days"
"CD015532_data","Subgroup","Early ≤ 12 days vs late > 12 days"
"CD015532_data","Subgroup","Early ≤ 14 (±1) days vs late > 14 (±1) days"
"CD015532_data","Subgroup","PP"
"CD015532_data","Subgroup","ITT"
"CD015536_pub2_data","Analysis.group","1"
"CD015536_pub2_data","Analysis.group","2"
"CD015536_pub2_data","Analysis.group","3"
"CD015536_pub2_data","Analysis.name","All-cause mortality"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events"
"CD015536_pub2_data","Analysis.name","Mortality due to hepatitis B-related liver disease"
"CD015536_pub2_data","Analysis.name","Proportion of people with non-serious adverse events"
"CD015536_pub2_data","Analysis.name","Proportion of people without histological improvement"
"CD015536_pub2_data","Analysis.name","Proportion of people with detectable HBsAg"
"CD015536_pub2_data","Analysis.name","Proportion of people with detectable HBV-DNA"
"CD015536_pub2_data","Analysis.name","Proportion of people with detectable HBeAg"
"CD015536_pub2_data","Analysis.name","Proportion of people without HBeAg seroconversion"
"CD015536_pub2_data","Analysis.name","Proportion of people without normalisation of transaminases"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (risk of bias)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (age of participants)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (history of treatment with other antivirals)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (co-interventions)"
"CD015536_pub2_data","Analysis.name","All-cause mortality (conducting the analyses according to the 'best-worst' case scenario)"
"CD015536_pub2_data","Analysis.name","All-cause mortality (conducting the analyses according to the 'worst-best' case scenario)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (restricting the analysis to trials at low risk of bias)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (restricting the analysis to treatment-naïve participants)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (restricting the analysis to no industry-funded trials)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (restricting the analysis to trials with no mixed populations)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (conducting the analyses with fixed-effect model)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (restricting the analysis to trial with no missing data (if the missing data were thought to introduce serious bias))"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (conducting the analyses according to the 'best-worst' case scenario)"
"CD015536_pub2_data","Analysis.name","Proportion of people with serious adverse events (conducting the analyses according to the 'worst-best' case scenario)"
"CD015536_pub2_data","Subgroup","Low risk of bias"
"CD015536_pub2_data","Subgroup","Some concerns"
"CD015536_pub2_data","Subgroup","High risk of bias"
"CD015536_pub2_data","Subgroup","Children"
"CD015536_pub2_data","Subgroup","Adults"
"CD015536_pub2_data","Subgroup","Participants with treatment-naïve"
"CD015536_pub2_data","Subgroup","Participants with previous treatment"
"CD015536_pub2_data","Subgroup","With co-interventions"
"CD015536_pub2_data","Subgroup","Without co-interventions"
"CD015551_pub2_data","Analysis.group","1"
"CD015551_pub2_data","Analysis.group","2"
"CD015551_pub2_data","Analysis.group","3"
"CD015551_pub2_data","Analysis.group","4"
"CD015551_pub2_data","Analysis.group","5"
"CD015551_pub2_data","Analysis.name","Incidence of herpes zoster (up to 29.4 months after final dose)"
"CD015551_pub2_data","Analysis.name","All-cause mortality (up to 28 days after final dose)"
"CD015551_pub2_data","Analysis.name","Any-grade adverse events (up to 30 days after final dose)"
"CD015551_pub2_data","Analysis.name","Serious adverse events (up to 30 days after final dose)"
"CD015551_pub2_data","Analysis.name","Localised events at the injection site (up to 30 days after final dose)"
"CD015551_pub2_data","Analysis.name","Systemic events (up to 30 days after final dose)"
"CD015551_pub2_data","Analysis.name","All-cause mortality (up to 15 days post-surgery)"
"CD015551_pub2_data","Analysis.name","Any-grade adverse events (up to 15 days post-surgery)"
"CD015551_pub2_data","Analysis.name","Serious adverse events (up to 15 days post-surgery)"
"CD015551_pub2_data","Analysis.name","Incidence of influenza (within 7 months)"
"CD015551_pub2_data","Analysis.name","All-cause mortality (from 180 days to 3 years post-surgery) (hazard ratio)"
"CD015551_pub2_data","Analysis.name","Any-grade adverse events (up to 118 days after final dose)"
"CD015551_pub2_data","Analysis.name","Incidence of COVID-19 without previous infection (up to 6 months after second dose) "
"CD015551_pub2_data","Analysis.name","Incidence of COVID-19 with and without previous infection (up to 6 months after second dose) "
"CD015551_pub2_data","Analysis.name","Any-grade adverse events (up to 6 months after second dose)"
"CD015551_pub2_data","Analysis.name","Serious adverse events (up to 6 months after second dose)"
"CD015551_pub2_data","Analysis.name","Incidence of COVID-19 (up to 16.3 months after at least one dose) "
"CD015551_pub2_data","Analysis.name","All-cause mortality (up to 16.3 months after at least one dose) "
"CD015573_data","Analysis.group","1"
"CD015573_data","Analysis.group","2"
"CD015573_data","Analysis.name","Recurrence"
"CD015573_data","Analysis.name","Minor complications of treatment"
"CD015573_data","Analysis.name","Complications of treatment"
"CD015573_data","Analysis.name","Duration of hospital stay (days)"
"CD015573_data","Subgroup","Minor complications"
"CD015573_data","Subgroup","Major complications"
"CD015584_pub2_data","Analysis.group","1"
"CD015584_pub2_data","Analysis.group","2"
"CD015584_pub2_data","Analysis.group","3"
"CD015584_pub2_data","Analysis.group","4"
"CD015584_pub2_data","Analysis.name","Pain: during tenaculum placement"
"CD015584_pub2_data","Analysis.name","Pain: during intrauterine device placement"
"CD015584_pub2_data","Analysis.name","Pain: after intrauterine device placement before clinic discharge"
"CD015584_pub2_data","Analysis.name","Providers' ease of placement"
"CD015584_pub2_data","Analysis.name","Need for adjunctive placement measures: cervical dilation"
"CD015584_pub2_data","Analysis.name","Placement success"
"CD015584_pub2_data","Analysis.name","Patient satisfaction with procedure"
"CD015584_pub2_data","Analysis.name","Misoprostol side effects occurring before clinic discharge: preplacement abdominal pain or cramping"
"CD015584_pub2_data","Analysis.name","Misoprostol side effects occurring before clinic discharge: diarrhea"
"CD015584_pub2_data","Analysis.name","Adverse events occurring before clinic discharge: vasovagal reaction"
"CD015584_pub2_data","Analysis.name","Need for adjunctive placement measures: ultrasound guidance"
"CD015584_pub2_data","Analysis.name","Need for adjunctive placement measures: local anesthesia"
"CD015584_pub2_data","Analysis.name","Need for adjunctive placement measures: analgesia"
"CD015584_pub2_data","Analysis.name","Misoprostol side effects occurring before clinic discharge: nausea"
"CD015584_pub2_data","Analysis.name","Misoprostol side effects occurring before clinic discharge: vomiting"
"CD015584_pub2_data","Analysis.name","Adverse events occurring before clinic discharge: uterine perforation"
"CD015584_pub2_data","Analysis.name","Pain: during intrauterine device placement (dichotomous; % moderate/severe pain)"
"CD015584_pub2_data","Analysis.name","Providers' ease of placement (dichotomous; % easy placement)"
"CD015584_pub2_data","Analysis.name","Placement success (restricted to studies with low overall risk of bias)"
"CD015584_pub2_data","Subgroup","No recent failed IUD placement attempt"
"CD015584_pub2_data","Subgroup","Recent failed IUD placement attempt"
"CD015588_pub2_data","Analysis.group","1"
"CD015588_pub2_data","Analysis.group","2"
"CD015588_pub2_data","Analysis.group","3"
"CD015588_pub2_data","Analysis.group","4"
"CD015588_pub2_data","Analysis.group","5"
"CD015588_pub2_data","Analysis.group","6"
"CD015588_pub2_data","Analysis.name","All-cause death"
"CD015588_pub2_data","Analysis.name","All-cause death (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Cardiovascular death"
"CD015588_pub2_data","Analysis.name","Cardiovascular death (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Myocardial infarction"
"CD015588_pub2_data","Analysis.name","Myocardial infarction (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Nonfatal myocardial infarction"
"CD015588_pub2_data","Analysis.name","Nonfatal myocardial infarction (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Fatal myocardial infarction"
"CD015588_pub2_data","Analysis.name","Fatal or nonfatal myocardial infarction"
"CD015588_pub2_data","Analysis.name","Fatal or nonfatal myocardial infarction (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Stroke"
"CD015588_pub2_data","Analysis.name","Stroke (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Nonfatal stroke"
"CD015588_pub2_data","Analysis.name","Nonfatal stroke (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Fatal or nonfatal stroke"
"CD015588_pub2_data","Analysis.name","Fatal or nonfatal stroke (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Kidney failure"
"CD015588_pub2_data","Analysis.name","Kidney failure (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","3P-MACE"
"CD015588_pub2_data","Analysis.name","3P-MACE (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","4P-MACE"
"CD015588_pub2_data","Analysis.name","4P-MACE (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Heart failure"
"CD015588_pub2_data","Analysis.name","Heart failure (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Hospital admission for heart failure"
"CD015588_pub2_data","Analysis.name","Hospital admission for heart failure (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","eGFR"
"CD015588_pub2_data","Analysis.name","Change eGFR"
"CD015588_pub2_data","Analysis.name","Creatinine clearance"
"CD015588_pub2_data","Analysis.name","Doubling of serum creatinine"
"CD015588_pub2_data","Analysis.name","Doubling of serum creatinine (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Kidney composite outcome"
"CD015588_pub2_data","Analysis.name","Kidney composite outcome (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Albuminuria progression (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Moderately increased albuminuria (normo- to microalbuminuria)"
"CD015588_pub2_data","Analysis.name","Severely increased albuminuria (micro- to macroalbuminuria)"
"CD015588_pub2_data","Analysis.name","Albuminuria regression (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Micro- to normoalbuminuria"
"CD015588_pub2_data","Analysis.name","Macro- to normoalbuminuria"
"CD015588_pub2_data","Analysis.name","Macro- to microalbuminuria"
"CD015588_pub2_data","Analysis.name","Hypoglycaemia"
"CD015588_pub2_data","Analysis.name","Hypoglycaemia (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Hypoglycaemia requiring third-party assistance"
"CD015588_pub2_data","Analysis.name","HbA1c [%]"
"CD015588_pub2_data","Analysis.name","Change HbA1c [%]"
"CD015588_pub2_data","Analysis.name","Withdrawn due to adverse events"
"CD015588_pub2_data","Analysis.name","Withdrawn due to adverse events (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Amputation"
"CD015588_pub2_data","Analysis.name","Amputation (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Fracture"
"CD015588_pub2_data","Analysis.name","Fracture (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Genital infection"
"CD015588_pub2_data","Analysis.name","Genital infection (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Diabetic ketoacidosis"
"CD015588_pub2_data","Analysis.name","Diabetic ketoacidosis (Hazard Ratio)"
"CD015588_pub2_data","Analysis.name","Hospitalisation due to heart failure"
"CD015588_pub2_data","Analysis.name","HbA1c"
"CD015588_pub2_data","Analysis.name","Genital mycotic infection"
"CD015588_pub2_data","Subgroup","CKD stages 3-5"
"CD015588_pub2_data","Subgroup","CKD stages 1-2"
"CD015588_pub2_data","Subgroup","All CKD stages"
"CD015588_pub2_data","Subgroup","CKD stage 1-2"
"CD015588_pub2_data","Subgroup","CKD stage 3-5"
"CD015588_pub2_data","Subgroup","Stage 1-2 CKD"
"CD015588_pub2_data","Subgroup","Stage 3-5 CKD"
"CD015588_pub2_data","Subgroup","All-stage CKD"
"CD015592_pub3_data","Analysis.group","1"
"CD015592_pub3_data","Analysis.group","2"
"CD015592_pub3_data","Analysis.name","Successful lumbar puncture procedure at the first attempt"
"CD015592_pub3_data","Analysis.name","Episodes of bradycardia"
"CD015592_pub3_data","Analysis.name","Time to perform the lumbar puncture"
"CD015592_pub3_data","Analysis.name","Episodes of desaturation (decrease of SpO2 to less than 80%)"
"CD015592_pub3_data","Analysis.name","Apnea: number of episodes (interruption of breathing for more than 20 seconds) during the procedure"
"CD015594_pub2_data","Analysis.group","1"
"CD015594_pub2_data","Analysis.name","Neonatal Facial Coding System pain score during the procedure"
"CD015594_pub2_data","Analysis.name","Apnea: occurrence of one or more episodes"
"CD015594_pub2_data","Analysis.name","Adverse events"
"CD015636_pub2_data","Analysis.group","1"
"CD015636_pub2_data","Analysis.group","2"
"CD015636_pub2_data","Analysis.group","3"
"CD015636_pub2_data","Analysis.name","All serotypes"
"CD015636_pub2_data","Analysis.name","Subgroup investigations – dengue virus (DENV) serotype"
"CD015636_pub2_data","Analysis.name","Hospitalizations due to DF or DHF"
"CD015636_pub2_data","Subgroup","All serotypes"
"CD015636_pub2_data","Subgroup","DENV-1 serotype"
"CD015636_pub2_data","Subgroup","DENV-3 serotype"
"CD015636_pub2_data","Subgroup","DENV-4 serotype"
"CD015636_pub2_data","Subgroup","Unknown serotype"
"CD015636_pub2_data","Subgroup","DENV-2 serotype"
"CD015673_pub2_data","Analysis.group","1"
"CD015673_pub2_data","Analysis.group","2"
"CD015673_pub2_data","Analysis.group","3"
"CD015673_pub2_data","Analysis.name","Number of participants with continuous abstinence"
"CD015673_pub2_data","Analysis.name","Number of heavy-drinking participants"
"CD015673_pub2_data","Analysis.name","% Abstinent days"
"CD015673_pub2_data","Analysis.name","% Heavy-drinking days"
"CD015673_pub2_data","Analysis.name","Number of drinks per drinking day"
"CD015673_pub2_data","Analysis.name","Adverse events"
"CD015673_pub2_data","Analysis.name","Serious adverse events"
"CD015673_pub2_data","Analysis.name","Dropouts"
"CD015673_pub2_data","Analysis.name","Dropouts due to adverse events"
"CD015673_pub2_data","Analysis.name","Craving"
"CD015673_pub2_data","Analysis.name","Alcohol-related consequences"
"CD015698_pub2_data","Analysis.group","1"
"CD015698_pub2_data","Analysis.group","2"
"CD015698_pub2_data","Analysis.name","Overall survival (Subgroup analysis: IPC Types)"
"CD015698_pub2_data","Analysis.name","Overall survival (Subgroup analysis: Chemotherapy drugs)"
"CD015698_pub2_data","Analysis.name","Overall survival (Sensitivity analysis: Excluding studies with overall high risk of bias)"
"CD015698_pub2_data","Analysis.name","Disease-free survival"
"CD015698_pub2_data","Analysis.name","Anastomotic leakage (Subgroup analysis: IPC Types)"
"CD015698_pub2_data","Analysis.name","Intra-abdominal abscess"
"CD015698_pub2_data","Analysis.name","Overall survival"
"CD015698_pub2_data","Analysis.name","Serious adverse events"
"CD015698_pub2_data","Analysis.name","Grade III-V toxicities"
"CD015698_pub2_data","Analysis.name","Anastomotic leakage"
"CD015698_pub2_data","Analysis.name","&nbsp;Anastomotic leakage (Sensitivity analysis: Excluding studies with overall high risk of bias)"
"CD015698_pub2_data","Subgroup","HIPEC"
"CD015698_pub2_data","Subgroup","NIPEC"
"CD015698_pub2_data","Subgroup","CDDP + 5-Fu"
"CD015698_pub2_data","Subgroup","CDDP"
"CD015698_pub2_data","Subgroup","5-Fu"
"CD015698_pub2_data","Subgroup","Mitomycin C"
"CD015701_pub2_data","Analysis.group","1"
"CD015701_pub2_data","Analysis.group","2"
"CD015701_pub2_data","Analysis.group","3"
"CD015701_pub2_data","Analysis.group","4"
"CD015701_pub2_data","Analysis.name","HIV acquisition"
"CD015701_pub2_data","Analysis.name","Pregnancy"
"CD015701_pub2_data","Analysis.name","Discontinuation of method"
"CD015701_pub2_data","Analysis.name","Adverse events"
"CD015701_pub2_data","Analysis.name","Amenorrhoea"
"CD015701_pub2_data","Analysis.name","Condomless sexual activity"
"CD015701_pub2_data","Subgroup","DMPA vs IUD"
"CD015701_pub2_data","Subgroup","DMPA/NET-EN vs IUD"
"CD015701_pub2_data","Subgroup","Amenorrhea (by diary)"
"CD015701_pub2_data","Subgroup","Amenorrhea (by interview)"
"CD015701_pub2_data","Subgroup","Condomless Sexual Activity (by diary)"
"CD015701_pub2_data","Subgroup","Condomless Sexual Activity (by interview)"
"CD015711_pub2_data","Analysis.group","1"
"CD015711_pub2_data","Analysis.group","2"
"CD015711_pub2_data","Analysis.group","3"
"CD015711_pub2_data","Analysis.name","Spectacle independence for near vision"
"CD015711_pub2_data","Analysis.name","Spectacle independence for intermediate vision"
"CD015711_pub2_data","Analysis.name","Proportion of overall patient satisfaction with the procedure and its results"
"CD015711_pub2_data","Analysis.name","Frequency of any ocular AE"
"CD015711_pub2_data","Analysis.name","Proportion of participants who required further procedures"
"CD015711_pub2_data","Analysis.name","Proportion of participants achieving 0.0 LogMAR or better for distance vision"
"CD015711_pub2_data","Analysis.name","Proportion of participants achieving 0.2 LogMAR or better for near vision"
"CD015711_pub2_data","Analysis.name","Change in quality of life"
"CD015711_pub2_data","Analysis.name","Mean binocular uncorrected VA (LogMAR)"
"CD015711_pub2_data","Subgroup","Near VA"
"CD015711_pub2_data","Subgroup","Intermediate VA"
"CD015711_pub2_data","Subgroup","Distance VA"
"CD015721_pub2_data","Analysis.group","1"
"CD015721_pub2_data","Analysis.name","Functional independence: mRS score < 3 within 90 days"
"CD015721_pub2_data","Analysis.name","Excellent functional outcome: mRS score < 2 within 90 days"
"CD015721_pub2_data","Analysis.name","Mortality within 90 days"
"CD015721_pub2_data","Analysis.name","Asymptomatic intracranial haemorrhage within 90 days"
"CD015721_pub2_data","Analysis.name","Symptomatic intracranial haemorrhage within 90 days"
"CD015721_pub2_data","Analysis.name","Successful revascularisation: TICI grades 2b to 3"
"CD015721_pub2_data","Analysis.name","Complete revascularisation: TICI grade 3"
"CD015746_pub2_data","Analysis.group","1"
"CD015746_pub2_data","Analysis.group","2"
"CD015746_pub2_data","Analysis.group","3"
"CD015746_pub2_data","Analysis.group","4"
"CD015746_pub2_data","Analysis.group","5"
"CD015746_pub2_data","Analysis.group","6"
"CD015746_pub2_data","Analysis.group","7"
"CD015746_pub2_data","Analysis.group","8"
"CD015746_pub2_data","Analysis.name","Acute typhoid fever"
"CD015746_pub2_data","Analysis.name","All-cause mortality"
"CD015746_pub2_data","Analysis.name","Adverse events"
"CD015746_pub2_data","Analysis.name","Serious adverse events"
"CD015746_pub2_data","Analysis.name","Acute typhoid fever sensitivity analysis for risk of bias and heterogeneity"
"CD015746_pub2_data","Analysis.name","All-cause mortality sensitivity analysis for heterogeneity"
"CD015746_pub2_data","Analysis.name","Adverse events sensitivity analysis for risk of bias"
"CD015746_pub2_data","Analysis.name","Serious adverse events sensitivity analysis for risk of bias and trial phase"
"CD015746_pub2_data","Analysis.name","Acute typhoid fever sensitivity analysis for cRCTs (Mitra 2016)"
"CD015746_pub2_data","Analysis.name","Acute typhoid fever sensitivity analysis for cRCTs (Qadri 2021)"
"CD015746_pub2_data","Analysis.name","All-cause mortality sensitivity analysis for cRCTs (Qadri 2021)"
"CD015746_pub2_data","Analysis.name","Serious adverse events sensitivity analysis for cRCTs (Qadri 2021)"
"CD015746_pub2_data","Analysis.name","Serious adverse events sensitivity analysis for risk of bias or trial phase"
"CD015746_pub2_data","Analysis.name","Adverse events sensitivity analysis for trial phase"
"CD015746_pub2_data","Analysis.name","Adverse events sensitivity analysis for heterogeneity"
"CD015746_pub2_data","Analysis.name","Acute typhoid fever 12 months post vaccination"
"CD015746_pub2_data","Analysis.name","Acute typhoid fever from 12 to 24 months post vaccination"
"CD015746_pub2_data","Analysis.name","Acute typhoid fever ≥ two years post vaccination"
"CD015746_pub2_data","Subgroup","Vi-TT versus no vaccine"
"CD015746_pub2_data","Subgroup","Vi-rEPA versus placebo"
"CD015746_pub2_data","Subgroup","Vi-TT versus Meningococcal A vaccine"
"CD015746_pub2_data","Subgroup","Vi-TT versus Japanese Encephalitis vaccine"
"CD015746_pub2_data","Subgroup","Vi-TT versus Japanese Encephalitis virus vaccine"
"CD015746_pub2_data","Subgroup","Vi-DT versus placebo"
"CD015746_pub2_data","Subgroup","Vi-DT versus Meningococcal A vaccine"
"CD015746_pub2_data","Subgroup","Vi-TT versus ViPS"
"CD015746_pub2_data","Subgroup","Vi-CRM197 versus ViPS"
"CD015746_pub2_data","Subgroup","Vi-DT versus ViPS "
"CD015746_pub2_data","Subgroup","Vi-TT versus Vi-DT"
"CD015746_pub2_data","Subgroup","Vi-TT versus Vi-CRM197"
"CD015746_pub2_data","Subgroup","Vi-TT vs Vi-DT"
"CD015749_pub2_data","Analysis.group","1"
"CD015749_pub2_data","Analysis.group","2"
"CD015749_pub2_data","Analysis.group","3"
"CD015749_pub2_data","Analysis.name","Changes in physical function and strength"
"CD015749_pub2_data","Analysis.name","Occurrence of adverse events"
"CD015749_pub2_data","Analysis.name","Body composition and weight"
"CD015749_pub2_data","Analysis.name","Appetite"
"CD015749_pub2_data","Analysis.name","Fatigue"
"CD015749_pub2_data","Analysis.name","Biochemical markers "
"CD015749_pub2_data","Analysis.name","Quality of life"
"CD015749_pub2_data","Analysis.name","Appetite "
"CD015749_pub2_data","Analysis.name","Survival"
"CD015749_pub2_data","Subgroup","Physical function at 6 weeks"
"CD015749_pub2_data","Subgroup","Strength at 6 weeks"
"CD015749_pub2_data","Subgroup","Weight at 6 weeks"
"CD015749_pub2_data","Subgroup","Body composition at 6 weeks"
"CD015749_pub2_data","Subgroup","Appetite at 6 weeks"
"CD015749_pub2_data","Subgroup","Fatigue at 6 weeks"
"CD015749_pub2_data","Subgroup","Biochemical markers at 6 weeks"
"CD015749_pub2_data","Subgroup","Strength at 4 months"
"CD015749_pub2_data","Subgroup","Physical function at 4 months"
"CD015749_pub2_data","Subgroup","Weight (post intervention/follow-up closest to 6 months)"
"CD015749_pub2_data","Subgroup","Body composition (post intervention/follow-up closest to 6 months)"
"CD015749_pub2_data","Subgroup","Quality of life at 3 months"
"CD015749_pub2_data","Subgroup","Appetite (post intervention/follow-up closest to 6 months)"
"CD015749_pub2_data","Subgroup","Fatigue at 4 months"
"CD015749_pub2_data","Subgroup","Biochemical markers (post intervention/follow-up closest to 6 months)"
"CD015749_pub2_data","Subgroup","Physical function (post intervention/follow-up closest to 6 months)"
"CD015749_pub2_data","Subgroup","Strength (post intervention/follow-up closest to 6 months)"
"CD015749_pub2_data","Subgroup","Weight (follow-up over 10 months (10–24 months))"
"CD015749_pub2_data","Subgroup","Body composition (follow-up over 10 months (10–24 months))"
"CD015749_pub2_data","Subgroup","Quality of life (post intervention/follow-up closest to 6 months)"
"CD015751_pub2_data","Analysis.group","1"
"CD015751_pub2_data","Analysis.group","2"
"CD015751_pub2_data","Analysis.name","Contact lens discomfort"
"CD015751_pub2_data","Analysis.name","Corneal fluorescein staining"
"CD015751_pub2_data","Analysis.name","Conjunctival redness"
"CD015751_pub2_data","Analysis.name","Participant discontinuation"
"CD015751_pub2_data","Analysis.name","Comfortable lens wear time (hours)"
"CD015751_pub2_data","Analysis.name","Other dry eye symptoms"
"CD015751_pub2_data","Subgroup","Postintervention value"
"CD015751_pub2_data","Subgroup","Change"
"CD015751_pub2_data","Subgroup","Depth"
"CD015751_pub2_data","Subgroup","Type"
"CD015751_pub2_data","Subgroup","Extent"
"CD015751_pub2_data","Subgroup","Nasal region"
"CD015751_pub2_data","Subgroup","Temporal region"
"CD015751_pub2_data","Subgroup","SPEED"
"CD015751_pub2_data","Subgroup","Likert scale"
"CD015751_pub2_data","Subgroup","Post-intervention value"
"CD015779_data","Analysis.group","1"
"CD015779_data","Analysis.group","2"
"CD015779_data","Analysis.name","Recurrence of rheumatic fever"
"CD015779_data","Analysis.name","Progression of rheumatic heart disease (latent RHD) "
"CD015779_data","Analysis.name","Progression of rheumatic heart disease (late-stage RHD)"
"CD015779_data","Analysis.name","Cardiac complications"
"CD015779_data","Analysis.name","All-cause mortality (latent RHD)"
"CD015779_data","Analysis.name","All-cause mortality (late-stage RHD)"
"CD015779_data","Analysis.name","Adverse events: anaphylaxis"
"CD015779_data","Analysis.name","Adverse events: sciatic nerve injury"
"CD015779_data","Analysis.name","Adverse events: delayed hypersensitivity or allergic reaction"
"CD015779_data","Analysis.name","Adverse events: local reactions to injection"
"CD015779_data","Analysis.name","Recurrence of rheumatic fever (count, risk ratio)"
"CD015779_data","Analysis.name","Recurrence of rheumatic fever (rate, rate ratio)"
"CD015779_data","Analysis.name","Progression of rheumatic heart disease "
"CD015779_data","Analysis.name","All-cause mortality"
"CD015779_data","Analysis.name","Poor treatment adherence"
"CD015779_data","Subgroup","Oral antibiotics"
"CD015779_data","Subgroup","Intramuscular antibiotics"
"CD015779_data","Subgroup","Recurrence of rheumatic fever including carditis"
"CD015779_data","Subgroup","Recurrence of rheumatic fever without carditis specified"
"CD015786_pub2_data","Analysis.group","1"
"CD015786_pub2_data","Analysis.group","2"
"CD015786_pub2_data","Analysis.group","3"
"CD015786_pub2_data","Analysis.name","Overall survival"
"CD015786_pub2_data","Analysis.name","Progression (disease)-free survival"
"CD015786_pub2_data","Analysis.name","Early adverse effects"
"CD015786_pub2_data","Analysis.name","Late adverse effects"
"CD015786_pub2_data","Analysis.name","Surgically related mortality "
"CD015786_pub2_data","Analysis.name","Quality of life (functional) 6 months postsurgery"
"CD015786_pub2_data","Analysis.name","Quality of life (functional) 12 months postsurgery"
"CD015786_pub2_data","Subgroup","Unadjusted data"
"CD015786_pub2_data","Subgroup","Adjusted data for age, etc."
"CD015786_pub2_data","Subgroup","Direct surgical morbidity"
"CD015786_pub2_data","Subgroup","Surgically-related systemic morbidity"
"CD015786_pub2_data","Subgroup","Blood transfusion"
"CD015786_pub2_data","Subgroup","Lymphoedema"
"CD015786_pub2_data","Subgroup","Lymphocyst"
"CD015786_pub2_data","Subgroup","Direct surgical morbidity: wound infection"
"CD015786_pub2_data","Subgroup","Direct surgical morbidity: vaginal bleeding"
"CD015786_pub2_data","Subgroup","Direct surgical morbidity: abdominal wall haematoma"
"CD015786_pub2_data","Subgroup","Direct surgical morbidity: skin dehiscence"
"CD015786_pub2_data","Subgroup","Direct surgical morbidity: intense acute pain"
"CD015786_pub2_data","Subgroup","Direct surgical morbidity: vascular complications"
"CD015786_pub2_data","Subgroup","Surgical-related systemic morbidity: urinary tract infection"
"CD015786_pub2_data","Subgroup","Surgical-related systemic morbidity: faecaloma"
"CD015786_pub2_data","Subgroup","Surgical-related systemic morbidity: sepsis"
"CD015786_pub2_data","Subgroup","Surgical-related systemic morbidity: neuropathic pain"
"CD015786_pub2_data","Subgroup","Surgical-related systemic morbidity"
"CD015788_pub2_data","Analysis.group","1"
"CD015788_pub2_data","Analysis.name","Difference in mean change in adherence"
"CD015788_pub2_data","Analysis.name","Difference in final mean adherence"
"CD015788_pub2_data","Analysis.name","Proportion of participants who were adherent"
"CD015788_pub2_data","Analysis.name","Change in intraocular pressure (IOP) mmHg"
"CD015788_pub2_data","Analysis.name","Visual field"
"CD015788_pub2_data","Subgroup","Three components (education + two or more components with or without standard) versus standard care alone or with single interventions"
"CD015788_pub2_data","Subgroup","Two components (education + reminders with or without standard) versus standard care alone"
"CD015788_pub2_data","Subgroup","Two components (education + education with or without standard) versus standard care alone"
"CD015788_pub2_data","Subgroup","Two components (education + other with or without standard) versus standard care alone"
"CD015788_pub2_data","Subgroup","Three or more components (education + two or more components with or without standard] versus standard care alone or with single interventions"
"CD015788_pub2_data","Subgroup","Two components (education + device with or without standard) versus standard care alone"
"CD015788_pub2_data","Subgroup","Three or more components (education + two or more with or without standard) versus standard care alone or with single interventions"
"CD015788_pub2_data","Subgroup","Two components (education + other with or without standard) versus standard care or other interventions"
"CD015788_pub2_data","Subgroup","Two components (device + other with or without standard) versus standard care or other interventions"
"CD015790_pub2_data","Analysis.group","1"
"CD015790_pub2_data","Analysis.name","Overall health-related quality of life – change score"
"CD015790_pub2_data","Analysis.name","Overall health-related quality of life – final value"
"CD015790_pub2_data","Analysis.name","Overall vision-related quality of life – change score"
"CD015790_pub2_data","Analysis.name","Overall vision-related quality of life – final value"
"CD015790_pub2_data","Analysis.name","Proportion of participants who experienced any adverse events"
"CD015790_pub2_data","Analysis.name","QOL subscore: psychological well-being, emotional distress, depression and anxiety-change score"
"CD015790_pub2_data","Analysis.name","QOL subscore: psychological well-being, emotional distress, depression and anxiety-final value"
"CD015790_pub2_data","Analysis.name","QOL subscore: physical functioning-change score"
"CD015790_pub2_data","Analysis.name","QOL subscore: physical functioning-final value"
"CD015790_pub2_data","Analysis.name","QOL subscore: self-efficacy-change score"
"CD015790_pub2_data","Analysis.name","QOL subscore: self-efficacy-final value"
"CD015790_pub2_data","Analysis.name","QOL subscore: adaptation to vision loss-final value"
"CD015790_pub2_data","Analysis.name","Reading speed"
"CD015790_pub2_data","Subgroup","Self-management intervention versus waiting list or no care: change score"
"CD015790_pub2_data","Subgroup","Self-management intervention versus active comparator: change score"
"CD015790_pub2_data","Subgroup","Self-management intervention versus active comparator: final values"
"CD015790_pub2_data","Subgroup","Self-management intervention versus waiting list or no care: final value"
"CD015790_pub2_data","Subgroup","Self-management intervention versus active comparator: final value"
"CD015790_pub2_data","Subgroup","Self-management intervention versus waiting list or no care"
"CD015790_pub2_data","Subgroup","Self-management intervention versus active comparator"
"CD015802_pub2_data","Analysis.group","1"
"CD015802_pub2_data","Analysis.group","2"
"CD015802_pub2_data","Analysis.name","Intermittent hypoxemia (IH): number of episodes in the 7 days after treatment discontinued"
"CD015802_pub2_data","Analysis.name","All-cause mortality prior to hospital discharge"
"CD015802_pub2_data","Analysis.name","Apnea: number of infants with at least 1 episode (interruption of breathing for more than 20 seconds, or as defined by the authors) in the 7 days after treatment discontinued"
"CD015802_pub2_data","Analysis.name","IH: number of infants with at least 1 episode in the 7 days after treatment discontinued"
"CD015804_pub2_data","Analysis.group","1"
"CD015804_pub2_data","Analysis.name","Change from baseline in best-corrected visual acuity (BCVA) at 8 to 12 weeks"
"CD015804_pub2_data","Analysis.name","Proportion of participants who lost fewer than 15 letters in BCVA from baseline at 24 to 48 weeks"
"CD015804_pub2_data","Analysis.name","Proportion of participants who experienced at least one serious ocular adverse event (AE) during the study period"
"CD015804_pub2_data","Analysis.name","Change from baseline in central subfield thickness (CST) at 4 to 12 weeks"
"CD015804_pub2_data","Analysis.name","Proportion of participants with a visual acuity Snellen equivalent of 20/40 or better at 24 to 48 weeks"
"CD015804_pub2_data","Analysis.name","Change from baseline in the subscale and composite scores NEI-VFQ-25 at 24 to 48 weeks"
"CD015804_pub2_data","Analysis.name","Proportion of participants who experienced at least one serious non-ocular AE during the study period"
"CD015804_pub2_data","Analysis.name","Proportion of participants who experienced TEAEs during the study period"
"CD015804_pub2_data","Analysis.name","Proportion of participants who experienced TEAEs leading to investigational product discontinuation or death"
"CD015804_pub2_data","Analysis.name","The cumulative incidence of antidrug antibodies (ADAs) during the study period"
"CD015804_pub2_data","Analysis.name","Mean maximum serum concentration after first injection (ng/mL)"
"CD015804_pub2_data","Analysis.name","Mean trough serum concentration after first injection (pg/mL)"
"CD015804_pub2_data","Subgroup","Aflibercept biosimilar versus reference aflibercept"
"CD015804_pub2_data","Subgroup","Ranibizumab biosimilar versus reference ranibizumab"
"CD015804_pub2_data","Subgroup","Aflibercept biosimiar versus reference aflibercept"
"CD015820_pub2_data","Analysis.group","1"
"CD015820_pub2_data","Analysis.group","2"
"CD015820_pub2_data","Analysis.group","3"
"CD015820_pub2_data","Analysis.group","4"
"CD015820_pub2_data","Analysis.name","Objective adherence (1 week to 3 months)"
"CD015820_pub2_data","Analysis.name","Subjective adherence (3 to 6 months) - subjective physician assessment % adherence"
"CD015820_pub2_data","Analysis.name","Subjective adherence (3 to 6 months) - 8‐Item Medication Adherence Scale self-reported questionnaire"
"CD015820_pub2_data","Analysis.name","Total hours of adherence (Baseline to 3 months)"
"CD015820_pub2_data","Analysis.name","Visual acuity (1 week to 3 months)"
"CD015820_pub2_data","Analysis.name","Visual acuity > 4 months - Proportion of participants with significant change"
"CD015820_pub2_data","Analysis.name","Stereoacuity (1 week to 3 months)"
"CD015820_pub2_data","Analysis.name","Adverse events"
"CD015820_pub2_data","Analysis.name","Visual acuity (at 3 months) - percentage of visual deficit corrected"
"CD015820_pub2_data","Analysis.name","Subjective adherence (1 week to 3 months) - 5-point scale"
"CD015820_pub2_data","Analysis.name","Stereoacuity (1 week to 10 weeks)"
"CD015820_pub2_data","Analysis.name","Stereoacuity (baseline to 3 months)"
"CD015820_pub2_data","Analysis.name","Subjective adherence (4 to 6 months)"
"CD015820_pub2_data","Analysis.name","Visual acuity (4 to 6 months)"
"CD015824_pub2_data","Analysis.group","1"
"CD015824_pub2_data","Analysis.group","2"
"CD015824_pub2_data","Analysis.group","3"
"CD015824_pub2_data","Analysis.name","Clinical worsening"
"CD015824_pub2_data","Analysis.name","Mortality"
"CD015824_pub2_data","Analysis.name","Hospitalisation"
"CD015824_pub2_data","Analysis.name","Change from baseline in 6-minute walk distance (6MWD) (subgroups with different formulations)"
"CD015824_pub2_data","Analysis.name","Change from baseline in 6MWD (subgroups with different study durations)"
"CD015824_pub2_data","Analysis.name","Worsening in World Health Organization functional class "
"CD015824_pub2_data","Analysis.name","Change from baseline in Borg Dyspnea Scale"
"CD015824_pub2_data","Analysis.name","Serious adverse events"
"CD015824_pub2_data","Analysis.name","Withdrawal from the trial"
"CD015824_pub2_data","Analysis.name","Change from baseline in 6-minute walk distance (6MWT) (subgroups with different formulations)"
"CD015824_pub2_data","Analysis.name","Change from baseline in 6-minute walk distance (6MWD)"
"CD015824_pub2_data","Analysis.name","Worsening in World Health Organization functional class"
"CD015824_pub2_data","Subgroup","Combination therapy versus ambrisentan"
"CD015824_pub2_data","Subgroup","Combination therapy versus bosentan"
"CD015824_pub2_data","Subgroup","Combination therapy versus macitentan"
"CD015824_pub2_data","Subgroup","Change from baseline in 6MWD at 3 months"
"CD015824_pub2_data","Subgroup","Change from baseline in 6MWD at 6 months"
"CD015824_pub2_data","Subgroup","Combination therapy versus sildenafil"
"CD015824_pub2_data","Subgroup","Combination therapy versus tadalafil"
"CD015824_pub2_data","Subgroup","Combination therapy versus PDE5is"
"CD015830_pub2_data","Analysis.group","1"
"CD015830_pub2_data","Analysis.name","Duration of delirium"
"CD015830_pub2_data","Analysis.name","Mortality in the ICU"
"CD015830_pub2_data","Analysis.name","ICUs length of stay"
"CD015830_pub2_data","Analysis.name","Hospital length of stay"
"CD015849_pub2_data","Analysis.group","1"
"CD015849_pub2_data","Analysis.group","2"
"CD015849_pub2_data","Analysis.group","3"
"CD015849_pub2_data","Analysis.group","4"
"CD015849_pub2_data","Analysis.group","5"
"CD015849_pub2_data","Analysis.group","6"
"CD015849_pub2_data","Analysis.group","8"
"CD015849_pub2_data","Analysis.group","9"
"CD015849_pub2_data","Analysis.group","10"
"CD015849_pub2_data","Analysis.group","11"
"CD015849_pub2_data","Analysis.name","All-cause death"
"CD015849_pub2_data","Analysis.name","All-cause death (Hazard ratio) "
"CD015849_pub2_data","Analysis.name","Cardiovascular death"
"CD015849_pub2_data","Analysis.name","Cardiovascular death (Hazard ratio) "
"CD015849_pub2_data","Analysis.name","3-point MACE"
"CD015849_pub2_data","Analysis.name","3-point MACE (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","4-point MACE"
"CD015849_pub2_data","Analysis.name","4-point MACE (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Kidney failure"
"CD015849_pub2_data","Analysis.name","Kidney failure (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Composite kidney outcome"
"CD015849_pub2_data","Analysis.name","Composite kidney outcome (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Severe hypoglycaemia"
"CD015849_pub2_data","Analysis.name","Severe hypoglycaemia (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Nonfatal myocardial infarction"
"CD015849_pub2_data","Analysis.name","Nonfatal myocardial infarction (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Fatal myocardial infarction"
"CD015849_pub2_data","Analysis.name","Myocardial infarction (undefined)"
"CD015849_pub2_data","Analysis.name","Fatal or nonfatal myocardial infarction"
"CD015849_pub2_data","Analysis.name","All myocardial infarction (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Nonfatal stroke"
"CD015849_pub2_data","Analysis.name","Nonfatal stroke (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Fatal or nonfatal stroke"
"CD015849_pub2_data","Analysis.name","Fatal or nonfatal stroke (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Ischaemic stroke"
"CD015849_pub2_data","Analysis.name","Haemorrhagic stroke"
"CD015849_pub2_data","Analysis.name","Heart failure"
"CD015849_pub2_data","Analysis.name","Hospitalisation due to heart failure"
"CD015849_pub2_data","Analysis.name","Hospitalisation due to heart failure (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Change in eGFR [%]"
"CD015849_pub2_data","Analysis.name","Increased urinary albumin-creatinine ratio"
"CD015849_pub2_data","Analysis.name","Body weight [kg]"
"CD015849_pub2_data","Analysis.name","Change in body weight [kg]"
"CD015849_pub2_data","Analysis.name","BMI [kg/m2]"
"CD015849_pub2_data","Analysis.name","Change in BMI [kg/m2]"
"CD015849_pub2_data","Analysis.name","Serious adverse events"
"CD015849_pub2_data","Analysis.name","Withdrawal due to adverse events"
"CD015849_pub2_data","Analysis.name","Withdrawal due to adverse events (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Hypoglycaemia"
"CD015849_pub2_data","Analysis.name","Lactic acidosis"
"CD015849_pub2_data","Analysis.name","Acute kidney injury"
"CD015849_pub2_data","Analysis.name","Acute kidney injury (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Diabetic ketoacidosis"
"CD015849_pub2_data","Analysis.name","HbA1c [%]"
"CD015849_pub2_data","Analysis.name","Change in HbA1c [%]"
"CD015849_pub2_data","Analysis.name","Coronary revascularisation"
"CD015849_pub2_data","Analysis.name","Coronary revascularisation (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Urinary albumin-creatinine ratio [mg/g]"
"CD015849_pub2_data","Analysis.name","Microalbuminuria [mg/L]"
"CD015849_pub2_data","Analysis.name","Urinary albumin excretion rate [µg/min]"
"CD015849_pub2_data","Analysis.name","Fatal stroke"
"CD015849_pub2_data","Analysis.name","All-cause death (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Cardiovascular death (Hazard ratio)"
"CD015849_pub2_data","Analysis.name","Myocardial infarction"
"CD015849_pub2_data","Analysis.name","Change in eGFR [mL/min]"
"CD015849_pub2_data","Analysis.name","eGFR loss"
"CD015849_pub2_data","Analysis.name","Change in creatinine clearance [mL/min]"
"CD015849_pub2_data","Analysis.name","Urinary albumin-creatinine ratio [%]"
"CD015849_pub2_data","Analysis.name","Urinary albumin excretion rate [%]"
"CD015849_pub2_data","Analysis.name","Urinary albumin excretion rate [mg/24 h]"
"CD015849_pub2_data","Analysis.name","Body weight increase"
"CD015849_pub2_data","Analysis.name","Change in HbA1c [mmol/mol]"
"CD015849_pub2_data","Analysis.name","HbA1c  [%]"
"CD015849_pub2_data","Subgroup","CKD stages 3-5"
"CD015849_pub2_data","Subgroup","Dialysis (HD/PD)"
"CD015849_pub2_data","Subgroup","All CKD stages"
"CD015849_pub2_data","Subgroup","CKD stages 1-2"
"CD015849_pub2_data","Subgroup","CKD stages 1-2 "
"CD015854_data","Analysis.group","1"
"CD015854_data","Analysis.group","2"
"CD015854_data","Analysis.group","3"
"CD015854_data","Analysis.group","4"
"CD015854_data","Analysis.group","5"
"CD015854_data","Analysis.group","6"
"CD015854_data","Analysis.group","7"
"CD015854_data","Analysis.group","8"
"CD015854_data","Analysis.group","9"
"CD015854_data","Analysis.group","10"
"CD015854_data","Analysis.name","Achievement of definitions of improvement (assessed with IMACS DOI, measured at 8 weeks) "
"CD015854_data","Analysis.name","Withdrawals for either lack of benefit or adverse events"
"CD015854_data","Analysis.name","Improvement in function or disability (assessed with change in Health Assessment Questionnaire) "
"CD015854_data","Analysis.name","Improvement of muscle strength (assessed with change in MMT8)"
"CD015854_data","Analysis.name","Improvement in muscle strength (assessed with change in MMT8) (GIV analysis)"
"CD015854_data","Analysis.name","Achievement of definitions of improvement (assessed with IMACS DOI) "
"CD015854_data","Analysis.name","Achievement of definitions of improvement (assessed with moderate or major improvement on Total Improvement Score (TIS))"
"CD015854_data","Analysis.name","Serious adverse event"
"CD015854_data","Analysis.name","Improvement of function or disability (assessed with change in Health Assessment Questionnaire) "
"CD015854_data","Analysis.name","Improvement in function or disability (assessed with change in triple Timed Up and Go test; 3TUG) "
"CD015854_data","Analysis.name","Improvement in muscle strength (assessed with change in muscle strength score) "
"CD015854_data","Analysis.name","Achievement of definitions of improvement (assessed with minimal improvement on Total Improvement Score (TIS), measured at 8 weeks)"
"CD015854_data","Analysis.name","Change in skin disease activity (assessed with change in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI))"
"CD015854_data","Analysis.name","Improvement of muscle strength (assessed with the achievement of > 15% improvement in muscle strength (MMT-8))"
"CD015854_data","Analysis.name","Improvement of function or disability (assessed with change in disability according to PROMIS physical function)"
"CD015854_data","Analysis.name","Achievement of definitions of improvement (assessed with minimal improvement on Total Improvement Score)"
"CD015854_data","Analysis.name","Change in skin disease activity (assessed with clinically meaningful improvement in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity scores)"
"CD015854_data","Analysis.name","Change in skin disease activity (assessed with change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI))"
"CD015854_data","Analysis.name","Improvement of function of disability (assessed with change of six-minute walking distance, measured at 12 weeks) "
"CD015854_data","Analysis.name","Improvement of function or disability (assessed with change of six-minute walking distance, measured at 6 months) "
"CD015854_data","Analysis.name","Improvement of muscle strength (assessed with change in MMT24, measured at 12 weeks)"
"CD015854_data","Analysis.name","Improvement of muscle strength (assessed with change in MMT24, measured at 6 months)"
"CD015854_data","Analysis.name","Achievement of definitions of improvement (assessed with IMACS DOI)"
"CD015854_data","Analysis.name","Achievement of definitions of improvement (assessed with minimal improvement on Total Improvement Score (TIS))"
"CD015854_data","Analysis.name","Improvement of function or disability (assessed with achievement of > 20% improvement on Health Assessment Questionnaire)"
"CD015854_data","Analysis.name","Improvement of function or disability (assessed with change in Health Assessment Questionnaire (HAQ))"
"CD015854_data","Analysis.name","Improvement of muscle strength (assessed with achievement of ≥ 15% improvement in muscle strength) "
"CD015854_data","Analysis.name","Improvement of muscle strength (assessed with change in muscle strength (range of scale 0 to 130))"
"CD015854_data","Analysis.name","Improvement of muscle strength (assessed with change in MMT8, range 0 to 150) "
"CD015854_data","Analysis.name","Improvement of muscle strength (assessed with change in SMD)"
"CD015854_data","Analysis.name","Change in skin disease activity (assessed with change in the modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI))"
"CD015854_data","Subgroup","Abatacept immediate vs placebo (at 3 or 6 months)"
"CD015854_data","Subgroup","Abatacept immediate vs abatacept delayed at 6 months"
"CD015854_data","Subgroup","Zilucoplan"
"CD015854_data","Subgroup","Eculizumab"
"CD015854_data","Subgroup","Low dose (0.6 mg/kg)"
"CD015854_data","Subgroup","High dose (1.8 mg/kg)"
"CD015854_data","Subgroup","Dermatomyositis "
"CD015854_data","Subgroup","Polymyositis "
"CD015854_data","Subgroup","Necrotising autoimmune myopathy"
"CD015854_data","Subgroup","Lebanasum 20 mg twice daily"
"CD015854_data","Subgroup","Lenabasum 5 mg twice daily"
"CD015854_data","Subgroup","Lenabasum 20 mg "
"CD015854_data","Subgroup","Lenabasam 20 mg "
"CD015854_data","Subgroup","Lenabasam 5 mg twice daily"
"CD015854_data","Subgroup","Lenabasum 20 mg"
"CD015854_data","Subgroup","Siponimod 2 mg "
"CD015854_data","Subgroup","Siponimod 10 mg "
"CD015854_data","Subgroup","0.5 mg"
"CD015854_data","Subgroup","2 mg"
"CD015854_data","Subgroup","10 mg"
"CD015854_data","Subgroup","Siponimod 0.5 mg "
"CD015854_data","Subgroup","Siponimod dosage 0.5 mg "
"CD015854_data","Subgroup","Siponimod dosage 2 mg "
"CD015854_data","Subgroup","Siponimod dosage 10 mg "
"CD015854_data","Subgroup","Etanercept week 24"
"CD015854_data","Subgroup","Infliximab week 16"
"CD015854_data","Subgroup","Infliximab"
"CD015854_data","Subgroup","Etanercept"
"CD015855_data","Analysis.group","1"
"CD015855_data","Analysis.group","2"
"CD015855_data","Analysis.group","3"
"CD015855_data","Analysis.group","4"
"CD015855_data","Analysis.group","5"
"CD015855_data","Analysis.group","6"
"CD015855_data","Analysis.group","7"
"CD015855_data","Analysis.group","8"
"CD015855_data","Analysis.group","9"
"CD015855_data","Analysis.group","10"
"CD015855_data","Analysis.group","11"
"CD015855_data","Analysis.group","12"
"CD015855_data","Analysis.name","Improvement in function or disability (assessed with change in NSS, ADL and HAQ) "
"CD015855_data","Analysis.name","Improvement in function or disability (SMD)"
"CD015855_data","Analysis.name","Improvement of muscle strength (assessed with achievement of meaningful improvement in muscle strength defined using the modified BMRC index) "
"CD015855_data","Analysis.name","Improvement of muscle strength (assessed with change in MMT or other validated muscle score)"
"CD015855_data","Analysis.name","Achievement of definitions of improvement (assessed with minimal improvement on Total Improvement Score (TIS)) "
"CD015855_data","Analysis.name","Change in skin disease activity (assessed with change in the CDASI) "
"CD015855_data","Analysis.name","Serious adverse event"
"CD015855_data","Analysis.name","Withdrawals for either lack of benefit or adverse events"
"CD015855_data","Analysis.name","Improvement of muscle strength (assessed with achievement of  ≥ 15% improvement in muscle strength)"
"CD015855_data","Analysis.name","Improvement in muscle strength (assessed with change in muscle strength)"
"CD015855_data","Analysis.name","Cumulative corticosteroid dose (mg/kg)"
"CD015855_data","Analysis.name","Improvement of function or disability (assessed with change in Functional Rating Scale (FRS))"
"CD015855_data","Analysis.name","Improvement in function or disability (assessed with change in 30 metre walking time)"
"CD015855_data","Analysis.name","Improvement of muscle strength (assessed with change in Manual Muscle Testing)"
"CD015855_data","Analysis.name","Achievement of definitions of improvement"
"CD015855_data","Analysis.name","Withdrawals for either lack of benefit or adverse events "
"CD015855_data","Analysis.name","Improvement in function or disability (assessed with change in 10 metre walk time)"
"CD015855_data","Analysis.name","Improvement of muscle strength (assessed with achievement of > 15% improvement in hand held myometry)"
"CD015855_data","Analysis.name","Improvement of muscle strength (assessed with mean change in summed myometry)"
"CD015855_data","Analysis.name","Cumulative corticosteroid dose "
"CD015855_data","Analysis.name","Improvement of function or disability (assessed with change in the Functional Rating Scale (FRS))"
"CD015855_data","Analysis.name","Improvement of function or disability (assessed with change in 30 metre walking time)"
"CD015855_data","Analysis.name","Withdrawals for either lack of benefit or adverse events  "
"CD015855_data","Analysis.name","Adverse events "
"CD015855_data","Analysis.name","Improvement in muscle strength (assessed with change in Manual Muscle Testing) "
"CD015855_data","Analysis.name","Improvement in function or disability (assessed with achievement of improvement in ADL (combined evaluation of strength and function))"
"CD015855_data","Analysis.name","Adverse events"
"CD015855_data","Subgroup","NSS"
"CD015855_data","Subgroup","ADL score "
"CD015855_data","Subgroup","HAQ"
"CD015855_data","Subgroup","ADL score"
"CD015855_data","Subgroup","MMT (potential score 0 to 90)"
"CD015855_data","Subgroup","MMT-8 (potential score 0 to 150)"
"CD015855_data","Subgroup","CDASI Total Activity Score"
"CD015855_data","Subgroup","CDASI Total Damage Score"
"CD015855_data","Subgroup","Achievement of at least minimal improvement (PRINTO definition)"
"CD015855_data","Subgroup","Achievement of at least minimal improvement (Total Improvement Score; 2016 ACR-EULAR Response Criteria)"
"CD015855_data","Subgroup","Achievement of IMACS DOI "
"CD015855_data","Subgroup","6 months"
"CD015855_data","Subgroup","12 months"
"CD015855_data","Subgroup","Time point unclear"
"CD015875_data","Analysis.group","1"
"CD015875_data","Analysis.group","2"
"CD015875_data","Analysis.group","3"
"CD015875_data","Analysis.group","4"
"CD015875_data","Analysis.group","5"
"CD015875_data","Analysis.group","6"
"CD015875_data","Analysis.group","7"
"CD015875_data","Analysis.group","8"
"CD015875_data","Analysis.name","Body Mass Index (kg/m2) (10 to 19 years)"
"CD015875_data","Analysis.name","Weight (kg) (10 to 19 years)"
"CD015875_data","Analysis.name","Waist circumference (cm) (10 to 19 years)"
"CD015875_data","Analysis.name","Total Body Fat Percentage (%TBF) (10 to 19 years)"
"CD015875_data","Analysis.name","Systolic blood pressure (mmHg) (10 to 19 years) "
"CD015875_data","Analysis.name","Diastolic blood pressure (mmHg) (10 to 19 years) "
"CD015875_data","Analysis.name","Adverse events (10 to 19 years) "
"CD015875_data","Analysis.name","BMI Z-scores (10 to 19 years)"
"CD015875_data","Analysis.name","BMI percentile (10 to 19 years)"
"CD015875_data","Analysis.name","Hip circumference (cm) (10 to 19 years)"
"CD015875_data","Analysis.name","Waist-to-hip ratio (10 to 19 years)"
"CD015875_data","Analysis.name","Skinfolds (mm) (10 to 19 years)"
"CD015875_data","Analysis.name","Total fat mass (kg) (10 to 19 years)"
"CD015875_data","Analysis.name","Total lean mass (kg) (10 to 19 years)"
"CD015875_data","Analysis.name","Trunk-fat mass (kg) (10 to 19 years)"
"CD015875_data","Analysis.name","Trunk lean mass (kg) (10 to 19 years)"
"CD015875_data","Analysis.name","Trunk adiposity (%) (10 to 19 years)"
"CD015875_data","Analysis.name","Visceral adipose tissue (L) (10 to 19 years)"
"CD015875_data","Analysis.name","Subcutaneous adipose tissue (L) (10 to 19 years)"
"CD015875_data","Analysis.name","Liver adiposity (%) (10 to 19 years)"
"CD015875_data","Analysis.name","Fasting insulin (uIU/mL) (10 to 19 years)"
"CD015875_data","Analysis.name","HOMA-IR (10 to 19 years)"
"CD015875_data","Analysis.name","Fasting glucose (mg/dL) (10 to 19 years)"
"CD015875_data","Analysis.name","Total cholesterol (mg/dL) (10 to 19 years)"
"CD015875_data","Analysis.name","LDL cholesterol (mg/dL) (10 to 19 years)"
"CD015875_data","Analysis.name","HDL cholesterol (mg/dL) (10 to 19 years)"
"CD015875_data","Analysis.name","Triglycerides (mg/dL) (10 to 19 years)"
"CD015875_data","Analysis.name","Free fatty acids (10 to 19 years)"
"CD015875_data","Analysis.name","Ghrelin (10 to 19 years)"
"CD015875_data","Analysis.name","Leptin (10 to 19 years)"
"CD015875_data","Analysis.name","PYY (10 to 19 years)"
"CD015875_data","Analysis.name","GLP1 active (10 to 19 years)"
"CD015875_data","Analysis.name","GLP1 total (10 to 19 years)"
"CD015875_data","Analysis.name","Systolic blood pressure (mmHg) (10 to 19 years)"
"CD015875_data","Analysis.name","Diastolic blood pressure (mmHg) (10 to 19 years)"
"CD015875_data","Analysis.name","Adverse events (10 to 19 years)"
"CD015875_data","Analysis.name","BMI Z-score (10 to 19 years)"
"CD015875_data","Analysis.name","Abnormal glycaemia (10 to 19 years)"
"CD015875_data","Analysis.name","Dyslipidaemia (10 to 19 years)"
"CD015875_data","Analysis.name","Metabolic syndrome (10 to 19 years) "
"CD015875_data","Analysis.name","HbA1c (%) (10 to 19 years)"
"CD015875_data","Analysis.name","Cholesterol (mg/dL) (10 to 19 years)"
"CD015875_data","Analysis.name","Phospholipids (mg/g) (10 to 19 years)"
"CD015875_data","Analysis.name","Long-chain fatty acids (mg/g) (10 to 19 years)"
"CD015875_data","Analysis.name","Body Mass Index (kg/m2) (0 to 19 years)"
"CD015875_data","Analysis.name","Weight (kg) (0 to 19 years)"
"CD015875_data","Analysis.name","Waist circumference (cm) (0 to 19 years)"
"CD015875_data","Analysis.name","Total Body Fat Percentage (%TBF) (0 to 19 years)"
"CD015875_data","Analysis.name","Systolic blood pressure (mmHg) (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: abdominal cramps (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: abdominal discomfort (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: abdominal distension (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: abdominal pain (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: constipation (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: diarrhoea (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: flatulence (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: migraine (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: vomiting (0 to 19 years)"
"CD015875_data","Analysis.name","BMI Z-scores (0 to 19 years)"
"CD015875_data","Analysis.name","Low-intensity physical activity (min/wk) (0 to 19 years)"
"CD015875_data","Analysis.name","Moderate-intensity physical activity (min/wk) (0 to 19 years)"
"CD015875_data","Analysis.name","Waist-iliac crest circumference (cm) (0 to 19 years)"
"CD015875_data","Analysis.name","Waist-umbilicus circumference (cm) (0 to 19 years)"
"CD015875_data","Analysis.name","Fat Mass Index (kg/m2) (0 to 19 years)"
"CD015875_data","Analysis.name","Fat-Free Mass Index (kg/m2) (0 to 19 years)"
"CD015875_data","Analysis.name","Trunk Fat Mass Index (kg/m2) (0 to 19 years)"
"CD015875_data","Analysis.name","Visceral fat area (cm2) (0 to 19 years)"
"CD015875_data","Analysis.name","Bone mineral density (0 to 19 years)"
"CD015875_data","Analysis.name","Fasting insulin (uIU/mL) (0 to 19 years)"
"CD015875_data","Analysis.name","HOMA-IR (0 to 19 years)"
"CD015875_data","Analysis.name","Fasting glucose (mg/dL) (0 to 19 years)"
"CD015875_data","Analysis.name","HbA1c (%) (0 to 19 years)"
"CD015875_data","Analysis.name","Total cholesterol (mg/dL) (0 to 19 years)"
"CD015875_data","Analysis.name","LDL cholesterol (mg/dL) (0 to 19 years)"
"CD015875_data","Analysis.name","HDL cholesterol (mg/dL) (0 to 19 years)"
"CD015875_data","Analysis.name","Triglycerides (mg/dL) (0 to 19 years)"
"CD015875_data","Analysis.name","Ghrelin (pg/mL) (0 to 19 years)"
"CD015875_data","Analysis.name","GIP (pg/mL) (0 to 19 years)"
"CD015875_data","Analysis.name","GLP1 (pg/mL) (0 to 19 years)"
"CD015875_data","Analysis.name","PYY (pg/mL) (0 to 19 years)"
"CD015875_data","Analysis.name","Leptin (ng/mL) (0 to 19 years)"
"CD015875_data","Analysis.name","Resistin (ng/mL) (0 to 19 years)"
"CD015875_data","Analysis.name","Adiponectin (ug/mL) (0 to 19 years)"
"CD015875_data","Analysis.name","Systolic blood pressure (0 to 19 years)"
"CD015875_data","Analysis.name","Diastolic blood pressure (mmHg) (0 to 19 years)"
"CD015875_data","Analysis.name","Mean arterial pressure (MAP) (mmHg) (0 to 19 years)"
"CD015875_data","Analysis.name","Heart rate (beats/min) (0 to 19 years)"
"CD015875_data","Analysis.name","Hip circumference (cm) (0 to 19 years)"
"CD015875_data","Analysis.name","Abdominal fat mass (%) (0 to 19 years)"
"CD015875_data","Analysis.name","Abdominal fat mass (g) (0 to 19 years)"
"CD015875_data","Analysis.name","Body fat mass (g) (0 to 19 years)"
"CD015875_data","Analysis.name","Omentin-1 (ng/mL) (0 to 19 years)"
"CD015875_data","Analysis.name","Retinol-binding protein 4 (mg/dL) (0 to 19 years)"
"CD015875_data","Analysis.name","Physical activity (0 to 19 years)"
"CD015875_data","Analysis.name","Waist-to-hip ratio (WHR) (0 to 19 years)"
"CD015875_data","Analysis.name","Total Body Fat Percentage (0 to 19 years)"
"CD015875_data","Analysis.name","Body weight Z-scores (0 to 19 years)"
"CD015875_data","Analysis.name","Total lean mass (kg) (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: nausea (0 to 19 years)"
"CD015875_data","Analysis.name","Adverse events: headache (0 to 19 years)"
"CD015877_data","Analysis.group","1"
"CD015877_data","Analysis.group","2"
"CD015877_data","Analysis.group","3"
"CD015877_data","Analysis.name","BMI reduction, stabilisation and/or maintenance (kg/m2) (0 to 9)"
"CD015877_data","Analysis.name","Weight reduction, stabilisation and/or maintenance (kg) (0 to 9)"
"CD015877_data","Analysis.name","Adiposity and fat distribution: waist circumference (cm) (0 to 9)"
"CD015877_data","Analysis.name","BMI reduction, stabilisation and/or maintenance (kg/m2) (10 to 19)"
"CD015877_data","Analysis.name","Weight reduction, stabilisation and/or maintenance (kg) (10 to 19)"
"CD015877_data","Analysis.name","Adiposity and fat distribution: waist circumference (cm) (10 to 19)"
"CD015877_data","Analysis.name","Resistance to insulin: Homeostasis Model Assessment - Insulin Resistance (HOMA-IR index) (0 to 19)"
"CD015894_pub2_data","Analysis.group","1"
"CD015894_pub2_data","Analysis.group","2"
"CD015894_pub2_data","Analysis.group","3"
"CD015894_pub2_data","Analysis.name","Pain assessed with a validated scale for procedural pain in newborns during the procedure"
"CD015894_pub2_data","Analysis.name","Pain assessed with a validated scale for procedural pain in newborns up to 10 minutes after the procedure"
"CD015894_pub2_data","Analysis.name","Pain assessed with a validated scale for procedural pain in newborns at one to two hours after the procedure"
"CD015894_pub2_data","Analysis.name","Any harms"
"CD015894_pub2_data","Subgroup","PIPP"
"CD015894_pub2_data","Subgroup","NIPPS"
"CD015894_pub2_data","Subgroup","NPASS"
"CD015894_pub2_data","Subgroup","NIPS"
"CD015932_pub2_data","Analysis.group","1"
"CD015932_pub2_data","Analysis.group","2"
"CD015932_pub2_data","Analysis.group","3"
"CD015932_pub2_data","Analysis.group","4"
"CD015932_pub2_data","Analysis.group","5"
"CD015932_pub2_data","Analysis.name","All-cause mortality"
"CD015932_pub2_data","Analysis.name","ICU length of stay"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications (pneumonia)"
"CD015932_pub2_data","Analysis.name","All-cause mortality up to 6 months (time-to-event)"
"CD015932_pub2_data","Analysis.name","In-hospital mortality (OR)"
"CD015932_pub2_data","Analysis.name","In-hospital mortality"
"CD015932_pub2_data","Analysis.name","Mortality up to 28 (± 2) days (time-to-event)"
"CD015932_pub2_data","Analysis.name","ICU length of stay (time-to-event, measure of association)"
"CD015932_pub2_data","Analysis.name","ICU length of stay (days)"
"CD015932_pub2_data","Analysis.name","Hospital length of stay (time-to-event, measure of association)"
"CD015932_pub2_data","Analysis.name","Hospital length of stay (days)"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications (ventilator-associated pneumonia)"
"CD015932_pub2_data","Analysis.name","All-cause mortality (with RCT)"
"CD015932_pub2_data","Analysis.name","All-cause mortality (time-to-event)"
"CD015932_pub2_data","Analysis.name","ICU length of stay (with RCT)"
"CD015932_pub2_data","Analysis.name","Number of patients in ICU at day 28 ± 7 (time-to-event)"
"CD015932_pub2_data","Analysis.name","Quality of life (GOSE < 5 at 6 months)"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications – (acute) respiratory failure)"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications – (acute) respiratory failure (time-to-event)"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications – ARDS (time-to-event)"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications – aspiration"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications – pneumonia"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications – pneumonia (with RCT)"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications – pulmonary embolism (time-to-event)"
"CD015932_pub2_data","Analysis.name","Rate of pulmonary complications – ventilator-associated pneumonia"
"CD015932_pub2_data","Analysis.name","Adverse events – granuloma formation in the trachea"
"CD015932_pub2_data","Analysis.name","Adverse events – infections of tracheostoma"
"CD015932_pub2_data","Analysis.name","Adverse event – surgical site infections"
"CD015932_pub2_data","Analysis.name","Adverse event – vocal cord palsy"
"CD015932_pub2_data","Subgroup","RCT"
"CD015932_pub2_data","Subgroup","NRSI"
"CD015932_pub2_data","Subgroup","≤ 10 days"
"CD015932_pub2_data","Subgroup","≤ 7 days"
"CD015932_pub2_data","Subgroup","≤ 48 hours"
"CD015932_pub2_data","Subgroup","< 6 days"
"CD015932_pub2_data","Subgroup","RCT: < 8 days"
"CD015932_pub2_data","Subgroup","≤ 3 days"
"CD015932_pub2_data","Subgroup","≤ 4 days"
"CD015932_pub2_data","Subgroup","percutaneous and open surgical"
"CD015932_pub2_data","Subgroup","open surgical"
"CD015932_pub2_data","Subgroup","percutaneous"
"CD015932_pub2_data","Subgroup","Percutaneous and open surgical"
"CD015932_pub2_data","Subgroup","Open surgical"
"CD015932_pub2_data","Subgroup","Percutaneous"
"CD015968_data","Analysis.group","1"
"CD015968_data","Analysis.group","2"
"CD015968_data","Analysis.name","BMI (z-score) Change"
"CD015968_data","Analysis.name","BMI (z-score) - End of study"
"CD015968_data","Analysis.name","BMI (kg/m2) - End of study"
"CD015968_data","Analysis.name","Waist circumference (cm) - End of study"
"CD015968_data","Analysis.name","Fat mass (%) - End of study"
"CD015968_data","Analysis.name","Blood pressure - systolic - End of study"
"CD015968_data","Analysis.name","Blood pressure - diastolic - End of study"
"CD015968_data","Analysis.name","Glycemia fasting - End of study"
"CD015968_data","Analysis.name","HDL cholesterol - End of study"
"CD015968_data","Analysis.name","LDL cholesterol - End of study"
"CD015968_data","Analysis.name","Total cholesterol - End of study"
"CD015968_data","Analysis.name","Triglyceride - End of study"
"CD015968_data","Analysis.name","BMI (percentile) Change"
"CD015968_data","Analysis.name","BMI (percentile) - End of study"
"CD015968_data","Analysis.name","BMI (Kg/m2) Change"
"CD015968_data","Analysis.name","Weight (Kg) Change"
"CD015968_data","Analysis.name","Weight (kg) - End of study"
"CD015968_data","Analysis.name","Fat mass (kg) - End of study"
"CD015968_data","Analysis.name","Waist circumference (cm) Change"
"CD015968_data","Analysis.name","Physical well-being - Change"
"CD015968_data","Analysis.name","Mental well-being - Change"
"CD015968_data","Analysis.name","Quality of life - Change"
"CD015968_data","Analysis.name","Glycemia fasting (mg/dL) - End of study"
"CD015968_data","Analysis.name","HDL cholesterol (mg/dL) - End of study"
"CD015968_data","Analysis.name","LDL cholesterol (mg/dL) - End of study"
"CD015968_data","Analysis.name","Total cholesterol (mg/dL) - End of study"
"CD015968_data","Analysis.name","Triglyceride (mg/dL) - End of study"
"CD016001_data","Analysis.group","1"
"CD016001_data","Analysis.group","2"
"CD016001_data","Analysis.name","Death"
"CD016001_data","Analysis.name","Disability"
"CD016001_data","Analysis.name","Secondary events"
"CD016001_data","Analysis.name","Falls"
"CD016001_data","Analysis.name","Blood pressure (systolic)"
"CD016001_data","Analysis.name","Blood pressure (diastolic)"
"CD016001_data","Analysis.name","Cardiorespiratory fitness (peak VO<sub>2</sub>)"
"CD016001_data","Analysis.name","Musculoskeletal fitness (strength, LL affected)"
"CD016001_data","Analysis.name","Musculoskeletal fitness (strength, LL unaffected)"
"CD016001_data","Analysis.name","Musculoskeletal fitness (strength, UL affected)"
"CD016001_data","Analysis.name","Musculoskeletal fitness (strength, UL unaffected)"
"CD016001_data","Analysis.name","Walking speed (comfortable)"
"CD016001_data","Analysis.name","Walking speed (maximal)"
"CD016001_data","Analysis.name","Walking endurance (6-MWT)"
"CD016001_data","Analysis.name","Balance"
"CD016001_data","Analysis.name","Functional mobility (Timed Up and Go)"
"CD016001_data","Analysis.name","Health status (overall)"
"CD016001_data","Analysis.name","Health status (physical)"
"CD016001_data","Analysis.name","Health status (mental)"
"CD016001_data","Analysis.name","Mood (anxiety)"
"CD016001_data","Analysis.name","Mood (depression)"
"CD016001_data","Analysis.name","Fatigue severity (overall)"
"CD016001_data","Analysis.name","Functional mobility (timed up and go)"
"CD016001_data","Subgroup","&lt; 12 Weeks"
"CD016001_data","Subgroup","≥ 12 Weeks"
"CD016002_data","Analysis.group","1"
"CD016002_data","Analysis.group","2"
"CD016002_data","Analysis.name","Death"
"CD016002_data","Analysis.name","Disability"
"CD016002_data","Analysis.name","Secondary events"
"CD016002_data","Analysis.name","Falls"
"CD016002_data","Analysis.name","Blood pressure (systolic)"
"CD016002_data","Analysis.name","Blood pressure (diastolic)"
"CD016002_data","Analysis.name","Cardiorespiratory fitness (peak VO<sub>2</sub>)"
"CD016002_data","Analysis.name","Musculoskeletal fitness (strength LL, affected side)"
"CD016002_data","Analysis.name","Musculoskeletal fitness (strength LL, unaffected side)"
"CD016002_data","Analysis.name","Musculoskeletal fitness (strength UL, affected side)"
"CD016002_data","Analysis.name","Musculoskeletal fitness (strength UL, unaffected side)"
"CD016002_data","Analysis.name","Walking independence (functional ambulation category)"
"CD016002_data","Analysis.name","Walking speed (comfortable)"
"CD016002_data","Analysis.name","Walking speed (maximal)"
"CD016002_data","Analysis.name","Walking endurance (6-MWT)"
"CD016002_data","Analysis.name","Balance"
"CD016002_data","Analysis.name","Functional mobility (timed up and go)"
"CD016002_data","Analysis.name","Health status (overall)"
"CD016002_data","Analysis.name","Health status (physical health)"
"CD016002_data","Analysis.name","Health status (mental health)"
"CD016002_data","Analysis.name","Health status (social health)"
"CD016002_data","Analysis.name","Mood (anxiety)"
"CD016002_data","Analysis.name","Mood (depression)"
"CD016002_data","Analysis.name","Cognitive function"
"CD016002_data","Analysis.name","Fatigue severity (overall)"
"CD016002_data","Analysis.name","Health status (physical)"
"CD016002_data","Analysis.name","Health status (mental)"
"CD016002_data","Analysis.name","Health status (social)"
"CD016002_data","Subgroup","&lt; 12 Weeks"
"CD016002_data","Subgroup","≥ 12 Weeks"
"CD016002_data","Subgroup","Chronic (&gt;6mth)"
"CD016002_data","Subgroup","Early sub-acute (7d to 3mth)"
"CD016002_data","Subgroup","Late subacute (3 to 6 mth)"
"CD016031_data","Analysis.group","1"
"CD016031_data","Analysis.group","2"
"CD016031_data","Analysis.group","3"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 1: ADL, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 2: ADL, intermediate ( 4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 3: HRQoL, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 4: HRQoL, intermediate (4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 5: Functional status, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 6: Functional status, early (≤ 4 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 7: Functional status, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 8: Functional status, intermediate (4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 9: Mortality, early (≤ 4 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 10: Mortality, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 11: Mortality, late (≥ 24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 12: Pain, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 13: Pain, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 14: Pain, intermediate (4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 15: Re-operation rate, early (≤ 4 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 16: Re-operation rate, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 17: Adverse events, implant related (categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 18: Adverse events, not implant related (categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 19: Operative details (Continuous data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 20: Operative details (Categorical data)"
"CD016031_data","Analysis.name","Comparison 1: Anterior vs posterior, Outcome 21: Post-operative care outcomes (Continuous data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 1: ADL, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 2: ADL, intermediate ( 4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 3: Functional status, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 4: Functional status, early (≤ 4 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 5: Functional status, intermediate (4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 6: Functional status, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 7: Mortality, early (≤ 4 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 8: Mortality, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 9: Pain, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 10: Pain, intermediate (4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 11: Re-operation rate, early (≤ 4 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 12: Re-operation rate, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 13: Adverse events, implant related (categorical data)"
"CD016031_data","Analysis.name","Comparison 2 Anterior vs lateral, Outcome 14: Adverse events, not implant related (categorical data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 15: Operative details (Continuous data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 16: Operative details (Categorical data)"
"CD016031_data","Analysis.name","Comparison 2: Anterior vs lateral, Outcome 17: Post-operative care outcomes (Continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 1: ADL, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 2: ADL, intermediate ( 4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 3: HRQoL, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 4: HRQoL, intermediate (4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 5: Functional status, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 6: Functional status, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 7: Functional status, intermediate (4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 8: Mortality, early (≤ 4 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 9: Mortality, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 10: Mortality, late (≥ 24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 11: Pain, early (≤ 4 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 12: Pain, intermediate (4-24 months, continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 13: Re-operation rate, early (≤ 4 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 14: Re-operation rate, intermediate (4-24 months, categorical data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 15: Adverse events, implant related (categorical data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 16: Adverse events, not implant related (categorical data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 17: Operative details (Continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 18: Operative details (Categorical data)"
"CD016031_data","Analysis.name","Comparison 3: Lateral vs posterior, Outcome 19: Post-operative care outcomes (Continuous data)"
"CD016031_data","Analysis.name","Comparison 3: Outcome 20: Post-operative care outcomes (Categorical data)"
"CD016031_data","Subgroup","Dislocation of the prosthesis (categorical data)"
"CD016031_data","Subgroup","Intra-operative fracture (categorical data)"
"CD016031_data","Subgroup","Post-operative periprosthetic fracture (categorical data)"
"CD016031_data","Subgroup","Superficial wound infection"
"CD016031_data","Subgroup","Deep wound infection"
"CD016031_data","Subgroup","Deep vein thrombosis (DVT)"
"CD016031_data","Subgroup","Pulmonary embolism (PE)"
"CD016031_data","Subgroup","Damage to nerve, vessel, or tendon"
"CD016031_data","Subgroup","Length of surgery (minutes)"
"CD016031_data","Subgroup","Operative blood loss (milliliters)"
"CD016031_data","Subgroup","Blood transfusion (categorical data)"
"CD016031_data","Subgroup","Length of hospital stay (days)"
"CD016031_data","Subgroup","Days to mobilization"
"CD016031_data","Subgroup","Leg length discrepancy (categorical data)"
"CD016031_data","Subgroup","Damage to the femoral nerve"
"CD016031_data","Subgroup","Post operative blood transfusion (units)"
"CD016031_data","Subgroup","Blood transfusion (participants transfused)"
"CD016031_data","Subgroup","Pneumonia"
"CD016031_data","Subgroup","Any medical complication"
"CD016031_data","Subgroup","Discharge home (or prefracture residence)"
"CD016058_pub2_data","Analysis.group","1"
"CD016058_pub2_data","Analysis.group","2"
"CD016058_pub2_data","Analysis.group","3"
"CD016058_pub2_data","Analysis.group","4"
"CD016058_pub2_data","Analysis.group","5"
"CD016058_pub2_data","Analysis.group","6"
"CD016058_pub2_data","Analysis.group","7"
"CD016058_pub2_data","Analysis.group","8"
"CD016058_pub2_data","Analysis.group","9"
"CD016058_pub2_data","Analysis.name","Vaping cessation at 6 months or longer"
"CD016058_pub2_data","Analysis.name","Number of participants reporting SAEs"
"CD016058_pub2_data","Analysis.name","Vaping cessation at between 3 & 6 months"
"CD016058_pub2_data","Analysis.name","Number of participants reporting AEs"
"CD016058_pub2_data","Analysis.name","Weight (lbs) at longest follow-up"
"CD016058_pub2_data","Analysis.name","Systolic blood pressure (mmHg) at longest follow-up"
"CD016058_pub2_data","Analysis.name","Heart rate (bpm) at longest follow-up"
"CD016058_pub2_data","Analysis.name","Number of  participants reporting SAEs"
"CD016058_pub2_data","Analysis.name","Change in combustible tobacco product use (tobacco cigarette use) at between 3 & 6 months"
"CD016058_pub2_data","Analysis.name","Mean change in systolic blood pressure (mmHg)"
"CD016058_pub2_data","Analysis.name","Mean change in diastolic blood pressure (mmHg)"
"CD016058_pub2_data","Analysis.name","Mean change in heart rate (bpm)"
"CD016058_pub2_data","Analysis.name","Cotinine (ng/ml) at longest follow-up"
"CD016058_pub2_data","Analysis.name","Diastolic blood pressure (mmHg) at longest follow-up"
"CD016058_pub2_data","Analysis.name","Vaping cessation at 6 months or longer (subgrouped by age)"
"CD016058_pub2_data","Analysis.name","Numbers of participants reporting SAEs"
"CD016058_pub2_data","Subgroup","Under 18 years"
"CD016058_pub2_data","Subgroup","Both under and over 18 years"
"CD016064_data","Analysis.group","1"
"CD016064_data","Analysis.group","2"
"CD016064_data","Analysis.group","3"
"CD016064_data","Analysis.group","4"
"CD016064_data","Analysis.group","5"
"CD016064_data","Analysis.group","6"
"CD016064_data","Analysis.group","7"
"CD016064_data","Analysis.group","8"
"CD016064_data","Analysis.group","9"
"CD016064_data","Analysis.group","10"
"CD016064_data","Analysis.group","11"
"CD016064_data","Analysis.group","12"
"CD016064_data","Analysis.group","13"
"CD016064_data","Analysis.group","14"
"CD016064_data","Analysis.group","15"
"CD016064_data","Analysis.group","16"
"CD016064_data","Analysis.group","17"
"CD016064_data","Analysis.group","18"
"CD016064_data","Analysis.group","19"
"CD016064_data","Analysis.group","20"
"CD016064_data","Analysis.group","21"
"CD016064_data","Analysis.name","Rate of falls"
"CD016064_data","Analysis.name","Risk of falling"
"CD016064_data","Analysis.name","Risk of fracture"
"CD016064_data","Analysis.name","Rate of falls sensitivity analyses: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Risk of falling sensitivity analyses: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Risk of fracture sensitivity analyses: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Multifactorial interventions (grouped by alignment with QCA theory): Rate of falls sensitivity analyses: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Multifactorial interventions (grouped by alignment with QCA theory): Risk of falling sensitivity analyses: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Multifactorial interventions (grouped by alignment with QCA theory): Risk of fracture sensitivity analyses: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Adverse events"
"CD016064_data","Analysis.name","Rate of falls sensitivity analysis: active exercise including Cadore 2014"
"CD016064_data","Analysis.name","Rate of falls sensitivity analysis: active exercise excluding trials with <40 participants"
"CD016064_data","Analysis.name","Rate of falls sensitivity analysis: active exercise excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Risk of falling sensitivity analysis: active exercise excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Risk of falling sensitivity analysis: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Rate of falls (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Risk of falling (grouped by level of cognition) sensitivity analysis: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Rate of falls sensitivity analysis: excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Medication review/deprescribing: Rate of falls sensitivity analysis excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Medication review/deprescribing: Risk of falling sensitivity analysis excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Medication review/deprescribing: Risk of fracture sensitivity analysis excluding trials at high risk of bias"
"CD016064_data","Analysis.name","Rate of falls (grouped by professional)"
"CD016064_data","Analysis.name","Risk of falling (grouped by professional)"
"CD016064_data","Analysis.name","Risk of falling sensitivity analysis: including trial that excludes falls during intervention period"
"CD016064_data","Analysis.name","Risk of fracture sensitivity analysis: excluding trials at high risk of bias"
"CD016064_data","Subgroup","Outcomes at end of intervention period"
"CD016064_data","Subgroup","Outcomes after period of post-intervention follow-up"
"CD016064_data","Subgroup","Outcomes after a period of post-intervention follow-up"
"CD016064_data","Subgroup","Trial length ≥12 months "
"CD016064_data","Subgroup","Trial length 6-11 months"
"CD016064_data","Subgroup","Trial length ≥12 months"
"CD016064_data","Subgroup","Trial length 5-11 months"
"CD016064_data","Subgroup","Participants with no cognitive impairment or mixed sample"
"CD016064_data","Subgroup","Participants with cognitive impairment"
"CD016064_data","Subgroup","Facility engagement and tailored intervention delivery"
"CD016064_data","Subgroup","Without facility engagement and tailored intervention delivery"
"CD016064_data","Subgroup","Active exercise"
"CD016064_data","Subgroup","Whole body vibration"
"CD016064_data","Subgroup","Active exercise: All fractures"
"CD016064_data","Subgroup","Active exercise: Hip fractures"
"CD016064_data","Subgroup","Active exercise: Severe soreness"
"CD016064_data","Subgroup","Active exercise: Severe bruises"
"CD016064_data","Subgroup","Active exercise: Severe fatigue"
"CD016064_data","Subgroup","Active exercise: Short-term aches and pains"
"CD016064_data","Subgroup","Whole body vibration: major adverse events"
"CD016064_data","Subgroup","Active Exercise"
"CD016064_data","Subgroup","All fractures: active exercise"
"CD016064_data","Subgroup","All fractures: whole body vibration"
"CD016064_data","Subgroup","Hip fractures: active exercise"
"CD016064_data","Subgroup","Gait, balance, functional training"
"CD016064_data","Subgroup","Strength/resistance"
"CD016064_data","Subgroup","Combination of exercise categories"
"CD016064_data","Subgroup","General physical activity"
"CD016064_data","Subgroup","Others (Whole body vibration)"
"CD016064_data","Subgroup","Gait, balance and functional training"
"CD016064_data","Subgroup","3D (Tai Chi)"
"CD016064_data","Subgroup","No cognitive impairment"
"CD016064_data","Subgroup","Mixed cognition"
"CD016064_data","Subgroup","Cognitive impairment"
"CD016064_data","Subgroup","All fractures - mixed cognition"
"CD016064_data","Subgroup","All fractures - cognitive impairment"
"CD016064_data","Subgroup","Hip fractures - cognitive impairment"
"CD016064_data","Subgroup","Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents"
"CD016064_data","Subgroup","NOT Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents"
"CD016064_data","Subgroup","Not Moderate/low intensity group OR ≥ 1h/wk for ambulatory residents"
"CD016064_data","Subgroup","Additional gait, balance, functional training"
"CD016064_data","Subgroup","Strength/resistance vs self-training"
"CD016064_data","Subgroup","Balance and strength vs self-training"
"CD016064_data","Subgroup","Flexibility (Yoga) vs 'Staying active' program"
"CD016064_data","Subgroup","3D (Tai Chi) vs 'Staying active' program"
"CD016064_data","Subgroup","Flexibility (Yoga) vs 3D (Tai Chi)"
"CD016064_data","Subgroup","3D exercises (""In balance"") vs Functional balance, strength & mobility"
"CD016064_data","Subgroup","Wii balance board vs Otago balance program"
"CD016064_data","Subgroup","Additional gait, balance, and functional training"
"CD016064_data","Subgroup","Additional whole body vibration"
"CD016064_data","Subgroup","Comparison of combination exercise programmes"
"CD016064_data","Subgroup","Total fractures"
"CD016064_data","Subgroup","Interventions including medication review/deprescribing vs usual care"
"CD016064_data","Subgroup","Education on harmful medications vs usual care"
"CD016064_data","Subgroup","Outreach pharmacist on hospital discharge vs usual care"
"CD016064_data","Subgroup","Addition of medication review software to medication review vs medication review"
"CD016064_data","Subgroup","Adverse events"
"CD016064_data","Subgroup","Serious adverse events"
"CD016064_data","Subgroup","Interventions including medication review vs usual care"
"CD016064_data","Subgroup","Interventions including deprescribing vs usual care"
"CD016064_data","Subgroup","Multidisciplinary"
"CD016064_data","Subgroup","Not multidisciplinary - pharmacist led"
"CD016064_data","Subgroup","Not multidisciplinary - medical doctor led"
"CD016064_data","Subgroup","Not multidisciplinary - nurse education"
"CD016064_data","Subgroup","Not multidisciplinary - software"
"CD016064_data","Subgroup","Vitamin D supplementation"
"CD016064_data","Subgroup","Education on vitamin D supplementation"
"CD016064_data","Subgroup","Education on Vitamin D + calcium + osteoporosis medications vs usual care"
"CD016064_data","Subgroup","Gastrointestinal disorders"
"CD016064_data","Subgroup","Dairy supplementation"
"CD016064_data","Subgroup","All fractures"
"CD016064_data","Subgroup","Hip fractures"
"CD016064_data","Subgroup","Wireless position-monitoring patch vs usual care"
"CD016064_data","Subgroup","Assistive home technology"
"CD016064_data","Subgroup","Staff education on fracture prevention vs usual care"
"CD016064_data","Subgroup","Guideline implementation programme vs control"
"CD016064_data","Subgroup","Dementia care mapping vs usual care"
"CD016064_data","Subgroup","Falls risk assessment tools vs usual care"
"CD016064_data","Subgroup","Model of ocular care vs referral to eyecare provider"
"CD016064_data","Subgroup","Staff rounding vs usual care"
"CD016064_data","Subgroup","Person-centred care & medication review vs medication review"
"CD016064_data","Subgroup","Falls risk assessment tools vs nurses' judgement"
"CD016064_data","Subgroup","Dedicated falls practice nurse vs usual care"
"CD016064_data","Subgroup","Cognitive training + Exercise vs exercise"
"CD016064_data","Subgroup","Lavender patch vs placebo"
"CD016064_data","Subgroup","Sunlight exposure vs usual care"
"CD016064_data","Subgroup","Additional podiatry vs usual care"
"CD016064_data","Subgroup","Exercise + management of urinary incontinence + fluid therapy vs usual care"
"CD016064_data","Subgroup","Sunlight exposure + calcium vs usual care"
"CD016119_data","Analysis.group","1"
"CD016119_data","Analysis.name","Requirement for blood transfusion"
"CD016119_data","Analysis.name","Incidence of haemorrhage"
"CD016119_data","Analysis.name","Size of fibroid on incidence of haemorrhage"
"CD016119_data","Analysis.name","Change in haemoglobin"
"CD016119_data","Analysis.name","Length of hospitalisation"
"CD016119_data","Analysis.name","Length of hospitalisation – sensitivity analysis"
"CD016119_data","Analysis.name","Length of operation"
"CD016119_data","Analysis.name","Major surgery at time of procedure"
"CD016119_data","Analysis.name","Postpartum fever"
"CD016119_data","Analysis.name","Estimated blood loss"
"CD016119_data","Analysis.name","Additional uterotonics or tranexamic acid"
"CD016119_data","Analysis.name","Postpartum haemoglobin concentration"
"CD016119_data","Analysis.name","Future major surgery"
"CD016119_data","Analysis.name","Fatigue"
"CD016119_data","Analysis.name","AUS pain score"
"CD016119_data","Analysis.name","VNRS-6 pain score"
"CD016119_data","Analysis.name","Intraoperative injury"
"CD016119_data","Analysis.name","Bladder injury"
"CD016119_data","Analysis.name","Ileus"
"CD016119_data","Analysis.name","Complications (unspecified)"
"CD016119_data","Subgroup","Country income status – high"
"CD016119_data","Subgroup","Country income status – lower middle "
"CD016119_data","Subgroup","Country income status – upper middle"
"CD016119_data","Subgroup","Fibroid size < 3 cm"
"CD016119_data","Subgroup","Fibroid size 3–6 cm"
"CD016119_data","Subgroup","Fibroid size > 6 cm"
"CD016119_data","Subgroup","Country income status – lower middle"
"CD016119_data","Subgroup","Country income status – upper middle "
"CD016119_data","Subgroup","Country income status – high "
"CD016120_data","Analysis.group","1"
"CD016120_data","Analysis.name","Allogenic (donor) blood transfusion"
"CD016120_data","Analysis.name","Transfusion related adverse reactions"
"CD016120_data","Analysis.name","Haemorrhage"
"CD016120_data","Analysis.name","Length of hospitalisation"
"CD016120_data","Analysis.name","Length of operation"
"CD016120_data","Analysis.name","Sepsis"
"CD016120_data","Analysis.name","Estimated blood loss"
"CD016120_data","Analysis.name"," Postpartum haemoglobin concentration"
"CD016120_data","Analysis.name","Change in haemoglobin"
"CD016120_data","Analysis.name","Major surgery including hysterectomy"
"CD016120_data","Analysis.name","Amniotic fluid embolism"
"CD016120_data","Analysis.name","Side effects"
"CD016120_data","Analysis.name","Clotting abnormalities: Prothrombin time (PT) at day 1 postpartum"
"CD016120_data","Analysis.name","Clotting abnormalities: Activated partial thromboplastin time (APTT) at day 1 postpartum"
"CD016120_data","Analysis.name","Clotting abnormalities: Activation coagulation time (ACT) at day 1 postpartum"
"CD016120_data","Analysis.name","Clotting abnormalities: Red blood cell count at day 1 postpartum"
"CD016120_data","Analysis.name","Clotting abnormalities: Platelets amount at day 1 postpartum"
"CD016120_data","Analysis.name","Clotting abnormalities: Fibrinogen count at day 1 postpartum"
"CD016120_data","Analysis.name","Maternal well-being: Mental fatigue"
"CD016120_data","Analysis.name","Maternal well-being: General fatigue"
"CD016120_data","Analysis.name","Maternal well-being: Physical fatigue"
"CD016120_data","Analysis.name","Maternal well-being: Reduced motivation"
"CD016120_data","Analysis.name","Maternal well-being: Reduced activity"
"CD016131_data","Analysis.group","1"
"CD016131_data","Analysis.group","2"
"CD016131_data","Analysis.group","3"
"CD016131_data","Analysis.group","4"
"CD016131_data","Analysis.group","5"
"CD016131_data","Analysis.name","RSV-associated lower respiratory tract illness"
"CD016131_data","Analysis.name","RSV-associated acute respiratory illness"
"CD016131_data","Analysis.name","Mortality from illness caused by RSV"
"CD016131_data","Analysis.name","All-cause mortality&nbsp;"
"CD016131_data","Analysis.name","Serious adverse events (SAEs) related to vaccination"
"CD016131_data","Analysis.name","Any unsolicited adverse events (spontaneously reported/ other adverse events)"
"CD016131_data","Analysis.name","Any solicited adverse events (Local reactions- redness, swelling, pain/tenderness and systemic reactions - fever, fatigue, etc.)"
"CD016131_data","Analysis.name","RSV-associated lower respiratory tract infection"
"CD016131_data","Analysis.name","All-cause mortality"
"CD016131_data","Analysis.name","Serious adverse events (SAEs) related to vaccination&nbsp;"
"CD016131_data","Analysis.name","Medically attended RSV-associated lower respiratory tract illness in infants"
"CD016131_data","Analysis.name","Medically attended RSV-associated severe lower respiratory tract illness in infants"
"CD016131_data","Analysis.name","Hospitalisation due to RSV disease"
"CD016131_data","Analysis.name","Mortality from illness caused by RSV disease"
"CD016131_data","Analysis.name","All-cause medically attended acute respiratory illnesses (MAARI)"
"CD016131_data","Analysis.name","RSV-associated medically attended acute respiratory illnesses (MAARI)"
"CD016131_data","Analysis.name","Acute otitis Media"
"CD016131_data","Analysis.name","Any solicited systemic reaction (fever)"
"CD016131_data","Analysis.name","New RSV infection"
"CD016131_data","Subgroup","Authorised vaccines"
"CD016131_data","Subgroup","Unauthorised vaccines"
"CD016131_data","Subgroup","Unauthorsied vaccines"
"CD016131_data","Subgroup","Authorised vaccines (RSV prefusion F protein-based vaccine )"
"CD016131_data","Subgroup","Unauthorised vaccines (recombinant RSV F protein nanoparticle vaccine)"
"CD016131_data","Subgroup","Authorised vaccines (RSV prefusion F protein-based vaccine)"
"CD016131_data","Subgroup","Unauthoorised vaccines (recombinant RSV F protein nanoparticle vaccine)"
"CD016136_data","Analysis.group","1"
"CD016136_data","Analysis.group","2"
"CD016136_data","Analysis.group","3"
"CD016136_data","Analysis.name","Implementation outcome"
"CD016136_data","Analysis.name","Excluding overall high risk of bias"
"CD016136_data","Analysis.name","ICC 0.07"
"CD016136_data","Analysis.name","ICC 0.351"
"CD016136_data","Analysis.name","Adjusting for clustering where the unit of analysis was unclear "
"CD016136_data","Analysis.name","Including trials that explicitly described a trial aim or objective to test the effectiveness of an implementation strategy on an implementation outcome"
"CD016136_data","Analysis.name","School type"
"CD016136_data","Analysis.name","Targeted health behaviour or risk factor"
"CD016136_data","Subgroup","High"
"CD016136_data","Subgroup","Elementary"
"CD016136_data","Subgroup","Middle"
"CD016136_data","Subgroup","Physical activity"
"CD016136_data","Subgroup","Diet"
"CD016136_data","Subgroup","Tobacco and/or alcohol use"
"CD016136_data","Subgroup","Diet and physical activity"
"CD016147_data","Analysis.group","1"
"CD016147_data","Analysis.group","2"
"CD016147_data","Analysis.group","3"
"CD016147_data","Analysis.group","4"
"CD016147_data","Analysis.group","5"
"CD016147_data","Analysis.name","Manual removal of the placenta (end of treatment)"
"CD016147_data","Analysis.name","PPH ≥ 1000 mL (end of treatment)"
"CD016147_data","Analysis.name","Adverse effects (shivering)"
"CD016147_data","Analysis.name","Adverse effects (nausea)"
"CD016147_data","Analysis.name","Adverse effects (vomiting)"
"CD016147_data","Analysis.name","Adverse effects (abdominal pain)"
"CD016147_data","Analysis.name","Adverse effects (headache)"
"CD016147_data","Analysis.name","Adverse effects (dizziness)"
"CD016147_data","Analysis.name","Adverse effects (dyspepsia)"
"CD016147_data","Analysis.name","Adverse effects (flushes)"
"CD016147_data","Analysis.name","Blood transfusion"
"CD016147_data","Analysis.name","Blood loss (mL)"
"CD016147_data","Analysis.name","Additional uterotonics"
"CD016148_data","Analysis.group","1"
"CD016148_data","Analysis.group","2"
"CD016148_data","Analysis.group","3"
"CD016148_data","Analysis.group","4"
"CD016148_data","Analysis.group","5"
"CD016148_data","Analysis.group","6"
"CD016148_data","Analysis.group","7"
"CD016148_data","Analysis.group","8"
"CD016148_data","Analysis.group","9"
"CD016148_data","Analysis.group","10"
"CD016148_data","Analysis.group","11"
"CD016148_data","Analysis.name","2nd degree tears"
"CD016148_data","Analysis.name","3rd or 4th degree tears"
"CD016148_data","Analysis.name","3rd degree tears"
"CD016148_data","Analysis.name","4th degree tears"
"CD016148_data","Analysis.name","PPH ≥ 500mL"
"CD016148_data","Analysis.name","Perineal pain"
"CD016148_data","Analysis.name","Breastfeeding"
"CD016148_data","Analysis.name","Maternal death"
"CD016148_data","Analysis.name","Maternal satisfaction (dichotomous)"
"CD016148_data","Analysis.name","Pain"
"CD016148_data","Analysis.name","Maternal satisfaction (continuous)"
"CD016148_data","Analysis.name","PPH ≥  500mL"
"CD016148_data","Analysis.name","1st and 2nd degree tears"
"CD016148_data","Analysis.name","Side effects"
"CD016168_data","Analysis.group","1"
"CD016168_data","Analysis.group","2"
"CD016168_data","Analysis.group","3"
"CD016168_data","Analysis.name","Severe maternal morbidity – composite excluding ICU admission"
"CD016168_data","Analysis.name","Severe maternal morbidity – ICU admission"
"CD016168_data","Analysis.name","Breastfeeding"
"CD016168_data","Analysis.name","Maternal death"
"CD016168_data","Analysis.name","Severe maternal morbidity – arterial embolisation"
"CD016168_data","Analysis.name","Severe maternal morbidity – hysterectomy (randomised studies)"
"CD016168_data","Analysis.name","Severe maternal morbidity – hysterectomy (non-randomised studies)"
"CD016168_data","Analysis.name","Adverse effects – thromboembolic events"
"CD016168_data","Analysis.name","Adverse effects – dizziness up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – shivering up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – fever up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – abdominal pain up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – headache up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – nausea or vomiting up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – fainting up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – palpitations up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – allergic reaction up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – urticaria up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – itching up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – shortness of breath up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – facial oedema up to 24 hours"
"CD016168_data","Analysis.name","Adverse effects – re-admission with the need for re-evacuation of uterine cavity at 6 weeks"
"CD016168_data","Analysis.name","Maternal death (randomised studies)"
"CD016168_data","Analysis.name","Maternal death (non-randomised studies)"
"CD016168_data","Analysis.name","Severe maternal morbidity – any organ failure"
"CD016168_data","Analysis.name","Severe maternal morbidity – laporotomy"
"CD016168_data","Analysis.name","Severe maternal morbidity – uterine artery embolisation"
"CD016168_data","Analysis.name","Adverse effects – maternal sepsis"
"CD016168_data","Analysis.name","Adverse effects – pulmonary embolism"
"CD016168_data","Analysis.name","Adverse effects – other venous/arterial thromboembolic event"
"CD016168_data","Analysis.name","Adverse effects – transfusion-related reactions"
"CD016168_data","Analysis.name","Other adverse events (as defined by study investigators)"
"CD016168_data","Analysis.name","Maternal wellbeing – general fatigue"
"CD016168_data","Analysis.name","Maternal wellbeing – physical fatigue"
"CD016168_data","Analysis.name","Maternal wellbeing – reduced activity"
"CD016168_data","Analysis.name","Maternal wellbeing – reduced motivation"
"CD016168_data","Analysis.name","Maternal wellbeing – mental fatigue"
"CD016211_data","Analysis.group","1"
"CD016211_data","Analysis.name","Maternal sepsis"
"CD016211_data","Analysis.name","Maternal sepsis: subgroup analysis (polypharmacy vs monopharmacy)"
"CD016211_data","Analysis.name","Maternal mortality"
"CD016211_data","Analysis.name","Maternal mortality: subgroup analysis (polypharmacy vs monopharmacy)"
"CD016211_data","Analysis.name","Neonatal sepsis"
"CD016211_data","Analysis.name","Neonatal sepsis: subgroup analysis (polypharmacy vs monopharmacy)"
"CD016211_data","Analysis.name","Neonatal mortality"
"CD016211_data","Analysis.name","Neonatal mortality: subgroup analysis (polypharmacy vs monopharmacy)"
"CD016211_data","Analysis.name","Other maternal infections: wound infection (any)"
"CD016211_data","Analysis.name","Other maternal infections: wound infection (perineal)"
"CD016211_data","Analysis.name","Adverse effects of antibiotics: vomiting"
"CD016211_data","Analysis.name","Adverse effects of antibiotics: diarrhea"
"CD016211_data","Analysis.name","Adverse effects of antibiotics: pyloric stenosis"
"CD016211_data","Analysis.name","NICU admission"
"CD016211_data","Analysis.name","Other maternal infections: chorioamnionitis"
"CD016211_data","Analysis.name","Other maternal infections: endometritis"
"CD016211_data","Analysis.name","Other maternal infections: mastitis or breast abscess"
"CD016211_data","Analysis.name","Other maternal infections: pyelonephritis"
"CD016211_data","Analysis.name","Other neonatal infections"
"CD016211_data","Analysis.name","Intrapartum stillbirth"
"CD016211_data","Subgroup","Polypharmacy"
"CD016211_data","Subgroup","Monopharmacy"
"CD016278_data","Analysis.group","1"
"CD016278_data","Analysis.name","Estimated blood loss ≥ 1000ml"
"CD016278_data","Analysis.name","Calculated blood loss ≥ 1000ml"
"CD016278_data","Analysis.name","Maternal death"
"CD016278_data","Analysis.name","Blood transfusion"
"CD016278_data","Analysis.name","Receipt of surgical interventions to control PPH"
"CD016278_data","Analysis.name","Thromboembolic events"
"CD016278_data","Analysis.name","Receipt of additional uterotonics"
"CD016278_data","Analysis.name","Hysterectomy"
"CD016278_data","Analysis.name","Clinical diagnosis of PPH"
"CD016278_data","Analysis.name","Estimated mean blood loss (mL)"
"CD016278_data","Analysis.name","Calculated mean blood loss (mL)"
"CD016278_data","Analysis.name","Myocardial infarction"
"CD016278_data","Analysis.name","Stroke"
"CD016278_data","Analysis.name","Seizures"
"CD016278_data","Analysis.name","Organ failure/dysfunction"
"CD016278_data","Analysis.name","ICU admission"
"CD016278_data","Analysis.name","Nausea"
"CD016278_data","Analysis.name","Vomiting"
"CD016278_data","Subgroup","Gravimetrically estimated blood loss"
"CD016278_data","Subgroup","Provider estimated blood loss"
